<?xml version="1.0" encoding="ISO-8859-1"?><COCHRANE_REVIEW DESCRIPTION="For publication" DOI="10.1002/14651858.CD005119.pub2" GROUP_ID="MUSKEL" ID="549204052415481681" MERGED_FROM="" MODIFIED="2010-03-17 22:50:53 +0100" MODIFIED_BY="Elizabeth Tanjong Ghogomu" REVIEW_NO="A005-R" REVMAN_SUB_VERSION="5.0.23" REVMAN_VERSION="5" SPLIT_FROM="" STAGE="R" STATUS="A" TYPE="INTERVENTION" VERSION_NO="8.0">
<COVER_SHEET MODIFIED="2010-03-17 17:48:22 -0400" MODIFIED_BY="[Empty name]">
<TITLE>Calcium supplementation for improving bone mineral density in children</TITLE>
<CONTACT>
<PERSON ID="D333C25182E26AA20080535F45D35AFA" ROLE="AUTHOR">
<PREFIX>Dr</PREFIX>
<FIRST_NAME>Tania</FIRST_NAME>
<MIDDLE_INITIALS>M</MIDDLE_INITIALS>
<LAST_NAME>Winzenberg</LAST_NAME>
<SUFFIX/>
<POSITION>Musculoskeletal Epidemiologist</POSITION>
<EMAIL_1>tania.winzenberg@utas.edu.au</EMAIL_1>
<EMAIL_2/>
<URL/>
<MOBILE_PHONE/>
<ADDRESS>
<DEPARTMENT>Menzies Research Institute</DEPARTMENT>
<ORGANISATION>University of Tasmania</ORGANISATION>
<ADDRESS_1>Private Bag 23</ADDRESS_1>
<ADDRESS_2/>
<CITY>Hobart</CITY>
<ZIP>7001</ZIP>
<REGION>TAS</REGION>
<COUNTRY CODE="AU">Australia</COUNTRY>
<PHONE_1>+613 62267770</PHONE_1>
<PHONE_2>+613 6226 7700</PHONE_2>
<FAX_1>+613 62267704</FAX_1>
<FAX_2/>
</ADDRESS>
<FOOTNOTE/>
</PERSON>
</CONTACT>
<CREATORS MODIFIED="2010-03-17 17:42:27 -0400" MODIFIED_BY="Elizabeth Tanjong Ghogomu">
<PERSON ID="D333C25182E26AA20080535F45D35AFA" ROLE="AUTHOR">
<PREFIX>Dr</PREFIX>
<FIRST_NAME>Tania</FIRST_NAME>
<MIDDLE_INITIALS>M</MIDDLE_INITIALS>
<LAST_NAME>Winzenberg</LAST_NAME>
<SUFFIX/>
<POSITION>Musculoskeletal Epidemiologist</POSITION>
<EMAIL_1>tania.winzenberg@utas.edu.au</EMAIL_1>
<EMAIL_2/>
<URL/>
<MOBILE_PHONE/>
<ADDRESS>
<DEPARTMENT>Menzies Research Institute</DEPARTMENT>
<ORGANISATION>University of Tasmania</ORGANISATION>
<ADDRESS_1>Private Bag 23</ADDRESS_1>
<ADDRESS_2/>
<CITY>Hobart</CITY>
<ZIP>7001</ZIP>
<REGION>TAS</REGION>
<COUNTRY CODE="AU">Australia</COUNTRY>
<PHONE_1>+613 62267770</PHONE_1>
<PHONE_2>+613 6226 7700</PHONE_2>
<FAX_1>+613 62267704</FAX_1>
<FAX_2/>
</ADDRESS>
<FOOTNOTE/>
</PERSON>
<PERSON ID="14744" ROLE="AUTHOR">
<PREFIX>Dr</PREFIX>
<FIRST_NAME>Kelly</FIRST_NAME>
<MIDDLE_INITIALS>A</MIDDLE_INITIALS>
<LAST_NAME>Shaw</LAST_NAME>
<SUFFIX/>
<POSITION>Honorary Associate</POSITION>
<EMAIL_1>kelly.shaw@dhhs.tas.gov.au</EMAIL_1>
<EMAIL_2/>
<URL/>
<MOBILE_PHONE/>
<ADDRESS>
<DEPARTMENT>Menzies Research Institute</DEPARTMENT>
<ORGANISATION>Public Health Unit</ORGANISATION>
<ADDRESS_1>2/152 Macquarie Street</ADDRESS_1>
<ADDRESS_2/>
<CITY>Hobart</CITY>
<ZIP>7000</ZIP>
<REGION>Tasmania</REGION>
<COUNTRY CODE="AU">Australia</COUNTRY>
<PHONE_1>+61 3 6222 7678</PHONE_1>
<PHONE_2/>
<FAX_1>+61 3 6222 7407</FAX_1>
<FAX_2/>
</ADDRESS>
<FOOTNOTE/>
</PERSON>
<PERSON ID="8FCCAE8F82E26AA201AFF012272816EE" ROLE="AUTHOR">
<PREFIX>Ms</PREFIX>
<FIRST_NAME>Jayne</FIRST_NAME>
<MIDDLE_INITIALS/>
<LAST_NAME>Fryer</LAST_NAME>
<SUFFIX/>
<POSITION>Statistical Officer</POSITION>
<EMAIL_1>Jayne.Fryer@workcover.nsw.gov.au</EMAIL_1>
<EMAIL_2/>
<URL/>
<MOBILE_PHONE/>
<ADDRESS>
<DEPARTMENT>Menzies Research Institute</DEPARTMENT>
<ORGANISATION>University of Tasmania</ORGANISATION>
<ADDRESS_1>Private Bag 23</ADDRESS_1>
<ADDRESS_2/>
<CITY>Hobart</CITY>
<ZIP>7001</ZIP>
<REGION>TAS</REGION>
<COUNTRY CODE="AU">Australia</COUNTRY>
<PHONE_1>+612 43215825</PHONE_1>
<PHONE_2/>
<FAX_1>+612 92875825</FAX_1>
<FAX_2/>
</ADDRESS>
<FOOTNOTE/>
</PERSON>
<PERSON ID="4728" ROLE="AUTHOR">
<PREFIX>Dr</PREFIX>
<FIRST_NAME>Graeme</FIRST_NAME>
<MIDDLE_INITIALS/>
<LAST_NAME>Jones</LAST_NAME>
<SUFFIX/>
<POSITION>Head, Musculoskeletal Unit</POSITION>
<EMAIL_1>G.Jones@utas.edu.au</EMAIL_1>
<EMAIL_2/>
<URL/>
<MOBILE_PHONE/>
<ADDRESS>
<DEPARTMENT>Menzies Research Institute</DEPARTMENT>
<ORGANISATION>University of Tasmania</ORGANISATION>
<ADDRESS_1>Private Bag 23</ADDRESS_1>
<ADDRESS_2/>
<CITY>Hobart</CITY>
<ZIP>7004</ZIP>
<REGION>TAS</REGION>
<COUNTRY CODE="AU">Australia</COUNTRY>
<PHONE_1>+613 62267705</PHONE_1>
<PHONE_2>+61 362 267700</PHONE_2>
<FAX_1>+61 362 267704</FAX_1>
<FAX_2/>
</ADDRESS>
<FOOTNOTE/>
</PERSON>
</CREATORS>
<DATES MODIFIED="2008-10-03 10:52:33 -0400" MODIFIED_BY="[Empty name]">
<UP_TO_DATE>
<DATE DAY="22" MONTH="2" YEAR="2006"/>
</UP_TO_DATE>
<LAST_SEARCH>
<DATE DAY="22" MONTH="2" YEAR="2006"/>
</LAST_SEARCH>
<NEXT_STAGE>
<DATE DAY="22" MONTH="2" YEAR="2008"/>
</NEXT_STAGE>
<PROTOCOL_PUBLISHED ISSUE="1" YEAR="2005"/>
<REVIEW_PUBLISHED ISSUE="2" YEAR="2006"/>
<LAST_CITATION_ISSUE ISSUE="2" YEAR="2006"/>
</DATES>
<WHATS_NEW MODIFIED="2010-03-17 17:48:22 -0400" MODIFIED_BY="[Empty name]">
<WHATS_NEW_ENTRY EVENT="FEEDBACK" MODIFIED="2010-03-17 17:46:44 -0400" MODIFIED_BY="[Empty name]">
<DATE DAY="19" MONTH="2" YEAR="2010"/>
<DESCRIPTION>
<P>Feedback from Tanis Fenton, 05 January 2010</P>
</DESCRIPTION>
</WHATS_NEW_ENTRY>
<WHATS_NEW_ENTRY EVENT="AMENDMENT" MODIFIED="2010-03-17 17:48:22 -0400" MODIFIED_BY="[Empty name]">
<DATE DAY="3" MONTH="10" YEAR="2008"/>
<DESCRIPTION>
<P>CMSG ID: A005-R</P>
</DESCRIPTION>
</WHATS_NEW_ENTRY>
</WHATS_NEW>
<HISTORY MODIFIED="2010-03-17 17:47:40 -0400" MODIFIED_BY="[Empty name]">
<WHATS_NEW_ENTRY EVENT="AMENDMENT" MODIFIED="2010-03-17 17:47:40 -0400" MODIFIED_BY="[Empty name]">
<DATE DAY="3" MONTH="10" YEAR="2008"/>
<DESCRIPTION>
<P>Converted to new review format. </P>
</DESCRIPTION>
</WHATS_NEW_ENTRY>
</HISTORY>
<SOURCES_OF_SUPPORT>
<INTERNAL_SOURCES>
<SOURCE>
<NAME>Menzies Research Institute</NAME>
<COUNTRY CODE="AU">Australia</COUNTRY>
<DESCRIPTION/>
</SOURCE>
</INTERNAL_SOURCES>
<EXTERNAL_SOURCES/>
</SOURCES_OF_SUPPORT>
<MESH_TERMS VERIFIED="NO"/>
<KEYWORDS/>
</COVER_SHEET>
<MAIN_TEXT>
<SUMMARY>
<TITLE>Calcium for improving bone mineral density in children</TITLE>
<SUMMARY_BODY>
<P>Do calcium supplements build stronger bones in children?</P>
</SUMMARY_BODY>
</SUMMARY>
<ABSTRACT>
<ABS_BACKGROUND>
<P>Clinical trials have shown that calcium supplementation in children can increase bone mineral density (BMD) although this effect may not be maintained. There has been no quantitative systematic review of this intervention.</P>
</ABS_BACKGROUND>
<ABS_OBJECTIVES>
<P>·To determine the effectiveness of calcium supplementation for improving BMD in children. <BR/>·To determine if any effect varies by sex, pubertal stage, ethnicity or level of physical activity, and if any effect persists after supplementation is ceased.</P>
</ABS_OBJECTIVES>
<ABS_SEARCH_STRATEGY>
<P>We searched CENTRAL, (Cochrane Central Register of Controlled Trials) (Issue 3, 2005), MEDLINE (1966 to 1 April 2005), EMBASE (1980 to 1 April 2005), CINAHL (1982 to 1 April 2005), AMED (1985 to 1 April 2005), MANTIS (1880 to 1 April 2005) ISI Web of Science (1945 to 1 April 2005), Food Science and Technology Abstracts (1969 to 1 April 2005) and Human Nutrition (1982 to 1 April 2005). Conference abstract books (Osteoporosis International, Journal of Bone and Mineral Research) were hand-searched. </P>
</ABS_SEARCH_STRATEGY>
<ABS_SELECTION_CRITERIA>
<P>Randomised controlled trials of calcium supplementation (including by food sources) compared with placebo, with a treatment period of at least 3 months in children without co-existent medical conditions affecting bone metabolism. Outcomes had to include areal or volumetric BMD, bone mineral content (BMC), or in the case of studies using quantitative ultrasound, broadband ultrasound attenuation and ultrasonic speed of sound, measured after at least 6 months of follow-up.</P>
</ABS_SELECTION_CRITERIA>
<ABS_DATA_COLLECTION>
<P>Two authors independently assessed trial quality and extracted data including adverse events. We contacted study authors for additional information.</P>
</ABS_DATA_COLLECTION>
<ABS_RESULTS>
<P>The 19 trials included 2859 participants, of which 1367 were randomised to supplementation and 1426 to placebo. There was no heterogeneity in the results of the main effects analyses to suggest that the studies were not comparable. There was no effect of calcium supplementation on femoral neck or lumbar spine BMD. There was a small effect on total body BMC (standardised mean difference (SMD) +0.14, 95% CI+0.01, +0.27) and upper limb BMD (SMD +0.14, 95%CI +0.04, +0.24). Only the effect in the upper limb persisted after supplementation ceased (SMD+0.14, 95%CI+0.01, +0.28). This effect is approximately equivalent to a 1.7% greater increase in supplemented groups, which at best would reduce absolute fracture risk in children by 0.1-0.2%per annum. There was no evidence of effect modification by baseline calcium intake, sex, ethnicity, physical activity or pubertal stage. Adverse events were reported infrequently and were minor. </P>
</ABS_RESULTS>
<ABS_CONCLUSIONS>
<P>While there is a small effect of calcium supplementation in the upper limb, the increase in BMD which results is unlikely to result in a clinically significant decrease in fracture risk. The results do not support the use of calcium supplementation in healthy children as a public health intervention. These results cannot be extrapolated to children with medical conditions affecting bone metabolism. </P>
</ABS_CONCLUSIONS>
</ABSTRACT>
<BODY>
<BACKGROUND>
<P>Osteoporosis is a systemic skeletal disorder characterized by low bone mass and microarchitectural deterioration of bone tissue, with a consequent increase in bone fragility and susceptibility to fracture (<LINK REF="REF-_x0031_993" TYPE="REFERENCE">1993</LINK>). It is a major and growing public health problem, particularly in women (<LINK REF="REF-Jones-1994" TYPE="REFERENCE">Jones 1994</LINK>; <LINK REF="REF-Cooley-2001" TYPE="REFERENCE">Cooley 2001</LINK>; <LINK REF="REF-Woolf-2003" TYPE="REFERENCE">Woolf 2003</LINK>). An estimated 10 million people already have osteoporosis and 18 million more have low bone mass (<LINK REF="REF-NIH-2000" TYPE="REFERENCE">NIH 2000</LINK>) in the United States alone. While the impact of osteoporosis is currently greatest in western population, its impact worldwide is expected to increase (<LINK REF="REF-Woolf-2003" TYPE="REFERENCE">Woolf 2003</LINK>). Low bone mineral density (BMD) is a major risk factor for osteoporotic fracture (<LINK REF="REF-Marshall-1996" TYPE="REFERENCE">Marshall 1996</LINK>). It is well accepted that childhood factors are likely to have an impact of future risk of osteoporosis (<LINK REF="REF-NIH-2000" TYPE="REFERENCE">NIH 2000</LINK>). Peak bone mass is the maximum bone mass attained by an individual and is reached in early adult life. At least 90% of peak bone mass is obtained by age 18 years (<LINK REF="REF-Bailey-1999" TYPE="REFERENCE">Bailey 1999</LINK>). BMD in later life is a function of peak bone mass and the rate of subsequent bone loss (<LINK REF="REF-Hansen-1991" TYPE="REFERENCE">Hansen 1991</LINK>). It has also been shown that peak bone mass is as important as rate of bone loss as a risk factor for fracture in later life (<LINK REF="REF-Riis-1996" TYPE="REFERENCE">Riis 1996</LINK>). Peak bone mass is influenced by genetic factors, but also modifiable lifestyle factors such as adequate nutrition, body weight and physical activity (<LINK REF="REF-Javaid-2002" TYPE="REFERENCE">Javaid 2002</LINK>). Maximizing peak bone mass is therefore a potential way to minimise the impact of age-related bone loss. In addition, there is evidence that low BMD is a risk factor for fracture in childhood (<LINK REF="REF-Ma-2003" TYPE="REFERENCE">Ma 2003</LINK>; <LINK REF="REF-Goulding-1998" TYPE="REFERENCE">Goulding 1998</LINK>; <LINK REF="REF-Goulding-2001" TYPE="REFERENCE">Goulding 2001</LINK>), suggesting that optimising age-appropriate bone mass may also have a more immediate effect on childhood fracture rates. </P>
<P>Strategies to maximise peak bone mass in girls and boys have been identified as a priority area for research (<LINK REF="REF-NIH-2000" TYPE="REFERENCE">NIH 2000</LINK>). Bone acts as a reservoir for calcium and other ions and is the major store of calcium within the body (<LINK REF="REF-Favus-2003" TYPE="REFERENCE">Favus 2003</LINK>). Calcium deposition in bone leads to increased bone mineral density and bone mineral content. Clinical trials have shown that BMD in children can be increased in the short-term by physical activity interventions ( <LINK REF="REF-Bradney-1998" TYPE="REFERENCE">Bradney 1998</LINK>; <LINK REF="REF-Fuchs-2001" TYPE="REFERENCE">Fuchs 2001</LINK>; <LINK REF="REF-Heinonen-2000" TYPE="REFERENCE">Heinonen 2000</LINK>; <LINK REF="REF-Morris-1997" TYPE="REFERENCE">Morris 1997</LINK>; <LINK REF="REF-MacKelvie-2003" TYPE="REFERENCE">MacKelvie 2003</LINK>; <LINK REF="REF-Sundberg-2001" TYPE="REFERENCE">Sundberg 2001</LINK>) and calcium supplementation (<LINK REF="STD-Bonjour-1995" TYPE="STUDY">Bonjour 1995</LINK>; <LINK REF="STD-Johnston-1992" TYPE="STUDY">Johnston 1992</LINK>; <LINK REF="STD-Lee-1994" TYPE="STUDY">Lee 1994</LINK>; <LINK REF="STD-Lee-1995" TYPE="STUDY">Lee 1995</LINK>; <LINK REF="STD-Lloyd-1993" TYPE="STUDY">Lloyd 1993</LINK>) although this effect may not be maintained (<LINK REF="STD-Lee-1994" TYPE="STUDY">Lee 1994</LINK>); and by increased dairy intake (<LINK REF="STD-Chan-1995" TYPE="STUDY">Chan 1995</LINK>). However, there has been no systematic review of effectiveness of calcium supplementation, the magnitude of its effect, the duration of any effect after supplementation ends and the impact of sex or pubertal stage on its effect. </P>
</BACKGROUND>
<OBJECTIVES>
<P>·To determine the effectiveness of calcium supplementation for improving BMD in children. <BR/>·To determine if any effect varies by sex, pubertal stage, ethnicity or level of physical activity.<BR/>·To determine if any effect persists after calcium supplementation is ceased.</P>
</OBJECTIVES>
<METHODS>
<SELECTION_CRITERIA>
<CRIT_STUDIES>
<P>All randomised controlled trials of calcium supplementation compared with placebo, with a treatment period of at least 3 months were included. The studies had to have areal or volumetric BMD, or bone mineral content (BMC) as an outcome, or in the case of studies using quantitative ultrasound, broadband ultrasound attenuation (BUA) and ultrasonic speed of sound (SOS).</P>
</CRIT_STUDIES>
<CRIT_PARTICIPANTS>
<P>Trials in children (age&lt;18 years) without co-existent medical conditions or treatments affecting bone metabolism were included.</P>
</CRIT_PARTICIPANTS>
<CRIT_INTERVENTIONS>
<P>Trials of calcium supplementation including supplementation by food sources. Trials of less than 3 months were excluded.</P>
</CRIT_INTERVENTIONS>
<CRIT_OUTCOMES>
<P>Fractures in later life would be the ideal outcome measure in intervention studies for osteoporosis prevention, however for intervention studies in children this would require following large numbers of subjects for decades and these studies have not been performed. Therefore, in this review BMD was used as a surrogate outcome, as is commonly seen in intervention studies in children (<LINK REF="REF-Gilsanz-1998" TYPE="REFERENCE">Gilsanz 1998</LINK>).</P>
<P>Data was extracted on areal BMD and BMC, measured a minimum of 6 months after the treatment was commenced. In the original review protocol, we aimed to use percentage change from baseline, but as this was available for only a small number of studies, this was not used. The available data also did not allow for calculation of volumetric BMD as was stipulated in the original review protocol. In the case of studies using quantitative ultrasound, broadband ultrasound attenuation (BUA) and ultrasonic speed of sound (SOS) were to be used, but in the absence of studies using these measures, these outcomes were not used. The outcome measures were converted to standardized mean differences (SMD) using Review Manager (version 4.2.7). We had sufficient extractable bone measurement data for meta-analysis of the following outcomes: total body BMC, femoral neck BMD; lumbar spine BMD; distal radius BMD and upper limb BMD. Upper limb BMD included those studies included in the outcome for distal radius and additional studies with upper limb outcomes at other sites. Where multiple upper limb sites were measured, we chose the distal radius or the site closest to that point as the outcome. Methods of measurement included dual energy x-ray absorptiometry (DXA), single photon absorptiometry (SPA) and dual photon absorptiometry (DPA). </P>
<P>Where possible we also determined sex, age, pubertal stage, physical activity, baseline height, baseline weight, dietary calcium intake, type of calcium supplement used, ethnicity and follow-up after cessation of treatment to assess possible effect modification by these variables. We also collected data on adverse effects, where available.<BR/> </P>
</CRIT_OUTCOMES>
</SELECTION_CRITERIA>
<SEARCH_METHODS>
<P>The search strategies included a search CENTRAL, (Cochrane Central Register of Controlled Trials) (Issue 3, 2005), MEDLINE (1966 to 1 April 2005), EMBASE (1980 to 1 April 2005), CINAHL (1982 to 1 April 2005), AMED (1985 to 1 April 2005), MANTIS (1880 to 1 April 2005) ISI Web of Science (1945 to 1 April 2005), Food Science and Technology Abstracts (1969 to 1 April 2005) and Human Nutrition (1982 to 1 April 2005). Conference abstract books (Osteoporosis International, Journal of Bone and Mineral Research) were also hand searched. <BR/> <BR/>For MEDLINE (OVID) the strategy used was:</P>
<P>1exp CALCIUM/<BR/>2exp Calcium, Dietary/<BR/>3calcium.tw.<BR/>4exp dairy products/<BR/>5dairy.tw.<BR/>6milk.tw.<BR/>7exp dietary supplements/<BR/>8or/1-7<BR/>9exp OSTEOPOROSIS/<BR/>10osteoporo$.tw.<BR/>11exp Bone Density/<BR/>12(bone adj2 loss).tw.<BR/>13(bone adj2 densit$).tw.<BR/>14bone mass.tw.<BR/>15bmd.tw.<BR/>16or/9-15<BR/>178 and 16<BR/>18limit 17 to all child &lt;0 to 18 years&gt;</P>
<P>The Dickersin filter (<LINK REF="REF-Robinson-2002" TYPE="REFERENCE">Robinson 2002</LINK>) for randomised controlled trials was applied to MEDLINE, and adapted for other databases where relevant. In the absence of evidence of publication bias we did not systematically contact content experts regarding unpublished studies. Informal contacts did not yield any unpublished studies. </P>
</SEARCH_METHODS>
<DATA_COLLECTION>
<P>Two reviewers (TW, KS) independently reviewed relevant articles identified by the search strategy, with initial screening of abstracts according to the inclusion criteria and with full text articles being reviewed if there was insufficient information in the abstract to assess eligibility. All data was extracted by two reviewers (TW, KS). Details regarding the study population, treatment periods, baseline demographic data and baseline and end of study outcomes were extracted independently. Differences in data extraction were resolved by referring back to the original article and establishing consensus. A third reviewer (GJ) was available to assist in reaching consensus if required, but was not needed. The same two reviewers (TW,KS) performed a quality assessment independently for each trial assessing randomisation, allocation concealment, blinding of those providing treatment and of treatment subjects, and description of withdrawals and dropouts (<LINK REF="REF-Jadad-1996" TYPE="REFERENCE">Jadad 1996</LINK>; <LINK REF="REF-Juni-2001" TYPE="REFERENCE">Juni 2001</LINK>). </P>
<P>For bone density, we calculated the SMD of the endpoints at end of trial between treatment and control groups for the various outcomes. Originally, we had planned to use percentage change from baseline as the outcome measure, but this was not possible with the data available to us, and end point data was therefore used instead. We assessed heterogeneity of the data using a Chi-square test on N-1 degrees of freedom. Meta-analysis was conducted according to a fixed-effect model for the main effect outcomes, as there was no heterogeneity for these outcomes. Where heterogeneity existed in subgroup analyses we used a random-effects model. In the absence of heterogeneity of the main effect outcomes and because of limited numbers of studies for each outcome, we did not perform meta-regression and we limited our subgroup analyses to key potential effect modifiers, namely: sex; ethnicity; baseline calcium intake; physical activity; type of supplementation (milk extract compared to other calcium supplement forms (calcium carbonate/calcium citrate malate/calcium phosphate)) and duration of supplementation. The baseline calcium subgroups were determined by whether the baseline dietary calcium intake was less than or greater than or equal to the median value of the individual study means, which was 794 mg/day. Due to study numbers, we were unable to perform analyses using other definitions of low calcium intake except in the case of upper limb BMD, where we also analysed in subgroups of baseline calcium intake of below compared to above the 25th percentile (i.e . 582 mg/day). Physical activity subgroups were chosen according to the data available in individual studies - where the studies had physical activity as a co-intervention or subgrouping, those in the low physical activity arm were included in the low physical activity subgroup for the review and those in the high physical activity arm in the high physical activity subgroup for the review. For study duration, we initially chose a cut-off of 24 months duration so as to sure of exceeding any period of rapid change from the bone remodeling transient. Because this left few studies in the longer duration subgroup, we repeated the analysis using an 18-month cut-off, which is likely to still have exceeded the time needed for the effects on bone of remodeling changes to appear and a new steady state to be reached. We also performed a subgroup analysis whether the calcium intake in the intervention group in the trial exceeded the probable threshold (approximately 1400 mg/day) below which skeletal accumulation varies with intake and above which skeletal accumulation appears constant regardless of intake (<LINK REF="REF-Jackman-1997" TYPE="REFERENCE">Jackman 1997</LINK>; <LINK REF="REF-Matkovic-1992" TYPE="REFERENCE">Matkovic 1992</LINK>). This was an analysis additional to those specified in the original protocol. </P>
<P>Where necessary the authors of the primary studies were contacted to obtain additional information. We aimed to use intention-to-treat data from the individual clinical trials wherever possible. If this data was not available, we used data from available treatment analysis. If no other data were available we used data from treatment received analysis. For the single study (<LINK REF="STD-Wang-1996" TYPE="STUDY">Wang 1996</LINK>) in which upper limb outcomes were presented as percent change from baseline, and no endpoint data could be obtained from the authors, we imputed endpoint data using the formula endpoint BMD= (100% +%change) X baseline BMD and assumed the endpoint standard deviation (SD) was the same as that seen at baseline (as was observed in other studies for upper limb outcomes). Where studies reported the outcome as absolute change from baseline and endpoint data were not available (<LINK REF="STD-Lloyd-1993" TYPE="STUDY">Lloyd 1993</LINK>; <LINK REF="STD-Bonjour-1995" TYPE="STUDY">Bonjour 1995</LINK>; <LINK REF="STD-Chevalley-2005" TYPE="STUDY">Chevalley 2005</LINK>; <LINK REF="STD-Iuliano_x002d_Burns-2003" TYPE="STUDY">Iuliano-Burns 2003</LINK>; <LINK REF="STD-Specker-2003" TYPE="STUDY">Specker 2003</LINK>) we imputed the endpoint using (baseline plus change) for the mean in both treatment and control arms, and using the standard deviation of the baseline data for the endpoint SD. </P>
<P>Funnel plots were performed for assessment of publication bias. </P>
<P>Our method of imputing the standard deviation for studies which gave change rather than endpoint data was likely to result in those studies being given more rather than less weight. We therefore performed a sensitivity analysis for the main effects omitting studies for which data was imputed (<LINK REF="STD-Wang-1996" TYPE="STUDY">Wang 1996</LINK>; <LINK REF="STD-Lloyd-1993" TYPE="STUDY">Lloyd 1993</LINK>; <LINK REF="STD-Bonjour-1995" TYPE="STUDY">Bonjour 1995</LINK>; <LINK REF="STD-Chevalley-2005" TYPE="STUDY">Chevalley 2005</LINK>; <LINK REF="STD-Iuliano_x002d_Burns-2003" TYPE="STUDY">Iuliano-Burns 2003</LINK>; <LINK REF="STD-Specker-2003" TYPE="STUDY">Specker 2003</LINK>) . We also performed a sensitivity analysis omitting the study (<LINK REF="STD-Bonjour-1995" TYPE="STUDY">Bonjour 1995</LINK>) that used treatment received rather than intention to treat or available data analysis. In the absence of heterogeneity of the main effect outcomes, sensitivity analyses were not performed to assess the impact of study quality on results.</P>
<P>Grading of evidence <BR/>We used the grading system described in the 2004 book Evidence-based Rheumatology (<LINK REF="REF-Tugwell-2004" TYPE="REFERENCE">Tugwell 2004</LINK>) and recommended by the Musculoskeletal Group:<BR/>Platinum: A published systematic review that has at least two individual controlled trials each satisfying the following : <BR/>·Sample sizes of at least 50 per group - if these do not find a statistically significant difference, they are adequately powered for a 20% relative difference in the relevant outcome. <BR/>·Blinding of patients and assessors for outcomes. <BR/>·Handling of withdrawals &gt;80% follow up (imputations based on methods such as Last Observation Carried Forward (LOCF) are acceptable). <BR/>·Concealment of treatment allocation. </P>
<P>Gold: At least one randomised clinical trial meeting all of the following criteria for the major outcome(s) as reported: <BR/>·Sample sizes of at least 50 per group - if these do not find a statistically significant difference, they are adequately powered for a 20% relative difference in the relevant outcome. <BR/>·Blinding of patients and assessors for outcomes. <BR/>·Handling of withdrawals &gt; 80% follow up (imputations based on methods such as LOCF are acceptable). <BR/>·Concealment of treatment allocation. </P>
<P>Silver: A randomised trial that does not meet the above criteria. Silver ranking would also include evidence from at least one study of non-randomised cohorts that did and did not receive the therapy, or evidence from at least one high quality case-control study. A randomised trial with a 'head-to-head' comparison of agents would be considered silver level ranking unless a reference were provided to a comparison of one of the agents to placebo showing at least a 20% relative difference. </P>
<P>Bronze: The bronze ranking is given to evidence if at least one high quality case series without controls (including simple before/after studies in which patients act as their own control) or if the conclusion is derived from expert opinion based on clinical experience without reference to any of the foregoing (for example, argument from physiology, bench research or first principles). </P>
<P>Clinical relevance </P>
<P>The SMD effect size was used to estimate an absolute benefit in mg/cm<SUP>2</SUP> by estimating the pooled SD from the means of the SD of the outcomes in treatment and control groups for each study, and multiplying the SMD by this (<LINK REF="REF-Alderson-2002" TYPE="REFERENCE">Alderson 2002</LINK>). Relative difference in the change from baseline was estimated as the absolute benefit divided by the mean of all the baseline means of the control groups, expressed as a percentage. The result of this analysis is reported in the text of the review results and discussion.</P>
<P>The review will be updated in future according to Cochrane Collaboration recommendations .</P>
</DATA_COLLECTION>
</METHODS>
<RESULTS>
<STUDY_DESCRIPTION>
<P>We identified 233 references to potential studies. Of these, 155 were excluded as they were not randomised controlled trials. Of the remaining 78 references, 9 were to trials without calcium supplementation as an intervention, 7 were to trials in participants with conditions predisposing to osteoporosis and 3 were to studies in adults. Of the remaining 59 references to RCTs of calcium supplementation in children, the following references were excluded for the following reasons:<BR/>·16 references were to studies with either no placebo (<LINK REF="STD-Barker-1998" TYPE="STUDY">Barker 1998</LINK>; <LINK REF="STD-Cadogan-1997" TYPE="STUDY">Cadogan 1997</LINK>; <LINK REF="STD-Chan-1995" TYPE="STUDY">Chan 1995</LINK>; <LINK REF="STD-Du-2004" TYPE="STUDY">Du 2004</LINK>; <LINK REF="STD-Fischer-1999a" TYPE="STUDY">Fischer 1999a</LINK>; <LINK REF="STD-Lau-1992" TYPE="STUDY">Lau 1992</LINK>; <LINK REF="STD-Lau-2004" TYPE="STUDY">Lau 2004</LINK>; <LINK REF="STD-Li-2002" TYPE="STUDY">Li 2002</LINK>; <LINK REF="STD-Magee-1996" TYPE="STUDY">Magee 1996</LINK>; <LINK REF="STD-Merrilees-2000" TYPE="STUDY">Merrilees 2000</LINK>; <LINK REF="STD-Renner-1998" TYPE="STUDY">Renner 1998</LINK>; <LINK REF="STD-Specker-1997" TYPE="STUDY">Specker 1997</LINK>; <LINK REF="STD-Zhang-2003" TYPE="STUDY">Zhang 2003</LINK>; <LINK REF="STD-Zhu-2003" TYPE="STUDY">Zhu 2003</LINK>; <LINK REF="STD-Zhu-2004" TYPE="STUDY">Zhu 2004</LINK>) or which used an active placebo i.e. a placebo which itself could affect bone (<LINK REF="STD-Gibbons-2004" TYPE="STUDY">Gibbons 2004</LINK>) <BR/>·3 were duplicate publications (<LINK REF="STD-Fischer-1999b" TYPE="STUDY">Fischer 1999b</LINK>; <LINK REF="STD-Nowson-1995" TYPE="STUDY">Nowson 1995</LINK>; <LINK REF="STD-Specker-2002" TYPE="STUDY">Specker 2002</LINK>)<BR/>·2 did not measure BMD or BMC or ultrasound measures of bone as outcomes (<LINK REF="STD-Lappe-2004" TYPE="STUDY">Lappe 2004</LINK>; <LINK REF="STD-Ohgitani-1997" TYPE="STUDY">Ohgitani 1997</LINK>)<BR/>·1 included vitamin D with calcium as the intervention (<LINK REF="STD-Moyer_x002d_Mileur-2003" TYPE="STUDY">Moyer-Mileur 2003</LINK>)<BR/>·1 had inadequate randomisation (<LINK REF="STD-Matkovic-1990" TYPE="STUDY">Matkovic 1990</LINK>)<BR/>·1 had outcomes measured after&lt; 6 months follow-up (<LINK REF="STD-Volek-2003" TYPE="STUDY">Volek 2003</LINK>)</P>
<P>The remaining 35 references to 19 studies were included in the systematic review.</P>
<P>Additional data was requested from authors of 8 eligible studies, of whom 5 supplied the additional information sought (<LINK REF="STD-Cameron-2004" TYPE="STUDY">Cameron 2004</LINK>; <LINK REF="STD-Johnston-1992" TYPE="STUDY">Johnston 1992</LINK>; <LINK REF="STD-Prentice-2005" TYPE="STUDY">Prentice 2005</LINK>; <LINK REF="STD-Stear-2003" TYPE="STUDY">Stear 2003</LINK>; <LINK REF="STD-Courteix-2005" TYPE="STUDY">Courteix 2005</LINK>) . In only one of the cases where additional information was not obtained, did this result in no usable data being available for the meta-analysis (<LINK REF="STD-Rodda-2004" TYPE="STUDY">Rodda 2004</LINK>). All other eligible studies provided useful data for pooling.</P>
<P>The 19 RCTs included a total of 2859 participants, of whom 1367 were randomised to receive calcium supplementation, 1426 were randomised to placebo, and 66 withdrew from the study and the intervention group to which they were randomised was not stated. The Characteristics of Included Studies table summarises the characteristics of these studies. Studies included children as young as 3 years old, up to 18 years of age. Calcium supplementation was by calcium citrate malate, calcium carbonate, calcium phosphate, calcium lactate gluconate, calcium phosphate milk extract or milk minerals with calcium dose ranging from 300 to 1200 mg per day. No studies used ultrasound measures of bone outcomes. One study used intention-to-treat analysis (<LINK REF="STD-Dibba-2000" TYPE="STUDY">Dibba 2000</LINK>); in one study the type of analysis was not stated (<LINK REF="STD-Rodda-2004" TYPE="STUDY">Rodda 2004</LINK>); in one study (<LINK REF="STD-Bonjour-1995" TYPE="STUDY">Bonjour 1995</LINK>) only data from treatment received analysis was available for the femoral neck, lumbar spine and upper limb BMD at end of the trial. The remaining studies used available data analysis. Five studies had loss to follow-up of less than 5% (<LINK REF="STD-Dibba-2000" TYPE="STUDY">Dibba 2000</LINK>; <LINK REF="STD-Lee-1994" TYPE="STUDY">Lee 1994</LINK>; <LINK REF="STD-Molgaard-2004" TYPE="STUDY">Molgaard 2004</LINK>; <LINK REF="STD-Prentice-2005" TYPE="STUDY">Prentice 2005</LINK>; <LINK REF="STD-Wang-1996" TYPE="STUDY">Wang 1996</LINK>), 5 had a loss to follow-up of between 5 and 20% (<LINK REF="STD-Bonjour-1995" TYPE="STUDY">Bonjour 1995</LINK>; <LINK REF="STD-Iuliano_x002d_Burns-2003" TYPE="STUDY">Iuliano-Burns 2003</LINK>; <LINK REF="STD-Lloyd-1993" TYPE="STUDY">Lloyd 1993</LINK>; <LINK REF="STD-Rozen-2003" TYPE="STUDY">Rozen 2003</LINK>; <LINK REF="STD-Stear-2003" TYPE="STUDY">Stear 2003</LINK>) and 8 had loss to follow-up of more than 20% (<LINK REF="STD-Cameron-2004" TYPE="STUDY">Cameron 2004</LINK>; <LINK REF="STD-Chevalley-2005" TYPE="STUDY">Chevalley 2005</LINK>; <LINK REF="STD-Courteix-2005" TYPE="STUDY">Courteix 2005</LINK>; <LINK REF="STD-Johnston-1992" TYPE="STUDY">Johnston 1992</LINK>; <LINK REF="STD-Lee-1995" TYPE="STUDY">Lee 1995</LINK>; <LINK REF="STD-Matkovic-2004" TYPE="STUDY">Matkovic 2004</LINK>; <LINK REF="STD-Nowson-1997" TYPE="STUDY">Nowson 1997</LINK>; <LINK REF="STD-Specker-2003" TYPE="STUDY">Specker 2003</LINK>) of their trial participants. One study did not report withdrawals and drop outs (<LINK REF="STD-Rodda-2004" TYPE="STUDY">Rodda 2004</LINK>). Three studies had physical activity as a co-intervention (<LINK REF="STD-Iuliano_x002d_Burns-2003" TYPE="STUDY">Iuliano-Burns 2003</LINK>; <LINK REF="STD-Prentice-2005" TYPE="STUDY">Prentice 2005</LINK>; <LINK REF="STD-Stear-2003" TYPE="STUDY">Stear 2003</LINK>) and one had physical activity subgroups of exercise (7.2 hours exercise per week) and sedentary (1.2 hours exercise per week) (<LINK REF="STD-Courteix-2005" TYPE="STUDY">Courteix 2005</LINK>).</P>
</STUDY_DESCRIPTION>
<STUDY_QUALITY>
<P>Two reviewers (KS, TW) independently rated the methodological quality of each eligible study. Any disagreement was resolved by consensus, with the third reviewer (GJ) not being required to contribute for these to be resolved. Adequate description of randomisation was given for four studies (<LINK REF="STD-Courteix-2005" TYPE="STUDY">Courteix 2005</LINK>; <LINK REF="STD-Dibba-2000" TYPE="STUDY">Dibba 2000</LINK>; <LINK REF="STD-Iuliano_x002d_Burns-2003" TYPE="STUDY">Iuliano-Burns 2003</LINK>; <LINK REF="STD-Prentice-2005" TYPE="STUDY">Prentice 2005</LINK>), the remaining studies were stated to be randomised but randomisation procedures were not described. Four studies (<LINK REF="STD-Bonjour-1995" TYPE="STUDY">Bonjour 1995</LINK>; <LINK REF="STD-Courteix-2005" TYPE="STUDY">Courteix 2005</LINK>; <LINK REF="STD-Dibba-2000" TYPE="STUDY">Dibba 2000</LINK>; <LINK REF="STD-Stear-2003" TYPE="STUDY">Stear 2003</LINK>) described adequate allocation concealment, the description in the remainder of the studies was unclear. Adequate description of blinding of subjects was given in all studies except two (<LINK REF="STD-Chevalley-2005" TYPE="STUDY">Chevalley 2005</LINK>; <LINK REF="STD-Specker-2003" TYPE="STUDY">Specker 2003</LINK>) in which the description was unclear, though all were controlled with adequate placebo. Thirteen studies gave an adequate description of withdrawals and drop outs (<LINK REF="STD-Bonjour-1995" TYPE="STUDY">Bonjour 1995</LINK>; <LINK REF="STD-Cameron-2004" TYPE="STUDY">Cameron 2004</LINK>; <LINK REF="STD-Chevalley-2005" TYPE="STUDY">Chevalley 2005</LINK>; <LINK REF="STD-Courteix-2005" TYPE="STUDY">Courteix 2005</LINK>; <LINK REF="STD-Dibba-2000" TYPE="STUDY">Dibba 2000</LINK>; <LINK REF="STD-Johnston-1992" TYPE="STUDY">Johnston 1992</LINK>; <LINK REF="STD-Lee-1994" TYPE="STUDY">Lee 1994</LINK>; <LINK REF="STD-Lee-1995" TYPE="STUDY">Lee 1995</LINK>; <LINK REF="STD-Lloyd-1993" TYPE="STUDY">Lloyd 1993</LINK>; <LINK REF="STD-Molgaard-2004" TYPE="STUDY">Molgaard 2004</LINK>; <LINK REF="STD-Nowson-1997" TYPE="STUDY">Nowson 1997</LINK>; <LINK REF="STD-Prentice-2005" TYPE="STUDY">Prentice 2005</LINK>; <LINK REF="STD-Specker-2003" TYPE="STUDY">Specker 2003</LINK>) and six did not (<LINK REF="STD-Iuliano_x002d_Burns-2003" TYPE="STUDY">Iuliano-Burns 2003</LINK>; <LINK REF="STD-Matkovic-2004" TYPE="STUDY">Matkovic 2004</LINK>; <LINK REF="STD-Rodda-2004" TYPE="STUDY">Rodda 2004</LINK>; <LINK REF="STD-Rozen-2003" TYPE="STUDY">Rozen 2003</LINK>; <LINK REF="STD-Stear-2003" TYPE="STUDY">Stear 2003</LINK>; <LINK REF="STD-Wang-1996" TYPE="STUDY">Wang 1996</LINK>). Overall, the risk of bias was rated as low in two studies (<LINK REF="STD-Courteix-2005" TYPE="STUDY">Courteix 2005</LINK>; <LINK REF="STD-Dibba-2000" TYPE="STUDY">Dibba 2000</LINK>), moderate in twelve studies ( <LINK REF="STD-Bonjour-1995" TYPE="STUDY">Bonjour 1995</LINK>; <LINK REF="STD-Cameron-2004" TYPE="STUDY">Cameron 2004</LINK>; <LINK REF="STD-Chevalley-2005" TYPE="STUDY">Chevalley 2005</LINK>; <LINK REF="STD-Johnston-1992" TYPE="STUDY">Johnston 1992</LINK>; <LINK REF="STD-Lee-1994" TYPE="STUDY">Lee 1994</LINK>; <LINK REF="STD-Lee-1995" TYPE="STUDY">Lee 1995</LINK>; <LINK REF="STD-Lloyd-1993" TYPE="STUDY">Lloyd 1993</LINK>; <LINK REF="STD-Molgaard-2004" TYPE="STUDY">Molgaard 2004</LINK>; <LINK REF="STD-Nowson-1997" TYPE="STUDY">Nowson 1997</LINK>; <LINK REF="STD-Prentice-2005" TYPE="STUDY">Prentice 2005</LINK>; <LINK REF="STD-Rodda-2004" TYPE="STUDY">Rodda 2004</LINK>; <LINK REF="STD-Specker-2003" TYPE="STUDY">Specker 2003</LINK>), and high in five studies (<LINK REF="STD-Iuliano_x002d_Burns-2003" TYPE="STUDY">Iuliano-Burns 2003</LINK>; <LINK REF="STD-Matkovic-2004" TYPE="STUDY">Matkovic 2004</LINK>; <LINK REF="STD-Rozen-2003" TYPE="STUDY">Rozen 2003</LINK>; <LINK REF="STD-Stear-2003" TYPE="STUDY">Stear 2003</LINK>; <LINK REF="STD-Wang-1996" TYPE="STUDY">Wang 1996</LINK>). </P>
</STUDY_QUALITY>
<INTERVENTION_EFFECTS>
<P>Comparison Tables 1 to 9 give the treatment effects, as standardised mean differences (SMD) at each site at the end of the period of calcium supplementation and the results at the longest period of follow-up available after calcium supplementation was ceased for each trial. There was no effect of calcium supplementation on BMD at the femoral neck (+0.07, 95%CI -0.05, +0.19) or lumbar spine BMD (+0.08, 95% CI -0.04, +0.20). There was a small effect on total body BMC (+0.14, 95% CI +0.01, +0.27) and upper limb BMD (+0.14, 95%CI +0.04, +0.24) which persisted after supplementation ceased only in the upper limb (+0.14, 95%CI +0.01, +0.28). As the effect at the distal radius alone was similar to that in the upper limb as defined in the methods, we discuss only the upper limb results in further detail. The effect at the upper limb is approximately equivalent to a treatment effect of 6.38 mg/cm<SUP>2</SUP> or an approximately 1.7% greater increase in supplemented groups over the course of supplementation; and to a 6.30 mg/cm<SUP>2</SUP> or 1.7% greater increase after follow-up after supplementation had ceased. A single study (<LINK REF="STD-Rozen-2003" TYPE="STUDY">Rozen 2003</LINK>) reported on total body BMC after cessation of supplementation, and this showed no persistent effect (SMD 0.0, 95%CI -0.40, +0.40). There was no significant heterogeneity for the results at any site (p= 0.29 to p&gt;0.99). </P>
<P>Subgroup Analyses</P>
<P>Subgroup analyses by baseline calcium intake, sex, ethnicity, physical activity, pubertal stage, type of supplementation (milk extract or other), duration of supplementation and by whether the calcium threshold was exceeded all did not demonstrate significant effect modification at any site (Comparison Tables 10 to 79). Point estimates of treatment effects during supplementation were greater at all sites in females than males (Tables 19 to 26), though these differences were not significant. At the upper limb, treatment effects during supplementation were similar in magnitude and not significant in both Caucasian and Chinese population studies but a relatively strong effect was seen in the single study in an African population (+0.44, 95%CI +0.12, +0.75). A single study described a gain in lumbar spine BMD of 0.045 g/cm<SUP>2</SUP> in Chinese but not Anglo-Celt girls (<LINK REF="STD-Rodda-2004" TYPE="STUDY">Rodda 2004</LINK>) but the study provided insufficient data to be included in the meta-analysis. Subgroup analysis by physical activity level showed no evidence of effect modification, though there were only two studies with extractable data for the femoral neck, lumbar spine and upper limb outcomes. One study not included in the meta-analysis demonstrated interaction between calcium supplementation and physical activity using femoral BMC as an outcome but not for tibia-fibula BMC (<LINK REF="STD-Iuliano_x002d_Burns-2003" TYPE="STUDY">Iuliano-Burns 2003</LINK>). </P>
<P>Numbers of studies available for subgroup analyses were limited for some outcomes, for example subgroup analysis by baseline calcium intake using a definition of low calcium intake as the mean baseline calcium intake of the participants in the study being in the lowest quartile. Only a single study (<LINK REF="STD-Rozen-2003" TYPE="STUDY">Rozen 2003</LINK>) measured TB BMC after supplementation ceased so subgroup analyses for this outcome were not possible. Only one study reported TB BMC for males (<LINK REF="STD-Prentice-2005" TYPE="STUDY">Prentice 2005</LINK>) and only one reported femoral neck and lumbar spine BMD after supplementation ceased for males (<LINK REF="STD-Chevalley-2005" TYPE="STUDY">Chevalley 2005</LINK>). There was only a single study with any results described in purely peri-pubertal children (<LINK REF="STD-Matkovic-2004" TYPE="STUDY">Matkovic 2004</LINK>) and insufficient data for any subgroup analysis by pubertal stage for effects after cessation of supplementation. No studies in Chinese populations had total body BMC data, and only a single study using milk extract as a supplement had total body BMC data. </P>
<P>Funnel plots for each outcome did not suggest the presence of publication bias (See Additional Figures:<LINK REF="FIG-01" TYPE="FIGURE">Figure 1</LINK>, <LINK REF="FIG-02" TYPE="FIGURE">Figure 2</LINK>, <LINK REF="FIG-03" TYPE="FIGURE">Figure 3</LINK>, <LINK REF="FIG-04" TYPE="FIGURE">Figure 4</LINK>, <LINK REF="FIG-05" TYPE="FIGURE">Figure 5</LINK>, <LINK REF="FIG-06" TYPE="FIGURE">Figure 6</LINK>, <LINK REF="FIG-07" TYPE="FIGURE">Figure 7</LINK>, <LINK REF="FIG-08" TYPE="FIGURE">Figure 8</LINK>, <LINK REF="FIG-09" TYPE="FIGURE">Figure 9</LINK>).</P>
<P>Sensitivity analyses omitting results only given from active treatment analysis (<LINK REF="STD-Bonjour-1995" TYPE="STUDY">Bonjour 1995</LINK> at end of supplementation) did not substantially alter the results of the review. Omitting the studies with imputed values reduced the effect at the upper limb after cessation of supplementation from an SMD of +0.14 (95%CI +0.01, +0.28) to +0.10 (95% CI -0.07, +0.28) and marginally widened the confidence interval around the effect on total body BMC at the end of supplementation (+0.15, 95%CI -0.01, +0.31) without changing the size of the point estimate of the treatment effect. Sensitivity analyses did not substantially affect the review results for any other outcomes.</P>
<P>Adverse events were reported infrequently and were minor in nature, including raised urinary calcium to creatinine ratio (1 child), and gastro-intestinal side effects (4 children).</P>
</INTERVENTION_EFFECTS>
</RESULTS>
<DISCUSSION>
<P>Calcium supplementation has little effect on BMD. At the only site where an effect was demonstrated, the upper limb, the effect is small, equating to an approximately 1.7 percentage point greater increase in BMD in the supplemented compared to the control group, an effect which persists after supplementation ceases with a 1.7 percentage point greater increase. It is important to note that this effect did not remain statistically significant when the studies for which imputed outcomes were used were excluded, and it is therefore possible that the upper limb effect may be smaller than indicated in the main analysis. The small increase in BMD at the upper limb is unlikely to result in a clinically significant decrease in fracture risk. Importantly, there were no effects seen at other sites at which fracture is common, namely the femoral neck and lumbar spine. </P>
<P>Children with upper limb fractures have been reported to have reduced BMD at the femoral neck, lumbar spine and total body compared to controls with the difference being in the order of 1-5% depending on site of BMD measurement (<LINK REF="REF-Ma-2003" TYPE="REFERENCE">Ma 2003</LINK>). Other studies examining distal forearm fractures in boys and girls (<LINK REF="REF-Goulding-1998" TYPE="REFERENCE">Goulding 1998</LINK>; <LINK REF="REF-Goulding-2001" TYPE="REFERENCE">Goulding 2001</LINK>) have reported a reduction in ultradistal radius BMD of around 4% in girls and 5% in boys and in 33% radius BMD of around 3% in both sexes. Based on the decrease in odds ratio for wrist and forearm fractures observed for each standard deviation increase in lumbar spine BMD (<LINK REF="REF-Ma-2003" TYPE="REFERENCE">Ma 2003</LINK>), the treatment effect observed in this review would result in an approximately 6% decrease in the relative risk of fracture. If this were applied to the peak incidence of all fracture in childhood (about 3% per annum (p.a.) in 15-19 year old boys and 1% p.a. in 10-14 year old girls) (<LINK REF="REF-Jones-2002" TYPE="REFERENCE">Jones 2002</LINK>), the decrease in absolute risk would be at most 0.2% p.a. in boys and 0.1% p.a. in girls. Therefore, while it is possible that the small increase in BMD from calcium supplementation could have an effect on reduction of fracture risk in childhood, the public health impact of this is likely to be small. Extrapolating these results to assess the potential for reduction in fracture risk in adult life is more problematic. Though the increase in upper limb BMD did persist after cessation of supplementation, the maximum length of follow-up after supplementation was withdrawn was only 7 years (<LINK REF="STD-Bonjour-1995" TYPE="STUDY">Bonjour 1995</LINK>) and the study participants in even this study had not yet all reached adulthood. The impact of a period of supplementation in childhood on upper limb BMD and fracture risk in later life remains unknown. Even in calcium supplement trials in post-menopausal women, the effect of calcium supplementation on fracture risk is unclear. While BMD increased by around 1.6 to 2 % (<LINK REF="REF-Shea-2004" TYPE="REFERENCE">Shea 2004</LINK>), the point estimate from the meta-analysis of the five studies that included fracture risk as an outcome only suggested a reduction in vertebral fractures (relative risk (RR) 0.79, 95%CI 0.55 to 1.13), and a smaller reduction in risk of non-vertebral fractures (RR 0.86, 95% CI 0.43 to 1.72). However, these results were not significant, probably due to small event numbers. The two studies providing data on non-vertebral fracture did not examine upper limb fractures separately as an outcome, probably due to small events numbers. Thus, the public health benefits of calcium supplementation in children, either in childhood or in later life appear marginal at best.</P>
<P>The literature pertaining to calcium supplement use in children has been qualitatively reviewed previously (<LINK REF="REF-French-2000" TYPE="REFERENCE">French 2000</LINK>; <LINK REF="REF-Wosje-2000" TYPE="REFERENCE">Wosje 2000</LINK>; <LINK REF="REF-Lanou-2005" TYPE="REFERENCE">Lanou 2005</LINK>). These reviews reported that overall calcium supplementation did appear to have a favourable effect on bone outcomes. One review of six intervention studies published up until 1999 (<LINK REF="REF-French-2000" TYPE="REFERENCE">French 2000</LINK>) reported that calcium supplement use showed consistent positive effects on bone mass gains in children and adolescents, most consistently at the lumbar spine and total body sites. A second review (<LINK REF="REF-Wosje-2000" TYPE="REFERENCE">Wosje 2000</LINK>) included one additional study and by contrast concluded that increases in BMD occurred mostly at cortical sites, are greater in populations with low baseline calcium intake and do not seem to persist beyond the supplementation period. The most recent review (<LINK REF="REF-Lanou-2005" TYPE="REFERENCE">Lanou 2005</LINK>) was aimed specifically at determining whether the literature supported the suggestion that dairy products are better for promoting bone integrity that other calcium-containing food sources or supplements. As part of this review the authors described 12 randomised controlled trials with duration of calcium supplementation more than 12 months. They reported that 9 out of 10 trials of calcium supplementation by non-dairy sources showed an increase in bone outcomes and one showed no effect and that the three trials of dairy products showed slight effects. None of these latter three trials met the inclusion criteria for our review, as they were not placebo-controlled (<LINK REF="STD-Cadogan-1997" TYPE="STUDY">Cadogan 1997</LINK>; <LINK REF="STD-Chan-1995" TYPE="STUDY">Chan 1995</LINK>) or did not have adequate randomisation (<LINK REF="STD-Matkovic-1990" TYPE="STUDY">Matkovic 1990</LINK>). In our review four studies used milk extract supplementation (<LINK REF="STD-Bonjour-1995" TYPE="STUDY">Bonjour 1995</LINK>; <LINK REF="STD-Chevalley-2005" TYPE="STUDY">Chevalley 2005</LINK>; <LINK REF="STD-Iuliano_x002d_Burns-2003" TYPE="STUDY">Iuliano-Burns 2003</LINK>; <LINK REF="STD-Courteix-2005" TYPE="STUDY">Courteix 2005</LINK>). In contrast to the qualitative reviews, the results of our quantitative review do not support the findings that calcium supplementation has significant beneficial effects in children for bone outcomes or that a particular type of calcium supplementation has any more effect on bone than any other. </P>
<P>Subgroup analyses demonstrated little effect modification across the subgroups tested, as one would expect given the lack of heterogeneity overall in the included studies. The consistently greater effects seen in females compared to males across all sites of bone outcome measurement at the end of supplementation, though not significant, are suggestive of a sex difference in the response of BMD and BMC to calcium supplementation. There were few studies on which to base an assessment of whether this sex difference persisted with withdrawal of supplementation, but on the available data the differences did not persist. The treatment effect on upper limb BMD in the single study performed in an African population was greater than that observed in either Caucasian or Chinese populations, but again not significantly so. Given that this was in a single study, some caution is needed in interpreting this result. The difference in effect may be explained by genetic factors, but the result could also be confounded by dietary, physical activity or other environmental factors. </P>
<P>It is interesting that there were no differences in treatment effects observed between shorter and longer studies. It has been hypothesised that calcium supplementation reduces bone remodeling rather than or as well as increasing bone modelling, thus accounting for the transient benefit of calcium supplementation seen in some individual studies (<LINK REF="REF-Heaney--2001" TYPE="REFERENCE">Heaney 2001</LINK>). If bone remodeling was affected by calcium supplementation more than bone modelling, one would expect the difference between treatment effects in shorter versus longer studies to be small, in other words that as the duration of supplementation increased, the rate of increase in BMD/BMC would drop. This is consistent with our data. However, one would also expect that after supplementation ceased there would be a decrease in treatment effect. This is observed in our data for total body BMC but not at the upper limb, which is the only site where an overall treatment effect was observed during supplementation. The reason for this inconsistency between sites is not clear. </P>
<P>During supplementation, the magnitude of changes in bone density outcomes were similar whether the total calcium intake in the intervention arms of the studies did or did not exceed the estimated threshold below which skeletal accumulation varies with intake. This observation supports the concept of a calcium threshold: exceeding the threshold would not be expected to result in greater bone deposition. However, this analysis cannot confirm the magnitude of the threshold. It is possible that any effect of calcium supplementation ceases at a level less than the 1400 mg/day intake predicted from the literature which we tested in this analysis. </P>
<P>The sensitivity analyses performed indicated that the overall review results if anything may have overestimated the treatment effects for the upper limb after calcium supplementation had ceased. Otherwise, the sensitivity analyses had little effect on the review results and do not alter the overall conclusion of the review that the public health benefits of calcium supplementation in children, either in the short-term or long-term, appear marginal at best.<BR/> <BR/>Limitations<BR/>No studies in this review measured fractures as an outcome. This is not surprising as a RCT examining fracture outcomes would require a large cohort of children followed for a lengthy period of time to have sufficient power and fracture events to detect an effect on fracture risk. However, this does add to the difficulty of interpreting the clinical and public health significance of the results. This review also did not assess changes in other bone indices such as bone size or geometry. The studies selected intentionally did not include trials in children with medical conditions or on medications that might affect bone metabolism. Therefore, the results of this review should not be extrapolated to children with such conditions. Meta-regression could not be performed in this review due to the small number of studies. However, in the absence of heterogeneity this is not a significant limitation. </P>
<P>It has been suggested that areal BMD only partly corrects for bone size and that adjustment of BMC for bone area, weight and height is desirable (<LINK REF="REF-Prentice-1994" TYPE="REFERENCE">Prentice 1994</LINK>). Only 3 studies provided such size adjusted data (<LINK REF="STD-Dibba-2000" TYPE="STUDY">Dibba 2000</LINK>; <LINK REF="STD-Prentice-2005" TYPE="STUDY">Prentice 2005</LINK>; <LINK REF="STD-Stear-2003" TYPE="STUDY">Stear 2003</LINK>) and so this outcome was not included in the meta-analysis. However, qualitatively the outcomes of these 3 studies were similar, whether they were analysed using BMD or size-adjusted BMC. <BR/> <BR/>Subgroup analyses identified areas in which there were gaps in studies in this review, particularly where studies have limited the number of sites measured for their outcomes. As a result, while there is no evidence of effect modification, in a number of areas studies are lacking, so that effect modification cannot be rule out. For example, one might expect that children with lower baseline calcium intake might benefit more from supplementation. While we did not find evidence of this, there were few studies performed in children with very low baseline calcium intake - the majority were performed in participants in whom the mean baseline calcium intake was close to or above 700 mg/day. Only three studies had baseline intakes below 500 mg/day. Our power to detect effect modification by very low baseline calcium intake (&lt; 500 mg/day) was limited. There were also few studies in which participants could be analysed by whether they were purely post-pubertal and only a single study with only an upper limb outcome in purely peripubertal children. Given that it appears that calcium accumulation in the skeleton accelerates during puberty (<LINK REF="REF-Abrams-1996" TYPE="REFERENCE">Abrams 1996</LINK>; <LINK REF="REF-Bonjour--1991" TYPE="REFERENCE">Bonjour 1991</LINK>), the absence of sufficient data in the peripubertal period is an important gap to be filled by further research. Other gaps were related to ethnicity and the impact of physical activity. Relatively few studies were in non-Caucasian populations, which resulted in single studies with smaller numbers of participants for some outcomes in ethnicity subgroups. For example, at the femoral neck there was only a single study of Arabs/Jews with a wide confidence interval for the point estimate, though the magnitude of the treatment effect point estimate was larger than that seen in Caucasians. While no effect modification by physical activity was observed, there were only two studies to assess this at the lumbar spine, femoral neck and upper limb. Individual results from studies which were not included in the meta-analysis suggest that effect modification could occur at other sites, but more studies are needed to assess this. The methods of assessing physical activity and calcium intake across the different studies were also variable, making classification into subgroups problematic. </P>
</DISCUSSION>
<CONCLUSIONS>
<IMPLICATIONS_PRACTICE>
<P>While there is a small effect of calcium supplementation at the upper limb, the resultant increase in BMD is unlikely to result in a clinically significant decrease in fracture risk. The results of this review do not support the use of calcium supplementation in healthy children as a public health intervention. However, these results cannot be extrapolated to children with medical conditions affecting bone metabolism.</P>
</IMPLICATIONS_PRACTICE>
<IMPLICATIONS_RESEARCH>
<P>While long-term fracture studies are desirable to properly assess any effect on fracture risk reduction, for reasons discussed above we recognise that these are unlikely to be feasible. The absence of sufficient data children with very low calcium intakes and in the peripubertal period are important gaps to be filled by further research. Long-term calcium supplement studies over the period of peak bone mineral content velocity, perhaps particularly in children with very low calcium intake, would be desirable. Other gaps were related to ethnicity, the impact of physical activity, and the provision of information from follow-up after supplementation ceases. Given the small treatment effects seen with calcium supplementation, it may also be appropriate to explore possible alternative nutritional interventions, such as vitamin D supplementation (<LINK REF="STD-Moyer_x002d_Mileur-2003" TYPE="STUDY">Moyer-Mileur 2003</LINK>; <LINK REF="STD-Zhu-2004-b" TYPE="STUDY">Zhu 2004 b</LINK>) and fruit and vegetable intake (<LINK REF="REF-Jones-2001" TYPE="REFERENCE">Jones 2001</LINK>).</P>
</IMPLICATIONS_RESEARCH>
</CONCLUSIONS>
</BODY>
<ACKNOWLEDGEMENTS>
<P>Thank you to Louise Falzon for her assistance with the design and implementation of the search strategy for this protocol; to Lara Maxwell for co-ordinating assistance with several parts of this review; to George Wells for statistical advice and to Guangju Zhai for assistance with translations. </P>
</ACKNOWLEDGEMENTS>
<CONFLICT_OF_INTEREST>
<P>None known.</P>
</CONFLICT_OF_INTEREST>
<CONTRIBUTIONS>
<P>Tania Winzenberg - wrote review protocol, reviewed articles to decide on inclusion, performed data extraction and quality assessment of articles, performed the analysis and wrote the discussion of review results with the input of other authors. She will also be responsible for regularly updating and improving the review, as per Cochrane requirements.</P>
<P>Kelly Shaw - reviewed articles to decide on inclusion, performed data extraction and quality assessment of articles, and had input into writing of discussion of review results. </P>
<P>Jayne Fryer - provided advice on statistical analysis and input into writing of review methods, results and discussion.</P>
<P>Graeme Jones - is the content expert in pediatric bone health for the review. He provided input into design of the protocol, was the deciding reviewer for any differences in data extraction between TW and KS, assisted with the analysis and with writing the discussion of review results.</P>
</CONTRIBUTIONS>
<PRO_REV_DIFF/>
<PUBLIC_NOTES/>
</MAIN_TEXT>
<STUDIES_AND_REFERENCES MODIFIED="2008-10-03 10:54:26 -0400" MODIFIED_BY="[Empty name]">
<STUDIES MODIFIED="2008-10-03 10:54:26 -0400" MODIFIED_BY="[Empty name]">
<INCLUDED_STUDIES>
<STUDY DATA_SOURCE="PUB" ID="STD-Bonjour-1995" NAME="Bonjour 1995" YEAR="1995">
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Bonjour JP, Carrie AL, Clavien H, Ferrari S, Slosman D, Theintz G, Rizzoli R</AU>
<TI>Calcium-fortified aliments selectively increase radial and femoral bone mass in prepubertal girls: a double-blind randomized trial.</TI>
<SO>Journal of Bone and Mineral Research</SO>
<YR>1995</YR>
<VL>10S</VL>
<PG>S152</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE NOTES="&lt;p&gt;Bonjour JP, Carrie AL, Ferrari S, Clavien H, Slosman D, Theintz G, et al. Calcium-enriched foods and bone mass growth in prepubertal girls: a randomized, double-blind, placebo-controlled trial. J-Clin-Invest 1997;99:1287-1294.&lt;/p&gt;" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Bonjour JP, Carrie AL, Ferrari S, Clavien H, Slosman D, Theintz G, et al</AU>
<TI>Calcium-enriched foods and bone mass growth in prepubertal girls: a randomized, double-blind, placebo-controlled trial</TI>
<SO>Journal of Clinical Investigation</SO>
<YR>1997</YR>
<VL>99</VL>
<PG>1287-1294</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Bonjour JP, Chevalley T, Ammann P, Slosman D, Rizzoli R</AU>
<TI>Gain in bone mineral mass in prepubertal girls 3.5 years after discontinuation of calcium supplementation: a follow-up study</TI>
<SO>Lancet</SO>
<YR>2001</YR>
<VL>358</VL>
<PG>1208-1212</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE NOTES="&lt;p&gt;Chevalley T, Bonjour JP, Hans D, Slosman D, Rizzoli R. Interdependence between calcium intake and menarcheal age on bone mass gain: a 8 years follow-up from pre-puberty to post-menarche. J Bone Miner Res 2003;18:S33.&lt;/p&gt;" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Chevalley T, Bonjour JP, Hans D, Slosman D, Rizzoli R</AU>
<TI>Interdependence between calcium intake and menarcheal age on bone mass gain: a 8 years follow-up from pre-puberty to post-menarche</TI>
<SO>Journal of Bone and Mineral Research</SO>
<YR>2003</YR>
<VL>18</VL>
<PG>S33</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE NOTES="&lt;p&gt;8. Interaction between calcium intake and menarcheal age on bone mass gain: an eight-year follow-up study from prepuberty to postmenarche. J Clin Endocrinol Metab 2005;90(1):44-51.&lt;/p&gt;" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Chevalley T, Rizzoli R, Hans D, Ferrari S, Bonjour JP.</AU>
<TI>Interaction between calcium intake and menarcheal age on bone mass gain: an eight-year follow-up study from prepuberty to postmenarche</TI>
<SO>Journal of Clinical Endocrinology and Metabolism</SO>
<YR>2005</YR>
<VL>90</VL>
<NO>1</NO>
<PG>44-51</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Cameron-2004" NAME="Cameron 2004" YEAR="2004">
<REFERENCE NOTES="&lt;p&gt;Cameron MA, Paton LM, Nowson CA, Margerison C, Frame M, Wark JD. The effect of calcium supplementation on bone density in premenarcheal females: a co-twin approach. J Clin Endocrinol Metab 2004;89:4916-22.&lt;/p&gt;" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Cameron MA, Paton LM, Nowson CA, Margerison C, Frame M, Wark JD</AU>
<TI>The effect of calcium supplementation on bone density in premenarcheal females: a co-twin approach</TI>
<SO>Journal of Clinical Endocrinology and Metabolism</SO>
<YR>2004</YR>
<VL>89</VL>
<PG>4916-22</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Chevalley-2005" NAME="Chevalley 2005" YEAR="2005">
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Chevalley T, Bonjour JP, Ferrari S, Hans D, Rizzoli R.</AU>
<TI>Skeletal site selectivity in the effects of calcium supplementation on areal bone mineral density gain: a randomized, double-blind, placebo-controlled trial in prepubertal boys</TI>
<SO>Journal of Clinical Endocrinology and Metabolism</SO>
<YR>2005</YR>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="MIX" ID="STD-Courteix-2005" NAME="Courteix 2005" YEAR="2005">
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Courteix D, Jaffre C, Lespessailles E, Benhamou L</AU>
<TI>Cumulative effects of calcium supplementation and physical activity on bone accretion in premenarchal children: a double-blind randomised placebo-controlled trial</TI>
<SO>International Journal of Sports Medicine</SO>
<YR>2005</YR>
<VL>26</VL>
<PG>332-8</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Dibba-2000" NAME="Dibba 2000" YEAR="2000">
<REFERENCE NOTES="&lt;p&gt;Dibba B, Prentice A, Ceesay M, Mendy M, Darboe S, Stirling DM, et al. Bone mineral contents and plasma osteocalcin concentrations of Gambian children 12 and 24 mo after the withdrawal of a calcium supplement. Am J Clin Nutr 2002;76:681-6.&lt;/p&gt;" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Dibba B, Prentice A, Ceesay M, Mendy M, Darboe S, Stirling DM, et al</AU>
<TI>Bone mineral contents and plasma osteocalcin concentrations of Gambian children 12 and 24 mo after the withdrawal of a calcium supplement</TI>
<SO>American Journal of Clinical Nutrition</SO>
<YR>2002</YR>
<VL>76</VL>
<PG>681-6</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE NOTES="&lt;p&gt;Dibba B, Prentice A, Ceesay M, Stirling DM, Cole TJ, Poskitt EM. Effect of calcium supplementation on bone mineral accretion in gambian children accustomed to a low-calcium diet. Am J Clin Nutr 2000;71:544-9.&lt;/p&gt;" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Dibba B, Prentice A, Ceesay M, Stirling DM, Cole TJ, Poskitt EM</AU>
<TI>Effect of calcium supplementation on bone mineral accretion in gambian children accustomed to a low-calcium diet</TI>
<SO>American Journal of Clinical Nutrition</SO>
<YR>2000</YR>
<VL>71</VL>
<PG>544-9</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Iuliano_x002d_Burns-2003" NAME="Iuliano-Burns 2003" YEAR="2003">
<REFERENCE NOTES="&lt;p&gt;Iuliano Burns S, Saxon L, Naughton G, Gibbons K, Bass SL. Regional specificity of exercise and calcium during skeletal growth in girls: a randomized controlled trial. J-Bone-Miner-Res 2003;18:156-162.&lt;/p&gt;" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Iuliano-Burns S, Saxon L, Naughton G, Gibbons K, Bass SL</AU>
<TI>Regional specificity of exercise and calcium during skeletal growth in girls: a randomized controlled trial</TI>
<SO>Journal of Bone and Mineral Research</SO>
<YR>2003</YR>
<VL>18</VL>
<PG>156-162</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="MIX" ID="STD-Johnston-1992" NAME="Johnston 1992" YEAR="1992">
<REFERENCE NOTES="&lt;p&gt;Johnston CC, Jr., Miller JZ, Slemenda CW, Reister TK, Hui S, Christian JC, et al. Calcium supplementation and increases in bone mineral density in children. N-Engl-J-Med 1992;327:82-87.&lt;/p&gt;" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Johnston CC, Jr, Miller JZ, Slemenda CW, Reister TK, Hui S, Christian JC, Peacock, M.</AU>
<TI>Calcium supplementation and increases in bone mineral density in children</TI>
<SO>New England Journal of Medicine</SO>
<YR>1992</YR>
<VL>327</VL>
<PG>82-87</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE NOTES="&lt;p&gt;Slemenda CW, Peacock M, Hui S, Zhou L, Johnston CC. Reduced rates of skeletal remodeling are associated with increased bone mineral density during the development of peak skeletal mass. J Bone Miner Res 1997;12:676-82.&lt;/p&gt;" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Slemenda CW, Peacock M, Hui S, Zhou L, Johnston CC</AU>
<TI>Reduced rates of skeletal remodeling are associated with increased bone mineral density during the development of peak skeletal mass</TI>
<SO>Journal of Bone and Mineral Research</SO>
<YR>1997</YR>
<VL>12</VL>
<PG>676-82</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE NOTES="&lt;p&gt;Slemenda CW, Reister TK, Peacock M, Johnston CC. Bone growth in children following the cessation of calcium supplementation. J Bone Miner Res 1993;8:S154.&lt;/p&gt;" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Slemenda CW, Reister TK, Peacock M, Johnston CC</AU>
<TI>Bone growth in children following the cessation of calcium supplementation</TI>
<SO>Journal of Bone and Mineral Research</SO>
<YR>1993</YR>
<VL>8</VL>
<PG>S154</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Lee-1994" NAME="Lee 1994" YEAR="1994">
<REFERENCE NOTES="&lt;p&gt;Lee WT, Leung SS, Leung DM, Wang SH, Xu YC, Zeng WP, et al. Bone mineral acquisition in low calcium intake children following the withdrawal of calcium supplement. Acta Paediatr 1997;86:570-6.&lt;/p&gt;" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Lee WT, Leung SS, Leung DM, Wang SH, Xu YC, Zeng WP, et al</AU>
<TI>Bone mineral acquisition in low calcium intake children following the withdrawal of calcium supplement</TI>
<SO>Acta Paediatrica</SO>
<YR>1997</YR>
<VL>86</VL>
<PG>570-6</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE NOTES="&lt;p&gt;Lee WTK, Leung SSF, Wang SH, Xu YC, Zeng WP, Lau J, et al. Double-blind, controlled calcium supplementation and bone mineral accretion in children accustomed to a low-calcium diet. AM.-J.-CLIN.-NUTR 1994;60:744-750.&lt;/p&gt;" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Lee WTK, Leung SSF, Wang SH, Xu YC, Zeng WP, Lau J, et al</AU>
<TI>Double-blind, controlled calcium supplementation and bone mineral accretion in children accustomed to a low-calcium diet. AM.-J.-CLIN</TI>
<SO>American Journal of Clinical Nutrition</SO>
<YR>1994</YR>
<VL>60</VL>
<PG>744-750</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Lee-1995" NAME="Lee 1995" YEAR="1995">
<REFERENCE NOTES="&lt;p&gt;Lee WT, Leung SS, Leung DM, Cheng JC. A follow-up study on the effects of calcium-supplement withdrawal and puberty on bone acquisition of children. Am J Clin Nutr 1996;64:71-7.&lt;/p&gt;" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Lee WT, Leung SS, Leung DM, Cheng JC</AU>
<TI>A follow-up study on the effects of calcium-supplement withdrawal and puberty on bone acquisition of children</TI>
<SO>American Journal of Clinical Nutrition</SO>
<YR>1996</YR>
<VL>64</VL>
<PG>71-7</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE NOTES="&lt;p&gt;Lee WT, Leung SS, Leung DM, Tsang HS, Lau J, Cheng JC. A randomized double-blind controlled calcium supplementation trial, and bone and height acquisition in children. Br-J-Nutr 1995;74:125-139.&lt;/p&gt;" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Lee WT, Leung SS, Leung DM, Tsang HS, Lau J, Cheng JC</AU>
<TI>A randomized double-blind controlled calcium supplementation trial, and bone and height acquisition in children</TI>
<SO>British Journal of Nutrition</SO>
<YR>1995</YR>
<VL>74</VL>
<PG>125-139</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Lloyd-1993" NAME="Lloyd 1993" YEAR="1993">
<REFERENCE NOTES="&lt;p&gt;Lloyd T, Andon MB, Rollings N, Martel JK, Landis JR, Demers LM, et al. Calcium supplementation and bone mineral density in adolescent girls. Jama 1993;270:841-844.&lt;/p&gt;" PRIMARY="YES" TYPE="JOURNAL_ARTICLE">
<AU>Lloyd T, Andon MB, Rollings N, Martel JK, Landis JR, Demers LM, et al</AU>
<TI>Calcium supplementation and bone mineral density in adolescent girls</TI>
<SO>Journal of the American Medical Association</SO>
<YR>1993</YR>
<VL>270</VL>
<PG>841-844</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Lloyd T, Martel JK, Rollings N, Andon MB, Kulin H, Demers LM, et al</AU>
<TI>The effect of calcium supplementation and Tanner Stage on bone density, content and area in teenage women</TI>
<SO>Osteoporosis International</SO>
<YR>1996</YR>
<VL>6</VL>
<PG>276-283</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE NOTES="&lt;p&gt;Lloyd T, Rollings N, Andon MB, Eggli DF, Mauger E, Chinchilli VM. Enhanced bone gain in early adolesence due to calcium supplementation does not persist in late adolesence. J Bone Miner Res 1996:S154.&lt;/p&gt;" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Lloyd T, Rollings N, Andon MB, Eggli DF, Mauger E, Chinchilli VM</AU>
<TI>Enhanced bone gain in early adolesence due to calcium supplementation does not persist in late adolesence</TI>
<SO>Journal of Bone and Mineral Research</SO>
<YR>1996</YR>
<PG>S154</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Lloyd T, Rollings N, Chinchilli VM, Martel JK, Eggli DF, Demers LM, et al.</AU>
<TI>The effect of starting calcium supplementation at age 12 or at age 14 on bone acquisition in teenage girls.</TI>
<SO>Journal of Bone and Mineral Research</SO>
<YR>1995</YR>
<VL>10</VL>
<PG>S152</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Matkovic-2004" NAME="Matkovic 2004" YEAR="2004">
<REFERENCE NOTES="&lt;p&gt;Landoll JD, Badenhop-Stevens NE, Ha E, Mobley SL, Clairmont A, Matkovic V. Forearm pQCT measurements in young adult women accustomed to different calcium intakes during adolescence. J Bone Miner Res 2003;18:S182.&lt;/p&gt;" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Landoll JD, Badenhop-Stevens NE, Ha E, Mobley SL, Clairmont A, Matkovic V</AU>
<TI>Forearm pQCT measurements in young adult women accustomed to different calcium intakes during adolescence</TI>
<SO>Journal of Bone and Mineral Research</SO>
<YR>2003</YR>
<VL>18</VL>
<PG>S182</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Matkovic V, Badenhop-Stevens N, Landoll JD, Goel P, Li B</AU>
<TI>Long term effect of calcium supplementation and dairy products on bone mass of young females</TI>
<SO>Journal of Bone and Mineral Research</SO>
<YR>2002</YR>
<PG>S172</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE NOTES="&lt;p&gt;24. Matkovic V, Goel PK, Badenhop-Stevens NE, Landoll JD, Li B, Ilich JZ, et al. Calcium supplementation and bone mineral density in females from childhood to young adulthood: a randomized controlled trial. Am J Clin Nutr 2005;81(1):175-88.&lt;/p&gt;" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Matkovic V, Goel PK, Badenhop-Stevens NE, Landoll JD, Li B, Ilich JZ, et al.</AU>
<TI>Calcium supplementation and bone mineral density in females from childhood to young adulthood: a randomized controlled trial</TI>
<SO>American Journal of Clinical Nutrition</SO>
<YR>2005</YR>
<VL>81</VL>
<NO>1</NO>
<PG>175-88</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Matkovic V, Landoll JD, Badenhop-Stevens NE, Ha EY, Crncevic-Orlic Z, Li B, et al</AU>
<TI>Nutrition influences skeletal development from childhood to adulthood: a study of hip, spine, and forearm in adolescent females</TI>
<SO>Journal of Nutrition</SO>
<YR>2004</YR>
<VL>134</VL>
<PG>701S-705S</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Molgaard-2004" NAME="Molgaard 2004" YEAR="2004">
<REFERENCE NOTES="&lt;p&gt;26. Molgaard C, Thomsen BL, Michaelsen KF. Effect of habitual dietary calcium intake on calcium supplementation in 12-14-y-old girls. Am J Clin Nutr 2004;80(5):1422-7.&lt;/p&gt;" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Molgaard C, Thomsen BL, Michaelsen KF.</AU>
<TI>Effect of habitual dietary calcium intake on calcium supplementation in 12-14-y-old girls</TI>
<SO>American Journal of Clinical Nutrition</SO>
<YR>2004</YR>
<VL>80</VL>
<NO>5</NO>
<PG>1422-7</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Nowson-1997" NAME="Nowson 1997" YEAR="1997">
<REFERENCE NOTES="&lt;p&gt;Nowson CA, Green RM, Hopper JL, Sherwin AJ, Young D, Kaymakci B, et al. A co-twin study of the effect of calcium supplementation on bone density during adolescence. Osteoporos Int 1997;7:219-25.&lt;/p&gt;" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Nowson CA, Green RM, Hopper JL, Sherwin AJ, Young D, Kaymakci B, et al</AU>
<TI>A co-twin study of the effect of calcium supplementation on bone density during adolescence</TI>
<SO>Osteoporosis International</SO>
<YR>1997</YR>
<VL>7</VL>
<PG>219-25</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="MIX" ID="STD-Prentice-2005" NAME="Prentice 2005" YEAR="2005">
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Prentice A, Ginty F, Stear SJ, Jones SC, Laskey MA, Cole TJ.</AU>
<TI>Calcium supplementation increases stature and bone mineral mass of 16-18 year old boys*</TI>
<SO>Journal of Clinical Endocrinology and Metabolism</SO>
<YR>2005</YR>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Rodda-2004" NAME="Rodda 2004" YEAR="">
<REFERENCE NOTES="&lt;p&gt;Rodda C, Urdampilleta M, Hu J, Strauss B, Briganti E, Gilfillan C. Ethnic differences in effect of calcium supplementation on bone density in peripubertal girls in a double-blind, placebo-controlled randomised trial. Australian and New Zealand Bone and Mineral Society 2004 Annual Scientific Meeting Abstract Book 2004:50.&lt;/p&gt;" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Rodda C, Urdampilleta M, Hu J, Strauss B, Briganti E, Gilfillan C</AU>
<TI>Ethnic differences in effect of calcium supplementation on bone density in peripubertal girls in a double-blind, placebo-controlled randomised trial</TI>
<SO>Australian and New Zealand Bone Mineral Society 2004 Annual Scientific Meeting Final Program and Abstract Book</SO>
<YR>2004</YR>
<PG>50</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Rozen-2003" NAME="Rozen 2003" YEAR="2003">
<REFERENCE NOTES="&lt;p&gt;11. Sustained effect of short-term calcium supplementation on bone mass in adolescent girls with low calcium intake. Am J Clin Nutr 2005;81(1):168-74.&lt;/p&gt;" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Dodiuk-Gad RP, Rozen GS, Rennert G, Rennert HS, Ish-Shalom S.</AU>
<TI>Sustained effect of short-term calcium supplementation on bone mass in adolescent girls with low calcium intake</TI>
<SO>American Journal of Clinical Nutrition</SO>
<YR>2005</YR>
<VL>81</VL>
<NO>1</NO>
<PG>168-74</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE NOTES="&lt;p&gt;Rozen GS, Rennert G, Dodiuk-Gad RP, Rennert HS, Ish-Shalom N, Diab G, et al. Calcium supplementation provides an extended window of opportunity for bone mass accretion after menarche. Am J Clin Nutr 2003;78:993-8.&lt;/p&gt;" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Rozen GS, Rennert G, Dodiuk-Gad RP, Rennert HS, Ish-Shalom N, Diab G, et al</AU>
<TI>Calcium supplementation provides an extended window of opportunity for bone mass accretion after menarche</TI>
<SO>American Journal of Clinical Nutrition</SO>
<YR>2003</YR>
<VL>78</VL>
<PG>993-8</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Specker-2003" NAME="Specker 2003" YEAR="2003">
<REFERENCE NOTES="&lt;p&gt;Specker B, Binkley T. Randomized trial of physical activity and calcium supplementation on bone mineral content in 3- to 5-year-old children. J Bone Miner Res 2003;18:885-92.&lt;/p&gt;" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Specker B, Binkley T</AU>
<TI>Randomized trial of physical activity and calcium supplementation on bone mineral content in 3- to 5-year-old children</TI>
<SO>Journal of Bone and Mineral Research</SO>
<YR>2003</YR>
<VL>18</VL>
<PG>885-92</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="MIX" ID="STD-Stear-2003" NAME="Stear 2003" YEAR="2003">
<REFERENCE NOTES="&lt;p&gt;Stear SJ, Prentice A, Jones SC, J. CT. Effect of a calcium and exercise intervention on the bone mineral status of 16-18-y-old adolescent girls. American Journal of Clinical Nutrition. 2003;77:985-992.&lt;/p&gt;" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Stear SJ, Prentice A, Jones SC, Cole,TJ</AU>
<TI>Effect of a calcium and exercise intervention on the bone mineral status of 16-18-y-old adolescent girls.</TI>
<SO>American Journal of Clinical Nutrition</SO>
<YR>2003</YR>
<VL>77</VL>
<PG>985-992</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Wang-1996" NAME="Wang 1996" YEAR="1996">
<REFERENCE NOTES="&lt;p&gt;Wang S, Xue Y, Li D, Shu S, Zhen W. Effect of calcium supplmentation on bone mineral content in children accustomed to low calcium diet. The Journal of Nutrition 1996;18:97-102.&lt;/p&gt;" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Wang S, Xue Y, Li D, Shu S, Zhen W</AU>
<TI>Effect of calcium supplmentation on bone mineral content in children accustomed to low calcium diet</TI>
<SO>Acta Nutrimenta Sinica</SO>
<YR>1996</YR>
<VL>18</VL>
<NO>1</NO>
<PG>97-102</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
</INCLUDED_STUDIES>
<EXCLUDED_STUDIES MODIFIED="2008-10-03 10:54:26 -0400" MODIFIED_BY="[Empty name]">
<STUDY DATA_SOURCE="PUB" ID="STD-Abrams-2001" NAME="Abrams 2001" YEAR="2001">
<REFERENCE NOTES="&lt;p&gt;Abrams S. Calcium turnover and nutrition through the life cycle. Proceedings of the Nutrition Society 2001;60:283-289.&lt;/p&gt;" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Abrams S.</AU>
<TI>Calcium turnover and nutrition through the life cycle</TI>
<SO>Proceedings of the Nutrition Society</SO>
<YR>2001</YR>
<VL>60</VL>
<PG>283-289</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Adiyaman-2004" NAME="Adiyaman 2004" YEAR="2004">
<REFERENCE PRIMARY="NO" TYPE="CORRESPONDENCE">
<AU>Adiyaman P, Ocal G, Berberoglu M, Evliyaoglu O, Aycan Z, Cetinkaya E.</AU>
<TI>The clinical and radiological assessment of cyclic intravenous pamidronate administration in children with osteogenesis imperfecta</TI>
<SO>Turkish Journal of Pediatrics</SO>
<YR>2004</YR>
<VL>46</VL>
<NO>4</NO>
<PG>322-328</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Albertson-1997" NAME="Albertson 1997" YEAR="1997">
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Albertson AM, Tobelmann RC, Marquart L</AU>
<TI>Estimated dietary calcium intake and food sources for adolescent females: 1980-92</TI>
<SO>Journal of Adolescent Health</SO>
<YR>1997</YR>
<VL>20</VL>
<PG>20-26</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Ali-2001" NAME="Ali 2001" YEAR="2001">
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Ali N, Siktberg L</AU>
<TI>Osteoporosis prevention in female adolescents: calcium intake and exercise participation</TI>
<SO>Pediatric Nursing</SO>
<YR>2001</YR>
<VL>27</VL>
<PG>132</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Anderson-2001" NAME="Anderson 2001" YEAR="2001">
<REFERENCE NOTES="&lt;p&gt;Anderson JJ. Calcium requirements during adolescence to maximize bone health. J-Am-Coll-Nutr 2001;20:186S-191S.&lt;/p&gt;" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Anderson JJ</AU>
<TI>Calcium requirements during adolescence to maximize bone health</TI>
<SO>JOURNAL OF THE AMERICAN COLLEGE OF NUTRITION</SO>
<YR>2001</YR>
<VL>20</VL>
<PG>186S-191S</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Andon-1994" NAME="Andon 1994" YEAR="1994">
<REFERENCE NOTES="&lt;p&gt;Andon MB, Lloyd T, Matkovic V. Supplementation trials with calcium citrate malate: evidence in favor of increasing the calcium RDA during childhood and adolescence. J-Nutr 1994;124(Suppl):1412S-1417S.&lt;/p&gt;" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Andon MB, Lloyd T, Matkovic V</AU>
<TI>Supplementation trials with calcium citrate malate: evidence in favor of increasing the calcium RDA during childhood and adolescence</TI>
<SO>Journal of Nutrition</SO>
<YR>1994</YR>
<VL>124</VL>
<NO>Suppl</NO>
<PG>1412S-1417S</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Anonymous-1992" NAME="Anonymous 1992" YEAR="1992">
<REFERENCE NOTES="&lt;p&gt;Anonymous. Maximizing peak bone mass: calcium supplementation increases bone mineral density in children. Nutrition-Reviews 1992;50:335-337.&lt;/p&gt;" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Anonymous</AU>
<TI>Maximizing peak bone mass: calcium supplementation increases bone mineral density in children</TI>
<SO>Nutrition Reviews</SO>
<YR>1992</YR>
<VL>50</VL>
<PG>335-337</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Anonymous-1993a" NAME="Anonymous 1993a" YEAR="1993">
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Anonymous</AU>
<TI>Calcium supplementation in teenage girls</TI>
<SO>Nurses' Drug Alert</SO>
<YR>1993</YR>
<VL>17</VL>
<PG>77</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Anonymous-1993b" NAME="Anonymous 1993b" YEAR="1993">
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Anonymous</AU>
<TI>Osteoporosis prevention: giving young girls calcium supplements can be helpful</TI>
<SO>School Nurse News</SO>
<YR>1993</YR>
<VL>10</VL>
<PG>7</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Anonymous-1994" NAME="Anonymous 1994" YEAR="1994">
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Anonymous</AU>
<TI>ADA supports efforts to reduce osteoporosis risk and recommends improvements for child nutrition programs</TI>
<SO>Journal of the American Dietetic Association</SO>
<YR>1994</YR>
<VL>94</VL>
<PG>606</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Anonymous-1997a" NAME="Anonymous 1997a" YEAR="1997">
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Anonymous</AU>
<TI>Intake of dietary calcium to reduce the incidence of osteoporosis. Council on Scientific Affairs, American Medical Association</TI>
<SO>Archives of Family Medicine</SO>
<YR>1997</YR>
<VL>6</VL>
<PG>495-9</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Anonymous-1997b" NAME="Anonymous 1997b" YEAR="1997">
<REFERENCE NOTES="&lt;p&gt;Anonymous. Teens, calcium and osteoporosis. J-Am-Dent-Assoc 1997;128:154.&lt;/p&gt;" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Anonymous</AU>
<TI>Teens, calcium and osteoporosis</TI>
<SO>Journal of the American Dental Association</SO>
<YR>1997</YR>
<VL>128</VL>
<PG>154</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Anonymous-1998" NAME="Anonymous 1998" YEAR="1998">
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Anonymous</AU>
<TI>Food labeling: health claims; calcium consumption by adolescents and adults, bone density and the risk of fractures--FDA. Interim final rule</TI>
<SO>Federal Register</SO>
<YR>1998</YR>
<VL>63</VL>
<PG>34101-4</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Anonymous-2000" NAME="Anonymous 2000" YEAR="2000">
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Anonymous</AU>
<TI>Osteoporosis prevention, diagnosis, and therapy</TI>
<SO>NIH Consensus Statement</SO>
<YR>2000</YR>
<VL>17</VL>
<PG>1-45</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Anonymous-2004" NAME="Anonymous 2004" YEAR="2004">
<REFERENCE NOTES="&lt;p&gt;2. Anonymous. Soft Drinks in Schools. Pediatrics 2004;113(1 I):152-154.&lt;/p&gt;" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Anonymous.</AU>
<TI>Soft Drinks in Schools</TI>
<SO>Pediatrics</SO>
<YR>2004</YR>
<VL>113</VL>
<NO>1 I</NO>
<PG>152-154</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Antoniazzi--2003" NAME="Antoniazzi  2003" YEAR="2003">
<REFERENCE NOTES="&lt;p&gt;Antoniazzi F, Zamboni G, Bertoldo F, Lauriola S, Mengarda F, Pietrobelli A, et al. Bone mass at final height in precocious puberty after gonadotropin-releasing hormone agonist with and without calcium supplementation. J Clin Endocrinol Metab 2003;88:1096-101.&lt;/p&gt;" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Antoniazzi F, Zamboni G, Bertoldo F, Lauriola S, Mengarda F, Pietrobelli A, et al</AU>
<TI>Bone mass at final height in precocious puberty after gonadotropin-releasing hormone agonist with and without calcium supplementation</TI>
<SO>Journal of Clinical Endocrinology and Metabolism</SO>
<YR>2003</YR>
<VL>88</VL>
<PG>1096-101</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Antoniazzi-1999" NAME="Antoniazzi 1999" YEAR="1999">
<REFERENCE NOTES="&lt;p&gt;Antoniazzi F, Bertoldo F, Lauriola S, Sirpresi S, Gasperi E, Zamboni G, et al. Prevention of bone demineralization by calcium supplementation in precocious puberty during gonadotropin-releasing hormone agonist treatment. Journal of Clinical Endocrinology &amp;amp; Metabolism. 1999;84:1992-1996.&lt;/p&gt;" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Antoniazzi F, Bertoldo F, Lauriola S, Sirpresi S, Gasperi E, Zamboni G, et al</AU>
<TI>Prevention of bone demineralization by calcium supplementation in precocious puberty during gonadotropin-releasing hormone agonist treatment.</TI>
<SO>Journal of Clinical Endocrinology and Metabolism</SO>
<YR>1999</YR>
<VL>84</VL>
<PG>1992-1996</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Appleby-1998" NAME="Appleby 1998" YEAR="1998;">
<REFERENCE NOTES="&lt;p&gt;Appleby P. Milk intake and bone mineral acquisition in adolescent girls. Adding milk to adolescent diet may not be best means of preventing osteoporosis.[comment]. BMJ 1998;316:1747; author reply 1747-8.&lt;/p&gt;" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Appleby P</AU>
<TI>Milk intake and bone mineral acquisition in adolescent girls. Adding milk to adolescent diet may not be best means of preventing osteoporosis.[comment]</TI>
<SO>British Medical Journal</SO>
<YR>1998</YR>
<VL>316</VL>
<PG>1747; author reply 1747-8</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Ausenhus-1988" NAME="Ausenhus 1988" YEAR="1988">
<REFERENCE NOTES="&lt;p&gt;Not RCT Ausenhus MK. Osteoporosis: prevention during the adolescent and young adult years. Nurse Practitioner 1988;13:42.&lt;/p&gt;" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Ausenhus MK</AU>
<TI>Osteoporosis: prevention during the adolescent and young adult years</TI>
<SO>Nurse Practitioner</SO>
<YR>1988</YR>
<VL>13</VL>
<PG>42</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Badenhop-2004" NAME="Badenhop 2004" YEAR="2004">
<REFERENCE NOTES="&lt;p&gt;3. Badenhop-Stevens N, Matkovic V. Calcium needs in children. Orthopaedic Nursing 2004;23(4):228-34.&lt;/p&gt;" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Badenhop-Stevens N, Matkovic V.</AU>
<TI>Calcium needs in children</TI>
<SO>Orthopaedic Nursing</SO>
<YR>2004</YR>
<VL>23</VL>
<NO>4</NO>
<PG>228-34</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Barker-1998" NAME="Barker 1998" YEAR="1998">
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Barker M, Lambert HL, Cadogan J, Jones N, Wallace F, Eastell R</AU>
<TI>Milk supplementation and bone growth in adolescent girls; is the effect ephemeral?</TI>
<SO>Bone</SO>
<YR>1998</YR>
<VL>23</VL>
<PG>S606</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Barr-1998" NAME="Barr 1998" YEAR="1998">
<REFERENCE NOTES="&lt;p&gt;Barr SI, McKay HA. Nutrition, exercise, and bone status in youth. Int-J-Sport-Nutr 1998;8:124-142.&lt;/p&gt;" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Barr SI, McKay HA</AU>
<TI>Nutrition, exercise, and bone status in youth</TI>
<SO>International Journal of Sport Nutrition</SO>
<YR>1998</YR>
<VL>8</VL>
<PG>124-142</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Barr-2001" NAME="Barr 2001" YEAR="2001">
<REFERENCE NOTES="&lt;p&gt;Barr SI, Petit MA, Vigna YM, Prior JC. Eating attitudes and habitual calcium intake in peripubertal girls are associated with initial bone mineral content and its change over 2 years. J-Bone-Miner-Res 2001;16:940-947.&lt;/p&gt;" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Barr SI, Petit MA, Vigna YM, Prior JC</AU>
<TI>Eating attitudes and habitual calcium intake in peripubertal girls are associated with initial bone mineral content and its change over 2 years</TI>
<SO>Journal of Bone and Mineral Research</SO>
<YR>2001</YR>
<VL>16</VL>
<PG>940-947</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Bateson-2002" NAME="Bateson 2002" YEAR="2002">
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Bateson A, Finch P</AU>
<TI>Professional. Do adolescents eat enough calcium?</TI>
<SO>Community Practitioner</SO>
<YR>2002</YR>
<VL>75</VL>
<PG>428-31</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Berthier-1994" NAME="Berthier 1994" YEAR="1994">
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Berthier AM</AU>
<TI>Milk products: effective prevention against osteoporosis</TI>
<SO>Revue-Laitiere-Francaise</SO>
<YR>1994</YR>
<PG>56</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Black-2002" NAME="Black 2002" YEAR="2002">
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Black RE, Williams SM, Jones IE, Goulding A</AU>
<TI>Children who avoid drinking cow milk have low dietary calcium intakes and poor bone health</TI>
<SO>American Journal of Clinical Nutrition</SO>
<YR>2002</YR>
<VL>76</VL>
<PG>675-680</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Blalock-2002" NAME="Blalock 2002" YEAR="2002">
<REFERENCE NOTES="&lt;p&gt;Blalock SJ, DeVellis BM, Patterson CC, Campbell MK, Orenstein DR, A. DM. Effects of an osteoporosis prevention program incorporating tailored educational materials. American Journal of Health Promotion. 2002;16:146-156.&lt;/p&gt;" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Blalock SJ, DeVellis BM, Patterson CC, Campbell MK, Orenstein DR, A</AU>
<TI>Effects of an osteoporosis prevention program incorporating tailored educational materials.</TI>
<SO>American Journal of Health Promotion</SO>
<YR>2002</YR>
<VL>16</VL>
<PG>146-156</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Bonjour-1999" NAME="Bonjour 1999" YEAR="1999">
<REFERENCE NOTES="&lt;p&gt;Bonjour JP, Rizzoli R. [The property of calcium in the child and the adolescent: importance in the acquisition of bone mineral density]. Arch-Pediatr 1999;6 (Suppl 2).&lt;/p&gt;" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Bonjour JP, Rizzoli R</AU>
<TI>[The property of calcium in the child and the adolescent: importance in the acquisition of bone mineral density]</TI>
<SO>Archives de pediatrie</SO>
<YR>1999</YR>
<VL>6 (Suppl 2)</VL>
<PG>155s-157s</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Bonofiglio-2004" NAME="Bonofiglio 2004" YEAR="2004">
<REFERENCE NOTES="&lt;p&gt;4. Bonofiglio D, Garofalo C, Catalano S, Marsico S, Aquila S, Ando S. Low calcium intake is associated with decreased adrenal androgens and reduced bone age in premenarcheal girls in the last pubertal stages. J Bone Miner Metab 2004;22(1):64-70.&lt;/p&gt;" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Bonofiglio D, Garofalo C, Catalano S, Marsico S, Aquila S, Ando S.</AU>
<TI>Low calcium intake is associated with decreased adrenal androgens and reduced bone age in premenarcheal girls in the last pubertal stages</TI>
<SO>Journal of Bone and Mineral Metabolism</SO>
<YR>2004</YR>
<VL>22</VL>
<NO>1</NO>
<PG>64-70</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Boot-1997" NAME="Boot 1997" YEAR="1997">
<REFERENCE NOTES="&lt;p&gt;Boot AM, de Ridder MA, Pols HA, Krenning EP, de Muinck Keizer Schrama SM. Bone mineral density in children and adolescents: relation to puberty, calcium intake, and physical activity. J-Clin-Endocrinol-Metab 1997;82:57-62.&lt;/p&gt;" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Boot AM, de Ridder MA, Pols HA, Krenning EP, de Muinck Keizer Schrama SM</AU>
<TI>Bone mineral density in children and adolescents: relation to puberty, calcium intake, and physical activity</TI>
<SO>Journal of Clinical Endocrinology and Metabolism</SO>
<YR>1997</YR>
<VL>82</VL>
<PG>57-62</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Bourges" NAME="Bourges" YEAR="">
<REFERENCE NOTES="&lt;p&gt;5. Bourges O, Dorgeret S, Alberti C, Hugot JP, Sebag G, Cezard JP. [Low bone mineral density in children with Crohn's disease].[see comment].800-6, 2004 Jul.&lt;/p&gt;" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Bourges O, Dorgeret S, Alberti C, Hugot JP, Sebag G, Cezard JP.</AU>
<TI>[Low bone mineral density in children with Crohn's disease].[see comment]</TI>
<SO>Archives de Pediatrie</SO>
<YR>2004</YR>
<VL>11</VL>
<NO>7</NO>
<PG>800-806</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Brown-2004" NAME="Brown 2004" YEAR="2004">
<REFERENCE NOTES="&lt;p&gt;6. Brown SJ, Schoenly L. Test of an educational intervention for osteoporosis prevention with U.S. adolescents. Orthopaedic Nursing 2004;23(4):245-51.&lt;/p&gt;" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Brown SJ, Schoenly L.</AU>
<TI>Test of an educational intervention for osteoporosis prevention with U.S. adolescents</TI>
<SO>Orthopaedic Nursing</SO>
<YR>2004</YR>
<VL>23</VL>
<NO>4</NO>
<PG>245-51</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Burckhardt-2001" NAME="Burckhardt 2001" YEAR="2001">
<REFERENCE NOTES="&lt;p&gt;Burckhardt P, Dawson-Hughes B, Heaney RP. Nutritional aspects of osteoporosis. San Diego: Academic Press; 2001.&lt;/p&gt;" PRIMARY="NO" TYPE="BOOK_SECTION">
<AU>Burckhardt P, Dawson-Hughes B, Heaney RP</AU>
<TI>Nutritional aspects of osteoporosis</TI>
<SO>A critical appraisal of the evidence relating calcium and dairy intake to bone health in early life</SO>
<YR>2001</YR>
<PG>107-123</PG>
<ED>Specker B, Wosje K</ED>
<PB>Academic Press</PB>
<CY>San Diego</CY>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Cadogan-1997" NAME="Cadogan 1997" YEAR="1997">
<REFERENCE NOTES="&lt;p&gt;Cadogan J, Eastell R, Jones N, Barker ME. Milk intake and bone mineral acquisition in adolescent girls: randomised, controlled intervention trial. BMJ 1997;315:1255-1260.&lt;/p&gt;" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Cadogan J, Eastell R, Jones N, Barker ME</AU>
<TI>Milk intake and bone mineral acquisition in adolescent girls: randomised, controlled intervention trial</TI>
<SO>British Medical Journal</SO>
<YR>1997</YR>
<VL>315</VL>
<PG>1255-1260</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Carter-2001" NAME="Carter 2001" YEAR="2001">
<REFERENCE NOTES="&lt;p&gt;Carter LM, Whiting SJ, Drinkwater DT, Zello GA, Faulkner RA, Bailey DA. Self-reported calcium intake and bone mineral content in children and adolescents. J Am Coll Nutr 2001;20:502-9.&lt;/p&gt;" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Carter LM, Whiting SJ, Drinkwater DT, Zello GA, Faulkner RA, Bailey DA</AU>
<TI>Self-reported calcium intake and bone mineral content in children and adolescents</TI>
<SO>Journal of the American College of Nutrition</SO>
<YR>2001</YR>
<VL>20</VL>
<PG>502-9</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Chan-1987" NAME="Chan 1987" YEAR="1987">
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Chan GM, McMurry M, Westover K, et al</AU>
<TI>Effects of increased dietary calcium intake upon the calcium and bone mineral status of lactating adolescent and adult women</TI>
<SO>American Journal of Clinical Nutrition</SO>
<YR>1987</YR>
<VL>46</VL>
<PG>319-323</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Chan-1991" NAME="Chan 1991" YEAR="1991">
<REFERENCE NOTES="&lt;p&gt;Chan GM. Dietary calcium and bone mineral status of children and adolescents. Am-J-Dis-Child 1991;145:631-634.&lt;/p&gt;" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Chan GM</AU>
<TI>Dietary calcium and bone mineral status of children and adolescents</TI>
<SO>American Journal of Diseases of Children</SO>
<YR>1991</YR>
<VL>145</VL>
<PG>631-634</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Chan-1995" NAME="Chan 1995" YEAR="1995">
<REFERENCE NOTES="&lt;p&gt;1995;126:551-556.&lt;/p&gt;" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Chan GM, Hoffman K, McMurry M.</AU>
<TI>Effects of dairy products on bone and body composition in pubertal girls.</TI>
<SO>Journal of Pediatrics</SO>
<YR>1995</YR>
<VL>126</VL>
<PG>551-56</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Cheng-1999" NAME="Cheng 1999" YEAR="1999">
<REFERENCE NOTES="&lt;p&gt;Cheng JC, Maffulli N, Leung SS, Lee WT, Lau JT, Chan KM. Axial and peripheral bone mineral acquisition: a 3-year longitudinal study in Chinese adolescents. Eur J Pediatr 1999;158:506-12.&lt;/p&gt;" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Cheng JC, Maffulli N, Leung SS, Lee WT, Lau JT, Chan KM</AU>
<TI>Axial and peripheral bone mineral acquisition: a 3-year longitudinal study in Chinese adolescents</TI>
<SO>European Journal of Pediatrics</SO>
<YR>1999</YR>
<VL>158</VL>
<PG>506-12</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Chevalley-2004" NAME="Chevalley 2004" YEAR="2004">
<REFERENCE NOTES="&lt;p&gt;Chevalley T, Bonjour JP, Rizzoli R. [Modifying bone mass in child and adolescent: why?]. Schweizerische Rundschau fur Medizin Praxis 2004;93:415-21.&lt;/p&gt;" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Chevalley T, Bonjour JP, Rizzoli R</AU>
<TI>[Modifying bone mass in child and adolescent: why?]</TI>
<TO>Ameliorer la masse osseuse chez l'enfant et l'adolescent: pourquoi, comment?</TO>
<SO>Schweizerische Rundschau fur Medizin Praxis</SO>
<YR>2004</YR>
<VL>93</VL>
<PG>415-21</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Clements-1991" NAME="Clements 1991" YEAR="1991">
<REFERENCE NOTES="&lt;p&gt;Not RCT Clements D, Harding K. Strategies for preventing osteoporosis.[comment]. BMJ 1991;303:1060.&lt;/p&gt;" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Clements D, Harding K</AU>
<TI>Strategies for preventing osteoporosis.[comment]</TI>
<SO>British Medical Journal</SO>
<YR>1991</YR>
<VL>303</VL>
<PG>1060</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-DeBar--2004" NAME="DeBar  2004" YEAR="2004">
<REFERENCE NOTES="&lt;p&gt;9. DeBar LL, Ritenbaugh C, Vuckovic N, Stevens VJ, Aickin M, Elliot D, et al. YOUTH: decisions and challenges in designing an osteoporosis prevention intervention for teen girls. Prev Med 2004;39(5):1047-55.&lt;/p&gt;" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>DeBar LL, Ritenbaugh C, Vuckovic N, Stevens VJ, Aickin M, Elliot D, et al.</AU>
<TI>YOUTH: decisions and challenges in designing an osteoporosis prevention intervention for teen girls</TI>
<SO>Preventive Medicine</SO>
<YR>2004</YR>
<VL>39</VL>
<NO>5</NO>
<PG>1047-55</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-DiMeglio-2005" NAME="DiMeglio 2005" YEAR="2005">
<REFERENCE NOTES="&lt;p&gt;10. Journal of Pediatric Endocrinology &amp;amp; Metabolism 2005;18(1):43-53.&lt;/p&gt;" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>DiMeglio LA, Ford L, McClintock C, Peacock M.</AU>
<TI>A comparison of oral and intravenous bisphosphonate therapy for children with osteogenesis imperfecta.</TI>
<SO>Journal of Pediatric Endocrinology &amp; Metabolism</SO>
<YR>2005</YR>
<VL>18</VL>
<NO>1</NO>
<PG>43-53</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Dowd-2001" NAME="Dowd 2001" YEAR="2001">
<REFERENCE NOTES="&lt;p&gt;Dowd R. Role of calcium, vitamin D, and other essential nutrients in the prevention and treatment of osteoporosis. Nurs-Clin-North-Am 2001;36:417-431.&lt;/p&gt;" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Dowd R</AU>
<TI>Role of calcium, vitamin D, and other essential nutrients in the prevention and treatment of osteoporosis</TI>
<SO>Nursing Clinics of North America</SO>
<YR>2001</YR>
<VL>36</VL>
<PG>417-431</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Du-2002" NAME="Du 2002" YEAR="2002">
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Du XQ, Greenfield H, Fraser DR, Ge KY, Liu ZH, He W</AU>
<TI>Milk consumption and bone mineral content in Chinese adolescent girls</TI>
<SO>Bone</SO>
<YR>2002</YR>
<VL>30</VL>
<PG>521-528</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Du-2004" NAME="Du 2004" YEAR="2004">
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Du XQ, Zhu K, Trube A, Zhang Q, Ma GS, Hu XQ, et al</AU>
<TI>School-milk intervention trial enhances growth and bone mineral accretion in Chinese girls aged 10-12 years in Beijing</TI>
<SO>British Journal of Nutrition</SO>
<YR>2004</YR>
<VL>92</VL>
<PG>159-168</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Edwards-1998" NAME="Edwards 1998" YEAR="1998">
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Edwards M</AU>
<TI>Health promotion: maximising bone mass in young women</TI>
<SO>Community Practitioner</SO>
<YR>1998</YR>
<VL>71</VL>
<PG>256-9</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-El_x002d_Husseini-2004" NAME="El-Husseini 2004" YEAR="2004">
<REFERENCE NOTES="&lt;p&gt;12. El-Husseini AA, El-Agroudy AE, El-Sayed MF, Sobh MA, Ghoneim MA. Treatment of osteopenia and osteoporosis in renal transplant children and adolescents. Pediatric Transplantation 2004;8(4):357-361.&lt;/p&gt;" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>El-Husseini AA, El-Agroudy AE, El-Sayed MF, Sobh MA, Ghoneim MA.</AU>
<TI>Treatment of osteopenia and osteoporosis in renal transplant children and adolescents</TI>
<SO>Pediatric Transplantation</SO>
<YR>2004</YR>
<VL>8</VL>
<NO>4</NO>
<PG>357-361</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Elgan-2002" NAME="Elgan 2002" YEAR="2002">
<REFERENCE NOTES="&lt;p&gt;Elgan C, Dykes AK, Samsioe G. Bone mineral density and lifestyle among female students aged 16-24 years. Gynecol-Endocrinol 2002;16:91-98.&lt;/p&gt;" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Elgan C, Dykes AK, Samsioe G</AU>
<TI>Bone mineral density and lifestyle among female students aged 16-24 years</TI>
<SO>Gynecological Endocrinology</SO>
<YR>2002</YR>
<VL>16</VL>
<PG>91-98</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Feskanich-1997" NAME="Feskanich 1997" YEAR="1997">
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Feskanich D, Willett WC, Stampfer MJ, Colditz GA</AU>
<TI>Milk, dietary calcium, and bone fractures in women: a 12-year prospective study</TI>
<SO>American Journal of Public Health</SO>
<YR>1997</YR>
<VL>87</VL>
<PG>992-7</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Fischer-1999a" NAME="Fischer 1999a" YEAR="1999">
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Fischer GS, Milinarsky TA, Giadrosich RV, Casanova ZD</AU>
<TI>Effects of calcium supplementation on bone density in girls</TI>
<SO>Revista-Medica-de-Chile</SO>
<YR>1999</YR>
<VL>127</VL>
<PG>23-27</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Fischer-1999b" NAME="Fischer 1999b" YEAR="1999">
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Fischer S, Milinarsky A, Giadrosich V, Casanova D</AU>
<TI>[Calcium supplementation and bone absorptiometry in girls]</TI>
<SO>Revista Medica de Chile</SO>
<YR>1999</YR>
<VL>127</VL>
<PG>23-7</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Fisher-2004" NAME="Fisher 2004" YEAR="2004">
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Fisher JO, Mitchell DC, Smiciklas-Wright H, Mannino ML, Birch LL</AU>
<TI>Meeting calcium recommendations during middle childhood reflects mother-daughter beverage choices and predicts bone mineral status</TI>
<SO>American Journal of Clinical Nutrition</SO>
<YR>2004</YR>
<VL>79</VL>
<PG>698-706</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Fujita-1992" NAME="Fujita 1992" YEAR="1992">
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Fujita T, Fukase M</AU>
<TI>Comparison of osteoporosis and calcium intake between Japan and the United States</TI>
<SO>Proceedings of the Society for Experimental Biology &amp; Medicine</SO>
<YR>1992</YR>
<VL>200</VL>
<PG>149-152</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Gharib--2004" NAME="Gharib  2004" YEAR="2004">
<REFERENCE NOTES="&lt;p&gt;13. Gharib S. An IV drug for osteoporosis? Harvard Health Letter 2004;29(8):8.&lt;/p&gt;" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Gharib S.</AU>
<TI>An IV drug for osteoporosis?</TI>
<SO>Harvard Health Letter</SO>
<YR>2004</YR>
<VL>29</VL>
<NO>8</NO>
<PG>8</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Gibbons-2004" NAME="Gibbons 2004" YEAR="2004">
<REFERENCE NOTES="&lt;p&gt;14. Gibbons MJ, Gilchrist NL, Frampton C, Maguire P, Reilly PH, March RL, et al. The effects of a high calcium dairy food on bone health in pre-pubertal children in New Zealand. Asia Pac J Clin Nutr 2004;13(4):341-7.&lt;/p&gt;" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Gibbons MJ, Gilchrist NL, Frampton C, Maguire P, Reilly PH, March RL, et al.</AU>
<TI>The effects of a high calcium dairy food on bone health in pre-pubertal children in New Zealand</TI>
<SO>Asia Pacific Journal of Clinical Nutrition</SO>
<YR>2004</YR>
<VL>13</VL>
<NO>4</NO>
<PG>341-7</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Ginty-2004" NAME="Ginty 2004" YEAR="2004">
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Ginty F, Prentice A</AU>
<TI>Can osteoporosis be prevented with dietary strategies during adolescence?[comment]</TI>
<SO>British Journal of Nutrition</SO>
<YR>2004</YR>
<VL>92</VL>
<PG>5-6</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Goulding-2004" NAME="Goulding 2004" YEAR="2004">
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Goulding A, Rockell JEP, Black RE, Grant AM, Jones IE, Williams SM</AU>
<TI>Children who avoid drinking cow's milk are at increased risk for prepubertal bone fractures</TI>
<SO>Journal of the American Dietetic Association</SO>
<YR>2004</YR>
<VL>104</VL>
<PG>250-253</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Griffiths-1998" NAME="Griffiths 1998" YEAR="1998">
<REFERENCE NOTES="&lt;p&gt;Griffiths ID, Francis RM. Milk intake and bone mineral acquisition in adolescent girls. Results in two groups are not so different. BMJ 1998;316:1747.&lt;/p&gt;" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Griffiths ID, Francis RM</AU>
<TI>Milk intake and bone mineral acquisition in adolescent girls. Results in two groups are not so different</TI>
<SO>British Medical Journal</SO>
<YR>1998</YR>
<VL>316</VL>
<PG>1747</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Grossklaus-1998" NAME="Grossklaus 1998" YEAR="1998">
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Grossklaus R</AU>
<TI>[The significance of milk and dairy product consumption in the prevention of osteoporosis.]</TI>
<SO>Molkerei Zeitung Welt der Milch</SO>
<YR>1998</YR>
<VL>52</VL>
<PG>9-11</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Gulati--2005" NAME="Gulati  2005" YEAR="2005">
<REFERENCE NOTES="&lt;p&gt;15. Gulati S, Gulati K. Bone disease in nephrotic syndrome - Prevention is better than cure. Pediatric Nephrology 2005;20(1):111-112.&lt;/p&gt;" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Gulati S, Gulati K.</AU>
<TI>Bone disease in nephrotic syndrome - Prevention is better than cure</TI>
<SO>Pediatric Nephrology</SO>
<YR>2005</YR>
<VL>20</VL>
<NO>1</NO>
<PG>111-112</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Hampton-2004" NAME="Hampton 2004" YEAR="2004">
<REFERENCE NOTES="&lt;p&gt;16. Hampton T. Experts urge early investment in bone health. JAMA: Journal of the American Medical Association 2004;291(7):811-2.&lt;/p&gt;" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Hampton T.</AU>
<TI>Experts urge early investment in bone health</TI>
<SO>Journal of the American Medical Association</SO>
<YR>2004</YR>
<VL>291</VL>
<NO>7</NO>
<PG>811-2</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Harel-1998" NAME="Harel 1998" YEAR="1998">
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Harel Z, Riggs S, Vaz R, White L, Menzies G</AU>
<TI>Adolescents and calcium: what they do and do not know and how much they consume</TI>
<SO>Journal of Adolescent Health</SO>
<YR>1998</YR>
<VL>22</VL>
<PG>225-8</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Henderson-1994" NAME="Henderson 1994" YEAR="1994">
<REFERENCE NOTES="&lt;p&gt;Henderson RC, Hayes PR. Bone mineralization in children and adolescents with a milk allergy. Bone-Miner 1994;27:1-12.&lt;/p&gt;" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Henderson RC, Hayes PR</AU>
<TI>Bone mineralization in children and adolescents with a milk allergy</TI>
<SO>Bone and Mineral</SO>
<YR>1994</YR>
<VL>27</VL>
<PG>1-12</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Hidvegi-2003" NAME="Hidvegi 2003" YEAR="2003">
<REFERENCE NOTES="&lt;p&gt;Hidvegi E, Arato A, Cserhati E, Horvath C, Szabo A. Slight decrease in bone mineralization in cow milk-sensitive children. J-Pediatr-Gastroenterol-Nutr 2003;36:44-49.&lt;/p&gt;" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Hidvegi E, Arato A, Cserhati E, Horvath C, Szabo A</AU>
<TI>Slight decrease in bone mineralization in cow milk-sensitive children</TI>
<SO>Journal of Pediatric Gastroenterology and Nutrition</SO>
<YR>2003</YR>
<VL>36</VL>
<PG>44-49</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Homik-2005" MODIFIED="2008-10-03 10:54:26 -0400" MODIFIED_BY="[Empty name]" NAME="Homik 2005" YEAR="">
<REFERENCE MODIFIED="2008-10-03 10:54:26 -0400" MODIFIED_BY="[Empty name]" NOTES="&lt;p&gt;18. Homik J, Suarez-Almazor ME, Shea B, Cranney A, Wells G, Tugwell P. Calcium and vitamin D for corticosteroid-induced osteoporosis. In. Oxford: The Cochrane Library.; 2005.&lt;/p&gt;" NOTES_MODIFIED="2008-10-03 10:54:26 -0400" NOTES_MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="COCHRANE_REVIEW">
<AU>Homik J, Suarez-Almazor ME, Shea B, Cranney A, Wells G, Tugwell P.</AU>
<TI>Calcium and vitamin D for corticosteroid-induced osteoporosis.</TI>
<SO>Cochrane Database of Systematic Reviews</SO>
<YR>2005</YR>
<VL>DOI: 10.1002/14651858.CD000952</VL>
<NO>4</NO>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Hoppe-2000" NAME="Hoppe 2000" YEAR="2000">
<REFERENCE NOTES="&lt;p&gt;Hoppe C, Molgaard C, Michaelsen KF. Bone size and bone mass in 10-year-old Danish children: effect of current diet. Osteoporos-Int 2000;11:1024-1030.&lt;/p&gt;" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Hoppe C, Molgaard C, Michaelsen KF</AU>
<TI>Bone size and bone mass in 10-year-old Danish children: effect of current diet</TI>
<SO>Osteoporosis International</SO>
<YR>2000</YR>
<VL>11</VL>
<PG>1024-1030</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Hosokawa-1996" NAME="Hosokawa 1996" YEAR="1996">
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Hosokawa M, Yanagi H, Kawanami K, Tanaka K, Kobayashi K, Amagai H, et al</AU>
<TI>[Relationship between dietary life style in youth and osteoporosis]</TI>
<SO>Nippon-Koshu-Eisei-Zasshi</SO>
<YR>1996</YR>
<VL>43</VL>
<PG>606-614</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Howat-2001" NAME="Howat 2001" YEAR="2001">
<REFERENCE NOTES="&lt;p&gt;Howat PM, Crombie A, Brooks ER. Dietary/supplement intake and bone mineral density. J-Am-Diet-Assoc 2001;101:520-521.&lt;/p&gt;" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Howat PM, Crombie A, Brooks ER</AU>
<TI>Dietary/supplement intake and bone mineral density</TI>
<SO>Journal of the American Dietetic Association</SO>
<YR>2001</YR>
<VL>101</VL>
<PG>520-521</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Iki-2003" NAME="Iki 2003" YEAR="2003">
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Iki M</AU>
<TI>[Evidence-based evaluation of preventive procedures for osteoporosis, osteoporotic fractures and other diseases]</TI>
<SO>Nippon Eiseigaku Zasshi - Japanese Journal of Hygiene</SO>
<YR>2003</YR>
<VL>58</VL>
<PG>311-6</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Ilich-1996" NAME="Ilich 1996" YEAR="1996">
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Ilich JZ, Badenhop NE, Matkovic V</AU>
<TI>Primary prevention of osteoporosis: pediatric approach to disease of the elderly</TI>
<SO>Womens Health Issues</SO>
<YR>1996</YR>
<VL>6</VL>
<PG>194-203</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Infante-2000" NAME="Infante 2000" YEAR="2000">
<REFERENCE NOTES="&lt;p&gt;Infante D, Tormo R. Risk of inadequate bone mineralization in diseases involving long-term suppression of dairy products. J-Pediatr-Gastroenterol-Nutr 2000;30:310-313.&lt;/p&gt;" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Infante D, Tormo R</AU>
<TI>Risk of inadequate bone mineralization in diseases involving long-term suppression of dairy products</TI>
<SO>Journal of Pediatric Gastroenterology and Nutrition</SO>
<YR>2000</YR>
<VL>30</VL>
<PG>310-313</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Kalkwarf-1997" NAME="Kalkwarf 1997" YEAR="1997">
<REFERENCE NOTES="&lt;p&gt;Kalkwarf HJ, Specker BL, Bianchi DC, Ranz JHM. The effect of calcium supplementation on bone density during lactation and after weaning.[see comment]. New England Journal of Medicine. 1997;337:523-528.&lt;/p&gt;" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Kalkwarf HJ, Specker BL, Bianchi DC, Ranz JHM</AU>
<TI>The effect of calcium supplementation on bone density during lactation and after weaning.[see comment].</TI>
<SO>New England Journal of Medicine</SO>
<YR>1997</YR>
<VL>337</VL>
<PG>523-528</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Kalkwarf-2003" NAME="Kalkwarf 2003" YEAR="2003">
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Kalkwarf HJ, Khoury JC, Lanphear BP</AU>
<TI>Milk intake during childhood and adolescence, adult bone density, and osteoporotic fractures in US women.[see comment]</TI>
<SO>American Journal of Clinical Nutrition</SO>
<YR>2003</YR>
<VL>77</VL>
<PG>257-65</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Kalusk-2001" NAME="Kalusk 2001" YEAR="2001">
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Kalusk DN, Basch CE, Zybert P, Deckelbaum RJ, Shea S</AU>
<TI>Calcium intake in preschool children - A study of dietary patterns in a low socioeconomic community</TI>
<SO>Public Health Reviews</SO>
<YR>2001</YR>
<VL>29</VL>
<PG>71-83</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Kanis-1994" NAME="Kanis 1994" YEAR="1994">
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Kanis JA</AU>
<TI>Calcium nutrition and its implications for osteoporosis. 1. Children and healthy adults</TI>
<SO>European-Journal-of-Clinical-Nutrition</SO>
<YR>1994</YR>
<VL>48</VL>
<PG>757-767</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Kardinaal-1999" NAME="Kardinaal 1999" YEAR="1999">
<REFERENCE NOTES="&lt;p&gt;Kardinaal AF, Ando S, Charles P, Charzewska J, Rotily M, Vaananen K, et al. Dietary calcium and bone density in adolescent girls and young women in Europe. J-Bone-Miner-Res 1999;14:583-592.&lt;/p&gt;" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Kardinaal AF, Ando S, Charles P, Charzewska J, Rotily M, Vaananen K, et al</AU>
<TI>Dietary calcium and bone density in adolescent girls and young women in Europe</TI>
<SO>Journal of Bone and Mineral Research</SO>
<YR>1999</YR>
<VL>14</VL>
<PG>583-592</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Kasper-2001" NAME="Kasper 2001" YEAR="2001">
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Kasper MJ, Peterson MG, Allegrante JP</AU>
<TI>The need for comprehensive educational osteoporosis prevention programs for young women: results from a second osteoporosis prevention survey</TI>
<SO>Arthritis &amp; Rheumatism</SO>
<YR>2001</YR>
<VL>45</VL>
<PG>28-34</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Kerstetter-1995" NAME="Kerstetter 1995" YEAR="1995">
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Kerstetter JE, Insogna K</AU>
<TI>Do dairy products improve bone density in adolescent girls?</TI>
<SO>Nutrition Reviews</SO>
<YR>1995</YR>
<VL>53</VL>
<PG>328-332</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Koenig-2000" NAME="Koenig 2000" YEAR="2000">
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Koenig J, Elmadfa I</AU>
<TI>Status of calcium and vitamin D of different population groups in Austria</TI>
<SO>International Journal for Vitamin and Nutrition Research</SO>
<YR>2000</YR>
<VL>70</VL>
<PG>214-220</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Kowalski--2004" NAME="Kowalski  2004" YEAR="2004">
<REFERENCE NOTES="&lt;p&gt;19. Kowalski IM, Siwik P, Skibniewska K. Compression fractures of the spine - Juvenile osteopeny. Eurorehab. Issue 2004;2(pp 53-59).&lt;/p&gt;" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Kowalski IM, Siwik P, Skibniewska K.</AU>
<TI>Compression fractures of the spine - Juvenile osteopeny. Eurorehab</TI>
<SO>Issue</SO>
<YR>2004</YR>
<VL>2</VL>
<NO>pp 53-59</NO>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Kreipe-1995" NAME="Kreipe 1995" YEAR="1995">
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Kreipe RE</AU>
<TI>Bone mineral density in adolescents</TI>
<SO>Pediatric Annals</SO>
<YR>1995</YR>
<VL>24</VL>
<PG>308-15</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Kubota-2003" NAME="Kubota 2003" YEAR="2003">
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Kubota M</AU>
<TI>[Optimization of calcium intake for the prevention of osteoporosis and osteoporotic fractures: a review of the evidence]</TI>
<SO>Nippon Eiseigaku Zasshi - Japanese Journal of Hygiene</SO>
<YR>2003</YR>
<VL>58</VL>
<PG>317-27</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Kun-2001" NAME="Kun 2001" YEAR="2001">
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Kun Z, Greenfield H, Xueqin D, Fraser DR</AU>
<TI>Improvement of bone health in childhood and adolescence</TI>
<SO>Nutrition Research Reviews</SO>
<YR>2001</YR>
<VL>14</VL>
<PG>119-151</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Lappe-2004" NAME="Lappe 2004" YEAR="2004">
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Lappe JM, Rafferty KA, Davies KM, Lypaczewski G</AU>
<TI>Girls on a high-calcium diet gain weight at the same rate as girls on a normal diet: A pilot study</TI>
<SO>Journal of the American Dietetic Association</SO>
<YR>2004</YR>
<VL>104</VL>
<PG>1361-1367</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-LaRosa-2004" NAME="LaRosa 2004" YEAR="2004">
<REFERENCE NOTES="&lt;p&gt;20. LaRosa DF, Apter AJ. Preventing and managing osteoporosis in patients with asthma and COPD. Journal of Respiratory Diseases. 2004 Oct; ;25(10):426-8.&lt;/p&gt;" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>LaRosa DF, Apter AJ.</AU>
<TI>Preventing and managing osteoporosis in patients with asthma and COPD.</TI>
<SO>Journal of Respiratory Diseases</SO>
<YR>2004</YR>
<VL>25</VL>
<NO>10</NO>
<PG>426-8</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Lau-1992" NAME="Lau 1992" YEAR="1992">
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Lau EMC, Lee WTK, Leung S, Cheng J</AU>
<TI>Milk supplementation - A feasible and effective way to enhance bone gain for Chinese adolescents in Hong Kong?</TI>
<SO>Journal of Applied Nutrition</SO>
<YR>1992</YR>
<VL>44</VL>
<PG>16-21</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Lau-2004" NAME="Lau 2004" YEAR="2004">
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Lau EMC, Lynn H, Chan YH, Lau W, Woo J</AU>
<TI>Benefits of milk powder supplementation on bone accretion in Chinese children</TI>
<SO>Osteoporosis International</SO>
<YR>2004</YR>
<VL>15</VL>
<PG>654-658</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Lee-1993" NAME="Lee 1993" YEAR="1993">
<REFERENCE NOTES="&lt;p&gt;Lee WT, Leung SS, Lui SS, Lau J. Relationship between long-term calcium intake and bone mineral content of children aged from birth to 5 years. Br-J-Nutr 1993;70:235-248.&lt;/p&gt;" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Lee WT, Leung SS, Lui SS, Lau J</AU>
<TI>Relationship between long-term calcium intake and bone mineral content of children aged from birth to 5 years</TI>
<SO>British Journal of Nutrition</SO>
<YR>1993</YR>
<VL>70</VL>
<PG>235-248</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Lee-2003" NAME="Lee 2003" YEAR="2003">
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Lee SM, Reicks M</AU>
<TI>Environmental and behavioral factors are associated with the calcium intake of low-income adolescent girls</TI>
<SO>Journal of the American Dietetic Association</SO>
<YR>2003</YR>
<VL>103</VL>
<PG>1526-1529</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Levers_x002d_Landis-2003" NAME="Levers-Landis 2003" YEAR="2003">
<REFERENCE NOTES="&lt;p&gt;Ievers-Landis CE, Burant C, Drotar D, Morgan L, Trapl ES, Kent Kwoh C. Social support, knowledge, and self-efficacy as correlates of osteoporosis preventive behaviors among preadolescent females. Journal of Pediatric Psychology 2003;28:335-345.&lt;/p&gt;" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Levers-Landis CE, Burant C, Drotar D, Morgan L, Trapl ES, Kent Kwoh C</AU>
<TI>Social support, knowledge, and self-efficacy as correlates of osteoporosis preventive behaviors among preadolescent females</TI>
<SO>Journal of Pediatric Psychology</SO>
<YR>2003</YR>
<VL>28</VL>
<PG>335-345</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Li-2002" NAME="Li 2002" YEAR="2002">
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Li J, Li H, Wang S</AU>
<TI>[Effects of calcium supplementation on bone mineral accretion in adolescents]</TI>
<SO>Wei Sheng Yan Jiu</SO>
<YR>2002</YR>
<VL>31</VL>
<PG>363-6</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Lloyd-2000" NAME="Lloyd 2000" YEAR="2000">
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Lloyd T, Chinchilli VM, Johnson Rollings N, Kieselhorst K, Eggli DF, Marcus R</AU>
<TI>Adult female hip bone density reflects teenage sports-exercise patterns but not teenage calcium intake</TI>
<SO>Pediatrics</SO>
<YR>2000</YR>
<VL>106</VL>
<PG>40-44</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Lloyd-2002" NAME="Lloyd 2002" YEAR="2002">
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Lloyd T, Beck TJ, Lin HM, Tulchinsky M, Eggli DF, Oreskovic TL, et al</AU>
<TI>Modifiable determinants of bone status in young women</TI>
<SO>Bone</SO>
<YR>2002</YR>
<VL>30</VL>
<PG>416-421</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Lysen-1997" NAME="Lysen 1997" YEAR="1997">
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Lysen VC, Walker R</AU>
<TI>Osteoporosis risk factors in eighth grade students</TI>
<SO>Journal of School Health</SO>
<YR>1997</YR>
<VL>67</VL>
<PG>317-21</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Ma--2004" NAME="Ma  2004" YEAR="2004">
<REFERENCE NOTES="&lt;p&gt;21. Ma D, Jones G. Soft drink and milk consumption, physical activity, bone mass, and upper limb fractures in children: a population-based case-control study. Calcif Tissue Int 2004;75(4):286-91.&lt;/p&gt;" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Ma D, Jones G.</AU>
<TI>Soft drink and milk consumption, physical activity, bone mass, and upper limb fractures in children: a population-based case-control study</TI>
<SO>Calcified Tissue International</SO>
<YR>2004</YR>
<VL>75</VL>
<NO>4</NO>
<PG>286-91</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Mackelvie-2001" NAME="Mackelvie 2001" YEAR="2001">
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Mackelvie KJ, McKay HA, Khan KM, Crocker PR</AU>
<TI>Lifestyle risk factors for osteoporosis in Asian and Caucasian girls</TI>
<SO>Medicine and Science in Sports and Exercise</SO>
<YR>2001</YR>
<VL>33</VL>
<PG>181-1824</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Magee-1996" NAME="Magee 1996" YEAR="">
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Magee M, Moyer-Mileur L, Chan, G</AU>
<TI>Bone mineralization and dietary intake in adolescent females following cessation of dairy supplementation.</TI>
<SO>Journal of the American Dietetic Association</SO>
<YR>1996</YR>
<VL>96</VL>
<NO>9 Suppl</NO>
<PG>A-56</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Maggiolini-1999" NAME="Maggiolini 1999" YEAR="1999">
<REFERENCE NOTES="&lt;p&gt;Maggiolini M, Bonofiglio D, Giorno A, Catalano S, Marsico S, Aquila S, et al. The effect of dietary calcium intake on bone mineral density in healthy adolescent girls and young women in southern Italy. Int-J-Epidemiol 1999;28:479-484.&lt;/p&gt;" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Maggiolini M, Bonofiglio D, Giorno A, Catalano S, Marsico S, Aquila S, et al</AU>
<TI>The effect of dietary calcium intake on bone mineral density in healthy adolescent girls and young women in southern Italy</TI>
<SO>International Journal of Epidemiology</SO>
<YR>1999</YR>
<VL>28</VL>
<PG>479-484</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Mahana-1988" NAME="Mahana 1988" YEAR="1988">
<REFERENCE NOTES="&lt;p&gt;Not RCT Mahana D. [Risk of osteoporosis in Chilean adolescents caused by low calcium ingestion]. Rev-Med-Chil 1988;116:482-483.&lt;/p&gt;" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Mahana D</AU>
<TI>[Risk of osteoporosis in Chilean adolescents caused by low calcium ingestion]</TI>
<SO>Revista-Medica-de-Chile</SO>
<YR>1988</YR>
<VL>116</VL>
<PG>482-483</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Mallet-2000" NAME="Mallet 2000" YEAR="2000">
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Mallet E</AU>
<TI>[Do children and adolescents need supplements during puberty of calcium and vitamin D?].[comment]</TI>
<SO>Archives de Pediatrie</SO>
<YR>2000</YR>
<VL>7</VL>
<PG>117-20</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Mallet-2003" NAME="Mallet 2003" YEAR="2003">
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Mallet E</AU>
<TI>[Osteoporosis in adolescents]</TI>
<SO>Archives de Pediatrie</SO>
<YR>2003</YR>
<VL>10 Suppl 1</VL>
<PG>204s-205s</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Marrero-2004" NAME="Marrero 2004" YEAR="2004">
<REFERENCE NOTES="&lt;p&gt;22. Marrero Montelongo M, Navarro Rodriguez MC, Lainez Sevillano P, Torres Garcia M, Serra Majem L. Present intake of calcium from lactic products in the 6 to 75 year old Canary Islands population. Data from the Canary Islands Nutritional Survey (ENCA). [Spanish]. Revista Espanola de Enfermedades Metabolicas Oseas 2004;13(2):25-29.&lt;/p&gt;" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Marrero Montelongo M, Navarro Rodriguez MC, Lainez Sevillano P, Torres Garcia M, Serra Majem L.</AU>
<TI>Present intake of calcium from lactic products in the 6 to 75 year old Canary Islands population. Data from the Canary Islands Nutritional Survey (ENCA). [Spanish]</TI>
<SO>Revista Espanola de Enfermedades Metabolicas Oseas</SO>
<YR>2004</YR>
<VL>13</VL>
<NO>2</NO>
<PG>25-29</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Martin--2004" NAME="Martin  2004" YEAR="2004">
<REFERENCE NOTES="&lt;p&gt;23. Martin JT, Coviak CP, Gendler P, Kim KK, Cooper K, Rodrigues-Fisher L. Female adolescents' knowledge of bone health promotion behaviors and osteoporosis risk factors. Orthopaedic Nursing 2004;23(4):235-44.&lt;/p&gt;" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Martin JT, Coviak CP, Gendler P, Kim KK, Cooper K, Rodrigues-Fisher L.</AU>
<TI>Female adolescents' knowledge of bone health promotion behaviors and osteoporosis risk factors</TI>
<SO>Orthopaedic Nursing</SO>
<YR>2004</YR>
<VL>23</VL>
<NO>4</NO>
<PG>235-44</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Matkovic-1990" NAME="Matkovic 1990" YEAR="1990">
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Matkovic V, Fontana D, Tominac C, Goel P, Chesnut CH, 3rd.</AU>
<TI>Factors that influence peak bone mass formation: a study of calcium balance and the inheritance of bone mass in adolescent females.</TI>
<SO>American Journal of Clinical Nutrition</SO>
<YR>1990</YR>
<VL>52</VL>
<PG>878-88</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Matkovic-2002" NAME="Matkovic 2002" YEAR="2002">
<REFERENCE NOTES="&lt;p&gt;Matkovic V, Badenhop Stevens N, Ha E, Crncevic Orlic Z, Clairmont A. Nutrition and Bone Health in Children and Adolescents. Clinical-Reviews-in-Bone-and-Mineral-Metabolism 2002;1:233-248.&lt;/p&gt;" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Matkovic V, Badenhop Stevens N, Ha E, Crncevic Orlic Z, Clairmont A</AU>
<TI>Nutrition and Bone Health in Children and Adolescents</TI>
<SO>Clinical Reviews in Bone and Mineral Metabolism</SO>
<YR>2002</YR>
<VL>1</VL>
<PG>233-248</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-McCulloch-1990" NAME="McCulloch 1990" YEAR="1990">
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>McCulloch R, Bailey D, Houston S, Dodd B</AU>
<TI>Effects of physical activity, dietary calcium intake and selected lifestyle factors on bone density in young women</TI>
<SO>Canadian Medical Association Journal</SO>
<YR>1990</YR>
<VL>142</VL>
<PG>221-227</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Meier-2004" NAME="Meier 2004" YEAR="2004">
<REFERENCE NOTES="&lt;p&gt;25. Meier C WHWWKLBSMJ. Supplementation with oral vitamin d3 and calcium during winter prevents seasonal bone loss: a randomized controlled open-label prospective trial. J Bone Miner Res.&lt;/p&gt;" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Meier C, Woitge HW, Witte K, Lemmer B, Seibel MJ.</AU>
<TI>Supplementation with oral vitamin d3 and calcium during winter prevents seasonal bone loss: a randomized controlled open-label prospective trial</TI>
<SO>Journal of Bone and Mineral Research</SO>
<YR>2004</YR>
<VL>19</VL>
<NO>8</NO>
<PG>1221-30.</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Merrilees-2000" NAME="Merrilees 2000" YEAR="2000">
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Merrilees MJ, Smart EJ, Gilchrist NL, Frampton C, Turner JG, Hooke E, et al</AU>
<TI>Effects of dairy food supplements on bone mineral density in teenage girls</TI>
<SO>European Journal of Nutrition</SO>
<YR>2000</YR>
<VL>39</VL>
<PG>256-262</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Meschino-2004" NAME="Meschino 2004" YEAR="2004">
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Meschino J</AU>
<TI>Calcium Supplementation Increases Bone Density in Teenage Girls</TI>
<SO>Dynamic Chiropractic</SO>
<YR>2004</YR>
<VL>22</VL>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Moelgaard-2001" NAME="Moelgaard 2001" YEAR="2001">
<REFERENCE NOTES="&lt;p&gt;Moelgaard C, Thomsen BL, Michaelsen KF. The Influence of Calcium Intake and Physical Activity on Bone Mineral Content and Bone Size in Healthy Children and Adolescents. Osteoporosis-International 2001;12:887-894.&lt;/p&gt;" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Moelgaard C, Thomsen BL, Michaelsen KF</AU>
<TI>The Influence of Calcium Intake and Physical Activity on Bone Mineral Content and Bone Size in Healthy Children and Adolescents</TI>
<SO>Osteoporosis International</SO>
<YR>2001</YR>
<VL>12</VL>
<PG>887-894</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Monge-2001" NAME="Monge 2001" YEAR="2001">
<REFERENCE NOTES="&lt;p&gt;Monge Rojas R, Nunez HP. Dietary calcium intake by a group of 13 18-year-old Costa Rican teenagers. Arch-Latinoam-Nutr; 2001;51:127-131.&lt;/p&gt;" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Monge Rojas R, Nunez HP</AU>
<TI>Dietary calcium intake by a group of 13 18-year-old Costa Rican teenagers</TI>
<SO>Archivos Latinoamericanos De Nutricion</SO>
<YR>2001</YR>
<VL>51</VL>
<PG>127-131</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Moya-1997" NAME="Moya 1997" YEAR="1997">
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Moya M</AU>
<TI>[Calcium supplements in pediatrics: facts and fiction]</TI>
<SO>Anales Espanoles de Pediatria</SO>
<YR>1997</YR>
<VL>46</VL>
<PG>427</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Moyer_x002d_Mileur-2003" NAME="Moyer-Mileur 2003" YEAR="2003">
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Moyer-Mileur LJ, Xie B, Ball SD, Pratt T</AU>
<TI>Bone mass and density response to a 12-month trial of calcium and vitamin D supplement in preadolescent girls</TI>
<SO>Journal of Musculoskeletal Neuronal Interactions</SO>
<YR>2003</YR>
<VL>3</VL>
<PG>63-70</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Naunton-2004" NAME="Naunton 2004" YEAR="2004">
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Naunton M, Peterson GM, Jones G, Griffin GM, Bleasel MD.</AU>
<TI>Multifaceted educational program increases prescribing of preventive medication for corticosteroid induced osteoporosis</TI>
<SO>Journal of Rheumatology</SO>
<YR>2004</YR>
<VL>31</VL>
<NO>3</NO>
<PG>550-6</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Neville-2002" NAME="Neville 2002" YEAR="2002">
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Neville CE, Robson PJ, Murray LJ, Strain JJ, Twisk J, Gallagher AM, et al</AU>
<TI>The effect of nutrient intake on bone mineral status in young adults: The Northern Ireland young hearts project</TI>
<SO>Calcified Tissue International</SO>
<YR>2002</YR>
<VL>70</VL>
<PG>89-98</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-New-1998" NAME="New 1998" YEAR="1998">
<REFERENCE NOTES="&lt;p&gt;New S, Ferns G, Starkey B. Milk intake and bone mineral acquisition in adolescent girls. Increases in bone density may be result of micronutrients in additional cereal. BMJ 1998;316:1747.&lt;/p&gt;" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>New S, Ferns G, Starkey B</AU>
<TI>Milk intake and bone mineral acquisition in adolescent girls. Increases in bone density may be result of micronutrients in additional cereal</TI>
<SO>British Medical Journal</SO>
<YR>1998</YR>
<VL>316</VL>
<PG>1747</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-NIH-2001" NAME="NIH 2001" YEAR="2001">
<REFERENCE NOTES="&lt;p&gt;Nih Consensus Development Panel on Osteoporosis Prevention D, Therapy. Osteoporosis prevention, diagnosis, and therapy.[see comment]. JAMA 2001;285:785-95.&lt;/p&gt;" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>NIH Consensus Development Panel on Osteoporosis Prevention D, Therapy</AU>
<TI>Osteoporosis prevention, diagnosis, and therapy.[see comment]</TI>
<SO>Journal of the American Medical Association</SO>
<YR>2001</YR>
<VL>285</VL>
<PG>785-95</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Novotny-2004" NAME="Novotny 2004" YEAR="2004">
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Novotny R, Daida YG, Grove JS, Acharya S, Vogt TM, Paperny D</AU>
<TI>Adolescent dairy consumption and physical activity associated with bone mass</TI>
<SO>Preventive Medicine</SO>
<YR>2004</YR>
<VL>39</VL>
<PG>355-360</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Nowson-1995" NAME="Nowson 1995" YEAR="1995">
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Nowson CA, Green RM, Guest CS, Larkins RG, Sherwin AJ, Hopper JL, et al</AU>
<TI>The effect of calcium supplementation for 18 months on bone mass in adolescent female twins</TI>
<SO>Proceedings-of-the-Nutrition-Society-of-Australia</SO>
<YR>1995</YR>
<VL>19</VL>
<PG>56</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-O_x0027_-Brien-1998" NAME="O' Brien 1998" YEAR="1998">
<REFERENCE NOTES="&lt;p&gt;O' Brien KO, Abrams SA, Liang LK, Ellis KJ, Gagel RF. Bone turnover response to changes in calcium intake is altered in girls and adult women in families with histories of osteoporosis. J-Bone-Miner-Res 1998;13:491-499.&lt;/p&gt;" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>O' Brien KO, Abrams SA, Liang LK, Ellis KJ, Gagel RF</AU>
<TI>Bone turnover response to changes in calcium intake is altered in girls and adult women in families with histories of osteoporosis</TI>
<SO>Journal of Bone and Mineral Research</SO>
<YR>1998</YR>
<VL>13</VL>
<PG>491-499</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Oellingrath-1989" NAME="Oellingrath 1989" YEAR="1989">
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Oellingrath IM</AU>
<TI>[Can calcium in the diet prevent osteoporosis and high blood pressure?]</TI>
<SO>Meieriposten</SO>
<YR>1989</YR>
<VL>78</VL>
<PG>33-36</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Ohgitani-1997" NAME="Ohgitani 1997" YEAR="1997">
<REFERENCE NOTES="&lt;p&gt;Ohgitani S, Fujii Y, Fujita T. [Effects of calcium supplementation using AAACa or milk on nocturnal bone resorption in young women]. [Japanese]. Nippon Ronen Igakkai Zasshi - Japanese Journal of Geriatrics. . 1997;34:743-747.&lt;/p&gt;" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Ohgitani S, Fujii Y, Fujita T</AU>
<TI>[Effects of calcium supplementation using AAACa or milk on nocturnal bone resorption in young women]. [Japanese].</TI>
<SO>Nippon Ronen Igakkai Zasshi - Japanese Journal of Geriatrics.</SO>
<YR>1997</YR>
<VL>34</VL>
<PG>743-747</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Oria-2003" NAME="Oria 2003" YEAR="2003">
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Oria E</AU>
<TI>Preventive and nutritional factors of osteoporosis. [Spanish]</TI>
<SO>Anales del Sistema Sanitario de Navarra</SO>
<YR>2003</YR>
<VL>26</VL>
<PG>81-90</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Parr-2002" NAME="Parr 2002" YEAR="2002">
<REFERENCE NOTES="&lt;p&gt;Parr RM, Dey A, McCloskey EV, Aras N, Balogh A, Borelli A, et al. Contribution of calcium and other dietary components to global variations in bone mineral density in young adults. Food-Nutr-Bull 2002;23 (Suppl 3):180-184.&lt;/p&gt;" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Parr RM, Dey A, McCloskey EV, Aras N, Balogh A, Borelli A, et al</AU>
<TI>Contribution of calcium and other dietary components to global variations in bone mineral density in young adults</TI>
<SO>Food and Nutrition Bulletin</SO>
<YR>2002</YR>
<VL>23</VL>
<NO>Suppl 3</NO>
<PG>180-184</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Pena-2004" NAME="Pena 2004" YEAR="2004">
<REFERENCE NOTES="&lt;p&gt;28. Pena MJM, Gonzalez-Montero R. Management of the metabolic alterations in children infected with HIV. [Spanish, English]. Nutrition &amp;amp; Metabolic Disorders in HIV Infection 2004;3(2):361-371.&lt;/p&gt;" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Pena MJM, Gonzalez-Montero R.</AU>
<TI>Management of the metabolic alterations in children infected with HIV. [Spanish, English]</TI>
<SO>Nutrition &amp; Metabolic Disorders in HIV Infection</SO>
<YR>2004</YR>
<VL>3</VL>
<NO>2</NO>
<PG>361-371</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Peterson-2000" NAME="Peterson 2000" YEAR="2000">
<REFERENCE NOTES="&lt;p&gt;Peterson BA, Klesges RC, Kaufman EM, Cooper TV, Vukadinovich CM. The effects of an educational intervention on calcium intake and bone mineral content in young women with low calcium intake. American Journal of Health Promotion. 2000;14:149-156.&lt;/p&gt;" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Peterson BA, Klesges RC, Kaufman EM, Cooper TV, Vukadinovich CM</AU>
<TI>The effects of an educational intervention on calcium intake and bone mineral content in young women with low calcium intake.</TI>
<SO>American Journal of Health Promotion</SO>
<YR>2000</YR>
<VL>14</VL>
<PG>149-156</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Piaseu-2002" NAME="Piaseu 2002" YEAR="2002">
<REFERENCE NOTES="&lt;p&gt;Piaseu N, Schepp K, Belza B. Causal analysis of exercise and calcium intake behaviors for osteoporosis prevention among young women in Thailand. Health Care for Women International. 2002;23:364-376.&lt;/p&gt;" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Piaseu N, Schepp K, Belza B</AU>
<TI>Causal analysis of exercise and calcium intake behaviors for osteoporosis prevention among young women in Thailand.</TI>
<SO>Health Care for Women International</SO>
<YR>2002</YR>
<VL>23</VL>
<PG>364-376</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Picard-1988" NAME="Picard 1988" YEAR="1988">
<REFERENCE NOTES="&lt;p&gt;Not RCT Picard D, Ste-Marie LG, Coutu D, Carrier L, Chartrand R, Lepage R, et al. Premenopausal bone mineral content relates to height, weight and calcium intake during early adulthood. Bone Miner 1988;4:299-309.&lt;/p&gt;" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Picard D, Ste-Marie LG, Coutu D, Carrier L, Chartrand R, Lepage R, et al</AU>
<TI>Premenopausal bone mineral content relates to height, weight and calcium intake during early adulthood</TI>
<SO>Bone and Mineral</SO>
<YR>1988</YR>
<VL>4</VL>
<PG>299-309</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Portsmouth-1994" NAME="Portsmouth 1994" YEAR="1994">
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Portsmouth K, Henderson K, Graham N, Price R, Cole J, Allen J</AU>
<TI>Dietary calcium intake in 18-year-old women: comparison with recommended daily intake and dietary energy intake</TI>
<SO>Journal of Advanced Nursing</SO>
<YR>1994</YR>
<VL>20</VL>
<PG>1073-8</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Prestridge-1993" NAME="Prestridge 1993" YEAR="1993">
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Prestridge LL, Schanler RJ, Shulman RJ, Burns PA, Laine LL</AU>
<TI>Effect of parenteral calcium and phosphorus therapy on mineral retention and bone mineral content in very low birth weight infants</TI>
<SO>Journal of Pediatrics</SO>
<YR>1993</YR>
<VL>122</VL>
<PG>761-8</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Prynne-2004" NAME="Prynne 2004" YEAR="2004">
<REFERENCE NOTES="&lt;p&gt;30. Prynne CJ, Ginty F, Paul AA, Bolton-Smith C, Stear SJ, Jones SC, et al. Dietary acid-base balance and intake of bone-related nutrients in Cambridge teenagers.[erratum appears in Eur J Clin Nutr. 2004 Nov;58(11):1558].1462-71, 2004 Nov.&lt;/p&gt;" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Prynne CJ, Ginty F, Paul AA, Bolton-Smith C, Stear SJ, Jones SC, et al.</AU>
<TI>Dietary acid-base balance and intake of bone-related nutrients in Cambridge teenagers.</TI>
<SO>European Journal of Clinical Nutrition</SO>
<YR>2004</YR>
<VL>58</VL>
<NO>11</NO>
<PG>1462-71</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Purdie-1994" NAME="Purdie 1994" YEAR="1994">
<REFERENCE NOTES="&lt;p&gt;Purdie DW. Bone density and milk. Target schoolchildren for intervention.[comment]. BMJ 1994;308:1566.&lt;/p&gt;" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Purdie DW</AU>
<TI>Bone density and milk. Target schoolchildren for intervention.[comment]</TI>
<SO>British Medical Journal</SO>
<YR>1994</YR>
<VL>308</VL>
<PG>1566</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Recker-1993" NAME="Recker 1993" YEAR="1993">
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Recker RR</AU>
<TI>Prevention of osteoporosis: calcium nutrition</TI>
<SO>Osteoporosis International</SO>
<YR>1993</YR>
<VL>3 Suppl 1</VL>
<PG>163-5</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Reid-1998" NAME="Reid 1998" YEAR="1998">
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Reid IR</AU>
<TI>The roles of calcium and vitamin D in the prevention of osteoporosis. [Review] [35 refs]. Endocrinology &amp; Metabolism Clinics of North America</TI>
<YR>1998</YR>
<VL>27</VL>
<PG>389-398</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Remer-2002" NAME="Remer 2002" YEAR="2002">
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Remer T, Boye KR, Manz F</AU>
<TI>Long-term increase in bone mass through high calcium intake before puberty</TI>
<SO>Lancet</SO>
<YR>2002</YR>
<VL>359</VL>
<PG>2037-2038</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Renner-1991a" NAME="Renner 1991a" YEAR="1991">
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Renner E, Knie G, Schatz H, Stracke H, Weber K, Minne HW, et al</AU>
<TI>On the incidence of osteoporosis in relation to the calcium intake with milk and milk products</TI>
<SO>International-Dairy-Journal</SO>
<YR>1991</YR>
<VL>1</VL>
<PG>77-82</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Renner-1991b" NAME="Renner 1991b" YEAR="1991">
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Renner E, Knie G, Stracke H</AU>
<TI>Effect of calcium intake through milk and dairy products on bone mineral content and incidence of osteoporosis</TI>
<SO>Milchwissenschaft Giessen</SO>
<YR>1991</YR>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Renner-1994" NAME="Renner 1994" YEAR="1994">
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Renner E</AU>
<TI>Dairy calcium, bone metabolism, and prevention of osteoporosis</TI>
<SO>Journal of Dairy Science</SO>
<YR>1994</YR>
<VL>77</VL>
<PG>3498-505</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Renner-1998" NAME="Renner 1998" YEAR="1998">
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Renner E, Hermes M, Stracke H</AU>
<TI>Bone mineral density of adolescents as affected by calcium intake through milk and milk products</TI>
<SO>International Dairy Journal</SO>
<YR>1998</YR>
<VL>8</VL>
<PG>759-764</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Roberts-2000" NAME="Roberts 2000" YEAR="2000">
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Roberts SB, Heyman MB</AU>
<TI>Micronutrient shortfalls in young children's diets: common, and owing to inadequate intakes both at home and at child care centers</TI>
<SO>Nutrition Reviews</SO>
<YR>2000</YR>
<VL>58</VL>
<PG>27-29</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Robertson-2005" NAME="Robertson 2005" YEAR="2005">
<REFERENCE NOTES="&lt;p&gt;31. Robertson L. 4 proven steps to stronger bones and a healthier body: don't assume that the calcium you consume ends up in your bones. Vibrant Life 2005;21(1):10-2.&lt;/p&gt;" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Robertson L.</AU>
<TI>4 proven steps to stronger bones and a healthier body: don't assume that the calcium you consume ends up in your bones</TI>
<SO>Vibrant Life</SO>
<YR>2005</YR>
<VL>21</VL>
<NO>1</NO>
<PG>10-2</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Roux-1995" NAME="Roux 1995" YEAR="1995">
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Roux C</AU>
<TI>Calcium supplementation for the prevention and treatment of osteoporosis</TI>
<SO>Revue du Rhumatisme</SO>
<YR>1995</YR>
<VL>62</VL>
<PG>729-732</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Rozen-2001" NAME="Rozen 2001" YEAR="2001">
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Rozen GS, Rennert G, Rennert HS, Diab G, Daud D, Ish-Shalom S</AU>
<TI>Calcium intake and bone mass development among Israeli adolescent girls</TI>
<SO>Journal of the American College of Nutrition</SO>
<YR>2001</YR>
<VL>20</VL>
<PG>219-24</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Ruiz-1995" NAME="Ruiz 1995" YEAR="1995">
<REFERENCE NOTES="&lt;p&gt;Ruiz JC, Mandel C, Garabedian M. Influence of spontaneous calcium intake and physical exercise on the vertebral and femoral bone mineral density of children and adolescents. J Bone Miner Res 1995;10:675-82.&lt;/p&gt;" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Ruiz JC, Mandel C, Garabedian M</AU>
<TI>Influence of spontaneous calcium intake and physical exercise on the vertebral and femoral bone mineral density of children and adolescents</TI>
<SO>Journal of Bone and Mineral Research</SO>
<YR>1995</YR>
<VL>10</VL>
<PG>675-82</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Runyan-2003" NAME="Runyan 2003" YEAR="2003">
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Runyan SM, Stadler DD, Bainbridge CN, Miller SC, Moyer-Mileur LJ</AU>
<TI>Familial resemblance of bone mineralization, calcium intake, and physical activity in early-adolescent daughters, their mothers, and maternal grandmothers</TI>
<SO>Journal of the American Dietetic Association</SO>
<YR>2003</YR>
<VL>103</VL>
<PG>1320-1325</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Sagara-2002" NAME="Sagara 2002" YEAR="2002">
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Sagara T, Nishijo M, Hirokawa W, Morikawa Y, Miura K, Tabata M, et al</AU>
<TI>[The effects of nutrition and life-style on calcaneal bone mass in high school students]</TI>
<SO>Nippon-Koshu-Eisei-Zasshi</SO>
<YR>2002</YR>
<VL>49</VL>
<PG>389-398</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Saggese" NAME="Saggese" YEAR="1991">
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Saggese G, Betelloni S, Baroncelli GI, Perri G, Calderazzi A</AU>
<TI>Mineral metabolism and calcitriol therapy in idiopathic juvenile osteoporosis</TI>
<SO>American Journal of Diseases of Children</SO>
<YR>1991</YR>
<VL>149</VL>
<PG>457-462</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Sakkers-2004" NAME="Sakkers 2004" YEAR="">
<REFERENCE NOTES="&lt;p&gt;32. Sakkers R, Kok D, Engelbert R, van Dongen A, Jansen M, Pruijs H, et al. Skeletal effects and functional outcome with olpadronate in children with osteogenesis imperfecta: a 2-year randomised placebo-controlled study.[see comment].1427-31, 2004 May 1.&lt;/p&gt;" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Sakkers R, Kok D, Engelbert R, van Dongen A, Jansen M, Pruijs H, et al.</AU>
<TI>Skeletal effects and functional outcome with olpadronate in children with osteogenesis imperfecta: a 2-year randomised placebo-controlled study.</TI>
<SO>Lancet</SO>
<YR>2004</YR>
<PG>1427-31</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Scholz-1993" NAME="Scholz 1993" YEAR="1993">
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Scholz Ahrens KE, Jaeger W, Barth CA</AU>
<TI>Milch und Milchprodukte in der Praevention der Osteoporose. [Milk and dairy products in the prevention of osteoporosis.]</TI>
<SO>Molkerei Zeitung Welt der Milch</SO>
<YR>1993</YR>
<VL>47</VL>
<PG>5-8</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Schonau-2004" NAME="Schonau 2004" YEAR="2004">
<REFERENCE NOTES="&lt;p&gt;33. Schonau E. The peak bone mass concept: Is it still relevant? Pediatric Nephrology 2004;19(8):825-831.&lt;/p&gt;" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Schonau E.</AU>
<TI>The peak bone mass concept: Is it still relevant?</TI>
<SO>Pediatric Nephrology</SO>
<YR>2004</YR>
<VL>19</VL>
<NO>8</NO>
<PG>825-831</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Smart-1994" NAME="Smart 1994" YEAR="1994">
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Smart EJ, Gilchrist NL, Turner JC, March R, Maguire P, Sadler WA, et al</AU>
<TI>The effects of dairy supplementation on bone mineral density on teenage girls: baseline randomisation data</TI>
<SO>Proceedings of the Nutrition Society of New Zealand</SO>
<YR>1994</YR>
<VL>19</VL>
<PG>73-80</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Solomons-1996" NAME="Solomons 1996" YEAR="1996">
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Solomons NW, Kirstetter J, Insogna K</AU>
<TI>The effects of dairy products on body composition, bone mineralization, and weight in adolescent girls</TI>
<SO>Nutrition Reviews</SO>
<YR>1996</YR>
<VL>54</VL>
<PG>64-65</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Soroko-1994" NAME="Soroko 1994" YEAR="1994">
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Soroko S, Holbrook TL, Edelstein S, Barrett-Connor E</AU>
<TI>Lifetime milk consumption and bone mineral density in older women</TI>
<SO>American Journal of Public Health</SO>
<YR>1994</YR>
<VL>84</VL>
<PG>1319-22</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Specker-1997" NAME="Specker 1997" YEAR="1997">
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Specker BL, Beck A, Kalkwarf H, Ho M</AU>
<TI>Randomized trial of varying mineral intake on total body bone mineral accretion during the first year of life</TI>
<SO>Pediatrics</SO>
<YR>1997</YR>
<VL>99</VL>
<PG>E12</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Specker-1999" NAME="Specker 1999" YEAR="1999">
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Specker BL, Mulligan L, Ho M</AU>
<TI>Longitudinal Study of Calcium Intake, Physical Activity, and Bone Mineral Content in Infants 6-18 Months of Age</TI>
<SO>Journal of Bone and Mineral Research</SO>
<YR>1999</YR>
<VL>14</VL>
<PG>569-576</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Specker-2002" NAME="Specker 2002" YEAR="2002">
<REFERENCE NOTES="&lt;p&gt;Specker B, Binkley T, Wermers J. Randomized trial of physical activity and calcium supplementation on BMC in 3-5 year old healthy children: the South Dakota Children's Health Study. Journal of Bone and Mineral Research 2002:S.&lt;/p&gt;" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Specker B, Binkley T, Wermers J</AU>
<TI>Randomized trial of physical activity and calcium supplementation on BMC in 3-5 year old healthy children: the South Dakota Children's Health Study</TI>
<SO>Journal of Bone and Mineral Research</SO>
<YR>2002</YR>
<VL>19</VL>
<PG>S</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Stallings-1994" NAME="Stallings 1994" YEAR="1994">
<REFERENCE NOTES="&lt;p&gt;Stallings VA, Oddleifson NW, Negrini BY, Zemel BS, Wellens R. Bone mineral content and dietary calcium intake in children prescribed a low-lactose diet. Journal-of-Pediatric-Gastroenterology-and-Nutrition 1994;18:440-445.&lt;/p&gt;" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Stallings VA, Oddleifson NW, Negrini BY, Zemel BS, Wellens R</AU>
<TI>Bone mineral content and dietary calcium intake in children prescribed a low-lactose diet</TI>
<SO>Journal of Pediatric Gastroenterology and Nutrition</SO>
<YR>1994</YR>
<VL>18</VL>
<PG>440-445</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Szumera-2004" NAME="Szumera 2004" YEAR="2004">
<REFERENCE NOTES="&lt;p&gt;35. Szumera M, Sikorska-Wisniewska G, Gumkowska-Kaminska B, Landowski P, Korzon M. Does a gluten-free diet and therapy influence a bone mineralisation in children with celiac disease?. [Polish]. Pediatria Wspolczesna 2004;6(3):289-293.&lt;/p&gt;" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Szumera M, Sikorska-Wisniewska G, Gumkowska-Kaminska B, Landowski P, Korzon M.</AU>
<TI>Does a gluten-free diet and therapy influence a bone mineralisation in children with celiac disease?. [Polish]</TI>
<SO>Pediatria Wspolczesna</SO>
<YR>2004</YR>
<VL>6</VL>
<NO>3</NO>
<PG>289-293</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Taha-2001" NAME="Taha 2001" YEAR="2001">
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Taha W, Chin D, Silverberg AI, Lashiker L, Khateeb N, Anhalt H</AU>
<TI>Reduced spinal bone mineral density in adolescents of an Ultra-Orthodox Jewish community in Brooklyn</TI>
<SO>Pediatrics</SO>
<YR>2001</YR>
<VL>107</VL>
<PG>E79</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Teegarden-1994" NAME="Teegarden 1994" YEAR="1994">
<REFERENCE NOTES="&lt;p&gt;Teegarden D, Weaver CM. Calcium supplementation increases bone density in adolescent girls. [Review] [8 refs]. Nutrition Reviews. . 1994;52:171-173.&lt;/p&gt;" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Teegarden D, Weaver CM</AU>
<TI>Calcium supplementation increases bone density in adolescent girls.</TI>
<SO>Nutrition Reviews.</SO>
<YR>1994</YR>
<VL>52</VL>
<PG>171-173</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Teegarden-1999" NAME="Teegarden 1999" YEAR="1999">
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Teegarden D, Lyle RM, Proulx WR, Johnston CC, Weaver CM</AU>
<TI>Previous milk consumption is associated with greater bone density in young women</TI>
<SO>American Journal of Clinical Nutrition</SO>
<YR>1999</YR>
<VL>69</VL>
<PG>1014-1017</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Teesalu-1996" NAME="Teesalu 1996" YEAR="1996;">
<REFERENCE NOTES="&lt;p&gt;Teesalu S, Vihalemm T, Vaasa IO. Nutrition in prevention of osteoporosis. Scandinavian Journal of Rheumatology - Supplement 1996;103:81-2; discussion 83.&lt;/p&gt;" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Teesalu S, Vihalemm T, Vaasa IO</AU>
<TI>Nutrition in prevention of osteoporosis</TI>
<SO>Scandinavian Journal of Rheumatology - Supplement</SO>
<YR>1996;103:81-2</YR>
<PG>81-2; discussion 83</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-ter-Meulen-2004" NAME="ter Meulen 2004" YEAR="2004">
<REFERENCE NOTES="&lt;p&gt;36. ter Meulen Cg vRIHRJCMHBGFCFHvGTHLBW. No important influence of limited steroid exposure on bone mass during the first year after renal transplantation: a prospective, randomized, multicenter study. Transplantation.&lt;/p&gt;" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>ter Meulen CG, van Riemsdijk I, Hene RJ, Christiaans MH, Borm GF, Corstens FH, et al. 36</AU>
<TI>No important influence of limited steroid exposure on bone mass during the first year after renal transplantation: a prospective, randomized, multicenter study</TI>
<SO>Transplantation</SO>
<YR>2004</YR>
<VL>78</VL>
<NO>1</NO>
<PG>101-6</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Torres-2004" NAME="Torres 2004" YEAR="2004">
<REFERENCE NOTES="&lt;p&gt;37. Torres A GSGAGABYCMTHDGJJCMDLVSE. Treatment with intermittent calcitriol and calcium reduces bone loss after renal transplantation. Kidney International.&lt;/p&gt;" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Torres A, Garcia S, Gomez A, Gonzalez A, Barrios Y, Concepcion MT, et al.</AU>
<TI>Treatment with intermittent calcitriol and calcium reduces bone loss after renal transplantation</TI>
<SO>Kidney International</SO>
<YR>2004</YR>
<VL>65</VL>
<NO>2</NO>
<PG>705-12</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Tortolani-2002" NAME="Tortolani 2002" YEAR="2002">
<REFERENCE NOTES="&lt;p&gt;Tortolani PJ, McCarthy EF, Sponseller PD. Bone mineral density deficiency in children. J-Am-Acad-Orthop-Surg 2002;10:57-66.&lt;/p&gt;" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Tortolani PJ, McCarthy EF, Sponseller PD</AU>
<TI>Bone mineral density deficiency in children</TI>
<SO>Journal of the American Academy of Orthopaedic Surgeons</SO>
<YR>2002</YR>
<VL>10</VL>
<PG>57-66</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Tounian-2003" NAME="Tounian 2003" YEAR="2003">
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Tounian P</AU>
<TI>[Nutritional risk in children]</TI>
<SO>Archives de Pediatrie</SO>
<YR>2003</YR>
<VL>10 Suppl 1</VL>
<PG>28s-29s</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Tsukahara-1997" NAME="Tsukahara 1997" YEAR="1997">
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Tsukahara N, Sato K, Ezawa I</AU>
<TI>Effects of physical characteristics and dietary habits on bone mineral density in adolescent girls</TI>
<SO>Journal of Nutritional Science and Vitaminology</SO>
<YR>1997</YR>
<VL>43</VL>
<PG>643-655</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Tucker-2003" NAME="Tucker 2003" YEAR="2003">
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Tucker KL</AU>
<TI>Does milk intake in childhood protect against later osteoporosis?[comment]</TI>
<SO>American Journal of Clinical Nutrition</SO>
<YR>2003</YR>
<VL>77</VL>
<PG>10-1</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Turner-1992" NAME="Turner 1992" YEAR="1992">
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Turner JG, Gilchrist NL, Ayling EM, Hassall AJ, Hooke EA, Sadler WA</AU>
<TI>Factors affecting bone mineral density in high school girls</TI>
<SO>New Zealand Medical Journal</SO>
<YR>1992</YR>
<VL>105</VL>
<PG>95-96</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Turner-2000" NAME="Turner 2000" YEAR="2000">
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Turner P</AU>
<TI>Types of activity, fitness levels and calcium intake amongst 14-16 year old scholars: sufficient for bone health?</TI>
<SO>Advances in Physiotherapy</SO>
<YR>2000</YR>
<VL>2</VL>
<PG>51-62</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Tussing-2005" NAME="Tussing 2005" YEAR="2005">
<REFERENCE NOTES="&lt;p&gt;38. Tussing L, Chapman-Novakofski K. Osteoporosis prevention education: behavior theories and calcium intake. Journal of the American Dietetic Association 2005;105(1):92-7.&lt;/p&gt;" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Tussing L, Chapman-Novakofski K.</AU>
<TI>Osteoporosis prevention education: behavior theories and calcium intake</TI>
<SO>Journal of the American Dietetic Association</SO>
<YR>2005</YR>
<VL>105</VL>
<NO>1</NO>
<PG>92-7</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Tylavsky-1992" NAME="Tylavsky 1992" YEAR="1992">
<REFERENCE NOTES="&lt;p&gt;Tylavsky FA, Anderson JJ, Talmage RV, Taft TN. Are calcium intakes and physical activity patterns during adolescence related to radial bone mass of white college-age females? Osteoporos Int 1992;2:232-40.&lt;/p&gt;" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Tylavsky FA, Anderson JJ, Talmage RV, Taft TN</AU>
<TI>Are calcium intakes and physical activity patterns during adolescence related to radial bone mass of white college-age females?</TI>
<SO>Osteoporosis International</SO>
<YR>1992</YR>
<VL>2</VL>
<PG>232-40</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Ulrich-1996" NAME="Ulrich 1996" YEAR="1996">
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Ulrich CM, Georgiou CC, Snow Harter CM, Gillis DE</AU>
<TI>Bone mineral density in mother-daughter pairs: relations to lifetime exercise, lifetime milk consumption, and calcium supplements</TI>
<SO>American Journal of Clinical Nutrition</SO>
<YR>1996</YR>
<VL>63</VL>
<PG>72-79</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Valerio-2004" NAME="Valerio 2004" YEAR="2004">
<REFERENCE NOTES="&lt;p&gt;39. Valerio G, Del Puente A, Buono P, Esposito A, Zanatta M, Mozzillo E, et al. Quantitative ultrasound of proximal phalanxes in patients with type 1 diabetes mellitus. Diabetes Research &amp;amp; Clinical Practice 2004;64(3):161-166.&lt;/p&gt;" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Valerio G, Del Puente A, Buono P, Esposito A, Zanatta M, Mozzillo E, et al.</AU>
<TI>Quantitative ultrasound of proximal phalanxes in patients with type 1 diabetes mellitus</TI>
<SO>Diabetes Research &amp; Clinical Practice</SO>
<YR>2004</YR>
<VL>64</VL>
<NO>3</NO>
<PG>161-166</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-VandenBergh-1995" NAME="VandenBergh 1995" YEAR="1995">
<REFERENCE NOTES="&lt;p&gt;VandenBergh MF, DeMan SA, Witteman JC, Hofman A, Trouerbach WT, Grobbee DE. Physical activity, calcium intake, and bone mineral content in children in The Netherlands. J-Epidemiol-Community-Health 1995;49:299-304.&lt;/p&gt;" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>VandenBergh MF, DeMan SA, Witteman JC, Hofman A, Trouerbach WT, Grobbee DE</AU>
<TI>Physical activity, calcium intake, and bone mineral content in children in The Netherlands</TI>
<SO>Journal of Epidemiology and Community Health</SO>
<YR>1995</YR>
<VL>49</VL>
<PG>299-304</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Vigano-2004" NAME="Vigano 2004" YEAR="2004">
<REFERENCE NOTES="&lt;p&gt;40. Vigano A, Mora S. Adverse effects of antiretroviral therapy: Focus on bone density. Expert Opinion on Drug Safety 2004;3(3):199-208.&lt;/p&gt;" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Vigano A, Mora S.</AU>
<TI>Adverse effects of antiretroviral therapy: Focus on bone density</TI>
<SO>Expert Opinion on Drug Safety</SO>
<YR>2004</YR>
<VL>3</VL>
<NO>3</NO>
<PG>199-208</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Volek-2003" NAME="Volek 2003" YEAR="2003">
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Volek JS, Gomes AL, Scheett TP, Sharman MJ, French DN, Rubin MR, et al</AU>
<TI>Increasing fluid milk favorably affects bone mineral density responses to resistance training in adolescent boys</TI>
<SO>Journal of the American Dietetic Association</SO>
<YR>2003</YR>
<VL>103</VL>
<PG>1353-1356</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Wallace-2002" NAME="Wallace 2002" YEAR="2002">
<REFERENCE NOTES="&lt;p&gt;Wallace LS, Ballard JE. Lifetime physical activity and calcium intake related to bone density in young women. J Womens Health Gend Based Med 2002;11:389-98.&lt;/p&gt;" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Wallace LS, Ballard JE</AU>
<TI>Lifetime physical activity and calcium intake related to bone density in young women</TI>
<SO>Journal of Womens Health and Gender-based Medicine</SO>
<YR>2002</YR>
<VL>11</VL>
<PG>389-98</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Wang-1999" NAME="Wang 1999" YEAR="1999">
<REFERENCE NOTES="&lt;p&gt;Wang MC, Moore EC, Crawford PB, Hudes M, Sabry ZI, Marcus R, et al. Influence of Pre-adolescent Diet on Quantitative Ultrasound Measurements of the Calcaneus in Young Adult Women. Osteoporos-Int 1999;9:532-535.&lt;/p&gt;" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Wang MC, Moore EC, Crawford PB, Hudes M, Sabry ZI, Marcus R, et al</AU>
<TI>Influence of Pre-adolescent Diet on Quantitative Ultrasound Measurements of the Calcaneus in Young Adult Women</TI>
<SO>Osteoporosis International</SO>
<YR>1999</YR>
<VL>9</VL>
<PG>532-535</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Wang-2003" NAME="Wang 2003" YEAR="2003">
<REFERENCE NOTES="&lt;p&gt;Wang MC, Crawford PB, Hudes M, Van Loan M, Siemering K, Bachrach LK. Diet in midpuberty and sedentary activity in prepuberty predict peak bone mass. Am-J-Clin-Nutr 2003;77:495-503.&lt;/p&gt;" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Wang MC, Crawford PB, Hudes M, Van Loan M, Siemering K, Bachrach LK</AU>
<TI>Diet in midpuberty and sedentary activity in prepuberty predict peak bone mass</TI>
<SO>American Journal of Clinical Nutrition</SO>
<YR>2003</YR>
<VL>77</VL>
<PG>495-503</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Wastney-2003" NAME="Wastney 2003" YEAR="">
<REFERENCE NOTES="&lt;p&gt;Wastney ME, Martin BR, Bryant RJ, Weaver CM. Calcium utilization in young women: New insights from modeling. In: Mathematical Modeling in Nutrition and the Health Sciences; 2003. p. 193-205.&lt;/p&gt;" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Wastney ME, Martin BR, Bryant RJ, Weaver CM</AU>
<TI>Calcium utilization in young women: New insights from modeling. In: Mathematical Modeling in Nutrition and the Health Sciences; 2003. p</TI>
<PG>Mathematical Modeling in Nutrition and the Health Sciences; 2003. p. 193-205</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Weaver-1999" NAME="Weaver 1999" YEAR="1999">
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Weaver CM, Peacock M, Johnston CC, Jr</AU>
<TI>Adolescent nutrition in the prevention of postmenopausal osteoporosis</TI>
<SO>Journal of Clinical Endocrinology &amp; Metabolism</SO>
<YR>1999</YR>
<VL>84</VL>
<PG>1839-1843</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Welten-1995" NAME="Welten 1995" YEAR="1995">
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Welten DC, Kemper HC, Post GB, van Staveren WA</AU>
<TI>A meta-analysis of the effect of calcium intake on bone mass in young and middle aged females and males</TI>
<SO>Journal of Nutrition</SO>
<YR>1995</YR>
<VL>125</VL>
<PG>2802-13</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Welten-1997" NAME="Welten 1997" YEAR="1997">
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Welten DC, Kemper HC, Post GB, Van Staveren WA, Twisk JW</AU>
<TI>Longitudinal development and tracking of calcium and dairy intake from teenager to adult</TI>
<SO>European Journal of Clinical Nutrition</SO>
<YR>1997</YR>
<VL>51</VL>
<PG>612-8</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Whiting-2001" NAME="Whiting 2001" YEAR="2001">
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Whiting SJ, Healey A, Psiuk S, Mirwald R, Kowalski K, Bailey DA</AU>
<TI>Relationship between carbonated and other low nutrient dense beverages and bone mineral content of adolescents</TI>
<SO>Nutrition Research</SO>
<YR>2001</YR>
<VL>21</VL>
<PG>1107-1115</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Whiting-2004" NAME="Whiting 2004" YEAR="2004">
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Whiting SJ, Vatanparast H, Baxter-Jones A, Faulkner RA, Mirwald R, Bailey DA</AU>
<TI>Factors that affect bone mineral accrual in the adolescent growth spurt</TI>
<SO>Journal of Nutrition</SO>
<YR>2004</YR>
<VL>134</VL>
<PG>696S-700S</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Winters_x002d_Stone-2004" NAME="Winters-Stone 2004" YEAR="2004">
<REFERENCE NOTES="&lt;p&gt;41. Winters-Stone KM, Snow CM. One year of oral calcium supplementation maintains cortical bone density in young adult female distance runners. International Journal of Sport Nutrition and Exercise Metabolism 2004;14(1):7-17.&lt;/p&gt;" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Winters-Stone KM, Snow CM.</AU>
<TI>One year of oral calcium supplementation maintains cortical bone density in young adult female distance runners</TI>
<SO>International Journal of Sport Nutrition and Exercise Metabolism</SO>
<YR>2004</YR>
<VL>14</VL>
<NO>1</NO>
<PG>7-17</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Yeste-2004" NAME="Yeste 2004" YEAR="2004">
<REFERENCE NOTES="&lt;p&gt;42. Yeste D, Almar J, Clemente M, Gussinye M, Audi L, Carrascosa A. Areal bone mineral density of the lumbar spine in 80 premature newborns. A prospective and longitudinal study. Journal of Pediatric Endocrinology &amp;amp; Metabolism 2004;17(7):959-966.&lt;/p&gt;" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Yeste D, Almar J, Clemente M, Gussinye M, Audi L, Carrascosa A.</AU>
<TI>Areal bone mineral density of the lumbar spine in 80 premature newborns. A prospective and longitudinal study</TI>
<SO>Journal of Pediatric Endocrinology &amp; Metabolism</SO>
<YR>2004</YR>
<VL>17</VL>
<NO>7</NO>
<PG>959-966</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Zacharin-2004" NAME="Zacharin 2004" YEAR="2004">
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Zacharin M.</AU>
<TI>Current advances in bone health of disabled children</TI>
<YR>2004</YR>
<PG>545-51</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Zanchetta-1995" NAME="Zanchetta 1995" YEAR="1995">
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Zanchetta JR, Plotkin H, Alvarez Filgueira ML</AU>
<TI>Bone mass in children: normative values for the 2-20-year-old population</TI>
<SO>Bone</SO>
<YR>1995</YR>
<VL>16</VL>
<PG>393S-399S</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Zhang-2003" NAME="Zhang 2003" YEAR="2003">
<REFERENCE NOTES="&lt;p&gt;Zhang Q, Ma GS, Greenfield H, Du XQ, Zhu K, Fraser DR. Effects of fortified milk consumption on regional bone mineral accrual in Chinese girls. Asia Pac J Clin Nutr 2003;12 Suppl:S46.&lt;/p&gt;" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Zhang Q, Ma GS, Greenfield H, Du XQ, Zhu K, Fraser DR</AU>
<TI>Effects of fortified milk consumption on regional bone mineral accrual in Chinese girls</TI>
<SO>Asia Pacific Journal of Clinical Nutrition</SO>
<YR>2003</YR>
<VL>12 Suppl</VL>
<PG>S46</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Zhu-2003" NAME="Zhu 2003" YEAR="2003">
<REFERENCE NOTES="&lt;p&gt;Zhu K, Greenfield H, Du X, Zhang Q, Fraser DR. Effects of milk supplementation on cortical bone gain in Chinese girls aged 10-12 years. Asia Pac J Clin Nutr 2003;12 Suppl:S47.&lt;/p&gt;" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Zhu K, Greenfield H, Du X, Zhang Q, Fraser DR</AU>
<TI>Effects of milk supplementation on cortical bone gain in Chinese girls aged 10-12 years</TI>
<SO>Asia Pacific Journal of Clinical Nutrition</SO>
<YR>2003</YR>
<VL>12 Suppl</VL>
<PG>S47</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Zhu-2004" NAME="Zhu 2004" YEAR="2004">
<REFERENCE NOTES="&lt;p&gt;Zhu K, Greenfield H, Zhang Q, Ma G, Zhang Z, Hu X, et al. Bone mineral accretion and growth in Chinese adolescent girls following the withdrawal of school milk intervention: preliminary results after two years. Asia Pac J Clin Nutr 2004;13:S83.&lt;/p&gt;" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Zhu K, Greenfield H, Zhang Q, Ma G, Zhang Z, Hu X, et al</AU>
<TI>Bone mineral accretion and growth in Chinese adolescent girls following the withdrawal of school milk intervention: preliminary results after two years</TI>
<SO>Asia Pacific Journal of Clinical Nutrition</SO>
<YR>2004</YR>
<VL>13</VL>
<PG>S83</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Zhu-2004-b" NAME="Zhu 2004 b" YEAR="2004">
<REFERENCE NOTES="&lt;p&gt;44. Zhu K, Du X, Greenfield H, Zhang Q, Ma G, Hu X, et al. Bone mass in Chinese premenarcheal girls: the roles of body composition, calcium intake and physical activity. Br J Nutr 2004;92(6):985-93.&lt;/p&gt;" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Zhu K, Du X, Greenfield H, Zhang Q, Ma G, Hu X, et al.</AU>
<TI>Bone mass in Chinese premenarcheal girls: the roles of body composition, calcium intake and physical activity</TI>
<SO>British Journal of Nutrition</SO>
<YR>2004</YR>
<VL>92</VL>
<NO>6</NO>
<PG>985-93</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Ziccardi-2004" NAME="Ziccardi 2004" YEAR="2004">
<REFERENCE NOTES="&lt;p&gt;45. Ziccardi SL, Sedlak CA, Doheny MO. Knowledge and health beliefs of osteoporosis in college nursing students. Orthopaedic Nursing 2004;23(2):128-33.&lt;/p&gt;" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Ziccardi SL, Sedlak CA, Doheny MO.</AU>
<TI>Knowledge and health beliefs of osteoporosis in college nursing students</TI>
<SO>Orthopaedic Nursing</SO>
<YR>2004</YR>
<VL>23</VL>
<NO>2</NO>
<PG>128-33</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Zwart-2004" NAME="Zwart 2004" YEAR="2004">
<REFERENCE NOTES="&lt;p&gt;46. Zwart SR, Hargens AR, Smith SM. The ratio of animal protein intake to potassium intake is a predictor of bone resorption in space flight analogues and in ambulatory subjects. American Journal of Clinical Nutrition 2004;80(4):1058-65.&lt;/p&gt;" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Zwart SR, Hargens AR, Smith SM.</AU>
<TI>The ratio of animal protein intake to potassium intake is a predictor of bone resorption in space flight analogues and in ambulatory subjects</TI>
<SO>American Journal of Clinical Nutrition</SO>
<YR>2004</YR>
<VL>80</VL>
<NO>4</NO>
<PG>1058-65</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Zwiauer-2003" NAME="Zwiauer 2003" YEAR="2003">
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Zwiauer K</AU>
<TI>Dietary calcium for children and prevention of osteoporosis</TI>
<SO>Journal fur Ernahrungsmedizin</SO>
<YR>2003</YR>
<VL>5</VL>
<PG>30-34</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
</EXCLUDED_STUDIES>
<AWAITING_STUDIES/>
<ONGOING_STUDIES/>
</STUDIES>
<OTHER_REFERENCES>
<ADDITIONAL_REFERENCES>
<REFERENCE ID="REF-_x0031_993" NAME="1993" NOTES="&lt;p&gt;Consensus development conference: diagnosis, prophylaxis, and treatment of osteoporosis. Am J Med 1993;94:646-50.&lt;/p&gt;" TYPE="JOURNAL_ARTICLE">
<TI>Consensus development conference: diagnosis, prophylaxis, and treatment of osteoporosis.</TI>
<SO>American Journal of Medicine</SO>
<YR>1993</YR>
<VL>94</VL>
<PG>646-50</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Abrams-1996" NAME="Abrams 1996" TYPE="JOURNAL_ARTICLE">
<AU>Abrams SA, O'Brien KO, Stuff JE</AU>
<TI>Changes in calcium kinetics associated with menarche.</TI>
<SO>Journal of Clinical Endocrinology and Metabolism</SO>
<YR>1996</YR>
<VL>81</VL>
<NO>6</NO>
<PG>20117-2020</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Alderson-2002" NAME="Alderson 2002" NOTES="&lt;p&gt;[http://www.cochrane-net.org/openlearning/HTML/modA1.htm]&lt;/p&gt;" TYPE="OTHER">
<AU>Alderson P, Green S.</AU>
<TI>Additional Module 1: Meta-analysis of Continuous Data [http://www.cochrane-net.org/openlearning/HTML/modA1.htm]</TI>
<SO>Cochrane Collaboration: open learning material for reviewers</SO>
<YR>2002</YR>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Bailey-1999" NAME="Bailey 1999" NOTES="&lt;p&gt;[5.] Bailey DA, McKay HA, Mirwald RL, Crocker PR, Faulkner RA. A six-year longitudinal study of the relationship of physical activity to bone mineral accrual in growing children: the university of Saskatchewan bone mineral accrual study. J Bone Miner Res 1999;14:1672-9.&lt;/p&gt;" TYPE="JOURNAL_ARTICLE">
<AU>Bailey DA, McKay HA, Mirwald RL, Crocker PR, Faulkner RA.</AU>
<TI>A six-year longitudinal study of the relationship of physical activity to bone mineral accrual in growing children: the university of Saskatchewan bone mineral accrual study</TI>
<SO>Journal of Bone and Mineral Research</SO>
<YR>1999</YR>
<VL>14</VL>
<PG>1672-9</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Bonjour--1991" NAME="Bonjour  1991" TYPE="JOURNAL_ARTICLE">
<AU>Bonjour JP, Theintz G, Buchs B, Slosman D, Rizzoli R</AU>
<TI>Critical years and stages of puberty for spinal and femoral bone mass accumulation during adolescence.</TI>
<SO>Journal of Clinical Endocrinology and Metabolism</SO>
<YR>1991</YR>
<VL>73</VL>
<NO>3</NO>
<PG>555-563</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Bonjour-1997" NAME="Bonjour 1997" NOTES="&lt;p&gt;Bonjour JP, Carrie AL, Ferrari S, Clavien H, Slosman D, Theintz G, et al. Calcium-enriched foods and bone mass growth in prepubertal girls: a randomized, double-blind, placebo-controlled trial. J-Clin-Invest 1997;99:1287-1294.&lt;/p&gt;" TYPE="JOURNAL_ARTICLE">
<AU>Bonjour JP, Carrie AL, Ferrari S, Clavien H, Slosman D, Theintz G, et al</AU>
<TI>Calcium-enriched foods and bone mass growth in prepubertal girls: a randomized, double-blind, placebo-controlled trial</TI>
<SO>Journal of Clinical Investigation</SO>
<YR>1997</YR>
<VL>99</VL>
<PG>1287-1294</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Bradney-1998" NAME="Bradney 1998" NOTES="&lt;p&gt;[13.] Bradney M, Pearce G, Naughton G, Sullivan C, Bass S, Beck T, et al. Moderate exercise during growth in prepubertal boys: changes in bone mass, size, volumetric density, and bone strength: a controlled prospective study. J Bone Miner Res 1998;13:1814-21.&lt;/p&gt;" TYPE="JOURNAL_ARTICLE">
<AU>Bradney M, Pearce G, Naughton G, Sullivan C, Bass S, Beck T, et al.</AU>
<TI>Moderate exercise during growth in prepubertal boys: changes in bone mass, size, volumetric density, and bone strength: a controlled prospective study</TI>
<SO>Journal of Bone and Mineral Research</SO>
<YR>1998</YR>
<VL>13</VL>
<PG>1814-21</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Cooley-2001" NAME="Cooley 2001" TYPE="JOURNAL_ARTICLE">
<AU>Cooley H, Jones G</AU>
<TI>A population-based study of fracture incidence in southern Tasmania: lifetime fracture risk and evidence for geographic variations within the same country.</TI>
<SO>Osteoporosis International</SO>
<YR>2001</YR>
<VL>12</VL>
<NO>2</NO>
<PG>124-130</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Favus-2003" NAME="Favus 2003" TYPE="BOOK">
<AU>Favus MJ</AU>
<SO>Primer on the metabolic bone diseases and disorders of mineral metabolism. 5th ed.</SO>
<YR>2003</YR>
<PB>Lippincott Williams &amp; Wilkins</PB>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-French-2000" NAME="French 2000" TYPE="JOURNAL_ARTICLE">
<AU>French SA, Fulkerson JA, Story M</AU>
<TI>Increasing weight-bearing physical activity and calcium intake for bone mass growth in children and adolescents: a review of intervention trials.</TI>
<SO>Preventive Medicine</SO>
<YR>2000</YR>
<VL>31</VL>
<NO>6</NO>
<PG>722-31</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Fuchs-2001" NAME="Fuchs 2001" NOTES="&lt;p&gt;[14.] Fuchs RK, Bauer JJ, Snow CM. Jumping improves hip and lumbar spine bone mass in prepubescent children: a randomized controlled trial. J Bone Miner Res 2001;16:148-56.&lt;/p&gt;" TYPE="JOURNAL_ARTICLE">
<AU>Fuchs RK, Bauer JJ, Snow CM.</AU>
<TI>Jumping improves hip and lumbar spine bone mass in prepubescent children: a randomized controlled trial</TI>
<SO>Journal of Bone and Mineral Research</SO>
<YR>2001</YR>
<VL>16</VL>
<PG>148-56</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Gilsanz-1998" NAME="Gilsanz 1998" TYPE="JOURNAL_ARTICLE">
<AU>Gilsanz V</AU>
<TI>Bone density in children: a review of the available techniques and indications.</TI>
<SO>European Journal of Radiology</SO>
<YR>1998</YR>
<VL>26</VL>
<NO>2</NO>
<PG>177-182</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Goulding-1998" NAME="Goulding 1998" NOTES="&lt;p&gt;[11.] Bone mineral density in girls with forearm fractures. J Bone Miner Res 1998;13:143-8.&lt;/p&gt;" TYPE="JOURNAL_ARTICLE">
<AU>Goulding A, Cannan R, Williams SM, Gold EJ, Taylor RW, Lewis-Barned NJ.</AU>
<TI>Bone mineral density in girls with forearm fractures</TI>
<SO>Journal of Bone and Mineral Research</SO>
<YR>1998</YR>
<VL>13</VL>
<PG>143-8</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Goulding-2001" NAME="Goulding 2001" NOTES="&lt;p&gt;[10.] Bone mineral density and body composition in boys with distal forearm fractures: a dual-energy x-ray absorptiometry study. J Pediatr 2001;139:509-15.&lt;/p&gt;" TYPE="JOURNAL_ARTICLE">
<AU>Goulding A, Jones IE, Taylor RW, Williams SM, Manning PJ.</AU>
<TI>Bone mineral density and body composition in boys with distal forearm fractures: a dual-energy x-ray absorptiometry study</TI>
<SO>Journal of Pediatrics</SO>
<YR>2001</YR>
<VL>139</VL>
<PG>509-15</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Hansen-1991" NAME="Hansen 1991" NOTES="&lt;p&gt;[6.] Hansen MA, Overgaard K, Riis BJ, Christiansen C. Role of peak bone mass and bone loss in postmenopausal osteoporosis: 12 year study. BMJ 1991;303:961-4.&lt;/p&gt;" TYPE="JOURNAL_ARTICLE">
<AU>Hansen MA, Overgaard K, Riis BJ, Christiansen C.</AU>
<TI>Role of peak bone mass and bone loss in postmenopausal osteoporosis: 12 year study</TI>
<SO>British Medical Journal</SO>
<YR>1991</YR>
<VL>303</VL>
<PG>961-4</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Heaney--2001" NAME="Heaney  2001" TYPE="JOURNAL_ARTICLE">
<AU>Heaney RP, Abrams S, Dawson-Hughes B, Looker A, Marcus R, Matkovic V, Weaver C</AU>
<TI>Peak bone mass.</TI>
<SO>Osteoporosis International</SO>
<YR>2001</YR>
<VL>11</VL>
<NO>2</NO>
<PG>985-1009</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Heinonen-2000" NAME="Heinonen 2000" NOTES="&lt;p&gt;[15.] Heinonen A, Sievanen H, Kannus P, Oja P, Pasanen M, Vuori I. High-impact exercise and bones of growing girls: a 9-month controlled trial. Osteoporos Int 2000;11:1010-7.&lt;/p&gt;" TYPE="JOURNAL_ARTICLE">
<AU>Heinonen A, Sievanen H, Kannus P, Oja P, Pasanen M, Vuori I.</AU>
<TI>High-impact exercise and bones of growing girls: a 9-month controlled trial</TI>
<SO>Osteoporosis International</SO>
<YR>2000</YR>
<VL>11</VL>
<PG>1010-7</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Jackman-1997" NAME="Jackman 1997" TYPE="JOURNAL_ARTICLE">
<AU>Jackman LA, Millane SS, Martin BR, Wood OB, McCabe GP, Peacock M, Weaver CM:</AU>
<TI>Calcium retention in relation to calcium intake and postmenarcheal age in adolescent females.</TI>
<SO>American Journal of Clinical Nutrition</SO>
<YR>1997</YR>
<VL>66</VL>
<NO>2</NO>
<PG>327-333</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Jadad-1996" NAME="Jadad 1996" TYPE="JOURNAL_ARTICLE">
<AU>Jadad AR, Moore RA, Carroll D, Jenkinson C, Reynolds DJ, Gavaghan DJ, et al.</AU>
<TI>Assessing the quality of reports of randomized clinical trials: is blinding necessary?</TI>
<SO>Controlled Clinical Trials</SO>
<YR>1996</YR>
<VL>17</VL>
<PG>1-12</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Javaid-2002" NAME="Javaid 2002" NOTES="&lt;p&gt;[8.] Javaid MK, Cooper C. Prenatal and childhood influences on osteoporosis. Best Pract Res Clin Endocrinol Metab 2002;16:349-67.&lt;/p&gt;" TYPE="JOURNAL_ARTICLE">
<AU>Javaid MK, Cooper C.</AU>
<TI>Prenatal and childhood influences on osteoporosis</TI>
<SO>Best Practice and Research in Clinical Endocrinology and Metabolism</SO>
<YR>2002</YR>
<VL>16</VL>
<PG>349-67</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Jones-1994" NAME="Jones 1994" NOTES="&lt;p&gt;[2.] Jones G, Nguyen T, Sambrook PN, Kelly PJ, Gilbert C, Eisman JA. Symptomatic fracture incidence in elderly men and women: the Dubbo Osteoporosis Epidemiology Study (DOES). Osteoporos Int 1994;4:277-82.&lt;/p&gt;" TYPE="JOURNAL_ARTICLE">
<AU>Jones G, Nguyen T, Sambrook PN, Kelly PJ, Gilbert C, Eisman JA.</AU>
<TI>Symptomatic fracture incidence in elderly men and women: the Dubbo Osteoporosis Epidemiology Study (DOES)</TI>
<SO>Osteoporosis International</SO>
<YR>1994</YR>
<VL>4</VL>
<PG>277-82</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Jones-2001" NAME="Jones 2001" TYPE="JOURNAL_ARTICLE">
<AU>Jones G, Riley MD, Whiting S</AU>
<TI>Association between urinary potassium, urinary sodium, current diet, and bone density in prepubertal children.</TI>
<SO>American Journal of Clinical Nutrition</SO>
<YR>2001</YR>
<VL>73</VL>
<PG>839-44</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Jones-2002" NAME="Jones 2002" TYPE="JOURNAL_ARTICLE">
<AU>Jones G, Cooley HM</AU>
<TI>Symptomatic fracture incidence in those under 50 years of age in southern Tasmania.</TI>
<SO>Journal of Paediatrics and Child Health</SO>
<YR>2002</YR>
<VL>38</VL>
<NO>3</NO>
<PG>278-283</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Juni-2001" NAME="Juni 2001" TYPE="JOURNAL_ARTICLE">
<AU>Juni P, Altman DG, Egger M.</AU>
<TI>Systematic reviews in health care: Assessing the quality of controlled clinical trials.</TI>
<SO>British Medical Journal</SO>
<YR>2001</YR>
<VL>323</VL>
<PG>42-6</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Lanou-2005" NAME="Lanou 2005" TYPE="JOURNAL_ARTICLE">
<AU>Lanou AJ, Berkow SE, Barnard ND</AU>
<TI>Calcium, dairy products, and bone health in children and young adults: a reevaluation of the evidence.</TI>
<SO>Pediatrics</SO>
<YR>2005</YR>
<VL>115</VL>
<NO>3</NO>
<PG>736-743</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Ma-2003" NAME="Ma 2003" NOTES="&lt;p&gt;[9.] Ma D, Jones G. The association between bone mineral density, metacarpal morphometry, and upper limb fractures in children: a population-based case-control study. J Clin Endocrinol Metab 2003;88:1486-91.&lt;/p&gt;" TYPE="JOURNAL_ARTICLE">
<AU>Ma D, Jones G.</AU>
<TI>The association between bone mineral density, metacarpal morphometry, and upper limb fractures in children: a population-based case-control study</TI>
<SO>Journal of Clinical Endocrinology and Metabolism</SO>
<YR>2003</YR>
<VL>88</VL>
<PG>1486-91</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-MacKelvie-2003" NAME="MacKelvie 2003" NOTES="&lt;p&gt;[17.] MacKelvie KJ, Khan KM, Petit MA, Janssen PA, McKay HA. A school-based exercise intervention elicits substantial bone health benefits: a 2-year randomized controlled trial in girls. Pediatrics 2003;112:e447.&lt;/p&gt;" TYPE="JOURNAL_ARTICLE">
<AU>MacKelvie KJ, Khan KM, Petit MA, Janssen PA, McKay HA.</AU>
<TI>A school-based exercise intervention elicits substantial bone health benefits: a 2-year randomized controlled trial in girls</TI>
<SO>Pediatrics</SO>
<YR>2003</YR>
<VL>112</VL>
<PG>e447</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Marshall-1996" NAME="Marshall 1996" NOTES="&lt;p&gt;[4.] Marshall D, Johnell O, Wedel H. Meta-analysis of how well measures of bone mineral density predict occurrence of osteoporotic fractures. BMJ 1996;312:1254-9.&lt;/p&gt;" TYPE="JOURNAL_ARTICLE">
<AU>Marshall D, Johnell O, Wedel H.</AU>
<TI>Meta-analysis of how well measures of bone mineral density predict occurrence of osteoporotic fractures</TI>
<SO>British Medical Journal</SO>
<YR>1996</YR>
<VL>312</VL>
<PG>1254-9</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Matkovic-1992" NAME="Matkovic 1992" TYPE="JOURNAL_ARTICLE">
<AU>Matkovic V, Heaney RP</AU>
<TI>Calcium balance during human growth: evidence for threshold behavior.</TI>
<SO>American Journal of Clinical Nutrition</SO>
<YR>1992</YR>
<VL>55</VL>
<NO>5</NO>
<PG>992-996</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Morris-1997" NAME="Morris 1997" NOTES="&lt;p&gt;[12.] Morris FL, Naughton GA, Gibbs JL, Carlson JS, Wark JD. Prospective ten-month exercise intervention in premenarcheal girls: positive effects on bone and lean mass. J Bone Miner Res 1997;12:1453-62.&lt;/p&gt;" TYPE="JOURNAL_ARTICLE">
<AU>Morris FL, Naughton GA, Gibbs JL, Carlson JS, Wark JD.</AU>
<TI>Prospective ten-month exercise intervention in premenarcheal girls: positive effects on bone and lean mass</TI>
<SO>Journal of Bone and Mineral Research</SO>
<YR>1997</YR>
<VL>12</VL>
<PG>1453-62</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-NIH-2000" NAME="NIH 2000" NOTES="&lt;p&gt;Osteoporosis Prevention, Diagnosis and Therapy. NIH Consensus Statement 2000 Mar 27-29 2000;17:1-45.&lt;/p&gt;" TYPE="JOURNAL_ARTICLE">
<TI>Osteoporosis Prevention, Diagnosis and Therapy.</TI>
<SO>NIH Consensus Statement</SO>
<YR>2000</YR>
<VL>17</VL>
<PG>1-45</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Prentice-1994" NAME="Prentice 1994" TYPE="JOURNAL_ARTICLE">
<AU>Prentice A, Parsons TJ, Cole TJ</AU>
<TI>Uncritical use of bone mineral density in absorptiometry may lead to size-related artifacts in the identification of bone mineral determinants.</TI>
<SO>American Journal of Clinical Nutrition</SO>
<YR>1994</YR>
<VL>60</VL>
<NO>6</NO>
<PG>837-842</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Riis-1996" NAME="Riis 1996" NOTES="&lt;p&gt;[7.] Riis BJ, Hansen MA, Jensen AM, Overgaard K, Christiansen C. Low bone mass and fast rate of bone loss at menopause: equal risk factors for future fracture: a 15-year follow-up study. Bone 1996;19:9-12.&lt;/p&gt;" TYPE="JOURNAL_ARTICLE">
<AU>Riis BJ, Hansen MA, Jensen AM, Overgaard K, Christiansen C.</AU>
<TI>Low bone mass and fast rate of bone loss at menopause: equal risk factors for future fracture: a 15-year follow-up study</TI>
<SO>Bone</SO>
<YR>1996</YR>
<VL>19</VL>
<PG>9-12</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Robinson-2002" NAME="Robinson 2002" TYPE="JOURNAL_ARTICLE">
<AU>Robinson KA, Dickersin K.</AU>
<TI>Development of a highly sensitive search strategy for the retrieval of controlled trials using PubMed</TI>
<SO>International Journal of Epidemiology</SO>
<YR>2002</YR>
<VL>31</VL>
<PG>150-3</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Shea-2004" NAME="Shea 2004" TYPE="JOURNAL_ARTICLE">
<AU>Shea B, Wells G, Cranney A, Zytaruk N, Robinson V, Griffith L, Hamel C, Ortiz Z, Peterson J, Adachi J et al</AU>
<TI>Calcium supplementation on bone loss in postmenopausal women.</TI>
<SO>Cochrane Database Syst Rev 2004</SO>
<YR>2004</YR>
<VL>2004</VL>
<NO>1</NO>
<PG>CD004526</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Sundberg-2001" NAME="Sundberg 2001" NOTES="&lt;p&gt;[16.] Sundberg M, Gardsell P, Johnell O, Karlsson MK, Ornstein E, Sandstedt B, et al. Peripubertal moderate exercise increases bone mass in boys but not in girls: a population-based intervention study. Osteoporos Int 2001;12:230-8.&lt;/p&gt;" TYPE="JOURNAL_ARTICLE">
<AU>Sundberg M, Gardsell P, Johnell O, Karlsson MK, Ornstein E, Sandstedt B, et al.</AU>
<TI>Peripubertal moderate exercise increases bone mass in boys but not in girls: a population-based intervention study</TI>
<SO>Osteoporosis International</SO>
<YR>2001</YR>
<VL>12</VL>
<PG>230-8</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Tugwell-2004" NAME="Tugwell 2004" TYPE="BOOK">
<AU>Tugwell, P (Ed)</AU>
<SO>Evidence-based Rheumatology.</SO>
<YR>2004</YR>
<PB>BMJ Publishing Group</PB>
<CY>London</CY>
<IDENTIFIERS>
<IDENTIFIER TYPE="OTHER" VALUE="ISBN 0 7279 1446 4."/>
</IDENTIFIERS>
</REFERENCE>
<REFERENCE ID="REF-Woolf-2003" NAME="Woolf 2003" TYPE="JOURNAL_ARTICLE">
<AU>Woolf AD, Pfleger B.</AU>
<TI>Burden of major musculoskeletal conditions.</TI>
<SO>Bulletin of the World Health Organization</SO>
<YR>2003</YR>
<VL>81</VL>
<NO>9</NO>
<PG>646-56</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Wosje-2000" NAME="Wosje 2000" TYPE="JOURNAL_ARTICLE">
<AU>Wosje KS, Specker BL.</AU>
<TI>Role of calcium in bone health during childhood.</TI>
<SO>Nutrition Reviews</SO>
<YR>2000</YR>
<VL>58</VL>
<NO>9</NO>
<PG>253-68</PG>
<IDENTIFIERS/>
</REFERENCE>
</ADDITIONAL_REFERENCES>
<OTHER_VERSIONS_REFERENCES/>
<PENDING_REFERENCES/>
</OTHER_REFERENCES>
</STUDIES_AND_REFERENCES>
<CHARACTERISTICS_OF_STUDIES>
<CHARACTERISTICS_OF_INCLUDED_STUDIES SORT_BY="STUDY" USER_DEF_1_ENABLED="NO" USER_DEF_2_ENABLED="NO" USER_DEF_3_ENABLED="NO">
<INCLUDED_CHAR STUDY_ID="STD-Bonjour-1995">
<CHAR_METHODS>
<P>STUDY DESIGN: randomised controlled trial<BR/>LOCATION AND SETTING: Community (Youth Health Service), Switzerland<BR/>DURATION OF SUPPLEMENTATION: 1 year <BR/>DURATION OF FOLLOW-UP: 8 years<BR/>QUALITY ASSESSMENT: Moderate risk of bias<BR/> RANDOMISED: States random but no description<BR/> ALLOCATION CONCEALMENT: Yes<BR/> BLINDING OF SUBJECT: Yes<BR/> DESCRIPTION OF WITHDRAWALS/DROPOUTS: Yes </P>
<P>TYPE OF ANALYSIS: Available data and treatment received<BR/>COMPLIANCE: Assessed<BR/>CONFOUNDERS MEASURED: pubertal status, spontaneous calcium intake<BR/>
</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS>
<P>N SCREENED: unknown<BR/>N RANDOMISED: 149<BR/>N COMPLETED: 144 (1 year); 122 (8 years)<BR/>M=0%<BR/>F=100% <BR/>ETHNICITY: CAUCASIAN<BR/>MEAN BASELINE AGE (yrs): 7.93 <BR/>BASELINE AGE RANGE (yrs): 6.6-9.4<BR/>INCLUSION CRITERIA: healthy prepubertal, Caucasian females<BR/>EXCLUSION CRITERIA: no parental approval, ratio weight/height &lt; 3rd or &gt; 97th percentile according to Geneva reference values, presence of physical signs of puberty, chronic disease, gastro-intestinal disease capable of inducing malabsorption, congenital or acquired bone disease, regular use of medication.<BR/>BASELINE CALCIUM INTAKE (mg/day): 752<BR/>PUBERTAL STATUS: prepubertal<BR/>
</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS>
<P>1. Foods supplemented by milk extract (850 mg Calcium per day)<BR/>2. Unsupplemented foods<BR/>CO-INTERVENTIONS: Nil<BR/>
</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES>
<P>BONE MEASURES: SITES<BR/> AREAL BONE MINERAL DENSITY: distal radial metaphysis, diaphysis of radius, femoral neck, femoral trochanter, femoral diaphysis and L2-4 vertebrae. <BR/> BONE MINERAL CONTENT: distal radial metaphysis, diaphysis of radius, femoral neck, femoral trochanter, femoral diaphysis and L2-4 vertebrae. <BR/> BONE AREA: distal radial metaphysis, diaphysis of radius, femoral neck, femoral trochanter, femoral diaphysis and L2-4 vertebrae. <BR/>METHOD OF MEASUREMENT: DXA<BR/>FOLLOW-UP ASSESSMENT POINTS(yrs): 0, 1, 2, 4.5, 8.5 <BR/>OTHER OUTCOMES MEASURED: weight, height<BR/>BONE MEASURES INCLUDED IN STUDY ANALYSES: <BR/> AREAL BONE MINERAL DENSITY: distal radial metaphysis, diaphysis of radius, femoral neck, femoral trochanter, femoral diaphysis and L2-4 vertebrae, mean of the 6 sites. . <BR/> BONE MINERAL CONTENT: L2-4 vertebrae, mean of all 6 sites<BR/> BONE AREA: femoral diaphysis and L2-4 vertebrae, mean of the 6 sites. <BR/>SUB-GROUPS IDENTIFIED: Spontaneous calcium intake (defined by median); early vs late menarcheal age<BR/>
</P>
</CHAR_OUTCOMES>
<CHAR_NOTES/>
</INCLUDED_CHAR>
<INCLUDED_CHAR STUDY_ID="STD-Cameron-2004">
<CHAR_METHODS>
<P>STUDY DESIGN: randomised controlled trial<BR/>LOCATION AND SETTING: Community (Twin register), Australia<BR/>DURATION OF SUPPLEMENTATION: 2 years <BR/>DURATION OF FOLLOW-UP: 2 years<BR/>QUALITY ASSESSMENT: Moderate risk of bias<BR/> RANDOMISED: States random but no description<BR/> ALLOCATION CONCEALMENT: Not described or unclear<BR/> BLINDING OF SUBJECT: Yes<BR/> DESCRIPTION OF WITHDRAWALS/DROPOUTS: Yes </P>
<P>TYPE OF ANALYSIS: Available Data<BR/>COMPLIANCE: Assessed<BR/>CONFOUNDERS MEASURED: spontaneous calcium intake, physical activity, medical history and medication use.<BR/>
</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS>
<P>N SCREENED: unknown<BR/>N RANDOMISED: 128 <BR/>N COMPLETED: 104 (6 months); 48 (2 years)<BR/>M=0%<BR/>F=100% <BR/>ETHNICITY: unknown<BR/>MEAN BASELINE AGE (yrs): 10.3 <BR/>BASELINE AGE RANGE (yrs): 8-13<BR/>INCLUSION CRITERIA: premenarcheal female twins<BR/>EXCLUSION CRITERIA: nil<BR/>BASELINE CALCIUM INTAKE (mg/day): 716<BR/>PUBERTAL STAGE: prepubertal<BR/>
</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS>
<P>1. Calcium carbonate 1200 mg<BR/>2. Placebo<BR/>CO-INTERVENTIONS: Nil<BR/>
</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES>
<P>BONE MEASURES: SITES<BR/> AREAL BONE MINERAL DENSITY: total hip, femoral neck, total forearm and L2-4 vertebrae. <BR/> BONE MINERAL CONTENT: total body<BR/> METHOD OF MEASUREMENT: DXA<BR/>FOLLOW-UP ASSESSMENT POINTS(yrs): 0, 0.5, 1, 1.5, 2 <BR/>OTHER OUTCOMES MEASURED: weight, height, fat mass, lean mass<BR/>BONE MEASURES INCLUDED IN ANALYSES: <BR/> AREAL BONE MINERAL DENSITY: total hip, femoral neck, total forearm and L2-4 vertebrae. <BR/> BONE MINERAL CONTENT: total body<BR/>SUB-GROUPS IDENTIFIED: Menarche vs premenarche <BR/>
</P>
</CHAR_OUTCOMES>
<CHAR_NOTES/>
</INCLUDED_CHAR>
<INCLUDED_CHAR STUDY_ID="STD-Chevalley-2005">
<CHAR_METHODS>
<P>STUDY DESIGN: randomised controlled trial<BR/>LOCATION AND SETTING: Community (Public Youth Health Service), Switzerland<BR/>DURATION OF SUPPLEMENTATION: 1 year <BR/>DURATION OF FOLLOW-UP: 2 years<BR/>QUALITY ASSESSMENT: Moderate risk of bias<BR/> RANDOMISED: States random but no description<BR/> ALLOCATION CONCEALMENT: Not described or unclear<BR/> BLINDING OF SUBJECT: Unclear<BR/> DESCRIPTION OF WITHDRAWALS/DROPOUTS: Yes </P>
<P>TYPE OF ANALYSIS: Available Data<BR/>COMPLIANCE: Assessed<BR/>CONFOUNDERS MEASURED: spontaneous calcium intake, physical activity, <BR/>
</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS>
<P>N SCREENED: unknown<BR/>N RANDOMISED: 235<BR/>N COMPLETED: 232 (1 year); 172 (2 years)<BR/>M=100%<BR/>F=0% <BR/>ETHNICITY: CAUCASIAN<BR/>MEAN BASELINE AGE (yrs): 7.44 <BR/>BASELINE AGE RANGE (yrs): 6.5-8.5<BR/>INCLUSION CRITERIA: healthy prepubertal, Caucasian males with spontatneous calcium intake below the 75th centile of a community sample of 990 boys<BR/>EXCLUSION CRITERIA: ratio weight/height &lt; 3rd or &gt; 97th percentile according to Geneva reference values, presence of physical signs of puberty, chronic disease, gastro-intestinal disease capable of inducing malabsorption, congenital or acquired bone disease, regular use of medication.<BR/>BASELINE CALCIUM INTAKE (mg/day): 752<BR/>PUBERTAL STAGE: prepubertal<BR/>
</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS>
<P>1. Foods supplemented by calcium phosphate milk extract (850 mg Calcium per day)<BR/>2. Unsupplemented foods<BR/>CO-INTERVENTIONS: Nil<BR/>
</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES>
<P>BONE MEASURES MEASURED: SITES<BR/> AREAL BONE MINERAL DENSITY: distal radial metaphysis, diaphysis of radius, femoral neck, femoral trochanter, femoral diaphysis and L2-4 vertebrae. <BR/> BONE MINERAL CONTENT: total body, distal radial metaphysis, diaphysis of radius, femoral neck, femoral trochanter, femoral diaphysis and L2-4 vertebrae. <BR/> BONE AREA: distal radial metaphysis, diaphysis of radius, femoral neck, femoral trochanter, femoral diaphysis and L2-4 vertebrae. <BR/>METHOD OF MEASUREMENT: DXA<BR/>FOLLOW-UP ASSESSMENT POINTS(yrs): 0, 1, 2 <BR/>OTHER OUTCOMES MEASURED: weight, height<BR/>BONE MEASURES INCLUDED IN ANALYSES: <BR/> AREAL BONE MINERAL DENSITY: distal radial metaphysis, diaphysis of radius, femoral neck, femoral trochanter, femoral diaphysis and L2-4 vertebrae, mean at the 5 appendicular sites. <BR/> BONE MINERAL CONTENT: distal radial metaphysis, diaphysis of radius, femoral neck, femoral trochanter, femoral diaphysis and L2-4 vertebrae, mean at the 5 appendicular sites. <BR/> BONE AREA: distal radial metaphysis, diaphysis of radius, femoral neck, femoral trochanter, femoral diaphysis and L2-4 vertebrae, mean at the 5 appendicular sites. </P>
<P>SUB-GROUPS IDENTIFIED: physical activity levels and spontaneous calcium intake (defined by above and below median)<BR/>
</P>
</CHAR_OUTCOMES>
<CHAR_NOTES/>
</INCLUDED_CHAR>
<INCLUDED_CHAR STUDY_ID="STD-Courteix-2005">
<CHAR_METHODS>
<P>STUDY DESIGN: randomised controlled trial<BR/>LOCATION AND SETTING: Community (school and sports clubs), France<BR/>DURATION OF SUPPLEMENTATION: 1 year <BR/>DURATION OF FOLLOW-UP: 1 year<BR/>QUALITY ASSESSMENT: low risk of bias<BR/> RANDOMISED: random and description consistent with this<BR/> ALLOCATION CONCEALMENT: Yes<BR/> BLINDING OF SUBJECT: Yes<BR/> DESCRIPTION OF WITHDRAWALS/DROPOUTS: Yes </P>
<P>TYPE OF ANALYSIS: Available Data<BR/>COMPLIANCE: Assessed<BR/>CONFOUNDERS MEASURED: physical activity, pubertal status, spontaneous calcium intake<BR/>
</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS>
<P>N SCREENED: 138<BR/>N RANDOMISED: 113<BR/>N COMPLETED: 85 (1 year)<BR/>M=0%<BR/>F=100% <BR/>ETHNICITY: CAUCASIAN<BR/>MEAN BASELINE AGE (yrs): 9.91 <BR/>BASELINE AGE RANGE (yrs): 8-13<BR/>INCLUSION CRITERIA: healthy Caucasian females, age 8-13, prepubescent and not expected to reach menarche before end of first year of study<BR/>EXCLUSION CRITERIA: children with swimming as a physical activity<BR/>BASELINE CALCIUM INTAKE (mg/day): 994<BR/>PUBERTAL STAGE: prepubertal<BR/>
</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS>
<P>1. 800 mg/day calcium as calcium phosphate<BR/>2. Placebo<BR/>CO-INTERVENTIONS: Nil<BR/>
</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES>
<P>BONE MEASURES: SITES<BR/> AREAL BONE MINERAL DENSITY: total body, dominant hip (femoral neck, trochanter and Ward's triangle), non-dominant radius (1/3, mid and distal) and L2-4 vertebrae. <BR/> BONE MINERAL CONTENT: total body, dominant hip (femoral neck, trochanter and Ward's triangle), non-dominant radius (1/3, mid and distal) and L2-4 vertebrae. <BR/>METHOD OF MEASUREMENT: DXA<BR/>FOLLOW-UP ASSESSMENT POINTS(yrs): 0, 1 <BR/>OTHER OUTCOMES MEASURED: BMI, height, bone age, fat mass, lean mass<BR/>BONE MEASURES INCLUDED IN ANALYSES: <BR/> AREAL BONE MINERAL DENSITY: total body, dominant hip (femoral neck, trochanter and Ward's triangle), non-dominant radius (1/3, mid and distal) and L2-4 vertebrae. <BR/> BONE MINERAL CONTENT: total body, dominant hip (femoral neck, trochanter and Ward's triangle), non-dominant radius (1/3, mid and distal) and L2-4 vertebrae. </P>
<P>
<BR/>SUB-GROUPS IDENTIFIED: exercise (7.2 hours exercise per week) and sedentary (1.2 hours exercise per week)<BR/>
</P>
</CHAR_OUTCOMES>
<CHAR_NOTES/>
</INCLUDED_CHAR>
<INCLUDED_CHAR STUDY_ID="STD-Dibba-2000">
<CHAR_METHODS>
<P>STUDY DESIGN: randomised controlled trial<BR/>LOCATION AND SETTING: Community (rural village), Gambia<BR/>DURATION OF SUPPLEMENTATION: 1 year <BR/>DURATION OF FOLLOW-UP: 3 years<BR/>QUALITY ASSESSMENT: Low risk of bias<BR/> RANDOMISED: random and description consistent with this<BR/> ALLOCATION CONCEALMENT: Yes<BR/> BLINDING OF SUBJECT: Yes<BR/> DESCRIPTION OF WITHDRAWALS/DROPOUTS: Yes </P>
<P>TYPE OF ANALYSIS: Intention-to-treat<BR/>COMPLIANCE: Assessed<BR/>CONFOUNDERS MEASURED: tanner stage status, spontaneous calcium intake, baseline serum vitamin D, grip strength<BR/>
</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS>
<P>N SCREENED: 162<BR/>N RANDOMISED: 160<BR/>N COMPLETED: 160<BR/>M=50%<BR/>F=50% <BR/>ETHNICITY: Gambian<BR/>MEAN BASELINE AGE (yrs): 10.3 <BR/>BASELINE AGE RANGE (yrs): 8.3-11.9<BR/>INCLUSION CRITERIA: 8.3-11.9 y.o children in a single rural village, healthy, no history of medical condition known to affect calcium or bone metabolism, no recent fracture, no alcohol, antacids, calcium or other nutritional supplements, non-smoking.<BR/>EXCLUSION CRITERIA: see inclusion criteria<BR/>BASELINE CALCIUM INTAKE (mg/day): 338<BR/>PUBERTAL STAGE: mixed <BR/>
</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS>
<P>1. Calcium carbonate 1000mg 5 days per week<BR/>2. Placebo<BR/>CO-INTERVENTIONS: Nil<BR/>
</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES>
<P>BONE MEASURES: SITES<BR/> AREAL BONE MINERAL DENSITY: midshaft and distal radius (left arm). <BR/> BONE MINERAL CONTENT: midshaft and distal radius (left arm).<BR/> BONE WIDTH: midshaft and distal radius (left arm).<BR/>METHOD OF MEASUREMENT: SPA<BR/>FOLLOW-UP ASSESSMENT POINTS(yrs): 0, 1, 2, 3 <BR/>OTHER OUTCOMES MEASURED: weight, height, triceps skinfold thickness, plasma osteocalcin (n=100 only)<BR/>BONE MEASURES INCLUDED IN ANALYSES: <BR/> AREAL BONE MINERAL DENSITY: midshaft and distal radius (left arm).<BR/> BONE MINERAL CONTENT: midshaft and distal radius (left arm).<BR/> BONE WIDTH: midshaft and distal radius (left arm).</P>
<P>SUB-GROUPS IDENTIFIED: sex<BR/>
</P>
</CHAR_OUTCOMES>
<CHAR_NOTES/>
</INCLUDED_CHAR>
<INCLUDED_CHAR STUDY_ID="STD-Iuliano_x002d_Burns-2003">
<CHAR_METHODS>
<P>STUDY DESIGN: randomised controlled trial<BR/>LOCATION AND SETTING: Community (school), Australia<BR/>DURATION OF SUPPLEMENTATION: 8.5 months <BR/>DURATION OF FOLLOW-UP: 8.5 months<BR/>QUALITY ASSESSMENT: High risk of bias<BR/> RANDOMISED: random and description consistent with this<BR/> ALLOCATION CONCEALMENT: Not described or unclear<BR/> BLINDING OF SUBJECT: Yes<BR/> DESCRIPTION OF WITHDRAWALS/DROPOUTS: No </P>
<P>TYPE OF ANALYSIS: Available Data<BR/>COMPLIANCE: Assessed<BR/>CONFOUNDERS MEASURED: Tanner stage, spontaneous calcium intake, physical activity<BR/>
</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS>
<P>N SCREENED: 75<BR/>N RANDOMISED: 72<BR/>N COMPLETED: 66 (8.5 months)<BR/>M=0%<BR/>F=100% <BR/>ETHNICITY: Asian 15%, 85% not stated<BR/>MEAN BASELINE AGE (yrs): 8.86 <BR/>BASELINE AGE RANGE (yrs): 7-11<BR/>INCLUSION CRITERIA: girls aged 7-11<BR/>EXCLUSION CRITERIA: BMI&gt; 4SD above the mean; &gt; 10 hr/week of weight-bearing exercise<BR/>BASELINE CALCIUM INTAKE (mg/day): 674 <BR/>PUBERTAL STAGE: mixed<BR/>
</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS>
<P>1. Foods fortified by 2 g milk minerals (400 mg calcium/day)<BR/>2. Unsupplemented foods<BR/>CO-INTERVENTIONS: Moderate-impact (ground reaction forces 2-4 times body weight) vs low-impact exercise (ground reaction forces approximately equal to body weight) 20 min 3 times per week.<BR/>
</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES>
<P>BONE MEASURES: SITES<BR/> BONE MINERAL CONTENT: total body, leg, femur, tibia/fibula, humerus, ulna/radius and lumbar spine. </P>
<P>METHOD OF MEASUREMENT: DXA<BR/>FOLLOW-UP ASSESSMENT POINTS(yrs): 0, 0.7 <BR/>OTHER OUTCOMES MEASURED: body composition, weight, sitting and standing height, limb lengths<BR/>BONE MEASURES INCLUDED IN ANALYSES: <BR/> BONE MINERAL CONTENT: total body, leg, femur, tibia/fibula, humerus, ulna/radius and lumbar spine. </P>
<P>
<BR/>SUB-GROUPS IDENTIFIED: by exercise intervention<BR/>
</P>
</CHAR_OUTCOMES>
<CHAR_NOTES/>
</INCLUDED_CHAR>
<INCLUDED_CHAR STUDY_ID="STD-Johnston-1992">
<CHAR_METHODS>
<P>STUDY DESIGN: randomised controlled trial<BR/>LOCATION AND SETTING: Community (Twin register), USA<BR/>DURATION OF SUPPLEMENTATION: 3 years <BR/>DURATION OF FOLLOW-UP: 6 years<BR/>QUALITY ASSESSMENT: Moderate risk of bias<BR/> RANDOMISED: States random but no description<BR/> ALLOCATION CONCEALMENT: Not described or unclear<BR/> BLINDING OF SUBJECT: Yes<BR/> DESCRIPTION OF WITHDRAWALS/DROPOUTS: Yes </P>
<P>TYPE OF ANALYSIS: Available Data<BR/>COMPLIANCE: Assessed<BR/>CONFOUNDERS MEASURED: physical activity, Tanner stage, spontaneous calcium intake, smoking, alcohol consumption<BR/>
</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS>
<P>N SCREENED: 142<BR/>N RANDOMISED: 140<BR/>N COMPLETED: 90 (3 years); 84 (6 years)<BR/>M=39%<BR/>F=61% <BR/>ETHNICITY: CAUCASIAN<BR/>MEAN BASELINE AGE (yrs): 10 <BR/>BASELINE AGE RANGE (yrs): 6-14<BR/>INCLUSION CRITERIA: healthy, Caucasian, monozygotic twins aged 6-14<BR/>EXCLUSION CRITERIA: baseline calcium intake &gt; 1200 mg.<BR/>BASELINE CALCIUM INTAKE (mg/day): 919<BR/>PUBERTAL STAGE: mixed<BR/>
</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS>
<P>1. 1000mg calcium daily as calcium citrate malate <BR/>2. Placebo<BR/>CO-INTERVENTIONS: Nil<BR/>
</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES>
<P>BONE MEASURES: SITES<BR/> AREAL BONE MINERAL DENSITY: distal radius, midshaft radius, femoral neck, Ward's triangle, greater trochanter and L2-4 vertebrae. <BR/> BONE MINERAL CONTENT: distal radius, midshaft radius, femoral neck, Ward's triangle, greater trochanter and L2-4 vertebrae. <BR/> BONE AREA: distal radius, midshaft radius, femoral neck, Ward's triangle, greater trochanter and L2-4 vertebrae.<BR/>METHOD OF MEASUREMENT: SPA for radius, DXA for other sites<BR/>FOLLOW-UP ASSESSMENT POINTS(yrs): 0, 0.5, 1,2 and 3 for radius, 0 and 3 for other sites <BR/>OTHER OUTCOMES MEASURED: weight, height, urinary calcium and creatinine, serum osteocalcin, tartrate resistant acid phosphatase and dietary calcium absorption by calcium-44 enrichment.<BR/>BONE MEASURES INCLUDED IN ANALYSES: <BR/> AREAL BONE MINERAL DENSITY: distal radius, midshaft radius, femoral neck, Ward's triangle, greater trochanter and L2-4 vertebrae.<BR/> BONE MINERAL CONTENT: distal radius, midshaft radius, femoral neck, Ward's triangle, greater trochanter and L2-4 vertebrae. <BR/> BONE AREA: distal radius, midshaft radius, femoral neck, Ward's triangle, greater trochanter and L2-4 vertebrae. </P>
<P>SUB-GROUPS IDENTIFIED: Prepubertal vs peri/post-pubertal<BR/>
</P>
</CHAR_OUTCOMES>
<CHAR_NOTES/>
</INCLUDED_CHAR>
<INCLUDED_CHAR STUDY_ID="STD-Lee-1994">
<CHAR_METHODS>
<P>STUDY DESIGN: randomised controlled trial<BR/>LOCATION AND SETTING: Community (school), China<BR/>DURATION OF SUPPLEMENTATION: 1.5 years <BR/>DURATION OF FOLLOW-UP: 2.5 years<BR/>QUALITY ASSESSMENT: Moderate risk of bias<BR/> RANDOMISED: States random but no description<BR/> ALLOCATION CONCEALMENT: Not described or unclear<BR/> BLINDING OF SUBJECT: Yes<BR/> DESCRIPTION OF WITHDRAWALS/DROPOUTS: Yes </P>
<P>TYPE OF ANALYSIS: Available Data<BR/>COMPLIANCE: Assessed<BR/>CONFOUNDERS MEASURED: physical activity, spontaneous calcium intake, baseline serum vitamin D (n=18), <BR/>
</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS>
<P>N SCREENED: unknown<BR/>N RANDOMISED: 163<BR/>N COMPLETED: 162 (1.5 years); 159 (2.5 years)<BR/>M=54%<BR/>F=46% <BR/>ETHNICITY: Chinese<BR/>MEAN BASELINE AGE (yrs): 7.18 <BR/>BASELINE AGE RANGE (yrs): 7 year olds only<BR/>INCLUSION CRITERIA:7 year old, healthy, low (&lt; 300 mg/day) habitual calcium intake<BR/>EXCLUSION CRITERIA: recent fracture or metabolic disease known to affect bone mass<BR/>BASELINE CALCIUM INTAKE (mg/day): 277<BR/>PUBERTAL STAGE: <BR/>
</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS>
<P>1. 300 mg/day calcium as calcium carbonate <BR/>2. Placebo<BR/>CO-INTERVENTIONS: Nil<BR/>
</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES>
<P>BONE MEASURES: SITES<BR/> AREAL BONE MINERAL DENSITY: midshaft radius <BR/> BONE MINERAL CONTENT: midshaft radius<BR/> BONE WIDTH : midshaft radius <BR/>METHOD OF MEASUREMENT: SPA<BR/>FOLLOW-UP ASSESSMENT POINTS: 0, 6-monthly until 2.5 years <BR/>OTHER OUTCOMES MEASURED: weight, height<BR/>BONE MEASURES INCLUDED IN ANALYSES: <BR/> AREAL BONE MINERAL DENSITY: midshaft radius <BR/> BONE MINERAL CONTENT: midshaft radius<BR/> BONE WIDTH : midshaft radius </P>
<P>SUB-GROUPS IDENTIFIED: Males and females<BR/>
</P>
</CHAR_OUTCOMES>
<CHAR_NOTES>
<P>Randomised by school class.</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR STUDY_ID="STD-Lee-1995">
<CHAR_METHODS>
<P>STUDY DESIGN: randomised controlled trial<BR/>LOCATION AND SETTING: Community (Well-baby clinic), hong Kong<BR/>DURATION OF SUPPLEMENTATION: 1.5 years <BR/>DURATION OF FOLLOW-UP: 3 years<BR/>QUALITY ASSESSMENT: Moderate risk of bias<BR/> RANDOMISED: States random but no description<BR/> ALLOCATION CONCEALMENT: Not described or unclear<BR/> BLINDING OF SUBJECT: Yes<BR/> DESCRIPTION OF WITHDRAWALS/DROPOUTS: Yes </P>
<P>TYPE OF ANALYSIS: Available Data<BR/>COMPLIANCE: Assessed<BR/>CONFOUNDERS MEASURED: physical activity, serum vitamin D (n=20), spontaneous calcium intake, dietary protein and energy intake, Tanner stage (at end of follow-up only).<BR/>
</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS>
<P>N SCREENED: unknown<BR/>N RANDOMISED: 109<BR/>N COMPLETED: 84 (1.5 years); 84 (3 years)<BR/>M=57%<BR/>F=43% <BR/>ETHNICITY: Chinese<BR/>MEAN BASELINE AGE (yrs): not given <BR/>BASELINE AGE RANGE (yrs): 7 year olds only<BR/>INCLUSION CRITERIA: 7-year olds, no recent metabolic disorder or fracture that might directly or indirectly affect bone metabolism, normal growth since birth.<BR/>EXCLUSION CRITERIA: see above<BR/>BASELINE CALCIUM INTAKE (mg/day): 567<BR/>PUBERTAL STAGE: assume prepubertal (age=7)<BR/>
</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS>
<P>1. Calcium 300mg/day as calcium carbonate<BR/>2. Placebo<BR/>CO-INTERVENTIONS: Nil<BR/>
</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES>
<P>BONE MEASURES: SITES<BR/> AREAL BONE MINERAL DENSITY: distal radius, femoral neck and L2-4 vertebrae. <BR/> BONE MINERAL CONTENT: distal radius, femoral neck and L2-4 vertebrae. <BR/> BONE AREA: distal radius, femoral neck and L2-4 vertebrae. <BR/>METHOD OF MEASUREMENT: SPA radius, DXA other sites<BR/>FOLLOW-UP ASSESSMENT POINTS(yrs): 0, 6-montly until 3 years <BR/>OTHER OUTCOMES MEASURED: weight, height<BR/>BONE MEASURES INCLUDED IN ANALYSES: <BR/> AREAL BONE MINERAL DENSITY: distal radius, femoral neck and L2-4 vertebrae. <BR/> BONE MINERAL CONTENT: distal radius, femoral neck and L2-4 vertebrae. <BR/> BONE AREA: distal radius, femoral neck and L2-4 vertebrae </P>
<P>SUB-GROUPS IDENTIFIED: Nil<BR/>
</P>
</CHAR_OUTCOMES>
<CHAR_NOTES/>
</INCLUDED_CHAR>
<INCLUDED_CHAR STUDY_ID="STD-Lloyd-1993">
<CHAR_METHODS>
<P>STUDY DESIGN: randomised controlled trial<BR/>LOCATION AND SETTING: Community (schools), USA<BR/>DURATION OF SUPPLEMENTATION: 2 years <BR/>DURATION OF FOLLOW-UP: 2 years<BR/>QUALITY ASSESSMENT: Moderate risk of bias<BR/> RANDOMISED: States random but no description<BR/> ALLOCATION CONCEALMENT: Not described or unclear<BR/> BLINDING OF SUBJECT: Yes<BR/> DESCRIPTION OF WITHDRAWALS/DROPOUTS: Yes </P>
<P>TYPE OF ANALYSIS: Available Data<BR/>COMPLIANCE: Assessed<BR/>CONFOUNDERS MEASURED: Tanner stage, Integrated Estrogen Exposure Score, spontaneous calcium intake, Urinary estradiol, testosterone, cortisol, luteinizing hormone and follicle-stimulating hormone .<BR/>
</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS>
<P>N SCREENED: unknown<BR/>N RANDOMISED: 112<BR/>N COMPLETED: 94 (1.5 years); 91 (2 years)<BR/>M=0%<BR/>F=100% <BR/>ETHNICITY: CAUCASIAN<BR/>MEAN BASELINE AGE (yrs): 11.9 <BR/>BASELINE AGE RANGE (yrs): unknown<BR/>INCLUSION CRITERIA: white female descendants of Northern Europeans, premenarcheal <BR/>EXCLUSION CRITERIA: Not between 80-120% of ideal body weight for height; regular medication; medical history known to affect bone development; known eating disorder.<BR/>BASELINE CALCIUM INTAKE (mg/day): 976<BR/>PUBERTAL STAGE: mixed<BR/>
</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS>
<P>1. 500 mg/day calcium as calcium citrate malate<BR/>2. Placebo<BR/>CO-INTERVENTIONS: Nil<BR/>
</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES>
<P>BONE MEASURES: SITES<BR/> AREAL BONE MINERAL DENSITY: Total body, pelvis and lumbar spine. <BR/> BONE MINERAL CONTENT: Total body, pelvis and lumbar spine. <BR/> BONE AREA: Total body, pelvis and lumbar spine.<BR/>METHOD OF MEASUREMENT: DXA<BR/>FOLLOW-UP ASSESSMENT POINTS(yrs): 0, 6-monthly to 2 years <BR/>OTHER OUTCOMES MEASURED: weight, height, urinary calcium &amp; creatinine<BR/>BONE MEASURES INCLUDED IN ANALYSES: <BR/> AREAL BONE MINERAL DENSITY: Total body, pelvis and lumbar spine. <BR/> BONE MINERAL CONTENT: Total body, pelvis and lumbar spine. <BR/> BONE AREA: Total body, pelvis and lumbar spine.</P>
<P>SUB-GROUPS IDENTIFIED: Above and below median Tanner score and median dietary calcium intake<BR/>
</P>
</CHAR_OUTCOMES>
<CHAR_NOTES>
<P>Randomisation stratified by BMI and baseline lumbar spine BMD</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR STUDY_ID="STD-Matkovic-2004">
<CHAR_METHODS>
<P>STUDY DESIGN: randomised controlled trial<BR/>LOCATION AND SETTING: Community (school), USA<BR/>DURATION OF SUPPLEMENTATION: 7 years <BR/>DURATION OF FOLLOW-UP: 7 years<BR/>QUALITY ASSESSMENT: High risk of bias<BR/> RANDOMISED: States random but no description<BR/> ALLOCATION CONCEALMENT: Not described or unclear<BR/> BLINDING OF SUBJECT: Yes<BR/> DESCRIPTION OF WITHDRAWALS/DROPOUTS: No </P>
<P>TYPE OF ANALYSIS: Available Data<BR/>COMPLIANCE: Assessed<BR/>CONFOUNDERS MEASURED: physical activity; dietary calcium, protein, energy intake; 24 hour urinary sodium; skeletal age, urinary and fecal calcium, serum calcium, serum vitamin D. <BR/>
</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS>
<P>N SCREENED: unknown<BR/>N RANDOMISED: 354<BR/>N COMPLETED: 220 (4 year); 179 (7 years)<BR/>M=0%<BR/>F=100% <BR/>ETHNICITY: white<BR/>MEAN BASELINE AGE (yrs): 10.8 <BR/>BASELINE AGE RANGE (yrs): unknown<BR/>INCLUSION CRITERIA: white, normal physical and mental health, pubertal stage 2, calcium intake &lt;1480 mg/day, female<BR/>EXCLUSION CRITERIA: history of metabolic bone, kidney, liver or celiac disease; use of oral corticosteroids, hormones, diuretics or antiseizure medications,; other current systemic, chronic disease; and the presence of clinically significant abnormal laboratory data on screening<BR/>BASELINE CALCIUM INTAKE (mg/day): 837<BR/>PUBERTAL STAGE: peripubertal (Tanner stage 2)<BR/>
</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS>
<P>1. 1000 mg/day calcium as calcium citrate malate<BR/>2. Placebo<BR/>CO-INTERVENTIONS: Nil<BR/>
</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES>
<P>BONE MEASURES: SITES<BR/> AREAL BONE MINERAL DENSITY: distal radius, radius at 33% of the radius length, total body. <BR/> BONE AREA: distal radius, radius at 33% of the radius length, total body. <BR/>METHOD OF MEASUREMENT: DXA<BR/>FOLLOW-UP ASSESSMENT POINTS(yrs): 0, 1, 2, 4.5, 8.5 <BR/>OTHER OUTCOMES MEASURED: metacarpal cortical index at 4 and 7 years, weight, height, body composition, serum osteocalcin and PTH and urinary N-telopeptides.<BR/>BONE MEASURES INCLUDED IN ANALYSES: <BR/> AREAL BONE MINERAL DENSITY: distal radius, radius at 33% of the radius length, total body. <BR/> BONE AREA: distal radius, radius at 33% of the radius length, total body.<BR/>SUB-GROUPS IDENTIFIED: nil<BR/>
</P>
</CHAR_OUTCOMES>
<CHAR_NOTES/>
</INCLUDED_CHAR>
<INCLUDED_CHAR STUDY_ID="STD-Molgaard-2004">
<CHAR_METHODS>
<P>STUDY DESIGN: randomised controlled trial<BR/>LOCATION AND SETTING: Population-based, Denmark<BR/>DURATION OF SUPPLEMENTATION: 1 years <BR/>DURATION OF FOLLOW-UP: 2 years<BR/>QUALITY ASSESSMENT: Moderate risk of bias<BR/> RANDOMISED: States random but no description<BR/> ALLOCATION CONCEALMENT: Not described or unclear<BR/> BLINDING OF SUBJECT: Yes<BR/> DESCRIPTION OF WITHDRAWALS/DROPOUTS: Yes </P>
<P>TYPE OF ANALYSIS: Available Data<BR/>COMPLIANCE: Assessed<BR/>CONFOUNDERS MEASURED: pubertal status, spontaneous calcium intake, physical activity, serum vitamin D<BR/>
</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS>
<P>N SCREENED: 241<BR/>N RANDOMISED: 113<BR/>N COMPLETED: 111 (1 year); <BR/>M=0%<BR/>F=100% <BR/>ETHNICITY: white<BR/>MEAN BASELINE AGE (yrs): 13.2 <BR/>BASELINE AGE RANGE (yrs): 12-14<BR/>INCLUSION CRITERIA: 12 years old +/- 6 months, girls<BR/>EXCLUSION CRITERIA: nonwhite ethnic origin, abnormal weight for height (&lt; 3rd, &gt; 97th percentile), diseases or intake of drugs with a potential effect on bones. Two groups recruited by calcium intake (high between 40th and 60th percentile = 1000-1304 mg/day by FFQ; low &lt; 20th percentile, &lt; 713 mg/day)<BR/>BASELINE CALCIUM INTAKE (mg/day): 841<BR/>PUBERTAL STAGE: mixed<BR/>
</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS>
<P>1. 500 mg/day of calcium as calcium carbonate<BR/>2. Placebo<BR/>CO-INTERVENTIONS: Nil<BR/>
</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES>
<P>BONE MEASURES: SITES<BR/> AREAL BONE MINERAL DENSITY: total body. <BR/> BONE MINERAL CONTENT: total body. <BR/> BONE AREA: total body. <BR/>METHOD OF MEASUREMENT: DXA<BR/>FOLLOW-UP ASSESSMENT POINTS(yrs): 0, 1 <BR/>OTHER OUTCOMES MEASURED: weight, height, serum alkaline phosphatase<BR/>BONE MEASURES INCLUDED IN ANALYSES: <BR/> AREAL BONE MINERAL DENSITY: total body. <BR/> BONE MINERAL CONTENT: total body. <BR/> BONE AREA: total body. </P>
<P>SUB-GROUPS IDENTIFIED: Spontaneous calcium intake (defined as high between 40th and 60th percentile = 1000-1304 mg/day by FFQ; low &lt; 20th percentile, &lt; 713 mg/day)<BR/>
</P>
</CHAR_OUTCOMES>
<CHAR_NOTES>
<P>Study also gives results as size-adjusted BMC ie BMC adjusted for bone area, weight and height. <BR/>In second year of follow-up, all participants were given supplements and no results are reported from the second year.<BR/>
</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR STUDY_ID="STD-Nowson-1997">
<CHAR_METHODS>
<P>STUDY DESIGN: randomised controlled trial<BR/>LOCATION AND SETTING: Community (Twin register), Australia<BR/>DURATION OF SUPPLEMENTATION: 1.5 years <BR/>DURATION OF FOLLOW-UP: 1.5 years<BR/>QUALITY ASSESSMENT: Moderate risk of bias<BR/> RANDOMISED: States random but no description<BR/> ALLOCATION CONCEALMENT: Not described or unclear<BR/> BLINDING OF SUBJECT: Yes<BR/> DESCRIPTION OF WITHDRAWALS/DROPOUTS: Yes </P>
<P>TYPE OF ANALYSIS: Available Data<BR/>COMPLIANCE: Assessed<BR/>CONFOUNDERS MEASURED: physical activity, pre vs post menarcheal, spontaneous calcium intake<BR/>
</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS>
<P>N SCREENED: unknown<BR/>N RANDOMISED: 110<BR/>N COMPLETED: 56 (1.5 years); <BR/>M=0%<BR/>F=100% <BR/>ETHNICITY: not stated<BR/>MEAN BASELINE AGE (yrs): 14 <BR/>BASELINE AGE RANGE (yrs): 10-17<BR/>INCLUSION CRITERIA: female twin pairs<BR/>EXCLUSION CRITERIA: none stated<BR/>BASELINE CALCIUM INTAKE (mg/day): 734<BR/>PUBERTAL STAGE: mixed<BR/>
</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS>
<P>1. 1000 mg/day calcium as calcium carbonate/calcium lactate gluconate combination<BR/>2. Placebo<BR/>CO-INTERVENTIONS: Nil<BR/>
</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES>
<P>BONE MEASURES: SITES<BR/> AREAL BONE MINERAL DENSITY: forearm, femoral neck, Ward's triangle, total hip and L2-4 vertebrae. <BR/> BONE MINERAL CONTENT: total body</P>
<P>METHOD OF MEASUREMENT: DXA<BR/>FOLLOW-UP ASSESSMENT POINTS(yrs): 0 (all sites), 6-monthly to 1.5 (hip and spine) <BR/>OTHER OUTCOMES MEASURED: weight, height, fat mass, lean mass<BR/>BONE MEASURES INCLUDED IN ANALYSES: <BR/> AREAL BONE MINERAL DENSITY: forearm, femoral neck, Ward's triangle, total hip and L2-4 vertebrae. <BR/> BONE MINERAL CONTENT: total body <BR/>SUB-GROUPS IDENTIFIED: Pre vs post menarcheal<BR/>
</P>
</CHAR_OUTCOMES>
<CHAR_NOTES/>
</INCLUDED_CHAR>
<INCLUDED_CHAR STUDY_ID="STD-Prentice-2005">
<CHAR_METHODS>
<P>STUDY DESIGN: randomised controlled trial<BR/>LOCATION AND SETTING: Community (college), UK<BR/>DURATION OF SUPPLEMENTATION: 1.06 years <BR/>DURATION OF FOLLOW-UP: 1.06 years<BR/>QUALITY ASSESSMENT: Moderate risk of bias<BR/> RANDOMISED: random and description consistent with this<BR/> ALLOCATION CONCEALMENT: Not described or unclear<BR/> BLINDING OF SUBJECT: Yes<BR/> DESCRIPTION OF WITHDRAWALS/DROPOUTS: Yes </P>
<P>TYPE OF ANALYSIS: Available Data<BR/>COMPLIANCE: Assessed<BR/>CONFOUNDERS MEASURED: physical activity, ethnic group, medical history, smoking and alcohol intake, consumption of dietary supplements and antacids, calcium intake, plasma testosterone concentration.<BR/>
</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS>
<P>N SCREENED: unknown<BR/>N RANDOMISED: 150<BR/>N COMPLETED: 143 (1 year)<BR/>M=100%<BR/>F=0% <BR/>ETHNICITY: 90% white<BR/>MEAN BASELINE AGE (yrs): 16.8 <BR/>BASELINE AGE RANGE (yrs): 16-18<BR/>INCLUSION CRITERIA: male sixth form students aged 16-18<BR/>EXCLUSION CRITERIA: any medical problem, history of eating disorders, medication known to affect bone metabolism<BR/>BASELINE CALCIUM INTAKE (mg/day): 1198<BR/>PUBERTAL STAGE: post-pubertal (assumed from age)<BR/>
</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS>
<P>1. 1000 mg/day calcium as calcium carbonate <BR/>2. Placebo<BR/>CO-INTERVENTIONS: Exercise in low physical activity group<BR/>
</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES>
<P>BONE MEASURES: SITES<BR/> AREAL BONE MINERAL DENSITY: left hip (total, femoral neck, greater trochanter, intertrochanter) and non-dominant forearm (total, ultradistal and 1/3 sites of radius). <BR/> BONE MINERAL CONTENT: total body, left hip (total, femoral neck, greater trochanter, intertrochanter) and non-dominant forearm (total, ultradistal and 1/3 sites of radius). <BR/> BONE AREA: left hip (total, femoral neck, greater trochanter, intertrochanter) and non-dominant forearm (total, ultradistal and 1/3 sites of radius).<BR/>METHOD OF MEASUREMENT: DXA<BR/>FOLLOW-UP ASSESSMENT POINTS(yrs): 0, 0.43, 1.06 <BR/>OTHER OUTCOMES MEASURED: weight, height, fat mass, lean mass<BR/>BONE MEASURES INCLUDED IN ANALYSES: <BR/> AREAL BONE MINERAL DENSITY: left hip (total, femoral neck, greater trochanter, intertrochanter) and non-dominant forearm (total, ultradistal and 1/3 sites of radius). <BR/> BONE MINERAL CONTENT: total body, left hip (total, femoral neck, greater trochanter, intertrochanter) and non-dominant forearm (total, ultradistal and 1/3 sites of radius). <BR/> BONE AREA: left hip (total, femoral neck, greater trochanter, intertrochanter) and non-dominant forearm (total, ultradistal and 1/3 sites of radius).<BR/>SUB-GROUPS IDENTIFIED: High vs low physical activity; above and below median calcium intake<BR/>
</P>
</CHAR_OUTCOMES>
<CHAR_NOTES>
<P>Study also gives results as size-adjusted BMC ie BMC adjusted for bone area, weight and height</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR STUDY_ID="STD-Rodda-2004">
<CHAR_METHODS>
<P>STUDY DESIGN: randomised controlled trial<BR/>LOCATION AND SETTING: Community (schools), Australia<BR/>DURATION OF SUPPLEMENTATION: 1-4 years <BR/>DURATION OF FOLLOW-UP: 4 years<BR/>QUALITY ASSESSMENT: Moderate risk of bias<BR/> RANDOMISED: States random but no description<BR/> ALLOCATION CONCEALMENT: Not described or unclear<BR/> BLINDING OF SUBJECT: Yes<BR/> DESCRIPTION OF WITHDRAWALS/DROPOUTS: No </P>
<P>TYPE OF ANALYSIS: not stated<BR/>COMPLIANCE: not stated<BR/>CONFOUNDERS MEASURED: Pubertal status, no others stated<BR/>
</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS>
<P>N SCREENED: unknown<BR/>N RANDOMISED: 93<BR/>N COMPLETED: unknown<BR/>M=0%<BR/>F=100% <BR/>ETHNICITY: Chinese 43%, anglocelt 57%<BR/>MEAN BASELINE AGE (yrs): not stated <BR/>BASELINE AGE RANGE (yrs): 10-12<BR/>INCLUSION CRITERIA: healthy girls<BR/>EXCLUSION CRITERIA: not stated<BR/>BASELINE CALCIUM INTAKE (mg/day): not stated<BR/>PUBERTAL STAGE: not stated<BR/>
</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS>
<P>1. Calcium carbonate 1200 mg/day<BR/>2. Placebo<BR/>CO-INTERVENTIONS: Nil<BR/>
</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES>
<P>BONE MEASURES: SITES<BR/> AREAL BONE MINERAL DENSITY: total body and lumbar spine. <BR/> BONE MINERAL CONTENT: total body and lumbar spine<BR/>METHOD OF MEASUREMENT: DXA<BR/>FOLLOW-UP ASSESSMENT POINTS(yrs): 0, yearly up to 4 years <BR/>OTHER OUTCOMES MEASURED: bone age, height, weight, sitting height, date of menarche, bone age<BR/>BONE MEASURES INCLUDED IN ANALYSES: <BR/> AREAL BONE MINERAL DENSITY: total body and lumbar spine. <BR/> BONE MINERAL CONTENT: total body and lumbar spine<BR/>SUB-GROUPS IDENTIFIED: Chinese vs Anglocelt ethnicity<BR/>
</P>
</CHAR_OUTCOMES>
<CHAR_NOTES>
<P>Information about this study is limited as it has only been published as an abstract and no further information was available.</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR STUDY_ID="STD-Rozen-2003">
<CHAR_METHODS>
<P>STUDY DESIGN: randomised controlled trial<BR/>LOCATION AND SETTING: Community (school), Israel<BR/>DURATION OF SUPPLEMENTATION: 1 years <BR/>DURATION OF FOLLOW-UP: 4.5 years<BR/>QUALITY ASSESSMENT: High risk of bias<BR/> RANDOMISED: States random but no description<BR/> ALLOCATION CONCEALMENT: Not described or unclear<BR/> BLINDING OF SUBJECT: Yes<BR/> DESCRIPTION OF WITHDRAWALS/DROPOUTS: No </P>
<P>TYPE OF ANALYSIS: Available Data and treatment received<BR/>COMPLIANCE: Assessed<BR/>CONFOUNDERS MEASURED: spontaneous calcium intake, serum vitamin D<BR/>
</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS>
<P>N SCREENED: unknown<BR/>N RANDOMISED: 112<BR/>N COMPLETED: 100 (1 year); 96 (4.5 years)<BR/>M=0%<BR/>F=100% <BR/>ETHNICITY: 76% Jewish, 24% arab<BR/>MEAN BASELINE AGE (yrs): 14.85 <BR/>BASELINE AGE RANGE (yrs): 12-17<BR/>INCLUSION CRITERIA: girls, calcium intake &lt; 800 mg; &gt;= 1 year post menarcheal, age &lt; 15.5, no chronic disease, nonsmoking and no use of contraceptives.<BR/>EXCLUSION CRITERIA: Pregnancy between cessation of supplementation and follow-up (for follow-up study)<BR/>BASELINE CALCIUM INTAKE (mg/day): 582<BR/>PUBERTAL STAGE: post pubertal<BR/>
</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS>
<P>1. 1000 mg/day calcium as calcium carbonate<BR/>2. Placebo<BR/>CO-INTERVENTIONS: Nil<BR/>
</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES>
<P>BONE MEASURES: SITES<BR/> AREAL BONE MINERAL DENSITY: total body, lumbar spine (L2-4) and femoral neck <BR/> BONE MINERAL CONTENT: total body, lumbar spine (L2-4) and femoral neck<BR/>METHOD OF MEASUREMENT: DXA<BR/>FOLLOW-UP ASSESSMENT POINTS(yrs): 0, 0.5,1, 4.5 <BR/>OTHER OUTCOMES MEASURED: weight, height, bone-specific alkaline phosphatase, urinary deoxypyridinline cross-links, serum PTH and osteocalcin.<BR/>BONE MEASURES INCLUDED IN ANALYSES: <BR/> AREAL BONE MINERAL DENSITY: total body, lumbar spine (L2-4) and femoral neck <BR/> BONE MINERAL CONTENT: total body, lumbar spine (L2-4) and femoral neck<BR/>SUB-GROUPS IDENTIFIED: &lt; 24 months post-menarche vs &gt; 24 months post-menarche<BR/>
</P>
</CHAR_OUTCOMES>
<CHAR_NOTES/>
</INCLUDED_CHAR>
<INCLUDED_CHAR STUDY_ID="STD-Specker-2003">
<CHAR_METHODS>
<P>STUDY DESIGN: randomised controlled trial<BR/>LOCATION AND SETTING: Community (child care centres), USA<BR/>DURATION OF SUPPLEMENTATION: 1 years <BR/>DURATION OF FOLLOW-UP: 1 years<BR/>QUALITY ASSESSMENT: Moderate risk of bias<BR/> RANDOMISED: States random but no description<BR/> ALLOCATION CONCEALMENT: Not described or unclear<BR/> BLINDING OF SUBJECT: unclear<BR/> DESCRIPTION OF WITHDRAWALS/DROPOUTS: Yes </P>
<P>TYPE OF ANALYSIS: Available Data<BR/>COMPLIANCE: Assessed<BR/>CONFOUNDERS MEASURED: spontaneous calcium intake, physical activity by accelerometer<BR/>
</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS>
<P>N SCREENED: unknown<BR/>N RANDOMISED: 239 <BR/>N COMPLETED: 178 (1 year)<BR/>M= 53%<BR/>F= 47% <BR/>ETHNICITY: white 94%, other 6%<BR/>MEAN BASELINE AGE (yrs): 3.92 <BR/>BASELINE AGE RANGE (yrs): 3-5<BR/>INCLUSION CRITERIA: enrolled in child care centre, no known disorders that affected bone metabolism<BR/>EXCLUSION CRITERIA: see inclusion criteria<BR/>BASELINE CALCIUM INTAKE (mg/day): 946<BR/>PUBERTAL STAGE: prepubertal<BR/>
</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS>
<P>1. 1000 mg/day calcium as calcium carbonate<BR/>2. Placebo<BR/>CO-INTERVENTIONS: Gross motor vs fine motor exercise 30 min per day 5 days per week<BR/>
</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES>
<P>BONE MEASURES: SITES<BR/> BONE MINERAL CONTENT: total body, arm, leg <BR/> BONE AREA: total body, arm, leg <BR/>METHOD OF MEASUREMENT: DXA<BR/>FOLLOW-UP ASSESSMENT POINTS(yrs): 0, 1 <BR/>OTHER OUTCOMES MEASURED: weight, height, fat mass, lean mass, distal tibial periosteal and endosteal circumferences, cortical thickness and cortical area.<BR/>BONE MEASURES INCLUDED IN ANALYSES: <BR/> BONE MINERAL CONTENT: total body, arm, leg <BR/> BONE AREA: total body, arm, leg </P>
<P>SUB-GROUPS IDENTIFIED: By exercise intervention<BR/>
</P>
</CHAR_OUTCOMES>
<CHAR_NOTES/>
</INCLUDED_CHAR>
<INCLUDED_CHAR STUDY_ID="STD-Stear-2003">
<CHAR_METHODS>
<P>STUDY DESIGN: randomised controlled trial<BR/>LOCATION AND SETTING: Community (college), UK<BR/>DURATION OF SUPPLEMENTATION: 15.5 months <BR/>DURATION OF FOLLOW-UP: 15.5 months<BR/>QUALITY ASSESSMENT: High risk of bias<BR/> RANDOMISED: States random but no description<BR/> ALLOCATION CONCEALMENT: Yes<BR/> BLINDING OF SUBJECT: Yes<BR/> DESCRIPTION OF WITHDRAWALS/DROPOUTS: No </P>
<P>TYPE OF ANALYSIS: Available Data and treatment received<BR/>COMPLIANCE: Assessed<BR/>CONFOUNDERS MEASURED: spontaneous calcium intake and physical activity<BR/>
</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS>
<P>N SCREENED: unknown<BR/>N RANDOMISED: 144<BR/>N COMPLETED: 131 (15.5 months)<BR/>M=0%<BR/>F=100% <BR/>ETHNICITY: not stated<BR/>MEAN BASELINE AGE (yrs): 17.3 <BR/>BASELINE AGE RANGE (yrs): 16-18<BR/>INCLUSION CRITERIA: female sixth form college students<BR/>EXCLUSION CRITERIA: any medical problem, history of eating disorders, medication known to interfere with bone metabolism<BR/>BASELINE CALCIUM INTAKE (mg/day): 938<BR/>PUBERTAL STAGE: post pubertal<BR/>
</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS>
<P>1. 1000 mg/day of calcium as calcium carbonate<BR/>2. Placebo<BR/>CO-INTERVENTIONS: exercise (45 min 3 times per week aerobics with moderate to high impact movements) and no exercise groups<BR/>
</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES>
<P>BONE MEASURES: SITES<BR/> AREAL BONE MINERAL DENSITY: unpublished data femoral neck, lumbar spine, distal radius. <BR/> BONE MINERAL CONTENT: total body, spine, radius (total, ultradistal, distal third), hip (total, femoral neck, trochanter, intertrochanter), lumbar spine<BR/> BONE AREA: total body, spine, radius (total, ultradistal, distal third), hip (total, femoral neck, trochanter, intertrochanter), lumbar spine<BR/>METHOD OF MEASUREMENT: DXA<BR/>FOLLOW-UP ASSESSMENT POINTS(yrs): 0, 1.29 <BR/>OTHER OUTCOMES MEASURED: weight, height, <BR/>BONE MEASURES INCLUDED IN ANALYSES: <BR/> AREAL BONE MINERAL DENSITY: unpublished data femoral neck, lumbar spine, distal radius. <BR/> BONE MINERAL CONTENT: total body, spine, radius (total, ultradistal, distal third), hip (total, femoral neck, trochanter, intertrochanter), lumbar spine<BR/> BONE AREA: total body, spine, radius (total, ultradistal, distal third), hip (total, femoral neck, trochanter, intertrochanter), lumbar spine</P>
<P>SUB-GROUPS IDENTIFIED: Exercise groups; high compliance groups for calcium and exercise<BR/>
</P>
</CHAR_OUTCOMES>
<CHAR_NOTES>
<P>Compliance to exercise was poor; only 27% of subjects attended more than 50% of the intervention target.<BR/>Study also gives results as size-adjusted BMC ie BMC adjusted for bone area, weight and height<BR/>
</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR STUDY_ID="STD-Wang-1996">
<CHAR_METHODS>
<P>STUDY DESIGN: randomised controlled trial<BR/>LOCATION AND SETTING: Community (school), China<BR/>DURATION OF SUPPLEMENTATION: 1.5 years <BR/>DURATION OF FOLLOW-UP: 1.5 years<BR/>QUALITY ASSESSMENT: High risk of bias<BR/> RANDOMISED: States random but no description<BR/> ALLOCATION CONCEALMENT: Not described or unclear<BR/> BLINDING OF SUBJECT: Yes<BR/> DESCRIPTION OF WITHDRAWALS/DROPOUTS: No </P>
<P>TYPE OF ANALYSIS: Available Data<BR/>COMPLIANCE: Not reported<BR/>CONFOUNDERS MEASURED: serum vitamin D, physical activity, spontaneous calcium intake<BR/>
</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS>
<P>N SCREENED: unknown<BR/>N RANDOMISED: 163<BR/>N COMPLETED: 162 (1.5 years) <BR/>M=54%<BR/>F=46% <BR/>ETHNICITY: Chinese<BR/>MEAN BASELINE AGE (yrs): 7.2 <BR/>BASELINE AGE RANGE (yrs): not stated<BR/>INCLUSION CRITERIA: healthy, no metabolic disease or recent medication related to bone metabolism<BR/>EXCLUSION CRITERIA: see inclusion criteria<BR/>BASELINE CALCIUM INTAKE (mg/day): 277<BR/>PUBERTAL STAGE: prepubertal (assumed from age)<BR/>
</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS>
<P>1. 300 mg/day calcium as calcium carbonate<BR/>2. Placebo<BR/>CO-INTERVENTIONS: Nil<BR/>
</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES>
<P>BONE MEASURES: SITES<BR/> AREAL BONE MINERAL DENSITY: distal radius. <BR/> BONE MINERAL CONTENT: distal radius. <BR/> BONE WIDTH: distal radius . <BR/>METHOD OF MEASUREMENT: SPA<BR/>FOLLOW-UP ASSESSMENT POINTS(yrs): 0, 1, 2, 4.5, 8.5 <BR/>OTHER OUTCOMES MEASURED: weight, height<BR/>BONE MEASURES INCLUDED IN ANALYSES: <BR/> AREAL BONE MINERAL DENSITY: distal radius. <BR/> BONE MINERAL CONTENT: distal radius. <BR/> BONE WIDTH: distal radius . </P>
<P>SUB-GROUPS IDENTIFIED: nil<BR/>
</P>
</CHAR_OUTCOMES>
<CHAR_NOTES>
<P>Chinese language paper.</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<FOOTNOTES/>
</CHARACTERISTICS_OF_INCLUDED_STUDIES>
<CHARACTERISTICS_OF_EXCLUDED_STUDIES SORT_BY="STUDY">
<EXCLUDED_CHAR STUDY_ID="STD-Abrams-2001">
<CHAR_REASON_FOR_EXCLUSION>
<P>Not a randomised controlled trial</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR STUDY_ID="STD-Adiyaman-2004">
<CHAR_REASON_FOR_EXCLUSION>
<P>Not a randomised controlled trial</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR STUDY_ID="STD-Albertson-1997">
<CHAR_REASON_FOR_EXCLUSION>
<P>Not a randomised controlled trial</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR STUDY_ID="STD-Ali-2001">
<CHAR_REASON_FOR_EXCLUSION>
<P>Not a randomised controlled trial</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR STUDY_ID="STD-Anderson-2001">
<CHAR_REASON_FOR_EXCLUSION>
<P>Not a randomised controlled trial</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR STUDY_ID="STD-Andon-1994">
<CHAR_REASON_FOR_EXCLUSION>
<P>Not a randomised controlled trial</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR STUDY_ID="STD-Anonymous-1992">
<CHAR_REASON_FOR_EXCLUSION>
<P>Not a randomised controlled trial</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR STUDY_ID="STD-Anonymous-1993a">
<CHAR_REASON_FOR_EXCLUSION>
<P>Not a randomised controlled trial</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR STUDY_ID="STD-Anonymous-1993b">
<CHAR_REASON_FOR_EXCLUSION>
<P>Not a randomised controlled trial</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR STUDY_ID="STD-Anonymous-1994">
<CHAR_REASON_FOR_EXCLUSION>
<P>Not a randomised controlled trial</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR STUDY_ID="STD-Anonymous-1997a">
<CHAR_REASON_FOR_EXCLUSION>
<P>Not a randomised controlled trial</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR STUDY_ID="STD-Anonymous-1997b">
<CHAR_REASON_FOR_EXCLUSION>
<P>Not a randomised controlled trial</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR STUDY_ID="STD-Anonymous-1998">
<CHAR_REASON_FOR_EXCLUSION>
<P>Not a randomised controlled trial</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR STUDY_ID="STD-Anonymous-2000">
<CHAR_REASON_FOR_EXCLUSION>
<P>Not a randomised controlled trial</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR STUDY_ID="STD-Anonymous-2004">
<CHAR_REASON_FOR_EXCLUSION>
<P>Not a randomised controlled trial</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR STUDY_ID="STD-Antoniazzi--2003">
<CHAR_REASON_FOR_EXCLUSION>
<P>Condition predisposing to osteoporosis (participants undergoing treatment with gonadotrophin-releasing hormone agonist treatment)</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR STUDY_ID="STD-Antoniazzi-1999">
<CHAR_REASON_FOR_EXCLUSION>
<P>Condition predisposing to osteoporosis (participants undergoing treatment with gonadotrophin-releasing hormone agonist treatment)</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR STUDY_ID="STD-Appleby-1998">
<CHAR_REASON_FOR_EXCLUSION>
<P>Not a randomised controlled trial</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR STUDY_ID="STD-Ausenhus-1988">
<CHAR_REASON_FOR_EXCLUSION>
<P>Not a randomised controlled trial</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR STUDY_ID="STD-Badenhop-2004">
<CHAR_REASON_FOR_EXCLUSION>
<P>Not a randomised controlled trial</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR STUDY_ID="STD-Barker-1998">
<CHAR_REASON_FOR_EXCLUSION>
<P>No placebo used</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR STUDY_ID="STD-Barr-1998">
<CHAR_REASON_FOR_EXCLUSION>
<P>Not a randomised controlled trial</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR STUDY_ID="STD-Barr-2001">
<CHAR_REASON_FOR_EXCLUSION>
<P>Not a randomised controlled trial</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR STUDY_ID="STD-Bateson-2002">
<CHAR_REASON_FOR_EXCLUSION>
<P>Not a randomised controlled trial</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR STUDY_ID="STD-Berthier-1994">
<CHAR_REASON_FOR_EXCLUSION>
<P>Not a randomised controlled trial</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR STUDY_ID="STD-Black-2002">
<CHAR_REASON_FOR_EXCLUSION>
<P>Not a randomised controlled trial</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR STUDY_ID="STD-Blalock-2002">
<CHAR_REASON_FOR_EXCLUSION>
<P>No calcium intervention</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR STUDY_ID="STD-Bonjour-1999">
<CHAR_REASON_FOR_EXCLUSION>
<P>Not a randomised controlled trial</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR STUDY_ID="STD-Bonofiglio-2004">
<CHAR_REASON_FOR_EXCLUSION>
<P>Not a randomised controlled trial</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR STUDY_ID="STD-Boot-1997">
<CHAR_REASON_FOR_EXCLUSION>
<P>Not a randomised controlled trial</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR STUDY_ID="STD-Bourges">
<CHAR_REASON_FOR_EXCLUSION>
<P>Not a randomised controlled trial</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR STUDY_ID="STD-Brown-2004">
<CHAR_REASON_FOR_EXCLUSION>
<P>No calcium intervention</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR STUDY_ID="STD-Burckhardt-2001">
<CHAR_REASON_FOR_EXCLUSION>
<P>Not a randomised controlled trial</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR STUDY_ID="STD-Cadogan-1997">
<CHAR_REASON_FOR_EXCLUSION>
<P>No placebo used</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR STUDY_ID="STD-Carter-2001">
<CHAR_REASON_FOR_EXCLUSION>
<P>Not a randomised controlled trial</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR STUDY_ID="STD-Chan-1987">
<CHAR_REASON_FOR_EXCLUSION>
<P>Trial in lactating adolscents ie condition predisposing to bone loss</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR STUDY_ID="STD-Chan-1991">
<CHAR_REASON_FOR_EXCLUSION>
<P>Not a randomised controlled trial</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR STUDY_ID="STD-Chan-1995">
<CHAR_REASON_FOR_EXCLUSION>
<P>No placebo used</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR STUDY_ID="STD-Cheng-1999">
<CHAR_REASON_FOR_EXCLUSION>
<P>Not a randomised controlled trial</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR STUDY_ID="STD-Chevalley-2004">
<CHAR_REASON_FOR_EXCLUSION>
<P>Not a randomised controlled trial</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR STUDY_ID="STD-Clements-1991">
<CHAR_REASON_FOR_EXCLUSION>
<P>Not a randomised controlled trial</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR STUDY_ID="STD-DeBar--2004">
<CHAR_REASON_FOR_EXCLUSION>
<P>No calcium intervention</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR STUDY_ID="STD-DiMeglio-2005">
<CHAR_REASON_FOR_EXCLUSION>
<P>No calcium intervention</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR STUDY_ID="STD-Dowd-2001">
<CHAR_REASON_FOR_EXCLUSION>
<P>Not a randomised controlled trial</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR STUDY_ID="STD-Du-2002">
<CHAR_REASON_FOR_EXCLUSION>
<P>Not a randomised controlled trial</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR STUDY_ID="STD-Du-2004">
<CHAR_REASON_FOR_EXCLUSION>
<P>No placebo used</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR STUDY_ID="STD-Edwards-1998">
<CHAR_REASON_FOR_EXCLUSION>
<P>Not a randomised controlled trial</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR STUDY_ID="STD-El_x002d_Husseini-2004">
<CHAR_REASON_FOR_EXCLUSION>
<P>Condition presiposing to osteoporosis (renal transplantion)</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR STUDY_ID="STD-Elgan-2002">
<CHAR_REASON_FOR_EXCLUSION>
<P>Not a randomised controlled trial</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR STUDY_ID="STD-Feskanich-1997">
<CHAR_REASON_FOR_EXCLUSION>
<P>Not a randomised controlled trial</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR STUDY_ID="STD-Fischer-1999a">
<CHAR_REASON_FOR_EXCLUSION>
<P>No placebo</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR STUDY_ID="STD-Fischer-1999b">
<CHAR_REASON_FOR_EXCLUSION>
<P>Duplicate paper to Fischer 1999a</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR STUDY_ID="STD-Fisher-2004">
<CHAR_REASON_FOR_EXCLUSION>
<P>Not a randomised controlled trial</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR STUDY_ID="STD-Fujita-1992">
<CHAR_REASON_FOR_EXCLUSION>
<P>Not a randomised controlled trial</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR STUDY_ID="STD-Gharib--2004">
<CHAR_REASON_FOR_EXCLUSION>
<P>Not a randomised controlled trial</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR STUDY_ID="STD-Gibbons-2004">
<CHAR_REASON_FOR_EXCLUSION>
<P>Active placebo used (400 mg calcium)</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR STUDY_ID="STD-Ginty-2004">
<CHAR_REASON_FOR_EXCLUSION>
<P>Not a randomised controlled trial</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR STUDY_ID="STD-Goulding-2004">
<CHAR_REASON_FOR_EXCLUSION>
<P>Not a randomised controlled trial</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR STUDY_ID="STD-Griffiths-1998">
<CHAR_REASON_FOR_EXCLUSION>
<P>Not a randomised controlled trial</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR STUDY_ID="STD-Grossklaus-1998">
<CHAR_REASON_FOR_EXCLUSION>
<P>Not a randomised controlled trial</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR STUDY_ID="STD-Gulati--2005">
<CHAR_REASON_FOR_EXCLUSION>
<P>Not a randomised controlled trial</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR STUDY_ID="STD-Hampton-2004">
<CHAR_REASON_FOR_EXCLUSION>
<P>Not a randomised controlled trial</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR STUDY_ID="STD-Harel-1998">
<CHAR_REASON_FOR_EXCLUSION>
<P>Not a randomised controlled trial</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR STUDY_ID="STD-Henderson-1994">
<CHAR_REASON_FOR_EXCLUSION>
<P>Not a randomised controlled trial</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR STUDY_ID="STD-Hidvegi-2003">
<CHAR_REASON_FOR_EXCLUSION>
<P>Not a randomised controlled trial</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR STUDY_ID="STD-Homik-2005">
<CHAR_REASON_FOR_EXCLUSION>
<P>Not a randomised controlled trial</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR STUDY_ID="STD-Hoppe-2000">
<CHAR_REASON_FOR_EXCLUSION>
<P>Not a randomised controlled trial</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR STUDY_ID="STD-Hosokawa-1996">
<CHAR_REASON_FOR_EXCLUSION>
<P>Not a randomised controlled trial</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR STUDY_ID="STD-Howat-2001">
<CHAR_REASON_FOR_EXCLUSION>
<P>Not a randomised controlled trial</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR STUDY_ID="STD-Iki-2003">
<CHAR_REASON_FOR_EXCLUSION>
<P>Not a randomised controlled trial</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR STUDY_ID="STD-Ilich-1996">
<CHAR_REASON_FOR_EXCLUSION>
<P>Not a randomised controlled trial</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR STUDY_ID="STD-Infante-2000">
<CHAR_REASON_FOR_EXCLUSION>
<P>Not a randomised controlled trial</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR STUDY_ID="STD-Kalkwarf-1997">
<CHAR_REASON_FOR_EXCLUSION>
<P>Adult participants and participants lactating</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR STUDY_ID="STD-Kalkwarf-2003">
<CHAR_REASON_FOR_EXCLUSION>
<P>Not a randomised controlled trial</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR STUDY_ID="STD-Kalusk-2001">
<CHAR_REASON_FOR_EXCLUSION>
<P>Not a randomised controlled trial</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR STUDY_ID="STD-Kanis-1994">
<CHAR_REASON_FOR_EXCLUSION>
<P>Not a randomised controlled trial</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR STUDY_ID="STD-Kardinaal-1999">
<CHAR_REASON_FOR_EXCLUSION>
<P>Not a randomised controlled trial</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR STUDY_ID="STD-Kasper-2001">
<CHAR_REASON_FOR_EXCLUSION>
<P>Not a randomised controlled trial</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR STUDY_ID="STD-Kerstetter-1995">
<CHAR_REASON_FOR_EXCLUSION>
<P>Not a randomised controlled trial</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR STUDY_ID="STD-Koenig-2000">
<CHAR_REASON_FOR_EXCLUSION>
<P>Not a randomised controlled trial</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR STUDY_ID="STD-Kowalski--2004">
<CHAR_REASON_FOR_EXCLUSION>
<P>Not a randomised controlled trial</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR STUDY_ID="STD-Kreipe-1995">
<CHAR_REASON_FOR_EXCLUSION>
<P>Not a randomised controlled trial</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR STUDY_ID="STD-Kubota-2003">
<CHAR_REASON_FOR_EXCLUSION>
<P>Not a randomised controlled trial</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR STUDY_ID="STD-Kun-2001">
<CHAR_REASON_FOR_EXCLUSION>
<P>Not a randomised controlled trial</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR STUDY_ID="STD-Lappe-2004">
<CHAR_REASON_FOR_EXCLUSION>
<P>No bone outcome measures (trial of calcium effect on wieght gain)</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR STUDY_ID="STD-LaRosa-2004">
<CHAR_REASON_FOR_EXCLUSION>
<P>Not a randomised controlled trial</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR STUDY_ID="STD-Lau-1992">
<CHAR_REASON_FOR_EXCLUSION>
<P>No placebo and no randomisation</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR STUDY_ID="STD-Lau-2004">
<CHAR_REASON_FOR_EXCLUSION>
<P>No placebo used</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR STUDY_ID="STD-Lee-1993">
<CHAR_REASON_FOR_EXCLUSION>
<P>Not a randomised controlled trial</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR STUDY_ID="STD-Lee-2003">
<CHAR_REASON_FOR_EXCLUSION>
<P>Not a randomised controlled trial</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR STUDY_ID="STD-Levers_x002d_Landis-2003">
<CHAR_REASON_FOR_EXCLUSION>
<P>Not a randomised controlled trial</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR STUDY_ID="STD-Li-2002">
<CHAR_REASON_FOR_EXCLUSION>
<P>No placebo used</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR STUDY_ID="STD-Lloyd-2000">
<CHAR_REASON_FOR_EXCLUSION>
<P>Not a randomised controlled trial</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR STUDY_ID="STD-Lloyd-2002">
<CHAR_REASON_FOR_EXCLUSION>
<P>Not a randomised controlled trial</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR STUDY_ID="STD-Lysen-1997">
<CHAR_REASON_FOR_EXCLUSION>
<P>Not a randomised controlled trial</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR STUDY_ID="STD-Ma--2004">
<CHAR_REASON_FOR_EXCLUSION>
<P>Not a randomised controlled trial</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR STUDY_ID="STD-Mackelvie-2001">
<CHAR_REASON_FOR_EXCLUSION>
<P>Not a randomised controlled trial</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR STUDY_ID="STD-Magee-1996">
<CHAR_REASON_FOR_EXCLUSION>
<P>No placebo used</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR STUDY_ID="STD-Maggiolini-1999">
<CHAR_REASON_FOR_EXCLUSION>
<P>Not a randomised controlled trial</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR STUDY_ID="STD-Mahana-1988">
<CHAR_REASON_FOR_EXCLUSION>
<P>Not a randomised controlled trial</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR STUDY_ID="STD-Mallet-2000">
<CHAR_REASON_FOR_EXCLUSION>
<P>Not a randomised controlled trial</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR STUDY_ID="STD-Mallet-2003">
<CHAR_REASON_FOR_EXCLUSION>
<P>Not a randomised controlled trial</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR STUDY_ID="STD-Marrero-2004">
<CHAR_REASON_FOR_EXCLUSION>
<P>Not a randomised controlled trial</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR STUDY_ID="STD-Martin--2004">
<CHAR_REASON_FOR_EXCLUSION>
<P>Not a randomised controlled trial</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR STUDY_ID="STD-Matkovic-1990">
<CHAR_REASON_FOR_EXCLUSION>
<P>Inadequate randomisation</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR STUDY_ID="STD-Matkovic-2002">
<CHAR_REASON_FOR_EXCLUSION>
<P>Not a randomised controlled trial</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR STUDY_ID="STD-McCulloch-1990">
<CHAR_REASON_FOR_EXCLUSION>
<P>Not a randomised controlled trial</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR STUDY_ID="STD-Meier-2004">
<CHAR_REASON_FOR_EXCLUSION>
<P>Participants were adults.</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR STUDY_ID="STD-Merrilees-2000">
<CHAR_REASON_FOR_EXCLUSION>
<P>No placebo used</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR STUDY_ID="STD-Meschino-2004">
<CHAR_REASON_FOR_EXCLUSION>
<P>Not a randomised controlled trial</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR STUDY_ID="STD-Moelgaard-2001">
<CHAR_REASON_FOR_EXCLUSION>
<P>Not a randomised controlled trial</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR STUDY_ID="STD-Monge-2001">
<CHAR_REASON_FOR_EXCLUSION>
<P>Not a randomised controlled trial</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR STUDY_ID="STD-Moya-1997">
<CHAR_REASON_FOR_EXCLUSION>
<P>Not a randomised controlled trial</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR STUDY_ID="STD-Moyer_x002d_Mileur-2003">
<CHAR_REASON_FOR_EXCLUSION>
<P>Intervention combined vitamin D and calcium with no capacity to seperate calcium effect.</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR STUDY_ID="STD-Naunton-2004">
<CHAR_REASON_FOR_EXCLUSION>
<P>Not a randomised controlled trial</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR STUDY_ID="STD-Neville-2002">
<CHAR_REASON_FOR_EXCLUSION>
<P>Not a randomised controlled trial</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR STUDY_ID="STD-New-1998">
<CHAR_REASON_FOR_EXCLUSION>
<P>Not a randomised controlled trial</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR STUDY_ID="STD-NIH-2001">
<CHAR_REASON_FOR_EXCLUSION>
<P>Not a randomised controlled trial</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR STUDY_ID="STD-Novotny-2004">
<CHAR_REASON_FOR_EXCLUSION>
<P>Not a randomised controlled trial</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR STUDY_ID="STD-Nowson-1995">
<CHAR_REASON_FOR_EXCLUSION>
<P>Duplicate data (conference abstract)</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR STUDY_ID="STD-O_x0027_-Brien-1998">
<CHAR_REASON_FOR_EXCLUSION>
<P>Not a randomised controlled trial</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR STUDY_ID="STD-Oellingrath-1989">
<CHAR_REASON_FOR_EXCLUSION>
<P>Not a randomised controlled trial</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR STUDY_ID="STD-Ohgitani-1997">
<CHAR_REASON_FOR_EXCLUSION>
<P>No BMD or BMC outcomes</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR STUDY_ID="STD-Oria-2003">
<CHAR_REASON_FOR_EXCLUSION>
<P>Not a randomised controlled trial</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR STUDY_ID="STD-Parr-2002">
<CHAR_REASON_FOR_EXCLUSION>
<P>Not a randomised controlled trial</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR STUDY_ID="STD-Pena-2004">
<CHAR_REASON_FOR_EXCLUSION>
<P>Not a randomised controlled trial</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR STUDY_ID="STD-Peterson-2000">
<CHAR_REASON_FOR_EXCLUSION>
<P>No calcium intervention</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR STUDY_ID="STD-Piaseu-2002">
<CHAR_REASON_FOR_EXCLUSION>
<P>No calcium intervention</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR STUDY_ID="STD-Picard-1988">
<CHAR_REASON_FOR_EXCLUSION>
<P>Not a randomised controlled trial</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR STUDY_ID="STD-Portsmouth-1994">
<CHAR_REASON_FOR_EXCLUSION>
<P>Not a randomised controlled trial</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR STUDY_ID="STD-Prestridge-1993">
<CHAR_REASON_FOR_EXCLUSION>
<P>Condition predisposing to osteoporosis (very low birth weight infants)</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR STUDY_ID="STD-Prynne-2004">
<CHAR_REASON_FOR_EXCLUSION>
<P>Not a randomised controlled trial</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR STUDY_ID="STD-Purdie-1994">
<CHAR_REASON_FOR_EXCLUSION>
<P>Not a randomised controlled trial</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR STUDY_ID="STD-Recker-1993">
<CHAR_REASON_FOR_EXCLUSION>
<P>Not a randomised controlled trial</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR STUDY_ID="STD-Reid-1998">
<CHAR_REASON_FOR_EXCLUSION>
<P>Not a randomised controlled trial</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR STUDY_ID="STD-Remer-2002">
<CHAR_REASON_FOR_EXCLUSION>
<P>Not a randomised controlled trial</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR STUDY_ID="STD-Renner-1991a">
<CHAR_REASON_FOR_EXCLUSION>
<P>Not a randomised controlled trial</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR STUDY_ID="STD-Renner-1991b">
<CHAR_REASON_FOR_EXCLUSION>
<P>Not a randomised controlled trial</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR STUDY_ID="STD-Renner-1994">
<CHAR_REASON_FOR_EXCLUSION>
<P>Not a randomised controlled trial</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR STUDY_ID="STD-Renner-1998">
<CHAR_REASON_FOR_EXCLUSION>
<P>No placebo or randomisation</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR STUDY_ID="STD-Roberts-2000">
<CHAR_REASON_FOR_EXCLUSION>
<P>Not a randomised controlled trial</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR STUDY_ID="STD-Robertson-2005">
<CHAR_REASON_FOR_EXCLUSION>
<P>Not a randomised controlled study</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR STUDY_ID="STD-Roux-1995">
<CHAR_REASON_FOR_EXCLUSION>
<P>Not a randomised controlled trial</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR STUDY_ID="STD-Rozen-2001">
<CHAR_REASON_FOR_EXCLUSION>
<P>Not a randomised controlled trial</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR STUDY_ID="STD-Ruiz-1995">
<CHAR_REASON_FOR_EXCLUSION>
<P>Not a randomised controlled trial</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR STUDY_ID="STD-Runyan-2003">
<CHAR_REASON_FOR_EXCLUSION>
<P>Not a randomised controlled trial</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR STUDY_ID="STD-Sagara-2002">
<CHAR_REASON_FOR_EXCLUSION>
<P>Not a randomised controlled trial</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR STUDY_ID="STD-Saggese">
<CHAR_REASON_FOR_EXCLUSION>
<P>Not a randomised controlled trial</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR STUDY_ID="STD-Sakkers-2004">
<CHAR_REASON_FOR_EXCLUSION>
<P>No calcium intervention</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR STUDY_ID="STD-Scholz-1993">
<CHAR_REASON_FOR_EXCLUSION>
<P>Not a randomised controlled trial</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR STUDY_ID="STD-Schonau-2004">
<CHAR_REASON_FOR_EXCLUSION>
<P>Not a randomised controlled trial</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR STUDY_ID="STD-Smart-1994">
<CHAR_REASON_FOR_EXCLUSION>
<P>Not a randomised controlled trial</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR STUDY_ID="STD-Solomons-1996">
<CHAR_REASON_FOR_EXCLUSION>
<P>No a randomised controlled study</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR STUDY_ID="STD-Soroko-1994">
<CHAR_REASON_FOR_EXCLUSION>
<P>Not a randomised controlled trial</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR STUDY_ID="STD-Specker-1997">
<CHAR_REASON_FOR_EXCLUSION>
<P>No placebo</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR STUDY_ID="STD-Specker-1999">
<CHAR_REASON_FOR_EXCLUSION>
<P>No calcium intervention</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR STUDY_ID="STD-Specker-2002">
<CHAR_REASON_FOR_EXCLUSION>
<P>Duplicate data (conference abstract)</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR STUDY_ID="STD-Stallings-1994">
<CHAR_REASON_FOR_EXCLUSION>
<P>Not a randomised controlled trial</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR STUDY_ID="STD-Szumera-2004">
<CHAR_REASON_FOR_EXCLUSION>
<P>Not a randomised controlled trial</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR STUDY_ID="STD-Taha-2001">
<CHAR_REASON_FOR_EXCLUSION>
<P>Not a randomised controlled trial</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR STUDY_ID="STD-Teegarden-1994">
<CHAR_REASON_FOR_EXCLUSION>
<P>Not a randomised controlled trial</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR STUDY_ID="STD-Teegarden-1999">
<CHAR_REASON_FOR_EXCLUSION>
<P>Not a randomised controlled trial</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR STUDY_ID="STD-Teesalu-1996">
<CHAR_REASON_FOR_EXCLUSION>
<P>Not a randomised controlled trial</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR STUDY_ID="STD-ter-Meulen-2004">
<CHAR_REASON_FOR_EXCLUSION>
<P>Condition predisposing to osteoporosis (renal transplantation)</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR STUDY_ID="STD-Torres-2004">
<CHAR_REASON_FOR_EXCLUSION>
<P>Condition predisposing to osteoporosis (renal transplanation)</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR STUDY_ID="STD-Tortolani-2002">
<CHAR_REASON_FOR_EXCLUSION>
<P>Not a randomised controlled trial</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR STUDY_ID="STD-Tounian-2003">
<CHAR_REASON_FOR_EXCLUSION>
<P>Not a randomised controlled trial</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR STUDY_ID="STD-Tsukahara-1997">
<CHAR_REASON_FOR_EXCLUSION>
<P>Not a randomised controlled trial</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR STUDY_ID="STD-Tucker-2003">
<CHAR_REASON_FOR_EXCLUSION>
<P>Not a randomised controlled trial</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR STUDY_ID="STD-Turner-1992">
<CHAR_REASON_FOR_EXCLUSION>
<P>Not a randomised controlled trial</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR STUDY_ID="STD-Turner-2000">
<CHAR_REASON_FOR_EXCLUSION>
<P>Not a randomised controlled trial</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR STUDY_ID="STD-Tussing-2005">
<CHAR_REASON_FOR_EXCLUSION>
<P>Not a randomised controlled trial</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR STUDY_ID="STD-Tylavsky-1992">
<CHAR_REASON_FOR_EXCLUSION>
<P>Not a randomised controlled trial</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR STUDY_ID="STD-Ulrich-1996">
<CHAR_REASON_FOR_EXCLUSION>
<P>Not a randomised controlled trial</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR STUDY_ID="STD-Valerio-2004">
<CHAR_REASON_FOR_EXCLUSION>
<P>Not a randomised controlled trial</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR STUDY_ID="STD-VandenBergh-1995">
<CHAR_REASON_FOR_EXCLUSION>
<P>Not a randomised controlled trial</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR STUDY_ID="STD-Vigano-2004">
<CHAR_REASON_FOR_EXCLUSION>
<P>Not a randomised controlled trial</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR STUDY_ID="STD-Volek-2003">
<CHAR_REASON_FOR_EXCLUSION>
<P>Outcomes measured at less than 6 months from baseline</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR STUDY_ID="STD-Wallace-2002">
<CHAR_REASON_FOR_EXCLUSION>
<P>Not a randomised controlled trial</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR STUDY_ID="STD-Wang-1999">
<CHAR_REASON_FOR_EXCLUSION>
<P>Not a randomised controlled trial</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR STUDY_ID="STD-Wang-2003">
<CHAR_REASON_FOR_EXCLUSION>
<P>Not a randomised controlled trial</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR STUDY_ID="STD-Wastney-2003">
<CHAR_REASON_FOR_EXCLUSION>
<P>Not a randomised controlled trial</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR STUDY_ID="STD-Weaver-1999">
<CHAR_REASON_FOR_EXCLUSION>
<P>Not a randomised controlled trial</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR STUDY_ID="STD-Welten-1995">
<CHAR_REASON_FOR_EXCLUSION>
<P>Not a randomised controlled trial</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR STUDY_ID="STD-Welten-1997">
<CHAR_REASON_FOR_EXCLUSION>
<P>Not a randomised controlled trial</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR STUDY_ID="STD-Whiting-2001">
<CHAR_REASON_FOR_EXCLUSION>
<P>Not a randomised controlled trial</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR STUDY_ID="STD-Whiting-2004">
<CHAR_REASON_FOR_EXCLUSION>
<P>Not a randomised controlled trial</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR STUDY_ID="STD-Winters_x002d_Stone-2004">
<CHAR_REASON_FOR_EXCLUSION>
<P>Participants aged &gt; 18 years</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR STUDY_ID="STD-Yeste-2004">
<CHAR_REASON_FOR_EXCLUSION>
<P>Not a randomised controlled trial</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR STUDY_ID="STD-Zacharin-2004">
<CHAR_REASON_FOR_EXCLUSION>
<P>Not a randomised controlled trial</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR STUDY_ID="STD-Zanchetta-1995">
<CHAR_REASON_FOR_EXCLUSION>
<P>Not a randomised controlled trial</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR STUDY_ID="STD-Zhang-2003">
<CHAR_REASON_FOR_EXCLUSION>
<P>No placebo used</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR STUDY_ID="STD-Zhu-2003">
<CHAR_REASON_FOR_EXCLUSION>
<P>No placebo used</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR STUDY_ID="STD-Zhu-2004">
<CHAR_REASON_FOR_EXCLUSION>
<P>No placebo used</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR STUDY_ID="STD-Zhu-2004-b">
<CHAR_REASON_FOR_EXCLUSION>
<P>Not a randomised controlled trial</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR STUDY_ID="STD-Ziccardi-2004">
<CHAR_REASON_FOR_EXCLUSION>
<P>Not a randomised controlled trial</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR STUDY_ID="STD-Zwart-2004">
<CHAR_REASON_FOR_EXCLUSION>
<P>No calcium intervention</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR STUDY_ID="STD-Zwiauer-2003">
<CHAR_REASON_FOR_EXCLUSION>
<P>Not a randomised controlled trial</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<FOOTNOTES/>
</CHARACTERISTICS_OF_EXCLUDED_STUDIES>
<CHARACTERISTICS_OF_AWAITING_STUDIES SORT_BY="STUDY" USER_DEF_1_ENABLED="NO" USER_DEF_2_ENABLED="NO" USER_DEF_3_ENABLED="NO">
<FOOTNOTES/>
</CHARACTERISTICS_OF_AWAITING_STUDIES>
<CHARACTERISTICS_OF_ONGOING_STUDIES SORT_BY="STUDY" USER_DEF_1_ENABLED="NO" USER_DEF_2_ENABLED="NO" USER_DEF_3_ENABLED="NO">
<FOOTNOTES/>
</CHARACTERISTICS_OF_ONGOING_STUDIES>
</CHARACTERISTICS_OF_STUDIES>
<QUALITY_ITEMS>
<QUALITY_ITEM CORE_ITEM="YES" ID="QIT-01" LEVEL="STUDY" NO="1">
<NAME>Adequate sequence generation?</NAME>
<DESCRIPTION>
<P>Was the allocation sequence adequately generated?</P>
</DESCRIPTION>
<QUALITY_ITEM_DATA/>
</QUALITY_ITEM>
<QUALITY_ITEM CORE_ITEM="YES" ID="QIT-02" LEVEL="STUDY" NO="2">
<NAME>Allocation concealment?</NAME>
<DESCRIPTION>
<P>Was allocation adequately concealed?</P>
</DESCRIPTION>
<QUALITY_ITEM_DATA>
<QUALITY_ITEM_DATA_ENTRY RESULT="YES" STUDY_ID="STD-Bonjour-1995">
<DESCRIPTION>
<P>A - Adequate</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY RESULT="UNKNOWN" STUDY_ID="STD-Cameron-2004">
<DESCRIPTION>
<P>B - Unclear</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY RESULT="UNKNOWN" STUDY_ID="STD-Chevalley-2005">
<DESCRIPTION>
<P>B - Unclear</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY RESULT="YES" STUDY_ID="STD-Courteix-2005">
<DESCRIPTION>
<P>A - Adequate</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY RESULT="YES" STUDY_ID="STD-Dibba-2000">
<DESCRIPTION>
<P>A - Adequate</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY RESULT="UNKNOWN" STUDY_ID="STD-Iuliano_x002d_Burns-2003">
<DESCRIPTION>
<P>B - Unclear</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY RESULT="UNKNOWN" STUDY_ID="STD-Johnston-1992">
<DESCRIPTION>
<P>B - Unclear</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY RESULT="UNKNOWN" STUDY_ID="STD-Lee-1994">
<DESCRIPTION>
<P>B - Unclear</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY RESULT="UNKNOWN" STUDY_ID="STD-Lee-1995">
<DESCRIPTION>
<P>B - Unclear</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY RESULT="UNKNOWN" STUDY_ID="STD-Lloyd-1993">
<DESCRIPTION>
<P>B - Unclear</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY RESULT="UNKNOWN" STUDY_ID="STD-Matkovic-2004">
<DESCRIPTION>
<P>B - Unclear</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY RESULT="UNKNOWN" STUDY_ID="STD-Molgaard-2004">
<DESCRIPTION>
<P>B - Unclear</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY RESULT="UNKNOWN" STUDY_ID="STD-Nowson-1997">
<DESCRIPTION>
<P>B - Unclear</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY RESULT="UNKNOWN" STUDY_ID="STD-Prentice-2005">
<DESCRIPTION>
<P>B - Unclear</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY RESULT="UNKNOWN" STUDY_ID="STD-Rodda-2004">
<DESCRIPTION>
<P>B - Unclear</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY RESULT="UNKNOWN" STUDY_ID="STD-Rozen-2003">
<DESCRIPTION>
<P>B - Unclear</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY RESULT="UNKNOWN" STUDY_ID="STD-Specker-2003">
<DESCRIPTION>
<P>B - Unclear</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY RESULT="YES" STUDY_ID="STD-Stear-2003">
<DESCRIPTION>
<P>A - Adequate</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY RESULT="UNKNOWN" STUDY_ID="STD-Wang-1996">
<DESCRIPTION>
<P>B - Unclear</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
</QUALITY_ITEM_DATA>
</QUALITY_ITEM>
<QUALITY_ITEM CORE_ITEM="YES" ID="QIT-03" LEVEL="GROUP" NO="3">
<NAME>Blinding?</NAME>
<DESCRIPTION>
<P>Was knowledge of the allocated interventions adequately prevented during the study?</P>
</DESCRIPTION>
<QUALITY_ITEM_DATA/>
</QUALITY_ITEM>
<QUALITY_ITEM CORE_ITEM="YES" ID="QIT-04" LEVEL="GROUP" NO="4">
<NAME>Incomplete outcome data addressed?</NAME>
<DESCRIPTION>
<P>Were incomplete outcome data adequately addressed?</P>
</DESCRIPTION>
<QUALITY_ITEM_DATA/>
</QUALITY_ITEM>
<QUALITY_ITEM CORE_ITEM="YES" ID="QIT-05" LEVEL="STUDY" NO="5">
<NAME>Free of selective reporting?</NAME>
<DESCRIPTION>
<P>Are reports of the study free of suggestion of selective outcome reporting?</P>
</DESCRIPTION>
<QUALITY_ITEM_DATA/>
</QUALITY_ITEM>
<QUALITY_ITEM CORE_ITEM="YES" ID="QIT-06" LEVEL="STUDY" NO="6">
<NAME>Free of other bias?</NAME>
<DESCRIPTION>
<P>Was the study apparently free of other problems that could put it at a high risk of bias?</P>
</DESCRIPTION>
<QUALITY_ITEM_DATA/>
</QUALITY_ITEM>
</QUALITY_ITEMS>
<SOF_TABLES/>
<ADDITIONAL_TABLES/>
<ANALYSES_AND_DATA CALCULATED_DATA="YES" MODIFIED="2008-10-03 10:57:00 -0400" MODIFIED_BY="[Empty name]">
<COMPARISON ID="CMP-001" MODIFIED="2008-10-03 10:57:00 -0400" MODIFIED_BY="[Empty name]" NO="1">
<NAME>Calcium supplementation vs placebo</NAME>
<CONT_OUTCOME CHI2="5.833956503938204" CI_END="0.1894099906117992" CI_START="-0.05259426682904429" CI_STUDY="95" CI_TOTAL="95" DF="9" EFFECT_MEASURE="SMD" EFFECT_SIZE="0.06840786189137744" ESTIMABLE="YES" I2="0.0" I2_Q="0.0" ID="CMP-001.01" NO="1" P_CHI2="0.7564148098212335" P_Q="1.0" P_Z="0.26783832457717716" Q="0.0" RANDOM="NO" SCALE="1.0" SORT_BY="STUDY" STUDIES="10" SUBGROUPS="NO" SUBGROUP_TEST="YES" TAU2="0.0" TOTALS="YES" TOTAL_1="519" TOTAL_2="554" UNITS="" WEIGHT="100.00000000000001" Z="1.1080544365982008">
<NAME>Femoral neck BMD (mg/cm2) at end supplementation (all data)</NAME>
<GROUP_LABEL_1>Treatment</GROUP_LABEL_1>
<GROUP_LABEL_2>Control</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours control</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours treatment</GRAPH_LABEL_2>
<CONT_DATA CI_END="0.6604385539390247" CI_START="-0.09794154702996843" EFFECT_SIZE="0.2812485034545282" ESTIMABLE="YES" MEAN_1="656.0" MEAN_2="635.0" ORDER="16912" SD_1="81.58" SD_2="65.52" SE="0.19346786648912906" STUDY_ID="STD-Bonjour-1995" TOTAL_1="55" TOTAL_2="53" WEIGHT="10.182915842113054"/>
<CONT_DATA CI_END="0.5507846604584942" CI_START="-0.5808184484700071" EFFECT_SIZE="-0.015016894005756475" ESTIMABLE="YES" MEAN_1="814.0" MEAN_2="816.0" ORDER="16913" SD_1="131.0" SD_2="131.0" SE="0.2886795670365482" STUDY_ID="STD-Cameron-2004" TOTAL_1="24" TOTAL_2="24" WEIGHT="4.573595467063528"/>
<CONT_DATA CI_END="0.17515393035443064" CI_START="-0.3398562006734309" EFFECT_SIZE="-0.08235113515950013" ESTIMABLE="YES" MEAN_1="698.0" MEAN_2="703.7" ORDER="16914" SD_1="70.0" SD_2="68.0" SE="0.13138254965147209" STUDY_ID="STD-Chevalley-2005" TOTAL_1="114" TOTAL_2="118" WEIGHT="22.080782911208967"/>
<CONT_DATA CI_END="0.8977163300128035" CI_START="-0.08113466441638145" EFFECT_SIZE="0.40829083279821105" ESTIMABLE="YES" MEAN_1="772.45" MEAN_2="737.0" ORDER="16915" SD_1="57.43" SD_2="93.77" SE="0.24971147484092482" STUDY_ID="STD-Courteix-2005" TOTAL_1="22" TOTAL_2="63" WEIGHT="6.112415100267862"/>
<CONT_DATA CI_END="0.37562699217396994" CI_START="-0.4508427758870757" EFFECT_SIZE="-0.037607891856552896" ESTIMABLE="YES" MEAN_1="847.72" MEAN_2="852.89" ORDER="16916" SD_1="128.13" SD_2="144.0" SE="0.21083799870307152" STUDY_ID="STD-Johnston-1992" TOTAL_1="45" TOTAL_2="45" WEIGHT="8.574169583656113"/>
<CONT_DATA CI_END="0.4140084286058978" CI_START="-0.44237274406664784" EFFECT_SIZE="-0.014182157730375022" ESTIMABLE="YES" MEAN_1="592.0" MEAN_2="593.0" ORDER="16917" SD_1="74.0" SD_2="65.0" SE="0.21846859927722423" STUDY_ID="STD-Lee-1995" TOTAL_1="44" TOTAL_2="40" WEIGHT="7.985677934320828"/>
<CONT_DATA CI_END="0.5859768774270062" CI_START="-0.46193881656079006" EFFECT_SIZE="0.06201903043310805" ESTIMABLE="YES" MEAN_1="877.0" MEAN_2="871.0" ORDER="16918" SD_1="90.0" SD_2="100.5" SE="0.26733034439755565" STUDY_ID="STD-Nowson-1997" TOTAL_1="28" TOTAL_2="28" WEIGHT="5.333266965361167"/>
<CONT_DATA CI_END="0.3203145893001051" CI_START="-0.3354338260641689" EFFECT_SIZE="-0.0075596183820319145" ESTIMABLE="YES" MEAN_1="1001.0" MEAN_2="1002.0" ORDER="16919" SD_1="134.0" SD_2="129.0" SE="0.16728583293793503" STUDY_ID="STD-Prentice-2005" TOTAL_1="73" TOTAL_2="70" WEIGHT="13.619824552271593"/>
<CONT_DATA CI_END="0.4921438634140949" CI_START="-0.3086206789419552" EFFECT_SIZE="0.09176159223606986" ESTIMABLE="YES" MEAN_1="1010.0" MEAN_2="1000.0" ORDER="16920" SD_1="70.0" SD_2="137.0" SE="0.2042804226690844" STUDY_ID="STD-Rozen-2003" TOTAL_1="49" TOTAL_2="47" WEIGHT="9.133481296727899"/>
<CONT_DATA CI_END="0.5643130591550494" CI_START="-0.12282562247230913" EFFECT_SIZE="0.2207437183413701" ESTIMABLE="YES" MEAN_1="870.0" MEAN_2="847.0" ORDER="16921" SD_1="100.0" SD_2="107.0" SE="0.17529370106987185" STUDY_ID="STD-Stear-2003" TOTAL_1="65" TOTAL_2="66" WEIGHT="12.403870347008995"/>
</CONT_OUTCOME>
<CONT_OUTCOME CHI2="4.977220570190811" CI_END="0.2581633593632865" CI_START="-0.05858426423327914" CI_STUDY="95" CI_TOTAL="95" DF="4" EFFECT_MEASURE="SMD" EFFECT_SIZE="0.09978954756500369" ESTIMABLE="YES" I2="19.63386103568537" I2_Q="0.0" ID="CMP-001.02" NO="2" P_CHI2="0.2896428687480078" P_Q="1.0" P_Z="0.21684871283710294" Q="0.0" RANDOM="NO" SCALE="1.0" SORT_BY="STUDY" STUDIES="5" SUBGROUPS="NO" SUBGROUP_TEST="YES" TAU2="0.0" TOTALS="YES" TOTAL_1="313" TOTAL_2="304" UNITS="" WEIGHT="100.0" Z="1.2349511389551244">
<NAME>Femoral Neck BMD (mg/cm2) at longest point after cessation of supplement (all data)</NAME>
<GROUP_LABEL_1>Treatment</GROUP_LABEL_1>
<GROUP_LABEL_2>Control</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours control</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours treatment</GRAPH_LABEL_2>
<CONT_DATA CI_END="0.7986994788224699" CI_START="0.08686283431210057" EFFECT_SIZE="0.4427811565672853" ESTIMABLE="YES" MEAN_1="885.0" MEAN_2="853.0" ORDER="16922" SD_1="70.2" SD_2="73.67" SE="0.18159431758064076" STUDY_ID="STD-Bonjour-1995" TOTAL_1="67" TOTAL_2="58" WEIGHT="19.800039110516856"/>
<CONT_DATA CI_END="0.22762896650934925" CI_START="-0.2940909927915369" EFFECT_SIZE="-0.033231013141093814" ESTIMABLE="YES" MEAN_1="722.4" MEAN_2="724.7" ORDER="16923" SD_1="70.0" SD_2="68.0" SE="0.13309427199074741" STUDY_ID="STD-Chevalley-2005" TOTAL_1="110" TOTAL_2="116" WEIGHT="36.85970262180859"/>
<CONT_DATA CI_END="0.43698040696836393" CI_START="-0.40842428898937033" EFFECT_SIZE="0.014278058989496793" ESTIMABLE="YES" MEAN_1="956.05" MEAN_2="954.05" ORDER="16924" SD_1="136.72" SD_2="140.89" SE="0.2156684262124658" STUDY_ID="STD-Johnston-1992" TOTAL_1="43" TOTAL_2="43" WEIGHT="14.037747254296471"/>
<CONT_DATA CI_END="0.4281849516340527" CI_START="-0.4281849516340527" EFFECT_SIZE="0.0" ESTIMABLE="YES" MEAN_1="603.0" MEAN_2="603.0" ORDER="16925" SD_1="76.0" SD_2="64.0" SE="0.21846572437632575" STUDY_ID="STD-Lee-1995" TOTAL_1="44" TOTAL_2="40" WEIGHT="13.680562008538146"/>
<CONT_DATA CI_END="0.5438493859396915" CI_START="-0.2575440066043698" EFFECT_SIZE="0.14315268966766082" ESTIMABLE="YES" MEAN_1="1010.0" MEAN_2="990.0" ORDER="16926" SD_1="140.0" SD_2="137.11" SE="0.20444084658324083" STUDY_ID="STD-Rozen-2003" TOTAL_1="49" TOTAL_2="47" WEIGHT="15.621949004839932"/>
</CONT_OUTCOME>
<CONT_OUTCOME CHI2="1.1024640714897922" CI_END="0.19656167519370077" CI_START="-0.035409590731488375" CI_STUDY="95" CI_TOTAL="95" DF="10" EFFECT_MEASURE="SMD" EFFECT_SIZE="0.0805760422311062" ESTIMABLE="YES" I2="0.0" I2_Q="0.0" ID="CMP-001.03" NO="3" P_CHI2="0.9997312530937471" P_Q="1.0" P_Z="0.17332387499636828" Q="0.0" RANDOM="NO" SCALE="1.0" SORT_BY="STUDY" STUDIES="11" SUBGROUPS="NO" SUBGROUP_TEST="YES" TAU2="0.0" TOTALS="YES" TOTAL_1="563" TOTAL_2="601" UNITS="" WEIGHT="100.00000000000001" Z="1.361600887591637">
<NAME>Lumbar spine BMD (mg/cm2) at end supplementation (all data)</NAME>
<GROUP_LABEL_1>Treatment</GROUP_LABEL_1>
<GROUP_LABEL_2>Control</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours control</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours treatment</GRAPH_LABEL_2>
<CONT_DATA CI_END="0.5114205026835856" CI_START="-0.24397376271812718" EFFECT_SIZE="0.13372336998272924" ESTIMABLE="YES" MEAN_1="647.0" MEAN_2="638.0" ORDER="16927" SD_1="74.16" SD_2="58.24" SE="0.1927061597458337" STUDY_ID="STD-Bonjour-1995" TOTAL_1="55" TOTAL_2="53" WEIGHT="9.43020248538449"/>
<CONT_DATA CI_END="0.6643854658079379" CI_START="-0.4679433402975458" EFFECT_SIZE="0.09822106275519607" ESTIMABLE="YES" MEAN_1="848.0" MEAN_2="833.0" ORDER="16928" SD_1="158.0" SD_2="142.0" SE="0.2888646972692225" STUDY_ID="STD-Cameron-2004" TOTAL_1="24" TOTAL_2="24" WEIGHT="4.196848320638333"/>
<CONT_DATA CI_END="0.27186034181968627" CI_START="-0.24293478100807947" EFFECT_SIZE="0.014462780405803406" ESTIMABLE="YES" MEAN_1="586.9" MEAN_2="586.1" ORDER="16929" SD_1="52.0" SD_2="58.0" SE="0.1313276996129531" STUDY_ID="STD-Chevalley-2005" TOTAL_1="114" TOTAL_2="118" WEIGHT="20.304838408962425"/>
<CONT_DATA CI_END="0.6270434570242918" CI_START="-0.3446758722743443" EFFECT_SIZE="0.1411837923749737" ESTIMABLE="YES" MEAN_1="740.64" MEAN_2="726.67" ORDER="16930" SD_1="65.03" SD_2="106.95" SE="0.2478921390809816" STUDY_ID="STD-Courteix-2005" TOTAL_1="22" TOTAL_2="63" WEIGHT="5.698843118900126"/>
<CONT_DATA CI_END="0.434960444536277" CI_START="-0.39145848587210075" EFFECT_SIZE="0.021750979332088152" ESTIMABLE="YES" MEAN_1="907.36" MEAN_2="902.96" ORDER="16931" SD_1="197.32" SD_2="203.75" SE="0.2108250296758167" STUDY_ID="STD-Johnston-1992" TOTAL_1="45" TOTAL_2="45" WEIGHT="7.87894141933801"/>
<CONT_DATA CI_END="0.4625164252125683" CI_START="-0.393919388343527" EFFECT_SIZE="0.034298518434520614" ESTIMABLE="YES" MEAN_1="525.0" MEAN_2="523.0" ORDER="16932" SD_1="61.0" SD_2="54.0" SE="0.21848253853426688" STUDY_ID="STD-Lee-1995" TOTAL_1="44" TOTAL_2="40" WEIGHT="7.336328090508805"/>
<CONT_DATA CI_END="0.6124201908396137" CI_START="-0.21201494446981703" EFFECT_SIZE="0.20020262318489837" ESTIMABLE="YES" MEAN_1="914.0" MEAN_2="894.0" ORDER="16933" SD_1="83.0" SD_2="112.0" SE="0.21031895019818475" STUDY_ID="STD-Lloyd-1993" TOTAL_1="44" TOTAL_2="47" WEIGHT="7.9169044070243535"/>
<CONT_DATA CI_END="0.6326118992120395" CI_START="-0.4158598560902002" EFFECT_SIZE="0.10837602156091967" ESTIMABLE="YES" MEAN_1="1017.0" MEAN_2="1001.0" ORDER="16934" SD_1="148.2" SD_2="142.9" SE="0.2674721993803078" STUDY_ID="STD-Nowson-1997" TOTAL_1="28" TOTAL_2="28" WEIGHT="4.895024998280832"/>
<CONT_DATA CI_END="0.45798631527414724" CI_START="-0.1984686132330601" EFFECT_SIZE="0.12975885102054358" ESTIMABLE="YES" MEAN_1="1047.0" MEAN_2="1032.0" ORDER="16935" SD_1="114.0" SD_2="116.0" SE="0.1674660691944444" STUDY_ID="STD-Prentice-2005" TOTAL_1="73" TOTAL_2="70" WEIGHT="12.487012848693666"/>
<CONT_DATA CI_END="0.40016282334497716" CI_START="-0.40016282334497716" EFFECT_SIZE="0.0" ESTIMABLE="YES" MEAN_1="1120.0" MEAN_2="1120.0" ORDER="16936" SD_1="140.0" SD_2="137.11" SE="0.2041684574315704" STUDY_ID="STD-Rozen-2003" TOTAL_1="49" TOTAL_2="47" WEIGHT="8.401076060027075"/>
<CONT_DATA CI_END="0.4411301457213726" CI_START="-0.24428861169722987" EFFECT_SIZE="0.09842076701207135" ESTIMABLE="YES" MEAN_1="999.0" MEAN_2="989.0" ORDER="16937" SD_1="100.0" SD_2="102.0" SE="0.17485493683177297" STUDY_ID="STD-Stear-2003" TOTAL_1="65" TOTAL_2="66" WEIGHT="11.453979842241894"/>
</CONT_OUTCOME>
<CONT_OUTCOME CHI2="1.1583576889270417" CI_END="0.16953284421813042" CI_START="-0.1465114883422407" CI_STUDY="95" CI_TOTAL="95" DF="4" EFFECT_MEASURE="SMD" EFFECT_SIZE="0.011510677937944852" ESTIMABLE="YES" I2="0.0" I2_Q="0.0" ID="CMP-001.04" NO="4" P_CHI2="0.8849060147469565" P_Q="1.0" P_Z="0.8864733826880066" Q="0.0" RANDOM="NO" SCALE="1.0" SORT_BY="STUDY" STUDIES="5" SUBGROUPS="NO" SUBGROUP_TEST="YES" TAU2="0.0" TOTALS="YES" TOTAL_1="313" TOTAL_2="304" UNITS="" WEIGHT="99.99999999999997" Z="0.14276803518824155">
<NAME>Lumbar Spine BMD (mg/cm2) at longest point after cessation of supplement (all data)</NAME>
<GROUP_LABEL_1>Treatment</GROUP_LABEL_1>
<GROUP_LABEL_2>Control</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours control</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours treatment</GRAPH_LABEL_2>
<CONT_DATA CI_END="0.4286491395175547" CI_START="-0.27466106073165153" EFFECT_SIZE="0.07699403939295155" ESTIMABLE="YES" MEAN_1="1019.0" MEAN_2="1014.0" ORDER="16938" SD_1="70.2" SD_2="57.3" SE="0.17941916427975904" STUDY_ID="STD-Bonjour-1995" TOTAL_1="67" TOTAL_2="58" WEIGHT="20.193062121230803"/>
<CONT_DATA CI_END="0.30604468824634573" CI_START="-0.21570630455408518" EFFECT_SIZE="0.04516919184613029" ESTIMABLE="YES" MEAN_1="605.0" MEAN_2="602.5" ORDER="16939" SD_1="52.0" SD_2="58.0" SE="0.13310218884528904" STUDY_ID="STD-Chevalley-2005" TOTAL_1="110" TOTAL_2="116" WEIGHT="36.69183613729448"/>
<CONT_DATA CI_END="0.46912926150434037" CI_START="-0.3763832168316114" EFFECT_SIZE="0.0463730223363645" ESTIMABLE="YES" MEAN_1="1061.23" MEAN_2="1052.39" ORDER="16940" SD_1="192.31" SD_2="185.47" SE="0.21569592222235875" STUDY_ID="STD-Johnston-1992" TOTAL_1="43" TOTAL_2="43" WEIGHT="13.971916152120873"/>
<CONT_DATA CI_END="0.22936706177064778" CI_START="-0.6292396856883473" EFFECT_SIZE="-0.19993631195884978" ESTIMABLE="YES" MEAN_1="538.0" MEAN_2="551.0" ORDER="16941" SD_1="61.0" SD_2="68.0" SE="0.2190363583799436" STUDY_ID="STD-Lee-1995" TOTAL_1="44" TOTAL_2="40" WEIGHT="13.549005508643"/>
<CONT_DATA CI_END="0.40016282334497716" CI_START="-0.40016282334497716" EFFECT_SIZE="0.0" ESTIMABLE="YES" MEAN_1="1150.0" MEAN_2="1150.0" ORDER="16942" SD_1="140.0" SD_2="137.11" SE="0.2041684574315704" STUDY_ID="STD-Rozen-2003" TOTAL_1="49" TOTAL_2="47" WEIGHT="15.594180080710826"/>
</CONT_OUTCOME>
<CONT_OUTCOME CHI2="4.575286896634283" CI_END="0.26841853898080825" CI_START="0.011094187411965523" CI_STUDY="95" CI_TOTAL="95" DF="8" EFFECT_MEASURE="SMD" EFFECT_SIZE="0.1397563631963869" ESTIMABLE="YES" I2="0.0" I2_Q="0.0" ID="CMP-001.05" NO="5" P_CHI2="0.8018545079137473" P_Q="1.0" P_Z="0.03325704729455614" Q="0.0" RANDOM="NO" SCALE="1.0" SORT_BY="STUDY" STUDIES="9" SUBGROUPS="NO" SUBGROUP_TEST="YES" TAU2="0.0" TOTALS="YES" TOTAL_1="449" TOTAL_2="504" UNITS="" WEIGHT="99.99999999999999" Z="2.128966316675517">
<NAME>Total Body BMC (mg) at end supplementation (all data)</NAME>
<GROUP_LABEL_1>Treatment</GROUP_LABEL_1>
<GROUP_LABEL_2>Control</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours control</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours treatment</GRAPH_LABEL_2>
<CONT_DATA CI_END="0.7244128544136019" CI_START="-0.4090865084137309" EFFECT_SIZE="0.15766317299993554" ESTIMABLE="YES" MEAN_1="1583.0" MEAN_2="1512.0" ORDER="16943" SD_1="504.0" SD_2="372.0" SE="0.289163314165013" STUDY_ID="STD-Cameron-2004" TOTAL_1="24" TOTAL_2="24" WEIGHT="5.153700938319747"/>
<CONT_DATA CI_END="1.0623077058025256" CI_START="0.07587704885842766" EFFECT_SIZE="0.5690923773304767" ESTIMABLE="YES" MEAN_1="1340.9" MEAN_2="1186.1" ORDER="16944" SD_1="216.37" SD_2="285.32" SE="0.2516450977479528" STUDY_ID="STD-Courteix-2005" TOTAL_1="22" TOTAL_2="63" WEIGHT="6.805008185954207"/>
<CONT_DATA CI_END="0.6238360632229405" CI_START="-0.3464242431167532" EFFECT_SIZE="0.13870591005309368" ESTIMABLE="YES" MEAN_1="1179.57" MEAN_2="1151.25" ORDER="16945" SD_1="209.01" SD_2="195.57" SE="0.2475199325071744" STUDY_ID="STD-Iuliano_x002d_Burns-2003" TOTAL_1="30" TOTAL_2="36" WEIGHT="7.033722738386755"/>
<CONT_DATA CI_END="0.6634749996606573" CI_START="-0.16217650854283872" EFFECT_SIZE="0.2506492455589093" ESTIMABLE="YES" MEAN_1="1783.0" MEAN_2="1714.0" ORDER="16946" SD_1="238.0" SD_2="302.0" SE="0.21062925510777997" STUDY_ID="STD-Lloyd-1993" TOTAL_1="44" TOTAL_2="47" WEIGHT="9.713331640661762"/>
<CONT_DATA CI_END="0.4506900805835923" CI_START="-0.29400382768340283" EFFECT_SIZE="0.07834312645009475" ESTIMABLE="YES" MEAN_1="1932.11" MEAN_2="1907.53" ORDER="16947" SD_1="292.33" SD_2="328.77" SE="0.18997642664381734" STUDY_ID="STD-Molgaard-2004" TOTAL_1="54" TOTAL_2="57" WEIGHT="11.940050720347894"/>
<CONT_DATA CI_END="0.3908635962567637" CI_START="-0.26504909971456003" EFFECT_SIZE="0.06290724827110186" ESTIMABLE="YES" MEAN_1="2796.0" MEAN_2="2770.0" ORDER="16948" SD_1="415.0" SD_2="407.0" SE="0.1673277420261493" STUDY_ID="STD-Prentice-2005" TOTAL_1="73" TOTAL_2="70" WEIGHT="15.391101406551368"/>
<CONT_DATA CI_END="0.3917077443497603" CI_START="-0.392434700377596" EFFECT_SIZE="-3.634780139178262E-4" ESTIMABLE="YES" MEAN_1="860.29" MEAN_2="860.34" ORDER="16949" SD_1="134.19" SD_2="138.69" SE="0.2000400137228469" STUDY_ID="STD-Rozen-2003" TOTAL_1="49" TOTAL_2="51" WEIGHT="10.768912529976115"/>
<CONT_DATA CI_END="0.3417017087255969" CI_START="-0.24604334021365062" EFFECT_SIZE="0.047829184255973135" ESTIMABLE="YES" MEAN_1="685.55" MEAN_2="681.5" ORDER="16950" SD_1="88.0" SD_2="80.55" SE="0.1499377166048217" STUDY_ID="STD-Specker-2003" TOTAL_1="88" TOTAL_2="90" WEIGHT="19.16830960071454"/>
<CONT_DATA CI_END="0.5619740238730728" CI_START="-0.12511989143932517" EFFECT_SIZE="0.21842706621687386" ESTIMABLE="YES" MEAN_1="2143.0" MEAN_2="2088.0" ORDER="16951" SD_1="265.0" SD_2="235.0" SE="0.175282280881717" STUDY_ID="STD-Stear-2003" TOTAL_1="65" TOTAL_2="66" WEIGHT="14.025862239087605"/>
</CONT_OUTCOME>
<CONT_OUTCOME CHI2="8.073176705722249" CI_END="0.27214379866967514" CI_START="0.036867948161045216" CI_STUDY="95" CI_TOTAL="95" DF="8" EFFECT_MEASURE="SMD" EFFECT_SIZE="0.15450587341536018" ESTIMABLE="YES" I2="0.9064177385140262" I2_Q="0.0" ID="CMP-001.06" NO="6" P_CHI2="0.42635491822990945" P_Q="1.0" P_Z="0.01004662511823083" Q="0.0" RANDOM="NO" SCALE="1.0" SORT_BY="STUDY" STUDIES="9" SUBGROUPS="NO" SUBGROUP_TEST="YES" TAU2="0.0" TOTALS="YES" TOTAL_1="542" TOTAL_2="598" UNITS="" WEIGHT="100.00000000000001" Z="2.5742204024709534">
<NAME>Distal Radius BMD (mg/cm2) at end supplementation (all data)</NAME>
<GROUP_LABEL_1>Treatment</GROUP_LABEL_1>
<GROUP_LABEL_2>Control</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours control</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours treatment</GRAPH_LABEL_2>
<CONT_DATA CI_END="0.5128125613720704" CI_START="-0.24259987277088774" EFFECT_SIZE="0.13510634430059137" ESTIMABLE="YES" MEAN_1="312.0" MEAN_2="308.0" ORDER="16952" SD_1="29.66" SD_2="29.12" SE="0.1927107947139731" STUDY_ID="STD-Bonjour-1995" TOTAL_1="55" TOTAL_2="53" WEIGHT="9.700328592044865"/>
<CONT_DATA CI_END="0.2574725427227148" CI_START="-0.7158349449146524" EFFECT_SIZE="-0.2291812010959688" ESTIMABLE="YES" MEAN_1="336.18" MEAN_2="351.0" ORDER="16953" SD_1="43.19" SD_2="69.75" SE="0.24829728895905548" STUDY_ID="STD-Courteix-2005" TOTAL_1="22" TOTAL_2="63" WEIGHT="5.843251446728712"/>
<CONT_DATA CI_END="0.7515904462890333" CI_START="0.12422571852871639" EFFECT_SIZE="0.4379080824088748" ESTIMABLE="YES" MEAN_1="253.0" MEAN_2="231.0" ORDER="16954" SD_1="50.0" SD_2="50.0" SE="0.16004496325159281" STUDY_ID="STD-Dibba-2000" TOTAL_1="80" TOTAL_2="80" WEIGHT="14.064182994645218"/>
<CONT_DATA CI_END="0.4929289406242539" CI_START="-0.3338062753225926" EFFECT_SIZE="0.07956133265083067" ESTIMABLE="YES" MEAN_1="317.09" MEAN_2="311.51" ORDER="16955" SD_1="69.4" SD_2="69.67" SE="0.2109057162447954" STUDY_ID="STD-Johnston-1992" TOTAL_1="45" TOTAL_2="45" WEIGHT="8.098821540257351"/>
<CONT_DATA CI_END="0.4501644946278604" CI_START="-0.40623244295249933" EFFECT_SIZE="0.02196602583768056" ESTIMABLE="YES" MEAN_1="492.0" MEAN_2="491.0" ORDER="16956" SD_1="39.0" SD_2="51.0" SE="0.2184726210112812" STUDY_ID="STD-Lee-1995" TOTAL_1="44" TOTAL_2="40" WEIGHT="7.547523829023321"/>
<CONT_DATA CI_END="0.5300115286945037" CI_START="-0.06471641800366129" EFFECT_SIZE="0.23264755534542125" ESTIMABLE="YES" MEAN_1="450.0" MEAN_2="438.0" ORDER="16957" SD_1="53.0" SD_2="50.0" SE="0.15171910080728607" STUDY_ID="STD-Matkovic-2004" TOTAL_1="79" TOTAL_2="98" WEIGHT="15.650132200857508"/>
<CONT_DATA CI_END="0.2749570234978052" CI_START="-0.38090719667338463" EFFECT_SIZE="-0.05297508658778973" ESTIMABLE="YES" MEAN_1="479.0" MEAN_2="482.0" ORDER="16958" SD_1="61.0" SD_2="51.0" SE="0.16731537552336753" STUDY_ID="STD-Prentice-2005" TOTAL_1="73" TOTAL_2="70" WEIGHT="12.868467372323614"/>
<CONT_DATA CI_END="0.5639690051480064" CI_START="-0.12316306254107401" EFFECT_SIZE="0.2204029713034662" ESTIMABLE="YES" MEAN_1="427.0" MEAN_2="418.0" ORDER="16959" SD_1="38.0" SD_2="43.0" SE="0.17529201380971549" STUDY_ID="STD-Stear-2003" TOTAL_1="65" TOTAL_2="66" WEIGHT="11.723958432631655"/>
<CONT_DATA CI_END="0.5134677994735729" CI_START="-0.10432584171130158" EFFECT_SIZE="0.20457097888113565" ESTIMABLE="YES" MEAN_1="486.0" MEAN_2="479.0" ORDER="16960" SD_1="37.0" SD_2="31.0" SE="0.15760331466750202" STUDY_ID="STD-Wang-1996" TOTAL_1="79" TOTAL_2="83" WEIGHT="14.50333359148777"/>
</CONT_OUTCOME>
<CONT_OUTCOME CHI2="2.8160955985362586" CI_END="0.3987017951586933" CI_START="0.029157553391896907" CI_STUDY="95" CI_TOTAL="95" DF="3" EFFECT_MEASURE="SMD" EFFECT_SIZE="0.2139296742752951" ESTIMABLE="YES" I2="0.0" I2_Q="0.0" ID="CMP-001.07" NO="7" P_CHI2="0.4208572474022483" P_Q="1.0" P_Z="0.023253021489117242" Q="0.0" RANDOM="NO" SCALE="1.0" SORT_BY="STUDY" STUDIES="4" SUBGROUPS="NO" SUBGROUP_TEST="YES" TAU2="0.0" TOTALS="YES" TOTAL_1="234" TOTAL_2="221" UNITS="" WEIGHT="99.99999999999999" Z="2.2692517399232655">
<NAME>Distal Radius BMD (mg/cm2) at longest point after cessation of supplement</NAME>
<GROUP_LABEL_1>Treatment</GROUP_LABEL_1>
<GROUP_LABEL_2>Control</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours control</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours treatment</GRAPH_LABEL_2>
<CONT_DATA CI_END="0.7255999910161408" CI_START="0.016372536416859873" EFFECT_SIZE="0.37098626371650034" ESTIMABLE="YES" MEAN_1="429.0" MEAN_2="418.0" ORDER="16961" SD_1="26.32" SD_2="32.74" SE="0.18092869567848607" STUDY_ID="STD-Bonjour-1995" TOTAL_1="67" TOTAL_2="58" WEIGHT="27.149497819276153"/>
<CONT_DATA CI_END="0.6175167825952239" CI_START="-0.0059803321820287025" EFFECT_SIZE="0.30576822520659763" ESTIMABLE="YES" MEAN_1="256.0" MEAN_2="242.0" ORDER="16962" SD_1="43.0" SD_2="48.0" SE="0.15905830915652489" STUDY_ID="STD-Dibba-2000" TOTAL_1="80" TOTAL_2="80" WEIGHT="35.12885404818749"/>
<CONT_DATA CI_END="0.47390750843088114" CI_START="-0.3716306970386415" EFFECT_SIZE="0.05113840569611985" ESTIMABLE="YES" MEAN_1="365.23" MEAN_2="361.31" ORDER="16963" SD_1="77.08" SD_2="74.84" SE="0.21570248538723671" STUDY_ID="STD-Johnston-1992" TOTAL_1="43" TOTAL_2="43" WEIGHT="19.101453132876312"/>
<CONT_DATA CI_END="0.40686449035579997" CI_START="-0.44953091203190143" EFFECT_SIZE="-0.021333210838050704" ESTIMABLE="YES" MEAN_1="516.0" MEAN_2="517.0" ORDER="16964" SD_1="44.0" SD_2="49.0" SE="0.21847222937330457" STUDY_ID="STD-Lee-1995" TOTAL_1="44" TOTAL_2="40" WEIGHT="18.62019499966003"/>
</CONT_OUTCOME>
<CONT_OUTCOME CHI2="8.690639421510731" CI_END="0.237153842673891" CI_START="0.037921792367907534" CI_STUDY="95" CI_TOTAL="95" DF="11" EFFECT_MEASURE="SMD" EFFECT_SIZE="0.13753781752089927" ESTIMABLE="YES" I2="0.0" I2_Q="0.0" ID="CMP-001.08" NO="8" P_CHI2="0.6504234741691632" P_Q="1.0" P_Z="0.006808215777498085" Q="0.0" RANDOM="NO" SCALE="1.0" SORT_BY="STUDY" STUDIES="12" SUBGROUPS="NO" SUBGROUP_TEST="YES" TAU2="0.0" TOTALS="YES" TOTAL_1="757" TOTAL_2="822" UNITS="" WEIGHT="100.0" Z="2.7060823641497076">
<NAME>Upper Limb BMD (mg/cm2) at end supplementation (all data)</NAME>
<GROUP_LABEL_1>Treatment</GROUP_LABEL_1>
<GROUP_LABEL_2>Control</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours control</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours treatment</GRAPH_LABEL_2>
<CONT_DATA CI_END="0.5128125613720704" CI_START="-0.24259987277088774" EFFECT_SIZE="0.13510634430059137" ESTIMABLE="YES" MEAN_1="312.0" MEAN_2="308.0" ORDER="16965" SD_1="29.66" SD_2="29.12" SE="0.1927107947139731" STUDY_ID="STD-Bonjour-1995" TOTAL_1="55" TOTAL_2="53" WEIGHT="6.955849078431553"/>
<CONT_DATA CI_END="0.6586912100157563" CI_START="-0.47355455217399833" EFFECT_SIZE="0.09256832892087895" ESTIMABLE="YES" MEAN_1="418.0" MEAN_2="414.0" ORDER="16966" SD_1="43.0" SD_2="42.0" SE="0.28884351220756216" STUDY_ID="STD-Cameron-2004" TOTAL_1="24" TOTAL_2="24" WEIGHT="3.0962569962613915"/>
<CONT_DATA CI_END="0.30378712152378146" CI_START="-0.211071470037911" EFFECT_SIZE="0.046357825742935246" ESTIMABLE="YES" MEAN_1="309.6" MEAN_2="308.2" ORDER="16967" SD_1="28.0" SD_2="32.0" SE="0.13134389091402476" STUDY_ID="STD-Chevalley-2005" TOTAL_1="114" TOTAL_2="118" WEIGHT="14.974160370613857"/>
<CONT_DATA CI_END="0.2574725427227148" CI_START="-0.7158349449146524" EFFECT_SIZE="-0.2291812010959688" ESTIMABLE="YES" MEAN_1="336.18" MEAN_2="351.0" ORDER="16968" SD_1="43.19" SD_2="69.75" SE="0.24829728895905548" STUDY_ID="STD-Courteix-2005" TOTAL_1="22" TOTAL_2="63" WEIGHT="4.190041069753462"/>
<CONT_DATA CI_END="0.7515904462890333" CI_START="0.12422571852871639" EFFECT_SIZE="0.4379080824088748" ESTIMABLE="YES" MEAN_1="253.0" MEAN_2="231.0" ORDER="16969" SD_1="50.0" SD_2="50.0" SE="0.16004496325159281" STUDY_ID="STD-Dibba-2000" TOTAL_1="80" TOTAL_2="80" WEIGHT="10.085053655030164"/>
<CONT_DATA CI_END="0.4929289406242539" CI_START="-0.3338062753225926" EFFECT_SIZE="0.07956133265083067" ESTIMABLE="YES" MEAN_1="317.09" MEAN_2="311.51" ORDER="16970" SD_1="69.4" SD_2="69.67" SE="0.2109057162447954" STUDY_ID="STD-Johnston-1992" TOTAL_1="45" TOTAL_2="45" WEIGHT="5.807450728357776"/>
<CONT_DATA CI_END="0.4772672773224417" CI_START="-0.14587387711583635" EFFECT_SIZE="0.16569670010330265" ESTIMABLE="YES" MEAN_1="487.0" MEAN_2="480.0" ORDER="16971" SD_1="41.0" SD_2="43.0" SE="0.15896750127898673" STUDY_ID="STD-Lee-1994" TOTAL_1="77" TOTAL_2="82" WEIGHT="10.222227439652531"/>
<CONT_DATA CI_END="0.4501644946278604" CI_START="-0.40623244295249933" EFFECT_SIZE="0.02196602583768056" ESTIMABLE="YES" MEAN_1="492.0" MEAN_2="491.0" ORDER="16972" SD_1="39.0" SD_2="51.0" SE="0.2184726210112812" STUDY_ID="STD-Lee-1995" TOTAL_1="44" TOTAL_2="40" WEIGHT="5.412129720389707"/>
<CONT_DATA CI_END="0.5300115286945037" CI_START="-0.06471641800366129" EFFECT_SIZE="0.23264755534542125" ESTIMABLE="YES" MEAN_1="450.0" MEAN_2="438.0" ORDER="16973" SD_1="53.0" SD_2="50.0" SE="0.15171910080728607" STUDY_ID="STD-Matkovic-2004" TOTAL_1="79" TOTAL_2="98" WEIGHT="11.222295885516864"/>
<CONT_DATA CI_END="0.2749570234978052" CI_START="-0.38090719667338463" EFFECT_SIZE="-0.05297508658778973" ESTIMABLE="YES" MEAN_1="479.0" MEAN_2="482.0" ORDER="16974" SD_1="61.0" SD_2="51.0" SE="0.16731537552336753" STUDY_ID="STD-Prentice-2005" TOTAL_1="73" TOTAL_2="70" WEIGHT="9.227637606628175"/>
<CONT_DATA CI_END="0.5639690051480064" CI_START="-0.12316306254107401" EFFECT_SIZE="0.2204029713034662" ESTIMABLE="YES" MEAN_1="427.0" MEAN_2="418.0" ORDER="16975" SD_1="38.0" SD_2="43.0" SE="0.17529201380971549" STUDY_ID="STD-Stear-2003" TOTAL_1="65" TOTAL_2="66" WEIGHT="8.40694051602222"/>
<CONT_DATA CI_END="0.5134677994735729" CI_START="-0.10432584171130158" EFFECT_SIZE="0.20457097888113565" ESTIMABLE="YES" MEAN_1="486.0" MEAN_2="479.0" ORDER="16976" SD_1="37.0" SD_2="31.0" SE="0.15760331466750202" STUDY_ID="STD-Wang-1996" TOTAL_1="79" TOTAL_2="83" WEIGHT="10.399956933342306"/>
</CONT_OUTCOME>
<CONT_OUTCOME CHI2="4.257893444483907" CI_END="0.28060290645354324" CI_START="0.009198414668455085" CI_STUDY="95" CI_TOTAL="95" DF="5" EFFECT_MEASURE="SMD" EFFECT_SIZE="0.14490066056099918" ESTIMABLE="YES" I2="0.0" I2_Q="0.0" ID="CMP-001.09" NO="9" P_CHI2="0.5129142367746995" P_Q="1.0" P_Z="0.03636542200991858" Q="0.0" RANDOM="NO" SCALE="1.0" SORT_BY="STUDY" STUDIES="6" SUBGROUPS="NO" SUBGROUP_TEST="YES" TAU2="0.0" TOTALS="YES" TOTAL_1="421" TOTAL_2="419" UNITS="" WEIGHT="100.0" Z="2.0928178024445336">
<NAME>Upper Limb BMD (mg/cm2) at longest point after cessation of supplement (all data)</NAME>
<GROUP_LABEL_1>Treatment</GROUP_LABEL_1>
<GROUP_LABEL_2>Control</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours control</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours treatment</GRAPH_LABEL_2>
<CONT_DATA CI_END="0.7255999910161408" CI_START="0.016372536416859873" EFFECT_SIZE="0.37098626371650034" ESTIMABLE="YES" MEAN_1="429.0" MEAN_2="418.0" ORDER="16977" SD_1="26.32" SD_2="32.74" SE="0.18092869567848607" STUDY_ID="STD-Bonjour-1995" TOTAL_1="67" TOTAL_2="58" WEIGHT="14.644110051046827"/>
<CONT_DATA CI_END="0.3702338023671409" CI_START="-0.15184477483414238" EFFECT_SIZE="0.10919451376649926" ESTIMABLE="YES" MEAN_1="319.7" MEAN_2="316.4" ORDER="16978" SD_1="28.0" SD_2="32.0" SE="0.13318575783008577" STUDY_ID="STD-Chevalley-2005" TOTAL_1="110" TOTAL_2="116" WEIGHT="27.02478927761913"/>
<CONT_DATA CI_END="0.6175167825952239" CI_START="-0.0059803321820287025" EFFECT_SIZE="0.30576822520659763" ESTIMABLE="YES" MEAN_1="256.0" MEAN_2="242.0" ORDER="16979" SD_1="43.0" SD_2="48.0" SE="0.15905830915652489" STUDY_ID="STD-Dibba-2000" TOTAL_1="80" TOTAL_2="80" WEIGHT="18.948078085023493"/>
<CONT_DATA CI_END="0.47390750843088114" CI_START="-0.3716306970386415" EFFECT_SIZE="0.05113840569611985" ESTIMABLE="YES" MEAN_1="365.23" MEAN_2="361.31" ORDER="16980" SD_1="77.08" SD_2="74.84" SE="0.21570248538723671" STUDY_ID="STD-Johnston-1992" TOTAL_1="43" TOTAL_2="43" WEIGHT="10.303092295657489"/>
<CONT_DATA CI_END="0.3110243308527212" CI_START="-0.3110243308527212" EFFECT_SIZE="0.0" ESTIMABLE="YES" MEAN_1="505.0" MEAN_2="505.0" ORDER="16981" SD_1="45.0" SD_2="40.0" SE="0.15868879903204416" STUDY_ID="STD-Lee-1994" TOTAL_1="77" TOTAL_2="82" WEIGHT="19.036422798835908"/>
<CONT_DATA CI_END="0.40686449035579997" CI_START="-0.44953091203190143" EFFECT_SIZE="-0.021333210838050704" ESTIMABLE="YES" MEAN_1="516.0" MEAN_2="517.0" ORDER="16982" SD_1="44.0" SD_2="49.0" SE="0.21847222937330457" STUDY_ID="STD-Lee-1995" TOTAL_1="44" TOTAL_2="40" WEIGHT="10.043507491817147"/>
</CONT_OUTCOME>
<CONT_OUTCOME CHI2="5.833956503938205" CI_END="0.1894099906117992" CI_START="-0.05259426682904429" CI_STUDY="95" CI_TOTAL="95" DF="9" EFFECT_MEASURE="SMD" EFFECT_SIZE="0.06840786189137744" ESTIMABLE="YES" I2="0.0" I2_Q="45.76117075984902" ID="CMP-001.10" NO="10" P_CHI2="0.7564148098212335" P_Q="0.17451835953176253" P_Z="0.26783832457717716" Q="1.843697612963477" RANDOM="NO" SCALE="1.0" SORT_BY="STUDY" STUDIES="10" SUBGROUPS="YES" SUBGROUP_TEST="YES" TAU2="0.0" TOTALS="YES" TOTAL_1="519" TOTAL_2="554" UNITS="" WEIGHT="100.0" Z="1.1080544365982008">
<NAME>Femoral neck BMD (mg/cm2) (end trial) by baseline calcium intake</NAME>
<GROUP_LABEL_1>Treatment</GROUP_LABEL_1>
<GROUP_LABEL_2>Control</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours control</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours treatment</GRAPH_LABEL_2>
<CONT_SUBGROUP CHI2="0.6184654461230222" CI_END="0.15574071930442032" CI_START="-0.18960348251508488" DF="4" EFFECT_SIZE="-0.01693138160533229" ESTIMABLE="YES" I2="0.0" ID="CMP-001.10.01" NO="1" P_CHI2="0.9609898198188062" P_Z="0.8475977015193762" STUDIES="5" TAU2="0.0" TOTAL_1="259" TOTAL_2="257" WEIGHT="49.106804574682386" Z="0.19218448133841498">
<NAME>Low baseline calcium</NAME>
<CONT_DATA CI_END="0.5507846604584942" CI_START="-0.5808184484700071" EFFECT_SIZE="-0.015016894005756475" ESTIMABLE="YES" MEAN_1="814.0" MEAN_2="816.0" ORDER="16983" SD_1="131.0" SD_2="131.0" SE="0.2886795670365482" STUDY_ID="STD-Cameron-2004" TOTAL_1="24" TOTAL_2="24" WEIGHT="4.573595467063528"/>
<CONT_DATA CI_END="0.17515393035443064" CI_START="-0.3398562006734309" EFFECT_SIZE="-0.08235113515950013" ESTIMABLE="YES" MEAN_1="698.0" MEAN_2="703.7" ORDER="16984" SD_1="70.0" SD_2="68.0" SE="0.13138254965147209" STUDY_ID="STD-Chevalley-2005" TOTAL_1="114" TOTAL_2="118" WEIGHT="22.080782911208967"/>
<CONT_DATA CI_END="0.4140084286058978" CI_START="-0.44237274406664784" EFFECT_SIZE="-0.014182157730375022" ESTIMABLE="YES" MEAN_1="592.0" MEAN_2="593.0" ORDER="16985" SD_1="74.0" SD_2="65.0" SE="0.21846859927722423" STUDY_ID="STD-Lee-1995" TOTAL_1="44" TOTAL_2="40" WEIGHT="7.985677934320828"/>
<CONT_DATA CI_END="0.5859768774270062" CI_START="-0.46193881656079006" EFFECT_SIZE="0.06201903043310805" ESTIMABLE="YES" MEAN_1="877.0" MEAN_2="871.0" ORDER="16986" SD_1="90.0" SD_2="100.5" SE="0.26733034439755565" STUDY_ID="STD-Nowson-1997" TOTAL_1="28" TOTAL_2="28" WEIGHT="5.333266965361167"/>
<CONT_DATA CI_END="0.4921438634140949" CI_START="-0.3086206789419552" EFFECT_SIZE="0.09176159223606986" ESTIMABLE="YES" MEAN_1="1010.0" MEAN_2="1000.0" ORDER="16987" SD_1="70.0" SD_2="137.0" SE="0.2042804226690844" STUDY_ID="STD-Rozen-2003" TOTAL_1="49" TOTAL_2="47" WEIGHT="9.133481296727899"/>
</CONT_SUBGROUP>
<CONT_SUBGROUP CHI2="3.3717934448517055" CI_END="0.32036619947785805" CI_START="-0.018862936705974886" DF="4" EFFECT_SIZE="0.15075163138594158" ESTIMABLE="YES" I2="0.0" ID="CMP-001.10.02" NO="2" P_CHI2="0.4976383825060099" P_Z="0.08150927936871394" STUDIES="5" TAU2="0.0" TOTAL_1="260" TOTAL_2="297" WEIGHT="50.89319542531762" Z="1.7419952274794315">
<NAME>High baseline calcium</NAME>
<CONT_DATA CI_END="0.6604385539390247" CI_START="-0.09794154702996843" EFFECT_SIZE="0.2812485034545282" ESTIMABLE="YES" MEAN_1="656.0" MEAN_2="635.0" ORDER="16988" SD_1="81.58" SD_2="65.52" SE="0.19346786648912906" STUDY_ID="STD-Bonjour-1995" TOTAL_1="55" TOTAL_2="53" WEIGHT="10.182915842113054"/>
<CONT_DATA CI_END="0.8977163300128035" CI_START="-0.08113466441638145" EFFECT_SIZE="0.40829083279821105" ESTIMABLE="YES" MEAN_1="772.45" MEAN_2="737.0" ORDER="16989" SD_1="57.43" SD_2="93.77" SE="0.24971147484092482" STUDY_ID="STD-Courteix-2005" TOTAL_1="22" TOTAL_2="63" WEIGHT="6.112415100267862"/>
<CONT_DATA CI_END="0.37562699217396994" CI_START="-0.4508427758870757" EFFECT_SIZE="-0.037607891856552896" ESTIMABLE="YES" MEAN_1="847.72" MEAN_2="852.89" ORDER="16990" SD_1="128.13" SD_2="144.0" SE="0.21083799870307152" STUDY_ID="STD-Johnston-1992" TOTAL_1="45" TOTAL_2="45" WEIGHT="8.574169583656113"/>
<CONT_DATA CI_END="0.3203145893001051" CI_START="-0.3354338260641689" EFFECT_SIZE="-0.0075596183820319145" ESTIMABLE="YES" MEAN_1="1001.0" MEAN_2="1002.0" ORDER="16991" SD_1="134.0" SD_2="129.0" SE="0.16728583293793503" STUDY_ID="STD-Prentice-2005" TOTAL_1="73" TOTAL_2="70" WEIGHT="13.619824552271593"/>
<CONT_DATA CI_END="0.5643130591550494" CI_START="-0.12282562247230913" EFFECT_SIZE="0.2207437183413701" ESTIMABLE="YES" MEAN_1="870.0" MEAN_2="847.0" ORDER="16992" SD_1="100.0" SD_2="107.0" SE="0.17529370106987185" STUDY_ID="STD-Stear-2003" TOTAL_1="65" TOTAL_2="66" WEIGHT="12.403870347008995"/>
</CONT_SUBGROUP>
</CONT_OUTCOME>
<CONT_OUTCOME CHI2="1.1024640714897922" CI_END="0.19656167519370077" CI_START="-0.03540959073148839" CI_STUDY="95" CI_TOTAL="95" DF="10" EFFECT_MEASURE="SMD" EFFECT_SIZE="0.08057604223110619" ESTIMABLE="YES" I2="0.0" I2_Q="0.0" ID="CMP-001.11" NO="11" P_CHI2="0.9997312530937471" P_Q="0.4655993159551164" P_Z="0.17332387499636842" Q="0.532400849057217" RANDOM="NO" SCALE="1.0" SORT_BY="STUDY" STUDIES="11" SUBGROUPS="YES" SUBGROUP_TEST="YES" TAU2="0.0" TOTALS="YES" TOTAL_1="563" TOTAL_2="601" UNITS="" WEIGHT="100.00000000000001" Z="1.3616008875916368">
<NAME>Lumbar spine BMD (mg/cm2) (end trial) by baseline calcium intake</NAME>
<GROUP_LABEL_1>Treatment</GROUP_LABEL_1>
<GROUP_LABEL_2>Control</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours control</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours treatment</GRAPH_LABEL_2>
<CONT_SUBGROUP CHI2="0.17647852722398402" CI_END="0.20561276590102717" CI_START="-0.13967542287753915" DF="4" EFFECT_SIZE="0.03296867151174401" ESTIMABLE="YES" I2="0.0" ID="CMP-001.11.01" NO="1" P_CHI2="0.9963285290547745" P_Z="0.7081952477829712" STUDIES="5" TAU2="0.0" TOTAL_1="259" TOTAL_2="257" WEIGHT="45.13411587841747" Z="0.37428102600166946">
<NAME>Low baseline calcium</NAME>
<CONT_DATA CI_END="0.6643854658079379" CI_START="-0.4679433402975458" EFFECT_SIZE="0.09822106275519607" ESTIMABLE="YES" MEAN_1="848.0" MEAN_2="833.0" ORDER="16993" SD_1="158.0" SD_2="142.0" SE="0.2888646972692225" STUDY_ID="STD-Cameron-2004" TOTAL_1="24" TOTAL_2="24" WEIGHT="4.196848320638333"/>
<CONT_DATA CI_END="0.27186034181968627" CI_START="-0.24293478100807947" EFFECT_SIZE="0.014462780405803406" ESTIMABLE="YES" MEAN_1="586.9" MEAN_2="586.1" ORDER="16994" SD_1="52.0" SD_2="58.0" SE="0.1313276996129531" STUDY_ID="STD-Chevalley-2005" TOTAL_1="114" TOTAL_2="118" WEIGHT="20.304838408962425"/>
<CONT_DATA CI_END="0.4625164252125683" CI_START="-0.393919388343527" EFFECT_SIZE="0.034298518434520614" ESTIMABLE="YES" MEAN_1="525.0" MEAN_2="523.0" ORDER="16995" SD_1="61.0" SD_2="54.0" SE="0.21848253853426688" STUDY_ID="STD-Lee-1995" TOTAL_1="44" TOTAL_2="40" WEIGHT="7.336328090508805"/>
<CONT_DATA CI_END="0.6326118992120395" CI_START="-0.4158598560902002" EFFECT_SIZE="0.10837602156091967" ESTIMABLE="YES" MEAN_1="1017.0" MEAN_2="1001.0" ORDER="16996" SD_1="148.2" SD_2="142.9" SE="0.2674721993803078" STUDY_ID="STD-Nowson-1997" TOTAL_1="28" TOTAL_2="28" WEIGHT="4.895024998280832"/>
<CONT_DATA CI_END="0.40016282334497716" CI_START="-0.40016282334497716" EFFECT_SIZE="0.0" ESTIMABLE="YES" MEAN_1="1120.0" MEAN_2="1120.0" ORDER="16997" SD_1="140.0" SD_2="137.11" SE="0.2041684574315704" STUDY_ID="STD-Rozen-2003" TOTAL_1="49" TOTAL_2="47" WEIGHT="8.401076060027075"/>
</CONT_SUBGROUP>
<CONT_SUBGROUP CHI2="0.3935846952085912" CI_END="0.2763251418471997" CI_START="-0.03684691278289086" DF="5" EFFECT_SIZE="0.11973911453215443" ESTIMABLE="YES" I2="0.0" ID="CMP-001.11.02" NO="2" P_CHI2="0.9955044531847057" P_Z="0.1339367705860557" STUDIES="6" TAU2="0.0" TOTAL_1="304" TOTAL_2="344" WEIGHT="54.865884121582546" Z="1.4987566646132677">
<NAME>High baseline calcium</NAME>
<CONT_DATA CI_END="0.5114205026835856" CI_START="-0.24397376271812718" EFFECT_SIZE="0.13372336998272924" ESTIMABLE="YES" MEAN_1="647.0" MEAN_2="638.0" ORDER="16998" SD_1="74.16" SD_2="58.24" SE="0.1927061597458337" STUDY_ID="STD-Bonjour-1995" TOTAL_1="55" TOTAL_2="53" WEIGHT="9.43020248538449"/>
<CONT_DATA CI_END="0.6270434570242918" CI_START="-0.3446758722743443" EFFECT_SIZE="0.1411837923749737" ESTIMABLE="YES" MEAN_1="740.64" MEAN_2="726.67" ORDER="16999" SD_1="65.03" SD_2="106.95" SE="0.2478921390809816" STUDY_ID="STD-Courteix-2005" TOTAL_1="22" TOTAL_2="63" WEIGHT="5.698843118900126"/>
<CONT_DATA CI_END="0.434960444536277" CI_START="-0.39145848587210075" EFFECT_SIZE="0.021750979332088152" ESTIMABLE="YES" MEAN_1="907.36" MEAN_2="902.96" ORDER="17000" SD_1="197.32" SD_2="203.75" SE="0.2108250296758167" STUDY_ID="STD-Johnston-1992" TOTAL_1="45" TOTAL_2="45" WEIGHT="7.87894141933801"/>
<CONT_DATA CI_END="0.6124201908396137" CI_START="-0.21201494446981703" EFFECT_SIZE="0.20020262318489837" ESTIMABLE="YES" MEAN_1="914.0" MEAN_2="894.0" ORDER="17001" SD_1="83.0" SD_2="112.0" SE="0.21031895019818475" STUDY_ID="STD-Lloyd-1993" TOTAL_1="44" TOTAL_2="47" WEIGHT="7.9169044070243535"/>
<CONT_DATA CI_END="0.45798631527414724" CI_START="-0.1984686132330601" EFFECT_SIZE="0.12975885102054358" ESTIMABLE="YES" MEAN_1="1047.0" MEAN_2="1032.0" ORDER="17002" SD_1="114.0" SD_2="116.0" SE="0.1674660691944444" STUDY_ID="STD-Prentice-2005" TOTAL_1="73" TOTAL_2="70" WEIGHT="12.487012848693666"/>
<CONT_DATA CI_END="0.4411301457213726" CI_START="-0.24428861169722987" EFFECT_SIZE="0.09842076701207135" ESTIMABLE="YES" MEAN_1="999.0" MEAN_2="989.0" ORDER="17003" SD_1="100.0" SD_2="102.0" SE="0.17485493683177297" STUDY_ID="STD-Stear-2003" TOTAL_1="65" TOTAL_2="66" WEIGHT="11.453979842241894"/>
</CONT_SUBGROUP>
</CONT_OUTCOME>
<CONT_OUTCOME CHI2="5.139687383874167" CI_END="0.2702879330567719" CI_START="0.012898789915857772" CI_STUDY="95" CI_TOTAL="95" DF="9" EFFECT_MEASURE="SMD" EFFECT_SIZE="0.14159336148631482" ESTIMABLE="YES" I2="0.0" I2_Q="0.0" ID="CMP-001.12" NO="12" P_CHI2="0.8219652892583728" P_Q="0.7749793531488975" P_Z="0.031051890100105124" Q="0.08172042457506645" RANDOM="NO" SCALE="1.0" SORT_BY="STUDY" STUDIES="9" SUBGROUPS="YES" SUBGROUP_TEST="YES" TAU2="0.0" TOTALS="YES" TOTAL_1="449" TOTAL_2="504" UNITS="" WEIGHT="99.99999999999999" Z="2.1564071085251935">
<NAME>Total Body BMC (mg) (end trial) by baseline calcium intake</NAME>
<GROUP_LABEL_1>Treatment</GROUP_LABEL_1>
<GROUP_LABEL_2>Control</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours control</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours treatment</GRAPH_LABEL_2>
<CONT_SUBGROUP CHI2="0.6127777469646106" CI_END="0.35328746084505724" CI_START="-0.1297117081698318" DF="3" EFFECT_SIZE="0.11178787633761272" ESTIMABLE="YES" I2="0.0" ID="CMP-001.12.01" NO="1" P_CHI2="0.8935010788398434" P_Z="0.3642752458664159" STUDIES="4" TAU2="0.0" TOTAL_1="127" TOTAL_2="138" WEIGHT="28.397995176070797" Z="0.907248813602759">
<NAME>Low baseline calcium</NAME>
<CONT_DATA CI_END="0.7244128544136019" CI_START="-0.4090865084137309" EFFECT_SIZE="0.15766317299993554" ESTIMABLE="YES" MEAN_1="1583.0" MEAN_2="1512.0" ORDER="17004" SD_1="504.0" SD_2="372.0" SE="0.289163314165013" STUDY_ID="STD-Cameron-2004" TOTAL_1="24" TOTAL_2="24" WEIGHT="5.156296560708882"/>
<CONT_DATA CI_END="0.6238360632229405" CI_START="-0.3464242431167532" EFFECT_SIZE="0.13870591005309368" ESTIMABLE="YES" MEAN_1="1179.57" MEAN_2="1151.25" ORDER="17005" SD_1="209.01" SD_2="195.57" SE="0.2475199325071744" STUDY_ID="STD-Iuliano_x002d_Burns-2003" TOTAL_1="30" TOTAL_2="36" WEIGHT="7.037265219496394"/>
<CONT_DATA CI_END="0.8081464159769864" CI_START="-0.29640623646144065" EFFECT_SIZE="0.25587008975777287" ESTIMABLE="YES" MEAN_1="1936.0" MEAN_2="1867.0" ORDER="17006" SD_1="232.81" SD_2="291.41" SE="0.2817788135779528" STUDY_ID="STD-Molgaard-2004" TOTAL_1="24" TOTAL_2="27" WEIGHT="5.430097184770929"/>
<CONT_DATA CI_END="0.3917077443497603" CI_START="-0.392434700377596" EFFECT_SIZE="-3.634780139178262E-4" ESTIMABLE="YES" MEAN_1="860.29" MEAN_2="860.34" ORDER="17007" SD_1="134.19" SD_2="138.69" SE="0.2000400137228469" STUDY_ID="STD-Rozen-2003" TOTAL_1="49" TOTAL_2="51" WEIGHT="10.774336211094592"/>
</CONT_SUBGROUP>
<CONT_SUBGROUP CHI2="4.44518921233449" CI_END="0.3055034247791163" CI_START="0.0013255418864000779" DF="5" EFFECT_SIZE="0.15341448333275817" ESTIMABLE="YES" I2="0.0" ID="CMP-001.12.02" NO="2" P_CHI2="0.4872505229531855" P_Z="0.04803640947912599" STUDIES="6" TAU2="0.0" TOTAL_1="322" TOTAL_2="366" WEIGHT="71.60200482392919" Z="1.9770461887597461">
<NAME>High baseline calcium</NAME>
<CONT_DATA CI_END="1.0623077058025256" CI_START="0.07587704885842766" EFFECT_SIZE="0.5690923773304767" ESTIMABLE="YES" MEAN_1="1340.9" MEAN_2="1186.1" ORDER="17008" SD_1="216.37" SD_2="285.32" SE="0.2516450977479528" STUDY_ID="STD-Courteix-2005" TOTAL_1="22" TOTAL_2="63" WEIGHT="6.808435476714207"/>
<CONT_DATA CI_END="0.6634749996606573" CI_START="-0.16217650854283872" EFFECT_SIZE="0.2506492455589093" ESTIMABLE="YES" MEAN_1="1783.0" MEAN_2="1714.0" ORDER="17009" SD_1="238.0" SD_2="302.0" SE="0.21062925510777997" STUDY_ID="STD-Lloyd-1993" TOTAL_1="44" TOTAL_2="47" WEIGHT="9.71822368647143"/>
<CONT_DATA CI_END="0.4633042530680887" CI_START="-0.5489409169301754" EFFECT_SIZE="-0.042818331931043375" ESTIMABLE="YES" MEAN_1="1929.0" MEAN_2="1944.0" ORDER="17010" SD_1="332.03" SD_2="358.98" SE="0.25823055372004916" STUDY_ID="STD-Molgaard-2004" TOTAL_1="30" TOTAL_2="30" WEIGHT="6.465602810016454"/>
<CONT_DATA CI_END="0.3908635962567637" CI_START="-0.26504909971456003" EFFECT_SIZE="0.06290724827110186" ESTIMABLE="YES" MEAN_1="2796.0" MEAN_2="2770.0" ORDER="17011" SD_1="415.0" SD_2="407.0" SE="0.1673277420261493" STUDY_ID="STD-Prentice-2005" TOTAL_1="73" TOTAL_2="70" WEIGHT="15.398853018040356"/>
<CONT_DATA CI_END="0.3417017087255969" CI_START="-0.24604334021365062" EFFECT_SIZE="0.047829184255973135" ESTIMABLE="YES" MEAN_1="685.55" MEAN_2="681.5" ORDER="17012" SD_1="88.0" SD_2="80.55" SE="0.1499377166048217" STUDY_ID="STD-Specker-2003" TOTAL_1="88" TOTAL_2="90" WEIGHT="19.177963574462137"/>
<CONT_DATA CI_END="0.5619740238730728" CI_START="-0.12511989143932517" EFFECT_SIZE="0.21842706621687386" ESTIMABLE="YES" MEAN_1="2143.0" MEAN_2="2088.0" ORDER="17013" SD_1="265.0" SD_2="235.0" SE="0.175282280881717" STUDY_ID="STD-Stear-2003" TOTAL_1="65" TOTAL_2="66" WEIGHT="14.032926258224611"/>
</CONT_SUBGROUP>
</CONT_OUTCOME>
<CONT_OUTCOME CHI2="8.073176705722247" CI_END="0.27214379866967514" CI_START="0.036867948161045216" CI_STUDY="95" CI_TOTAL="95" DF="8" EFFECT_MEASURE="SMD" EFFECT_SIZE="0.15450587341536018" ESTIMABLE="YES" I2="0.9064177385140044" I2_Q="39.66536077442424" ID="CMP-001.13" NO="13" P_CHI2="0.4263549182299098" P_Q="0.1979517368988304" P_Z="0.01004662511823083" Q="1.657422689246978" RANDOM="NO" SCALE="1.0" SORT_BY="STUDY" STUDIES="9" SUBGROUPS="YES" SUBGROUP_TEST="YES" TAU2="0.0" TOTALS="YES" TOTAL_1="542" TOTAL_2="598" UNITS="" WEIGHT="100.00000000000001" Z="2.5742204024709534">
<NAME>Distal radius BMD (mg/cm2) (end trial) by baseline calcium intake</NAME>
<GROUP_LABEL_1>Treatment</GROUP_LABEL_1>
<GROUP_LABEL_2>Control</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours control</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours treatment</GRAPH_LABEL_2>
<CONT_SUBGROUP CHI2="2.545723597065967" CI_END="0.4530277022414243" CI_START="0.06152632025510707" DF="2" EFFECT_SIZE="0.2572770112482657" ESTIMABLE="YES" I2="21.436875460279037" ID="CMP-001.13.01" NO="1" P_CHI2="0.28002919854889097" P_Z="0.009995079974375806" STUDIES="3" TAU2="0.0" TOTAL_1="203" TOTAL_2="203" WEIGHT="36.11504041515631" Z="2.5759994692142905">
<NAME>Low baseline calcium</NAME>
<CONT_DATA CI_END="0.7515904462890333" CI_START="0.12422571852871639" EFFECT_SIZE="0.4379080824088748" ESTIMABLE="YES" MEAN_1="253.0" MEAN_2="231.0" ORDER="17014" SD_1="50.0" SD_2="50.0" SE="0.16004496325159281" STUDY_ID="STD-Dibba-2000" TOTAL_1="80" TOTAL_2="80" WEIGHT="14.064182994645218"/>
<CONT_DATA CI_END="0.4501644946278604" CI_START="-0.40623244295249933" EFFECT_SIZE="0.02196602583768056" ESTIMABLE="YES" MEAN_1="492.0" MEAN_2="491.0" ORDER="17015" SD_1="39.0" SD_2="51.0" SE="0.2184726210112812" STUDY_ID="STD-Lee-1995" TOTAL_1="44" TOTAL_2="40" WEIGHT="7.547523829023321"/>
<CONT_DATA CI_END="0.5134677994735729" CI_START="-0.10432584171130158" EFFECT_SIZE="0.20457097888113565" ESTIMABLE="YES" MEAN_1="486.0" MEAN_2="479.0" ORDER="17016" SD_1="37.0" SD_2="31.0" SE="0.15760331466750202" STUDY_ID="STD-Wang-1996" TOTAL_1="79" TOTAL_2="83" WEIGHT="14.50333359148777"/>
</CONT_SUBGROUP>
<CONT_SUBGROUP CHI2="3.870030419409302" CI_END="0.24358768953131923" CI_START="-0.050771799142137" DF="5" EFFECT_SIZE="0.09640794519459112" ESTIMABLE="YES" I2="0.0" ID="CMP-001.13.02" NO="2" P_CHI2="0.5682762422392849" P_Z="0.19919590569762208" STUDIES="6" TAU2="0.0" TOTAL_1="339" TOTAL_2="395" WEIGHT="63.884959584843706" Z="1.2838458257720777">
<NAME>High baseline calcium</NAME>
<CONT_DATA CI_END="0.5128125613720704" CI_START="-0.24259987277088774" EFFECT_SIZE="0.13510634430059137" ESTIMABLE="YES" MEAN_1="312.0" MEAN_2="308.0" ORDER="17017" SD_1="29.66" SD_2="29.12" SE="0.1927107947139731" STUDY_ID="STD-Bonjour-1995" TOTAL_1="55" TOTAL_2="53" WEIGHT="9.700328592044865"/>
<CONT_DATA CI_END="0.2574725427227148" CI_START="-0.7158349449146524" EFFECT_SIZE="-0.2291812010959688" ESTIMABLE="YES" MEAN_1="336.18" MEAN_2="351.0" ORDER="17018" SD_1="43.19" SD_2="69.75" SE="0.24829728895905548" STUDY_ID="STD-Courteix-2005" TOTAL_1="22" TOTAL_2="63" WEIGHT="5.843251446728712"/>
<CONT_DATA CI_END="0.4929289406242539" CI_START="-0.3338062753225926" EFFECT_SIZE="0.07956133265083067" ESTIMABLE="YES" MEAN_1="317.09" MEAN_2="311.51" ORDER="17019" SD_1="69.4" SD_2="69.67" SE="0.2109057162447954" STUDY_ID="STD-Johnston-1992" TOTAL_1="45" TOTAL_2="45" WEIGHT="8.098821540257351"/>
<CONT_DATA CI_END="0.5300115286945037" CI_START="-0.06471641800366129" EFFECT_SIZE="0.23264755534542125" ESTIMABLE="YES" MEAN_1="450.0" MEAN_2="438.0" ORDER="17020" SD_1="53.0" SD_2="50.0" SE="0.15171910080728607" STUDY_ID="STD-Matkovic-2004" TOTAL_1="79" TOTAL_2="98" WEIGHT="15.650132200857508"/>
<CONT_DATA CI_END="0.2749570234978052" CI_START="-0.38090719667338463" EFFECT_SIZE="-0.05297508658778973" ESTIMABLE="YES" MEAN_1="479.0" MEAN_2="482.0" ORDER="17021" SD_1="61.0" SD_2="51.0" SE="0.16731537552336753" STUDY_ID="STD-Prentice-2005" TOTAL_1="73" TOTAL_2="70" WEIGHT="12.868467372323614"/>
<CONT_DATA CI_END="0.5639690051480064" CI_START="-0.12316306254107401" EFFECT_SIZE="0.2204029713034662" ESTIMABLE="YES" MEAN_1="427.0" MEAN_2="418.0" ORDER="17022" SD_1="38.0" SD_2="43.0" SE="0.17529201380971549" STUDY_ID="STD-Stear-2003" TOTAL_1="65" TOTAL_2="66" WEIGHT="11.723958432631655"/>
</CONT_SUBGROUP>
</CONT_OUTCOME>
<CONT_OUTCOME CHI2="8.69063942151073" CI_END="0.237153842673891" CI_START="0.037921792367907534" CI_STUDY="95" CI_TOTAL="95" DF="11" EFFECT_MEASURE="SMD" EFFECT_SIZE="0.13753781752089927" ESTIMABLE="YES" I2="0.0" I2_Q="0.0" ID="CMP-001.14" NO="14" P_CHI2="0.6504234741691635" P_Q="0.456849878289745" P_Z="0.006808215777498085" Q="0.5536016649586326" RANDOM="NO" SCALE="1.0" SORT_BY="STUDY" STUDIES="12" SUBGROUPS="YES" SUBGROUP_TEST="YES" TAU2="0.0" TOTALS="YES" TOTAL_1="757" TOTAL_2="822" UNITS="" WEIGHT="100.0" Z="2.7060823641497076">
<NAME>Upper limb BMD (mg/cm2) (end trial) by baseline calcium intake</NAME>
<GROUP_LABEL_1>Treatment</GROUP_LABEL_1>
<GROUP_LABEL_2>Control</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours control</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours treatment</GRAPH_LABEL_2>
<CONT_SUBGROUP CHI2="4.267007337142795" CI_END="0.3076302731368713" CI_START="0.036984972938270744" DF="5" EFFECT_SIZE="0.17230762303757102" ESTIMABLE="YES" I2="0.0" ID="CMP-001.14.01" NO="1" P_CHI2="0.5116483323942613" P_Z="0.012572982371729682" STUDIES="6" TAU2="0.0" TOTAL_1="418" TOTAL_2="427" WEIGHT="54.18978511528996" Z="2.495640864020366">
<NAME>Low baseline calcium</NAME>
<CONT_DATA CI_END="0.6586912100157563" CI_START="-0.47355455217399833" EFFECT_SIZE="0.09256832892087895" ESTIMABLE="YES" MEAN_1="418.0" MEAN_2="414.0" ORDER="17023" SD_1="43.0" SD_2="42.0" SE="0.28884351220756216" STUDY_ID="STD-Cameron-2004" TOTAL_1="24" TOTAL_2="24" WEIGHT="3.0962569962613915"/>
<CONT_DATA CI_END="0.30378712152378146" CI_START="-0.211071470037911" EFFECT_SIZE="0.046357825742935246" ESTIMABLE="YES" MEAN_1="309.6" MEAN_2="308.2" ORDER="17024" SD_1="28.0" SD_2="32.0" SE="0.13134389091402476" STUDY_ID="STD-Chevalley-2005" TOTAL_1="114" TOTAL_2="118" WEIGHT="14.974160370613857"/>
<CONT_DATA CI_END="0.7515904462890333" CI_START="0.12422571852871639" EFFECT_SIZE="0.4379080824088748" ESTIMABLE="YES" MEAN_1="253.0" MEAN_2="231.0" ORDER="17025" SD_1="50.0" SD_2="50.0" SE="0.16004496325159281" STUDY_ID="STD-Dibba-2000" TOTAL_1="80" TOTAL_2="80" WEIGHT="10.085053655030164"/>
<CONT_DATA CI_END="0.4772672773224417" CI_START="-0.14587387711583635" EFFECT_SIZE="0.16569670010330265" ESTIMABLE="YES" MEAN_1="487.0" MEAN_2="480.0" ORDER="17026" SD_1="41.0" SD_2="43.0" SE="0.15896750127898673" STUDY_ID="STD-Lee-1994" TOTAL_1="77" TOTAL_2="82" WEIGHT="10.222227439652531"/>
<CONT_DATA CI_END="0.4501644946278604" CI_START="-0.40623244295249933" EFFECT_SIZE="0.02196602583768056" ESTIMABLE="YES" MEAN_1="492.0" MEAN_2="491.0" ORDER="17027" SD_1="39.0" SD_2="51.0" SE="0.2184726210112812" STUDY_ID="STD-Lee-1995" TOTAL_1="44" TOTAL_2="40" WEIGHT="5.412129720389707"/>
<CONT_DATA CI_END="0.5134677994735729" CI_START="-0.10432584171130158" EFFECT_SIZE="0.20457097888113565" ESTIMABLE="YES" MEAN_1="486.0" MEAN_2="479.0" ORDER="17028" SD_1="37.0" SD_2="31.0" SE="0.15760331466750202" STUDY_ID="STD-Wang-1996" TOTAL_1="79" TOTAL_2="83" WEIGHT="10.399956933342306"/>
</CONT_SUBGROUP>
<CONT_SUBGROUP CHI2="3.870030419409302" CI_END="0.24358768953131923" CI_START="-0.050771799142137" DF="5" EFFECT_SIZE="0.09640794519459112" ESTIMABLE="YES" I2="0.0" ID="CMP-001.14.02" NO="2" P_CHI2="0.5682762422392849" P_Z="0.19919590569762208" STUDIES="6" TAU2="0.0" TOTAL_1="339" TOTAL_2="395" WEIGHT="45.81021488471005" Z="1.2838458257720777">
<NAME>High baseline calcium</NAME>
<CONT_DATA CI_END="0.5128125613720704" CI_START="-0.24259987277088774" EFFECT_SIZE="0.13510634430059137" ESTIMABLE="YES" MEAN_1="312.0" MEAN_2="308.0" ORDER="17029" SD_1="29.66" SD_2="29.12" SE="0.1927107947139731" STUDY_ID="STD-Bonjour-1995" TOTAL_1="55" TOTAL_2="53" WEIGHT="6.955849078431553"/>
<CONT_DATA CI_END="0.2574725427227148" CI_START="-0.7158349449146524" EFFECT_SIZE="-0.2291812010959688" ESTIMABLE="YES" MEAN_1="336.18" MEAN_2="351.0" ORDER="17030" SD_1="43.19" SD_2="69.75" SE="0.24829728895905548" STUDY_ID="STD-Courteix-2005" TOTAL_1="22" TOTAL_2="63" WEIGHT="4.190041069753462"/>
<CONT_DATA CI_END="0.4929289406242539" CI_START="-0.3338062753225926" EFFECT_SIZE="0.07956133265083067" ESTIMABLE="YES" MEAN_1="317.09" MEAN_2="311.51" ORDER="17031" SD_1="69.4" SD_2="69.67" SE="0.2109057162447954" STUDY_ID="STD-Johnston-1992" TOTAL_1="45" TOTAL_2="45" WEIGHT="5.807450728357776"/>
<CONT_DATA CI_END="0.5300115286945037" CI_START="-0.06471641800366129" EFFECT_SIZE="0.23264755534542125" ESTIMABLE="YES" MEAN_1="450.0" MEAN_2="438.0" ORDER="17032" SD_1="53.0" SD_2="50.0" SE="0.15171910080728607" STUDY_ID="STD-Matkovic-2004" TOTAL_1="79" TOTAL_2="98" WEIGHT="11.222295885516864"/>
<CONT_DATA CI_END="0.2749570234978052" CI_START="-0.38090719667338463" EFFECT_SIZE="-0.05297508658778973" ESTIMABLE="YES" MEAN_1="479.0" MEAN_2="482.0" ORDER="17033" SD_1="61.0" SD_2="51.0" SE="0.16731537552336753" STUDY_ID="STD-Prentice-2005" TOTAL_1="73" TOTAL_2="70" WEIGHT="9.227637606628175"/>
<CONT_DATA CI_END="0.5639690051480064" CI_START="-0.12316306254107401" EFFECT_SIZE="0.2204029713034662" ESTIMABLE="YES" MEAN_1="427.0" MEAN_2="418.0" ORDER="17034" SD_1="38.0" SD_2="43.0" SE="0.17529201380971549" STUDY_ID="STD-Stear-2003" TOTAL_1="65" TOTAL_2="66" WEIGHT="8.40694051602222"/>
</CONT_SUBGROUP>
</CONT_OUTCOME>
<CONT_OUTCOME CHI2="4.97722057019081" CI_END="0.2859451518574186" CI_START="-0.07415640164141268" CI_STUDY="95" CI_TOTAL="95" DF="4" EFFECT_MEASURE="SMD" EFFECT_SIZE="0.10589437510800295" ESTIMABLE="YES" I2="19.633861035685356" I2_Q="53.23450773687496" ID="CMP-001.15" NO="15" P_CHI2="0.28964286874800793" P_Q="0.1436583772190554" P_Z="0.24902300050576687" Q="2.1383288224007595" RANDOM="YES" SCALE="1.0" SORT_BY="STUDY" STUDIES="5" SUBGROUPS="YES" SUBGROUP_TEST="NO" TAU2="0.008372358437612458" TOTALS="YES" TOTAL_1="313" TOTAL_2="304" UNITS="" WEIGHT="100.00000000000001" Z="1.1527257206222201">
<NAME>Femoral neck BMD (mg/cm2) at longest point after supplement ceased by baseline calcium intake</NAME>
<GROUP_LABEL_1>Treatment</GROUP_LABEL_1>
<GROUP_LABEL_2>Control</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours control</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours treatment</GRAPH_LABEL_2>
<CONT_SUBGROUP CHI2="0.5289613342865856" CI_END="0.2099928180380793" CI_START="-0.17941830427501998" DF="2" EFFECT_SIZE="0.01528725688152966" ESTIMABLE="YES" I2="0.0" ID="CMP-001.15.01" NO="1" P_CHI2="0.7676045029680955" P_Z="0.8776995706956688" STUDIES="3" TAU2="0.0" TOTAL_1="203" TOTAL_2="203" WEIGHT="64.2147736237936" Z="0.1538860663877979">
<NAME>Low baseline calcium</NAME>
<CONT_DATA CI_END="0.22762896650934925" CI_START="-0.2940909927915369" EFFECT_SIZE="-0.033231013141093814" ESTIMABLE="YES" MEAN_1="722.4" MEAN_2="724.7" ORDER="17035" SD_1="70.0" SD_2="68.0" SE="0.13309427199074741" STUDY_ID="STD-Chevalley-2005" TOTAL_1="110" TOTAL_2="116" WEIGHT="32.35034675376019"/>
<CONT_DATA CI_END="0.4281849516340527" CI_START="-0.4281849516340527" EFFECT_SIZE="0.0" ESTIMABLE="YES" MEAN_1="603.0" MEAN_2="603.0" ORDER="17036" SD_1="76.0" SD_2="64.0" SE="0.21846572437632575" STUDY_ID="STD-Lee-1995" TOTAL_1="44" TOTAL_2="40" WEIGHT="15.042977661610646"/>
<CONT_DATA CI_END="0.5438493859396915" CI_START="-0.2575440066043698" EFFECT_SIZE="0.14315268966766082" ESTIMABLE="YES" MEAN_1="1010.0" MEAN_2="990.0" ORDER="17037" SD_1="140.0" SD_2="137.11" SE="0.20444084658324083" STUDY_ID="STD-Rozen-2003" TOTAL_1="49" TOTAL_2="47" WEIGHT="16.821449208422756"/>
</CONT_SUBGROUP>
<CONT_SUBGROUP CHI2="2.309930413503465" CI_END="0.66310720801958" CI_START="-0.17445808339586089" DF="1" EFFECT_SIZE="0.24432456231185956" ESTIMABLE="YES" I2="56.70865260034813" ID="CMP-001.15.02" NO="2" P_CHI2="0.12854993828648675" P_Z="0.2528415897618468" STUDIES="2" TAU2="0.05206276919560965" TOTAL_1="110" TOTAL_2="101" WEIGHT="35.78522637620641" Z="1.1434746582215618">
<NAME>High baseline calcium</NAME>
<CONT_DATA CI_END="0.7986994788224699" CI_START="0.08686283431210057" EFFECT_SIZE="0.4427811565672853" ESTIMABLE="YES" MEAN_1="885.0" MEAN_2="853.0" ORDER="17038" SD_1="70.2" SD_2="73.67" SE="0.18159431758064076" STUDY_ID="STD-Bonjour-1995" TOTAL_1="67" TOTAL_2="58" WEIGHT="20.409404475448845"/>
<CONT_DATA CI_END="0.43698040696836393" CI_START="-0.40842428898937033" EFFECT_SIZE="0.014278058989496793" ESTIMABLE="YES" MEAN_1="956.05" MEAN_2="954.05" ORDER="17039" SD_1="136.72" SD_2="140.89" SE="0.2156684262124658" STUDY_ID="STD-Johnston-1992" TOTAL_1="43" TOTAL_2="43" WEIGHT="15.375821900757561"/>
</CONT_SUBGROUP>
</CONT_OUTCOME>
<CONT_OUTCOME CHI2="1.1583576889270417" CI_END="0.16953284421813042" CI_START="-0.1465114883422407" CI_STUDY="95" CI_TOTAL="95" DF="4" EFFECT_MEASURE="SMD" EFFECT_SIZE="0.011510677937944849" ESTIMABLE="YES" I2="0.0" I2_Q="0.0" ID="CMP-001.16" NO="16" P_CHI2="0.8849060147469565" P_Q="0.6360692220446355" P_Z="0.8864733826880067" Q="0.22391995713257506" RANDOM="NO" SCALE="1.0" SORT_BY="STUDY" STUDIES="5" SUBGROUPS="YES" SUBGROUP_TEST="YES" TAU2="0.0" TOTALS="YES" TOTAL_1="313" TOTAL_2="304" UNITS="" WEIGHT="99.99999999999999" Z="0.1427680351882415">
<NAME>Lumbar spine BMD (mg/cm2) at longest point after supplement ceased by baseline calcium intake</NAME>
<GROUP_LABEL_1>Treatment</GROUP_LABEL_1>
<GROUP_LABEL_2>Control</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours control</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours treament</GRAPH_LABEL_2>
<CONT_SUBGROUP CHI2="0.922525959420224" CI_END="0.17878218018438294" CI_START="-0.21072862992665833" DF="2" EFFECT_SIZE="-0.015973224871137708" ESTIMABLE="YES" I2="0.0" ID="CMP-001.16.01" NO="1" P_CHI2="0.6304868841104716" P_Z="0.8722902502020691" STUDIES="3" TAU2="0.0" TOTAL_1="203" TOTAL_2="203" WEIGHT="65.8350217266483" Z="0.16075007240730704">
<NAME>Low baseline calcium</NAME>
<CONT_DATA CI_END="0.30604468824634573" CI_START="-0.21570630455408518" EFFECT_SIZE="0.04516919184613029" ESTIMABLE="YES" MEAN_1="605.0" MEAN_2="602.5" ORDER="17040" SD_1="52.0" SD_2="58.0" SE="0.13310218884528904" STUDY_ID="STD-Chevalley-2005" TOTAL_1="110" TOTAL_2="116" WEIGHT="36.69183613729448"/>
<CONT_DATA CI_END="0.22936706177064778" CI_START="-0.6292396856883473" EFFECT_SIZE="-0.19993631195884978" ESTIMABLE="YES" MEAN_1="538.0" MEAN_2="551.0" ORDER="17041" SD_1="61.0" SD_2="68.0" SE="0.2190363583799436" STUDY_ID="STD-Lee-1995" TOTAL_1="44" TOTAL_2="40" WEIGHT="13.549005508643"/>
<CONT_DATA CI_END="0.40016282334497716" CI_START="-0.40016282334497716" EFFECT_SIZE="0.0" ESTIMABLE="YES" MEAN_1="1150.0" MEAN_2="1150.0" ORDER="17042" SD_1="140.0" SD_2="137.11" SE="0.2041684574315704" STUDY_ID="STD-Rozen-2003" TOTAL_1="49" TOTAL_2="47" WEIGHT="15.594180080710826"/>
</CONT_SUBGROUP>
<CONT_SUBGROUP CHI2="0.01191177237424267" CI_END="0.33482210314090216" CI_START="-0.2058792200161363" DF="1" EFFECT_SIZE="0.06447144156238294" ESTIMABLE="YES" I2="0.0" ID="CMP-001.16.02" NO="2" P_CHI2="0.9130906045406861" P_Z="0.6402142420103869" STUDIES="2" TAU2="0.0" TOTAL_1="110" TOTAL_2="101" WEIGHT="34.16497827335168" Z="0.4673992760211888">
<NAME>High baseline calcium</NAME>
<CONT_DATA CI_END="0.4286491395175547" CI_START="-0.27466106073165153" EFFECT_SIZE="0.07699403939295155" ESTIMABLE="YES" MEAN_1="1019.0" MEAN_2="1014.0" ORDER="17043" SD_1="70.2" SD_2="57.3" SE="0.17941916427975904" STUDY_ID="STD-Bonjour-1995" TOTAL_1="67" TOTAL_2="58" WEIGHT="20.193062121230803"/>
<CONT_DATA CI_END="0.46912926150434037" CI_START="-0.3763832168316114" EFFECT_SIZE="0.0463730223363645" ESTIMABLE="YES" MEAN_1="1061.23" MEAN_2="1052.39" ORDER="17044" SD_1="192.31" SD_2="185.47" SE="0.21569592222235875" STUDY_ID="STD-Johnston-1992" TOTAL_1="43" TOTAL_2="43" WEIGHT="13.971916152120873"/>
</CONT_SUBGROUP>
</CONT_OUTCOME>
<CONT_OUTCOME CHI2="2.8160955985362586" CI_END="0.3987017951586933" CI_START="0.029157553391896907" CI_STUDY="95" CI_TOTAL="95" DF="3" EFFECT_MEASURE="SMD" EFFECT_SIZE="0.2139296742752951" ESTIMABLE="YES" I2="0.0" I2_Q="0.0" ID="CMP-001.17" NO="17" P_CHI2="0.4208572474022483" P_Q="0.8059850616212753" P_Z="0.023253021489117242" Q="0.06032369375139934" RANDOM="NO" SCALE="1.0" SORT_BY="STUDY" STUDIES="4" SUBGROUPS="YES" SUBGROUP_TEST="YES" TAU2="0.0" TOTALS="YES" TOTAL_1="234" TOTAL_2="221" UNITS="" WEIGHT="100.0" Z="2.2692517399232655">
<NAME>Distal radius BMD (mg/cm2) at longest point after supplement ceased by baseline calcium intake</NAME>
<GROUP_LABEL_1>Treatment</GROUP_LABEL_1>
<GROUP_LABEL_2>Control</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours control</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours treatment</GRAPH_LABEL_2>
<CONT_SUBGROUP CHI2="1.4650944343566596" CI_END="0.4444803211846409" CI_START="-0.05957829990890734" DF="1" EFFECT_SIZE="0.1924510106378668" ESTIMABLE="YES" I2="31.74501407213987" ID="CMP-001.17.01" NO="1" P_CHI2="0.2261215889110585" P_Z="0.1344870570460741" STUDIES="2" TAU2="0.0" TOTAL_1="124" TOTAL_2="120" WEIGHT="53.749049047847535" Z="1.4966396123539358">
<NAME>Low baseline calcium</NAME>
<CONT_DATA CI_END="0.6175167825952239" CI_START="-0.0059803321820287025" EFFECT_SIZE="0.30576822520659763" ESTIMABLE="YES" MEAN_1="256.0" MEAN_2="242.0" ORDER="17045" SD_1="43.0" SD_2="48.0" SE="0.15905830915652489" STUDY_ID="STD-Dibba-2000" TOTAL_1="80" TOTAL_2="80" WEIGHT="35.1288540481875"/>
<CONT_DATA CI_END="0.40686449035579997" CI_START="-0.44953091203190143" EFFECT_SIZE="-0.021333210838050704" ESTIMABLE="YES" MEAN_1="516.0" MEAN_2="517.0" ORDER="17046" SD_1="44.0" SD_2="49.0" SE="0.21847222937330457" STUDY_ID="STD-Lee-1995" TOTAL_1="44" TOTAL_2="40" WEIGHT="18.620194999660033"/>
</CONT_SUBGROUP>
<CONT_SUBGROUP CHI2="1.2906774704281996" CI_END="0.510581946531807" CI_START="-0.03280112732757931" DF="1" EFFECT_SIZE="0.23889040960211386" ESTIMABLE="YES" I2="22.52130970658095" ID="CMP-001.17.02" NO="2" P_CHI2="0.2559232529622504" P_Z="0.08482725394900052" STUDIES="2" TAU2="0.0" TOTAL_1="110" TOTAL_2="101" WEIGHT="46.25095095215247" Z="1.7233389172270288">
<NAME>High baseline calcium</NAME>
<CONT_DATA CI_END="0.7255999910161408" CI_START="0.016372536416859873" EFFECT_SIZE="0.37098626371650034" ESTIMABLE="YES" MEAN_1="429.0" MEAN_2="418.0" ORDER="17047" SD_1="26.32" SD_2="32.74" SE="0.18092869567848607" STUDY_ID="STD-Bonjour-1995" TOTAL_1="67" TOTAL_2="58" WEIGHT="27.149497819276156"/>
<CONT_DATA CI_END="0.47390750843088114" CI_START="-0.3716306970386415" EFFECT_SIZE="0.05113840569611985" ESTIMABLE="YES" MEAN_1="365.23" MEAN_2="361.31" ORDER="17048" SD_1="77.08" SD_2="74.84" SE="0.21570248538723671" STUDY_ID="STD-Johnston-1992" TOTAL_1="43" TOTAL_2="43" WEIGHT="19.101453132876316"/>
</CONT_SUBGROUP>
</CONT_OUTCOME>
<CONT_OUTCOME CHI2="4.569678112982538" CI_END="0.3208724402970041" CI_START="0.04921441616255223" CI_STUDY="95" CI_TOTAL="95" DF="5" EFFECT_MEASURE="SMD" EFFECT_SIZE="0.18504342822977818" ESTIMABLE="YES" I2="0.0" I2_Q="0.0" ID="CMP-001.18" NO="18" P_CHI2="0.47061527510901036" P_Q="0.6537756985876366" P_Z="0.007582631581730898" Q="0.20117300917394942" RANDOM="NO" SCALE="1.0" SORT_BY="STUDY" STUDIES="6" SUBGROUPS="YES" SUBGROUP_TEST="YES" TAU2="0.0" TOTALS="YES" TOTAL_1="421" TOTAL_2="419" UNITS="" WEIGHT="99.99999999999999" Z="2.670110379119057">
<NAME>Upper limb BMD (mg/cm2) at longest point after supplement ceased by baseline calcium intake</NAME>
<GROUP_LABEL_1>Treatment</GROUP_LABEL_1>
<GROUP_LABEL_2>Control</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours control</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours treatment</GRAPH_LABEL_2>
<CONT_SUBGROUP CHI2="3.0778276333803887" CI_END="0.3239357229611554" CI_START="0.01026495213714207" DF="3" EFFECT_SIZE="0.16710033754914874" ESTIMABLE="YES" I2="2.5286547088054543" ID="CMP-001.18.01" NO="1" P_CHI2="0.37978090303594003" P_Z="0.03677577790196128" STUDIES="4" TAU2="0.0" TOTAL_1="311" TOTAL_2="318" WEIGHT="75.00616705414166" Z="2.088244579119992">
<NAME>Low baseline calcium</NAME>
<CONT_DATA CI_END="0.5201854123124395" CI_START="-0.003704661341557558" EFFECT_SIZE="0.258240375485441" ESTIMABLE="YES" MEAN_1="24.7" MEAN_2="19.4" ORDER="17049" SD_1="21.7" SD_2="19.2" SE="0.1336478827637587" STUDY_ID="STD-Chevalley-2005" TOTAL_1="110" TOTAL_2="116" WEIGHT="26.888386094926197"/>
<CONT_DATA CI_END="0.6175167825952239" CI_START="-0.0059803321820287025" EFFECT_SIZE="0.30576822520659763" ESTIMABLE="YES" MEAN_1="256.0" MEAN_2="242.0" ORDER="17050" SD_1="43.0" SD_2="48.0" SE="0.15905830915652489" STUDY_ID="STD-Dibba-2000" TOTAL_1="80" TOTAL_2="80" WEIGHT="18.98349529219736"/>
<CONT_DATA CI_END="0.3110243308527212" CI_START="-0.3110243308527212" EFFECT_SIZE="0.0" ESTIMABLE="YES" MEAN_1="505.0" MEAN_2="505.0" ORDER="17051" SD_1="45.0" SD_2="40.0" SE="0.15868879903204416" STUDY_ID="STD-Lee-1994" TOTAL_1="77" TOTAL_2="82" WEIGHT="19.072005137429322"/>
<CONT_DATA CI_END="0.40686449035579997" CI_START="-0.44953091203190143" EFFECT_SIZE="-0.021333210838050704" ESTIMABLE="YES" MEAN_1="516.0" MEAN_2="517.0" ORDER="17052" SD_1="44.0" SD_2="49.0" SE="0.21847222937330457" STUDY_ID="STD-Lee-1995" TOTAL_1="44" TOTAL_2="40" WEIGHT="10.06228052958878"/>
</CONT_SUBGROUP>
<CONT_SUBGROUP CHI2="1.2906774704281996" CI_END="0.510581946531807" CI_START="-0.03280112732757931" DF="1" EFFECT_SIZE="0.23889040960211386" ESTIMABLE="YES" I2="22.52130970658095" ID="CMP-001.18.02" NO="2" P_CHI2="0.2559232529622504" P_Z="0.08482725394900052" STUDIES="2" TAU2="0.0" TOTAL_1="110" TOTAL_2="101" WEIGHT="24.99383294585833" Z="1.7233389172270288">
<NAME>High baseline calcium</NAME>
<CONT_DATA CI_END="0.7255999910161408" CI_START="0.016372536416859873" EFFECT_SIZE="0.37098626371650034" ESTIMABLE="YES" MEAN_1="429.0" MEAN_2="418.0" ORDER="17053" SD_1="26.32" SD_2="32.74" SE="0.18092869567848607" STUDY_ID="STD-Bonjour-1995" TOTAL_1="67" TOTAL_2="58" WEIGHT="14.671482403917"/>
<CONT_DATA CI_END="0.47390750843088114" CI_START="-0.3716306970386415" EFFECT_SIZE="0.05113840569611985" ESTIMABLE="YES" MEAN_1="365.23" MEAN_2="361.31" ORDER="17054" SD_1="77.08" SD_2="74.84" SE="0.21570248538723671" STUDY_ID="STD-Johnston-1992" TOTAL_1="43" TOTAL_2="43" WEIGHT="10.322350541941328"/>
</CONT_SUBGROUP>
</CONT_OUTCOME>
<CONT_OUTCOME CHI2="5.833956503938205" CI_END="0.1894099906117992" CI_START="-0.05259426682904429" CI_STUDY="95" CI_TOTAL="95" DF="9" EFFECT_MEASURE="SMD" EFFECT_SIZE="0.06840786189137744" ESTIMABLE="YES" I2="0.0" I2_Q="46.2806767086915" ID="CMP-001.19" NO="19" P_CHI2="0.7564148098212335" P_Q="0.15543510762386403" P_Z="0.26783832457717716" Q="3.723055089794084" RANDOM="NO" SCALE="1.0" SORT_BY="STUDY" STUDIES="10" SUBGROUPS="YES" SUBGROUP_TEST="YES" TAU2="0.0" TOTALS="YES" TOTAL_1="519" TOTAL_2="554" UNITS="" WEIGHT="100.0" Z="1.1080544365982008">
<NAME>Femoral neck BMD (mg/cm2) (at end supplementation) by sex</NAME>
<GROUP_LABEL_1>Treatment</GROUP_LABEL_1>
<GROUP_LABEL_2>Control</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours control</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours treatment</GRAPH_LABEL_2>
<CONT_SUBGROUP CHI2="0.12363038381955833" CI_END="0.14869599086754398" CI_START="-0.2563321545355913" DF="1" EFFECT_SIZE="-0.05381808183402365" ESTIMABLE="YES" I2="0.0" ID="CMP-001.19.01" NO="1" P_CHI2="0.725129986107834" P_Z="0.6024642277675009" STUDIES="2" TAU2="0.0" TOTAL_1="187" TOTAL_2="188" WEIGHT="35.70060746348056" Z="0.5208601096436257">
<NAME>Male</NAME>
<CONT_DATA CI_END="0.17515393035443064" CI_START="-0.3398562006734309" EFFECT_SIZE="-0.08235113515950013" ESTIMABLE="YES" MEAN_1="698.0" MEAN_2="703.7" ORDER="17055" SD_1="70.0" SD_2="68.0" SE="0.13138254965147209" STUDY_ID="STD-Chevalley-2005" TOTAL_1="114" TOTAL_2="118" WEIGHT="22.080782911208967"/>
<CONT_DATA CI_END="0.3203145893001051" CI_START="-0.3354338260641689" EFFECT_SIZE="-0.0075596183820319145" ESTIMABLE="YES" MEAN_1="1001.0" MEAN_2="1002.0" ORDER="17056" SD_1="134.0" SD_2="129.0" SE="0.16728583293793503" STUDY_ID="STD-Prentice-2005" TOTAL_1="73" TOTAL_2="70" WEIGHT="13.619824552271593"/>
</CONT_SUBGROUP>
<CONT_SUBGROUP CHI2="1.9813179175911144" CI_END="0.36779430984360173" CI_START="0.017539693070316525" DF="5" EFFECT_SIZE="0.1926670014569591" ESTIMABLE="YES" I2="0.0" ID="CMP-001.19.02" NO="2" P_CHI2="0.8517240073929316" P_Z="0.031063202176103623" STUDIES="6" TAU2="0.0" TOTAL_1="243" TOTAL_2="281" WEIGHT="47.73954501854251" Z="2.156262134922232">
<NAME>Female</NAME>
<CONT_DATA CI_END="0.6604385539390247" CI_START="-0.09794154702996843" EFFECT_SIZE="0.2812485034545282" ESTIMABLE="YES" MEAN_1="656.0" MEAN_2="635.0" ORDER="17057" SD_1="81.58" SD_2="65.52" SE="0.19346786648912906" STUDY_ID="STD-Bonjour-1995" TOTAL_1="55" TOTAL_2="53" WEIGHT="10.182915842113054"/>
<CONT_DATA CI_END="0.5507846604584942" CI_START="-0.5808184484700071" EFFECT_SIZE="-0.015016894005756475" ESTIMABLE="YES" MEAN_1="814.0" MEAN_2="816.0" ORDER="17058" SD_1="131.0" SD_2="131.0" SE="0.2886795670365482" STUDY_ID="STD-Cameron-2004" TOTAL_1="24" TOTAL_2="24" WEIGHT="4.573595467063528"/>
<CONT_DATA CI_END="0.8977163300128035" CI_START="-0.08113466441638145" EFFECT_SIZE="0.40829083279821105" ESTIMABLE="YES" MEAN_1="772.45" MEAN_2="737.0" ORDER="17059" SD_1="57.43" SD_2="93.77" SE="0.24971147484092482" STUDY_ID="STD-Courteix-2005" TOTAL_1="22" TOTAL_2="63" WEIGHT="6.112415100267862"/>
<CONT_DATA CI_END="0.5859768774270062" CI_START="-0.46193881656079006" EFFECT_SIZE="0.06201903043310805" ESTIMABLE="YES" MEAN_1="877.0" MEAN_2="871.0" ORDER="17060" SD_1="90.0" SD_2="100.5" SE="0.26733034439755565" STUDY_ID="STD-Nowson-1997" TOTAL_1="28" TOTAL_2="28" WEIGHT="5.333266965361167"/>
<CONT_DATA CI_END="0.4921438634140949" CI_START="-0.3086206789419552" EFFECT_SIZE="0.09176159223606986" ESTIMABLE="YES" MEAN_1="1010.0" MEAN_2="1000.0" ORDER="17061" SD_1="70.0" SD_2="137.0" SE="0.2042804226690844" STUDY_ID="STD-Rozen-2003" TOTAL_1="49" TOTAL_2="47" WEIGHT="9.133481296727899"/>
<CONT_DATA CI_END="0.5643130591550494" CI_START="-0.12282562247230913" EFFECT_SIZE="0.2207437183413701" ESTIMABLE="YES" MEAN_1="870.0" MEAN_2="847.0" ORDER="17062" SD_1="100.0" SD_2="107.0" SE="0.17529370106987185" STUDY_ID="STD-Stear-2003" TOTAL_1="65" TOTAL_2="66" WEIGHT="12.403870347008995"/>
</CONT_SUBGROUP>
<CONT_SUBGROUP CHI2="0.005953112733447678" CI_END="0.27103661023577424" CI_START="-0.32365914628719644" DF="1" EFFECT_SIZE="-0.026311268025711078" ESTIMABLE="YES" I2="0.0" ID="CMP-001.19.03" NO="3" P_CHI2="0.9384991123093063" P_Z="0.8623131942503369" STUDIES="2" TAU2="0.0" TOTAL_1="89" TOTAL_2="85" WEIGHT="16.55984751797694" Z="0.17343032013372742">
<NAME>Mixed</NAME>
<CONT_DATA CI_END="0.37562699217396994" CI_START="-0.4508427758870757" EFFECT_SIZE="-0.037607891856552896" ESTIMABLE="YES" MEAN_1="847.72" MEAN_2="852.89" ORDER="17063" SD_1="128.13" SD_2="144.0" SE="0.21083799870307152" STUDY_ID="STD-Johnston-1992" TOTAL_1="45" TOTAL_2="45" WEIGHT="8.574169583656113"/>
<CONT_DATA CI_END="0.4140084286058978" CI_START="-0.44237274406664784" EFFECT_SIZE="-0.014182157730375022" ESTIMABLE="YES" MEAN_1="592.0" MEAN_2="593.0" ORDER="17064" SD_1="74.0" SD_2="65.0" SE="0.21846859927722423" STUDY_ID="STD-Lee-1995" TOTAL_1="44" TOTAL_2="40" WEIGHT="7.985677934320828"/>
</CONT_SUBGROUP>
</CONT_OUTCOME>
<CONT_OUTCOME CHI2="1.1024640714897922" CI_END="0.19656167519370077" CI_START="-0.03540959073148839" CI_STUDY="95" CI_TOTAL="95" DF="10" EFFECT_MEASURE="SMD" EFFECT_SIZE="0.08057604223110619" ESTIMABLE="YES" I2="0.0" I2_Q="0.0" ID="CMP-001.20" NO="20" P_CHI2="0.9997312530937471" P_Q="0.8624420296485815" P_Z="0.17332387499636842" Q="0.29597471847993706" RANDOM="NO" SCALE="1.0" SORT_BY="STUDY" STUDIES="11" SUBGROUPS="YES" SUBGROUP_TEST="YES" TAU2="0.0" TOTALS="YES" TOTAL_1="563" TOTAL_2="601" UNITS="" WEIGHT="100.00000000000003" Z="1.3616008875916368">
<NAME>Lumbar spine BMD (mg/cm2) (at end supplementation) by sex</NAME>
<GROUP_LABEL_1>Treatment</GROUP_LABEL_1>
<GROUP_LABEL_2>Control</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours control</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours treatment</GRAPH_LABEL_2>
<CONT_SUBGROUP CHI2="0.29350057875070507" CI_END="0.26091194897106934" CI_START="-0.14417777352176242" DF="1" EFFECT_SIZE="0.05836708772465346" ESTIMABLE="YES" I2="0.0" ID="CMP-001.20.01" NO="1" P_CHI2="0.5879860406640061" P_Z="0.5722096344150154" STUDIES="2" TAU2="0.0" TOTAL_1="187" TOTAL_2="188" WEIGHT="32.79185125765609" Z="0.5648002576754338">
<NAME>Male</NAME>
<CONT_DATA CI_END="0.27186034181968627" CI_START="-0.24293478100807947" EFFECT_SIZE="0.014462780405803406" ESTIMABLE="YES" MEAN_1="586.9" MEAN_2="586.1" ORDER="17065" SD_1="52.0" SD_2="58.0" SE="0.1313276996129531" STUDY_ID="STD-Chevalley-2005" TOTAL_1="114" TOTAL_2="118" WEIGHT="20.304838408962425"/>
<CONT_DATA CI_END="0.45798631527414724" CI_START="-0.1984686132330601" EFFECT_SIZE="0.12975885102054358" ESTIMABLE="YES" MEAN_1="1047.0" MEAN_2="1032.0" ORDER="17066" SD_1="114.0" SD_2="116.0" SE="0.1674660691944444" STUDY_ID="STD-Prentice-2005" TOTAL_1="73" TOTAL_2="70" WEIGHT="12.487012848693666"/>
</CONT_SUBGROUP>
<CONT_SUBGROUP CHI2="0.5112808371642364" CI_END="0.2708815120487563" CI_START="-0.05082678254260939" DF="6" EFFECT_SIZE="0.11002736475307345" ESTIMABLE="YES" I2="0.0" ID="CMP-001.20.02" NO="2" P_CHI2="0.9976985075598984" P_Z="0.1800329852185952" STUDIES="7" TAU2="0.0" TOTAL_1="287" TOTAL_2="328" WEIGHT="51.99287923249711" Z="1.3406534792880878">
<NAME>Female</NAME>
<CONT_DATA CI_END="0.5114205026835856" CI_START="-0.24397376271812718" EFFECT_SIZE="0.13372336998272924" ESTIMABLE="YES" MEAN_1="647.0" MEAN_2="638.0" ORDER="17067" SD_1="74.16" SD_2="58.24" SE="0.1927061597458337" STUDY_ID="STD-Bonjour-1995" TOTAL_1="55" TOTAL_2="53" WEIGHT="9.43020248538449"/>
<CONT_DATA CI_END="0.6643854658079379" CI_START="-0.4679433402975458" EFFECT_SIZE="0.09822106275519607" ESTIMABLE="YES" MEAN_1="848.0" MEAN_2="833.0" ORDER="17068" SD_1="158.0" SD_2="142.0" SE="0.2888646972692225" STUDY_ID="STD-Cameron-2004" TOTAL_1="24" TOTAL_2="24" WEIGHT="4.196848320638333"/>
<CONT_DATA CI_END="0.6270434570242918" CI_START="-0.3446758722743443" EFFECT_SIZE="0.1411837923749737" ESTIMABLE="YES" MEAN_1="740.64" MEAN_2="726.67" ORDER="17069" SD_1="65.03" SD_2="106.95" SE="0.2478921390809816" STUDY_ID="STD-Courteix-2005" TOTAL_1="22" TOTAL_2="63" WEIGHT="5.698843118900126"/>
<CONT_DATA CI_END="0.6124201908396137" CI_START="-0.21201494446981703" EFFECT_SIZE="0.20020262318489837" ESTIMABLE="YES" MEAN_1="914.0" MEAN_2="894.0" ORDER="17070" SD_1="83.0" SD_2="112.0" SE="0.21031895019818475" STUDY_ID="STD-Lloyd-1993" TOTAL_1="44" TOTAL_2="47" WEIGHT="7.9169044070243535"/>
<CONT_DATA CI_END="0.6326118992120395" CI_START="-0.4158598560902002" EFFECT_SIZE="0.10837602156091967" ESTIMABLE="YES" MEAN_1="1017.0" MEAN_2="1001.0" ORDER="17071" SD_1="148.2" SD_2="142.9" SE="0.2674721993803078" STUDY_ID="STD-Nowson-1997" TOTAL_1="28" TOTAL_2="28" WEIGHT="4.895024998280832"/>
<CONT_DATA CI_END="0.40016282334497716" CI_START="-0.40016282334497716" EFFECT_SIZE="0.0" ESTIMABLE="YES" MEAN_1="1120.0" MEAN_2="1120.0" ORDER="17072" SD_1="140.0" SD_2="137.11" SE="0.2041684574315704" STUDY_ID="STD-Rozen-2003" TOTAL_1="49" TOTAL_2="47" WEIGHT="8.401076060027075"/>
<CONT_DATA CI_END="0.4411301457213726" CI_START="-0.24428861169722987" EFFECT_SIZE="0.09842076701207135" ESTIMABLE="YES" MEAN_1="999.0" MEAN_2="989.0" ORDER="17073" SD_1="100.0" SD_2="102.0" SE="0.17485493683177297" STUDY_ID="STD-Stear-2003" TOTAL_1="65" TOTAL_2="66" WEIGHT="11.453979842241894"/>
</CONT_SUBGROUP>
<CONT_SUBGROUP CHI2="0.0017079370949135437" CI_END="0.32514856633615885" CI_START="-0.2695465441766419" DF="1" EFFECT_SIZE="0.02780101107975844" ESTIMABLE="YES" I2="0.0" ID="CMP-001.20.03" NO="3" P_CHI2="0.9670350590531874" P_Z="0.8546017562383408" STUDIES="2" TAU2="0.0" TOTAL_1="89" TOTAL_2="85" WEIGHT="15.215269509846815" Z="0.18325013771557713">
<NAME>Mixed</NAME>
<CONT_DATA CI_END="0.434960444536277" CI_START="-0.39145848587210075" EFFECT_SIZE="0.021750979332088152" ESTIMABLE="YES" MEAN_1="907.36" MEAN_2="902.96" ORDER="17074" SD_1="197.32" SD_2="203.75" SE="0.2108250296758167" STUDY_ID="STD-Johnston-1992" TOTAL_1="45" TOTAL_2="45" WEIGHT="7.87894141933801"/>
<CONT_DATA CI_END="0.4625164252125683" CI_START="-0.393919388343527" EFFECT_SIZE="0.034298518434520614" ESTIMABLE="YES" MEAN_1="525.0" MEAN_2="523.0" ORDER="17075" SD_1="61.0" SD_2="54.0" SE="0.21848253853426688" STUDY_ID="STD-Lee-1995" TOTAL_1="44" TOTAL_2="40" WEIGHT="7.336328090508805"/>
</CONT_SUBGROUP>
</CONT_OUTCOME>
<CONT_OUTCOME CHI2="4.575286896634282" CI_END="0.26841853898080836" CI_START="0.011094187411965578" CI_STUDY="95" CI_TOTAL="95" DF="8" EFFECT_MEASURE="SMD" EFFECT_SIZE="0.13975636319638696" ESTIMABLE="YES" I2="0.0" I2_Q="0.0" ID="CMP-001.21" NO="21" P_CHI2="0.8018545079137475" P_Q="0.6394310886256147" P_Z="0.033257047294556065" Q="0.894352927393073" RANDOM="NO" SCALE="1.0" SORT_BY="STUDY" STUDIES="9" SUBGROUPS="YES" SUBGROUP_TEST="YES" TAU2="0.0" TOTALS="YES" TOTAL_1="449" TOTAL_2="504" UNITS="" WEIGHT="100.00000000000003" Z="2.128966316675518">
<NAME>Total Body BMC (mg) (at end supplementation) by sex</NAME>
<GROUP_LABEL_1>Treatment</GROUP_LABEL_1>
<GROUP_LABEL_2>Control</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours control</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours treatment</GRAPH_LABEL_2>
<CONT_SUBGROUP CHI2="0.0" CI_END="0.3908635962567637" CI_START="-0.26504909971456003" DF="0" EFFECT_SIZE="0.06290724827110186" ESTIMABLE="YES" I2="0.0" ID="CMP-001.21.01" NO="1" P_CHI2="1.0" P_Z="0.7069523641233881" STUDIES="1" TAU2="0.0" TOTAL_1="73" TOTAL_2="70" WEIGHT="15.39110140655137" Z="0.3759522928437711">
<NAME>Male</NAME>
<CONT_DATA CI_END="0.3908635962567637" CI_START="-0.26504909971456003" EFFECT_SIZE="0.06290724827110186" ESTIMABLE="YES" MEAN_1="2796.0" MEAN_2="2770.0" ORDER="17076" SD_1="415.0" SD_2="407.0" SE="0.1673277420261493" STUDY_ID="STD-Prentice-2005" TOTAL_1="73" TOTAL_2="70" WEIGHT="15.39110140655137"/>
</CONT_SUBGROUP>
<CONT_SUBGROUP CHI2="3.6809339692412086" CI_END="0.3438048610327017" CI_START="0.0257095353571406" DF="6" EFFECT_SIZE="0.18475719819492115" ESTIMABLE="YES" I2="0.0" ID="CMP-001.21.02" NO="2" P_CHI2="0.7197621609792402" P_Z="0.02279902212526305" STUDIES="7" TAU2="0.0" TOTAL_1="288" TOTAL_2="344" WEIGHT="65.4405889927341" Z="2.2767857627427897">
<NAME>Female</NAME>
<CONT_DATA CI_END="0.7244128544136019" CI_START="-0.4090865084137309" EFFECT_SIZE="0.15766317299993554" ESTIMABLE="YES" MEAN_1="1583.0" MEAN_2="1512.0" ORDER="17077" SD_1="504.0" SD_2="372.0" SE="0.289163314165013" STUDY_ID="STD-Cameron-2004" TOTAL_1="24" TOTAL_2="24" WEIGHT="5.153700938319748"/>
<CONT_DATA CI_END="1.0623077058025256" CI_START="0.07587704885842766" EFFECT_SIZE="0.5690923773304767" ESTIMABLE="YES" MEAN_1="1340.9" MEAN_2="1186.1" ORDER="17078" SD_1="216.37" SD_2="285.32" SE="0.2516450977479528" STUDY_ID="STD-Courteix-2005" TOTAL_1="22" TOTAL_2="63" WEIGHT="6.8050081859542075"/>
<CONT_DATA CI_END="0.6238360632229405" CI_START="-0.3464242431167532" EFFECT_SIZE="0.13870591005309368" ESTIMABLE="YES" MEAN_1="1179.57" MEAN_2="1151.25" ORDER="17079" SD_1="209.01" SD_2="195.57" SE="0.2475199325071744" STUDY_ID="STD-Iuliano_x002d_Burns-2003" TOTAL_1="30" TOTAL_2="36" WEIGHT="7.033722738386756"/>
<CONT_DATA CI_END="0.6634749996606573" CI_START="-0.16217650854283872" EFFECT_SIZE="0.2506492455589093" ESTIMABLE="YES" MEAN_1="1783.0" MEAN_2="1714.0" ORDER="17080" SD_1="238.0" SD_2="302.0" SE="0.21062925510777997" STUDY_ID="STD-Lloyd-1993" TOTAL_1="44" TOTAL_2="47" WEIGHT="9.713331640661764"/>
<CONT_DATA CI_END="0.4506900805835923" CI_START="-0.29400382768340283" EFFECT_SIZE="0.07834312645009475" ESTIMABLE="YES" MEAN_1="1932.11" MEAN_2="1907.53" ORDER="17081" SD_1="292.33" SD_2="328.77" SE="0.18997642664381734" STUDY_ID="STD-Molgaard-2004" TOTAL_1="54" TOTAL_2="57" WEIGHT="11.940050720347896"/>
<CONT_DATA CI_END="0.3917077443497603" CI_START="-0.392434700377596" EFFECT_SIZE="-3.634780139178262E-4" ESTIMABLE="YES" MEAN_1="860.29" MEAN_2="860.34" ORDER="17082" SD_1="134.19" SD_2="138.69" SE="0.2000400137228469" STUDY_ID="STD-Rozen-2003" TOTAL_1="49" TOTAL_2="51" WEIGHT="10.768912529976117"/>
<CONT_DATA CI_END="0.5619740238730728" CI_START="-0.12511989143932517" EFFECT_SIZE="0.21842706621687386" ESTIMABLE="YES" MEAN_1="2143.0" MEAN_2="2088.0" ORDER="17083" SD_1="265.0" SD_2="235.0" SE="0.175282280881717" STUDY_ID="STD-Stear-2003" TOTAL_1="65" TOTAL_2="66" WEIGHT="14.025862239087607"/>
</CONT_SUBGROUP>
<CONT_SUBGROUP CHI2="2.1417003561084948E-33" CI_END="0.3417017087255969" CI_START="-0.24604334021365062" DF="0" EFFECT_SIZE="0.04782918425597313" ESTIMABLE="YES" I2="100.0" ID="CMP-001.21.03" NO="3" P_CHI2="0.0" P_Z="0.7497313044168908" STUDIES="1" TAU2="0.0" TOTAL_1="88" TOTAL_2="90" WEIGHT="19.168309600714544" Z="0.3189936817700947">
<NAME>Mixed</NAME>
<CONT_DATA CI_END="0.3417017087255969" CI_START="-0.24604334021365062" EFFECT_SIZE="0.047829184255973135" ESTIMABLE="YES" MEAN_1="685.55" MEAN_2="681.5" ORDER="17084" SD_1="88.0" SD_2="80.55" SE="0.1499377166048217" STUDY_ID="STD-Specker-2003" TOTAL_1="88" TOTAL_2="90" WEIGHT="19.168309600714544"/>
</CONT_SUBGROUP>
</CONT_OUTCOME>
<CONT_OUTCOME CHI2="8.073176705722247" CI_END="0.27214379866967514" CI_START="0.036867948161045216" CI_STUDY="95" CI_TOTAL="95" DF="8" EFFECT_MEASURE="SMD" EFFECT_SIZE="0.15450587341536018" ESTIMABLE="YES" I2="0.9064177385140044" I2_Q="7.19742517781747" ID="CMP-001.22" NO="22" P_CHI2="0.4263549182299098" P_Q="0.340426626228428" P_Z="0.01004662511823083" Q="2.155112618192078" RANDOM="NO" SCALE="1.0" SORT_BY="STUDY" STUDIES="9" SUBGROUPS="YES" SUBGROUP_TEST="YES" TAU2="0.0" TOTALS="YES" TOTAL_1="542" TOTAL_2="598" UNITS="" WEIGHT="100.00000000000003" Z="2.5742204024709534">
<NAME>Distal Radius BMD (mg/cm2) (at end supplementation) by sex</NAME>
<GROUP_LABEL_1>Treatment</GROUP_LABEL_1>
<GROUP_LABEL_2>Control</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours control</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours treatment</GRAPH_LABEL_2>
<CONT_SUBGROUP CHI2="0.0" CI_END="0.2749570234978052" CI_START="-0.38090719667338463" DF="0" EFFECT_SIZE="-0.05297508658778973" ESTIMABLE="YES" I2="0.0" ID="CMP-001.22.01" NO="1" P_CHI2="1.0" P_Z="0.7515333538754873" STUDIES="1" TAU2="0.0" TOTAL_1="73" TOTAL_2="70" WEIGHT="12.868467372323614" Z="0.31661816149341965">
<NAME>Male</NAME>
<CONT_DATA CI_END="0.2749570234978052" CI_START="-0.38090719667338463" EFFECT_SIZE="-0.05297508658778973" ESTIMABLE="YES" MEAN_1="479.0" MEAN_2="482.0" ORDER="17085" SD_1="61.0" SD_2="51.0" SE="0.16731537552336753" STUDY_ID="STD-Prentice-2005" TOTAL_1="73" TOTAL_2="70" WEIGHT="12.868467372323614"/>
</CONT_SUBGROUP>
<CONT_SUBGROUP CHI2="2.792371943698612" CI_END="0.3239462653155287" CI_START="-0.035190015313554784" DF="3" EFFECT_SIZE="0.14437812500098696" ESTIMABLE="YES" I2="0.0" ID="CMP-001.22.02" NO="2" P_CHI2="0.424757265300591" P_Z="0.11505592023059788" STUDIES="4" TAU2="0.0" TOTAL_1="221" TOTAL_2="280" WEIGHT="42.917670672262744" Z="1.5758693310610654">
<NAME>Female</NAME>
<CONT_DATA CI_END="0.5128125613720704" CI_START="-0.24259987277088774" EFFECT_SIZE="0.13510634430059137" ESTIMABLE="YES" MEAN_1="312.0" MEAN_2="308.0" ORDER="17086" SD_1="29.66" SD_2="29.12" SE="0.1927107947139731" STUDY_ID="STD-Bonjour-1995" TOTAL_1="55" TOTAL_2="53" WEIGHT="9.700328592044865"/>
<CONT_DATA CI_END="0.2574725427227148" CI_START="-0.7158349449146524" EFFECT_SIZE="-0.2291812010959688" ESTIMABLE="YES" MEAN_1="336.18" MEAN_2="351.0" ORDER="17087" SD_1="43.19" SD_2="69.75" SE="0.24829728895905548" STUDY_ID="STD-Courteix-2005" TOTAL_1="22" TOTAL_2="63" WEIGHT="5.843251446728712"/>
<CONT_DATA CI_END="0.5300115286945037" CI_START="-0.06471641800366129" EFFECT_SIZE="0.23264755534542125" ESTIMABLE="YES" MEAN_1="450.0" MEAN_2="438.0" ORDER="17088" SD_1="53.0" SD_2="50.0" SE="0.15171910080728607" STUDY_ID="STD-Matkovic-2004" TOTAL_1="79" TOTAL_2="98" WEIGHT="15.650132200857508"/>
<CONT_DATA CI_END="0.5639690051480064" CI_START="-0.12316306254107401" EFFECT_SIZE="0.2204029713034662" ESTIMABLE="YES" MEAN_1="427.0" MEAN_2="418.0" ORDER="17089" SD_1="38.0" SD_2="43.0" SE="0.17529201380971549" STUDY_ID="STD-Stear-2003" TOTAL_1="65" TOTAL_2="66" WEIGHT="11.723958432631655"/>
</CONT_SUBGROUP>
<CONT_SUBGROUP CHI2="3.1256921438315577" CI_END="0.40164056857239017" CI_START="0.04780773810507194" DF="3" EFFECT_SIZE="0.22472415333873105" ESTIMABLE="YES" I2="4.021257950166547" ID="CMP-001.22.03" NO="3" P_CHI2="0.372649266985858" P_Z="0.01278866520114802" STUDIES="4" TAU2="0.0" TOTAL_1="248" TOTAL_2="248" WEIGHT="44.21386195541366" Z="2.4896007892679237">
<NAME>Mixed</NAME>
<CONT_DATA CI_END="0.7515904462890333" CI_START="0.12422571852871639" EFFECT_SIZE="0.4379080824088748" ESTIMABLE="YES" MEAN_1="253.0" MEAN_2="231.0" ORDER="17090" SD_1="50.0" SD_2="50.0" SE="0.16004496325159281" STUDY_ID="STD-Dibba-2000" TOTAL_1="80" TOTAL_2="80" WEIGHT="14.064182994645218"/>
<CONT_DATA CI_END="0.4929289406242539" CI_START="-0.3338062753225926" EFFECT_SIZE="0.07956133265083067" ESTIMABLE="YES" MEAN_1="317.09" MEAN_2="311.51" ORDER="17091" SD_1="69.4" SD_2="69.67" SE="0.2109057162447954" STUDY_ID="STD-Johnston-1992" TOTAL_1="45" TOTAL_2="45" WEIGHT="8.098821540257351"/>
<CONT_DATA CI_END="0.4501644946278604" CI_START="-0.40623244295249933" EFFECT_SIZE="0.02196602583768056" ESTIMABLE="YES" MEAN_1="492.0" MEAN_2="491.0" ORDER="17092" SD_1="39.0" SD_2="51.0" SE="0.2184726210112812" STUDY_ID="STD-Lee-1995" TOTAL_1="44" TOTAL_2="40" WEIGHT="7.547523829023321"/>
<CONT_DATA CI_END="0.5134677994735729" CI_START="-0.10432584171130158" EFFECT_SIZE="0.20457097888113565" ESTIMABLE="YES" MEAN_1="486.0" MEAN_2="479.0" ORDER="17093" SD_1="37.0" SD_2="31.0" SE="0.15760331466750202" STUDY_ID="STD-Wang-1996" TOTAL_1="79" TOTAL_2="83" WEIGHT="14.50333359148777"/>
</CONT_SUBGROUP>
</CONT_OUTCOME>
<CONT_OUTCOME CHI2="8.776450208455154" CI_END="0.23680167256850854" CI_START="0.03756634980009886" CI_STUDY="95" CI_TOTAL="95" DF="12" EFFECT_MEASURE="SMD" EFFECT_SIZE="0.1371840111843037" ESTIMABLE="YES" I2="0.0" I2_Q="13.85981972849436" ID="CMP-001.23" NO="23" P_CHI2="0.7218967103090689" P_Q="0.31320470690408464" P_Z="0.00695321230105541" Q="2.3217968591384306" RANDOM="NO" SCALE="1.0" SORT_BY="STUDY" STUDIES="12" SUBGROUPS="YES" SUBGROUP_TEST="YES" TAU2="0.0" TOTALS="YES" TOTAL_1="757" TOTAL_2="822" UNITS="" WEIGHT="100.0" Z="2.6990768247306756">
<NAME>Upper Limb BMD (mg/cm2) (at end supplementation) by sex</NAME>
<GROUP_LABEL_1>Treatment</GROUP_LABEL_1>
<GROUP_LABEL_2>Control</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours control</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours treatment</GRAPH_LABEL_2>
<CONT_SUBGROUP CHI2="0.4179425032885922" CI_END="0.21128445431227658" CI_START="-0.15482561594410862" DF="2" EFFECT_SIZE="0.028229419184083965" ESTIMABLE="YES" I2="0.0" ID="CMP-001.23.01" NO="1" P_CHI2="0.8114186589836162" P_Z="0.7624604065190069" STUDIES="3" TAU2="0.0" TOTAL_1="228" TOTAL_2="231" WEIGHT="29.61483558394186" Z="0.30225142327575016">
<NAME>Male</NAME>
<CONT_DATA CI_END="0.30378712152378146" CI_START="-0.211071470037911" EFFECT_SIZE="0.046357825742935246" ESTIMABLE="YES" MEAN_1="309.6" MEAN_2="308.2" ORDER="17094" SD_1="28.0" SD_2="32.0" SE="0.13134389091402476" STUDY_ID="STD-Chevalley-2005" TOTAL_1="114" TOTAL_2="118" WEIGHT="14.974652287246176"/>
<CONT_DATA CI_END="0.5447272733498184" CI_START="-0.3116748037745598" EFFECT_SIZE="0.11652623478762932" ESTIMABLE="YES" MEAN_1="482.0" MEAN_2="477.0" ORDER="17095" SD_1="42.0" SD_2="43.0" SE="0.21847393214354152" STUDY_ID="STD-Lee-1994" TOTAL_1="41" TOTAL_2="43" WEIGHT="5.412242552642546"/>
<CONT_DATA CI_END="0.2749570234978052" CI_START="-0.38090719667338463" EFFECT_SIZE="-0.05297508658778973" ESTIMABLE="YES" MEAN_1="479.0" MEAN_2="482.0" ORDER="17096" SD_1="61.0" SD_2="51.0" SE="0.16731537552336753" STUDY_ID="STD-Prentice-2005" TOTAL_1="73" TOTAL_2="70" WEIGHT="9.227940744053138"/>
</CONT_SUBGROUP>
<CONT_SUBGROUP CHI2="2.911018702196574" CI_END="0.3090233478454335" CI_START="-0.01132739337818145" DF="5" EFFECT_SIZE="0.14884797723362603" ESTIMABLE="YES" I2="0.0" ID="CMP-001.23.02" NO="2" P_CHI2="0.7137020838446531" P_Z="0.06855247236296073" STUDIES="6" TAU2="0.0" TOTAL_1="281" TOTAL_2="343" WEIGHT="38.67953185038059" Z="1.821357886891253">
<NAME>Female</NAME>
<CONT_DATA CI_END="0.5128125613720704" CI_START="-0.24259987277088774" EFFECT_SIZE="0.13510634430059137" ESTIMABLE="YES" MEAN_1="312.0" MEAN_2="308.0" ORDER="17097" SD_1="29.66" SD_2="29.12" SE="0.1927107947139731" STUDY_ID="STD-Bonjour-1995" TOTAL_1="55" TOTAL_2="53" WEIGHT="6.956077585257238"/>
<CONT_DATA CI_END="0.6586912100157563" CI_START="-0.47355455217399833" EFFECT_SIZE="0.09256832892087895" ESTIMABLE="YES" MEAN_1="418.0" MEAN_2="414.0" ORDER="17098" SD_1="43.0" SD_2="42.0" SE="0.28884351220756216" STUDY_ID="STD-Cameron-2004" TOTAL_1="24" TOTAL_2="24" WEIGHT="3.096358711501291"/>
<CONT_DATA CI_END="0.2574725427227148" CI_START="-0.7158349449146524" EFFECT_SIZE="-0.2291812010959688" ESTIMABLE="YES" MEAN_1="336.18" MEAN_2="351.0" ORDER="17099" SD_1="43.19" SD_2="69.75" SE="0.24829728895905548" STUDY_ID="STD-Courteix-2005" TOTAL_1="22" TOTAL_2="63" WEIGHT="4.190178716929751"/>
<CONT_DATA CI_END="0.6680742760106473" CI_START="-0.24064066501041775" EFFECT_SIZE="0.21371680550011474" ESTIMABLE="YES" MEAN_1="492.0" MEAN_2="483.0" ORDER="17100" SD_1="39.0" SD_2="44.0" SE="0.23181929570872029" STUDY_ID="STD-Lee-1994" TOTAL_1="36" TOTAL_2="39" WEIGHT="4.807035594465895"/>
<CONT_DATA CI_END="0.5300115286945037" CI_START="-0.06471641800366129" EFFECT_SIZE="0.23264755534542125" ESTIMABLE="YES" MEAN_1="450.0" MEAN_2="438.0" ORDER="17101" SD_1="53.0" SD_2="50.0" SE="0.15171910080728607" STUDY_ID="STD-Matkovic-2004" TOTAL_1="79" TOTAL_2="98" WEIGHT="11.222664549526215"/>
<CONT_DATA CI_END="0.5639690051480064" CI_START="-0.12316306254107401" EFFECT_SIZE="0.2204029713034662" ESTIMABLE="YES" MEAN_1="427.0" MEAN_2="418.0" ORDER="17102" SD_1="38.0" SD_2="43.0" SE="0.17529201380971549" STUDY_ID="STD-Stear-2003" TOTAL_1="65" TOTAL_2="66" WEIGHT="8.407216692700203"/>
</CONT_SUBGROUP>
<CONT_SUBGROUP CHI2="3.1256921438315577" CI_END="0.40164056857239017" CI_START="0.04780773810507194" DF="3" EFFECT_SIZE="0.22472415333873105" ESTIMABLE="YES" I2="4.021257950166547" ID="CMP-001.23.03" NO="3" P_CHI2="0.372649266985858" P_Z="0.01278866520114802" STUDIES="4" TAU2="0.0" TOTAL_1="248" TOTAL_2="248" WEIGHT="31.705632565677547" Z="2.4896007892679237">
<NAME>Mixed</NAME>
<CONT_DATA CI_END="0.7515904462890333" CI_START="0.12422571852871639" EFFECT_SIZE="0.4379080824088748" ESTIMABLE="YES" MEAN_1="253.0" MEAN_2="231.0" ORDER="17103" SD_1="50.0" SD_2="50.0" SE="0.16004496325159281" STUDY_ID="STD-Dibba-2000" TOTAL_1="80" TOTAL_2="80" WEIGHT="10.08538495945779"/>
<CONT_DATA CI_END="0.4929289406242539" CI_START="-0.3338062753225926" EFFECT_SIZE="0.07956133265083067" ESTIMABLE="YES" MEAN_1="317.09" MEAN_2="311.51" ORDER="17104" SD_1="69.4" SD_2="69.67" SE="0.2109057162447954" STUDY_ID="STD-Johnston-1992" TOTAL_1="45" TOTAL_2="45" WEIGHT="5.807641509111685"/>
<CONT_DATA CI_END="0.4501644946278604" CI_START="-0.40623244295249933" EFFECT_SIZE="0.02196602583768056" ESTIMABLE="YES" MEAN_1="492.0" MEAN_2="491.0" ORDER="17105" SD_1="39.0" SD_2="51.0" SE="0.2184726210112812" STUDY_ID="STD-Lee-1995" TOTAL_1="44" TOTAL_2="40" WEIGHT="5.412307514440248"/>
<CONT_DATA CI_END="0.5134677994735729" CI_START="-0.10432584171130158" EFFECT_SIZE="0.20457097888113565" ESTIMABLE="YES" MEAN_1="486.0" MEAN_2="479.0" ORDER="17106" SD_1="37.0" SD_2="31.0" SE="0.15760331466750202" STUDY_ID="STD-Wang-1996" TOTAL_1="79" TOTAL_2="83" WEIGHT="10.40029858266783"/>
</CONT_SUBGROUP>
</CONT_OUTCOME>
<CONT_OUTCOME CHI2="4.97722057019081" CI_END="0.25816335936328655" CI_START="-0.058584264233279115" CI_STUDY="95" CI_TOTAL="95" DF="4" EFFECT_MEASURE="SMD" EFFECT_SIZE="0.09978954756500372" ESTIMABLE="YES" I2="19.633861035685356" I2_Q="47.011257781731445" ID="CMP-001.24" NO="24" P_CHI2="0.28964286874800793" P_Q="0.1514965237770316" P_Z="0.21684871283710272" Q="3.774386626807824" RANDOM="NO" SCALE="1.0" SORT_BY="STUDY" STUDIES="5" SUBGROUPS="YES" SUBGROUP_TEST="YES" TAU2="0.0" TOTALS="YES" TOTAL_1="313" TOTAL_2="304" UNITS="" WEIGHT="100.0" Z="1.2349511389551246">
<NAME>Femoral neck BMD (mg/cm2) at longest point after supplement ceased by sex</NAME>
<GROUP_LABEL_1>Treatment</GROUP_LABEL_1>
<GROUP_LABEL_2>Control</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours control</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours treatment</GRAPH_LABEL_2>
<CONT_SUBGROUP CHI2="0.0" CI_END="0.22762896650934925" CI_START="-0.2940909927915369" DF="0" EFFECT_SIZE="-0.033231013141093814" ESTIMABLE="YES" I2="0.0" ID="CMP-001.24.01" NO="1" P_CHI2="1.0" P_Z="0.8028346211727498" STUDIES="1" TAU2="0.0" TOTAL_1="110" TOTAL_2="116" WEIGHT="36.85970262180859" Z="0.2496802653040095">
<NAME>Male</NAME>
<CONT_DATA CI_END="0.22762896650934925" CI_START="-0.2940909927915369" EFFECT_SIZE="-0.033231013141093814" ESTIMABLE="YES" MEAN_1="722.4" MEAN_2="724.7" ORDER="17107" SD_1="70.0" SD_2="68.0" SE="0.13309427199074741" STUDY_ID="STD-Chevalley-2005" TOTAL_1="110" TOTAL_2="116" WEIGHT="36.85970262180859"/>
</CONT_SUBGROUP>
<CONT_SUBGROUP CHI2="1.200670714821703" CI_END="0.5767390365945972" CI_START="0.044536550732225344" DF="1" EFFECT_SIZE="0.3106377936634113" ESTIMABLE="YES" I2="16.71321806591262" ID="CMP-001.24.02" NO="2" P_CHI2="0.2731877293659092" P_Z="0.022137686569274975" STUDIES="2" TAU2="0.0" TOTAL_1="116" TOTAL_2="105" WEIGHT="35.42198811535679" Z="2.2879971589411823">
<NAME>Female</NAME>
<CONT_DATA CI_END="0.7986994788224699" CI_START="0.08686283431210057" EFFECT_SIZE="0.4427811565672853" ESTIMABLE="YES" MEAN_1="885.0" MEAN_2="853.0" ORDER="17108" SD_1="70.2" SD_2="73.67" SE="0.18159431758064076" STUDY_ID="STD-Bonjour-1995" TOTAL_1="67" TOTAL_2="58" WEIGHT="19.800039110516856"/>
<CONT_DATA CI_END="0.5438493859396915" CI_START="-0.2575440066043698" EFFECT_SIZE="0.14315268966766082" ESTIMABLE="YES" MEAN_1="1010.0" MEAN_2="990.0" ORDER="17109" SD_1="140.0" SD_2="137.11" SE="0.20444084658324083" STUDY_ID="STD-Rozen-2003" TOTAL_1="49" TOTAL_2="47" WEIGHT="15.621949004839932"/>
</CONT_SUBGROUP>
<CONT_SUBGROUP CHI2="0.0021632285612830024" CI_END="0.308046380354268" CI_START="-0.29358433063284184" DF="1" EFFECT_SIZE="0.007231024860713113" ESTIMABLE="YES" I2="0.0" ID="CMP-001.24.03" NO="3" P_CHI2="0.9629033602060514" P_Z="0.9624225451597224" STUDIES="2" TAU2="0.0" TOTAL_1="87" TOTAL_2="83" WEIGHT="27.718309262834616" Z="0.04711377939819005">
<NAME>Mixed</NAME>
<CONT_DATA CI_END="0.43698040696836393" CI_START="-0.40842428898937033" EFFECT_SIZE="0.014278058989496793" ESTIMABLE="YES" MEAN_1="956.05" MEAN_2="954.05" ORDER="17110" SD_1="136.72" SD_2="140.89" SE="0.2156684262124658" STUDY_ID="STD-Johnston-1992" TOTAL_1="43" TOTAL_2="43" WEIGHT="14.037747254296471"/>
<CONT_DATA CI_END="0.4281849516340527" CI_START="-0.4281849516340527" EFFECT_SIZE="0.0" ESTIMABLE="YES" MEAN_1="603.0" MEAN_2="603.0" ORDER="17111" SD_1="76.0" SD_2="64.0" SE="0.21846572437632575" STUDY_ID="STD-Lee-1995" TOTAL_1="44" TOTAL_2="40" WEIGHT="13.680562008538146"/>
</CONT_SUBGROUP>
</CONT_OUTCOME>
<CONT_OUTCOME CHI2="1.1583576889270417" CI_END="0.16953284421813042" CI_START="-0.1465114883422407" CI_STUDY="95" CI_TOTAL="95" DF="4" EFFECT_MEASURE="SMD" EFFECT_SIZE="0.011510677937944849" ESTIMABLE="YES" I2="0.0" I2_Q="0.0" ID="CMP-001.25" NO="25" P_CHI2="0.8849060147469565" P_Q="0.8040721756211325" P_Z="0.8864733826880067" Q="0.4361327945799258" RANDOM="NO" SCALE="1.0" SORT_BY="STUDY" STUDIES="5" SUBGROUPS="YES" SUBGROUP_TEST="YES" TAU2="0.0" TOTALS="YES" TOTAL_1="313" TOTAL_2="304" UNITS="" WEIGHT="99.99999999999999" Z="0.1427680351882415">
<NAME>Lumbar spine BMD (mg/cm2) at longest point after supplement ceased by sex</NAME>
<GROUP_LABEL_1>Treatment</GROUP_LABEL_1>
<GROUP_LABEL_2>Control</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours control</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours treatment</GRAPH_LABEL_2>
<CONT_SUBGROUP CHI2="0.0" CI_END="0.30604468824634573" CI_START="-0.21570630455408518" DF="0" EFFECT_SIZE="0.04516919184613029" ESTIMABLE="YES" I2="0.0" ID="CMP-001.25.01" NO="1" P_CHI2="1.0" P_Z="0.7343406251656113" STUDIES="1" TAU2="0.0" TOTAL_1="110" TOTAL_2="116" WEIGHT="36.69183613729448" Z="0.33935724301748765">
<NAME>Male</NAME>
<CONT_DATA CI_END="0.30604468824634573" CI_START="-0.21570630455408518" EFFECT_SIZE="0.04516919184613029" ESTIMABLE="YES" MEAN_1="605.0" MEAN_2="602.5" ORDER="17112" SD_1="52.0" SD_2="58.0" SE="0.13310218884528904" STUDY_ID="STD-Chevalley-2005" TOTAL_1="110" TOTAL_2="116" WEIGHT="36.69183613729448"/>
</CONT_SUBGROUP>
<CONT_SUBGROUP CHI2="0.08024368484309044" CI_END="0.30759611979823087" CI_START="-0.22070786997706918" DF="1" EFFECT_SIZE="0.04344412491058084" ESTIMABLE="YES" I2="0.0" ID="CMP-001.25.02" NO="2" P_CHI2="0.7769674575595417" P_Z="0.7471889221191461" STUDIES="2" TAU2="0.0" TOTAL_1="116" TOTAL_2="105" WEIGHT="35.78724220194163" Z="0.3223482003261557">
<NAME>Female</NAME>
<CONT_DATA CI_END="0.4286491395175547" CI_START="-0.27466106073165153" EFFECT_SIZE="0.07699403939295155" ESTIMABLE="YES" MEAN_1="1019.0" MEAN_2="1014.0" ORDER="17113" SD_1="70.2" SD_2="57.3" SE="0.17941916427975904" STUDY_ID="STD-Bonjour-1995" TOTAL_1="67" TOTAL_2="58" WEIGHT="20.193062121230803"/>
<CONT_DATA CI_END="0.40016282334497716" CI_START="-0.40016282334497716" EFFECT_SIZE="0.0" ESTIMABLE="YES" MEAN_1="1150.0" MEAN_2="1150.0" ORDER="17114" SD_1="140.0" SD_2="137.11" SE="0.2041684574315704" STUDY_ID="STD-Rozen-2003" TOTAL_1="49" TOTAL_2="47" WEIGHT="15.594180080710826"/>
</CONT_SUBGROUP>
<CONT_SUBGROUP CHI2="0.6419812095040255" CI_END="0.22633274440115408" CI_START="-0.37611102855233264" DF="1" EFFECT_SIZE="-0.07488914207558928" ESTIMABLE="YES" I2="0.0" ID="CMP-001.25.03" NO="3" P_CHI2="0.4229945327519281" P_Z="0.6260584611928532" STUDIES="2" TAU2="0.0" TOTAL_1="87" TOTAL_2="83" WEIGHT="27.520921660763875" Z="0.4872820598067356">
<NAME>Mixed</NAME>
<CONT_DATA CI_END="0.46912926150434037" CI_START="-0.3763832168316114" EFFECT_SIZE="0.0463730223363645" ESTIMABLE="YES" MEAN_1="1061.23" MEAN_2="1052.39" ORDER="17115" SD_1="192.31" SD_2="185.47" SE="0.21569592222235875" STUDY_ID="STD-Johnston-1992" TOTAL_1="43" TOTAL_2="43" WEIGHT="13.971916152120873"/>
<CONT_DATA CI_END="0.22936706177064778" CI_START="-0.6292396856883473" EFFECT_SIZE="-0.19993631195884978" ESTIMABLE="YES" MEAN_1="538.0" MEAN_2="551.0" ORDER="17116" SD_1="61.0" SD_2="68.0" SE="0.2190363583799436" STUDY_ID="STD-Lee-1995" TOTAL_1="44" TOTAL_2="40" WEIGHT="13.549005508643"/>
</CONT_SUBGROUP>
</CONT_OUTCOME>
<CONT_OUTCOME CHI2="5.739321705724885" CI_END="0.3215747525208754" CI_START="0.049810873314644954" CI_STUDY="95" CI_TOTAL="95" DF="6" EFFECT_MEASURE="SMD" EFFECT_SIZE="0.18569281291776019" ESTIMABLE="YES" I2="0.0" I2_Q="0.0" ID="CMP-001.26" NO="26" P_CHI2="0.4530158077537374" P_Q="0.646267045017231" P_Z="0.007396662764984777" Q="0.8730850252169446" RANDOM="YES" SCALE="1.0" SORT_BY="STUDY" STUDIES="6" SUBGROUPS="YES" SUBGROUP_TEST="NO" TAU2="0.0" TOTALS="YES" TOTAL_1="421" TOTAL_2="419" UNITS="" WEIGHT="100.0" Z="2.678437079789816">
<NAME>Upper limb BMD (mg/cm2) at longest point after supplement ceased by sex</NAME>
<GROUP_LABEL_1>Treatment</GROUP_LABEL_1>
<GROUP_LABEL_2>Control</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours control</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours treatment</GRAPH_LABEL_2>
<CONT_SUBGROUP CHI2="2.698118374524263" CI_END="0.48992513685209593" CI_START="-0.32323974635558506" DF="1" EFFECT_SIZE="0.08334269524825542" ESTIMABLE="YES" I2="62.937133913691916" ID="CMP-001.26.01" NO="1" P_CHI2="0.10046681984695227" P_Z="0.6878604477276302" STUDIES="2" TAU2="0.05576038585789715" TOTAL_1="151" TOTAL_2="159" WEIGHT="36.96235119949185" Z="0.4017602934763211">
<NAME>Male</NAME>
<CONT_DATA CI_END="0.5201854123124395" CI_START="-0.003704661341557558" EFFECT_SIZE="0.258240375485441" ESTIMABLE="YES" MEAN_1="24.7" MEAN_2="19.4" ORDER="17117" SD_1="21.7" SD_2="19.2" SE="0.1336478827637587" STUDY_ID="STD-Chevalley-2005" TOTAL_1="110" TOTAL_2="116" WEIGHT="26.90934499420822"/>
<CONT_DATA CI_END="0.2658584000112977" CI_START="-0.591265801305108" EFFECT_SIZE="-0.16270370064690512" ESTIMABLE="YES" MEAN_1="497.0" MEAN_2="504.0" ORDER="17118" SD_1="47.0" SD_2="38.0" SE="0.21865815088371315" STUDY_ID="STD-Lee-1994" TOTAL_1="41" TOTAL_2="43" WEIGHT="10.053006205283632"/>
</CONT_SUBGROUP>
<CONT_SUBGROUP CHI2="0.386366399048959" CI_END="0.5812421572712068" CI_START="0.02228478240585119" DF="1" EFFECT_SIZE="0.301763469838529" ESTIMABLE="YES" I2="0.0" ID="CMP-001.26.02" NO="2" P_CHI2="0.5342159363040431" P_Z="0.03432392778299686" STUDIES="2" TAU2="0.0" TOTAL_1="103" TOTAL_2="97" WEIGHT="23.63883585736061" Z="2.1162455647922207">
<NAME>Female</NAME>
<CONT_DATA CI_END="0.7255999910161408" CI_START="0.016372536416859873" EFFECT_SIZE="0.37098626371650034" ESTIMABLE="YES" MEAN_1="429.0" MEAN_2="418.0" ORDER="17119" SD_1="26.32" SD_2="32.74" SE="0.18092869567848607" STUDY_ID="STD-Bonjour-1995" TOTAL_1="67" TOTAL_2="58" WEIGHT="14.682918498331"/>
<CONT_DATA CI_END="0.642328236009215" CI_START="-0.26577807603909887" EFFECT_SIZE="0.18827507998505807" ESTIMABLE="YES" MEAN_1="514.0" MEAN_2="506.0" ORDER="17120" SD_1="41.0" SD_2="43.0" SE="0.23166403036263433" STUDY_ID="STD-Lee-1994" TOTAL_1="36" TOTAL_2="39" WEIGHT="8.955917359029609"/>
</CONT_SUBGROUP>
<CONT_SUBGROUP CHI2="1.7817519069347183" CI_END="0.3718799369612026" CI_START="-0.061082445361413246" DF="2" EFFECT_SIZE="0.15539874579989468" ESTIMABLE="YES" I2="0.0" ID="CMP-001.26.03" NO="3" P_CHI2="0.41029623364075785" P_Z="0.15944532100949513" STUDIES="3" TAU2="0.0" TOTAL_1="167" TOTAL_2="163" WEIGHT="39.39881294314753" Z="1.4069395284486315">
<NAME>Mixed</NAME>
<CONT_DATA CI_END="0.6175167825952239" CI_START="-0.0059803321820287025" EFFECT_SIZE="0.30576822520659763" ESTIMABLE="YES" MEAN_1="256.0" MEAN_2="242.0" ORDER="17121" SD_1="43.0" SD_2="48.0" SE="0.15905830915652489" STUDY_ID="STD-Dibba-2000" TOTAL_1="80" TOTAL_2="80" WEIGHT="18.998292504809726"/>
<CONT_DATA CI_END="0.47390750843088114" CI_START="-0.3716306970386415" EFFECT_SIZE="0.05113840569611985" ESTIMABLE="YES" MEAN_1="365.23" MEAN_2="361.31" ORDER="17122" SD_1="77.08" SD_2="74.84" SE="0.21570248538723671" STUDY_ID="STD-Johnston-1992" TOTAL_1="43" TOTAL_2="43" WEIGHT="10.330396584742054"/>
<CONT_DATA CI_END="0.40686449035579997" CI_START="-0.44953091203190143" EFFECT_SIZE="-0.021333210838050704" ESTIMABLE="YES" MEAN_1="516.0" MEAN_2="517.0" ORDER="17123" SD_1="44.0" SD_2="49.0" SE="0.21847222937330457" STUDY_ID="STD-Lee-1995" TOTAL_1="44" TOTAL_2="40" WEIGHT="10.070123853595753"/>
</CONT_SUBGROUP>
</CONT_OUTCOME>
<CONT_OUTCOME CHI2="5.819573316587783" CI_END="0.1929982820193633" CI_START="-0.06087737569756159" CI_STUDY="95" CI_TOTAL="95" DF="8" EFFECT_MEASURE="SMD" EFFECT_SIZE="0.06606045316090085" ESTIMABLE="YES" I2="0.0" I2_Q="0.0" ID="CMP-001.27" NO="27" P_CHI2="0.6674342572695227" P_Q="0.8864952064943933" P_Z="0.30773025495083695" Q="0.24095913006017078" RANDOM="NO" SCALE="1.0" SORT_BY="STUDY" STUDIES="9" SUBGROUPS="YES" SUBGROUP_TEST="YES" TAU2="0.0" TOTALS="YES" TOTAL_1="470" TOTAL_2="507" UNITS="" WEIGHT="100.0" Z="1.0199962466833163">
<NAME>Femoral neck BMD (mg/cm2) (at end supplementation) by pubertal status</NAME>
<GROUP_LABEL_1>Treatment</GROUP_LABEL_1>
<GROUP_LABEL_2>Control</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours control</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours treatment</GRAPH_LABEL_2>
<CONT_SUBGROUP CHI2="4.605231221881473" CI_END="0.23549570256076136" CI_START="-0.10359290594797205" DF="4" EFFECT_SIZE="0.06595139830639465" ESTIMABLE="YES" I2="13.142254812434913" ID="CMP-001.27.01" NO="1" P_CHI2="0.33025164163823273" P_Z="0.44581502084879554" STUDIES="5" TAU2="0.0" TOTAL_1="259" TOTAL_2="298" WEIGHT="56.055176297999914" Z="0.76241054501399">
<NAME>Pre-pubertal</NAME>
<CONT_DATA CI_END="0.6604385539390247" CI_START="-0.09794154702996843" EFFECT_SIZE="0.2812485034545282" ESTIMABLE="YES" MEAN_1="656.0" MEAN_2="635.0" ORDER="17124" SD_1="81.58" SD_2="65.52" SE="0.19346786648912906" STUDY_ID="STD-Bonjour-1995" TOTAL_1="55" TOTAL_2="53" WEIGHT="11.206455345082311"/>
<CONT_DATA CI_END="0.5507846604584942" CI_START="-0.5808184484700071" EFFECT_SIZE="-0.015016894005756475" ESTIMABLE="YES" MEAN_1="814.0" MEAN_2="816.0" ORDER="17125" SD_1="131.0" SD_2="131.0" SE="0.2886795670365482" STUDY_ID="STD-Cameron-2004" TOTAL_1="24" TOTAL_2="24" WEIGHT="5.033312084948218"/>
<CONT_DATA CI_END="0.17515393035443064" CI_START="-0.3398562006734309" EFFECT_SIZE="-0.08235113515950013" ESTIMABLE="YES" MEAN_1="698.0" MEAN_2="703.7" ORDER="17126" SD_1="70.0" SD_2="68.0" SE="0.13138254965147209" STUDY_ID="STD-Chevalley-2005" TOTAL_1="114" TOTAL_2="118" WEIGHT="24.300240865741277"/>
<CONT_DATA CI_END="0.8977163300128035" CI_START="-0.08113466441638145" EFFECT_SIZE="0.40829083279821105" ESTIMABLE="YES" MEAN_1="772.45" MEAN_2="737.0" ORDER="17127" SD_1="57.43" SD_2="93.77" SE="0.24971147484092482" STUDY_ID="STD-Courteix-2005" TOTAL_1="22" TOTAL_2="63" WEIGHT="6.726806735303874"/>
<CONT_DATA CI_END="0.4140084286058978" CI_START="-0.44237274406664784" EFFECT_SIZE="-0.014182157730375022" ESTIMABLE="YES" MEAN_1="592.0" MEAN_2="593.0" ORDER="17128" SD_1="74.0" SD_2="65.0" SE="0.21846859927722423" STUDY_ID="STD-Lee-1995" TOTAL_1="44" TOTAL_2="40" WEIGHT="8.78836126692423"/>
</CONT_SUBGROUP>
<CONT_SUBGROUP CHI2="0.0" CI_END="0.0" CI_START="0.0" DF="0" EFFECT_SIZE="0.0" ESTIMABLE="NO" I2="0.0" ID="CMP-001.27.02" NO="2" P_CHI2="0.0" P_Z="0.0" STUDIES="0" TAU2="0.0" TOTAL_1="0" TOTAL_2="0" WEIGHT="0.0" Z="0.0">
<NAME>Peri-pubertal</NAME>
</CONT_SUBGROUP>
<CONT_SUBGROUP CHI2="0.887757706417337" CI_END="0.3384549653993418" CI_START="-0.1359383130656664" DF="1" EFFECT_SIZE="0.1012583261668377" ESTIMABLE="YES" I2="0.0" ID="CMP-001.27.03" NO="3" P_CHI2="0.346085781408495" P_Z="0.4027606480783884" STUDIES="2" TAU2="0.0" TOTAL_1="138" TOTAL_2="136" WEIGHT="28.639476091586495" Z="0.8367010302674451">
<NAME>Post-pubertal</NAME>
<CONT_DATA CI_END="0.3203145893001051" CI_START="-0.3354338260641689" EFFECT_SIZE="-0.0075596183820319145" ESTIMABLE="YES" MEAN_1="1001.0" MEAN_2="1002.0" ORDER="17129" SD_1="134.0" SD_2="129.0" SE="0.16728583293793503" STUDY_ID="STD-Prentice-2005" TOTAL_1="73" TOTAL_2="70" WEIGHT="14.988826188827176"/>
<CONT_DATA CI_END="0.5643130591550494" CI_START="-0.12282562247230913" EFFECT_SIZE="0.2207437183413701" ESTIMABLE="YES" MEAN_1="870.0" MEAN_2="847.0" ORDER="17130" SD_1="100.0" SD_2="107.0" SE="0.17529370106987185" STUDY_ID="STD-Stear-2003" TOTAL_1="65" TOTAL_2="66" WEIGHT="13.650649902759321"/>
</CONT_SUBGROUP>
<CONT_SUBGROUP CHI2="0.08562525822880201" CI_END="0.32506355312442736" CI_START="-0.32386885362082596" DF="1" EFFECT_SIZE="5.97349751800724E-4" ESTIMABLE="YES" I2="0.0" ID="CMP-001.27.04" NO="4" P_CHI2="0.7698142131543666" P_Z="0.9971209684069765" STUDIES="2" TAU2="0.0" TOTAL_1="73" TOTAL_2="73" WEIGHT="15.305347610413595" Z="0.003608338827075917">
<NAME>Mixed</NAME>
<CONT_DATA CI_END="0.37562699217396994" CI_START="-0.4508427758870757" EFFECT_SIZE="-0.037607891856552896" ESTIMABLE="YES" MEAN_1="847.72" MEAN_2="852.89" ORDER="17131" SD_1="128.13" SD_2="144.0" SE="0.21083799870307152" STUDY_ID="STD-Johnston-1992" TOTAL_1="45" TOTAL_2="45" WEIGHT="9.436005369211262"/>
<CONT_DATA CI_END="0.5859768774270062" CI_START="-0.46193881656079006" EFFECT_SIZE="0.06201903043310805" ESTIMABLE="YES" MEAN_1="877.0" MEAN_2="871.0" ORDER="17132" SD_1="90.0" SD_2="100.5" SE="0.26733034439755565" STUDY_ID="STD-Nowson-1997" TOTAL_1="28" TOTAL_2="28" WEIGHT="5.8693422412023315"/>
</CONT_SUBGROUP>
</CONT_OUTCOME>
<CONT_OUTCOME CHI2="0.9324267729429164" CI_END="0.20915397552206966" CI_START="-0.03322168556654642" CI_STUDY="95" CI_TOTAL="95" DF="9" EFFECT_MEASURE="SMD" EFFECT_SIZE="0.08796614497776162" ESTIMABLE="YES" I2="0.0" I2_Q="0.0" ID="CMP-001.28" NO="28" P_CHI2="0.999578086745782" P_Q="0.9259541728640016" P_Z="0.15483139814965394" Q="0.15386111530887725" RANDOM="NO" SCALE="1.0" SORT_BY="STUDY" STUDIES="10" SUBGROUPS="YES" SUBGROUP_TEST="YES" TAU2="0.0" TOTALS="YES" TOTAL_1="514" TOTAL_2="554" UNITS="" WEIGHT="100.0" Z="1.4226715276680026">
<NAME>Lumbar spine BMD (mg/cm2) (at end supplementation) by pubertal status</NAME>
<GROUP_LABEL_1>Treatment</GROUP_LABEL_1>
<GROUP_LABEL_2>Control</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours control</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours treatment</GRAPH_LABEL_2>
<CONT_SUBGROUP CHI2="0.40263265121936387" CI_END="0.23360880244489207" CI_START="-0.10487469739603124" DF="4" EFFECT_SIZE="0.06436705252443041" ESTIMABLE="YES" I2="0.0" ID="CMP-001.28.01" NO="1" P_CHI2="0.9822607957818799" P_Z="0.4560145794224879" STUDIES="5" TAU2="0.0" TOTAL_1="259" TOTAL_2="298" WEIGHT="51.274685775973595" Z="0.7454254331343861">
<NAME>Pre-pubertal</NAME>
<CONT_DATA CI_END="0.5114205026835856" CI_START="-0.24397376271812718" EFFECT_SIZE="0.13372336998272924" ESTIMABLE="YES" MEAN_1="647.0" MEAN_2="638.0" ORDER="17133" SD_1="74.16" SD_2="58.24" SE="0.1927061597458337" STUDY_ID="STD-Bonjour-1995" TOTAL_1="55" TOTAL_2="53" WEIGHT="10.295101819716066"/>
<CONT_DATA CI_END="0.6643854658079379" CI_START="-0.4679433402975458" EFFECT_SIZE="0.09822106275519607" ESTIMABLE="YES" MEAN_1="848.0" MEAN_2="833.0" ORDER="17134" SD_1="158.0" SD_2="142.0" SE="0.2888646972692225" STUDY_ID="STD-Cameron-2004" TOTAL_1="24" TOTAL_2="24" WEIGHT="4.581765964181667"/>
<CONT_DATA CI_END="0.27186034181968627" CI_START="-0.24293478100807947" EFFECT_SIZE="0.014462780405803406" ESTIMABLE="YES" MEAN_1="586.9" MEAN_2="586.1" ORDER="17135" SD_1="52.0" SD_2="58.0" SE="0.1313276996129531" STUDY_ID="STD-Chevalley-2005" TOTAL_1="114" TOTAL_2="118" WEIGHT="22.167114563778817"/>
<CONT_DATA CI_END="0.6270434570242918" CI_START="-0.3446758722743443" EFFECT_SIZE="0.1411837923749737" ESTIMABLE="YES" MEAN_1="740.64" MEAN_2="726.67" ORDER="17136" SD_1="65.03" SD_2="106.95" SE="0.2478921390809816" STUDY_ID="STD-Courteix-2005" TOTAL_1="22" TOTAL_2="63" WEIGHT="6.221517539479744"/>
<CONT_DATA CI_END="0.4625164252125683" CI_START="-0.393919388343527" EFFECT_SIZE="0.034298518434520614" ESTIMABLE="YES" MEAN_1="525.0" MEAN_2="523.0" ORDER="17137" SD_1="61.0" SD_2="54.0" SE="0.21848253853426688" STUDY_ID="STD-Lee-1995" TOTAL_1="44" TOTAL_2="40" WEIGHT="8.009185888817301"/>
</CONT_SUBGROUP>
<CONT_SUBGROUP CHI2="0.0" CI_END="0.0" CI_START="0.0" DF="0" EFFECT_SIZE="0.0" ESTIMABLE="NO" I2="0.0" ID="CMP-001.28.02" NO="2" P_CHI2="0.0" P_Z="0.0" STUDIES="0" TAU2="0.0" TOTAL_1="0" TOTAL_2="0" WEIGHT="0.0" Z="0.0">
<NAME>Peri-pubertal</NAME>
</CONT_SUBGROUP>
<CONT_SUBGROUP CHI2="0.016753497614296228" CI_END="0.351812181224459" CI_START="-0.12228035213035512" DF="1" EFFECT_SIZE="0.11476591454705196" ESTIMABLE="YES" I2="0.0" ID="CMP-001.28.03" NO="3" P_CHI2="0.8970132196102168" P_Z="0.3426632105829328" STUDIES="2" TAU2="0.0" TOTAL_1="138" TOTAL_2="136" WEIGHT="26.13676194124801" Z="0.9489162698821871">
<NAME>Post-pubertal</NAME>
<CONT_DATA CI_END="0.45798631527414724" CI_START="-0.1984686132330601" EFFECT_SIZE="0.12975885102054358" ESTIMABLE="YES" MEAN_1="1047.0" MEAN_2="1032.0" ORDER="17138" SD_1="114.0" SD_2="116.0" SE="0.1674660691944444" STUDY_ID="STD-Prentice-2005" TOTAL_1="73" TOTAL_2="70" WEIGHT="13.632270240288758"/>
<CONT_DATA CI_END="0.4411301457213726" CI_START="-0.24428861169722987" EFFECT_SIZE="0.09842076701207135" ESTIMABLE="YES" MEAN_1="999.0" MEAN_2="989.0" ORDER="17139" SD_1="100.0" SD_2="102.0" SE="0.17485493683177297" STUDY_ID="STD-Stear-2003" TOTAL_1="65" TOTAL_2="66" WEIGHT="12.504491700959251"/>
</CONT_SUBGROUP>
<CONT_SUBGROUP CHI2="0.35917950880037913" CI_END="0.3655103255646107" CI_START="-0.14445988492367434" DF="2" EFFECT_SIZE="0.1105252203204682" ESTIMABLE="YES" I2="0.0" ID="CMP-001.28.04" NO="4" P_CHI2="0.8356129875971554" P_Z="0.3955691015233149" STUDIES="3" TAU2="0.0" TOTAL_1="117" TOTAL_2="120" WEIGHT="22.588552282778387" Z="0.8495611969336727">
<NAME>Mixed</NAME>
<CONT_DATA CI_END="0.434960444536277" CI_START="-0.39145848587210075" EFFECT_SIZE="0.021750979332088152" ESTIMABLE="YES" MEAN_1="907.36" MEAN_2="902.96" ORDER="17140" SD_1="197.32" SD_2="203.75" SE="0.2108250296758167" STUDY_ID="STD-Johnston-1992" TOTAL_1="45" TOTAL_2="45" WEIGHT="8.601565477451762"/>
<CONT_DATA CI_END="0.6124201908396137" CI_START="-0.21201494446981703" EFFECT_SIZE="0.20020262318489837" ESTIMABLE="YES" MEAN_1="914.0" MEAN_2="894.0" ORDER="17141" SD_1="83.0" SD_2="112.0" SE="0.21031895019818475" STUDY_ID="STD-Lloyd-1993" TOTAL_1="44" TOTAL_2="47" WEIGHT="8.643010274020794"/>
<CONT_DATA CI_END="0.6326118992120395" CI_START="-0.4158598560902002" EFFECT_SIZE="0.10837602156091967" ESTIMABLE="YES" MEAN_1="1017.0" MEAN_2="1001.0" ORDER="17142" SD_1="148.2" SD_2="142.9" SE="0.2674721993803078" STUDY_ID="STD-Nowson-1997" TOTAL_1="28" TOTAL_2="28" WEIGHT="5.34397653130583"/>
</CONT_SUBGROUP>
</CONT_OUTCOME>
<CONT_OUTCOME CHI2="4.0254304314711336" CI_END="0.29287173942204225" CI_START="0.020461897518635086" CI_STUDY="95" CI_TOTAL="95" DF="7" EFFECT_MEASURE="SMD" EFFECT_SIZE="0.15666681847033867" ESTIMABLE="YES" I2="0.0" I2_Q="0.0" ID="CMP-001.29" NO="29" P_CHI2="0.7768437863553843" P_Q="0.9669242490551808" P_Z="0.024170577843024187" Q="0.06727024598394671" RANDOM="NO" SCALE="1.0" SORT_BY="STUDY" STUDIES="8" SUBGROUPS="YES" SUBGROUP_TEST="YES" TAU2="0.0" TOTALS="YES" TOTAL_1="400" TOTAL_2="453" UNITS="" WEIGHT="100.0" Z="2.2544069599601184">
<NAME>Total body BMC (mg) (at end supplementation) by pubertal status</NAME>
<GROUP_LABEL_1>Treatment</GROUP_LABEL_1>
<GROUP_LABEL_2>Control</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours control</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours treatment</GRAPH_LABEL_2>
<CONT_SUBGROUP CHI2="3.173736453606219" CI_END="0.4105854025409188" CI_START="-0.05063883713488945" DF="2" EFFECT_SIZE="0.17997328270301466" ESTIMABLE="YES" I2="36.98279522461729" ID="CMP-001.29.01" NO="1" P_CHI2="0.2045653854600339" P_Z="0.12611914853401382" STUDIES="3" TAU2="0.0" TOTAL_1="134" TOTAL_2="177" WEIGHT="34.88360346997368" Z="1.5295863570626467">
<NAME>Pre-pubertal</NAME>
<CONT_DATA CI_END="0.7244128544136019" CI_START="-0.4090865084137309" EFFECT_SIZE="0.15766317299993554" ESTIMABLE="YES" MEAN_1="1583.0" MEAN_2="1512.0" ORDER="17143" SD_1="504.0" SD_2="372.0" SE="0.289163314165013" STUDY_ID="STD-Cameron-2004" TOTAL_1="24" TOTAL_2="24" WEIGHT="5.775678728616943"/>
<CONT_DATA CI_END="1.0623077058025256" CI_START="0.07587704885842766" EFFECT_SIZE="0.5690923773304767" ESTIMABLE="YES" MEAN_1="1340.9" MEAN_2="1186.1" ORDER="17144" SD_1="216.37" SD_2="285.32" SE="0.2516450977479528" STUDY_ID="STD-Courteix-2005" TOTAL_1="22" TOTAL_2="63" WEIGHT="7.626275078447596"/>
<CONT_DATA CI_END="0.3417017087255969" CI_START="-0.24604334021365062" EFFECT_SIZE="0.047829184255973135" ESTIMABLE="YES" MEAN_1="685.55" MEAN_2="681.5" ORDER="17145" SD_1="88.0" SD_2="80.55" SE="0.1499377166048217" STUDY_ID="STD-Specker-2003" TOTAL_1="88" TOTAL_2="90" WEIGHT="21.48164966290914"/>
</CONT_SUBGROUP>
<CONT_SUBGROUP CHI2="0.0" CI_END="0.0" CI_START="0.0" DF="0" EFFECT_SIZE="0.0" ESTIMABLE="NO" I2="0.0" ID="CMP-001.29.02" NO="2" P_CHI2="0.0" P_Z="0.0" STUDIES="0" TAU2="0.0" TOTAL_1="0" TOTAL_2="0" WEIGHT="0.0" Z="0.0">
<NAME>Peri-pubertal</NAME>
</CONT_SUBGROUP>
<CONT_SUBGROUP CHI2="0.4118767739094761" CI_END="0.374278690305324" CI_START="-0.10016203938501148" DF="1" EFFECT_SIZE="0.13705832546015626" ESTIMABLE="YES" I2="0.0" ID="CMP-001.29.03" NO="3" P_CHI2="0.5210184783753486" P_Z="0.2574644803333357" STUDIES="2" TAU2="0.0" TOTAL_1="138" TOTAL_2="136" WEIGHT="32.96716926768515" Z="1.132404386354469">
<NAME>Post-pubertal</NAME>
<CONT_DATA CI_END="0.3908635962567637" CI_START="-0.26504909971456003" EFFECT_SIZE="0.06290724827110186" ESTIMABLE="YES" MEAN_1="2796.0" MEAN_2="2770.0" ORDER="17146" SD_1="415.0" SD_2="407.0" SE="0.1673277420261493" STUDY_ID="STD-Prentice-2005" TOTAL_1="73" TOTAL_2="70" WEIGHT="17.248586611389022"/>
<CONT_DATA CI_END="0.5619740238730728" CI_START="-0.12511989143932517" EFFECT_SIZE="0.21842706621687386" ESTIMABLE="YES" MEAN_1="2143.0" MEAN_2="2088.0" ORDER="17147" SD_1="265.0" SD_2="235.0" SE="0.175282280881717" STUDY_ID="STD-Stear-2003" TOTAL_1="65" TOTAL_2="66" WEIGHT="15.718582656296132"/>
</CONT_SUBGROUP>
<CONT_SUBGROUP CHI2="0.3725469579714916" CI_END="0.3917045478473037" CI_START="-0.0887336451067117" DF="2" EFFECT_SIZE="0.151485451370296" ESTIMABLE="YES" I2="0.0" ID="CMP-001.29.04" NO="4" P_CHI2="0.8300466131177006" P_Z="0.21646597511624166" STUDIES="3" TAU2="0.0" TOTAL_1="128" TOTAL_2="140" WEIGHT="32.14922726234117" Z="1.2359801249023181">
<NAME>Mixed</NAME>
<CONT_DATA CI_END="0.6238360632229405" CI_START="-0.3464242431167532" EFFECT_SIZE="0.13870591005309368" ESTIMABLE="YES" MEAN_1="1179.57" MEAN_2="1151.25" ORDER="17148" SD_1="209.01" SD_2="195.57" SE="0.2475199325071744" STUDY_ID="STD-Iuliano_x002d_Burns-2003" TOTAL_1="30" TOTAL_2="36" WEIGHT="7.882592197197698"/>
<CONT_DATA CI_END="0.6634749996606573" CI_START="-0.16217650854283872" EFFECT_SIZE="0.2506492455589093" ESTIMABLE="YES" MEAN_1="1783.0" MEAN_2="1714.0" ORDER="17149" SD_1="238.0" SD_2="302.0" SE="0.21062925510777997" STUDY_ID="STD-Lloyd-1993" TOTAL_1="44" TOTAL_2="47" WEIGHT="10.88559146376518"/>
<CONT_DATA CI_END="0.4506900805835923" CI_START="-0.29400382768340283" EFFECT_SIZE="0.07834312645009475" ESTIMABLE="YES" MEAN_1="1932.11" MEAN_2="1907.53" ORDER="17150" SD_1="292.33" SD_2="328.77" SE="0.18997642664381734" STUDY_ID="STD-Molgaard-2004" TOTAL_1="54" TOTAL_2="57" WEIGHT="13.38104360137829"/>
</CONT_SUBGROUP>
</CONT_OUTCOME>
<CONT_OUTCOME CHI2="8.073176705722247" CI_END="0.2721437986696752" CI_START="0.036867948161045244" CI_STUDY="95" CI_TOTAL="95" DF="8" EFFECT_MEASURE="SMD" EFFECT_SIZE="0.1545058734153602" ESTIMABLE="YES" I2="0.9064177385140044" I2_Q="0.0" ID="CMP-001.30" NO="30" P_CHI2="0.4263549182299098" P_Q="0.4502459721093486" P_Z="0.01004662511823081" Q="2.641584056259047" RANDOM="NO" SCALE="1.0" SORT_BY="STUDY" STUDIES="9" SUBGROUPS="YES" SUBGROUP_TEST="YES" TAU2="0.0" TOTALS="YES" TOTAL_1="542" TOTAL_2="598" UNITS="" WEIGHT="100.00000000000001" Z="2.574220402470954">
<NAME>Distal radius BMD (mg/cm2) (at end supplementation) by pubertal status</NAME>
<GROUP_LABEL_1>Treatment</GROUP_LABEL_1>
<GROUP_LABEL_2>Control</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours control</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours treatment</GRAPH_LABEL_2>
<CONT_SUBGROUP CHI2="2.3269249187859313" CI_END="0.274430231901482" CI_START="-0.10929075846902862" DF="3" EFFECT_SIZE="0.08256973671622671" ESTIMABLE="YES" I2="0.0" ID="CMP-001.30.01" NO="1" P_CHI2="0.50738258343097" P_Z="0.39895067342166846" STUDIES="4" TAU2="0.0" TOTAL_1="200" TOTAL_2="239" WEIGHT="37.59443745928467" Z="0.8434967814530898">
<NAME>Pre-pubertal</NAME>
<CONT_DATA CI_END="0.5128125613720704" CI_START="-0.24259987277088774" EFFECT_SIZE="0.13510634430059137" ESTIMABLE="YES" MEAN_1="312.0" MEAN_2="308.0" ORDER="17151" SD_1="29.66" SD_2="29.12" SE="0.1927107947139731" STUDY_ID="STD-Bonjour-1995" TOTAL_1="55" TOTAL_2="53" WEIGHT="9.700328592044865"/>
<CONT_DATA CI_END="0.2574725427227148" CI_START="-0.7158349449146524" EFFECT_SIZE="-0.2291812010959688" ESTIMABLE="YES" MEAN_1="336.18" MEAN_2="351.0" ORDER="17152" SD_1="43.19" SD_2="69.75" SE="0.24829728895905548" STUDY_ID="STD-Courteix-2005" TOTAL_1="22" TOTAL_2="63" WEIGHT="5.843251446728712"/>
<CONT_DATA CI_END="0.4501644946278604" CI_START="-0.40623244295249933" EFFECT_SIZE="0.02196602583768056" ESTIMABLE="YES" MEAN_1="492.0" MEAN_2="491.0" ORDER="17153" SD_1="39.0" SD_2="51.0" SE="0.2184726210112812" STUDY_ID="STD-Lee-1995" TOTAL_1="44" TOTAL_2="40" WEIGHT="7.547523829023321"/>
<CONT_DATA CI_END="0.5134677994735729" CI_START="-0.10432584171130158" EFFECT_SIZE="0.20457097888113565" ESTIMABLE="YES" MEAN_1="486.0" MEAN_2="479.0" ORDER="17154" SD_1="37.0" SD_2="31.0" SE="0.15760331466750202" STUDY_ID="STD-Wang-1996" TOTAL_1="79" TOTAL_2="83" WEIGHT="14.50333359148777"/>
</CONT_SUBGROUP>
<CONT_SUBGROUP CHI2="3.3467244517032986E-32" CI_END="0.5300115286945037" CI_START="-0.06471641800366132" DF="0" EFFECT_SIZE="0.23264755534542123" ESTIMABLE="YES" I2="100.00000000000001" ID="CMP-001.30.02" NO="2" P_CHI2="0.0" P_Z="0.12517491671720213" STUDIES="1" TAU2="0.0" TOTAL_1="79" TOTAL_2="98" WEIGHT="15.650132200857508" Z="1.5334097955202797">
<NAME>Peri-pubertal</NAME>
<CONT_DATA CI_END="0.5300115286945037" CI_START="-0.06471641800366129" EFFECT_SIZE="0.23264755534542125" ESTIMABLE="YES" MEAN_1="450.0" MEAN_2="438.0" ORDER="17155" SD_1="53.0" SD_2="50.0" SE="0.15171910080728607" STUDY_ID="STD-Matkovic-2004" TOTAL_1="79" TOTAL_2="98" WEIGHT="15.650132200857508"/>
</CONT_SUBGROUP>
<CONT_SUBGROUP CHI2="1.2727072058354556" CI_END="0.31457003129536165" CI_START="-0.15986491063938701" DF="1" EFFECT_SIZE="0.07735256032798732" ESTIMABLE="YES" I2="21.427332585615382" ID="CMP-001.30.03" NO="3" P_CHI2="0.25925952562024335" P_Z="0.5227509002858703" STUDIES="2" TAU2="0.0" TOTAL_1="138" TOTAL_2="136" WEIGHT="24.59242580495527" Z="0.6391107355480928">
<NAME>Post-pubertal</NAME>
<CONT_DATA CI_END="0.2749570234978052" CI_START="-0.38090719667338463" EFFECT_SIZE="-0.05297508658778973" ESTIMABLE="YES" MEAN_1="479.0" MEAN_2="482.0" ORDER="17156" SD_1="61.0" SD_2="51.0" SE="0.16731537552336753" STUDY_ID="STD-Prentice-2005" TOTAL_1="73" TOTAL_2="70" WEIGHT="12.868467372323614"/>
<CONT_DATA CI_END="0.5639690051480064" CI_START="-0.12316306254107401" EFFECT_SIZE="0.2204029713034662" ESTIMABLE="YES" MEAN_1="427.0" MEAN_2="418.0" ORDER="17157" SD_1="38.0" SD_2="43.0" SE="0.17529201380971549" STUDY_ID="STD-Stear-2003" TOTAL_1="65" TOTAL_2="66" WEIGHT="11.723958432631655"/>
</CONT_SUBGROUP>
<CONT_SUBGROUP CHI2="1.8319605248418132" CI_END="0.5568416344741518" CI_START="0.05707986066997489" DF="1" EFFECT_SIZE="0.3069607475720633" ESTIMABLE="YES" I2="45.41367095852961" ID="CMP-001.30.04" NO="4" P_CHI2="0.175896321405263" P_Z="0.016054457767487887" STUDIES="2" TAU2="0.0" TOTAL_1="125" TOTAL_2="125" WEIGHT="22.16300453490257" Z="2.4076751822338225">
<NAME>Mixed</NAME>
<CONT_DATA CI_END="0.7515904462890333" CI_START="0.12422571852871639" EFFECT_SIZE="0.4379080824088748" ESTIMABLE="YES" MEAN_1="253.0" MEAN_2="231.0" ORDER="17158" SD_1="50.0" SD_2="50.0" SE="0.16004496325159281" STUDY_ID="STD-Dibba-2000" TOTAL_1="80" TOTAL_2="80" WEIGHT="14.064182994645218"/>
<CONT_DATA CI_END="0.4929289406242539" CI_START="-0.3338062753225926" EFFECT_SIZE="0.07956133265083067" ESTIMABLE="YES" MEAN_1="317.09" MEAN_2="311.51" ORDER="17159" SD_1="69.4" SD_2="69.67" SE="0.2109057162447954" STUDY_ID="STD-Johnston-1992" TOTAL_1="45" TOTAL_2="45" WEIGHT="8.098821540257351"/>
</CONT_SUBGROUP>
</CONT_OUTCOME>
<CONT_OUTCOME CHI2="8.690639421510731" CI_END="0.237153842673891" CI_START="0.037921792367907534" CI_STUDY="95" CI_TOTAL="95" DF="11" EFFECT_MEASURE="SMD" EFFECT_SIZE="0.13753781752089927" ESTIMABLE="YES" I2="0.0" I2_Q="0.0" ID="CMP-001.31" NO="31" P_CHI2="0.6504234741691632" P_Q="0.4046921438394353" P_Z="0.006808215777498085" Q="2.916419334620981" RANDOM="NO" SCALE="1.0" SORT_BY="STUDY" STUDIES="12" SUBGROUPS="YES" SUBGROUP_TEST="YES" TAU2="0.0" TOTALS="YES" TOTAL_1="757" TOTAL_2="822" UNITS="" WEIGHT="100.0" Z="2.7060823641497076">
<NAME>Upper limb BMD (mg/cm2) (at end supplementation) by pubertal status</NAME>
<GROUP_LABEL_1>Treatment</GROUP_LABEL_1>
<GROUP_LABEL_2>Control</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours control</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours treatment</GRAPH_LABEL_2>
<CONT_SUBGROUP CHI2="2.669552356212481" CI_END="0.22271283002550896" CI_START="-0.045321622039372664" DF="6" EFFECT_SIZE="0.08869560399306815" ESTIMABLE="YES" I2="0.0" ID="CMP-001.31.01" NO="1" P_CHI2="0.8490303829833945" P_Z="0.19458023599776877" STUDIES="7" TAU2="0.0" TOTAL_1="415" TOTAL_2="463" WEIGHT="55.25062160844481" Z="1.297148094763281">
<NAME>Pre-pubertal</NAME>
<CONT_DATA CI_END="0.5128125613720704" CI_START="-0.24259987277088774" EFFECT_SIZE="0.13510634430059137" ESTIMABLE="YES" MEAN_1="312.0" MEAN_2="308.0" ORDER="17160" SD_1="29.66" SD_2="29.12" SE="0.1927107947139731" STUDY_ID="STD-Bonjour-1995" TOTAL_1="55" TOTAL_2="53" WEIGHT="6.955849078431553"/>
<CONT_DATA CI_END="0.6586912100157563" CI_START="-0.47355455217399833" EFFECT_SIZE="0.09256832892087895" ESTIMABLE="YES" MEAN_1="418.0" MEAN_2="414.0" ORDER="17161" SD_1="43.0" SD_2="42.0" SE="0.28884351220756216" STUDY_ID="STD-Cameron-2004" TOTAL_1="24" TOTAL_2="24" WEIGHT="3.0962569962613915"/>
<CONT_DATA CI_END="0.30378712152378146" CI_START="-0.211071470037911" EFFECT_SIZE="0.046357825742935246" ESTIMABLE="YES" MEAN_1="309.6" MEAN_2="308.2" ORDER="17162" SD_1="28.0" SD_2="32.0" SE="0.13134389091402476" STUDY_ID="STD-Chevalley-2005" TOTAL_1="114" TOTAL_2="118" WEIGHT="14.974160370613857"/>
<CONT_DATA CI_END="0.2574725427227148" CI_START="-0.7158349449146524" EFFECT_SIZE="-0.2291812010959688" ESTIMABLE="YES" MEAN_1="336.18" MEAN_2="351.0" ORDER="17163" SD_1="43.19" SD_2="69.75" SE="0.24829728895905548" STUDY_ID="STD-Courteix-2005" TOTAL_1="22" TOTAL_2="63" WEIGHT="4.190041069753462"/>
<CONT_DATA CI_END="0.4772672773224417" CI_START="-0.14587387711583635" EFFECT_SIZE="0.16569670010330265" ESTIMABLE="YES" MEAN_1="487.0" MEAN_2="480.0" ORDER="17164" SD_1="41.0" SD_2="43.0" SE="0.15896750127898673" STUDY_ID="STD-Lee-1994" TOTAL_1="77" TOTAL_2="82" WEIGHT="10.222227439652531"/>
<CONT_DATA CI_END="0.4501644946278604" CI_START="-0.40623244295249933" EFFECT_SIZE="0.02196602583768056" ESTIMABLE="YES" MEAN_1="492.0" MEAN_2="491.0" ORDER="17165" SD_1="39.0" SD_2="51.0" SE="0.2184726210112812" STUDY_ID="STD-Lee-1995" TOTAL_1="44" TOTAL_2="40" WEIGHT="5.412129720389707"/>
<CONT_DATA CI_END="0.5134677994735729" CI_START="-0.10432584171130158" EFFECT_SIZE="0.20457097888113565" ESTIMABLE="YES" MEAN_1="486.0" MEAN_2="479.0" ORDER="17166" SD_1="37.0" SD_2="31.0" SE="0.15760331466750202" STUDY_ID="STD-Wang-1996" TOTAL_1="79" TOTAL_2="83" WEIGHT="10.399956933342306"/>
</CONT_SUBGROUP>
<CONT_SUBGROUP CHI2="3.3467244517032986E-32" CI_END="0.5300115286945037" CI_START="-0.06471641800366132" DF="0" EFFECT_SIZE="0.23264755534542123" ESTIMABLE="YES" I2="100.00000000000001" ID="CMP-001.31.02" NO="2" P_CHI2="0.0" P_Z="0.12517491671720213" STUDIES="1" TAU2="0.0" TOTAL_1="79" TOTAL_2="98" WEIGHT="11.222295885516864" Z="1.5334097955202797">
<NAME>Peri-pubertal</NAME>
<CONT_DATA CI_END="0.5300115286945037" CI_START="-0.06471641800366129" EFFECT_SIZE="0.23264755534542125" ESTIMABLE="YES" MEAN_1="450.0" MEAN_2="438.0" ORDER="17167" SD_1="53.0" SD_2="50.0" SE="0.15171910080728607" STUDY_ID="STD-Matkovic-2004" TOTAL_1="79" TOTAL_2="98" WEIGHT="11.222295885516864"/>
</CONT_SUBGROUP>
<CONT_SUBGROUP CHI2="1.2727072058354556" CI_END="0.31457003129536165" CI_START="-0.15986491063938701" DF="1" EFFECT_SIZE="0.07735256032798732" ESTIMABLE="YES" I2="21.427332585615382" ID="CMP-001.31.03" NO="3" P_CHI2="0.25925952562024335" P_Z="0.5227509002858703" STUDIES="2" TAU2="0.0" TOTAL_1="138" TOTAL_2="136" WEIGHT="17.634578122650396" Z="0.6391107355480928">
<NAME>Post-pubertal</NAME>
<CONT_DATA CI_END="0.2749570234978052" CI_START="-0.38090719667338463" EFFECT_SIZE="-0.05297508658778973" ESTIMABLE="YES" MEAN_1="479.0" MEAN_2="482.0" ORDER="17168" SD_1="61.0" SD_2="51.0" SE="0.16731537552336753" STUDY_ID="STD-Prentice-2005" TOTAL_1="73" TOTAL_2="70" WEIGHT="9.227637606628175"/>
<CONT_DATA CI_END="0.5639690051480064" CI_START="-0.12316306254107401" EFFECT_SIZE="0.2204029713034662" ESTIMABLE="YES" MEAN_1="427.0" MEAN_2="418.0" ORDER="17169" SD_1="38.0" SD_2="43.0" SE="0.17529201380971549" STUDY_ID="STD-Stear-2003" TOTAL_1="65" TOTAL_2="66" WEIGHT="8.40694051602222"/>
</CONT_SUBGROUP>
<CONT_SUBGROUP CHI2="1.8319605248418132" CI_END="0.5568416344741518" CI_START="0.05707986066997489" DF="1" EFFECT_SIZE="0.3069607475720633" ESTIMABLE="YES" I2="45.41367095852961" ID="CMP-001.31.04" NO="4" P_CHI2="0.175896321405263" P_Z="0.016054457767487887" STUDIES="2" TAU2="0.0" TOTAL_1="125" TOTAL_2="125" WEIGHT="15.89250438338794" Z="2.4076751822338225">
<NAME>Mixed</NAME>
<CONT_DATA CI_END="0.7515904462890333" CI_START="0.12422571852871639" EFFECT_SIZE="0.4379080824088748" ESTIMABLE="YES" MEAN_1="253.0" MEAN_2="231.0" ORDER="17170" SD_1="50.0" SD_2="50.0" SE="0.16004496325159281" STUDY_ID="STD-Dibba-2000" TOTAL_1="80" TOTAL_2="80" WEIGHT="10.085053655030164"/>
<CONT_DATA CI_END="0.4929289406242539" CI_START="-0.3338062753225926" EFFECT_SIZE="0.07956133265083067" ESTIMABLE="YES" MEAN_1="317.09" MEAN_2="311.51" ORDER="17171" SD_1="69.4" SD_2="69.67" SE="0.2109057162447954" STUDY_ID="STD-Johnston-1992" TOTAL_1="45" TOTAL_2="45" WEIGHT="5.807450728357776"/>
</CONT_SUBGROUP>
</CONT_OUTCOME>
<CONT_OUTCOME CHI2="4.921287489611905" CI_END="0.18671739842304624" CI_START="-0.08784590647983265" CI_STUDY="95" CI_TOTAL="95" DF="6" EFFECT_MEASURE="SMD" EFFECT_SIZE="0.049435745971606805" ESTIMABLE="YES" I2="0.0" I2_Q="0.0" ID="CMP-001.32" NO="32" P_CHI2="0.5539476576620701" P_Q="0.937833534475426" P_Z="0.4803175499712099" Q="0.1283656469520018" RANDOM="NO" SCALE="1.0" SORT_BY="STUDY" STUDIES="7" SUBGROUPS="YES" SUBGROUP_TEST="YES" TAU2="0.0" TOTALS="YES" TOTAL_1="402" TOTAL_2="436" UNITS="" WEIGHT="100.0" Z="0.7057919242886013">
<NAME>Femoral neck BMD (mg/cm2) (at end supplementation) by ethnicity</NAME>
<GROUP_LABEL_1>Treatment</GROUP_LABEL_1>
<GROUP_LABEL_2>Control</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours control</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours treatment</GRAPH_LABEL_2>
<CONT_SUBGROUP CHI2="4.792921842659903" CI_END="0.20691702763447953" CI_START="-0.1040353145235233" DF="4" EFFECT_SIZE="0.05144085655547811" ESTIMABLE="YES" I2="16.543600515293605" ID="CMP-001.32.01" NO="1" P_CHI2="0.30921263150902956" P_Z="0.5166785438872843" STUDIES="5" TAU2="0.0" TOTAL_1="309" TOTAL_2="349" WEIGHT="77.9645762619359" Z="0.6484738174533377">
<NAME>Caucasian</NAME>
<CONT_DATA CI_END="0.6604385539390247" CI_START="-0.09794154702996843" EFFECT_SIZE="0.2812485034545282" ESTIMABLE="YES" MEAN_1="656.0" MEAN_2="635.0" ORDER="17172" SD_1="81.58" SD_2="65.52" SE="0.19346786648912906" STUDY_ID="STD-Bonjour-1995" TOTAL_1="55" TOTAL_2="53" WEIGHT="13.107236310007801"/>
<CONT_DATA CI_END="0.17515393035443064" CI_START="-0.3398562006734309" EFFECT_SIZE="-0.08235113515950013" ESTIMABLE="YES" MEAN_1="698.0" MEAN_2="703.7" ORDER="17173" SD_1="70.0" SD_2="68.0" SE="0.13138254965147209" STUDY_ID="STD-Chevalley-2005" TOTAL_1="114" TOTAL_2="118" WEIGHT="28.421921973494467"/>
<CONT_DATA CI_END="0.8977163300128035" CI_START="-0.08113466441638145" EFFECT_SIZE="0.40829083279821105" ESTIMABLE="YES" MEAN_1="772.45" MEAN_2="737.0" ORDER="17174" SD_1="57.43" SD_2="93.77" SE="0.24971147484092482" STUDY_ID="STD-Courteix-2005" TOTAL_1="22" TOTAL_2="63" WEIGHT="7.867772884141391"/>
<CONT_DATA CI_END="0.37562699217396994" CI_START="-0.4508427758870757" EFFECT_SIZE="-0.037607891856552896" ESTIMABLE="YES" MEAN_1="847.72" MEAN_2="852.89" ORDER="17175" SD_1="128.13" SD_2="144.0" SE="0.21083799870307152" STUDY_ID="STD-Johnston-1992" TOTAL_1="45" TOTAL_2="45" WEIGHT="11.036491770881723"/>
<CONT_DATA CI_END="0.3203145893001051" CI_START="-0.3354338260641689" EFFECT_SIZE="-0.0075596183820319145" ESTIMABLE="YES" MEAN_1="1001.0" MEAN_2="1002.0" ORDER="17176" SD_1="134.0" SD_2="129.0" SE="0.16728583293793503" STUDY_ID="STD-Prentice-2005" TOTAL_1="73" TOTAL_2="70" WEIGHT="17.531153323410525"/>
</CONT_SUBGROUP>
<CONT_SUBGROUP CHI2="0.0" CI_END="0.4140084286058978" CI_START="-0.44237274406664784" DF="0" EFFECT_SIZE="-0.014182157730375022" ESTIMABLE="YES" I2="0.0" ID="CMP-001.32.02" NO="2" P_CHI2="1.0" P_Z="0.9482406985725651" STUDIES="1" TAU2="0.0" TOTAL_1="44" TOTAL_2="40" WEIGHT="10.27899762736701" Z="0.0649162295052694">
<NAME>Chinese</NAME>
<CONT_DATA CI_END="0.4140084286058978" CI_START="-0.44237274406664784" EFFECT_SIZE="-0.014182157730375022" ESTIMABLE="YES" MEAN_1="592.0" MEAN_2="593.0" ORDER="17177" SD_1="74.0" SD_2="65.0" SE="0.21846859927722423" STUDY_ID="STD-Lee-1995" TOTAL_1="44" TOTAL_2="40" WEIGHT="10.27899762736701"/>
</CONT_SUBGROUP>
<CONT_SUBGROUP CHI2="0.0" CI_END="0.4921438634140949" CI_START="-0.3086206789419552" DF="0" EFFECT_SIZE="0.09176159223606986" ESTIMABLE="YES" I2="0.0" ID="CMP-001.32.03" NO="3" P_CHI2="1.0" P_Z="0.6532915329397968" STUDIES="1" TAU2="0.0" TOTAL_1="49" TOTAL_2="47" WEIGHT="11.756426110697097" Z="0.4491942548244834">
<NAME>Other</NAME>
<CONT_DATA CI_END="0.4921438634140949" CI_START="-0.3086206789419552" EFFECT_SIZE="0.09176159223606986" ESTIMABLE="YES" MEAN_1="1010.0" MEAN_2="1000.0" ORDER="17178" SD_1="70.0" SD_2="137.0" SE="0.2042804226690844" STUDY_ID="STD-Rozen-2003" TOTAL_1="49" TOTAL_2="47" WEIGHT="11.756426110697097"/>
</CONT_SUBGROUP>
</CONT_OUTCOME>
<CONT_OUTCOME CHI2="1.0713394151170839" CI_END="0.20547939875084337" CI_START="-0.054761714579848575" CI_STUDY="95" CI_TOTAL="95" DF="7" EFFECT_MEASURE="SMD" EFFECT_SIZE="0.0753588420854974" ESTIMABLE="YES" I2="0.0" I2_Q="0.0" ID="CMP-001.33" NO="33" P_CHI2="0.9935942076633952" P_Q="0.9000193574605393" P_Z="0.25633095313144383" Q="0.2106780190523332" RANDOM="NO" SCALE="1.0" SORT_BY="STUDY" STUDIES="8" SUBGROUPS="YES" SUBGROUP_TEST="YES" TAU2="0.0" TOTALS="YES" TOTAL_1="446" TOTAL_2="483" UNITS="" WEIGHT="100.0" Z="1.1351059370586922">
<NAME>Lumbar spine BMD (mg/cm2) (at end supplementation) by ethnicity</NAME>
<GROUP_LABEL_1>Treatment</GROUP_LABEL_1>
<GROUP_LABEL_2>Control</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours control</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours treatment</GRAPH_LABEL_2>
<CONT_SUBGROUP CHI2="0.8606613960647507" CI_END="0.23532655535814292" CI_START="-0.055281340288949904" DF="5" EFFECT_SIZE="0.09002260753459651" ESTIMABLE="YES" I2="0.0" ID="CMP-001.33.01" NO="1" P_CHI2="0.9730039272708202" P_Z="0.2246371889571015" STUDIES="6" TAU2="0.0" TOTAL_1="353" TOTAL_2="396" WEIGHT="80.19309906825016" Z="1.2142895716533388">
<NAME>Caucasian</NAME>
<CONT_DATA CI_END="0.5114205026835856" CI_START="-0.24397376271812718" EFFECT_SIZE="0.13372336998272924" ESTIMABLE="YES" MEAN_1="647.0" MEAN_2="638.0" ORDER="17179" SD_1="74.16" SD_2="58.24" SE="0.1927061597458337" STUDY_ID="STD-Bonjour-1995" TOTAL_1="55" TOTAL_2="53" WEIGHT="11.868735441225326"/>
<CONT_DATA CI_END="0.27186034181968627" CI_START="-0.24293478100807947" EFFECT_SIZE="0.014462780405803406" ESTIMABLE="YES" MEAN_1="586.9" MEAN_2="586.1" ORDER="17180" SD_1="52.0" SD_2="58.0" SE="0.1313276996129531" STUDY_ID="STD-Chevalley-2005" TOTAL_1="114" TOTAL_2="118" WEIGHT="25.555416824433095"/>
<CONT_DATA CI_END="0.6270434570242918" CI_START="-0.3446758722743443" EFFECT_SIZE="0.1411837923749737" ESTIMABLE="YES" MEAN_1="740.64" MEAN_2="726.67" ORDER="17181" SD_1="65.03" SD_2="106.95" SE="0.2478921390809816" STUDY_ID="STD-Courteix-2005" TOTAL_1="22" TOTAL_2="63" WEIGHT="7.172492998331971"/>
<CONT_DATA CI_END="0.434960444536277" CI_START="-0.39145848587210075" EFFECT_SIZE="0.021750979332088152" ESTIMABLE="YES" MEAN_1="907.36" MEAN_2="902.96" ORDER="17182" SD_1="197.32" SD_2="203.75" SE="0.2108250296758167" STUDY_ID="STD-Johnston-1992" TOTAL_1="45" TOTAL_2="45" WEIGHT="9.916337576840744"/>
<CONT_DATA CI_END="0.6124201908396137" CI_START="-0.21201494446981703" EFFECT_SIZE="0.20020262318489837" ESTIMABLE="YES" MEAN_1="914.0" MEAN_2="894.0" ORDER="17183" SD_1="83.0" SD_2="112.0" SE="0.21031895019818475" STUDY_ID="STD-Lloyd-1993" TOTAL_1="44" TOTAL_2="47" WEIGHT="9.964117320500124"/>
<CONT_DATA CI_END="0.45798631527414724" CI_START="-0.1984686132330601" EFFECT_SIZE="0.12975885102054358" ESTIMABLE="YES" MEAN_1="1047.0" MEAN_2="1032.0" ORDER="17184" SD_1="114.0" SD_2="116.0" SE="0.1674660691944444" STUDY_ID="STD-Prentice-2005" TOTAL_1="73" TOTAL_2="70" WEIGHT="15.7159989069189"/>
</CONT_SUBGROUP>
<CONT_SUBGROUP CHI2="0.0" CI_END="0.4625164252125683" CI_START="-0.393919388343527" DF="0" EFFECT_SIZE="0.034298518434520614" ESTIMABLE="YES" I2="0.0" ID="CMP-001.33.02" NO="2" P_CHI2="1.0" P_Z="0.8752565359284907" STUDIES="1" TAU2="0.0" TOTAL_1="44" TOTAL_2="40" WEIGHT="9.23341119676166" Z="0.15698516991160472">
<NAME>Chinese</NAME>
<CONT_DATA CI_END="0.4625164252125683" CI_START="-0.393919388343527" EFFECT_SIZE="0.034298518434520614" ESTIMABLE="YES" MEAN_1="525.0" MEAN_2="523.0" ORDER="17185" SD_1="61.0" SD_2="54.0" SE="0.21848253853426688" STUDY_ID="STD-Lee-1995" TOTAL_1="44" TOTAL_2="40" WEIGHT="9.23341119676166"/>
</CONT_SUBGROUP>
<CONT_SUBGROUP CHI2="0.0" CI_END="0.40016282334497716" CI_START="-0.40016282334497716" DF="0" EFFECT_SIZE="0.0" ESTIMABLE="YES" I2="0.0" ID="CMP-001.33.03" NO="3" P_CHI2="1.0" P_Z="1.0" STUDIES="1" TAU2="0.0" TOTAL_1="49" TOTAL_2="47" WEIGHT="10.573489734988184" Z="0.0">
<NAME>Other</NAME>
<CONT_DATA CI_END="0.40016282334497716" CI_START="-0.40016282334497716" EFFECT_SIZE="0.0" ESTIMABLE="YES" MEAN_1="1120.0" MEAN_2="1120.0" ORDER="17186" SD_1="140.0" SD_2="137.11" SE="0.2041684574315704" STUDY_ID="STD-Rozen-2003" TOTAL_1="49" TOTAL_2="47" WEIGHT="10.573489734988184"/>
</CONT_SUBGROUP>
</CONT_OUTCOME>
<CONT_OUTCOME CHI2="4.325581622725286" CI_END="0.2734342893719172" CI_START="-0.02613121491698872" CI_STUDY="95" CI_TOTAL="95" DF="5" EFFECT_MEASURE="SMD" EFFECT_SIZE="0.12365153722746425" ESTIMABLE="YES" I2="0.0" I2_Q="0.0" ID="CMP-001.34" MODIFIED="2008-10-03 10:57:00 -0400" MODIFIED_BY="[Empty name]" NO="34" P_CHI2="0.5035535863099156" P_Q="0.5023265184499297" P_Z="0.10565674668586252" Q="0.45001782142667546" RANDOM="NO" SCALE="1.0" SORT_BY="STUDY" STUDIES="6" SUBGROUPS="YES" SUBGROUP_TEST="YES" TAU2="0.0" TOTALS="YES" TOTAL_1="330" TOTAL_2="378" UNITS="" WEIGHT="100.0" Z="1.6180271501829186">
<NAME>Total body BMC (mg) (at end supplementation) by ethnicity</NAME>
<GROUP_LABEL_1>Treatment</GROUP_LABEL_1>
<GROUP_LABEL_2>Control</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours control</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours treatment</GRAPH_LABEL_2>
<CONT_SUBGROUP CHI2="3.8755638012986107" CI_END="0.30692027845254727" CI_START="-0.017232137600504627" DF="4" EFFECT_SIZE="0.14484407042602132" ESTIMABLE="YES" I2="0.0" ID="CMP-001.34.01" NO="1" P_CHI2="0.42310846450573136" P_Z="0.07984635459927353" STUDIES="5" TAU2="0.0" TOTAL_1="281" TOTAL_2="327" WEIGHT="85.40535018582538" Z="1.7515782536245095">
<NAME>Caucasian</NAME>
<CONT_DATA CI_END="1.0623077058025256" CI_START="0.07587704885842766" EFFECT_SIZE="0.5690923773304767" ESTIMABLE="YES" MEAN_1="1340.9" MEAN_2="1186.1" ORDER="17187" SD_1="216.37" SD_2="285.32" SE="0.2516450977479528" STUDY_ID="STD-Courteix-2005" TOTAL_1="22" TOTAL_2="63" WEIGHT="9.222538597108805"/>
<CONT_DATA CI_END="0.6634749996606573" CI_START="-0.16217650854283872" EFFECT_SIZE="0.2506492455589093" ESTIMABLE="YES" MEAN_1="1783.0" MEAN_2="1714.0" ORDER="17188" SD_1="238.0" SD_2="302.0" SE="0.21062925510777997" STUDY_ID="STD-Lloyd-1993" TOTAL_1="44" TOTAL_2="47" WEIGHT="13.164065863641582"/>
<CONT_DATA CI_END="0.4506900805835923" CI_START="-0.29400382768340283" EFFECT_SIZE="0.07834312645009475" ESTIMABLE="YES" MEAN_1="1932.11" MEAN_2="1907.53" ORDER="17189" SD_1="292.33" SD_2="328.77" SE="0.18997642664381734" STUDY_ID="STD-Molgaard-2004" TOTAL_1="54" TOTAL_2="57" WEIGHT="16.181843667305515"/>
<CONT_DATA CI_END="0.3908635962567637" CI_START="-0.26504909971456003" EFFECT_SIZE="0.06290724827110186" ESTIMABLE="YES" MEAN_1="2796.0" MEAN_2="2770.0" ORDER="17190" SD_1="415.0" SD_2="407.0" SE="0.1673277420261493" STUDY_ID="STD-Prentice-2005" TOTAL_1="73" TOTAL_2="70" WEIGHT="20.858906101967005"/>
<CONT_DATA CI_END="0.3417017087255969" CI_START="-0.24604334021365062" EFFECT_SIZE="0.047829184255973135" ESTIMABLE="YES" MEAN_1="685.55" MEAN_2="681.5" ORDER="17191" SD_1="88.0" SD_2="80.55" SE="0.1499377166048217" STUDY_ID="STD-Specker-2003" TOTAL_1="88" TOTAL_2="90" WEIGHT="25.977995955802477"/>
</CONT_SUBGROUP>
<CONT_SUBGROUP CHI2="0.0" CI_END="0.3917077443497603" CI_START="-0.392434700377596" DF="0" EFFECT_SIZE="-3.634780139178262E-4" ESTIMABLE="YES" I2="0.0" ID="CMP-001.34.02" MODIFIED="2008-10-03 10:57:00 -0400" MODIFIED_BY="[Empty name]" NO="2" P_CHI2="1.0" P_Z="0.9985502233750839" STUDIES="1" TAU2="0.0" TOTAL_1="49" TOTAL_2="51" WEIGHT="14.594649814174623" Z="0.0018170265396073243">
<NAME>Other</NAME>
<CONT_DATA CI_END="0.3917077443497603" CI_START="-0.392434700377596" EFFECT_SIZE="-3.634780139178262E-4" ESTIMABLE="YES" MEAN_1="860.29" MEAN_2="860.34" ORDER="17192" SD_1="134.19" SD_2="138.69" SE="0.2000400137228469" STUDY_ID="STD-Rozen-2003" TOTAL_1="49" TOTAL_2="51" WEIGHT="14.594649814174623"/>
</CONT_SUBGROUP>
</CONT_OUTCOME>
<CONT_OUTCOME CHI2="7.913086240719402" CI_END="0.27096029462344073" CI_START="0.020547839159981346" CI_STUDY="95" CI_TOTAL="95" DF="7" EFFECT_MEASURE="SMD" EFFECT_SIZE="0.14575406689171105" ESTIMABLE="YES" I2="11.538939586185911" I2_Q="52.34003653326873" ID="CMP-001.35" NO="35" P_CHI2="0.3403203842023971" P_Q="0.12267744905871669" P_Z="0.02251193195056703" Q="4.1963943203525265" RANDOM="NO" SCALE="1.0" SORT_BY="STUDY" STUDIES="8" SUBGROUPS="YES" SUBGROUP_TEST="YES" TAU2="0.0" TOTALS="YES" TOTAL_1="477" TOTAL_2="532" UNITS="" WEIGHT="100.0" Z="2.2816175112318358">
<NAME>Distal radius BMD (mg/cm2) (at end supplementation) by ethnicity</NAME>
<GROUP_LABEL_1>Treatment</GROUP_LABEL_1>
<GROUP_LABEL_2>Control</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours control</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours treatment</GRAPH_LABEL_2>
<CONT_SUBGROUP CHI2="3.2572047137525333" CI_END="0.2314207135319594" CI_START="-0.09434426448177377" DF="4" EFFECT_SIZE="0.06853822452509281" ESTIMABLE="YES" I2="0.0" ID="CMP-001.35.01" NO="1" P_CHI2="0.515741421869981" P_Z="0.4095305637078007" STUDIES="5" TAU2="0.0" TOTAL_1="274" TOTAL_2="329" WEIGHT="59.088513968317315" Z="0.8247200325373144">
<NAME>Caucasian</NAME>
<CONT_DATA CI_END="0.5128125613720704" CI_START="-0.24259987277088774" EFFECT_SIZE="0.13510634430059137" ESTIMABLE="YES" MEAN_1="312.0" MEAN_2="308.0" ORDER="17193" SD_1="29.66" SD_2="29.12" SE="0.1927107947139731" STUDY_ID="STD-Bonjour-1995" TOTAL_1="55" TOTAL_2="53" WEIGHT="10.98863113910925"/>
<CONT_DATA CI_END="0.2574725427227148" CI_START="-0.7158349449146524" EFFECT_SIZE="-0.2291812010959688" ESTIMABLE="YES" MEAN_1="336.18" MEAN_2="351.0" ORDER="17194" SD_1="43.19" SD_2="69.75" SE="0.24829728895905548" STUDY_ID="STD-Courteix-2005" TOTAL_1="22" TOTAL_2="63" WEIGHT="6.619294819953387"/>
<CONT_DATA CI_END="0.4929289406242539" CI_START="-0.3338062753225926" EFFECT_SIZE="0.07956133265083067" ESTIMABLE="YES" MEAN_1="317.09" MEAN_2="311.51" ORDER="17195" SD_1="69.4" SD_2="69.67" SE="0.2109057162447954" STUDY_ID="STD-Johnston-1992" TOTAL_1="45" TOTAL_2="45" WEIGHT="9.174427620971983"/>
<CONT_DATA CI_END="0.5300115286945037" CI_START="-0.06471641800366129" EFFECT_SIZE="0.23264755534542125" ESTIMABLE="YES" MEAN_1="450.0" MEAN_2="438.0" ORDER="17196" SD_1="53.0" SD_2="50.0" SE="0.15171910080728607" STUDY_ID="STD-Matkovic-2004" TOTAL_1="79" TOTAL_2="98" WEIGHT="17.72862933473747"/>
<CONT_DATA CI_END="0.2749570234978052" CI_START="-0.38090719667338463" EFFECT_SIZE="-0.05297508658778973" ESTIMABLE="YES" MEAN_1="479.0" MEAN_2="482.0" ORDER="17197" SD_1="61.0" SD_2="51.0" SE="0.16731537552336753" STUDY_ID="STD-Prentice-2005" TOTAL_1="73" TOTAL_2="70" WEIGHT="14.577531053545227"/>
</CONT_SUBGROUP>
<CONT_SUBGROUP CHI2="0.4594872066143417" CI_END="0.39258482504461445" CI_START="-0.10844619101806194" DF="1" EFFECT_SIZE="0.14206931701327627" ESTIMABLE="YES" I2="0.0" ID="CMP-001.35.02" NO="2" P_CHI2="0.49786375625261536" P_Z="0.2663484726099591" STUDIES="2" TAU2="0.0" TOTAL_1="123" TOTAL_2="123" WEIGHT="24.979436128978275" Z="1.1115110072123453">
<NAME>Chinese</NAME>
<CONT_DATA CI_END="0.4501644946278604" CI_START="-0.40623244295249933" EFFECT_SIZE="0.02196602583768056" ESTIMABLE="YES" MEAN_1="492.0" MEAN_2="491.0" ORDER="17198" SD_1="39.0" SD_2="51.0" SE="0.2184726210112812" STUDY_ID="STD-Lee-1995" TOTAL_1="44" TOTAL_2="40" WEIGHT="8.549911952342569"/>
<CONT_DATA CI_END="0.5134677994735729" CI_START="-0.10432584171130158" EFFECT_SIZE="0.20457097888113565" ESTIMABLE="YES" MEAN_1="486.0" MEAN_2="479.0" ORDER="17199" SD_1="37.0" SD_2="31.0" SE="0.15760331466750202" STUDY_ID="STD-Wang-1996" TOTAL_1="79" TOTAL_2="83" WEIGHT="16.429524176635706"/>
</CONT_SUBGROUP>
<CONT_SUBGROUP CHI2="0.0" CI_END="0.7515904462890333" CI_START="0.12422571852871639" DF="0" EFFECT_SIZE="0.4379080824088748" ESTIMABLE="YES" I2="0.0" ID="CMP-001.35.03" NO="3" P_CHI2="1.0" P_Z="0.006216143641262392" STUDIES="1" TAU2="0.0" TOTAL_1="80" TOTAL_2="80" WEIGHT="15.932049902704414" Z="2.7361565994456036">
<NAME>Other</NAME>
<CONT_DATA CI_END="0.7515904462890333" CI_START="0.12422571852871639" EFFECT_SIZE="0.4379080824088748" ESTIMABLE="YES" MEAN_1="253.0" MEAN_2="231.0" ORDER="17200" SD_1="50.0" SD_2="50.0" SE="0.16004496325159281" STUDY_ID="STD-Dibba-2000" TOTAL_1="80" TOTAL_2="80" WEIGHT="15.932049902704414"/>
</CONT_SUBGROUP>
</CONT_OUTCOME>
<CONT_OUTCOME CHI2="8.429339413965808" CI_END="0.23713177770175908" CI_START="0.025346671694098558" CI_STUDY="95" CI_TOTAL="95" DF="9" EFFECT_MEASURE="SMD" EFFECT_SIZE="0.1312392246979288" ESTIMABLE="YES" I2="0.0" I2_Q="57.254594515499335" ID="CMP-001.36" NO="36" P_CHI2="0.49152373979418884" P_Q="0.09638249123214016" P_Z="0.015136138690687544" Q="4.678865429701428" RANDOM="NO" SCALE="1.0" SORT_BY="STUDY" STUDIES="10" SUBGROUPS="YES" SUBGROUP_TEST="YES" TAU2="0.0" TOTALS="YES" TOTAL_1="668" TOTAL_2="732" UNITS="" WEIGHT="100.0" Z="2.4291052247800273">
<NAME>Upper limb BMD (mg/cm2) (at end supplementation) by ethnicity</NAME>
<GROUP_LABEL_1>Treatment</GROUP_LABEL_1>
<GROUP_LABEL_2>Control</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours control</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours treatment</GRAPH_LABEL_2>
<CONT_SUBGROUP CHI2="3.277569710426979" CI_END="0.19984102093389736" CI_START="-0.07544685959410921" DF="5" EFFECT_SIZE="0.06219708066989407" ESTIMABLE="YES" I2="0.0" ID="CMP-001.36.01" NO="1" P_CHI2="0.6572775223086992" P_Z="0.3758074128672422" STUDIES="6" TAU2="0.0" TOTAL_1="388" TOTAL_2="447" WEIGHT="59.1856804618131" Z="0.8856476923191161">
<NAME>Caucasian</NAME>
<CONT_DATA CI_END="0.5128125613720704" CI_START="-0.24259987277088774" EFFECT_SIZE="0.13510634430059137" ESTIMABLE="YES" MEAN_1="312.0" MEAN_2="308.0" ORDER="17201" SD_1="29.66" SD_2="29.12" SE="0.1927107947139731" STUDY_ID="STD-Bonjour-1995" TOTAL_1="55" TOTAL_2="53" WEIGHT="7.860000455267347"/>
<CONT_DATA CI_END="0.30378712152378146" CI_START="-0.211071470037911" EFFECT_SIZE="0.046357825742935246" ESTIMABLE="YES" MEAN_1="309.6" MEAN_2="308.2" ORDER="17202" SD_1="28.0" SD_2="32.0" SE="0.13134389091402476" STUDY_ID="STD-Chevalley-2005" TOTAL_1="114" TOTAL_2="118" WEIGHT="16.920566562495083"/>
<CONT_DATA CI_END="0.2574725427227148" CI_START="-0.7158349449146524" EFFECT_SIZE="-0.2291812010959688" ESTIMABLE="YES" MEAN_1="336.18" MEAN_2="351.0" ORDER="17203" SD_1="43.19" SD_2="69.75" SE="0.24829728895905548" STUDY_ID="STD-Courteix-2005" TOTAL_1="22" TOTAL_2="63" WEIGHT="4.7346807477423285"/>
<CONT_DATA CI_END="0.4929289406242539" CI_START="-0.3338062753225926" EFFECT_SIZE="0.07956133265083067" ESTIMABLE="YES" MEAN_1="317.09" MEAN_2="311.51" ORDER="17204" SD_1="69.4" SD_2="69.67" SE="0.2109057162447954" STUDY_ID="STD-Johnston-1992" TOTAL_1="45" TOTAL_2="45" WEIGHT="6.562328315945502"/>
<CONT_DATA CI_END="0.5300115286945037" CI_START="-0.06471641800366129" EFFECT_SIZE="0.23264755534542125" ESTIMABLE="YES" MEAN_1="450.0" MEAN_2="438.0" ORDER="17205" SD_1="53.0" SD_2="50.0" SE="0.15171910080728607" STUDY_ID="STD-Matkovic-2004" TOTAL_1="79" TOTAL_2="98" WEIGHT="12.681018488859584"/>
<CONT_DATA CI_END="0.2749570234978052" CI_START="-0.38090719667338463" EFFECT_SIZE="-0.05297508658778973" ESTIMABLE="YES" MEAN_1="479.0" MEAN_2="482.0" ORDER="17206" SD_1="61.0" SD_2="51.0" SE="0.16731537552336753" STUDY_ID="STD-Prentice-2005" TOTAL_1="73" TOTAL_2="70" WEIGHT="10.427085891503252"/>
</CONT_SUBGROUP>
<CONT_SUBGROUP CHI2="0.47290427383739997" CI_END="0.3465807850119811" CI_START="-0.04388783202901533" DF="2" EFFECT_SIZE="0.15134647649148286" ESTIMABLE="YES" I2="0.0" ID="CMP-001.36.02" NO="2" P_CHI2="0.7894236723159465" P_Z="0.12866875522585533" STUDIES="3" TAU2="0.0" TOTAL_1="200" TOTAL_2="205" WEIGHT="29.418366948340513" Z="1.5193725188890148">
<NAME>Chinese</NAME>
<CONT_DATA CI_END="0.4772672773224417" CI_START="-0.14587387711583635" EFFECT_SIZE="0.16569670010330265" ESTIMABLE="YES" MEAN_1="487.0" MEAN_2="480.0" ORDER="17207" SD_1="41.0" SD_2="43.0" SE="0.15896750127898673" STUDY_ID="STD-Lee-1994" TOTAL_1="77" TOTAL_2="82" WEIGHT="11.550956816853812"/>
<CONT_DATA CI_END="0.4501644946278604" CI_START="-0.40623244295249933" EFFECT_SIZE="0.02196602583768056" ESTIMABLE="YES" MEAN_1="492.0" MEAN_2="491.0" ORDER="17208" SD_1="39.0" SD_2="51.0" SE="0.2184726210112812" STUDY_ID="STD-Lee-1995" TOTAL_1="44" TOTAL_2="40" WEIGHT="6.115621771917609"/>
<CONT_DATA CI_END="0.5134677994735729" CI_START="-0.10432584171130158" EFFECT_SIZE="0.20457097888113565" ESTIMABLE="YES" MEAN_1="486.0" MEAN_2="479.0" ORDER="17209" SD_1="37.0" SD_2="31.0" SE="0.15760331466750202" STUDY_ID="STD-Wang-1996" TOTAL_1="79" TOTAL_2="83" WEIGHT="11.751788359569092"/>
</CONT_SUBGROUP>
<CONT_SUBGROUP CHI2="0.0" CI_END="0.7515904462890333" CI_START="0.12422571852871639" DF="0" EFFECT_SIZE="0.4379080824088748" ESTIMABLE="YES" I2="0.0" ID="CMP-001.36.03" NO="3" P_CHI2="1.0" P_Z="0.006216143641262392" STUDIES="1" TAU2="0.0" TOTAL_1="80" TOTAL_2="80" WEIGHT="11.395952589846393" Z="2.7361565994456036">
<NAME>Other</NAME>
<CONT_DATA CI_END="0.7515904462890333" CI_START="0.12422571852871639" EFFECT_SIZE="0.4379080824088748" ESTIMABLE="YES" MEAN_1="253.0" MEAN_2="231.0" ORDER="17210" SD_1="50.0" SD_2="50.0" SE="0.16004496325159281" STUDY_ID="STD-Dibba-2000" TOTAL_1="80" TOTAL_2="80" WEIGHT="11.395952589846393"/>
</CONT_SUBGROUP>
</CONT_OUTCOME>
<CONT_OUTCOME CHI2="4.977220570190811" CI_END="0.28594515185741864" CI_START="-0.0741564016414127" CI_STUDY="95" CI_TOTAL="95" DF="4" EFFECT_MEASURE="SMD" EFFECT_SIZE="0.10589437510800297" ESTIMABLE="YES" I2="19.63386103568537" I2_Q="0.0" ID="CMP-001.37" NO="37" P_CHI2="0.2896428687480078" P_Q="0.8763940698552606" P_Z="0.24902300050576687" Q="0.26387889046570034" RANDOM="YES" SCALE="1.0" SORT_BY="STUDY" STUDIES="5" SUBGROUPS="YES" SUBGROUP_TEST="NO" TAU2="0.008372358437612465" TOTALS="YES" TOTAL_1="313" TOTAL_2="304" UNITS="" WEIGHT="100.0" Z="1.1527257206222201">
<NAME>Femoral neck BMD (mg/cm2) at longest point after supplementation ceased by ethnicity</NAME>
<GROUP_LABEL_1>Treatment</GROUP_LABEL_1>
<GROUP_LABEL_2>Control</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours control</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours treatment</GRAPH_LABEL_2>
<CONT_SUBGROUP CHI2="4.713341679725111" CI_END="0.4356493635528436" CI_START="-0.1696411142030983" DF="2" EFFECT_SIZE="0.13300412467487266" ESTIMABLE="YES" I2="57.56726043004285" ID="CMP-001.37.01" NO="1" P_CHI2="0.09473529677384573" P_Z="0.38904564590823953" STUDIES="3" TAU2="0.04106034684792629" TOTAL_1="220" TOTAL_2="217" WEIGHT="68.13557312996659" Z="0.8613493974809735">
<NAME>Caucasian</NAME>
<CONT_DATA CI_END="0.7986994788224699" CI_START="0.08686283431210057" EFFECT_SIZE="0.4427811565672853" ESTIMABLE="YES" MEAN_1="885.0" MEAN_2="853.0" ORDER="17211" SD_1="70.2" SD_2="73.67" SE="0.18159431758064076" STUDY_ID="STD-Bonjour-1995" TOTAL_1="67" TOTAL_2="58" WEIGHT="20.40940447544884"/>
<CONT_DATA CI_END="0.22762896650934925" CI_START="-0.2940909927915369" EFFECT_SIZE="-0.033231013141093814" ESTIMABLE="YES" MEAN_1="722.4" MEAN_2="724.7" ORDER="17212" SD_1="70.0" SD_2="68.0" SE="0.13309427199074741" STUDY_ID="STD-Chevalley-2005" TOTAL_1="110" TOTAL_2="116" WEIGHT="32.350346753760185"/>
<CONT_DATA CI_END="0.43698040696836393" CI_START="-0.40842428898937033" EFFECT_SIZE="0.014278058989496793" ESTIMABLE="YES" MEAN_1="956.05" MEAN_2="954.05" ORDER="17213" SD_1="136.72" SD_2="140.89" SE="0.2156684262124658" STUDY_ID="STD-Johnston-1992" TOTAL_1="43" TOTAL_2="43" WEIGHT="15.375821900757563"/>
</CONT_SUBGROUP>
<CONT_SUBGROUP CHI2="0.0" CI_END="0.4281849516340527" CI_START="-0.4281849516340527" DF="0" EFFECT_SIZE="0.0" ESTIMABLE="YES" I2="0.0" ID="CMP-001.37.02" NO="2" P_CHI2="1.0" P_Z="1.0" STUDIES="1" TAU2="0.0" TOTAL_1="44" TOTAL_2="40" WEIGHT="15.04297766161065" Z="0.0">
<NAME>Chinese</NAME>
<CONT_DATA CI_END="0.4281849516340527" CI_START="-0.4281849516340527" EFFECT_SIZE="0.0" ESTIMABLE="YES" MEAN_1="603.0" MEAN_2="603.0" ORDER="17214" SD_1="76.0" SD_2="64.0" SE="0.21846572437632575" STUDY_ID="STD-Lee-1995" TOTAL_1="44" TOTAL_2="40" WEIGHT="15.04297766161065"/>
</CONT_SUBGROUP>
<CONT_SUBGROUP CHI2="0.0" CI_END="0.5438493859396915" CI_START="-0.2575440066043698" DF="0" EFFECT_SIZE="0.14315268966766082" ESTIMABLE="YES" I2="0.0" ID="CMP-001.37.03" NO="3" P_CHI2="1.0" P_Z="0.4837926157451463" STUDIES="1" TAU2="0.0" TOTAL_1="49" TOTAL_2="47" WEIGHT="16.821449208422756" Z="0.7002156959341992">
<NAME>Other</NAME>
<CONT_DATA CI_END="0.5438493859396915" CI_START="-0.2575440066043698" EFFECT_SIZE="0.14315268966766082" ESTIMABLE="YES" MEAN_1="1010.0" MEAN_2="990.0" ORDER="17215" SD_1="140.0" SD_2="137.11" SE="0.20444084658324083" STUDY_ID="STD-Rozen-2003" TOTAL_1="49" TOTAL_2="47" WEIGHT="16.821449208422756"/>
</CONT_SUBGROUP>
</CONT_OUTCOME>
<CONT_OUTCOME CHI2="1.1583576889270417" CI_END="0.16953284421813045" CI_START="-0.14651148834224073" CI_STUDY="95" CI_TOTAL="95" DF="4" EFFECT_MEASURE="SMD" EFFECT_SIZE="0.011510677937944852" ESTIMABLE="YES" I2="0.0" I2_Q="0.0" ID="CMP-001.38" NO="38" P_CHI2="0.8849060147469565" P_Q="0.5665711623444691" P_Z="0.8864733826880067" Q="1.1363057522887656" RANDOM="NO" SCALE="1.0" SORT_BY="STUDY" STUDIES="5" SUBGROUPS="YES" SUBGROUP_TEST="YES" TAU2="0.0" TOTALS="YES" TOTAL_1="313" TOTAL_2="304" UNITS="" WEIGHT="100.0" Z="0.14276803518824152">
<NAME>Lumbar spine BMD (mg/cm2) at longest point after supplementation ceased by ethnicity</NAME>
<GROUP_LABEL_1>Treatment</GROUP_LABEL_1>
<GROUP_LABEL_2>Control</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours control</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours treatment</GRAPH_LABEL_2>
<CONT_SUBGROUP CHI2="0.022051936638276124" CI_END="0.2422033420829051" CI_START="-0.13325105519254934" DF="2" EFFECT_SIZE="0.054476143445177864" ESTIMABLE="YES" I2="0.0" ID="CMP-001.38.01" NO="1" P_CHI2="0.9890345954863036" P_Z="0.5695206254114955" STUDIES="3" TAU2="0.0" TOTAL_1="220" TOTAL_2="217" WEIGHT="70.85681441064617" Z="0.5687576437723965">
<NAME>Caucasian</NAME>
<CONT_DATA CI_END="0.4286491395175547" CI_START="-0.27466106073165153" EFFECT_SIZE="0.07699403939295155" ESTIMABLE="YES" MEAN_1="1019.0" MEAN_2="1014.0" ORDER="17216" SD_1="70.2" SD_2="57.3" SE="0.17941916427975904" STUDY_ID="STD-Bonjour-1995" TOTAL_1="67" TOTAL_2="58" WEIGHT="20.193062121230806"/>
<CONT_DATA CI_END="0.30604468824634573" CI_START="-0.21570630455408518" EFFECT_SIZE="0.04516919184613029" ESTIMABLE="YES" MEAN_1="605.0" MEAN_2="602.5" ORDER="17217" SD_1="52.0" SD_2="58.0" SE="0.13310218884528904" STUDY_ID="STD-Chevalley-2005" TOTAL_1="110" TOTAL_2="116" WEIGHT="36.69183613729449"/>
<CONT_DATA CI_END="0.46912926150434037" CI_START="-0.3763832168316114" EFFECT_SIZE="0.0463730223363645" ESTIMABLE="YES" MEAN_1="1061.23" MEAN_2="1052.39" ORDER="17218" SD_1="192.31" SD_2="185.47" SE="0.21569592222235875" STUDY_ID="STD-Johnston-1992" TOTAL_1="43" TOTAL_2="43" WEIGHT="13.971916152120874"/>
</CONT_SUBGROUP>
<CONT_SUBGROUP CHI2="0.0" CI_END="0.22936706177064778" CI_START="-0.6292396856883473" DF="0" EFFECT_SIZE="-0.19993631195884978" ESTIMABLE="YES" I2="0.0" ID="CMP-001.38.02" NO="2" P_CHI2="1.0" P_Z="0.3613479312122819" STUDIES="1" TAU2="0.0" TOTAL_1="44" TOTAL_2="40" WEIGHT="13.549005508643003" Z="0.9127996531609488">
<NAME>Chinese</NAME>
<CONT_DATA CI_END="0.22936706177064778" CI_START="-0.6292396856883473" EFFECT_SIZE="-0.19993631195884978" ESTIMABLE="YES" MEAN_1="538.0" MEAN_2="551.0" ORDER="17219" SD_1="61.0" SD_2="68.0" SE="0.2190363583799436" STUDY_ID="STD-Lee-1995" TOTAL_1="44" TOTAL_2="40" WEIGHT="13.549005508643003"/>
</CONT_SUBGROUP>
<CONT_SUBGROUP CHI2="0.0" CI_END="0.40016282334497716" CI_START="-0.40016282334497716" DF="0" EFFECT_SIZE="0.0" ESTIMABLE="YES" I2="0.0" ID="CMP-001.38.03" NO="3" P_CHI2="1.0" P_Z="1.0" STUDIES="1" TAU2="0.0" TOTAL_1="49" TOTAL_2="47" WEIGHT="15.594180080710828" Z="0.0">
<NAME>Other</NAME>
<CONT_DATA CI_END="0.40016282334497716" CI_START="-0.40016282334497716" EFFECT_SIZE="0.0" ESTIMABLE="YES" MEAN_1="1150.0" MEAN_2="1150.0" ORDER="17220" SD_1="140.0" SD_2="137.11" SE="0.2041684574315704" STUDY_ID="STD-Rozen-2003" TOTAL_1="49" TOTAL_2="47" WEIGHT="15.594180080710828"/>
</CONT_SUBGROUP>
</CONT_OUTCOME>
<CONT_OUTCOME CHI2="2.816095598536258" CI_END="0.3987017951586933" CI_START="0.029157553391896907" CI_STUDY="95" CI_TOTAL="95" DF="3" EFFECT_MEASURE="SMD" EFFECT_SIZE="0.2139296742752951" ESTIMABLE="YES" I2="0.0" I2_Q="0.0" ID="CMP-001.39" NO="39" P_CHI2="0.4208572474022484" P_Q="0.4664013247195148" P_Z="0.023253021489117242" Q="1.5254181281080585" RANDOM="NO" SCALE="1.0" SORT_BY="STUDY" STUDIES="4" SUBGROUPS="YES" SUBGROUP_TEST="YES" TAU2="0.0" TOTALS="YES" TOTAL_1="234" TOTAL_2="221" UNITS="" WEIGHT="100.0" Z="2.2692517399232655">
<NAME>Distal radius BMD (mg/cm2) at longest point after supplementation ceased by ethnicity</NAME>
<GROUP_LABEL_1>Treatment</GROUP_LABEL_1>
<GROUP_LABEL_2>Control</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours control</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours treatment</GRAPH_LABEL_2>
<CONT_SUBGROUP CHI2="1.2906774704281996" CI_END="0.510581946531807" CI_START="-0.03280112732757931" DF="1" EFFECT_SIZE="0.23889040960211386" ESTIMABLE="YES" I2="22.52130970658095" ID="CMP-001.39.01" NO="1" P_CHI2="0.2559232529622504" P_Z="0.08482725394900052" STUDIES="2" TAU2="0.0" TOTAL_1="110" TOTAL_2="101" WEIGHT="46.25095095215247" Z="1.7233389172270288">
<NAME>Caucasian</NAME>
<CONT_DATA CI_END="0.7255999910161408" CI_START="0.016372536416859873" EFFECT_SIZE="0.37098626371650034" ESTIMABLE="YES" MEAN_1="429.0" MEAN_2="418.0" ORDER="17221" SD_1="26.32" SD_2="32.74" SE="0.18092869567848607" STUDY_ID="STD-Bonjour-1995" TOTAL_1="67" TOTAL_2="58" WEIGHT="27.149497819276156"/>
<CONT_DATA CI_END="0.47390750843088114" CI_START="-0.3716306970386415" EFFECT_SIZE="0.05113840569611985" ESTIMABLE="YES" MEAN_1="365.23" MEAN_2="361.31" ORDER="17222" SD_1="77.08" SD_2="74.84" SE="0.21570248538723671" STUDY_ID="STD-Johnston-1992" TOTAL_1="43" TOTAL_2="43" WEIGHT="19.101453132876316"/>
</CONT_SUBGROUP>
<CONT_SUBGROUP CHI2="0.0" CI_END="0.40686449035579997" CI_START="-0.44953091203190143" DF="0" EFFECT_SIZE="-0.021333210838050704" ESTIMABLE="YES" I2="0.0" ID="CMP-001.39.02" NO="2" P_CHI2="1.0" P_Z="0.9222124093658169" STUDIES="1" TAU2="0.0" TOTAL_1="44" TOTAL_2="40" WEIGHT="18.620194999660033" Z="0.0976472428520814">
<NAME>Chinese</NAME>
<CONT_DATA CI_END="0.40686449035579997" CI_START="-0.44953091203190143" EFFECT_SIZE="-0.021333210838050704" ESTIMABLE="YES" MEAN_1="516.0" MEAN_2="517.0" ORDER="17223" SD_1="44.0" SD_2="49.0" SE="0.21847222937330457" STUDY_ID="STD-Lee-1995" TOTAL_1="44" TOTAL_2="40" WEIGHT="18.620194999660033"/>
</CONT_SUBGROUP>
<CONT_SUBGROUP CHI2="0.0" CI_END="0.6175167825952239" CI_START="-0.0059803321820287025" DF="0" EFFECT_SIZE="0.30576822520659763" ESTIMABLE="YES" I2="0.0" ID="CMP-001.39.03" NO="3" P_CHI2="1.0" P_Z="0.05455976831896743" STUDIES="1" TAU2="0.0" TOTAL_1="80" TOTAL_2="80" WEIGHT="35.1288540481875" Z="1.9223656206837931">
<NAME>Other</NAME>
<CONT_DATA CI_END="0.6175167825952239" CI_START="-0.0059803321820287025" EFFECT_SIZE="0.30576822520659763" ESTIMABLE="YES" MEAN_1="256.0" MEAN_2="242.0" ORDER="17224" SD_1="43.0" SD_2="48.0" SE="0.15905830915652489" STUDY_ID="STD-Dibba-2000" TOTAL_1="80" TOTAL_2="80" WEIGHT="35.1288540481875"/>
</CONT_SUBGROUP>
</CONT_OUTCOME>
<CONT_OUTCOME CHI2="4.569678112982537" CI_END="0.3208724402970041" CI_START="0.04921441616255223" CI_STUDY="95" CI_TOTAL="95" DF="5" EFFECT_MEASURE="SMD" EFFECT_SIZE="0.18504342822977818" ESTIMABLE="YES" I2="0.0" I2_Q="38.70033289980513" ID="CMP-001.40" NO="40" P_CHI2="0.4706152751090106" P_Q="0.19566928179105814" P_Z="0.007582631581730898" Q="3.2626604590380266" RANDOM="NO" SCALE="1.0" SORT_BY="STUDY" STUDIES="6" SUBGROUPS="YES" SUBGROUP_TEST="YES" TAU2="0.0" TOTALS="YES" TOTAL_1="421" TOTAL_2="419" UNITS="" WEIGHT="100.0" Z="2.670110379119057">
<NAME>Upper limb BMD (mg/cm2) at longest point after supplementation ceased by ethnicity</NAME>
<GROUP_LABEL_1>Treatment</GROUP_LABEL_1>
<GROUP_LABEL_2>Control</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours control</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours treatment</GRAPH_LABEL_2>
<CONT_SUBGROUP CHI2="1.3007758237307883" CI_END="0.4374933210262463" CI_START="0.060344055634999644" DF="2" EFFECT_SIZE="0.24891868833062294" ESTIMABLE="YES" I2="0.0" ID="CMP-001.40.01" NO="1" P_CHI2="0.521843340297104" P_Z="0.00967722578106823" STUDIES="3" TAU2="0.0" TOTAL_1="220" TOTAL_2="217" WEIGHT="51.88221904078453" Z="2.587154259472647">
<NAME>Caucasian</NAME>
<CONT_DATA CI_END="0.7255999910161408" CI_START="0.016372536416859873" EFFECT_SIZE="0.37098626371650034" ESTIMABLE="YES" MEAN_1="429.0" MEAN_2="418.0" ORDER="17225" SD_1="26.32" SD_2="32.74" SE="0.18092869567848607" STUDY_ID="STD-Bonjour-1995" TOTAL_1="67" TOTAL_2="58" WEIGHT="14.671482403917"/>
<CONT_DATA CI_END="0.5201854123124395" CI_START="-0.003704661341557558" EFFECT_SIZE="0.258240375485441" ESTIMABLE="YES" MEAN_1="24.7" MEAN_2="19.4" ORDER="17226" SD_1="21.7" SD_2="19.2" SE="0.1336478827637587" STUDY_ID="STD-Chevalley-2005" TOTAL_1="110" TOTAL_2="116" WEIGHT="26.888386094926197"/>
<CONT_DATA CI_END="0.47390750843088114" CI_START="-0.3716306970386415" EFFECT_SIZE="0.05113840569611985" ESTIMABLE="YES" MEAN_1="365.23" MEAN_2="361.31" ORDER="17227" SD_1="77.08" SD_2="74.84" SE="0.21570248538723671" STUDY_ID="STD-Johnston-1992" TOTAL_1="43" TOTAL_2="43" WEIGHT="10.322350541941328"/>
</CONT_SUBGROUP>
<CONT_SUBGROUP CHI2="0.006241830213721836" CI_END="0.24427821013338338" CI_START="-0.25901416450018905" DF="1" EFFECT_SIZE="-0.007367977183402845" ESTIMABLE="YES" I2="0.0" ID="CMP-001.40.02" NO="2" P_CHI2="0.9370284439143731" P_Z="0.954237709264799" STUDIES="2" TAU2="0.0" TOTAL_1="121" TOTAL_2="122" WEIGHT="29.1342856670181" Z="0.05738600720464463">
<NAME>Chinese</NAME>
<CONT_DATA CI_END="0.3110243308527212" CI_START="-0.3110243308527212" EFFECT_SIZE="0.0" ESTIMABLE="YES" MEAN_1="505.0" MEAN_2="505.0" ORDER="17228" SD_1="45.0" SD_2="40.0" SE="0.15868879903204416" STUDY_ID="STD-Lee-1994" TOTAL_1="77" TOTAL_2="82" WEIGHT="19.072005137429322"/>
<CONT_DATA CI_END="0.40686449035579997" CI_START="-0.44953091203190143" EFFECT_SIZE="-0.021333210838050704" ESTIMABLE="YES" MEAN_1="516.0" MEAN_2="517.0" ORDER="17229" SD_1="44.0" SD_2="49.0" SE="0.21847222937330457" STUDY_ID="STD-Lee-1995" TOTAL_1="44" TOTAL_2="40" WEIGHT="10.06228052958878"/>
</CONT_SUBGROUP>
<CONT_SUBGROUP CHI2="0.0" CI_END="0.6175167825952239" CI_START="-0.0059803321820287025" DF="0" EFFECT_SIZE="0.30576822520659763" ESTIMABLE="YES" I2="0.0" ID="CMP-001.40.03" NO="3" P_CHI2="1.0" P_Z="0.05455976831896743" STUDIES="1" TAU2="0.0" TOTAL_1="80" TOTAL_2="80" WEIGHT="18.98349529219736" Z="1.9223656206837931">
<NAME>Other</NAME>
<CONT_DATA CI_END="0.6175167825952239" CI_START="-0.0059803321820287025" EFFECT_SIZE="0.30576822520659763" ESTIMABLE="YES" MEAN_1="256.0" MEAN_2="242.0" ORDER="17230" SD_1="43.0" SD_2="48.0" SE="0.15905830915652489" STUDY_ID="STD-Dibba-2000" TOTAL_1="80" TOTAL_2="80" WEIGHT="18.98349529219736"/>
</CONT_SUBGROUP>
</CONT_OUTCOME>
<CONT_OUTCOME CHI2="9.999290005021443" CI_END="0.8320480580590197" CI_START="-0.2440001323893088" CI_STUDY="95" CI_TOTAL="95" DF="3" EFFECT_MEASURE="SMD" EFFECT_SIZE="0.2940239628348555" ESTIMABLE="YES" I2="69.99786986382573" I2_Q="0.0" ID="CMP-001.41" NO="41" P_CHI2="0.018572210236166842" P_Q="0.860589041558701" P_Z="0.2841255127304163" Q="0.030843942840308003" RANDOM="YES" SCALE="4.0" SORT_BY="STUDY" STUDIES="2" SUBGROUPS="YES" SUBGROUP_TEST="NO" TAU2="0.2074562157702222" TOTALS="YES" TOTAL_1="87" TOTAL_2="129" UNITS="" WEIGHT="100.0" Z="1.071097712655338">
<NAME>Femoral neck BMD (mg/cm2) (at end supplementation) by physical activity level</NAME>
<GROUP_LABEL_1>Treatment</GROUP_LABEL_1>
<GROUP_LABEL_2>Control</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours control</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours treatment</GRAPH_LABEL_2>
<CONT_SUBGROUP CHI2="6.918920035683907" CI_END="1.4721088575148085" CI_START="-0.6516605090668501" DF="1" EFFECT_SIZE="0.41022417422397917" ESTIMABLE="YES" I2="85.54687733284152" ID="CMP-001.41.01" NO="1" P_CHI2="0.008528916541362674" P_Z="0.4489495042660334" STUDIES="2" TAU2="0.5036765580037945" TOTAL_1="49" TOTAL_2="80" WEIGHT="52.12620255902562" Z="0.7571675340254221">
<NAME>High</NAME>
<CONT_DATA CI_END="1.6517546321920717" CI_START="0.31222654491885593" EFFECT_SIZE="0.9819905885554638" ESTIMABLE="YES" MEAN_1="847.0" MEAN_2="754.0" ORDER="17231" SD_1="49.0" SD_2="102.0" SE="0.34172262802766845" STUDY_ID="STD-Courteix-2005" TOTAL_1="12" TOTAL_2="42" WEIGHT="23.24091966291766"/>
<CONT_DATA CI_END="0.34983518322998797" CI_START="-0.5561490670325926" EFFECT_SIZE="-0.10315694190130231" ESTIMABLE="YES" MEAN_1="858.0" MEAN_2="869.0" ORDER="17232" SD_1="110.0" SD_2="101.0" SE="0.231122678122881" STUDY_ID="STD-Stear-2003" TOTAL_1="37" TOTAL_2="38" WEIGHT="28.885282896107963"/>
</CONT_SUBGROUP>
<CONT_SUBGROUP CHI2="3.0495260264972273" CI_END="1.0006216467540887" CI_START="-0.6073041355535092" DF="1" EFFECT_SIZE="0.19665875560028973" ESTIMABLE="YES" I2="67.20801884256655" ID="CMP-001.41.02" NO="2" P_CHI2="0.08076094014339041" P_Z="0.6316326250961697" STUDIES="2" TAU2="0.22889600594168802" TOTAL_1="38" TOTAL_2="49" WEIGHT="47.87379744097437" Z="0.47943018572395363">
<NAME>Low</NAME>
<CONT_DATA CI_END="0.4951767017695483" CI_START="-1.0173184204563968" EFFECT_SIZE="-0.2610708593434242" ESTIMABLE="YES" MEAN_1="683.0" MEAN_2="703.0" ORDER="17233" SD_1="69.0" SD_2="77.0" SE="0.3858476824462882" STUDY_ID="STD-Courteix-2005" TOTAL_1="10" TOTAL_2="21" WEIGHT="21.147021879219736"/>
<CONT_DATA CI_END="1.099168575051754" CI_START="0.029334225023041838" EFFECT_SIZE="0.5642514000373978" ESTIMABLE="YES" MEAN_1="876.0" MEAN_2="819.0" ORDER="17234" SD_1="88.0" SD_2="110.0" SE="0.27292194103244466" STUDY_ID="STD-Stear-2003" TOTAL_1="28" TOTAL_2="28" WEIGHT="26.72677556175464"/>
</CONT_SUBGROUP>
</CONT_OUTCOME>
<CONT_OUTCOME CHI2="8.442680897496885" CI_END="0.6473352584967031" CI_START="-0.3365546970047438" CI_STUDY="95" CI_TOTAL="95" DF="3" EFFECT_MEASURE="SMD" EFFECT_SIZE="0.15539028074597966" ESTIMABLE="YES" I2="64.4662633063693" I2_Q="0.0" ID="CMP-001.42" NO="42" P_CHI2="0.03769626174982521" P_Q="0.5943026704349073" P_Z="0.5358555509552032" Q="0.28367491145848334" RANDOM="YES" SCALE="1.0" SORT_BY="STUDY" STUDIES="2" SUBGROUPS="YES" SUBGROUP_TEST="NO" TAU2="0.15978367991435657" TOTALS="YES" TOTAL_1="87" TOTAL_2="129" UNITS="" WEIGHT="100.0" Z="0.6190923123195562">
<NAME>Lumbar spine BMD (mg/cm2) (at end supplementation) by physical activity level</NAME>
<GROUP_LABEL_1>Treatment</GROUP_LABEL_1>
<GROUP_LABEL_2>Control</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours control</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours treatment</GRAPH_LABEL_2>
<CONT_SUBGROUP CHI2="4.438758808289682" CI_END="1.0246768168218838" CI_START="-0.6474750214420837" DF="1" EFFECT_SIZE="0.18860089768990007" ESTIMABLE="YES" I2="77.47117959794453" ID="CMP-001.42.01" NO="1" P_CHI2="0.03513181935742493" P_Z="0.6583979758892028" STUDIES="2" TAU2="0.28370798528978686" TOTAL_1="49" TOTAL_2="80" WEIGHT="52.75268889948153" Z="0.44212607786611086">
<NAME>High</NAME>
<CONT_DATA CI_END="1.3043044515242415" CI_START="-0.003835129860864761" EFFECT_SIZE="0.6502346608316883" ESTIMABLE="YES" MEAN_1="817.0" MEAN_2="748.0" ORDER="17235" SD_1="76.0" SD_2="111.0" SE="0.33371520897923235" STUDY_ID="STD-Courteix-2005" TOTAL_1="12" TOTAL_2="42" WEIGHT="23.234216906791126"/>
<CONT_DATA CI_END="0.24835267766346192" CI_START="-0.6595165056425426" EFFECT_SIZE="-0.20558191398954034" ESTIMABLE="YES" MEAN_1="994.0" MEAN_2="1015.0" ORDER="17236" SD_1="107.0" SD_2="95.0" SE="0.23160353722495944" STUDY_ID="STD-Stear-2003" TOTAL_1="37" TOTAL_2="38" WEIGHT="29.518471992690397"/>
</CONT_SUBGROUP>
<CONT_SUBGROUP CHI2="3.7202471777487194" CI_END="1.0070558176436326" CI_START="-0.7765262312509414" DF="1" EFFECT_SIZE="0.11526479319634562" ESTIMABLE="YES" I2="73.12006562410343" ID="CMP-001.42.02" NO="2" P_CHI2="0.05375665914305605" P_Z="0.8000154483327996" STUDIES="2" TAU2="0.30530097695593256" TOTAL_1="38" TOTAL_2="49" WEIGHT="47.24731110051847" Z="0.253327110452039">
<NAME>Low</NAME>
<CONT_DATA CI_END="0.37659610509541275" CI_START="-1.1432763041152807" EFFECT_SIZE="-0.383340099509934" ESTIMABLE="YES" MEAN_1="649.0" MEAN_2="684.0" ORDER="17237" SD_1="53.0" SD_2="101.0" SE="0.387729677993895" STUDY_ID="STD-Courteix-2005" TOTAL_1="10" TOTAL_2="21" WEIGHT="20.31467737861984"/>
<CONT_DATA CI_END="1.06412089906537" CI_START="-0.0031604679256383994" EFFECT_SIZE="0.5304802155698659" ESTIMABLE="YES" MEAN_1="1006.0" MEAN_2="954.0" ORDER="17238" SD_1="91.0" SD_2="102.0" SE="0.2722706578818764" STUDY_ID="STD-Stear-2003" TOTAL_1="28" TOTAL_2="28" WEIGHT="26.932633721898636"/>
</CONT_SUBGROUP>
</CONT_OUTCOME>
<CONT_OUTCOME CHI2="5.518746549083234" CI_END="0.36692861269027266" CI_START="-0.007713915488472639" CI_STUDY="95" CI_TOTAL="95" DF="7" EFFECT_MEASURE="SMD" EFFECT_SIZE="0.1796073486009" ESTIMABLE="YES" I2="0.0" I2_Q="0.0" ID="CMP-001.43" NO="43" P_CHI2="0.5969237542365919" P_Q="0.6459606904423156" P_Z="0.06021003817007599" Q="0.2110307917948102" RANDOM="NO" SCALE="1.0" SORT_BY="STUDY" STUDIES="4" SUBGROUPS="YES" SUBGROUP_TEST="YES" TAU2="0.0" TOTALS="YES" TOTAL_1="208" TOTAL_2="255" UNITS="" WEIGHT="100.0" Z="1.8792523973601885">
<NAME>Total body BMC (mg) (at end supplementation) by physical activity level</NAME>
<GROUP_LABEL_1>Treatment</GROUP_LABEL_1>
<GROUP_LABEL_2>Control</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours control</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours treatment</GRAPH_LABEL_2>
<CONT_SUBGROUP CHI2="4.055878931635977" CI_END="0.47649522908784425" CI_START="-0.035490666444924046" DF="3" EFFECT_SIZE="0.2205022813214601" ESTIMABLE="YES" I2="26.033295111451427" ID="CMP-001.43.01" NO="1" P_CHI2="0.2554931831084527" P_Z="0.09136592038816006" STUDIES="4" TAU2="0.0" TOTAL_1="111" TOTAL_2="143" WEIGHT="53.54490558268428" Z="1.6882360770867">
<NAME>High</NAME>
<CONT_DATA CI_END="1.4884579110768363" CI_START="0.1651098518289762" EFFECT_SIZE="0.8267838814529063" ESTIMABLE="YES" MEAN_1="1449.9" MEAN_2="1191.3" ORDER="17239" SD_1="242.1" SD_2="323.7" SE="0.3375949940116912" STUDY_ID="STD-Courteix-2005" TOTAL_1="12" TOTAL_2="42" WEIGHT="8.014676204673613"/>
<CONT_DATA CI_END="0.6336024180056734" CI_START="-0.7134050591141754" EFFECT_SIZE="-0.03990132055425094" ESTIMABLE="YES" MEAN_1="1147.7" MEAN_2="1156.3" ORDER="17240" SD_1="243.6" SD_2="176.07" SE="0.3436306707023373" STUDY_ID="STD-Iuliano_x002d_Burns-2003" TOTAL_1="16" TOTAL_2="18" WEIGHT="7.735602375513736"/>
<CONT_DATA CI_END="0.5356785383790135" CI_START="-0.2870406135290676" EFFECT_SIZE="0.12431896242497291" ESTIMABLE="YES" MEAN_1="685.0" MEAN_2="674.0" ORDER="17241" SD_1="93.0" SD_2="82.0" SE="0.20988119128657076" STUDY_ID="STD-Specker-2003" TOTAL_1="46" TOTAL_2="45" WEIGHT="20.73628420176892"/>
<CONT_DATA CI_END="0.6241996465315398" CI_START="-0.28288675575485067" EFFECT_SIZE="0.1706564453883446" ESTIMABLE="YES" MEAN_1="2144.0" MEAN_2="2101.0" ORDER="17242" SD_1="273.0" SD_2="224.0" SE="0.23140384451994328" STUDY_ID="STD-Stear-2003" TOTAL_1="37" TOTAL_2="38" WEIGHT="17.058342800728013"/>
</CONT_SUBGROUP>
<CONT_SUBGROUP CHI2="1.2518368256524472" CI_END="0.40730514362107306" CI_START="-0.14236279001465793" DF="3" EFFECT_SIZE="0.13247117680320755" ESTIMABLE="YES" I2="0.0" ID="CMP-001.43.02" NO="2" P_CHI2="0.740600488926775" P_Z="0.3448063323810724" STUDIES="4" TAU2="0.0" TOTAL_1="97" TOTAL_2="112" WEIGHT="46.45509441731572" Z="0.9447112324947419">
<NAME>Low</NAME>
<CONT_DATA CI_END="0.9272932294219011" CI_START="-0.5816044409286812" EFFECT_SIZE="0.1728443942466099" ESTIMABLE="YES" MEAN_1="1210.1" MEAN_2="1175.7" ORDER="17243" SD_1="193.9" SD_2="193.8" SE="0.3849299482675637" STUDY_ID="STD-Courteix-2005" TOTAL_1="10" TOTAL_2="21" WEIGHT="6.164737305665491"/>
<CONT_DATA CI_END="1.045987889295217" CI_START="-0.3622787973048704" EFFECT_SIZE="0.34185454599517334" ESTIMABLE="YES" MEAN_1="1216.0" MEAN_2="1146.2" ORDER="17244" SD_1="170.25" SD_2="218.5" SE="0.3592583072210294" STUDY_ID="STD-Iuliano_x002d_Burns-2003" TOTAL_1="14" TOTAL_2="18" WEIGHT="7.0772467751720685"/>
<CONT_DATA CI_END="0.37697031276223697" CI_START="-0.4494940851916264" EFFECT_SIZE="-0.03626188621469475" ESTIMABLE="YES" MEAN_1="686.0" MEAN_2="689.0" ORDER="17245" SD_1="84.0" SD_2="80.0" SE="0.21083662875259676" STUDY_ID="STD-Specker-2003" TOTAL_1="45" TOTAL_2="45" WEIGHT="20.54877094151822"/>
<CONT_DATA CI_END="0.7959648588991588" CI_START="-0.25678648650835645" EFFECT_SIZE="0.2695891861954012" ESTIMABLE="YES" MEAN_1="2140.0" MEAN_2="2070.0" ORDER="17246" SD_1="260.0" SD_2="252.0" SE="0.26856395161122437" STUDY_ID="STD-Stear-2003" TOTAL_1="28" TOTAL_2="28" WEIGHT="12.664339394959937"/>
</CONT_SUBGROUP>
</CONT_OUTCOME>
<CONT_OUTCOME CHI2="5.9887631610646235" CI_END="0.5048907325626718" CI_START="-0.31919435770192384" CI_STUDY="95" CI_TOTAL="95" DF="3" EFFECT_MEASURE="SMD" EFFECT_SIZE="0.09284818743037399" ESTIMABLE="YES" I2="49.906183976280516" I2_Q="46.03782802624803" ID="CMP-001.44" NO="44" P_CHI2="0.11215825426747283" P_Q="0.17341765810048926" P_Z="0.6587415960841008" Q="1.853150018658284" RANDOM="YES" SCALE="1.0" SORT_BY="STUDY" STUDIES="2" SUBGROUPS="YES" SUBGROUP_TEST="NO" TAU2="0.087203033027689" TOTALS="YES" TOTAL_1="87" TOTAL_2="129" UNITS="" WEIGHT="100.0" Z="0.4416512458317334">
<NAME>Distal radius BMD (mg/cm2) (at end supplementation) by physical activity level</NAME>
<GROUP_LABEL_1>Treatment</GROUP_LABEL_1>
<GROUP_LABEL_2>Control</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours control</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours treatment</GRAPH_LABEL_2>
<CONT_SUBGROUP CHI2="0.005876243690827717" CI_END="0.31300989200417384" CI_START="-0.42687065599415863" DF="1" EFFECT_SIZE="-0.056930381994992396" ESTIMABLE="YES" I2="0.0" ID="CMP-001.44.01" NO="1" P_CHI2="0.9388966825936327" P_Z="0.7629415276257976" STUDIES="2" TAU2="0.0" TOTAL_1="49" TOTAL_2="80" WEIGHT="54.1770414789552" Z="0.3016203051645686">
<NAME>High</NAME>
<CONT_DATA CI_END="0.5642891293300121" CI_START="-0.7191670825511713" EFFECT_SIZE="-0.07743897661057969" ESTIMABLE="YES" MEAN_1="363.0" MEAN_2="369.0" ORDER="17247" SD_1="50.0" SD_2="82.0" SE="0.3274183153376598" STUDY_ID="STD-Courteix-2005" TOTAL_1="12" TOTAL_2="42" WEIGHT="22.73415167365206"/>
<CONT_DATA CI_END="0.4060170927551902" CI_START="-0.49946231359778986" EFFECT_SIZE="-0.04672261042129983" ESTIMABLE="YES" MEAN_1="422.0" MEAN_2="424.0" ORDER="17248" SD_1="37.0" SD_2="47.0" SE="0.23099388904471868" STUDY_ID="STD-Stear-2003" TOTAL_1="37" TOTAL_2="38" WEIGHT="31.44288980530314"/>
</CONT_SUBGROUP>
<CONT_SUBGROUP CHI2="4.129736898715512" CI_END="1.164065611650412" CI_START="-0.7190784745885351" DF="1" EFFECT_SIZE="0.22249356853093846" ESTIMABLE="YES" I2="75.7853823493929" ID="CMP-001.44.02" NO="2" P_CHI2="0.04213601527756594" P_Z="0.6432642461096936" STUDIES="2" TAU2="0.35201267257278857" TOTAL_1="38" TOTAL_2="49" WEIGHT="45.8229585210448" Z="0.4631396867601142">
<NAME>Low</NAME>
<CONT_DATA CI_END="0.4596197060631283" CI_START="-1.0547887881887323" EFFECT_SIZE="-0.29758454106280197" ESTIMABLE="YES" MEAN_1="304.0" MEAN_2="315.0" ORDER="17249" SD_1="36.0" SD_2="36.0" SE="0.3863357965241508" STUDY_ID="STD-Courteix-2005" TOTAL_1="10" TOTAL_2="21" WEIGHT="18.69102976010353"/>
<CONT_DATA CI_END="1.205475683568702" CI_START="0.12701960241495602" EFFECT_SIZE="0.666247642991829" ESTIMABLE="YES" MEAN_1="435.0" MEAN_2="410.0" ORDER="17250" SD_1="37.0" SD_2="37.0" SE="0.27512140265343393" STUDY_ID="STD-Stear-2003" TOTAL_1="28" TOTAL_2="28" WEIGHT="27.131928760941264"/>
</CONT_SUBGROUP>
</CONT_OUTCOME>
<CONT_OUTCOME CHI2="5.9887631610646235" CI_END="0.5048907325626719" CI_START="-0.3191943577019239" CI_STUDY="95" CI_TOTAL="95" DF="3" EFFECT_MEASURE="SMD" EFFECT_SIZE="0.09284818743037399" ESTIMABLE="YES" I2="49.906183976280516" I2_Q="46.03782802624803" ID="CMP-001.45" NO="45" P_CHI2="0.11215825426747283" P_Q="0.17341765810048926" P_Z="0.6587415960841009" Q="1.853150018658284" RANDOM="YES" SCALE="1.0" SORT_BY="STUDY" STUDIES="2" SUBGROUPS="YES" SUBGROUP_TEST="NO" TAU2="0.087203033027689" TOTALS="YES" TOTAL_1="87" TOTAL_2="129" UNITS="" WEIGHT="100.0" Z="0.4416512458317333">
<NAME>Upper limb BMD (mg/cm2) (at end supplementation) by physical activity level</NAME>
<GROUP_LABEL_1>Treatment</GROUP_LABEL_1>
<GROUP_LABEL_2>Control</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours control</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours treatment</GRAPH_LABEL_2>
<CONT_SUBGROUP CHI2="0.005876243690827717" CI_END="0.31300989200417384" CI_START="-0.42687065599415863" DF="1" EFFECT_SIZE="-0.056930381994992396" ESTIMABLE="YES" I2="0.0" ID="CMP-001.45.01" NO="1" P_CHI2="0.9388966825936327" P_Z="0.7629415276257976" STUDIES="2" TAU2="0.0" TOTAL_1="49" TOTAL_2="80" WEIGHT="54.1770414789552" Z="0.3016203051645686">
<NAME>High</NAME>
<CONT_DATA CI_END="0.5642891293300121" CI_START="-0.7191670825511713" EFFECT_SIZE="-0.07743897661057969" ESTIMABLE="YES" MEAN_1="363.0" MEAN_2="369.0" ORDER="17251" SD_1="50.0" SD_2="82.0" SE="0.3274183153376598" STUDY_ID="STD-Courteix-2005" TOTAL_1="12" TOTAL_2="42" WEIGHT="22.73415167365206"/>
<CONT_DATA CI_END="0.4060170927551902" CI_START="-0.49946231359778986" EFFECT_SIZE="-0.04672261042129983" ESTIMABLE="YES" MEAN_1="422.0" MEAN_2="424.0" ORDER="17252" SD_1="37.0" SD_2="47.0" SE="0.23099388904471868" STUDY_ID="STD-Stear-2003" TOTAL_1="37" TOTAL_2="38" WEIGHT="31.44288980530314"/>
</CONT_SUBGROUP>
<CONT_SUBGROUP CHI2="4.129736898715512" CI_END="1.164065611650412" CI_START="-0.7190784745885351" DF="1" EFFECT_SIZE="0.22249356853093846" ESTIMABLE="YES" I2="75.7853823493929" ID="CMP-001.45.02" NO="2" P_CHI2="0.04213601527756594" P_Z="0.6432642461096936" STUDIES="2" TAU2="0.35201267257278857" TOTAL_1="38" TOTAL_2="49" WEIGHT="45.8229585210448" Z="0.4631396867601142">
<NAME>Low</NAME>
<CONT_DATA CI_END="0.4596197060631283" CI_START="-1.0547887881887323" EFFECT_SIZE="-0.29758454106280197" ESTIMABLE="YES" MEAN_1="304.0" MEAN_2="315.0" ORDER="17253" SD_1="36.0" SD_2="36.0" SE="0.3863357965241508" STUDY_ID="STD-Courteix-2005" TOTAL_1="10" TOTAL_2="21" WEIGHT="18.69102976010353"/>
<CONT_DATA CI_END="1.205475683568702" CI_START="0.12701960241495602" EFFECT_SIZE="0.666247642991829" ESTIMABLE="YES" MEAN_1="435.0" MEAN_2="410.0" ORDER="17254" SD_1="37.0" SD_2="37.0" SE="0.27512140265343393" STUDY_ID="STD-Stear-2003" TOTAL_1="28" TOTAL_2="28" WEIGHT="27.131928760941264"/>
</CONT_SUBGROUP>
</CONT_OUTCOME>
<CONT_OUTCOME CHI2="5.833956503938204" CI_END="0.1894099906117992" CI_START="-0.05259426682904429" CI_STUDY="95" CI_TOTAL="95" DF="9" EFFECT_MEASURE="SMD" EFFECT_SIZE="0.06840786189137744" ESTIMABLE="YES" I2="0.0" I2_Q="0.0" ID="CMP-001.46" NO="46" P_CHI2="0.7564148098212335" P_Q="0.8478286231677898" P_Z="0.26783832457717716" Q="0.036821683579635334" RANDOM="NO" SCALE="1.0" SORT_BY="STUDY" STUDIES="10" SUBGROUPS="YES" SUBGROUP_TEST="YES" TAU2="0.0" TOTALS="YES" TOTAL_1="519" TOTAL_2="554" UNITS="" WEIGHT="100.00000000000001" Z="1.1080544365982008">
<NAME>Femoral neck BMD (mg/cm2) at end supplementation by calcium threshold</NAME>
<GROUP_LABEL_1>Treatment</GROUP_LABEL_1>
<GROUP_LABEL_2>Control</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours control</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours treatment</GRAPH_LABEL_2>
<CONT_SUBGROUP CHI2="5.67166867773291" CI_END="0.20670446777327778" CI_START="-0.0591205994148553" DF="7" EFFECT_SIZE="0.07379193417921125" ESTIMABLE="YES" I2="0.0" ID="CMP-001.46.01" NO="1" P_CHI2="0.5785663120661375" P_Z="0.2765263868927934" STUDIES="8" TAU2="0.0" TOTAL_1="426" TOTAL_2="467" WEIGHT="82.88084076895129" Z="1.0881557173721714">
<NAME>Above</NAME>
<CONT_DATA CI_END="0.6604385539390247" CI_START="-0.09794154702996843" EFFECT_SIZE="0.2812485034545282" ESTIMABLE="YES" MEAN_1="656.0" MEAN_2="635.0" ORDER="17255" SD_1="81.58" SD_2="65.52" SE="0.19346786648912906" STUDY_ID="STD-Bonjour-1995" TOTAL_1="55" TOTAL_2="53" WEIGHT="10.182915842113054"/>
<CONT_DATA CI_END="0.5507846604584942" CI_START="-0.5808184484700071" EFFECT_SIZE="-0.015016894005756475" ESTIMABLE="YES" MEAN_1="814.0" MEAN_2="816.0" ORDER="17256" SD_1="131.0" SD_2="131.0" SE="0.2886795670365482" STUDY_ID="STD-Cameron-2004" TOTAL_1="24" TOTAL_2="24" WEIGHT="4.573595467063528"/>
<CONT_DATA CI_END="0.17515393035443064" CI_START="-0.3398562006734309" EFFECT_SIZE="-0.08235113515950013" ESTIMABLE="YES" MEAN_1="698.0" MEAN_2="703.7" ORDER="17257" SD_1="70.0" SD_2="68.0" SE="0.13138254965147209" STUDY_ID="STD-Chevalley-2005" TOTAL_1="114" TOTAL_2="118" WEIGHT="22.080782911208967"/>
<CONT_DATA CI_END="0.8977163300128035" CI_START="-0.08113466441638145" EFFECT_SIZE="0.40829083279821105" ESTIMABLE="YES" MEAN_1="772.45" MEAN_2="737.0" ORDER="17258" SD_1="57.43" SD_2="93.77" SE="0.24971147484092482" STUDY_ID="STD-Courteix-2005" TOTAL_1="22" TOTAL_2="63" WEIGHT="6.112415100267862"/>
<CONT_DATA CI_END="0.37562699217396994" CI_START="-0.4508427758870757" EFFECT_SIZE="-0.037607891856552896" ESTIMABLE="YES" MEAN_1="847.72" MEAN_2="852.89" ORDER="17259" SD_1="128.13" SD_2="144.0" SE="0.21083799870307152" STUDY_ID="STD-Johnston-1992" TOTAL_1="45" TOTAL_2="45" WEIGHT="8.574169583656113"/>
<CONT_DATA CI_END="0.5859768774270062" CI_START="-0.46193881656079006" EFFECT_SIZE="0.06201903043310805" ESTIMABLE="YES" MEAN_1="877.0" MEAN_2="871.0" ORDER="17260" SD_1="90.0" SD_2="100.5" SE="0.26733034439755565" STUDY_ID="STD-Nowson-1997" TOTAL_1="28" TOTAL_2="28" WEIGHT="5.333266965361167"/>
<CONT_DATA CI_END="0.3203145893001051" CI_START="-0.3354338260641689" EFFECT_SIZE="-0.0075596183820319145" ESTIMABLE="YES" MEAN_1="1001.0" MEAN_2="1002.0" ORDER="17261" SD_1="134.0" SD_2="129.0" SE="0.16728583293793503" STUDY_ID="STD-Prentice-2005" TOTAL_1="73" TOTAL_2="70" WEIGHT="13.619824552271593"/>
<CONT_DATA CI_END="0.5643130591550494" CI_START="-0.12282562247230913" EFFECT_SIZE="0.2207437183413701" ESTIMABLE="YES" MEAN_1="870.0" MEAN_2="847.0" ORDER="17262" SD_1="100.0" SD_2="107.0" SE="0.17529370106987185" STUDY_ID="STD-Stear-2003" TOTAL_1="65" TOTAL_2="66" WEIGHT="12.403870347008995"/>
</CONT_SUBGROUP>
<CONT_SUBGROUP CHI2="0.12546614262565783" CI_END="0.3347914832239619" CI_START="-0.25010874470687905" DF="1" EFFECT_SIZE="0.042341369258541456" ESTIMABLE="YES" I2="0.0" ID="CMP-001.46.02" NO="2" P_CHI2="0.7231800797759302" P_Z="0.7765892936213316" STUDIES="2" TAU2="0.0" TOTAL_1="93" TOTAL_2="87" WEIGHT="17.119159231048727" Z="0.2837665462926275">
<NAME>Below</NAME>
<CONT_DATA CI_END="0.4140084286058978" CI_START="-0.44237274406664784" EFFECT_SIZE="-0.014182157730375022" ESTIMABLE="YES" MEAN_1="592.0" MEAN_2="593.0" ORDER="17263" SD_1="74.0" SD_2="65.0" SE="0.21846859927722423" STUDY_ID="STD-Lee-1995" TOTAL_1="44" TOTAL_2="40" WEIGHT="7.985677934320828"/>
<CONT_DATA CI_END="0.4921438634140949" CI_START="-0.3086206789419552" EFFECT_SIZE="0.09176159223606986" ESTIMABLE="YES" MEAN_1="1010.0" MEAN_2="1000.0" ORDER="17264" SD_1="70.0" SD_2="137.0" SE="0.2042804226690844" STUDY_ID="STD-Rozen-2003" TOTAL_1="49" TOTAL_2="47" WEIGHT="9.133481296727899"/>
</CONT_SUBGROUP>
</CONT_OUTCOME>
<CONT_OUTCOME CHI2="1.1024640714897922" CI_END="0.19656167519370077" CI_START="-0.03540959073148839" CI_STUDY="95" CI_TOTAL="95" DF="10" EFFECT_MEASURE="SMD" EFFECT_SIZE="0.08057604223110619" ESTIMABLE="YES" I2="0.0" I2_Q="0.0" ID="CMP-001.47" NO="47" P_CHI2="0.9997312530937471" P_Q="0.9779964492854252" P_Z="0.17332387499636842" Q="7.607037642558545E-4" RANDOM="NO" SCALE="1.0" SORT_BY="STUDY" STUDIES="11" SUBGROUPS="YES" SUBGROUP_TEST="YES" TAU2="0.0" TOTALS="YES" TOTAL_1="563" TOTAL_2="601" UNITS="" WEIGHT="100.0" Z="1.3616008875916368">
<NAME>Lumbar spine BMD (mg/cm2) at end supplementation by calcium threshold</NAME>
<GROUP_LABEL_1>Treatment</GROUP_LABEL_1>
<GROUP_LABEL_2>Control</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours control</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours treatment</GRAPH_LABEL_2>
<CONT_SUBGROUP CHI2="0.5781488007297275" CI_END="0.2142276383491662" CI_START="-0.05125854627521405" DF="7" EFFECT_SIZE="0.08148454603697607" ESTIMABLE="YES" I2="0.0" ID="CMP-001.47.01" NO="1" P_CHI2="0.9991070560938868" P_Z="0.22892726722214618" STUDIES="8" TAU2="0.0" TOTAL_1="426" TOTAL_2="467" WEIGHT="76.34569144243977" Z="1.2031268275223301">
<NAME>Above</NAME>
<CONT_DATA CI_END="0.5114205026835856" CI_START="-0.24397376271812718" EFFECT_SIZE="0.13372336998272924" ESTIMABLE="YES" MEAN_1="647.0" MEAN_2="638.0" ORDER="17265" SD_1="74.16" SD_2="58.24" SE="0.1927061597458337" STUDY_ID="STD-Bonjour-1995" TOTAL_1="55" TOTAL_2="53" WEIGHT="9.43020248538449"/>
<CONT_DATA CI_END="0.6643854658079379" CI_START="-0.4679433402975458" EFFECT_SIZE="0.09822106275519607" ESTIMABLE="YES" MEAN_1="848.0" MEAN_2="833.0" ORDER="17266" SD_1="158.0" SD_2="142.0" SE="0.2888646972692225" STUDY_ID="STD-Cameron-2004" TOTAL_1="24" TOTAL_2="24" WEIGHT="4.196848320638333"/>
<CONT_DATA CI_END="0.27186034181968627" CI_START="-0.24293478100807947" EFFECT_SIZE="0.014462780405803406" ESTIMABLE="YES" MEAN_1="586.9" MEAN_2="586.1" ORDER="17267" SD_1="52.0" SD_2="58.0" SE="0.1313276996129531" STUDY_ID="STD-Chevalley-2005" TOTAL_1="114" TOTAL_2="118" WEIGHT="20.304838408962425"/>
<CONT_DATA CI_END="0.6270434570242918" CI_START="-0.3446758722743443" EFFECT_SIZE="0.1411837923749737" ESTIMABLE="YES" MEAN_1="740.64" MEAN_2="726.67" ORDER="17268" SD_1="65.03" SD_2="106.95" SE="0.2478921390809816" STUDY_ID="STD-Courteix-2005" TOTAL_1="22" TOTAL_2="63" WEIGHT="5.698843118900126"/>
<CONT_DATA CI_END="0.434960444536277" CI_START="-0.39145848587210075" EFFECT_SIZE="0.021750979332088152" ESTIMABLE="YES" MEAN_1="907.36" MEAN_2="902.96" ORDER="17269" SD_1="197.32" SD_2="203.75" SE="0.2108250296758167" STUDY_ID="STD-Johnston-1992" TOTAL_1="45" TOTAL_2="45" WEIGHT="7.87894141933801"/>
<CONT_DATA CI_END="0.6326118992120395" CI_START="-0.4158598560902002" EFFECT_SIZE="0.10837602156091967" ESTIMABLE="YES" MEAN_1="1017.0" MEAN_2="1001.0" ORDER="17270" SD_1="148.2" SD_2="142.9" SE="0.2674721993803078" STUDY_ID="STD-Nowson-1997" TOTAL_1="28" TOTAL_2="28" WEIGHT="4.895024998280832"/>
<CONT_DATA CI_END="0.45798631527414724" CI_START="-0.1984686132330601" EFFECT_SIZE="0.12975885102054358" ESTIMABLE="YES" MEAN_1="1047.0" MEAN_2="1032.0" ORDER="17271" SD_1="114.0" SD_2="116.0" SE="0.1674660691944444" STUDY_ID="STD-Prentice-2005" TOTAL_1="73" TOTAL_2="70" WEIGHT="12.487012848693666"/>
<CONT_DATA CI_END="0.4411301457213726" CI_START="-0.24428861169722987" EFFECT_SIZE="0.09842076701207135" ESTIMABLE="YES" MEAN_1="999.0" MEAN_2="989.0" ORDER="17272" SD_1="100.0" SD_2="102.0" SE="0.17485493683177297" STUDY_ID="STD-Stear-2003" TOTAL_1="65" TOTAL_2="66" WEIGHT="11.453979842241894"/>
</CONT_SUBGROUP>
<CONT_SUBGROUP CHI2="0.5235545669958088" CI_END="0.31612220234366345" CI_START="-0.16083461830161289" DF="2" EFFECT_SIZE="0.0776437920210253" ESTIMABLE="YES" I2="0.0" ID="CMP-001.47.02" NO="2" P_CHI2="0.7696824388957946" P_Z="0.5233923165397737" STUDIES="3" TAU2="0.0" TOTAL_1="137" TOTAL_2="134" WEIGHT="23.654308557560235" Z="0.6381250016655367">
<NAME>Below</NAME>
<CONT_DATA CI_END="0.4625164252125683" CI_START="-0.393919388343527" EFFECT_SIZE="0.034298518434520614" ESTIMABLE="YES" MEAN_1="525.0" MEAN_2="523.0" ORDER="17273" SD_1="61.0" SD_2="54.0" SE="0.21848253853426688" STUDY_ID="STD-Lee-1995" TOTAL_1="44" TOTAL_2="40" WEIGHT="7.336328090508805"/>
<CONT_DATA CI_END="0.6124201908396137" CI_START="-0.21201494446981703" EFFECT_SIZE="0.20020262318489837" ESTIMABLE="YES" MEAN_1="914.0" MEAN_2="894.0" ORDER="17274" SD_1="83.0" SD_2="112.0" SE="0.21031895019818475" STUDY_ID="STD-Lloyd-1993" TOTAL_1="44" TOTAL_2="47" WEIGHT="7.9169044070243535"/>
<CONT_DATA CI_END="0.40016282334497716" CI_START="-0.40016282334497716" EFFECT_SIZE="0.0" ESTIMABLE="YES" MEAN_1="1120.0" MEAN_2="1120.0" ORDER="17275" SD_1="140.0" SD_2="137.11" SE="0.2041684574315704" STUDY_ID="STD-Rozen-2003" TOTAL_1="49" TOTAL_2="47" WEIGHT="8.401076060027075"/>
</CONT_SUBGROUP>
</CONT_OUTCOME>
<CONT_OUTCOME CHI2="4.575286896634283" CI_END="0.26841853898080825" CI_START="0.011094187411965523" CI_STUDY="95" CI_TOTAL="95" DF="8" EFFECT_MEASURE="SMD" EFFECT_SIZE="0.1397563631963869" ESTIMABLE="YES" I2="0.0" I2_Q="0.0" ID="CMP-001.48" NO="48" P_CHI2="0.8018545079137473" P_Q="0.36405292983964865" P_Z="0.03325704729455614" Q="0.8238639110214674" RANDOM="NO" SCALE="1.0" SORT_BY="STUDY" STUDIES="9" SUBGROUPS="YES" SUBGROUP_TEST="YES" TAU2="0.0" TOTALS="YES" TOTAL_1="449" TOTAL_2="504" UNITS="" WEIGHT="99.99999999999999" Z="2.128966316675517">
<NAME>Total body BMC (mg) at end supplementation by calcium threshold</NAME>
<GROUP_LABEL_1>Treatment</GROUP_LABEL_1>
<GROUP_LABEL_2>Control</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours control</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours treatment</GRAPH_LABEL_2>
<CONT_SUBGROUP CHI2="2.844059576539332" CI_END="0.41070324332588715" CI_START="0.01065869825726537" DF="3" EFFECT_SIZE="0.21068097079157624" ESTIMABLE="YES" I2="0.0" ID="CMP-001.48.01" NO="1" P_CHI2="0.41629830397119616" P_Z="0.038979268659211905" STUDIES="4" TAU2="0.0" TOTAL_1="184" TOTAL_2="223" WEIGHT="41.375672769912924" Z="2.0644056771657415">
<NAME>Above</NAME>
<CONT_DATA CI_END="0.7244128544136019" CI_START="-0.4090865084137309" EFFECT_SIZE="0.15766317299993554" ESTIMABLE="YES" MEAN_1="1583.0" MEAN_2="1512.0" ORDER="17276" SD_1="504.0" SD_2="372.0" SE="0.289163314165013" STUDY_ID="STD-Cameron-2004" TOTAL_1="24" TOTAL_2="24" WEIGHT="5.153700938319747"/>
<CONT_DATA CI_END="1.0623077058025256" CI_START="0.07587704885842766" EFFECT_SIZE="0.5690923773304767" ESTIMABLE="YES" MEAN_1="1340.9" MEAN_2="1186.1" ORDER="17277" SD_1="216.37" SD_2="285.32" SE="0.2516450977479528" STUDY_ID="STD-Courteix-2005" TOTAL_1="22" TOTAL_2="63" WEIGHT="6.805008185954207"/>
<CONT_DATA CI_END="0.3908635962567637" CI_START="-0.26504909971456003" EFFECT_SIZE="0.06290724827110186" ESTIMABLE="YES" MEAN_1="2796.0" MEAN_2="2770.0" ORDER="17278" SD_1="415.0" SD_2="407.0" SE="0.1673277420261493" STUDY_ID="STD-Prentice-2005" TOTAL_1="73" TOTAL_2="70" WEIGHT="15.391101406551368"/>
<CONT_DATA CI_END="0.5619740238730728" CI_START="-0.12511989143932517" EFFECT_SIZE="0.21842706621687386" ESTIMABLE="YES" MEAN_1="2143.0" MEAN_2="2088.0" ORDER="17279" SD_1="265.0" SD_2="235.0" SE="0.175282280881717" STUDY_ID="STD-Stear-2003" TOTAL_1="65" TOTAL_2="66" WEIGHT="14.025862239087605"/>
</CONT_SUBGROUP>
<CONT_SUBGROUP CHI2="0.9073634090734835" CI_END="0.2577391639755115" CI_START="-0.0783402808913554" DF="4" EFFECT_SIZE="0.08969944154207805" ESTIMABLE="YES" I2="0.0" ID="CMP-001.48.02" NO="2" P_CHI2="0.9235020796951949" P_Z="0.29545630952529334" STUDIES="5" TAU2="0.0" TOTAL_1="265" TOTAL_2="281" WEIGHT="58.62432723008706" Z="1.0462268820128091">
<NAME>Below</NAME>
<CONT_DATA CI_END="0.6238360632229405" CI_START="-0.3464242431167532" EFFECT_SIZE="0.13870591005309368" ESTIMABLE="YES" MEAN_1="1179.57" MEAN_2="1151.25" ORDER="17280" SD_1="209.01" SD_2="195.57" SE="0.2475199325071744" STUDY_ID="STD-Iuliano_x002d_Burns-2003" TOTAL_1="30" TOTAL_2="36" WEIGHT="7.033722738386755"/>
<CONT_DATA CI_END="0.6634749996606573" CI_START="-0.16217650854283872" EFFECT_SIZE="0.2506492455589093" ESTIMABLE="YES" MEAN_1="1783.0" MEAN_2="1714.0" ORDER="17281" SD_1="238.0" SD_2="302.0" SE="0.21062925510777997" STUDY_ID="STD-Lloyd-1993" TOTAL_1="44" TOTAL_2="47" WEIGHT="9.713331640661762"/>
<CONT_DATA CI_END="0.4506900805835923" CI_START="-0.29400382768340283" EFFECT_SIZE="0.07834312645009475" ESTIMABLE="YES" MEAN_1="1932.11" MEAN_2="1907.53" ORDER="17282" SD_1="292.33" SD_2="328.77" SE="0.18997642664381734" STUDY_ID="STD-Molgaard-2004" TOTAL_1="54" TOTAL_2="57" WEIGHT="11.940050720347894"/>
<CONT_DATA CI_END="0.3917077443497603" CI_START="-0.392434700377596" EFFECT_SIZE="-3.634780139178262E-4" ESTIMABLE="YES" MEAN_1="860.29" MEAN_2="860.34" ORDER="17283" SD_1="134.19" SD_2="138.69" SE="0.2000400137228469" STUDY_ID="STD-Rozen-2003" TOTAL_1="49" TOTAL_2="51" WEIGHT="10.768912529976115"/>
<CONT_DATA CI_END="0.3417017087255969" CI_START="-0.24604334021365062" EFFECT_SIZE="0.047829184255973135" ESTIMABLE="YES" MEAN_1="685.55" MEAN_2="681.5" ORDER="17284" SD_1="88.0" SD_2="80.55" SE="0.1499377166048217" STUDY_ID="STD-Specker-2003" TOTAL_1="88" TOTAL_2="90" WEIGHT="19.16830960071454"/>
</CONT_SUBGROUP>
</CONT_OUTCOME>
<CONT_OUTCOME CHI2="8.073176705722247" CI_END="0.27214379866967514" CI_START="0.036867948161045216" CI_STUDY="95" CI_TOTAL="95" DF="8" EFFECT_MEASURE="SMD" EFFECT_SIZE="0.15450587341536018" ESTIMABLE="YES" I2="0.9064177385140044" I2_Q="39.665360774424265" ID="CMP-001.49" NO="49" P_CHI2="0.4263549182299098" P_Q="0.19795173689883028" P_Z="0.01004662511823083" Q="1.657422689246979" RANDOM="NO" SCALE="1.0" SORT_BY="STUDY" STUDIES="9" SUBGROUPS="YES" SUBGROUP_TEST="YES" TAU2="0.0" TOTALS="YES" TOTAL_1="542" TOTAL_2="598" UNITS="" WEIGHT="100.00000000000001" Z="2.5742204024709534">
<NAME>Distal radius BMD (mg/cm2) at end supplementation by calcium threshold</NAME>
<GROUP_LABEL_1>Treatment</GROUP_LABEL_1>
<GROUP_LABEL_2>Control</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours control</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours treatment</GRAPH_LABEL_2>
<CONT_SUBGROUP CHI2="3.870030419409301" CI_END="0.24358768953131923" CI_START="-0.050771799142137" DF="5" EFFECT_SIZE="0.09640794519459112" ESTIMABLE="YES" I2="0.0" ID="CMP-001.49.01" NO="1" P_CHI2="0.5682762422392851" P_Z="0.19919590569762208" STUDIES="6" TAU2="0.0" TOTAL_1="339" TOTAL_2="395" WEIGHT="63.884959584843706" Z="1.2838458257720777">
<NAME>Above</NAME>
<CONT_DATA CI_END="0.5128125613720704" CI_START="-0.24259987277088774" EFFECT_SIZE="0.13510634430059137" ESTIMABLE="YES" MEAN_1="312.0" MEAN_2="308.0" ORDER="17285" SD_1="29.66" SD_2="29.12" SE="0.1927107947139731" STUDY_ID="STD-Bonjour-1995" TOTAL_1="55" TOTAL_2="53" WEIGHT="9.700328592044865"/>
<CONT_DATA CI_END="0.2574725427227148" CI_START="-0.7158349449146524" EFFECT_SIZE="-0.2291812010959688" ESTIMABLE="YES" MEAN_1="336.18" MEAN_2="351.0" ORDER="17286" SD_1="43.19" SD_2="69.75" SE="0.24829728895905548" STUDY_ID="STD-Courteix-2005" TOTAL_1="22" TOTAL_2="63" WEIGHT="5.843251446728712"/>
<CONT_DATA CI_END="0.4929289406242539" CI_START="-0.3338062753225926" EFFECT_SIZE="0.07956133265083067" ESTIMABLE="YES" MEAN_1="317.09" MEAN_2="311.51" ORDER="17287" SD_1="69.4" SD_2="69.67" SE="0.2109057162447954" STUDY_ID="STD-Johnston-1992" TOTAL_1="45" TOTAL_2="45" WEIGHT="8.098821540257351"/>
<CONT_DATA CI_END="0.5300115286945037" CI_START="-0.06471641800366129" EFFECT_SIZE="0.23264755534542125" ESTIMABLE="YES" MEAN_1="450.0" MEAN_2="438.0" ORDER="17288" SD_1="53.0" SD_2="50.0" SE="0.15171910080728607" STUDY_ID="STD-Matkovic-2004" TOTAL_1="79" TOTAL_2="98" WEIGHT="15.650132200857508"/>
<CONT_DATA CI_END="0.2749570234978052" CI_START="-0.38090719667338463" EFFECT_SIZE="-0.05297508658778973" ESTIMABLE="YES" MEAN_1="479.0" MEAN_2="482.0" ORDER="17289" SD_1="61.0" SD_2="51.0" SE="0.16731537552336753" STUDY_ID="STD-Prentice-2005" TOTAL_1="73" TOTAL_2="70" WEIGHT="12.868467372323614"/>
<CONT_DATA CI_END="0.5639690051480064" CI_START="-0.12316306254107401" EFFECT_SIZE="0.2204029713034662" ESTIMABLE="YES" MEAN_1="427.0" MEAN_2="418.0" ORDER="17290" SD_1="38.0" SD_2="43.0" SE="0.17529201380971549" STUDY_ID="STD-Stear-2003" TOTAL_1="65" TOTAL_2="66" WEIGHT="11.723958432631655"/>
</CONT_SUBGROUP>
<CONT_SUBGROUP CHI2="2.545723597065967" CI_END="0.4530277022414243" CI_START="0.06152632025510707" DF="2" EFFECT_SIZE="0.2572770112482657" ESTIMABLE="YES" I2="21.436875460279037" ID="CMP-001.49.02" NO="2" P_CHI2="0.28002919854889097" P_Z="0.009995079974375806" STUDIES="3" TAU2="0.0" TOTAL_1="203" TOTAL_2="203" WEIGHT="36.11504041515631" Z="2.5759994692142905">
<NAME>Below</NAME>
<CONT_DATA CI_END="0.7515904462890333" CI_START="0.12422571852871639" EFFECT_SIZE="0.4379080824088748" ESTIMABLE="YES" MEAN_1="253.0" MEAN_2="231.0" ORDER="17291" SD_1="50.0" SD_2="50.0" SE="0.16004496325159281" STUDY_ID="STD-Dibba-2000" TOTAL_1="80" TOTAL_2="80" WEIGHT="14.064182994645218"/>
<CONT_DATA CI_END="0.4501644946278604" CI_START="-0.40623244295249933" EFFECT_SIZE="0.02196602583768056" ESTIMABLE="YES" MEAN_1="492.0" MEAN_2="491.0" ORDER="17292" SD_1="39.0" SD_2="51.0" SE="0.2184726210112812" STUDY_ID="STD-Lee-1995" TOTAL_1="44" TOTAL_2="40" WEIGHT="7.547523829023321"/>
<CONT_DATA CI_END="0.5134677994735729" CI_START="-0.10432584171130158" EFFECT_SIZE="0.20457097888113565" ESTIMABLE="YES" MEAN_1="486.0" MEAN_2="479.0" ORDER="17293" SD_1="37.0" SD_2="31.0" SE="0.15760331466750202" STUDY_ID="STD-Wang-1996" TOTAL_1="79" TOTAL_2="83" WEIGHT="14.50333359148777"/>
</CONT_SUBGROUP>
</CONT_OUTCOME>
<CONT_OUTCOME CHI2="8.690639421510731" CI_END="0.237153842673891" CI_START="0.037921792367907534" CI_STUDY="95" CI_TOTAL="95" DF="11" EFFECT_MEASURE="SMD" EFFECT_SIZE="0.13753781752089927" ESTIMABLE="YES" I2="0.0" I2_Q="48.09696855598861" ID="CMP-001.50" NO="50" P_CHI2="0.6504234741691632" P_Q="0.16512351301904116" P_Z="0.006808215777498085" Q="1.926669738122552" RANDOM="NO" SCALE="1.0" SORT_BY="STUDY" STUDIES="12" SUBGROUPS="YES" SUBGROUP_TEST="YES" TAU2="0.0" TOTALS="YES" TOTAL_1="757" TOTAL_2="822" UNITS="" WEIGHT="100.0" Z="2.7060823641497076">
<NAME>Upper limb BMD (mg/cm2) at end supplementation by calcium threshold</NAME>
<GROUP_LABEL_1>Treatment</GROUP_LABEL_1>
<GROUP_LABEL_2>Control</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours control</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours treatment</GRAPH_LABEL_2>
<CONT_SUBGROUP CHI2="3.98028869243205" CI_END="0.2091259866104249" CI_START="-0.04014664658566147" DF="7" EFFECT_SIZE="0.08448967001238171" ESTIMABLE="YES" I2="0.0" ID="CMP-001.50.01" NO="1" P_CHI2="0.7820450277971125" P_Z="0.18396699484535659" STUDIES="8" TAU2="0.0" TOTAL_1="477" TOTAL_2="537" WEIGHT="63.8806322515853" Z="1.3286393148475144">
<NAME>Above</NAME>
<CONT_DATA CI_END="0.5128125613720704" CI_START="-0.24259987277088774" EFFECT_SIZE="0.13510634430059137" ESTIMABLE="YES" MEAN_1="312.0" MEAN_2="308.0" ORDER="17294" SD_1="29.66" SD_2="29.12" SE="0.1927107947139731" STUDY_ID="STD-Bonjour-1995" TOTAL_1="55" TOTAL_2="53" WEIGHT="6.955849078431553"/>
<CONT_DATA CI_END="0.6586912100157563" CI_START="-0.47355455217399833" EFFECT_SIZE="0.09256832892087895" ESTIMABLE="YES" MEAN_1="418.0" MEAN_2="414.0" ORDER="17295" SD_1="43.0" SD_2="42.0" SE="0.28884351220756216" STUDY_ID="STD-Cameron-2004" TOTAL_1="24" TOTAL_2="24" WEIGHT="3.0962569962613915"/>
<CONT_DATA CI_END="0.30378712152378146" CI_START="-0.211071470037911" EFFECT_SIZE="0.046357825742935246" ESTIMABLE="YES" MEAN_1="309.6" MEAN_2="308.2" ORDER="17296" SD_1="28.0" SD_2="32.0" SE="0.13134389091402476" STUDY_ID="STD-Chevalley-2005" TOTAL_1="114" TOTAL_2="118" WEIGHT="14.974160370613857"/>
<CONT_DATA CI_END="0.2574725427227148" CI_START="-0.7158349449146524" EFFECT_SIZE="-0.2291812010959688" ESTIMABLE="YES" MEAN_1="336.18" MEAN_2="351.0" ORDER="17297" SD_1="43.19" SD_2="69.75" SE="0.24829728895905548" STUDY_ID="STD-Courteix-2005" TOTAL_1="22" TOTAL_2="63" WEIGHT="4.190041069753462"/>
<CONT_DATA CI_END="0.4929289406242539" CI_START="-0.3338062753225926" EFFECT_SIZE="0.07956133265083067" ESTIMABLE="YES" MEAN_1="317.09" MEAN_2="311.51" ORDER="17298" SD_1="69.4" SD_2="69.67" SE="0.2109057162447954" STUDY_ID="STD-Johnston-1992" TOTAL_1="45" TOTAL_2="45" WEIGHT="5.807450728357776"/>
<CONT_DATA CI_END="0.5300115286945037" CI_START="-0.06471641800366129" EFFECT_SIZE="0.23264755534542125" ESTIMABLE="YES" MEAN_1="450.0" MEAN_2="438.0" ORDER="17299" SD_1="53.0" SD_2="50.0" SE="0.15171910080728607" STUDY_ID="STD-Matkovic-2004" TOTAL_1="79" TOTAL_2="98" WEIGHT="11.222295885516864"/>
<CONT_DATA CI_END="0.2749570234978052" CI_START="-0.38090719667338463" EFFECT_SIZE="-0.05297508658778973" ESTIMABLE="YES" MEAN_1="479.0" MEAN_2="482.0" ORDER="17300" SD_1="61.0" SD_2="51.0" SE="0.16731537552336753" STUDY_ID="STD-Prentice-2005" TOTAL_1="73" TOTAL_2="70" WEIGHT="9.227637606628175"/>
<CONT_DATA CI_END="0.5639690051480064" CI_START="-0.12316306254107401" EFFECT_SIZE="0.2204029713034662" ESTIMABLE="YES" MEAN_1="427.0" MEAN_2="418.0" ORDER="17301" SD_1="38.0" SD_2="43.0" SE="0.17529201380971549" STUDY_ID="STD-Stear-2003" TOTAL_1="65" TOTAL_2="66" WEIGHT="8.40694051602222"/>
</CONT_SUBGROUP>
<CONT_SUBGROUP CHI2="2.7836809909561286" CI_END="0.3971107893899998" CI_START="0.06560651348072674" DF="3" EFFECT_SIZE="0.23135865143536324" ESTIMABLE="YES" I2="0.0" ID="CMP-001.50.02" NO="2" P_CHI2="0.4261934582871234" P_Z="0.006224032906126546" STUDIES="4" TAU2="0.0" TOTAL_1="280" TOTAL_2="285" WEIGHT="36.1193677484147" Z="2.735739218333164">
<NAME>Below</NAME>
<CONT_DATA CI_END="0.7515904462890333" CI_START="0.12422571852871639" EFFECT_SIZE="0.4379080824088748" ESTIMABLE="YES" MEAN_1="253.0" MEAN_2="231.0" ORDER="17302" SD_1="50.0" SD_2="50.0" SE="0.16004496325159281" STUDY_ID="STD-Dibba-2000" TOTAL_1="80" TOTAL_2="80" WEIGHT="10.085053655030164"/>
<CONT_DATA CI_END="0.4772672773224417" CI_START="-0.14587387711583635" EFFECT_SIZE="0.16569670010330265" ESTIMABLE="YES" MEAN_1="487.0" MEAN_2="480.0" ORDER="17303" SD_1="41.0" SD_2="43.0" SE="0.15896750127898673" STUDY_ID="STD-Lee-1994" TOTAL_1="77" TOTAL_2="82" WEIGHT="10.222227439652531"/>
<CONT_DATA CI_END="0.4501644946278604" CI_START="-0.40623244295249933" EFFECT_SIZE="0.02196602583768056" ESTIMABLE="YES" MEAN_1="492.0" MEAN_2="491.0" ORDER="17304" SD_1="39.0" SD_2="51.0" SE="0.2184726210112812" STUDY_ID="STD-Lee-1995" TOTAL_1="44" TOTAL_2="40" WEIGHT="5.412129720389707"/>
<CONT_DATA CI_END="0.5134677994735729" CI_START="-0.10432584171130158" EFFECT_SIZE="0.20457097888113565" ESTIMABLE="YES" MEAN_1="486.0" MEAN_2="479.0" ORDER="17305" SD_1="37.0" SD_2="31.0" SE="0.15760331466750202" STUDY_ID="STD-Wang-1996" TOTAL_1="79" TOTAL_2="83" WEIGHT="10.399956933342306"/>
</CONT_SUBGROUP>
</CONT_OUTCOME>
<CONT_OUTCOME CHI2="4.97722057019081" CI_END="0.2859451518574186" CI_START="-0.07415640164141268" CI_STUDY="95" CI_TOTAL="95" DF="4" EFFECT_MEASURE="SMD" EFFECT_SIZE="0.10589437510800295" ESTIMABLE="YES" I2="19.633861035685356" I2_Q="0.0" ID="CMP-001.51" NO="51" P_CHI2="0.28964286874800793" P_Q="0.851658733507517" P_Z="0.24902300050576687" Q="0.034969934647891776" RANDOM="YES" SCALE="1.0" SORT_BY="STUDY" STUDIES="5" SUBGROUPS="YES" SUBGROUP_TEST="NO" TAU2="0.008372358437612457" TOTALS="YES" TOTAL_1="313" TOTAL_2="304" UNITS="" WEIGHT="100.00000000000001" Z="1.1527257206222201">
<NAME>Femoral neck BMD (mg/cm2) at longest point after supplementation ceased end by calcium threshold</NAME>
<GROUP_LABEL_1>Treatment</GROUP_LABEL_1>
<GROUP_LABEL_2>Control</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours control</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours treatment</GRAPH_LABEL_2>
<CONT_SUBGROUP CHI2="4.7133416797251115" CI_END="0.43564936355284356" CI_START="-0.16964111420309833" DF="2" EFFECT_SIZE="0.13300412467487263" ESTIMABLE="YES" I2="57.567260430042865" ID="CMP-001.51.01" NO="1" P_CHI2="0.09473529677384573" P_Z="0.38904564590823965" STUDIES="3" TAU2="0.041060346847926296" TOTAL_1="220" TOTAL_2="217" WEIGHT="68.13557312996662" Z="0.8613493974809733">
<NAME>Above</NAME>
<CONT_DATA CI_END="0.7986994788224699" CI_START="0.08686283431210057" EFFECT_SIZE="0.4427811565672853" ESTIMABLE="YES" MEAN_1="885.0" MEAN_2="853.0" ORDER="17306" SD_1="70.2" SD_2="73.67" SE="0.18159431758064076" STUDY_ID="STD-Bonjour-1995" TOTAL_1="67" TOTAL_2="58" WEIGHT="20.409404475448845"/>
<CONT_DATA CI_END="0.22762896650934925" CI_START="-0.2940909927915369" EFFECT_SIZE="-0.033231013141093814" ESTIMABLE="YES" MEAN_1="722.4" MEAN_2="724.7" ORDER="17307" SD_1="70.0" SD_2="68.0" SE="0.13309427199074741" STUDY_ID="STD-Chevalley-2005" TOTAL_1="110" TOTAL_2="116" WEIGHT="32.3503467537602"/>
<CONT_DATA CI_END="0.43698040696836393" CI_START="-0.40842428898937033" EFFECT_SIZE="0.014278058989496793" ESTIMABLE="YES" MEAN_1="956.05" MEAN_2="954.05" ORDER="17308" SD_1="136.72" SD_2="140.89" SE="0.2156684262124658" STUDY_ID="STD-Johnston-1992" TOTAL_1="43" TOTAL_2="43" WEIGHT="15.375821900757561"/>
</CONT_SUBGROUP>
<CONT_SUBGROUP CHI2="0.22890895581780643" CI_END="0.36888929206415616" CI_START="-0.21625226946408765" DF="1" EFFECT_SIZE="0.07631851130003427" ESTIMABLE="YES" I2="0.0" ID="CMP-001.51.02" NO="2" P_CHI2="0.6323340249092009" P_Z="0.6091647138486523" STUDIES="2" TAU2="0.0" TOTAL_1="93" TOTAL_2="87" WEIGHT="31.8644268700334" Z="0.5112661391240461">
<NAME>Below</NAME>
<CONT_DATA CI_END="0.4281849516340527" CI_START="-0.4281849516340527" EFFECT_SIZE="0.0" ESTIMABLE="YES" MEAN_1="603.0" MEAN_2="603.0" ORDER="17309" SD_1="76.0" SD_2="64.0" SE="0.21846572437632575" STUDY_ID="STD-Lee-1995" TOTAL_1="44" TOTAL_2="40" WEIGHT="15.042977661610646"/>
<CONT_DATA CI_END="0.5438493859396915" CI_START="-0.2575440066043698" EFFECT_SIZE="0.14315268966766082" ESTIMABLE="YES" MEAN_1="1010.0" MEAN_2="990.0" ORDER="17310" SD_1="140.0" SD_2="137.11" SE="0.20444084658324083" STUDY_ID="STD-Rozen-2003" TOTAL_1="49" TOTAL_2="47" WEIGHT="16.821449208422756"/>
</CONT_SUBGROUP>
</CONT_OUTCOME>
<CONT_OUTCOME CHI2="1.1583576889270415" CI_END="0.16953284421813042" CI_START="-0.1465114883422407" CI_STUDY="95" CI_TOTAL="95" DF="4" EFFECT_MEASURE="SMD" EFFECT_SIZE="0.011510677937944849" ESTIMABLE="YES" I2="0.0" I2_Q="0.0" ID="CMP-001.52" NO="52" P_CHI2="0.8849060147469565" P_Q="0.4060055024376309" P_Z="0.8864733826880067" Q="0.6904683948387611" RANDOM="NO" SCALE="1.0" SORT_BY="STUDY" STUDIES="5" SUBGROUPS="YES" SUBGROUP_TEST="YES" TAU2="0.0" TOTALS="YES" TOTAL_1="313" TOTAL_2="304" UNITS="" WEIGHT="100.0" Z="0.1427680351882415">
<NAME>Lumbar spine BMD (mg/cm2) at longest point after supplementation ceased end by calcium threshold</NAME>
<GROUP_LABEL_1>Treatment</GROUP_LABEL_1>
<GROUP_LABEL_2>Control</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours control</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours treatment</GRAPH_LABEL_2>
<CONT_SUBGROUP CHI2="0.022051936638276128" CI_END="0.24220334208290506" CI_START="-0.13325105519254937" DF="2" EFFECT_SIZE="0.05447614344517786" ESTIMABLE="YES" I2="0.0" ID="CMP-001.52.01" NO="1" P_CHI2="0.9890345954863036" P_Z="0.5695206254114955" STUDIES="3" TAU2="0.0" TOTAL_1="220" TOTAL_2="217" WEIGHT="70.85681441064617" Z="0.5687576437723963">
<NAME>Above</NAME>
<CONT_DATA CI_END="0.4286491395175547" CI_START="-0.27466106073165153" EFFECT_SIZE="0.07699403939295155" ESTIMABLE="YES" MEAN_1="1019.0" MEAN_2="1014.0" ORDER="17311" SD_1="70.2" SD_2="57.3" SE="0.17941916427975904" STUDY_ID="STD-Bonjour-1995" TOTAL_1="67" TOTAL_2="58" WEIGHT="20.193062121230803"/>
<CONT_DATA CI_END="0.30604468824634573" CI_START="-0.21570630455408518" EFFECT_SIZE="0.04516919184613029" ESTIMABLE="YES" MEAN_1="605.0" MEAN_2="602.5" ORDER="17312" SD_1="52.0" SD_2="58.0" SE="0.13310218884528904" STUDY_ID="STD-Chevalley-2005" TOTAL_1="110" TOTAL_2="116" WEIGHT="36.69183613729448"/>
<CONT_DATA CI_END="0.46912926150434037" CI_START="-0.3763832168316114" EFFECT_SIZE="0.0463730223363645" ESTIMABLE="YES" MEAN_1="1061.23" MEAN_2="1052.39" ORDER="17313" SD_1="192.31" SD_2="185.47" SE="0.21569592222235875" STUDY_ID="STD-Johnston-1992" TOTAL_1="43" TOTAL_2="43" WEIGHT="13.971916152120873"/>
</CONT_SUBGROUP>
<CONT_SUBGROUP CHI2="0.4458373574500042" CI_END="0.1997653339338958" CI_START="-0.3856707617261006" DF="1" EFFECT_SIZE="-0.0929527138961024" ESTIMABLE="YES" I2="0.0" ID="CMP-001.52.02" NO="2" P_CHI2="0.5043184099635389" P_Z="0.5336872865909953" STUDIES="2" TAU2="0.0" TOTAL_1="93" TOTAL_2="87" WEIGHT="29.143185589353827" Z="0.6223872181855473">
<NAME>Below</NAME>
<CONT_DATA CI_END="0.22936706177064778" CI_START="-0.6292396856883473" EFFECT_SIZE="-0.19993631195884978" ESTIMABLE="YES" MEAN_1="538.0" MEAN_2="551.0" ORDER="17314" SD_1="61.0" SD_2="68.0" SE="0.2190363583799436" STUDY_ID="STD-Lee-1995" TOTAL_1="44" TOTAL_2="40" WEIGHT="13.549005508643"/>
<CONT_DATA CI_END="0.40016282334497716" CI_START="-0.40016282334497716" EFFECT_SIZE="0.0" ESTIMABLE="YES" MEAN_1="1150.0" MEAN_2="1150.0" ORDER="17315" SD_1="140.0" SD_2="137.11" SE="0.2041684574315704" STUDY_ID="STD-Rozen-2003" TOTAL_1="49" TOTAL_2="47" WEIGHT="15.594180080710826"/>
</CONT_SUBGROUP>
</CONT_OUTCOME>
<CONT_OUTCOME CHI2="2.8160955985362586" CI_END="0.3987017951586933" CI_START="0.029157553391896907" CI_STUDY="95" CI_TOTAL="95" DF="3" EFFECT_MEASURE="SMD" EFFECT_SIZE="0.2139296742752951" ESTIMABLE="YES" I2="0.0" I2_Q="0.0" ID="CMP-001.53" NO="53" P_CHI2="0.4208572474022483" P_Q="0.8059850616212753" P_Z="0.023253021489117242" Q="0.06032369375139934" RANDOM="NO" SCALE="1.0" SORT_BY="STUDY" STUDIES="4" SUBGROUPS="YES" SUBGROUP_TEST="YES" TAU2="0.0" TOTALS="YES" TOTAL_1="234" TOTAL_2="221" UNITS="" WEIGHT="100.0" Z="2.2692517399232655">
<NAME>Distal radius BMD (mg/cm2) at longest point after supplementation ceased end by calcium threshold</NAME>
<GROUP_LABEL_1>Treatment</GROUP_LABEL_1>
<GROUP_LABEL_2>Control</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours control</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours treatment</GRAPH_LABEL_2>
<CONT_SUBGROUP CHI2="1.2906774704281996" CI_END="0.510581946531807" CI_START="-0.03280112732757931" DF="1" EFFECT_SIZE="0.23889040960211386" ESTIMABLE="YES" I2="22.52130970658095" ID="CMP-001.53.01" NO="1" P_CHI2="0.2559232529622504" P_Z="0.08482725394900052" STUDIES="2" TAU2="0.0" TOTAL_1="110" TOTAL_2="101" WEIGHT="46.25095095215247" Z="1.7233389172270288">
<NAME>Above</NAME>
<CONT_DATA CI_END="0.7255999910161408" CI_START="0.016372536416859873" EFFECT_SIZE="0.37098626371650034" ESTIMABLE="YES" MEAN_1="429.0" MEAN_2="418.0" ORDER="17316" SD_1="26.32" SD_2="32.74" SE="0.18092869567848607" STUDY_ID="STD-Bonjour-1995" TOTAL_1="67" TOTAL_2="58" WEIGHT="27.149497819276156"/>
<CONT_DATA CI_END="0.47390750843088114" CI_START="-0.3716306970386415" EFFECT_SIZE="0.05113840569611985" ESTIMABLE="YES" MEAN_1="365.23" MEAN_2="361.31" ORDER="17317" SD_1="77.08" SD_2="74.84" SE="0.21570248538723671" STUDY_ID="STD-Johnston-1992" TOTAL_1="43" TOTAL_2="43" WEIGHT="19.101453132876316"/>
</CONT_SUBGROUP>
<CONT_SUBGROUP CHI2="1.4650944343566596" CI_END="0.4444803211846409" CI_START="-0.05957829990890734" DF="1" EFFECT_SIZE="0.1924510106378668" ESTIMABLE="YES" I2="31.74501407213987" ID="CMP-001.53.02" NO="2" P_CHI2="0.2261215889110585" P_Z="0.1344870570460741" STUDIES="2" TAU2="0.0" TOTAL_1="124" TOTAL_2="120" WEIGHT="53.749049047847535" Z="1.4966396123539358">
<NAME>Below</NAME>
<CONT_DATA CI_END="0.6175167825952239" CI_START="-0.0059803321820287025" EFFECT_SIZE="0.30576822520659763" ESTIMABLE="YES" MEAN_1="256.0" MEAN_2="242.0" ORDER="17318" SD_1="43.0" SD_2="48.0" SE="0.15905830915652489" STUDY_ID="STD-Dibba-2000" TOTAL_1="80" TOTAL_2="80" WEIGHT="35.1288540481875"/>
<CONT_DATA CI_END="0.40686449035579997" CI_START="-0.44953091203190143" EFFECT_SIZE="-0.021333210838050704" ESTIMABLE="YES" MEAN_1="516.0" MEAN_2="517.0" ORDER="17319" SD_1="44.0" SD_2="49.0" SE="0.21847222937330457" STUDY_ID="STD-Lee-1995" TOTAL_1="44" TOTAL_2="40" WEIGHT="18.620194999660033"/>
</CONT_SUBGROUP>
</CONT_OUTCOME>
<CONT_OUTCOME CHI2="4.569678112982537" CI_END="0.3208724402970041" CI_START="0.049214416162552205" CI_STUDY="95" CI_TOTAL="95" DF="5" EFFECT_MEASURE="SMD" EFFECT_SIZE="0.18504342822977815" ESTIMABLE="YES" I2="0.0" I2_Q="0.0" ID="CMP-001.54" NO="54" P_CHI2="0.4706152751090106" P_Q="0.3385309445878283" P_Z="0.007582631581730909" Q="0.9159872180899304" RANDOM="NO" SCALE="1.0" SORT_BY="STUDY" STUDIES="6" SUBGROUPS="YES" SUBGROUP_TEST="YES" TAU2="0.0" TOTALS="YES" TOTAL_1="421" TOTAL_2="419" UNITS="" WEIGHT="100.0" Z="2.6701103791190564">
<NAME>Upper limb BMD (mg/cm2) at longest point after supplementation ceased end by calcium threshold</NAME>
<GROUP_LABEL_1>Treatment</GROUP_LABEL_1>
<GROUP_LABEL_2>Control</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours control</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours treatment</GRAPH_LABEL_2>
<CONT_SUBGROUP CHI2="1.3007758237307883" CI_END="0.4374933210262463" CI_START="0.060344055634999644" DF="2" EFFECT_SIZE="0.24891868833062294" ESTIMABLE="YES" I2="0.0" ID="CMP-001.54.01" NO="1" P_CHI2="0.521843340297104" P_Z="0.00967722578106823" STUDIES="3" TAU2="0.0" TOTAL_1="220" TOTAL_2="217" WEIGHT="51.88221904078453" Z="2.587154259472647">
<NAME>Above</NAME>
<CONT_DATA CI_END="0.7255999910161408" CI_START="0.016372536416859873" EFFECT_SIZE="0.37098626371650034" ESTIMABLE="YES" MEAN_1="429.0" MEAN_2="418.0" ORDER="17320" SD_1="26.32" SD_2="32.74" SE="0.18092869567848607" STUDY_ID="STD-Bonjour-1995" TOTAL_1="67" TOTAL_2="58" WEIGHT="14.671482403917"/>
<CONT_DATA CI_END="0.5201854123124395" CI_START="-0.003704661341557558" EFFECT_SIZE="0.258240375485441" ESTIMABLE="YES" MEAN_1="24.7" MEAN_2="19.4" ORDER="17321" SD_1="21.7" SD_2="19.2" SE="0.1336478827637587" STUDY_ID="STD-Chevalley-2005" TOTAL_1="110" TOTAL_2="116" WEIGHT="26.888386094926197"/>
<CONT_DATA CI_END="0.47390750843088114" CI_START="-0.3716306970386415" EFFECT_SIZE="0.05113840569611985" ESTIMABLE="YES" MEAN_1="365.23" MEAN_2="361.31" ORDER="17322" SD_1="77.08" SD_2="74.84" SE="0.21570248538723671" STUDY_ID="STD-Johnston-1992" TOTAL_1="43" TOTAL_2="43" WEIGHT="10.322350541941328"/>
</CONT_SUBGROUP>
<CONT_SUBGROUP CHI2="2.352915071161818" CI_END="0.3119831620180774" CI_START="-0.07964123767199685" DF="2" EFFECT_SIZE="0.11617096217304029" ESTIMABLE="YES" I2="14.999056935257604" ID="CMP-001.54.02" NO="2" P_CHI2="0.3083692440377356" P_Z="0.24490969090107628" STUDIES="3" TAU2="0.0" TOTAL_1="201" TOTAL_2="202" WEIGHT="48.117780959215466" Z="1.1628024305365812">
<NAME>Below</NAME>
<CONT_DATA CI_END="0.6175167825952239" CI_START="-0.0059803321820287025" EFFECT_SIZE="0.30576822520659763" ESTIMABLE="YES" MEAN_1="256.0" MEAN_2="242.0" ORDER="17323" SD_1="43.0" SD_2="48.0" SE="0.15905830915652489" STUDY_ID="STD-Dibba-2000" TOTAL_1="80" TOTAL_2="80" WEIGHT="18.98349529219736"/>
<CONT_DATA CI_END="0.3110243308527212" CI_START="-0.3110243308527212" EFFECT_SIZE="0.0" ESTIMABLE="YES" MEAN_1="505.0" MEAN_2="505.0" ORDER="17324" SD_1="45.0" SD_2="40.0" SE="0.15868879903204416" STUDY_ID="STD-Lee-1994" TOTAL_1="77" TOTAL_2="82" WEIGHT="19.072005137429322"/>
<CONT_DATA CI_END="0.40686449035579997" CI_START="-0.44953091203190143" EFFECT_SIZE="-0.021333210838050704" ESTIMABLE="YES" MEAN_1="516.0" MEAN_2="517.0" ORDER="17325" SD_1="44.0" SD_2="49.0" SE="0.21847222937330457" STUDY_ID="STD-Lee-1995" TOTAL_1="44" TOTAL_2="40" WEIGHT="10.06228052958878"/>
</CONT_SUBGROUP>
</CONT_OUTCOME>
<CONT_OUTCOME CHI2="5.833956503938205" CI_END="0.1894099906117992" CI_START="-0.05259426682904429" CI_STUDY="95" CI_TOTAL="95" DF="9" EFFECT_MEASURE="SMD" EFFECT_SIZE="0.06840786189137744" ESTIMABLE="YES" I2="0.0" I2_Q="0.0" ID="CMP-001.55" NO="55" P_CHI2="0.7564148098212335" P_Q="0.536177505710397" P_Z="0.26783832457717716" Q="0.38267108137369377" RANDOM="NO" SCALE="1.0" SORT_BY="STUDY" STUDIES="10" SUBGROUPS="YES" SUBGROUP_TEST="YES" TAU2="0.0" TOTALS="YES" TOTAL_1="519" TOTAL_2="554" UNITS="" WEIGHT="100.0" Z="1.1080544365982008">
<NAME>Femoral neck BMD (mg/cm2) at end supplementation by duration of supplementation (&lt; 24 months vs &gt;= 24 months)</NAME>
<GROUP_LABEL_1>Treatment</GROUP_LABEL_1>
<GROUP_LABEL_2>Control</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours control</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours treatment</GRAPH_LABEL_2>
<CONT_SUBGROUP CHI2="5.447291690986569" CI_END="0.2131051935604239" CI_START="-0.0465712215981134" DF="7" EFFECT_SIZE="0.08326698598115524" ESTIMABLE="YES" I2="0.0" ID="CMP-001.55.01" NO="1" P_CHI2="0.6055489550083024" P_Z="0.20877132374959873" STUDIES="8" TAU2="0.0" TOTAL_1="450" TOTAL_2="485" WEIGHT="86.85223494928036" Z="1.2569512215780478">
<NAME>&lt;24 months duration</NAME>
<CONT_DATA CI_END="0.6604385539390247" CI_START="-0.09794154702996843" EFFECT_SIZE="0.2812485034545282" ESTIMABLE="YES" MEAN_1="656.0" MEAN_2="635.0" ORDER="17326" SD_1="81.58" SD_2="65.52" SE="0.19346786648912906" STUDY_ID="STD-Bonjour-1995" TOTAL_1="55" TOTAL_2="53" WEIGHT="10.182915842113054"/>
<CONT_DATA CI_END="0.17515393035443064" CI_START="-0.3398562006734309" EFFECT_SIZE="-0.08235113515950013" ESTIMABLE="YES" MEAN_1="698.0" MEAN_2="703.7" ORDER="17327" SD_1="70.0" SD_2="68.0" SE="0.13138254965147209" STUDY_ID="STD-Chevalley-2005" TOTAL_1="114" TOTAL_2="118" WEIGHT="22.080782911208967"/>
<CONT_DATA CI_END="0.8977163300128035" CI_START="-0.08113466441638145" EFFECT_SIZE="0.40829083279821105" ESTIMABLE="YES" MEAN_1="772.45" MEAN_2="737.0" ORDER="17328" SD_1="57.43" SD_2="93.77" SE="0.24971147484092482" STUDY_ID="STD-Courteix-2005" TOTAL_1="22" TOTAL_2="63" WEIGHT="6.112415100267862"/>
<CONT_DATA CI_END="0.4140084286058978" CI_START="-0.44237274406664784" EFFECT_SIZE="-0.014182157730375022" ESTIMABLE="YES" MEAN_1="592.0" MEAN_2="593.0" ORDER="17329" SD_1="74.0" SD_2="65.0" SE="0.21846859927722423" STUDY_ID="STD-Lee-1995" TOTAL_1="44" TOTAL_2="40" WEIGHT="7.985677934320828"/>
<CONT_DATA CI_END="0.5859768774270062" CI_START="-0.46193881656079006" EFFECT_SIZE="0.06201903043310805" ESTIMABLE="YES" MEAN_1="877.0" MEAN_2="871.0" ORDER="17330" SD_1="90.0" SD_2="100.5" SE="0.26733034439755565" STUDY_ID="STD-Nowson-1997" TOTAL_1="28" TOTAL_2="28" WEIGHT="5.333266965361167"/>
<CONT_DATA CI_END="0.3203145893001051" CI_START="-0.3354338260641689" EFFECT_SIZE="-0.0075596183820319145" ESTIMABLE="YES" MEAN_1="1001.0" MEAN_2="1002.0" ORDER="17331" SD_1="134.0" SD_2="129.0" SE="0.16728583293793503" STUDY_ID="STD-Prentice-2005" TOTAL_1="73" TOTAL_2="70" WEIGHT="13.619824552271593"/>
<CONT_DATA CI_END="0.4921438634140949" CI_START="-0.3086206789419552" EFFECT_SIZE="0.09176159223606986" ESTIMABLE="YES" MEAN_1="1010.0" MEAN_2="1000.0" ORDER="17332" SD_1="70.0" SD_2="137.0" SE="0.2042804226690844" STUDY_ID="STD-Rozen-2003" TOTAL_1="49" TOTAL_2="47" WEIGHT="9.133481296727899"/>
<CONT_DATA CI_END="0.5643130591550494" CI_START="-0.12282562247230913" EFFECT_SIZE="0.2207437183413701" ESTIMABLE="YES" MEAN_1="870.0" MEAN_2="847.0" ORDER="17333" SD_1="100.0" SD_2="107.0" SE="0.17529370106987185" STUDY_ID="STD-Stear-2003" TOTAL_1="65" TOTAL_2="66" WEIGHT="12.403870347008995"/>
</CONT_SUBGROUP>
<CONT_SUBGROUP CHI2="0.00399373157794202" CI_END="0.3039589632807951" CI_START="-0.36345769014533946" DF="1" EFFECT_SIZE="-0.029749363432272215" ESTIMABLE="YES" I2="0.0" ID="CMP-001.55.02" NO="2" P_CHI2="0.9496104478632111" P_Z="0.861294560782631" STUDIES="2" TAU2="0.0" TOTAL_1="69" TOTAL_2="69" WEIGHT="13.147765050719642" Z="0.17472647885223788">
<NAME>&gt;= 24 months duration</NAME>
<CONT_DATA CI_END="0.5507846604584942" CI_START="-0.5808184484700071" EFFECT_SIZE="-0.015016894005756475" ESTIMABLE="YES" MEAN_1="814.0" MEAN_2="816.0" ORDER="17334" SD_1="131.0" SD_2="131.0" SE="0.2886795670365482" STUDY_ID="STD-Cameron-2004" TOTAL_1="24" TOTAL_2="24" WEIGHT="4.573595467063528"/>
<CONT_DATA CI_END="0.37562699217396994" CI_START="-0.4508427758870757" EFFECT_SIZE="-0.037607891856552896" ESTIMABLE="YES" MEAN_1="847.72" MEAN_2="852.89" ORDER="17335" SD_1="128.13" SD_2="144.0" SE="0.21083799870307152" STUDY_ID="STD-Johnston-1992" TOTAL_1="45" TOTAL_2="45" WEIGHT="8.574169583656113"/>
</CONT_SUBGROUP>
</CONT_OUTCOME>
<CONT_OUTCOME CHI2="1.1024640714897922" CI_END="0.19656167519370077" CI_START="-0.03540959073148839" CI_STUDY="95" CI_TOTAL="95" DF="10" EFFECT_MEASURE="SMD" EFFECT_SIZE="0.08057604223110619" ESTIMABLE="YES" I2="0.0" I2_Q="0.0" ID="CMP-001.56" NO="56" P_CHI2="0.9997312530937471" P_Q="0.8137316784486205" P_Z="0.17332387499636842" Q="0.05551428018769311" RANDOM="NO" SCALE="1.0" SORT_BY="STUDY" STUDIES="11" SUBGROUPS="YES" SUBGROUP_TEST="YES" TAU2="0.0" TOTALS="YES" TOTAL_1="563" TOTAL_2="601" UNITS="" WEIGHT="100.0" Z="1.3616008875916368">
<NAME>Lumbar spine BMD (mg/cm2) at end supplementation by duration of supplementation (&lt; 24 months vs &gt;= 24 months)</NAME>
<GROUP_LABEL_1>Treatment</GROUP_LABEL_1>
<GROUP_LABEL_2>Control</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours control</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours treatment</GRAPH_LABEL_2>
<CONT_SUBGROUP CHI2="0.686262006505388" CI_END="0.20327605710542704" CI_START="-0.05606386101188035" DF="7" EFFECT_SIZE="0.07360609804677334" ESTIMABLE="YES" I2="0.0" ID="CMP-001.56.01" NO="1" P_CHI2="0.998439081270173" P_Z="0.2658984877097553" STUDIES="8" TAU2="0.0" TOTAL_1="450" TOTAL_2="485" WEIGHT="80.00730585299931" Z="1.1125576213758512">
<NAME>&lt;24 months duration</NAME>
<CONT_DATA CI_END="0.5114205026835856" CI_START="-0.24397376271812718" EFFECT_SIZE="0.13372336998272924" ESTIMABLE="YES" MEAN_1="647.0" MEAN_2="638.0" ORDER="17336" SD_1="74.16" SD_2="58.24" SE="0.1927061597458337" STUDY_ID="STD-Bonjour-1995" TOTAL_1="55" TOTAL_2="53" WEIGHT="9.43020248538449"/>
<CONT_DATA CI_END="0.27186034181968627" CI_START="-0.24293478100807947" EFFECT_SIZE="0.014462780405803406" ESTIMABLE="YES" MEAN_1="586.9" MEAN_2="586.1" ORDER="17337" SD_1="52.0" SD_2="58.0" SE="0.1313276996129531" STUDY_ID="STD-Chevalley-2005" TOTAL_1="114" TOTAL_2="118" WEIGHT="20.304838408962425"/>
<CONT_DATA CI_END="0.6270434570242918" CI_START="-0.3446758722743443" EFFECT_SIZE="0.1411837923749737" ESTIMABLE="YES" MEAN_1="740.64" MEAN_2="726.67" ORDER="17338" SD_1="65.03" SD_2="106.95" SE="0.2478921390809816" STUDY_ID="STD-Courteix-2005" TOTAL_1="22" TOTAL_2="63" WEIGHT="5.698843118900126"/>
<CONT_DATA CI_END="0.4625164252125683" CI_START="-0.393919388343527" EFFECT_SIZE="0.034298518434520614" ESTIMABLE="YES" MEAN_1="525.0" MEAN_2="523.0" ORDER="17339" SD_1="61.0" SD_2="54.0" SE="0.21848253853426688" STUDY_ID="STD-Lee-1995" TOTAL_1="44" TOTAL_2="40" WEIGHT="7.336328090508805"/>
<CONT_DATA CI_END="0.6326118992120395" CI_START="-0.4158598560902002" EFFECT_SIZE="0.10837602156091967" ESTIMABLE="YES" MEAN_1="1017.0" MEAN_2="1001.0" ORDER="17340" SD_1="148.2" SD_2="142.9" SE="0.2674721993803078" STUDY_ID="STD-Nowson-1997" TOTAL_1="28" TOTAL_2="28" WEIGHT="4.895024998280832"/>
<CONT_DATA CI_END="0.45798631527414724" CI_START="-0.1984686132330601" EFFECT_SIZE="0.12975885102054358" ESTIMABLE="YES" MEAN_1="1047.0" MEAN_2="1032.0" ORDER="17341" SD_1="114.0" SD_2="116.0" SE="0.1674660691944444" STUDY_ID="STD-Prentice-2005" TOTAL_1="73" TOTAL_2="70" WEIGHT="12.487012848693666"/>
<CONT_DATA CI_END="0.40016282334497716" CI_START="-0.40016282334497716" EFFECT_SIZE="0.0" ESTIMABLE="YES" MEAN_1="1120.0" MEAN_2="1120.0" ORDER="17342" SD_1="140.0" SD_2="137.11" SE="0.2041684574315704" STUDY_ID="STD-Rozen-2003" TOTAL_1="49" TOTAL_2="47" WEIGHT="8.401076060027075"/>
<CONT_DATA CI_END="0.4411301457213726" CI_START="-0.24428861169722987" EFFECT_SIZE="0.09842076701207135" ESTIMABLE="YES" MEAN_1="999.0" MEAN_2="989.0" ORDER="17343" SD_1="100.0" SD_2="102.0" SE="0.17485493683177297" STUDY_ID="STD-Stear-2003" TOTAL_1="65" TOTAL_2="66" WEIGHT="11.453979842241894"/>
</CONT_SUBGROUP>
<CONT_SUBGROUP CHI2="0.36068778479671115" CI_END="0.3678676963126265" CI_START="-0.15093058837793638" DF="2" EFFECT_SIZE="0.10846855396734507" ESTIMABLE="YES" I2="0.0" ID="CMP-001.56.02" NO="2" P_CHI2="0.8349830586694927" P_Z="0.4124641382562464" STUDIES="3" TAU2="0.0" TOTAL_1="113" TOTAL_2="116" WEIGHT="19.992694147000698" Z="0.8195650043752071">
<NAME>&gt;= 24 months duration</NAME>
<CONT_DATA CI_END="0.6643854658079379" CI_START="-0.4679433402975458" EFFECT_SIZE="0.09822106275519607" ESTIMABLE="YES" MEAN_1="848.0" MEAN_2="833.0" ORDER="17344" SD_1="158.0" SD_2="142.0" SE="0.2888646972692225" STUDY_ID="STD-Cameron-2004" TOTAL_1="24" TOTAL_2="24" WEIGHT="4.196848320638333"/>
<CONT_DATA CI_END="0.434960444536277" CI_START="-0.39145848587210075" EFFECT_SIZE="0.021750979332088152" ESTIMABLE="YES" MEAN_1="907.36" MEAN_2="902.96" ORDER="17345" SD_1="197.32" SD_2="203.75" SE="0.2108250296758167" STUDY_ID="STD-Johnston-1992" TOTAL_1="45" TOTAL_2="45" WEIGHT="7.87894141933801"/>
<CONT_DATA CI_END="0.6124201908396137" CI_START="-0.21201494446981703" EFFECT_SIZE="0.20020262318489837" ESTIMABLE="YES" MEAN_1="914.0" MEAN_2="894.0" ORDER="17346" SD_1="83.0" SD_2="112.0" SE="0.21031895019818475" STUDY_ID="STD-Lloyd-1993" TOTAL_1="44" TOTAL_2="47" WEIGHT="7.9169044070243535"/>
</CONT_SUBGROUP>
</CONT_OUTCOME>
<CONT_OUTCOME CHI2="4.575286896634283" CI_END="0.26841853898080825" CI_START="0.011094187411965523" CI_STUDY="95" CI_TOTAL="95" DF="8" EFFECT_MEASURE="SMD" EFFECT_SIZE="0.1397563631963869" ESTIMABLE="YES" I2="0.0" I2_Q="0.0" ID="CMP-001.57" NO="57" P_CHI2="0.8018545079137473" P_Q="0.6165569831488962" P_Z="0.03325704729455614" Q="0.2507365186386945" RANDOM="NO" SCALE="1.0" SORT_BY="STUDY" STUDIES="9" SUBGROUPS="YES" SUBGROUP_TEST="YES" TAU2="0.0" TOTALS="YES" TOTAL_1="449" TOTAL_2="504" UNITS="" WEIGHT="100.0" Z="2.128966316675517">
<NAME>Total body BMC (mg) at end supplementation by duration of supplementation (&lt; 24 months vs &gt;= 24 months)</NAME>
<GROUP_LABEL_1>Treatment</GROUP_LABEL_1>
<GROUP_LABEL_2>Control</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours control</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours treatment</GRAPH_LABEL_2>
<CONT_SUBGROUP CHI2="4.25698980156689" CI_END="0.26546460007128575" CI_START="-0.013424795647262955" DF="6" EFFECT_SIZE="0.1260199022120114" ESTIMABLE="YES" I2="0.0" ID="CMP-001.57.01" NO="1" P_CHI2="0.6419430091087576" P_Z="0.07651550415730825" STUDIES="7" TAU2="0.0" TOTAL_1="381" TOTAL_2="433" WEIGHT="85.13296742101849" Z="1.771271862341193">
<NAME>&lt;24 months duration</NAME>
<CONT_DATA CI_END="1.0623077058025256" CI_START="0.07587704885842766" EFFECT_SIZE="0.5690923773304767" ESTIMABLE="YES" MEAN_1="1340.9" MEAN_2="1186.1" ORDER="17347" SD_1="216.37" SD_2="285.32" SE="0.2516450977479528" STUDY_ID="STD-Courteix-2005" TOTAL_1="22" TOTAL_2="63" WEIGHT="6.805008185954207"/>
<CONT_DATA CI_END="0.6238360632229405" CI_START="-0.3464242431167532" EFFECT_SIZE="0.13870591005309368" ESTIMABLE="YES" MEAN_1="1179.57" MEAN_2="1151.25" ORDER="17348" SD_1="209.01" SD_2="195.57" SE="0.2475199325071744" STUDY_ID="STD-Iuliano_x002d_Burns-2003" TOTAL_1="30" TOTAL_2="36" WEIGHT="7.033722738386755"/>
<CONT_DATA CI_END="0.4506900805835923" CI_START="-0.29400382768340283" EFFECT_SIZE="0.07834312645009475" ESTIMABLE="YES" MEAN_1="1932.11" MEAN_2="1907.53" ORDER="17349" SD_1="292.33" SD_2="328.77" SE="0.18997642664381734" STUDY_ID="STD-Molgaard-2004" TOTAL_1="54" TOTAL_2="57" WEIGHT="11.940050720347894"/>
<CONT_DATA CI_END="0.3908635962567637" CI_START="-0.26504909971456003" EFFECT_SIZE="0.06290724827110186" ESTIMABLE="YES" MEAN_1="2796.0" MEAN_2="2770.0" ORDER="17350" SD_1="415.0" SD_2="407.0" SE="0.1673277420261493" STUDY_ID="STD-Prentice-2005" TOTAL_1="73" TOTAL_2="70" WEIGHT="15.391101406551368"/>
<CONT_DATA CI_END="0.3917077443497603" CI_START="-0.392434700377596" EFFECT_SIZE="-3.634780139178262E-4" ESTIMABLE="YES" MEAN_1="860.29" MEAN_2="860.34" ORDER="17351" SD_1="134.19" SD_2="138.69" SE="0.2000400137228469" STUDY_ID="STD-Rozen-2003" TOTAL_1="49" TOTAL_2="51" WEIGHT="10.768912529976115"/>
<CONT_DATA CI_END="0.3417017087255969" CI_START="-0.24604334021365062" EFFECT_SIZE="0.047829184255973135" ESTIMABLE="YES" MEAN_1="685.55" MEAN_2="681.5" ORDER="17352" SD_1="88.0" SD_2="80.55" SE="0.1499377166048217" STUDY_ID="STD-Specker-2003" TOTAL_1="88" TOTAL_2="90" WEIGHT="19.16830960071454"/>
<CONT_DATA CI_END="0.5619740238730728" CI_START="-0.12511989143932517" EFFECT_SIZE="0.21842706621687386" ESTIMABLE="YES" MEAN_1="2143.0" MEAN_2="2088.0" ORDER="17353" SD_1="265.0" SD_2="235.0" SE="0.175282280881717" STUDY_ID="STD-Stear-2003" TOTAL_1="65" TOTAL_2="66" WEIGHT="14.025862239087605"/>
</CONT_SUBGROUP>
<CONT_SUBGROUP CHI2="0.06756057642869781" CI_END="0.552101930808033" CI_START="-0.11527123537869083" DF="1" EFFECT_SIZE="0.21841534771467108" ESTIMABLE="YES" I2="0.0" ID="CMP-001.57.02" NO="2" P_CHI2="0.7949222679794785" P_Z="0.19952743024440567" STUDIES="2" TAU2="0.0" TOTAL_1="68" TOTAL_2="71" WEIGHT="14.867032578981508" Z="1.2828990941831613">
<NAME>&gt;= 24 months duration</NAME>
<CONT_DATA CI_END="0.7244128544136019" CI_START="-0.4090865084137309" EFFECT_SIZE="0.15766317299993554" ESTIMABLE="YES" MEAN_1="1583.0" MEAN_2="1512.0" ORDER="17354" SD_1="504.0" SD_2="372.0" SE="0.289163314165013" STUDY_ID="STD-Cameron-2004" TOTAL_1="24" TOTAL_2="24" WEIGHT="5.153700938319747"/>
<CONT_DATA CI_END="0.6634749996606573" CI_START="-0.16217650854283872" EFFECT_SIZE="0.2506492455589093" ESTIMABLE="YES" MEAN_1="1783.0" MEAN_2="1714.0" ORDER="17355" SD_1="238.0" SD_2="302.0" SE="0.21062925510777997" STUDY_ID="STD-Lloyd-1993" TOTAL_1="44" TOTAL_2="47" WEIGHT="9.713331640661762"/>
</CONT_SUBGROUP>
</CONT_OUTCOME>
<CONT_OUTCOME CHI2="8.073176705722247" CI_END="0.27214379866967514" CI_START="0.036867948161045216" CI_STUDY="95" CI_TOTAL="95" DF="8" EFFECT_MEASURE="SMD" EFFECT_SIZE="0.15450587341536018" ESTIMABLE="YES" I2="0.9064177385140044" I2_Q="0.0" ID="CMP-001.58" NO="58" P_CHI2="0.4263549182299098" P_Q="0.8094283224536711" P_Z="0.01004662511823083" Q="0.058159882703973764" RANDOM="NO" SCALE="1.0" SORT_BY="STUDY" STUDIES="9" SUBGROUPS="YES" SUBGROUP_TEST="YES" TAU2="0.0" TOTALS="YES" TOTAL_1="542" TOTAL_2="598" UNITS="" WEIGHT="100.00000000000003" Z="2.5742204024709534">
<NAME>Distal radius BMD (mg/cm2) at end supplementation by duration of supplementation (&lt; 24 months vs &gt;= 24 months)</NAME>
<GROUP_LABEL_1>Treatment</GROUP_LABEL_1>
<GROUP_LABEL_2>Control</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours control</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours treatment</GRAPH_LABEL_2>
<CONT_SUBGROUP CHI2="7.66782535674019" CI_END="0.2811453880881159" CI_START="0.011710116389075487" DF="6" EFFECT_SIZE="0.1464277522385957" ESTIMABLE="YES" I2="21.750956485649926" ID="CMP-001.58.01" NO="1" P_CHI2="0.26346324288020273" P_Z="0.03314431748955426" STUDIES="7" TAU2="0.0" TOTAL_1="418" TOTAL_2="455" WEIGHT="76.25104625888517" Z="2.1303307389195396">
<NAME>&lt;24 months duration</NAME>
<CONT_DATA CI_END="0.5128125613720704" CI_START="-0.24259987277088774" EFFECT_SIZE="0.13510634430059137" ESTIMABLE="YES" MEAN_1="312.0" MEAN_2="308.0" ORDER="17356" SD_1="29.66" SD_2="29.12" SE="0.1927107947139731" STUDY_ID="STD-Bonjour-1995" TOTAL_1="55" TOTAL_2="53" WEIGHT="9.700328592044865"/>
<CONT_DATA CI_END="0.2574725427227148" CI_START="-0.7158349449146524" EFFECT_SIZE="-0.2291812010959688" ESTIMABLE="YES" MEAN_1="336.18" MEAN_2="351.0" ORDER="17357" SD_1="43.19" SD_2="69.75" SE="0.24829728895905548" STUDY_ID="STD-Courteix-2005" TOTAL_1="22" TOTAL_2="63" WEIGHT="5.843251446728712"/>
<CONT_DATA CI_END="0.7515904462890333" CI_START="0.12422571852871639" EFFECT_SIZE="0.4379080824088748" ESTIMABLE="YES" MEAN_1="253.0" MEAN_2="231.0" ORDER="17358" SD_1="50.0" SD_2="50.0" SE="0.16004496325159281" STUDY_ID="STD-Dibba-2000" TOTAL_1="80" TOTAL_2="80" WEIGHT="14.064182994645218"/>
<CONT_DATA CI_END="0.4501644946278604" CI_START="-0.40623244295249933" EFFECT_SIZE="0.02196602583768056" ESTIMABLE="YES" MEAN_1="492.0" MEAN_2="491.0" ORDER="17359" SD_1="39.0" SD_2="51.0" SE="0.2184726210112812" STUDY_ID="STD-Lee-1995" TOTAL_1="44" TOTAL_2="40" WEIGHT="7.547523829023321"/>
<CONT_DATA CI_END="0.2749570234978052" CI_START="-0.38090719667338463" EFFECT_SIZE="-0.05297508658778973" ESTIMABLE="YES" MEAN_1="479.0" MEAN_2="482.0" ORDER="17360" SD_1="61.0" SD_2="51.0" SE="0.16731537552336753" STUDY_ID="STD-Prentice-2005" TOTAL_1="73" TOTAL_2="70" WEIGHT="12.868467372323614"/>
<CONT_DATA CI_END="0.5639690051480064" CI_START="-0.12316306254107401" EFFECT_SIZE="0.2204029713034662" ESTIMABLE="YES" MEAN_1="427.0" MEAN_2="418.0" ORDER="17361" SD_1="38.0" SD_2="43.0" SE="0.17529201380971549" STUDY_ID="STD-Stear-2003" TOTAL_1="65" TOTAL_2="66" WEIGHT="11.723958432631655"/>
<CONT_DATA CI_END="0.5134677994735729" CI_START="-0.10432584171130158" EFFECT_SIZE="0.20457097888113565" ESTIMABLE="YES" MEAN_1="486.0" MEAN_2="479.0" ORDER="17362" SD_1="37.0" SD_2="31.0" SE="0.15760331466750202" STUDY_ID="STD-Wang-1996" TOTAL_1="79" TOTAL_2="83" WEIGHT="14.50333359148777"/>
</CONT_SUBGROUP>
<CONT_SUBGROUP CHI2="0.3471914662780828" CI_END="0.42183563898050624" CI_START="-0.06095085401522829" DF="1" EFFECT_SIZE="0.18044239248263896" ESTIMABLE="YES" I2="0.0" ID="CMP-001.58.02" NO="2" P_CHI2="0.5557074918394906" P_Z="0.14289889710146245" STUDIES="2" TAU2="0.0" TOTAL_1="124" TOTAL_2="143" WEIGHT="23.74895374111486" Z="1.4650807165532613">
<NAME>&gt;= 24 months duration</NAME>
<CONT_DATA CI_END="0.4929289406242539" CI_START="-0.3338062753225926" EFFECT_SIZE="0.07956133265083067" ESTIMABLE="YES" MEAN_1="317.09" MEAN_2="311.51" ORDER="17363" SD_1="69.4" SD_2="69.67" SE="0.2109057162447954" STUDY_ID="STD-Johnston-1992" TOTAL_1="45" TOTAL_2="45" WEIGHT="8.098821540257351"/>
<CONT_DATA CI_END="0.5300115286945037" CI_START="-0.06471641800366129" EFFECT_SIZE="0.23264755534542125" ESTIMABLE="YES" MEAN_1="450.0" MEAN_2="438.0" ORDER="17364" SD_1="53.0" SD_2="50.0" SE="0.15171910080728607" STUDY_ID="STD-Matkovic-2004" TOTAL_1="79" TOTAL_2="98" WEIGHT="15.650132200857508"/>
</CONT_SUBGROUP>
</CONT_OUTCOME>
<CONT_OUTCOME CHI2="8.690639421510731" CI_END="0.237153842673891" CI_START="0.037921792367907534" CI_STUDY="95" CI_TOTAL="95" DF="11" EFFECT_MEASURE="SMD" EFFECT_SIZE="0.13753781752089927" ESTIMABLE="YES" I2="0.0" I2_Q="0.0" ID="CMP-001.59" NO="59" P_CHI2="0.6504234741691632" P_Q="0.7716459910992084" P_Z="0.006808215777498085" Q="0.08422913359645179" RANDOM="NO" SCALE="1.0" SORT_BY="STUDY" STUDIES="12" SUBGROUPS="YES" SUBGROUP_TEST="YES" TAU2="0.0" TOTALS="YES" TOTAL_1="757" TOTAL_2="822" UNITS="" WEIGHT="100.0" Z="2.7060823641497076">
<NAME>Upper limb BMD (mg/cm2) at end supplementation by duration of supplementation (&lt; 24 months vs &gt;= 24 months)</NAME>
<GROUP_LABEL_1>Treatment</GROUP_LABEL_1>
<GROUP_LABEL_2>Control</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours control</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours treatment</GRAPH_LABEL_2>
<CONT_SUBGROUP CHI2="8.180903483855982" CI_END="0.24159535877624866" CI_START="0.018671528157051323" DF="8" EFFECT_SIZE="0.13013344346664998" ESTIMABLE="YES" I2="2.2112897947393315" ID="CMP-001.59.01" NO="1" P_CHI2="0.416001617838053" P_Z="0.02212080754597422" STUDIES="9" TAU2="0.0" TOTAL_1="609" TOTAL_2="655" WEIGHT="79.87399638986398" Z="2.288287094927111">
<NAME>&lt;24 months duration</NAME>
<CONT_DATA CI_END="0.5128125613720704" CI_START="-0.24259987277088774" EFFECT_SIZE="0.13510634430059137" ESTIMABLE="YES" MEAN_1="312.0" MEAN_2="308.0" ORDER="17365" SD_1="29.66" SD_2="29.12" SE="0.1927107947139731" STUDY_ID="STD-Bonjour-1995" TOTAL_1="55" TOTAL_2="53" WEIGHT="6.955849078431553"/>
<CONT_DATA CI_END="0.30378712152378146" CI_START="-0.211071470037911" EFFECT_SIZE="0.046357825742935246" ESTIMABLE="YES" MEAN_1="309.6" MEAN_2="308.2" ORDER="17366" SD_1="28.0" SD_2="32.0" SE="0.13134389091402476" STUDY_ID="STD-Chevalley-2005" TOTAL_1="114" TOTAL_2="118" WEIGHT="14.974160370613857"/>
<CONT_DATA CI_END="0.2574725427227148" CI_START="-0.7158349449146524" EFFECT_SIZE="-0.2291812010959688" ESTIMABLE="YES" MEAN_1="336.18" MEAN_2="351.0" ORDER="17367" SD_1="43.19" SD_2="69.75" SE="0.24829728895905548" STUDY_ID="STD-Courteix-2005" TOTAL_1="22" TOTAL_2="63" WEIGHT="4.190041069753462"/>
<CONT_DATA CI_END="0.7515904462890333" CI_START="0.12422571852871639" EFFECT_SIZE="0.4379080824088748" ESTIMABLE="YES" MEAN_1="253.0" MEAN_2="231.0" ORDER="17368" SD_1="50.0" SD_2="50.0" SE="0.16004496325159281" STUDY_ID="STD-Dibba-2000" TOTAL_1="80" TOTAL_2="80" WEIGHT="10.085053655030164"/>
<CONT_DATA CI_END="0.4772672773224417" CI_START="-0.14587387711583635" EFFECT_SIZE="0.16569670010330265" ESTIMABLE="YES" MEAN_1="487.0" MEAN_2="480.0" ORDER="17369" SD_1="41.0" SD_2="43.0" SE="0.15896750127898673" STUDY_ID="STD-Lee-1994" TOTAL_1="77" TOTAL_2="82" WEIGHT="10.222227439652531"/>
<CONT_DATA CI_END="0.4501644946278604" CI_START="-0.40623244295249933" EFFECT_SIZE="0.02196602583768056" ESTIMABLE="YES" MEAN_1="492.0" MEAN_2="491.0" ORDER="17370" SD_1="39.0" SD_2="51.0" SE="0.2184726210112812" STUDY_ID="STD-Lee-1995" TOTAL_1="44" TOTAL_2="40" WEIGHT="5.412129720389707"/>
<CONT_DATA CI_END="0.2749570234978052" CI_START="-0.38090719667338463" EFFECT_SIZE="-0.05297508658778973" ESTIMABLE="YES" MEAN_1="479.0" MEAN_2="482.0" ORDER="17371" SD_1="61.0" SD_2="51.0" SE="0.16731537552336753" STUDY_ID="STD-Prentice-2005" TOTAL_1="73" TOTAL_2="70" WEIGHT="9.227637606628175"/>
<CONT_DATA CI_END="0.5639690051480064" CI_START="-0.12316306254107401" EFFECT_SIZE="0.2204029713034662" ESTIMABLE="YES" MEAN_1="427.0" MEAN_2="418.0" ORDER="17372" SD_1="38.0" SD_2="43.0" SE="0.17529201380971549" STUDY_ID="STD-Stear-2003" TOTAL_1="65" TOTAL_2="66" WEIGHT="8.40694051602222"/>
<CONT_DATA CI_END="0.5134677994735729" CI_START="-0.10432584171130158" EFFECT_SIZE="0.20457097888113565" ESTIMABLE="YES" MEAN_1="486.0" MEAN_2="479.0" ORDER="17373" SD_1="37.0" SD_2="31.0" SE="0.15760331466750202" STUDY_ID="STD-Wang-1996" TOTAL_1="79" TOTAL_2="83" WEIGHT="10.399956933342306"/>
</CONT_SUBGROUP>
<CONT_SUBGROUP CHI2="0.4255068040582982" CI_END="0.3889733547060712" CI_START="-0.055126295596709424" DF="2" EFFECT_SIZE="0.1669235295546809" ESTIMABLE="YES" I2="0.0" ID="CMP-001.59.02" NO="2" P_CHI2="0.8083555588237495" P_Z="0.1406481938202624" STUDIES="3" TAU2="0.0" TOTAL_1="148" TOTAL_2="167" WEIGHT="20.12600361013603" Z="1.47338150740009">
<NAME>&gt;= 24 months duration</NAME>
<CONT_DATA CI_END="0.6586912100157563" CI_START="-0.47355455217399833" EFFECT_SIZE="0.09256832892087895" ESTIMABLE="YES" MEAN_1="418.0" MEAN_2="414.0" ORDER="17374" SD_1="43.0" SD_2="42.0" SE="0.28884351220756216" STUDY_ID="STD-Cameron-2004" TOTAL_1="24" TOTAL_2="24" WEIGHT="3.0962569962613915"/>
<CONT_DATA CI_END="0.4929289406242539" CI_START="-0.3338062753225926" EFFECT_SIZE="0.07956133265083067" ESTIMABLE="YES" MEAN_1="317.09" MEAN_2="311.51" ORDER="17375" SD_1="69.4" SD_2="69.67" SE="0.2109057162447954" STUDY_ID="STD-Johnston-1992" TOTAL_1="45" TOTAL_2="45" WEIGHT="5.807450728357776"/>
<CONT_DATA CI_END="0.5300115286945037" CI_START="-0.06471641800366129" EFFECT_SIZE="0.23264755534542125" ESTIMABLE="YES" MEAN_1="450.0" MEAN_2="438.0" ORDER="17376" SD_1="53.0" SD_2="50.0" SE="0.15171910080728607" STUDY_ID="STD-Matkovic-2004" TOTAL_1="79" TOTAL_2="98" WEIGHT="11.222295885516864"/>
</CONT_SUBGROUP>
</CONT_OUTCOME>
<CONT_OUTCOME CHI2="4.977220570190812" CI_END="0.25816335936328655" CI_START="-0.05858426423327913" CI_STUDY="95" CI_TOTAL="95" DF="4" EFFECT_MEASURE="SMD" EFFECT_SIZE="0.0997895475650037" ESTIMABLE="YES" I2="19.63386103568539" I2_Q="0.0" ID="CMP-001.60" NO="60" P_CHI2="0.2896428687480078" P_Q="0.6689091709548016" P_Z="0.21684871283710272" Q="0.1828807553244225" RANDOM="NO" SCALE="1.0" SORT_BY="STUDY" STUDIES="5" SUBGROUPS="YES" SUBGROUP_TEST="YES" TAU2="0.0" TOTALS="YES" TOTAL_1="313" TOTAL_2="304" UNITS="" WEIGHT="100.0" Z="1.2349511389551246">
<NAME>Femoral neck BMD (mg/cm2) at longest point after supplementation ceased end by duration of supplementation (24</NAME>
<GROUP_LABEL_1>Treatment</GROUP_LABEL_1>
<GROUP_LABEL_2>Control</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours control</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours treatment</GRAPH_LABEL_2>
<CONT_SUBGROUP CHI2="4.794339814866389" CI_END="0.28457004934356944" CI_START="-0.05706268045106175" DF="3" EFFECT_SIZE="0.11375368444625386" ESTIMABLE="YES" I2="37.426212662324495" ID="CMP-001.60.01" NO="1" P_CHI2="0.18749115653434545" P_Z="0.19181756950682427" STUDIES="4" TAU2="0.0" TOTAL_1="270" TOTAL_2="261" WEIGHT="85.96225274570352" Z="1.3052211054685396">
<NAME>&lt;24 months duration</NAME>
<CONT_DATA CI_END="0.7986994788224699" CI_START="0.08686283431210057" EFFECT_SIZE="0.4427811565672853" ESTIMABLE="YES" MEAN_1="885.0" MEAN_2="853.0" ORDER="17377" SD_1="70.2" SD_2="73.67" SE="0.18159431758064076" STUDY_ID="STD-Bonjour-1995" TOTAL_1="67" TOTAL_2="58" WEIGHT="19.800039110516856"/>
<CONT_DATA CI_END="0.22762896650934925" CI_START="-0.2940909927915369" EFFECT_SIZE="-0.033231013141093814" ESTIMABLE="YES" MEAN_1="722.4" MEAN_2="724.7" ORDER="17378" SD_1="70.0" SD_2="68.0" SE="0.13309427199074741" STUDY_ID="STD-Chevalley-2005" TOTAL_1="110" TOTAL_2="116" WEIGHT="36.85970262180859"/>
<CONT_DATA CI_END="0.4281849516340527" CI_START="-0.4281849516340527" EFFECT_SIZE="0.0" ESTIMABLE="YES" MEAN_1="603.0" MEAN_2="603.0" ORDER="17379" SD_1="76.0" SD_2="64.0" SE="0.21846572437632575" STUDY_ID="STD-Lee-1995" TOTAL_1="44" TOTAL_2="40" WEIGHT="13.680562008538146"/>
<CONT_DATA CI_END="0.5438493859396915" CI_START="-0.2575440066043698" EFFECT_SIZE="0.14315268966766082" ESTIMABLE="YES" MEAN_1="1010.0" MEAN_2="990.0" ORDER="17380" SD_1="140.0" SD_2="137.11" SE="0.20444084658324083" STUDY_ID="STD-Rozen-2003" TOTAL_1="49" TOTAL_2="47" WEIGHT="15.621949004839932"/>
</CONT_SUBGROUP>
<CONT_SUBGROUP CHI2="6.469748123266079E-35" CI_END="0.43698040696836393" CI_START="-0.40842428898937033" DF="0" EFFECT_SIZE="0.014278058989496795" ESTIMABLE="YES" I2="99.99999999999999" ID="CMP-001.60.02" NO="2" P_CHI2="0.0" P_Z="0.9472156097162635" STUDIES="1" TAU2="0.0" TOTAL_1="43" TOTAL_2="43" WEIGHT="14.037747254296471" Z="0.06620375193645991">
<NAME>&gt;= 24 months duration</NAME>
<CONT_DATA CI_END="0.43698040696836393" CI_START="-0.40842428898937033" EFFECT_SIZE="0.014278058989496793" ESTIMABLE="YES" MEAN_1="956.05" MEAN_2="954.05" ORDER="17381" SD_1="136.72" SD_2="140.89" SE="0.2156684262124658" STUDY_ID="STD-Johnston-1992" TOTAL_1="43" TOTAL_2="43" WEIGHT="14.037747254296471"/>
</CONT_SUBGROUP>
</CONT_OUTCOME>
<CONT_OUTCOME CHI2="1.1583576889270417" CI_END="0.16953284421813045" CI_START="-0.14651148834224073" CI_STUDY="95" CI_TOTAL="95" DF="4" EFFECT_MEASURE="SMD" EFFECT_SIZE="0.011510677937944854" ESTIMABLE="YES" I2="0.0" I2_Q="0.0" ID="CMP-001.61" NO="61" P_CHI2="0.8849060147469565" P_Q="0.8616621731051575" P_Z="0.8864733826880066" Q="0.030366102842974474" RANDOM="NO" SCALE="1.0" SORT_BY="STUDY" STUDIES="5" SUBGROUPS="YES" SUBGROUP_TEST="YES" TAU2="0.0" TOTALS="YES" TOTAL_1="313" TOTAL_2="304" UNITS="" WEIGHT="100.0" Z="0.14276803518824155">
<NAME>Lumbar spine BMD (mg/cm2) at longest point after supplementation ceased end by duration of supplementation (24</NAME>
<GROUP_LABEL_1>Treatment</GROUP_LABEL_1>
<GROUP_LABEL_2>Control</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours control</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours treatment</GRAPH_LABEL_2>
<CONT_SUBGROUP CHI2="1.1279915860840672" CI_END="0.17622051450122728" CI_START="-0.16452322237322697" DF="3" EFFECT_SIZE="0.005848646064000138" ESTIMABLE="YES" I2="0.0" ID="CMP-001.61.01" NO="1" P_CHI2="0.770321498704515" P_Z="0.9463563858626672" STUDIES="4" TAU2="0.0" TOTAL_1="270" TOTAL_2="261" WEIGHT="86.02808384787913" Z="0.06728303063710173">
<NAME>&lt;24 months duration</NAME>
<CONT_DATA CI_END="0.4286491395175547" CI_START="-0.27466106073165153" EFFECT_SIZE="0.07699403939295155" ESTIMABLE="YES" MEAN_1="1019.0" MEAN_2="1014.0" ORDER="17382" SD_1="70.2" SD_2="57.3" SE="0.17941916427975904" STUDY_ID="STD-Bonjour-1995" TOTAL_1="67" TOTAL_2="58" WEIGHT="20.193062121230806"/>
<CONT_DATA CI_END="0.30604468824634573" CI_START="-0.21570630455408518" EFFECT_SIZE="0.04516919184613029" ESTIMABLE="YES" MEAN_1="605.0" MEAN_2="602.5" ORDER="17383" SD_1="52.0" SD_2="58.0" SE="0.13310218884528904" STUDY_ID="STD-Chevalley-2005" TOTAL_1="110" TOTAL_2="116" WEIGHT="36.69183613729449"/>
<CONT_DATA CI_END="0.22936706177064778" CI_START="-0.6292396856883473" EFFECT_SIZE="-0.19993631195884978" ESTIMABLE="YES" MEAN_1="538.0" MEAN_2="551.0" ORDER="17384" SD_1="61.0" SD_2="68.0" SE="0.2190363583799436" STUDY_ID="STD-Lee-1995" TOTAL_1="44" TOTAL_2="40" WEIGHT="13.549005508643003"/>
<CONT_DATA CI_END="0.40016282334497716" CI_START="-0.40016282334497716" EFFECT_SIZE="0.0" ESTIMABLE="YES" MEAN_1="1150.0" MEAN_2="1150.0" ORDER="17385" SD_1="140.0" SD_2="137.11" SE="0.2041684574315704" STUDY_ID="STD-Rozen-2003" TOTAL_1="49" TOTAL_2="47" WEIGHT="15.594180080710828"/>
</CONT_SUBGROUP>
<CONT_SUBGROUP CHI2="0.0" CI_END="0.46912926150434037" CI_START="-0.3763832168316114" DF="0" EFFECT_SIZE="0.0463730223363645" ESTIMABLE="YES" I2="0.0" ID="CMP-001.61.02" NO="2" P_CHI2="1.0" P_Z="0.8297731054772091" STUDIES="1" TAU2="0.0" TOTAL_1="43" TOTAL_2="43" WEIGHT="13.971916152120874" Z="0.21499257778530934">
<NAME>&gt;= 24 months duration</NAME>
<CONT_DATA CI_END="0.46912926150434037" CI_START="-0.3763832168316114" EFFECT_SIZE="0.0463730223363645" ESTIMABLE="YES" MEAN_1="1061.23" MEAN_2="1052.39" ORDER="17386" SD_1="192.31" SD_2="185.47" SE="0.21569592222235875" STUDY_ID="STD-Johnston-1992" TOTAL_1="43" TOTAL_2="43" WEIGHT="13.971916152120874"/>
</CONT_SUBGROUP>
</CONT_OUTCOME>
<CONT_OUTCOME CHI2="2.8160955985362586" CI_END="0.3987017951586933" CI_START="0.029157553391896907" CI_STUDY="95" CI_TOTAL="95" DF="3" EFFECT_MEASURE="SMD" EFFECT_SIZE="0.2139296742752951" ESTIMABLE="YES" I2="0.0" I2_Q="0.0" ID="CMP-001.62" NO="62" P_CHI2="0.4208572474022483" P_Q="0.40142244773309854" P_Z="0.023253021489117242" Q="0.7040624716032116" RANDOM="NO" SCALE="1.0" SORT_BY="STUDY" STUDIES="4" SUBGROUPS="YES" SUBGROUP_TEST="YES" TAU2="0.0" TOTALS="YES" TOTAL_1="234" TOTAL_2="221" UNITS="" WEIGHT="99.99999999999999" Z="2.2692517399232655">
<NAME>Distal radius BMD (mg/cm2) at longest point after supplementation ceased end by duration of supplementation (2</NAME>
<GROUP_LABEL_1>Treatment</GROUP_LABEL_1>
<GROUP_LABEL_2>Control</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours control</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours treatment</GRAPH_LABEL_2>
<CONT_SUBGROUP CHI2="2.112033126933047" CI_END="0.4577983701178954" CI_START="0.04693627243059689" DF="2" EFFECT_SIZE="0.25236732127424616" ESTIMABLE="YES" I2="5.304515611255304" ID="CMP-001.62.01" NO="1" P_CHI2="0.3478388301644867" P_Z="0.01605025824370589" STUDIES="3" TAU2="0.0" TOTAL_1="191" TOTAL_2="178" WEIGHT="80.89854686712367" Z="2.407770701442644">
<NAME>&lt;24 months duration</NAME>
<CONT_DATA CI_END="0.7255999910161408" CI_START="0.016372536416859873" EFFECT_SIZE="0.37098626371650034" ESTIMABLE="YES" MEAN_1="429.0" MEAN_2="418.0" ORDER="17387" SD_1="26.32" SD_2="32.74" SE="0.18092869567848607" STUDY_ID="STD-Bonjour-1995" TOTAL_1="67" TOTAL_2="58" WEIGHT="27.149497819276153"/>
<CONT_DATA CI_END="0.6175167825952239" CI_START="-0.0059803321820287025" EFFECT_SIZE="0.30576822520659763" ESTIMABLE="YES" MEAN_1="256.0" MEAN_2="242.0" ORDER="17388" SD_1="43.0" SD_2="48.0" SE="0.15905830915652489" STUDY_ID="STD-Dibba-2000" TOTAL_1="80" TOTAL_2="80" WEIGHT="35.12885404818749"/>
<CONT_DATA CI_END="0.40686449035579997" CI_START="-0.44953091203190143" EFFECT_SIZE="-0.021333210838050704" ESTIMABLE="YES" MEAN_1="516.0" MEAN_2="517.0" ORDER="17389" SD_1="44.0" SD_2="49.0" SE="0.21847222937330457" STUDY_ID="STD-Lee-1995" TOTAL_1="44" TOTAL_2="40" WEIGHT="18.62019499966003"/>
</CONT_SUBGROUP>
<CONT_SUBGROUP CHI2="0.0" CI_END="0.47390750843088114" CI_START="-0.3716306970386415" DF="0" EFFECT_SIZE="0.05113840569611985" ESTIMABLE="YES" I2="0.0" ID="CMP-001.62.02" NO="2" P_CHI2="1.0" P_Z="0.812595949150155" STUDIES="1" TAU2="0.0" TOTAL_1="43" TOTAL_2="43" WEIGHT="19.101453132876312" Z="0.23707842588978228">
<NAME>&gt;= 24 months duration</NAME>
<CONT_DATA CI_END="0.47390750843088114" CI_START="-0.3716306970386415" EFFECT_SIZE="0.05113840569611985" ESTIMABLE="YES" MEAN_1="365.23" MEAN_2="361.31" ORDER="17390" SD_1="77.08" SD_2="74.84" SE="0.21570248538723671" STUDY_ID="STD-Johnston-1992" TOTAL_1="43" TOTAL_2="43" WEIGHT="19.101453132876312"/>
</CONT_SUBGROUP>
</CONT_OUTCOME>
<CONT_OUTCOME CHI2="4.569678112982537" CI_END="0.3208724402970041" CI_START="0.04921441616255223" CI_STUDY="95" CI_TOTAL="95" DF="5" EFFECT_MEASURE="SMD" EFFECT_SIZE="0.18504342822977818" ESTIMABLE="YES" I2="0.0" I2_Q="0.0" ID="CMP-001.63" NO="63" P_CHI2="0.4706152751090106" P_Q="0.5121197608447519" P_Z="0.007582631581730898" Q="0.4297335083436975" RANDOM="NO" SCALE="1.0" SORT_BY="STUDY" STUDIES="6" SUBGROUPS="YES" SUBGROUP_TEST="YES" TAU2="0.0" TOTALS="YES" TOTAL_1="421" TOTAL_2="419" UNITS="" WEIGHT="99.99999999999999" Z="2.670110379119057">
<NAME>Upper limb BMD (mg/cm2) at longest point after supplementation ceased end by duration of supplementation (24)</NAME>
<GROUP_LABEL_1>Treatment</GROUP_LABEL_1>
<GROUP_LABEL_2>Control</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours control</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours treatment</GRAPH_LABEL_2>
<CONT_SUBGROUP CHI2="4.139944604638839" CI_END="0.3438900192663026" CI_START="0.057023126469834845" DF="4" EFFECT_SIZE="0.2004565728680687" ESTIMABLE="YES" I2="3.3803496907188153" ID="CMP-001.63.01" NO="1" P_CHI2="0.38739788868990466" P_Z="0.006159573003326152" STUDIES="5" TAU2="0.0" TOTAL_1="378" TOTAL_2="376" WEIGHT="89.67764945805865" Z="2.7391635155646754">
<NAME>&lt;24 months duration</NAME>
<CONT_DATA CI_END="0.7255999910161408" CI_START="0.016372536416859873" EFFECT_SIZE="0.37098626371650034" ESTIMABLE="YES" MEAN_1="429.0" MEAN_2="418.0" ORDER="17391" SD_1="26.32" SD_2="32.74" SE="0.18092869567848607" STUDY_ID="STD-Bonjour-1995" TOTAL_1="67" TOTAL_2="58" WEIGHT="14.671482403917"/>
<CONT_DATA CI_END="0.5201854123124395" CI_START="-0.003704661341557558" EFFECT_SIZE="0.258240375485441" ESTIMABLE="YES" MEAN_1="24.7" MEAN_2="19.4" ORDER="17392" SD_1="21.7" SD_2="19.2" SE="0.1336478827637587" STUDY_ID="STD-Chevalley-2005" TOTAL_1="110" TOTAL_2="116" WEIGHT="26.888386094926197"/>
<CONT_DATA CI_END="0.6175167825952239" CI_START="-0.0059803321820287025" EFFECT_SIZE="0.30576822520659763" ESTIMABLE="YES" MEAN_1="256.0" MEAN_2="242.0" ORDER="17393" SD_1="43.0" SD_2="48.0" SE="0.15905830915652489" STUDY_ID="STD-Dibba-2000" TOTAL_1="80" TOTAL_2="80" WEIGHT="18.98349529219736"/>
<CONT_DATA CI_END="0.3110243308527212" CI_START="-0.3110243308527212" EFFECT_SIZE="0.0" ESTIMABLE="YES" MEAN_1="505.0" MEAN_2="505.0" ORDER="17394" SD_1="45.0" SD_2="40.0" SE="0.15868879903204416" STUDY_ID="STD-Lee-1994" TOTAL_1="77" TOTAL_2="82" WEIGHT="19.072005137429322"/>
<CONT_DATA CI_END="0.40686449035579997" CI_START="-0.44953091203190143" EFFECT_SIZE="-0.021333210838050704" ESTIMABLE="YES" MEAN_1="516.0" MEAN_2="517.0" ORDER="17395" SD_1="44.0" SD_2="49.0" SE="0.21847222937330457" STUDY_ID="STD-Lee-1995" TOTAL_1="44" TOTAL_2="40" WEIGHT="10.06228052958878"/>
</CONT_SUBGROUP>
<CONT_SUBGROUP CHI2="0.0" CI_END="0.47390750843088114" CI_START="-0.3716306970386415" DF="0" EFFECT_SIZE="0.05113840569611985" ESTIMABLE="YES" I2="0.0" ID="CMP-001.63.02" NO="2" P_CHI2="1.0" P_Z="0.812595949150155" STUDIES="1" TAU2="0.0" TOTAL_1="43" TOTAL_2="43" WEIGHT="10.322350541941328" Z="0.23707842588978228">
<NAME>&gt;= 24 months duration</NAME>
<CONT_DATA CI_END="0.47390750843088114" CI_START="-0.3716306970386415" EFFECT_SIZE="0.05113840569611985" ESTIMABLE="YES" MEAN_1="365.23" MEAN_2="361.31" ORDER="17396" SD_1="77.08" SD_2="74.84" SE="0.21570248538723671" STUDY_ID="STD-Johnston-1992" TOTAL_1="43" TOTAL_2="43" WEIGHT="10.322350541941328"/>
</CONT_SUBGROUP>
</CONT_OUTCOME>
<CONT_OUTCOME CHI2="5.833956503938204" CI_END="0.18940999061179914" CI_START="-0.05259426682904429" CI_STUDY="95" CI_TOTAL="95" DF="9" EFFECT_MEASURE="SMD" EFFECT_SIZE="0.06840786189137743" ESTIMABLE="YES" I2="0.0" I2_Q="0.0" ID="CMP-001.64" NO="64" P_CHI2="0.7564148098212335" P_Q="0.46629741224605203" P_Z="0.26783832457717727" Q="0.5307366149756412" RANDOM="NO" SCALE="1.0" SORT_BY="STUDY" STUDIES="10" SUBGROUPS="YES" SUBGROUP_TEST="YES" TAU2="0.0" TOTALS="YES" TOTAL_1="519" TOTAL_2="554" UNITS="" WEIGHT="100.0" Z="1.1080544365982006">
<NAME>Femoral neck BMD (mg/cm2) at end supplementation by duration of supplementation (&lt; 18months vs &gt;= 18months)</NAME>
<GROUP_LABEL_1>Treatment</GROUP_LABEL_1>
<GROUP_LABEL_2>Control</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours control</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours treatment</GRAPH_LABEL_2>
<CONT_SUBGROUP CHI2="5.213649958301147" CI_END="0.23649879510570612" CI_START="-0.04571679900466455" DF="5" EFFECT_SIZE="0.09539099805052079" ESTIMABLE="YES" I2="4.097896099851788" ID="CMP-001.64.01" NO="1" P_CHI2="0.3903668132218875" P_Z="0.1851826936359141" STUDIES="6" TAU2="0.0" TOTAL_1="378" TOTAL_2="417" WEIGHT="73.53329004959836" Z="1.324965200578056">
<NAME>&lt;18months duration</NAME>
<CONT_DATA CI_END="0.6604385539390247" CI_START="-0.09794154702996843" EFFECT_SIZE="0.2812485034545282" ESTIMABLE="YES" MEAN_1="656.0" MEAN_2="635.0" ORDER="17397" SD_1="81.58" SD_2="65.52" SE="0.19346786648912906" STUDY_ID="STD-Bonjour-1995" TOTAL_1="55" TOTAL_2="53" WEIGHT="10.182915842113054"/>
<CONT_DATA CI_END="0.17515393035443064" CI_START="-0.3398562006734309" EFFECT_SIZE="-0.08235113515950013" ESTIMABLE="YES" MEAN_1="698.0" MEAN_2="703.7" ORDER="17398" SD_1="70.0" SD_2="68.0" SE="0.13138254965147209" STUDY_ID="STD-Chevalley-2005" TOTAL_1="114" TOTAL_2="118" WEIGHT="22.080782911208964"/>
<CONT_DATA CI_END="0.8977163300128035" CI_START="-0.08113466441638145" EFFECT_SIZE="0.40829083279821105" ESTIMABLE="YES" MEAN_1="772.45" MEAN_2="737.0" ORDER="17399" SD_1="57.43" SD_2="93.77" SE="0.24971147484092482" STUDY_ID="STD-Courteix-2005" TOTAL_1="22" TOTAL_2="63" WEIGHT="6.112415100267861"/>
<CONT_DATA CI_END="0.3203145893001051" CI_START="-0.3354338260641689" EFFECT_SIZE="-0.0075596183820319145" ESTIMABLE="YES" MEAN_1="1001.0" MEAN_2="1002.0" ORDER="17400" SD_1="134.0" SD_2="129.0" SE="0.16728583293793503" STUDY_ID="STD-Prentice-2005" TOTAL_1="73" TOTAL_2="70" WEIGHT="13.619824552271592"/>
<CONT_DATA CI_END="0.4921438634140949" CI_START="-0.3086206789419552" EFFECT_SIZE="0.09176159223606986" ESTIMABLE="YES" MEAN_1="1010.0" MEAN_2="1000.0" ORDER="17401" SD_1="70.0" SD_2="137.0" SE="0.2042804226690844" STUDY_ID="STD-Rozen-2003" TOTAL_1="49" TOTAL_2="47" WEIGHT="9.133481296727897"/>
<CONT_DATA CI_END="0.5643130591550494" CI_START="-0.12282562247230913" EFFECT_SIZE="0.2207437183413701" ESTIMABLE="YES" MEAN_1="870.0" MEAN_2="847.0" ORDER="17402" SD_1="100.0" SD_2="107.0" SE="0.17529370106987185" STUDY_ID="STD-Stear-2003" TOTAL_1="65" TOTAL_2="66" WEIGHT="12.403870347008993"/>
</CONT_SUBGROUP>
<CONT_SUBGROUP CHI2="0.0895699306614151" CI_END="0.22864286341393858" CI_START="-0.24176332598425815" DF="3" EFFECT_SIZE="-0.006560231285159793" ESTIMABLE="YES" I2="0.0" ID="CMP-001.64.02" NO="2" P_CHI2="0.9930589984387691" P_Z="0.9564038636237127" STUDIES="4" TAU2="0.0" TOTAL_1="141" TOTAL_2="137" WEIGHT="26.46670995040163" Z="0.05466687020260282">
<NAME>&gt;= 18 months duration</NAME>
<CONT_DATA CI_END="0.5507846604584942" CI_START="-0.5808184484700071" EFFECT_SIZE="-0.015016894005756475" ESTIMABLE="YES" MEAN_1="814.0" MEAN_2="816.0" ORDER="17403" SD_1="131.0" SD_2="131.0" SE="0.2886795670365482" STUDY_ID="STD-Cameron-2004" TOTAL_1="24" TOTAL_2="24" WEIGHT="4.5735954670635275"/>
<CONT_DATA CI_END="0.37562699217396994" CI_START="-0.4508427758870757" EFFECT_SIZE="-0.037607891856552896" ESTIMABLE="YES" MEAN_1="847.72" MEAN_2="852.89" ORDER="17404" SD_1="128.13" SD_2="144.0" SE="0.21083799870307152" STUDY_ID="STD-Johnston-1992" TOTAL_1="45" TOTAL_2="45" WEIGHT="8.574169583656111"/>
<CONT_DATA CI_END="0.4140084286058978" CI_START="-0.44237274406664784" EFFECT_SIZE="-0.014182157730375022" ESTIMABLE="YES" MEAN_1="592.0" MEAN_2="593.0" ORDER="17405" SD_1="74.0" SD_2="65.0" SE="0.21846859927722423" STUDY_ID="STD-Lee-1995" TOTAL_1="44" TOTAL_2="40" WEIGHT="7.985677934320827"/>
<CONT_DATA CI_END="0.5859768774270062" CI_START="-0.46193881656079006" EFFECT_SIZE="0.06201903043310805" ESTIMABLE="YES" MEAN_1="877.0" MEAN_2="871.0" ORDER="17406" SD_1="90.0" SD_2="100.5" SE="0.26733034439755565" STUDY_ID="STD-Nowson-1997" TOTAL_1="28" TOTAL_2="28" WEIGHT="5.333266965361166"/>
</CONT_SUBGROUP>
</CONT_OUTCOME>
<CONT_OUTCOME CHI2="1.102464071489792" CI_END="0.19656167519370077" CI_START="-0.03540959073148839" CI_STUDY="95" CI_TOTAL="95" DF="10" EFFECT_MEASURE="SMD" EFFECT_SIZE="0.08057604223110619" ESTIMABLE="YES" I2="0.0" I2_Q="0.0" ID="CMP-001.65" NO="65" P_CHI2="0.9997312530937471" P_Q="0.8980835758131116" P_Z="0.17332387499636842" Q="0.01640516351581245" RANDOM="NO" SCALE="1.0" SORT_BY="STUDY" STUDIES="11" SUBGROUPS="YES" SUBGROUP_TEST="YES" TAU2="0.0" TOTALS="YES" TOTAL_1="563" TOTAL_2="601" UNITS="" WEIGHT="100.00000000000001" Z="1.3616008875916368">
<NAME>Lumbar spine BMD (mg/cm2) at end supplementation by duration of supplementation (&lt; 18months vs &gt;= 18months)</NAME>
<GROUP_LABEL_1>Treatment</GROUP_LABEL_1>
<GROUP_LABEL_2>Control</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours control</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours treatment</GRAPH_LABEL_2>
<CONT_SUBGROUP CHI2="0.6364068100121841" CI_END="0.21623521784095784" CI_START="-0.06553583637060521" DF="5" EFFECT_SIZE="0.07534969073517632" ESTIMABLE="YES" I2="0.0" ID="CMP-001.65.01" NO="1" P_CHI2="0.9862757361988175" P_Z="0.29452533038127815" STUDIES="6" TAU2="0.0" TOTAL_1="378" TOTAL_2="417" WEIGHT="67.77595276420968" Z="1.0482459278893277">
<NAME>&lt;18months duration</NAME>
<CONT_DATA CI_END="0.5114205026835856" CI_START="-0.24397376271812718" EFFECT_SIZE="0.13372336998272924" ESTIMABLE="YES" MEAN_1="647.0" MEAN_2="638.0" ORDER="17407" SD_1="74.16" SD_2="58.24" SE="0.1927061597458337" STUDY_ID="STD-Bonjour-1995" TOTAL_1="55" TOTAL_2="53" WEIGHT="9.43020248538449"/>
<CONT_DATA CI_END="0.27186034181968627" CI_START="-0.24293478100807947" EFFECT_SIZE="0.014462780405803406" ESTIMABLE="YES" MEAN_1="586.9" MEAN_2="586.1" ORDER="17408" SD_1="52.0" SD_2="58.0" SE="0.1313276996129531" STUDY_ID="STD-Chevalley-2005" TOTAL_1="114" TOTAL_2="118" WEIGHT="20.304838408962425"/>
<CONT_DATA CI_END="0.6270434570242918" CI_START="-0.3446758722743443" EFFECT_SIZE="0.1411837923749737" ESTIMABLE="YES" MEAN_1="740.64" MEAN_2="726.67" ORDER="17409" SD_1="65.03" SD_2="106.95" SE="0.2478921390809816" STUDY_ID="STD-Courteix-2005" TOTAL_1="22" TOTAL_2="63" WEIGHT="5.698843118900126"/>
<CONT_DATA CI_END="0.45798631527414724" CI_START="-0.1984686132330601" EFFECT_SIZE="0.12975885102054358" ESTIMABLE="YES" MEAN_1="1047.0" MEAN_2="1032.0" ORDER="17410" SD_1="114.0" SD_2="116.0" SE="0.1674660691944444" STUDY_ID="STD-Prentice-2005" TOTAL_1="73" TOTAL_2="70" WEIGHT="12.487012848693666"/>
<CONT_DATA CI_END="0.40016282334497716" CI_START="-0.40016282334497716" EFFECT_SIZE="0.0" ESTIMABLE="YES" MEAN_1="1120.0" MEAN_2="1120.0" ORDER="17411" SD_1="140.0" SD_2="137.11" SE="0.2041684574315704" STUDY_ID="STD-Rozen-2003" TOTAL_1="49" TOTAL_2="47" WEIGHT="8.401076060027075"/>
<CONT_DATA CI_END="0.4411301457213726" CI_START="-0.24428861169722987" EFFECT_SIZE="0.09842076701207135" ESTIMABLE="YES" MEAN_1="999.0" MEAN_2="989.0" ORDER="17412" SD_1="100.0" SD_2="102.0" SE="0.17485493683177297" STUDY_ID="STD-Stear-2003" TOTAL_1="65" TOTAL_2="66" WEIGHT="11.453979842241894"/>
</CONT_SUBGROUP>
<CONT_SUBGROUP CHI2="0.4496520979617954" CI_END="0.2958900240793569" CI_START="-0.11275305674222892" DF="4" EFFECT_SIZE="0.09156848366856397" ESTIMABLE="YES" I2="0.0" ID="CMP-001.65.02" NO="2" P_CHI2="0.9782136164595088" P_Z="0.3797402640001848" STUDIES="5" TAU2="0.0" TOTAL_1="185" TOTAL_2="184" WEIGHT="32.22404723579034" Z="0.8783749855668636">
<NAME>&gt;= 18 months duration</NAME>
<CONT_DATA CI_END="0.6643854658079379" CI_START="-0.4679433402975458" EFFECT_SIZE="0.09822106275519607" ESTIMABLE="YES" MEAN_1="848.0" MEAN_2="833.0" ORDER="17413" SD_1="158.0" SD_2="142.0" SE="0.2888646972692225" STUDY_ID="STD-Cameron-2004" TOTAL_1="24" TOTAL_2="24" WEIGHT="4.196848320638333"/>
<CONT_DATA CI_END="0.434960444536277" CI_START="-0.39145848587210075" EFFECT_SIZE="0.021750979332088152" ESTIMABLE="YES" MEAN_1="907.36" MEAN_2="902.96" ORDER="17414" SD_1="197.32" SD_2="203.75" SE="0.2108250296758167" STUDY_ID="STD-Johnston-1992" TOTAL_1="45" TOTAL_2="45" WEIGHT="7.87894141933801"/>
<CONT_DATA CI_END="0.4625164252125683" CI_START="-0.393919388343527" EFFECT_SIZE="0.034298518434520614" ESTIMABLE="YES" MEAN_1="525.0" MEAN_2="523.0" ORDER="17415" SD_1="61.0" SD_2="54.0" SE="0.21848253853426688" STUDY_ID="STD-Lee-1995" TOTAL_1="44" TOTAL_2="40" WEIGHT="7.336328090508805"/>
<CONT_DATA CI_END="0.6124201908396137" CI_START="-0.21201494446981703" EFFECT_SIZE="0.20020262318489837" ESTIMABLE="YES" MEAN_1="914.0" MEAN_2="894.0" ORDER="17416" SD_1="83.0" SD_2="112.0" SE="0.21031895019818475" STUDY_ID="STD-Lloyd-1993" TOTAL_1="44" TOTAL_2="47" WEIGHT="7.9169044070243535"/>
<CONT_DATA CI_END="0.6326118992120395" CI_START="-0.4158598560902002" EFFECT_SIZE="0.10837602156091967" ESTIMABLE="YES" MEAN_1="1017.0" MEAN_2="1001.0" ORDER="17417" SD_1="148.2" SD_2="142.9" SE="0.2674721993803078" STUDY_ID="STD-Nowson-1997" TOTAL_1="28" TOTAL_2="28" WEIGHT="4.895024998280832"/>
</CONT_SUBGROUP>
</CONT_OUTCOME>
<CONT_OUTCOME CHI2="4.575286896634283" CI_END="0.26841853898080825" CI_START="0.011094187411965523" CI_STUDY="95" CI_TOTAL="95" DF="8" EFFECT_MEASURE="SMD" EFFECT_SIZE="0.1397563631963869" ESTIMABLE="YES" I2="0.0" I2_Q="0.0" ID="CMP-001.66" NO="66" P_CHI2="0.8018545079137473" P_Q="0.6165569831488962" P_Z="0.03325704729455614" Q="0.2507365186386945" RANDOM="NO" SCALE="1.0" SORT_BY="STUDY" STUDIES="9" SUBGROUPS="YES" SUBGROUP_TEST="YES" TAU2="0.0" TOTALS="YES" TOTAL_1="449" TOTAL_2="504" UNITS="" WEIGHT="100.0" Z="2.128966316675517">
<NAME>Total body BMC (mg) at end supplementation by duration of supplementation (&lt; 18months vs &gt;= 18months)</NAME>
<GROUP_LABEL_1>Treatment</GROUP_LABEL_1>
<GROUP_LABEL_2>Control</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours control</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours treatment</GRAPH_LABEL_2>
<CONT_SUBGROUP CHI2="4.25698980156689" CI_END="0.26546460007128575" CI_START="-0.013424795647262955" DF="6" EFFECT_SIZE="0.1260199022120114" ESTIMABLE="YES" I2="0.0" ID="CMP-001.66.01" NO="1" P_CHI2="0.6419430091087576" P_Z="0.07651550415730825" STUDIES="7" TAU2="0.0" TOTAL_1="381" TOTAL_2="433" WEIGHT="85.13296742101849" Z="1.771271862341193">
<NAME>&lt;18months duration</NAME>
<CONT_DATA CI_END="1.0623077058025256" CI_START="0.07587704885842766" EFFECT_SIZE="0.5690923773304767" ESTIMABLE="YES" MEAN_1="1340.9" MEAN_2="1186.1" ORDER="17418" SD_1="216.37" SD_2="285.32" SE="0.2516450977479528" STUDY_ID="STD-Courteix-2005" TOTAL_1="22" TOTAL_2="63" WEIGHT="6.805008185954207"/>
<CONT_DATA CI_END="0.6238360632229405" CI_START="-0.3464242431167532" EFFECT_SIZE="0.13870591005309368" ESTIMABLE="YES" MEAN_1="1179.57" MEAN_2="1151.25" ORDER="17419" SD_1="209.01" SD_2="195.57" SE="0.2475199325071744" STUDY_ID="STD-Iuliano_x002d_Burns-2003" TOTAL_1="30" TOTAL_2="36" WEIGHT="7.033722738386755"/>
<CONT_DATA CI_END="0.4506900805835923" CI_START="-0.29400382768340283" EFFECT_SIZE="0.07834312645009475" ESTIMABLE="YES" MEAN_1="1932.11" MEAN_2="1907.53" ORDER="17420" SD_1="292.33" SD_2="328.77" SE="0.18997642664381734" STUDY_ID="STD-Molgaard-2004" TOTAL_1="54" TOTAL_2="57" WEIGHT="11.940050720347894"/>
<CONT_DATA CI_END="0.3908635962567637" CI_START="-0.26504909971456003" EFFECT_SIZE="0.06290724827110186" ESTIMABLE="YES" MEAN_1="2796.0" MEAN_2="2770.0" ORDER="17421" SD_1="415.0" SD_2="407.0" SE="0.1673277420261493" STUDY_ID="STD-Prentice-2005" TOTAL_1="73" TOTAL_2="70" WEIGHT="15.391101406551368"/>
<CONT_DATA CI_END="0.3917077443497603" CI_START="-0.392434700377596" EFFECT_SIZE="-3.634780139178262E-4" ESTIMABLE="YES" MEAN_1="860.29" MEAN_2="860.34" ORDER="17422" SD_1="134.19" SD_2="138.69" SE="0.2000400137228469" STUDY_ID="STD-Rozen-2003" TOTAL_1="49" TOTAL_2="51" WEIGHT="10.768912529976115"/>
<CONT_DATA CI_END="0.3417017087255969" CI_START="-0.24604334021365062" EFFECT_SIZE="0.047829184255973135" ESTIMABLE="YES" MEAN_1="685.55" MEAN_2="681.5" ORDER="17423" SD_1="88.0" SD_2="80.55" SE="0.1499377166048217" STUDY_ID="STD-Specker-2003" TOTAL_1="88" TOTAL_2="90" WEIGHT="19.16830960071454"/>
<CONT_DATA CI_END="0.5619740238730728" CI_START="-0.12511989143932517" EFFECT_SIZE="0.21842706621687386" ESTIMABLE="YES" MEAN_1="2143.0" MEAN_2="2088.0" ORDER="17424" SD_1="265.0" SD_2="235.0" SE="0.175282280881717" STUDY_ID="STD-Stear-2003" TOTAL_1="65" TOTAL_2="66" WEIGHT="14.025862239087605"/>
</CONT_SUBGROUP>
<CONT_SUBGROUP CHI2="0.06756057642869781" CI_END="0.552101930808033" CI_START="-0.11527123537869083" DF="1" EFFECT_SIZE="0.21841534771467108" ESTIMABLE="YES" I2="0.0" ID="CMP-001.66.02" NO="2" P_CHI2="0.7949222679794785" P_Z="0.19952743024440567" STUDIES="2" TAU2="0.0" TOTAL_1="68" TOTAL_2="71" WEIGHT="14.867032578981508" Z="1.2828990941831613">
<NAME>&gt;= 18 months duration</NAME>
<CONT_DATA CI_END="0.7244128544136019" CI_START="-0.4090865084137309" EFFECT_SIZE="0.15766317299993554" ESTIMABLE="YES" MEAN_1="1583.0" MEAN_2="1512.0" ORDER="17425" SD_1="504.0" SD_2="372.0" SE="0.289163314165013" STUDY_ID="STD-Cameron-2004" TOTAL_1="24" TOTAL_2="24" WEIGHT="5.153700938319747"/>
<CONT_DATA CI_END="0.6634749996606573" CI_START="-0.16217650854283872" EFFECT_SIZE="0.2506492455589093" ESTIMABLE="YES" MEAN_1="1783.0" MEAN_2="1714.0" ORDER="17426" SD_1="238.0" SD_2="302.0" SE="0.21062925510777997" STUDY_ID="STD-Lloyd-1993" TOTAL_1="44" TOTAL_2="47" WEIGHT="9.713331640661762"/>
</CONT_SUBGROUP>
</CONT_OUTCOME>
<CONT_OUTCOME CHI2="8.073176705722247" CI_END="0.2721437986696751" CI_START="0.0368679481610452" CI_STUDY="95" CI_TOTAL="95" DF="8" EFFECT_MEASURE="SMD" EFFECT_SIZE="0.15450587341536015" ESTIMABLE="YES" I2="0.9064177385140044" I2_Q="0.0" ID="CMP-001.67" NO="67" P_CHI2="0.4263549182299098" P_Q="0.9090201333357026" P_Z="0.010046625118230837" Q="0.013058680005091361" RANDOM="NO" SCALE="1.0" SORT_BY="STUDY" STUDIES="9" SUBGROUPS="YES" SUBGROUP_TEST="YES" TAU2="0.0" TOTALS="YES" TOTAL_1="542" TOTAL_2="598" UNITS="" WEIGHT="100.0" Z="2.574220402470953">
<NAME>Distal radius BMD (mg/cm2) at end supplementation by duration of supplementation (&lt; 18months vs &gt;= 18months)</NAME>
<GROUP_LABEL_1>Treatment</GROUP_LABEL_1>
<GROUP_LABEL_2>Control</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours control</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours treatment</GRAPH_LABEL_2>
<CONT_SUBGROUP CHI2="7.206702339029982" CI_END="0.3079899708473576" CI_START="-0.01158808633755612" DF="4" EFFECT_SIZE="0.1482009422549007" ESTIMABLE="YES" I2="44.49611192713146" ID="CMP-001.67.01" NO="1" P_CHI2="0.12535993767248887" P_Z="0.06909086671203916" STUDIES="5" TAU2="0.0" TOTAL_1="295" TOTAL_2="332" WEIGHT="54.20018883837405" Z="1.8178251151106743">
<NAME>&lt;18 months duration</NAME>
<CONT_DATA CI_END="0.5128125613720704" CI_START="-0.24259987277088774" EFFECT_SIZE="0.13510634430059137" ESTIMABLE="YES" MEAN_1="312.0" MEAN_2="308.0" ORDER="17427" SD_1="29.66" SD_2="29.12" SE="0.1927107947139731" STUDY_ID="STD-Bonjour-1995" TOTAL_1="55" TOTAL_2="53" WEIGHT="9.700328592044862"/>
<CONT_DATA CI_END="0.2574725427227148" CI_START="-0.7158349449146524" EFFECT_SIZE="-0.2291812010959688" ESTIMABLE="YES" MEAN_1="336.18" MEAN_2="351.0" ORDER="17428" SD_1="43.19" SD_2="69.75" SE="0.24829728895905548" STUDY_ID="STD-Courteix-2005" TOTAL_1="22" TOTAL_2="63" WEIGHT="5.84325144672871"/>
<CONT_DATA CI_END="0.7515904462890333" CI_START="0.12422571852871639" EFFECT_SIZE="0.4379080824088748" ESTIMABLE="YES" MEAN_1="253.0" MEAN_2="231.0" ORDER="17429" SD_1="50.0" SD_2="50.0" SE="0.16004496325159281" STUDY_ID="STD-Dibba-2000" TOTAL_1="80" TOTAL_2="80" WEIGHT="14.064182994645215"/>
<CONT_DATA CI_END="0.2749570234978052" CI_START="-0.38090719667338463" EFFECT_SIZE="-0.05297508658778973" ESTIMABLE="YES" MEAN_1="479.0" MEAN_2="482.0" ORDER="17430" SD_1="61.0" SD_2="51.0" SE="0.16731537552336753" STUDY_ID="STD-Prentice-2005" TOTAL_1="73" TOTAL_2="70" WEIGHT="12.868467372323611"/>
<CONT_DATA CI_END="0.5639690051480064" CI_START="-0.12316306254107401" EFFECT_SIZE="0.2204029713034662" ESTIMABLE="YES" MEAN_1="427.0" MEAN_2="418.0" ORDER="17431" SD_1="38.0" SD_2="43.0" SE="0.17529201380971549" STUDY_ID="STD-Stear-2003" TOTAL_1="65" TOTAL_2="66" WEIGHT="11.723958432631651"/>
</CONT_SUBGROUP>
<CONT_SUBGROUP CHI2="0.853415686687174" CI_END="0.33579353492594166" CI_START="-0.011859086414032965" DF="3" EFFECT_SIZE="0.16196722425595433" ESTIMABLE="YES" I2="0.0" ID="CMP-001.67.02" NO="2" P_CHI2="0.8366526540093002" P_Z="0.06781293659478377" STUDIES="4" TAU2="0.0" TOTAL_1="247" TOTAL_2="266" WEIGHT="45.79981116162594" Z="1.8262478504780428">
<NAME>&gt;= 18 months duration</NAME>
<CONT_DATA CI_END="0.4929289406242539" CI_START="-0.3338062753225926" EFFECT_SIZE="0.07956133265083067" ESTIMABLE="YES" MEAN_1="317.09" MEAN_2="311.51" ORDER="17432" SD_1="69.4" SD_2="69.67" SE="0.2109057162447954" STUDY_ID="STD-Johnston-1992" TOTAL_1="45" TOTAL_2="45" WEIGHT="8.09882154025735"/>
<CONT_DATA CI_END="0.4501644946278604" CI_START="-0.40623244295249933" EFFECT_SIZE="0.02196602583768056" ESTIMABLE="YES" MEAN_1="492.0" MEAN_2="491.0" ORDER="17433" SD_1="39.0" SD_2="51.0" SE="0.2184726210112812" STUDY_ID="STD-Lee-1995" TOTAL_1="44" TOTAL_2="40" WEIGHT="7.547523829023319"/>
<CONT_DATA CI_END="0.5300115286945037" CI_START="-0.06471641800366129" EFFECT_SIZE="0.23264755534542125" ESTIMABLE="YES" MEAN_1="450.0" MEAN_2="438.0" ORDER="17434" SD_1="53.0" SD_2="50.0" SE="0.15171910080728607" STUDY_ID="STD-Matkovic-2004" TOTAL_1="79" TOTAL_2="98" WEIGHT="15.650132200857504"/>
<CONT_DATA CI_END="0.5134677994735729" CI_START="-0.10432584171130158" EFFECT_SIZE="0.20457097888113565" ESTIMABLE="YES" MEAN_1="486.0" MEAN_2="479.0" ORDER="17435" SD_1="37.0" SD_2="31.0" SE="0.15760331466750202" STUDY_ID="STD-Wang-1996" TOTAL_1="79" TOTAL_2="83" WEIGHT="14.503333591487765"/>
</CONT_SUBGROUP>
</CONT_OUTCOME>
<CONT_OUTCOME CHI2="8.690639421510733" CI_END="0.237153842673891" CI_START="0.037921792367907534" CI_STUDY="95" CI_TOTAL="95" DF="11" EFFECT_MEASURE="SMD" EFFECT_SIZE="0.13753781752089927" ESTIMABLE="YES" I2="0.0" I2_Q="0.0" ID="CMP-001.68" NO="68" P_CHI2="0.6504234741691632" P_Q="0.7074395444551542" P_Z="0.006808215777498085" Q="0.14084801011142112" RANDOM="NO" SCALE="1.0" SORT_BY="STUDY" STUDIES="12" SUBGROUPS="YES" SUBGROUP_TEST="YES" TAU2="0.0" TOTALS="YES" TOTAL_1="757" TOTAL_2="822" UNITS="" WEIGHT="100.00000000000003" Z="2.7060823641497076">
<NAME>Upper limb BMD (mg/cm2) at end supplementation by duration of supplementation (&lt; 18months vs &gt;= 18months)</NAME>
<GROUP_LABEL_1>Treatment</GROUP_LABEL_1>
<GROUP_LABEL_2>Control</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours control</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours treatment</GRAPH_LABEL_2>
<CONT_SUBGROUP CHI2="7.64071822100599" CI_END="0.25563774571565856" CI_START="-0.015886089968184164" DF="5" EFFECT_SIZE="0.11987582787373721" ESTIMABLE="YES" I2="34.56112559871771" ID="CMP-001.68.01" NO="1" P_CHI2="0.17717966145684771" P_Z="0.0835195424557584" STUDIES="6" TAU2="0.0" TOTAL_1="409" TOTAL_2="450" WEIGHT="53.83968229647944" Z="1.7306201104423238">
<NAME>&lt;18 months duration</NAME>
<CONT_DATA CI_END="0.5128125613720704" CI_START="-0.24259987277088774" EFFECT_SIZE="0.13510634430059137" ESTIMABLE="YES" MEAN_1="312.0" MEAN_2="308.0" ORDER="17436" SD_1="29.66" SD_2="29.12" SE="0.1927107947139731" STUDY_ID="STD-Bonjour-1995" TOTAL_1="55" TOTAL_2="53" WEIGHT="6.955849078431553"/>
<CONT_DATA CI_END="0.30378712152378146" CI_START="-0.211071470037911" EFFECT_SIZE="0.046357825742935246" ESTIMABLE="YES" MEAN_1="309.6" MEAN_2="308.2" ORDER="17437" SD_1="28.0" SD_2="32.0" SE="0.13134389091402476" STUDY_ID="STD-Chevalley-2005" TOTAL_1="114" TOTAL_2="118" WEIGHT="14.974160370613857"/>
<CONT_DATA CI_END="0.2574725427227148" CI_START="-0.7158349449146524" EFFECT_SIZE="-0.2291812010959688" ESTIMABLE="YES" MEAN_1="336.18" MEAN_2="351.0" ORDER="17438" SD_1="43.19" SD_2="69.75" SE="0.24829728895905548" STUDY_ID="STD-Courteix-2005" TOTAL_1="22" TOTAL_2="63" WEIGHT="4.190041069753462"/>
<CONT_DATA CI_END="0.7515904462890333" CI_START="0.12422571852871639" EFFECT_SIZE="0.4379080824088748" ESTIMABLE="YES" MEAN_1="253.0" MEAN_2="231.0" ORDER="17439" SD_1="50.0" SD_2="50.0" SE="0.16004496325159281" STUDY_ID="STD-Dibba-2000" TOTAL_1="80" TOTAL_2="80" WEIGHT="10.085053655030164"/>
<CONT_DATA CI_END="0.2749570234978052" CI_START="-0.38090719667338463" EFFECT_SIZE="-0.05297508658778973" ESTIMABLE="YES" MEAN_1="479.0" MEAN_2="482.0" ORDER="17440" SD_1="61.0" SD_2="51.0" SE="0.16731537552336753" STUDY_ID="STD-Prentice-2005" TOTAL_1="73" TOTAL_2="70" WEIGHT="9.227637606628175"/>
<CONT_DATA CI_END="0.5639690051480064" CI_START="-0.12316306254107401" EFFECT_SIZE="0.2204029713034662" ESTIMABLE="YES" MEAN_1="427.0" MEAN_2="418.0" ORDER="17441" SD_1="38.0" SD_2="43.0" SE="0.17529201380971549" STUDY_ID="STD-Stear-2003" TOTAL_1="65" TOTAL_2="66" WEIGHT="8.40694051602222"/>
</CONT_SUBGROUP>
<CONT_SUBGROUP CHI2="0.9090731903933212" CI_END="0.30475864687908394" CI_START="0.011517567302332998" DF="5" EFFECT_SIZE="0.15813810709070847" ESTIMABLE="YES" I2="0.0" ID="CMP-001.68.02" NO="2" P_CHI2="0.9695613021031438" P_Z="0.03452157460361029" STUDIES="6" TAU2="0.0" TOTAL_1="348" TOTAL_2="372" WEIGHT="46.16031770352058" Z="2.1139261588348086">
<NAME>&gt;= 18 months duration</NAME>
<CONT_DATA CI_END="0.6586912100157563" CI_START="-0.47355455217399833" EFFECT_SIZE="0.09256832892087895" ESTIMABLE="YES" MEAN_1="418.0" MEAN_2="414.0" ORDER="17442" SD_1="43.0" SD_2="42.0" SE="0.28884351220756216" STUDY_ID="STD-Cameron-2004" TOTAL_1="24" TOTAL_2="24" WEIGHT="3.0962569962613915"/>
<CONT_DATA CI_END="0.4929289406242539" CI_START="-0.3338062753225926" EFFECT_SIZE="0.07956133265083067" ESTIMABLE="YES" MEAN_1="317.09" MEAN_2="311.51" ORDER="17443" SD_1="69.4" SD_2="69.67" SE="0.2109057162447954" STUDY_ID="STD-Johnston-1992" TOTAL_1="45" TOTAL_2="45" WEIGHT="5.807450728357776"/>
<CONT_DATA CI_END="0.4772672773224417" CI_START="-0.14587387711583635" EFFECT_SIZE="0.16569670010330265" ESTIMABLE="YES" MEAN_1="487.0" MEAN_2="480.0" ORDER="17444" SD_1="41.0" SD_2="43.0" SE="0.15896750127898673" STUDY_ID="STD-Lee-1994" TOTAL_1="77" TOTAL_2="82" WEIGHT="10.222227439652531"/>
<CONT_DATA CI_END="0.4501644946278604" CI_START="-0.40623244295249933" EFFECT_SIZE="0.02196602583768056" ESTIMABLE="YES" MEAN_1="492.0" MEAN_2="491.0" ORDER="17445" SD_1="39.0" SD_2="51.0" SE="0.2184726210112812" STUDY_ID="STD-Lee-1995" TOTAL_1="44" TOTAL_2="40" WEIGHT="5.412129720389707"/>
<CONT_DATA CI_END="0.5300115286945037" CI_START="-0.06471641800366129" EFFECT_SIZE="0.23264755534542125" ESTIMABLE="YES" MEAN_1="450.0" MEAN_2="438.0" ORDER="17446" SD_1="53.0" SD_2="50.0" SE="0.15171910080728607" STUDY_ID="STD-Matkovic-2004" TOTAL_1="79" TOTAL_2="98" WEIGHT="11.222295885516864"/>
<CONT_DATA CI_END="0.5134677994735729" CI_START="-0.10432584171130158" EFFECT_SIZE="0.20457097888113565" ESTIMABLE="YES" MEAN_1="486.0" MEAN_2="479.0" ORDER="17447" SD_1="37.0" SD_2="31.0" SE="0.15760331466750202" STUDY_ID="STD-Wang-1996" TOTAL_1="79" TOTAL_2="83" WEIGHT="10.399956933342306"/>
</CONT_SUBGROUP>
</CONT_OUTCOME>
<CONT_OUTCOME CHI2="4.977220570190811" CI_END="0.28594515185741864" CI_START="-0.0741564016414127" CI_STUDY="95" CI_TOTAL="95" DF="4" EFFECT_MEASURE="SMD" EFFECT_SIZE="0.10589437510800297" ESTIMABLE="YES" I2="19.63386103568537" I2_Q="0.0" ID="CMP-001.69" NO="69" P_CHI2="0.2896428687480078" P_Q="0.4781177189882134" P_Z="0.24902300050576687" Q="0.5031537398147714" RANDOM="YES" SCALE="1.0" SORT_BY="STUDY" STUDIES="5" SUBGROUPS="YES" SUBGROUP_TEST="NO" TAU2="0.008372358437612464" TOTALS="YES" TOTAL_1="313" TOTAL_2="304" UNITS="" WEIGHT="100.0" Z="1.1527257206222201">
<NAME>Femoral neck BMD (mg/cm2) at longest point after cessation of supplementation by duration of supplementation</NAME>
<GROUP_LABEL_1>Treatment</GROUP_LABEL_1>
<GROUP_LABEL_2>Control</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours control</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours treatment</GRAPH_LABEL_2>
<CONT_SUBGROUP CHI2="4.471903601814756" CI_END="0.4556030432049202" CI_START="-0.12309546544732788" DF="2" EFFECT_SIZE="0.16625378887879613" ESTIMABLE="YES" I2="55.27631679742886" ID="CMP-001.69.01" NO="1" P_CHI2="0.10689045537675101" P_Z="0.26010091704921245" STUDIES="3" TAU2="0.036119260753275664" TOTAL_1="226" TOTAL_2="221" WEIGHT="69.5812004376318" Z="1.1261526809690714">
<NAME>&lt;18 months duration</NAME>
<CONT_DATA CI_END="0.7986994788224699" CI_START="0.08686283431210057" EFFECT_SIZE="0.4427811565672853" ESTIMABLE="YES" MEAN_1="885.0" MEAN_2="853.0" ORDER="17448" SD_1="70.2" SD_2="73.67" SE="0.18159431758064076" STUDY_ID="STD-Bonjour-1995" TOTAL_1="67" TOTAL_2="58" WEIGHT="20.40940447544884"/>
<CONT_DATA CI_END="0.22762896650934925" CI_START="-0.2940909927915369" EFFECT_SIZE="-0.033231013141093814" ESTIMABLE="YES" MEAN_1="722.4" MEAN_2="724.7" ORDER="17449" SD_1="70.0" SD_2="68.0" SE="0.13309427199074741" STUDY_ID="STD-Chevalley-2005" TOTAL_1="110" TOTAL_2="116" WEIGHT="32.35034675376019"/>
<CONT_DATA CI_END="0.5438493859396915" CI_START="-0.2575440066043698" EFFECT_SIZE="0.14315268966766082" ESTIMABLE="YES" MEAN_1="1010.0" MEAN_2="990.0" ORDER="17450" SD_1="140.0" SD_2="137.11" SE="0.20444084658324083" STUDY_ID="STD-Rozen-2003" TOTAL_1="49" TOTAL_2="47" WEIGHT="16.821449208422756"/>
</CONT_SUBGROUP>
<CONT_SUBGROUP CHI2="0.0021632285612830024" CI_END="0.308046380354268" CI_START="-0.29358433063284184" DF="1" EFFECT_SIZE="0.007231024860713113" ESTIMABLE="YES" I2="0.0" ID="CMP-001.69.02" NO="2" P_CHI2="0.9629033602060514" P_Z="0.9624225451597224" STUDIES="2" TAU2="0.0" TOTAL_1="87" TOTAL_2="83" WEIGHT="30.418799562368207" Z="0.04711377939819005">
<NAME>&gt;= 18 months duration</NAME>
<CONT_DATA CI_END="0.43698040696836393" CI_START="-0.40842428898937033" EFFECT_SIZE="0.014278058989496793" ESTIMABLE="YES" MEAN_1="956.05" MEAN_2="954.05" ORDER="17451" SD_1="136.72" SD_2="140.89" SE="0.2156684262124658" STUDY_ID="STD-Johnston-1992" TOTAL_1="43" TOTAL_2="43" WEIGHT="15.375821900757561"/>
<CONT_DATA CI_END="0.4281849516340527" CI_START="-0.4281849516340527" EFFECT_SIZE="0.0" ESTIMABLE="YES" MEAN_1="603.0" MEAN_2="603.0" ORDER="17452" SD_1="76.0" SD_2="64.0" SE="0.21846572437632575" STUDY_ID="STD-Lee-1995" TOTAL_1="44" TOTAL_2="40" WEIGHT="15.042977661610646"/>
</CONT_SUBGROUP>
</CONT_OUTCOME>
<CONT_OUTCOME CHI2="1.1583576889270417" CI_END="0.16953284421813042" CI_START="-0.1465114883422407" CI_STUDY="95" CI_TOTAL="95" DF="4" EFFECT_MEASURE="SMD" EFFECT_SIZE="0.011510677937944849" ESTIMABLE="YES" I2="0.0" I2_Q="0.0" ID="CMP-001.70" NO="70" P_CHI2="0.8849060147469565" P_Q="0.509035231833955" P_Z="0.8864733826880067" Q="0.4360498559078253" RANDOM="NO" SCALE="1.0" SORT_BY="STUDY" STUDIES="5" SUBGROUPS="YES" SUBGROUP_TEST="YES" TAU2="0.0" TOTALS="YES" TOTAL_1="313" TOTAL_2="304" UNITS="" WEIGHT="99.99999999999999" Z="0.1427680351882415">
<NAME>Lumbar spine BMD (mg/cm2) at longest point after cessation of supplementation by duration of supplementation</NAME>
<GROUP_LABEL_1>Treatment</GROUP_LABEL_1>
<GROUP_LABEL_2>Control</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours control</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours treatment</GRAPH_LABEL_2>
<CONT_SUBGROUP CHI2="0.08032662351519089" CI_END="0.22993182953029392" CI_START="-0.14129698262828114" DF="2" EFFECT_SIZE="0.0443174234510064" ESTIMABLE="YES" I2="0.0" ID="CMP-001.70.01" NO="1" P_CHI2="0.9606325445943602" P_Z="0.6398115150641082" STUDIES="3" TAU2="0.0" TOTAL_1="226" TOTAL_2="221" WEIGHT="72.47907833923611" Z="0.4679623510175162">
<NAME>&lt;18 months duration</NAME>
<CONT_DATA CI_END="0.4286491395175547" CI_START="-0.27466106073165153" EFFECT_SIZE="0.07699403939295155" ESTIMABLE="YES" MEAN_1="1019.0" MEAN_2="1014.0" ORDER="17453" SD_1="70.2" SD_2="57.3" SE="0.17941916427975904" STUDY_ID="STD-Bonjour-1995" TOTAL_1="67" TOTAL_2="58" WEIGHT="20.193062121230803"/>
<CONT_DATA CI_END="0.30604468824634573" CI_START="-0.21570630455408518" EFFECT_SIZE="0.04516919184613029" ESTIMABLE="YES" MEAN_1="605.0" MEAN_2="602.5" ORDER="17454" SD_1="52.0" SD_2="58.0" SE="0.13310218884528904" STUDY_ID="STD-Chevalley-2005" TOTAL_1="110" TOTAL_2="116" WEIGHT="36.69183613729448"/>
<CONT_DATA CI_END="0.40016282334497716" CI_START="-0.40016282334497716" EFFECT_SIZE="0.0" ESTIMABLE="YES" MEAN_1="1150.0" MEAN_2="1150.0" ORDER="17455" SD_1="140.0" SD_2="137.11" SE="0.2041684574315704" STUDY_ID="STD-Rozen-2003" TOTAL_1="49" TOTAL_2="47" WEIGHT="15.594180080710826"/>
</CONT_SUBGROUP>
<CONT_SUBGROUP CHI2="0.6419812095040255" CI_END="0.22633274440115408" CI_START="-0.37611102855233264" DF="1" EFFECT_SIZE="-0.07488914207558928" ESTIMABLE="YES" I2="0.0" ID="CMP-001.70.02" NO="2" P_CHI2="0.4229945327519281" P_Z="0.6260584611928532" STUDIES="2" TAU2="0.0" TOTAL_1="87" TOTAL_2="83" WEIGHT="27.520921660763875" Z="0.4872820598067356">
<NAME>&gt;= 18 months duration</NAME>
<CONT_DATA CI_END="0.46912926150434037" CI_START="-0.3763832168316114" EFFECT_SIZE="0.0463730223363645" ESTIMABLE="YES" MEAN_1="1061.23" MEAN_2="1052.39" ORDER="17456" SD_1="192.31" SD_2="185.47" SE="0.21569592222235875" STUDY_ID="STD-Johnston-1992" TOTAL_1="43" TOTAL_2="43" WEIGHT="13.971916152120873"/>
<CONT_DATA CI_END="0.22936706177064778" CI_START="-0.6292396856883473" EFFECT_SIZE="-0.19993631195884978" ESTIMABLE="YES" MEAN_1="538.0" MEAN_2="551.0" ORDER="17457" SD_1="61.0" SD_2="68.0" SE="0.2190363583799436" STUDY_ID="STD-Lee-1995" TOTAL_1="44" TOTAL_2="40" WEIGHT="13.549005508643"/>
</CONT_SUBGROUP>
</CONT_OUTCOME>
<CONT_OUTCOME CHI2="2.8160955985362586" CI_END="0.3987017951586933" CI_START="0.029157553391896934" CI_STUDY="95" CI_TOTAL="95" DF="3" EFFECT_MEASURE="SMD" EFFECT_SIZE="0.21392967427529513" ESTIMABLE="YES" I2="0.0" I2_Q="62.784938615755486" ID="CMP-001.71" NO="71" P_CHI2="0.4208572474022483" P_Q="0.10116485307029055" P_Z="0.023253021489117218" Q="2.687084107359187" RANDOM="NO" SCALE="1.0" SORT_BY="STUDY" STUDIES="4" SUBGROUPS="YES" SUBGROUP_TEST="YES" TAU2="0.0" TOTALS="YES" TOTAL_1="234" TOTAL_2="221" UNITS="" WEIGHT="100.0" Z="2.269251739923266">
<NAME>Distal radius BMD (mg/cm2) at longest point after cessation of supplementation by duration of supplementation</NAME>
<GROUP_LABEL_1>Treatment</GROUP_LABEL_1>
<GROUP_LABEL_2>Control</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours control</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours treatment</GRAPH_LABEL_2>
<CONT_SUBGROUP CHI2="0.07329045753226578" CI_END="0.5683350789696302" CI_START="0.1000634090925451" DF="1" EFFECT_SIZE="0.33419924403108764" ESTIMABLE="YES" I2="0.0" ID="CMP-001.71.01" NO="1" P_CHI2="0.7866047813998811" P_Z="0.00514837796425166" STUDIES="2" TAU2="0.0" TOTAL_1="147" TOTAL_2="138" WEIGHT="62.278351867463655" Z="2.797600299558493">
<NAME>&lt;18 months duration</NAME>
<CONT_DATA CI_END="0.7255999910161408" CI_START="0.016372536416859873" EFFECT_SIZE="0.37098626371650034" ESTIMABLE="YES" MEAN_1="429.0" MEAN_2="418.0" ORDER="17458" SD_1="26.32" SD_2="32.74" SE="0.18092869567848607" STUDY_ID="STD-Bonjour-1995" TOTAL_1="67" TOTAL_2="58" WEIGHT="27.149497819276156"/>
<CONT_DATA CI_END="0.6175167825952239" CI_START="-0.0059803321820287025" EFFECT_SIZE="0.30576822520659763" ESTIMABLE="YES" MEAN_1="256.0" MEAN_2="242.0" ORDER="17459" SD_1="43.0" SD_2="48.0" SE="0.15905830915652489" STUDY_ID="STD-Dibba-2000" TOTAL_1="80" TOTAL_2="80" WEIGHT="35.1288540481875"/>
</CONT_SUBGROUP>
<CONT_SUBGROUP CHI2="0.055721033644805885" CI_END="0.3162087324862899" CI_START="-0.28547893447297534" DF="1" EFFECT_SIZE="0.015364899006657287" ESTIMABLE="YES" I2="0.0" ID="CMP-001.71.02" NO="2" P_CHI2="0.8133915214303828" P_Z="0.9202644578386358" STUDIES="2" TAU2="0.0" TOTAL_1="87" TOTAL_2="83" WEIGHT="37.721648132536345" Z="0.10010060146764592">
<NAME>&gt;= 18 months duration</NAME>
<CONT_DATA CI_END="0.47390750843088114" CI_START="-0.3716306970386415" EFFECT_SIZE="0.05113840569611985" ESTIMABLE="YES" MEAN_1="365.23" MEAN_2="361.31" ORDER="17460" SD_1="77.08" SD_2="74.84" SE="0.21570248538723671" STUDY_ID="STD-Johnston-1992" TOTAL_1="43" TOTAL_2="43" WEIGHT="19.101453132876316"/>
<CONT_DATA CI_END="0.40686449035579997" CI_START="-0.44953091203190143" EFFECT_SIZE="-0.021333210838050704" ESTIMABLE="YES" MEAN_1="516.0" MEAN_2="517.0" ORDER="17461" SD_1="44.0" SD_2="49.0" SE="0.21847222937330457" STUDY_ID="STD-Lee-1995" TOTAL_1="44" TOTAL_2="40" WEIGHT="18.620194999660033"/>
</CONT_SUBGROUP>
</CONT_OUTCOME>
<CONT_OUTCOME CHI2="4.569678112982537" CI_END="0.3208724402970041" CI_START="0.04921441616255223" CI_STUDY="95" CI_TOTAL="95" DF="5" EFFECT_MEASURE="SMD" EFFECT_SIZE="0.18504342822977818" ESTIMABLE="YES" I2="0.0" I2_Q="76.50519889827177" ID="CMP-001.72" NO="72" P_CHI2="0.4706152751090106" P_Q="0.039106071985372415" P_Z="0.007582631581730898" Q="4.256260760285567" RANDOM="NO" SCALE="1.0" SORT_BY="STUDY" STUDIES="6" SUBGROUPS="YES" SUBGROUP_TEST="YES" TAU2="0.0" TOTALS="YES" TOTAL_1="421" TOTAL_2="419" UNITS="" WEIGHT="100.0" Z="2.670110379119057">
<NAME>Upper limb BMD (mg/cm2) at longest point after cessation of supplementation by duration of supplementation</NAME>
<GROUP_LABEL_1>Treatment</GROUP_LABEL_1>
<GROUP_LABEL_2>Control</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours control</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours treatment</GRAPH_LABEL_2>
<CONT_SUBGROUP CHI2="0.2528529264800004" CI_END="0.4750304001521078" CI_START="0.1258987153182745" DF="2" EFFECT_SIZE="0.30046455773519115" ESTIMABLE="YES" I2="0.0" ID="CMP-001.72.01" NO="1" P_CHI2="0.8812389557077016" P_Z="7.42162013067753E-4" STUDIES="3" TAU2="0.0" TOTAL_1="257" TOTAL_2="254" WEIGHT="60.54336379104056" Z="3.3735105541739245">
<NAME>&lt;18 months duration</NAME>
<CONT_DATA CI_END="0.7255999910161408" CI_START="0.016372536416859873" EFFECT_SIZE="0.37098626371650034" ESTIMABLE="YES" MEAN_1="429.0" MEAN_2="418.0" ORDER="17462" SD_1="26.32" SD_2="32.74" SE="0.18092869567848607" STUDY_ID="STD-Bonjour-1995" TOTAL_1="67" TOTAL_2="58" WEIGHT="14.671482403917"/>
<CONT_DATA CI_END="0.5201854123124395" CI_START="-0.003704661341557558" EFFECT_SIZE="0.258240375485441" ESTIMABLE="YES" MEAN_1="24.7" MEAN_2="19.4" ORDER="17463" SD_1="21.7" SD_2="19.2" SE="0.1336478827637587" STUDY_ID="STD-Chevalley-2005" TOTAL_1="110" TOTAL_2="116" WEIGHT="26.888386094926197"/>
<CONT_DATA CI_END="0.6175167825952239" CI_START="-0.0059803321820287025" EFFECT_SIZE="0.30576822520659763" ESTIMABLE="YES" MEAN_1="256.0" MEAN_2="242.0" ORDER="17464" SD_1="43.0" SD_2="48.0" SE="0.15905830915652489" STUDY_ID="STD-Dibba-2000" TOTAL_1="80" TOTAL_2="80" WEIGHT="18.98349529219736"/>
</CONT_SUBGROUP>
<CONT_SUBGROUP CHI2="0.06056442621696955" CI_END="0.22417627340268959" CI_START="-0.20830022172695611" DF="2" EFFECT_SIZE="0.007938025837866736" ESTIMABLE="YES" I2="0.0" ID="CMP-001.72.02" NO="2" P_CHI2="0.9701716999463524" P_Z="0.942642056465131" STUDIES="3" TAU2="0.0" TOTAL_1="164" TOTAL_2="165" WEIGHT="39.45663620895943" Z="0.0719495506728208">
<NAME>&gt;= 18 months duration</NAME>
<CONT_DATA CI_END="0.47390750843088114" CI_START="-0.3716306970386415" EFFECT_SIZE="0.05113840569611985" ESTIMABLE="YES" MEAN_1="365.23" MEAN_2="361.31" ORDER="17465" SD_1="77.08" SD_2="74.84" SE="0.21570248538723671" STUDY_ID="STD-Johnston-1992" TOTAL_1="43" TOTAL_2="43" WEIGHT="10.322350541941328"/>
<CONT_DATA CI_END="0.3110243308527212" CI_START="-0.3110243308527212" EFFECT_SIZE="0.0" ESTIMABLE="YES" MEAN_1="505.0" MEAN_2="505.0" ORDER="17466" SD_1="45.0" SD_2="40.0" SE="0.15868879903204416" STUDY_ID="STD-Lee-1994" TOTAL_1="77" TOTAL_2="82" WEIGHT="19.072005137429322"/>
<CONT_DATA CI_END="0.40686449035579997" CI_START="-0.44953091203190143" EFFECT_SIZE="-0.021333210838050704" ESTIMABLE="YES" MEAN_1="516.0" MEAN_2="517.0" ORDER="17467" SD_1="44.0" SD_2="49.0" SE="0.21847222937330457" STUDY_ID="STD-Lee-1995" TOTAL_1="44" TOTAL_2="40" WEIGHT="10.06228052958878"/>
</CONT_SUBGROUP>
</CONT_OUTCOME>
<CONT_OUTCOME CHI2="5.833956503938204" CI_END="0.1894099906117992" CI_START="-0.05259426682904429" CI_STUDY="95" CI_TOTAL="95" DF="9" EFFECT_MEASURE="SMD" EFFECT_SIZE="0.06840786189137744" ESTIMABLE="YES" I2="0.0" I2_Q="0.0" ID="CMP-001.73" NO="73" P_CHI2="0.7564148098212335" P_Q="0.7602964947079235" P_Z="0.26783832457717716" Q="0.09308081432861215" RANDOM="YES" SCALE="1.0" SORT_BY="STUDY" STUDIES="10" SUBGROUPS="YES" SUBGROUP_TEST="NO" TAU2="0.0" TOTALS="YES" TOTAL_1="519" TOTAL_2="554" UNITS="" WEIGHT="100.00000000000003" Z="1.1080544365982008">
<NAME>Femoral neck BMD (mg/cm2) at end supplementation by milk extract vs other calcium supplement</NAME>
<GROUP_LABEL_1>Treatment</GROUP_LABEL_1>
<GROUP_LABEL_2>Control</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours treatment</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours control</GRAPH_LABEL_2>
<CONT_SUBGROUP CHI2="4.322249130612068" CI_END="0.46401148063948994" CI_START="-0.15568441717133188" DF="2" EFFECT_SIZE="0.154163531734079" ESTIMABLE="YES" I2="53.72779449858359" ID="CMP-001.73.01" NO="1" P_CHI2="0.11519557801216584" P_Z="0.32947507979329527" STUDIES="3" TAU2="0.04024015991976548" TOTAL_1="191" TOTAL_2="234" WEIGHT="38.37611385358989" Z="0.9751717608449724">
<NAME>milk extract</NAME>
<CONT_DATA CI_END="0.6604385539390247" CI_START="-0.09794154702996843" EFFECT_SIZE="0.2812485034545282" ESTIMABLE="YES" MEAN_1="656.0" MEAN_2="635.0" ORDER="17468" SD_1="81.58" SD_2="65.52" SE="0.19346786648912906" STUDY_ID="STD-Bonjour-1995" TOTAL_1="55" TOTAL_2="53" WEIGHT="10.182915842113054"/>
<CONT_DATA CI_END="0.17515393035443064" CI_START="-0.3398562006734309" EFFECT_SIZE="-0.08235113515950013" ESTIMABLE="YES" MEAN_1="698.0" MEAN_2="703.7" ORDER="17469" SD_1="70.0" SD_2="68.0" SE="0.13138254965147209" STUDY_ID="STD-Chevalley-2005" TOTAL_1="114" TOTAL_2="118" WEIGHT="22.080782911208974"/>
<CONT_DATA CI_END="0.8977163300128035" CI_START="-0.08113466441638145" EFFECT_SIZE="0.40829083279821105" ESTIMABLE="YES" MEAN_1="772.45" MEAN_2="737.0" ORDER="17470" SD_1="57.43" SD_2="93.77" SE="0.24971147484092482" STUDY_ID="STD-Courteix-2005" TOTAL_1="22" TOTAL_2="63" WEIGHT="6.112415100267862"/>
</CONT_SUBGROUP>
<CONT_SUBGROUP CHI2="1.4186265589975235" CI_END="0.2076851294286854" CI_START="-0.10059708158462445" DF="6" EFFECT_SIZE="0.05354402392203046" ESTIMABLE="YES" I2="0.0" ID="CMP-001.73.02" NO="2" P_CHI2="0.9647155468686709" P_Z="0.4959771415781725" STUDIES="7" TAU2="0.0" TOTAL_1="328" TOTAL_2="320" WEIGHT="61.62388614641013" Z="0.6808330466398524">
<NAME>other calcium supplementation</NAME>
<CONT_DATA CI_END="0.5507846604584942" CI_START="-0.5808184484700071" EFFECT_SIZE="-0.015016894005756475" ESTIMABLE="YES" MEAN_1="814.0" MEAN_2="816.0" ORDER="17471" SD_1="131.0" SD_2="131.0" SE="0.2886795670365482" STUDY_ID="STD-Cameron-2004" TOTAL_1="24" TOTAL_2="24" WEIGHT="4.573595467063529"/>
<CONT_DATA CI_END="0.37562699217396994" CI_START="-0.4508427758870757" EFFECT_SIZE="-0.037607891856552896" ESTIMABLE="YES" MEAN_1="847.72" MEAN_2="852.89" ORDER="17472" SD_1="128.13" SD_2="144.0" SE="0.21083799870307152" STUDY_ID="STD-Johnston-1992" TOTAL_1="45" TOTAL_2="45" WEIGHT="8.574169583656113"/>
<CONT_DATA CI_END="0.4140084286058978" CI_START="-0.44237274406664784" EFFECT_SIZE="-0.014182157730375022" ESTIMABLE="YES" MEAN_1="592.0" MEAN_2="593.0" ORDER="17473" SD_1="74.0" SD_2="65.0" SE="0.21846859927722423" STUDY_ID="STD-Lee-1995" TOTAL_1="44" TOTAL_2="40" WEIGHT="7.985677934320828"/>
<CONT_DATA CI_END="0.5859768774270062" CI_START="-0.46193881656079006" EFFECT_SIZE="0.06201903043310805" ESTIMABLE="YES" MEAN_1="877.0" MEAN_2="871.0" ORDER="17474" SD_1="90.0" SD_2="100.5" SE="0.26733034439755565" STUDY_ID="STD-Nowson-1997" TOTAL_1="28" TOTAL_2="28" WEIGHT="5.333266965361167"/>
<CONT_DATA CI_END="0.3203145893001051" CI_START="-0.3354338260641689" EFFECT_SIZE="-0.0075596183820319145" ESTIMABLE="YES" MEAN_1="1001.0" MEAN_2="1002.0" ORDER="17475" SD_1="134.0" SD_2="129.0" SE="0.16728583293793503" STUDY_ID="STD-Prentice-2005" TOTAL_1="73" TOTAL_2="70" WEIGHT="13.619824552271593"/>
<CONT_DATA CI_END="0.4921438634140949" CI_START="-0.3086206789419552" EFFECT_SIZE="0.09176159223606986" ESTIMABLE="YES" MEAN_1="1010.0" MEAN_2="1000.0" ORDER="17476" SD_1="70.0" SD_2="137.0" SE="0.2042804226690844" STUDY_ID="STD-Rozen-2003" TOTAL_1="49" TOTAL_2="47" WEIGHT="9.133481296727899"/>
<CONT_DATA CI_END="0.5643130591550494" CI_START="-0.12282562247230913" EFFECT_SIZE="0.2207437183413701" ESTIMABLE="YES" MEAN_1="870.0" MEAN_2="847.0" ORDER="17477" SD_1="100.0" SD_2="107.0" SE="0.17529370106987185" STUDY_ID="STD-Stear-2003" TOTAL_1="65" TOTAL_2="66" WEIGHT="12.403870347008995"/>
</CONT_SUBGROUP>
</CONT_OUTCOME>
<CONT_OUTCOME CHI2="1.1024640714897924" CI_END="0.19656167519370077" CI_START="-0.035409590731488375" CI_STUDY="95" CI_TOTAL="95" DF="10" EFFECT_MEASURE="SMD" EFFECT_SIZE="0.0805760422311062" ESTIMABLE="YES" I2="0.0" I2_Q="0.0" ID="CMP-001.74" NO="74" P_CHI2="0.9997312530937471" P_Q="0.8609430480945102" P_Z="0.17332387499636828" Q="0.030685887174703774" RANDOM="NO" SCALE="1.0" SORT_BY="STUDY" STUDIES="11" SUBGROUPS="YES" SUBGROUP_TEST="YES" TAU2="0.0" TOTALS="YES" TOTAL_1="563" TOTAL_2="601" UNITS="" WEIGHT="100.0" Z="1.361600887591637">
<NAME>Lumbar spine BMD (mg/cm2) at end supplementation by milk extract vs other calcium supplement</NAME>
<GROUP_LABEL_1>Treatment</GROUP_LABEL_1>
<GROUP_LABEL_2>Control</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours treatment</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours control</GRAPH_LABEL_2>
<CONT_SUBGROUP CHI2="0.36946032507709226" CI_END="0.2614302892105832" CI_START="-0.1282646922444935" DF="2" EFFECT_SIZE="0.06658279848304485" ESTIMABLE="YES" I2="0.0" ID="CMP-001.74.01" NO="1" P_CHI2="0.8313286243063506" P_Z="0.5030146238007887" STUDIES="3" TAU2="0.0" TOTAL_1="191" TOTAL_2="234" WEIGHT="35.43388401324704" Z="0.6697540036537517">
<NAME>milk extract</NAME>
<CONT_DATA CI_END="0.5114205026835856" CI_START="-0.24397376271812718" EFFECT_SIZE="0.13372336998272924" ESTIMABLE="YES" MEAN_1="647.0" MEAN_2="638.0" ORDER="17478" SD_1="74.16" SD_2="58.24" SE="0.1927061597458337" STUDY_ID="STD-Bonjour-1995" TOTAL_1="55" TOTAL_2="53" WEIGHT="9.43020248538449"/>
<CONT_DATA CI_END="0.27186034181968627" CI_START="-0.24293478100807947" EFFECT_SIZE="0.014462780405803406" ESTIMABLE="YES" MEAN_1="586.9" MEAN_2="586.1" ORDER="17479" SD_1="52.0" SD_2="58.0" SE="0.1313276996129531" STUDY_ID="STD-Chevalley-2005" TOTAL_1="114" TOTAL_2="118" WEIGHT="20.304838408962425"/>
<CONT_DATA CI_END="0.6270434570242918" CI_START="-0.3446758722743443" EFFECT_SIZE="0.1411837923749737" ESTIMABLE="YES" MEAN_1="740.64" MEAN_2="726.67" ORDER="17480" SD_1="65.03" SD_2="106.95" SE="0.2478921390809816" STUDY_ID="STD-Courteix-2005" TOTAL_1="22" TOTAL_2="63" WEIGHT="5.698843118900126"/>
</CONT_SUBGROUP>
<CONT_SUBGROUP CHI2="0.7023178592379965" CI_END="0.23260057454185123" CI_START="-0.05608950593260943" DF="7" EFFECT_SIZE="0.0882555343046209" ESTIMABLE="YES" I2="0.0" ID="CMP-001.74.02" NO="2" P_CHI2="0.9983178648792357" P_Z="0.23077598585683345" STUDIES="8" TAU2="0.0" TOTAL_1="372" TOTAL_2="367" WEIGHT="64.56611598675296" Z="1.198362398798797">
<NAME>other calcium supplementation</NAME>
<CONT_DATA CI_END="0.6643854658079379" CI_START="-0.4679433402975458" EFFECT_SIZE="0.09822106275519607" ESTIMABLE="YES" MEAN_1="848.0" MEAN_2="833.0" ORDER="17481" SD_1="158.0" SD_2="142.0" SE="0.2888646972692225" STUDY_ID="STD-Cameron-2004" TOTAL_1="24" TOTAL_2="24" WEIGHT="4.196848320638333"/>
<CONT_DATA CI_END="0.434960444536277" CI_START="-0.39145848587210075" EFFECT_SIZE="0.021750979332088152" ESTIMABLE="YES" MEAN_1="907.36" MEAN_2="902.96" ORDER="17482" SD_1="197.32" SD_2="203.75" SE="0.2108250296758167" STUDY_ID="STD-Johnston-1992" TOTAL_1="45" TOTAL_2="45" WEIGHT="7.87894141933801"/>
<CONT_DATA CI_END="0.4625164252125683" CI_START="-0.393919388343527" EFFECT_SIZE="0.034298518434520614" ESTIMABLE="YES" MEAN_1="525.0" MEAN_2="523.0" ORDER="17483" SD_1="61.0" SD_2="54.0" SE="0.21848253853426688" STUDY_ID="STD-Lee-1995" TOTAL_1="44" TOTAL_2="40" WEIGHT="7.336328090508805"/>
<CONT_DATA CI_END="0.6124201908396137" CI_START="-0.21201494446981703" EFFECT_SIZE="0.20020262318489837" ESTIMABLE="YES" MEAN_1="914.0" MEAN_2="894.0" ORDER="17484" SD_1="83.0" SD_2="112.0" SE="0.21031895019818475" STUDY_ID="STD-Lloyd-1993" TOTAL_1="44" TOTAL_2="47" WEIGHT="7.9169044070243535"/>
<CONT_DATA CI_END="0.6326118992120395" CI_START="-0.4158598560902002" EFFECT_SIZE="0.10837602156091967" ESTIMABLE="YES" MEAN_1="1017.0" MEAN_2="1001.0" ORDER="17485" SD_1="148.2" SD_2="142.9" SE="0.2674721993803078" STUDY_ID="STD-Nowson-1997" TOTAL_1="28" TOTAL_2="28" WEIGHT="4.895024998280832"/>
<CONT_DATA CI_END="0.45798631527414724" CI_START="-0.1984686132330601" EFFECT_SIZE="0.12975885102054358" ESTIMABLE="YES" MEAN_1="1047.0" MEAN_2="1032.0" ORDER="17486" SD_1="114.0" SD_2="116.0" SE="0.1674660691944444" STUDY_ID="STD-Prentice-2005" TOTAL_1="73" TOTAL_2="70" WEIGHT="12.487012848693666"/>
<CONT_DATA CI_END="0.40016282334497716" CI_START="-0.40016282334497716" EFFECT_SIZE="0.0" ESTIMABLE="YES" MEAN_1="1120.0" MEAN_2="1120.0" ORDER="17487" SD_1="140.0" SD_2="137.11" SE="0.2041684574315704" STUDY_ID="STD-Rozen-2003" TOTAL_1="49" TOTAL_2="47" WEIGHT="8.401076060027075"/>
<CONT_DATA CI_END="0.4411301457213726" CI_START="-0.24428861169722987" EFFECT_SIZE="0.09842076701207135" ESTIMABLE="YES" MEAN_1="999.0" MEAN_2="989.0" ORDER="17488" SD_1="100.0" SD_2="102.0" SE="0.17485493683177297" STUDY_ID="STD-Stear-2003" TOTAL_1="65" TOTAL_2="66" WEIGHT="11.453979842241894"/>
</CONT_SUBGROUP>
</CONT_OUTCOME>
<CONT_OUTCOME CHI2="8.69063942151073" CI_END="0.237153842673891" CI_START="0.037921792367907534" CI_STUDY="95" CI_TOTAL="95" DF="11" EFFECT_MEASURE="SMD" EFFECT_SIZE="0.13753781752089927" ESTIMABLE="YES" I2="0.0" I2_Q="41.48774132032573" ID="CMP-001.75" NO="75" P_CHI2="0.6504234741691635" P_Q="0.1911095999678557" P_Z="0.006808215777498085" Q="1.7090435791831355" RANDOM="NO" SCALE="1.0" SORT_BY="STUDY" STUDIES="12" SUBGROUPS="YES" SUBGROUP_TEST="YES" TAU2="0.0" TOTALS="YES" TOTAL_1="757" TOTAL_2="822" UNITS="" WEIGHT="100.00000000000001" Z="2.7060823641497076">
<NAME>Upper limb BMD (mg/cm2) at end supplementation by milk extract vs other calcium supplement</NAME>
<GROUP_LABEL_1>Treatment</GROUP_LABEL_1>
<GROUP_LABEL_2>Control</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours treatment</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours control</GRAPH_LABEL_2>
<CONT_SUBGROUP CHI2="1.4007812683634766" CI_END="0.2207049325942065" CI_START="-0.16912232082943793" DF="2" EFFECT_SIZE="0.025791305882384298" ESTIMABLE="YES" I2="0.0" ID="CMP-001.75.01" NO="1" P_CHI2="0.4963914181076513" P_Z="0.7953684440988121" STUDIES="3" TAU2="0.0" TOTAL_1="191" TOTAL_2="234" WEIGHT="26.120050518798873" Z="0.2593458009914667">
<NAME>milk extract</NAME>
<CONT_DATA CI_END="0.5128125613720704" CI_START="-0.24259987277088774" EFFECT_SIZE="0.13510634430059137" ESTIMABLE="YES" MEAN_1="312.0" MEAN_2="308.0" ORDER="17489" SD_1="29.66" SD_2="29.12" SE="0.1927107947139731" STUDY_ID="STD-Bonjour-1995" TOTAL_1="55" TOTAL_2="53" WEIGHT="6.955849078431553"/>
<CONT_DATA CI_END="0.30378712152378146" CI_START="-0.211071470037911" EFFECT_SIZE="0.046357825742935246" ESTIMABLE="YES" MEAN_1="309.6" MEAN_2="308.2" ORDER="17490" SD_1="28.0" SD_2="32.0" SE="0.13134389091402476" STUDY_ID="STD-Chevalley-2005" TOTAL_1="114" TOTAL_2="118" WEIGHT="14.974160370613857"/>
<CONT_DATA CI_END="0.2574725427227148" CI_START="-0.7158349449146524" EFFECT_SIZE="-0.2291812010959688" ESTIMABLE="YES" MEAN_1="336.18" MEAN_2="351.0" ORDER="17491" SD_1="43.19" SD_2="69.75" SE="0.24829728895905548" STUDY_ID="STD-Courteix-2005" TOTAL_1="22" TOTAL_2="63" WEIGHT="4.190041069753462"/>
</CONT_SUBGROUP>
<CONT_SUBGROUP CHI2="5.580814573964117" CI_END="0.29294080965255276" CI_START="0.061150161750304244" DF="8" EFFECT_SIZE="0.1770454857014285" ESTIMABLE="YES" I2="0.0" ID="CMP-001.75.02" NO="2" P_CHI2="0.6940709591317176" P_Z="0.002752511498839196" STUDIES="9" TAU2="0.0" TOTAL_1="566" TOTAL_2="588" WEIGHT="73.87994948120114" Z="2.994105057651335">
<NAME>other calcium supplementation</NAME>
<CONT_DATA CI_END="0.6586912100157563" CI_START="-0.47355455217399833" EFFECT_SIZE="0.09256832892087895" ESTIMABLE="YES" MEAN_1="418.0" MEAN_2="414.0" ORDER="17492" SD_1="43.0" SD_2="42.0" SE="0.28884351220756216" STUDY_ID="STD-Cameron-2004" TOTAL_1="24" TOTAL_2="24" WEIGHT="3.0962569962613915"/>
<CONT_DATA CI_END="0.7515904462890333" CI_START="0.12422571852871639" EFFECT_SIZE="0.4379080824088748" ESTIMABLE="YES" MEAN_1="253.0" MEAN_2="231.0" ORDER="17493" SD_1="50.0" SD_2="50.0" SE="0.16004496325159281" STUDY_ID="STD-Dibba-2000" TOTAL_1="80" TOTAL_2="80" WEIGHT="10.085053655030164"/>
<CONT_DATA CI_END="0.4929289406242539" CI_START="-0.3338062753225926" EFFECT_SIZE="0.07956133265083067" ESTIMABLE="YES" MEAN_1="317.09" MEAN_2="311.51" ORDER="17494" SD_1="69.4" SD_2="69.67" SE="0.2109057162447954" STUDY_ID="STD-Johnston-1992" TOTAL_1="45" TOTAL_2="45" WEIGHT="5.807450728357776"/>
<CONT_DATA CI_END="0.4772672773224417" CI_START="-0.14587387711583635" EFFECT_SIZE="0.16569670010330265" ESTIMABLE="YES" MEAN_1="487.0" MEAN_2="480.0" ORDER="17495" SD_1="41.0" SD_2="43.0" SE="0.15896750127898673" STUDY_ID="STD-Lee-1994" TOTAL_1="77" TOTAL_2="82" WEIGHT="10.222227439652531"/>
<CONT_DATA CI_END="0.4501644946278604" CI_START="-0.40623244295249933" EFFECT_SIZE="0.02196602583768056" ESTIMABLE="YES" MEAN_1="492.0" MEAN_2="491.0" ORDER="17496" SD_1="39.0" SD_2="51.0" SE="0.2184726210112812" STUDY_ID="STD-Lee-1995" TOTAL_1="44" TOTAL_2="40" WEIGHT="5.412129720389707"/>
<CONT_DATA CI_END="0.5300115286945037" CI_START="-0.06471641800366129" EFFECT_SIZE="0.23264755534542125" ESTIMABLE="YES" MEAN_1="450.0" MEAN_2="438.0" ORDER="17497" SD_1="53.0" SD_2="50.0" SE="0.15171910080728607" STUDY_ID="STD-Matkovic-2004" TOTAL_1="79" TOTAL_2="98" WEIGHT="11.222295885516864"/>
<CONT_DATA CI_END="0.2749570234978052" CI_START="-0.38090719667338463" EFFECT_SIZE="-0.05297508658778973" ESTIMABLE="YES" MEAN_1="479.0" MEAN_2="482.0" ORDER="17498" SD_1="61.0" SD_2="51.0" SE="0.16731537552336753" STUDY_ID="STD-Prentice-2005" TOTAL_1="73" TOTAL_2="70" WEIGHT="9.227637606628175"/>
<CONT_DATA CI_END="0.5639690051480064" CI_START="-0.12316306254107401" EFFECT_SIZE="0.2204029713034662" ESTIMABLE="YES" MEAN_1="427.0" MEAN_2="418.0" ORDER="17499" SD_1="38.0" SD_2="43.0" SE="0.17529201380971549" STUDY_ID="STD-Stear-2003" TOTAL_1="65" TOTAL_2="66" WEIGHT="8.40694051602222"/>
<CONT_DATA CI_END="0.5134677994735729" CI_START="-0.10432584171130158" EFFECT_SIZE="0.20457097888113565" ESTIMABLE="YES" MEAN_1="486.0" MEAN_2="479.0" ORDER="17500" SD_1="37.0" SD_2="31.0" SE="0.15760331466750202" STUDY_ID="STD-Wang-1996" TOTAL_1="79" TOTAL_2="83" WEIGHT="10.399956933342306"/>
</CONT_SUBGROUP>
</CONT_OUTCOME>
<CONT_OUTCOME CHI2="4.977220570190811" CI_END="0.2859451518574186" CI_START="-0.0741564016414127" CI_STUDY="95" CI_TOTAL="95" DF="4" EFFECT_MEASURE="SMD" EFFECT_SIZE="0.10589437510800294" ESTIMABLE="YES" I2="19.63386103568537" I2_Q="0.0" ID="CMP-001.76" NO="76" P_CHI2="0.2896428687480078" P_Q="0.6372556499010743" P_Z="0.24902300050576687" Q="0.22234935086495966" RANDOM="YES" SCALE="1.0" SORT_BY="STUDY" STUDIES="5" SUBGROUPS="YES" SUBGROUP_TEST="NO" TAU2="0.008372358437612464" TOTALS="YES" TOTAL_1="313" TOTAL_2="304" UNITS="" WEIGHT="100.0" Z="1.15272572062222">
<NAME>Femoral neck BMD (mg/cm2) after supplementation ceased by milk extract vs other calcium supplement</NAME>
<GROUP_LABEL_1>Treatment</GROUP_LABEL_1>
<GROUP_LABEL_2>Control</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours treatment</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours control</GRAPH_LABEL_2>
<CONT_SUBGROUP CHI2="4.470013548640079" CI_END="0.6541674583317387" CI_START="-0.276680383692595" DF="1" EFFECT_SIZE="0.18874353731957189" ESTIMABLE="YES" I2="77.62870315450762" ID="CMP-001.76.01" NO="1" P_CHI2="0.03449476136715579" P_Z="0.4267153541639933" STUDIES="2" TAU2="0.08794850214807652" TOTAL_1="177" TOTAL_2="174" WEIGHT="52.75975122920903" Z="0.794824930047766">
<NAME>milk extract</NAME>
<CONT_DATA CI_END="0.7986994788224699" CI_START="0.08686283431210057" EFFECT_SIZE="0.4427811565672853" ESTIMABLE="YES" MEAN_1="885.0" MEAN_2="853.0" ORDER="17501" SD_1="70.2" SD_2="73.67" SE="0.18159431758064076" STUDY_ID="STD-Bonjour-1995" TOTAL_1="67" TOTAL_2="58" WEIGHT="20.40940447544884"/>
<CONT_DATA CI_END="0.22762896650934925" CI_START="-0.2940909927915369" EFFECT_SIZE="-0.033231013141093814" ESTIMABLE="YES" MEAN_1="722.4" MEAN_2="724.7" ORDER="17502" SD_1="70.0" SD_2="68.0" SE="0.13309427199074741" STUDY_ID="STD-Chevalley-2005" TOTAL_1="110" TOTAL_2="116" WEIGHT="32.35034675376019"/>
</CONT_SUBGROUP>
<CONT_SUBGROUP CHI2="0.2848576706857721" CI_END="0.2967917108029678" CI_START="-0.184344028270913" DF="2" EFFECT_SIZE="0.0562238412660274" ESTIMABLE="YES" I2="0.0" ID="CMP-001.76.02" NO="2" P_CHI2="0.8672492798568471" P_Z="0.6469028098604641" STUDIES="3" TAU2="0.0" TOTAL_1="136" TOTAL_2="130" WEIGHT="47.24024877079097" Z="0.4580690853106189">
<NAME>other calcium supplementation</NAME>
<CONT_DATA CI_END="0.43698040696836393" CI_START="-0.40842428898937033" EFFECT_SIZE="0.014278058989496793" ESTIMABLE="YES" MEAN_1="956.05" MEAN_2="954.05" ORDER="17503" SD_1="136.72" SD_2="140.89" SE="0.2156684262124658" STUDY_ID="STD-Johnston-1992" TOTAL_1="43" TOTAL_2="43" WEIGHT="15.375821900757563"/>
<CONT_DATA CI_END="0.4281849516340527" CI_START="-0.4281849516340527" EFFECT_SIZE="0.0" ESTIMABLE="YES" MEAN_1="603.0" MEAN_2="603.0" ORDER="17504" SD_1="76.0" SD_2="64.0" SE="0.21846572437632575" STUDY_ID="STD-Lee-1995" TOTAL_1="44" TOTAL_2="40" WEIGHT="15.04297766161065"/>
<CONT_DATA CI_END="0.5438493859396915" CI_START="-0.2575440066043698" EFFECT_SIZE="0.14315268966766082" ESTIMABLE="YES" MEAN_1="1010.0" MEAN_2="990.0" ORDER="17505" SD_1="140.0" SD_2="137.11" SE="0.20444084658324083" STUDY_ID="STD-Rozen-2003" TOTAL_1="49" TOTAL_2="47" WEIGHT="16.821449208422756"/>
</CONT_SUBGROUP>
</CONT_OUTCOME>
<CONT_OUTCOME CHI2="1.1583576889270417" CI_END="0.16953284421813042" CI_START="-0.1465114883422407" CI_STUDY="95" CI_TOTAL="95" DF="4" EFFECT_MEASURE="SMD" EFFECT_SIZE="0.011510677937944849" ESTIMABLE="YES" I2="0.0" I2_Q="0.0" ID="CMP-001.77" NO="77" P_CHI2="0.8849060147469565" P_Q="0.5218669577615416" P_Z="0.8864733826880067" Q="0.41020210499437293" RANDOM="NO" SCALE="1.0" SORT_BY="STUDY" STUDIES="5" SUBGROUPS="YES" SUBGROUP_TEST="YES" TAU2="0.0" TOTALS="YES" TOTAL_1="313" TOTAL_2="304" UNITS="" WEIGHT="99.99999999999997" Z="0.1427680351882415">
<NAME>Lumbar spine BMD (mg/cm2) after supplementation ceased by milk extract vs other calcium supplement</NAME>
<GROUP_LABEL_1>Treatment</GROUP_LABEL_1>
<GROUP_LABEL_2>Control</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours treatment</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours control</GRAPH_LABEL_2>
<CONT_SUBGROUP CHI2="0.020293991052886637" CI_END="0.2659835315714432" CI_START="-0.15305071093069605" DF="1" EFFECT_SIZE="0.05646641032037357" ESTIMABLE="YES" I2="0.0" ID="CMP-001.77.01" NO="1" P_CHI2="0.8867190669739884" P_Z="0.597343350093655" STUDIES="2" TAU2="0.0" TOTAL_1="177" TOTAL_2="174" WEIGHT="56.88489825852528" Z="0.528224757496414">
<NAME>milk extract</NAME>
<CONT_DATA CI_END="0.4286491395175547" CI_START="-0.27466106073165153" EFFECT_SIZE="0.07699403939295155" ESTIMABLE="YES" MEAN_1="1019.0" MEAN_2="1014.0" ORDER="17506" SD_1="70.2" SD_2="57.3" SE="0.17941916427975904" STUDY_ID="STD-Bonjour-1995" TOTAL_1="67" TOTAL_2="58" WEIGHT="20.193062121230803"/>
<CONT_DATA CI_END="0.30604468824634573" CI_START="-0.21570630455408518" EFFECT_SIZE="0.04516919184613029" ESTIMABLE="YES" MEAN_1="605.0" MEAN_2="602.5" ORDER="17507" SD_1="52.0" SD_2="58.0" SE="0.13310218884528904" STUDY_ID="STD-Chevalley-2005" TOTAL_1="110" TOTAL_2="116" WEIGHT="36.69183613729448"/>
</CONT_SUBGROUP>
<CONT_SUBGROUP CHI2="0.7278615928797821" CI_END="0.19285696402573965" CI_START="-0.2884623611630265" DF="2" EFFECT_SIZE="-0.047802698568643415" ESTIMABLE="YES" I2="0.0" ID="CMP-001.77.02" NO="2" P_CHI2="0.6949394074641091" P_Z="0.6970457516814133" STUDIES="3" TAU2="0.0" TOTAL_1="136" TOTAL_2="130" WEIGHT="43.115101741474696" Z="0.389311472260629">
<NAME>other calcium supplementation</NAME>
<CONT_DATA CI_END="0.46912926150434037" CI_START="-0.3763832168316114" EFFECT_SIZE="0.0463730223363645" ESTIMABLE="YES" MEAN_1="1061.23" MEAN_2="1052.39" ORDER="17508" SD_1="192.31" SD_2="185.47" SE="0.21569592222235875" STUDY_ID="STD-Johnston-1992" TOTAL_1="43" TOTAL_2="43" WEIGHT="13.971916152120873"/>
<CONT_DATA CI_END="0.22936706177064778" CI_START="-0.6292396856883473" EFFECT_SIZE="-0.19993631195884978" ESTIMABLE="YES" MEAN_1="538.0" MEAN_2="551.0" ORDER="17509" SD_1="61.0" SD_2="68.0" SE="0.2190363583799436" STUDY_ID="STD-Lee-1995" TOTAL_1="44" TOTAL_2="40" WEIGHT="13.549005508643"/>
<CONT_DATA CI_END="0.40016282334497716" CI_START="-0.40016282334497716" EFFECT_SIZE="0.0" ESTIMABLE="YES" MEAN_1="1150.0" MEAN_2="1150.0" ORDER="17510" SD_1="140.0" SD_2="137.11" SE="0.2041684574315704" STUDY_ID="STD-Rozen-2003" TOTAL_1="49" TOTAL_2="47" WEIGHT="15.594180080710826"/>
</CONT_SUBGROUP>
</CONT_OUTCOME>
<CONT_OUTCOME CHI2="4.257893444483905" CI_END="0.2806029064535433" CI_START="0.009198414668455113" CI_STUDY="95" CI_TOTAL="95" DF="5" EFFECT_MEASURE="SMD" EFFECT_SIZE="0.1449006605609992" ESTIMABLE="YES" I2="0.0" I2_Q="0.0" ID="CMP-001.78" NO="78" P_CHI2="0.5129142367746997" P_Q="0.4919308208804055" P_Z="0.03636542200991855" Q="0.47230038277586806" RANDOM="NO" SCALE="1.0" SORT_BY="STUDY" STUDIES="6" SUBGROUPS="YES" SUBGROUP_TEST="YES" TAU2="0.0" TOTALS="YES" TOTAL_1="421" TOTAL_2="419" UNITS="" WEIGHT="100.0" Z="2.092817802444534">
<NAME>Upper limb BMD (mg/cm2) after supplementation ceased by milk extract vs other calcium supplement</NAME>
<GROUP_LABEL_1>Treatment</GROUP_LABEL_1>
<GROUP_LABEL_2>Control</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours treatment</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours control</GRAPH_LABEL_2>
<CONT_SUBGROUP CHI2="1.3578359256022918" CI_END="0.41142193968979945" CI_START="-0.009024826582696793" DF="1" EFFECT_SIZE="0.20119855655355134" ESTIMABLE="YES" I2="26.353399468611602" ID="CMP-001.78.01" NO="1" P_CHI2="0.24391305711420885" P_Z="0.06067954463409919" STUDIES="2" TAU2="0.0" TOTAL_1="177" TOTAL_2="174" WEIGHT="41.668899328665965" Z="1.8758233204287675">
<NAME>milk extract</NAME>
<CONT_DATA CI_END="0.7255999910161408" CI_START="0.016372536416859873" EFFECT_SIZE="0.37098626371650034" ESTIMABLE="YES" MEAN_1="429.0" MEAN_2="418.0" ORDER="17511" SD_1="26.32" SD_2="32.74" SE="0.18092869567848607" STUDY_ID="STD-Bonjour-1995" TOTAL_1="67" TOTAL_2="58" WEIGHT="14.644110051046829"/>
<CONT_DATA CI_END="0.3702338023671409" CI_START="-0.15184477483414238" EFFECT_SIZE="0.10919451376649926" ESTIMABLE="YES" MEAN_1="319.7" MEAN_2="316.4" ORDER="17512" SD_1="28.0" SD_2="32.0" SE="0.13318575783008577" STUDY_ID="STD-Chevalley-2005" TOTAL_1="110" TOTAL_2="116" WEIGHT="27.024789277619135"/>
</CONT_SUBGROUP>
<CONT_SUBGROUP CHI2="2.427757136105745" CI_END="0.2823635307924335" CI_START="-0.07299516339600078" DF="3" EFFECT_SIZE="0.10468418369821635" ESTIMABLE="YES" I2="0.0" ID="CMP-001.78.02" NO="2" P_CHI2="0.48848876999276614" P_Z="0.24818821803777857" STUDIES="4" TAU2="0.0" TOTAL_1="244" TOTAL_2="245" WEIGHT="58.33110067133404" Z="1.1547612772951086">
<NAME>other calcium supplementation</NAME>
<CONT_DATA CI_END="0.6175167825952239" CI_START="-0.0059803321820287025" EFFECT_SIZE="0.30576822520659763" ESTIMABLE="YES" MEAN_1="256.0" MEAN_2="242.0" ORDER="17513" SD_1="43.0" SD_2="48.0" SE="0.15905830915652489" STUDY_ID="STD-Dibba-2000" TOTAL_1="80" TOTAL_2="80" WEIGHT="18.948078085023493"/>
<CONT_DATA CI_END="0.47390750843088114" CI_START="-0.3716306970386415" EFFECT_SIZE="0.05113840569611985" ESTIMABLE="YES" MEAN_1="365.23" MEAN_2="361.31" ORDER="17514" SD_1="77.08" SD_2="74.84" SE="0.21570248538723671" STUDY_ID="STD-Johnston-1992" TOTAL_1="43" TOTAL_2="43" WEIGHT="10.303092295657489"/>
<CONT_DATA CI_END="0.3110243308527212" CI_START="-0.3110243308527212" EFFECT_SIZE="0.0" ESTIMABLE="YES" MEAN_1="505.0" MEAN_2="505.0" ORDER="17515" SD_1="45.0" SD_2="40.0" SE="0.15868879903204416" STUDY_ID="STD-Lee-1994" TOTAL_1="77" TOTAL_2="82" WEIGHT="19.03642279883591"/>
<CONT_DATA CI_END="0.40686449035579997" CI_START="-0.44953091203190143" EFFECT_SIZE="-0.021333210838050704" ESTIMABLE="YES" MEAN_1="516.0" MEAN_2="517.0" ORDER="17516" SD_1="44.0" SD_2="49.0" SE="0.21847222937330457" STUDY_ID="STD-Lee-1995" TOTAL_1="44" TOTAL_2="40" WEIGHT="10.043507491817149"/>
</CONT_SUBGROUP>
</CONT_OUTCOME>
<CONT_OUTCOME CHI2="8.690639421510731" CI_END="0.237153842673891" CI_START="0.037921792367907534" CI_STUDY="95" CI_TOTAL="95" DF="11" EFFECT_MEASURE="SMD" EFFECT_SIZE="0.13753781752089927" ESTIMABLE="YES" I2="0.0" I2_Q="48.09696855598863" ID="CMP-001.79" NO="79" P_CHI2="0.6504234741691632" P_Q="0.16512351301904116" P_Z="0.006808215777498085" Q="1.9266697381225528" RANDOM="NO" SCALE="1.0" SORT_BY="STUDY" STUDIES="12" SUBGROUPS="YES" SUBGROUP_TEST="YES" TAU2="0.0" TOTALS="YES" TOTAL_1="757" TOTAL_2="822" UNITS="" WEIGHT="100.0" Z="2.7060823641497076">
<NAME>Upper limb BMD (mg/cm2) by calcium intake (lowest quartile vs above lowest quartile)</NAME>
<GROUP_LABEL_1>Control</GROUP_LABEL_1>
<GROUP_LABEL_2>Treatment</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours treatment</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours control</GRAPH_LABEL_2>
<CONT_SUBGROUP CHI2="2.783680990956128" CI_END="0.3971107893899998" CI_START="0.06560651348072674" DF="3" EFFECT_SIZE="0.23135865143536324" ESTIMABLE="YES" I2="0.0" ID="CMP-001.79.01" NO="1" P_CHI2="0.4261934582871235" P_Z="0.006224032906126546" STUDIES="4" TAU2="0.0" TOTAL_1="280" TOTAL_2="285" WEIGHT="36.11936774841471" Z="2.735739218333164">
<NAME>Lowest quartile</NAME>
<CONT_DATA CI_END="0.7515904462890333" CI_START="0.12422571852871639" EFFECT_SIZE="0.4379080824088748" ESTIMABLE="YES" MEAN_1="253.0" MEAN_2="231.0" ORDER="17517" SD_1="50.0" SD_2="50.0" SE="0.16004496325159281" STUDY_ID="STD-Dibba-2000" TOTAL_1="80" TOTAL_2="80" WEIGHT="10.085053655030164"/>
<CONT_DATA CI_END="0.4772672773224417" CI_START="-0.14587387711583635" EFFECT_SIZE="0.16569670010330265" ESTIMABLE="YES" MEAN_1="487.0" MEAN_2="480.0" ORDER="17518" SD_1="41.0" SD_2="43.0" SE="0.15896750127898673" STUDY_ID="STD-Lee-1994" TOTAL_1="77" TOTAL_2="82" WEIGHT="10.222227439652531"/>
<CONT_DATA CI_END="0.4501644946278604" CI_START="-0.40623244295249933" EFFECT_SIZE="0.02196602583768056" ESTIMABLE="YES" MEAN_1="492.0" MEAN_2="491.0" ORDER="17519" SD_1="39.0" SD_2="51.0" SE="0.2184726210112812" STUDY_ID="STD-Lee-1995" TOTAL_1="44" TOTAL_2="40" WEIGHT="5.412129720389707"/>
<CONT_DATA CI_END="0.5134677994735729" CI_START="-0.10432584171130158" EFFECT_SIZE="0.20457097888113565" ESTIMABLE="YES" MEAN_1="486.0" MEAN_2="479.0" ORDER="17520" SD_1="37.0" SD_2="31.0" SE="0.15760331466750202" STUDY_ID="STD-Wang-1996" TOTAL_1="79" TOTAL_2="83" WEIGHT="10.399956933342306"/>
</CONT_SUBGROUP>
<CONT_SUBGROUP CHI2="3.98028869243205" CI_END="0.20912598661042486" CI_START="-0.040146646585661486" DF="7" EFFECT_SIZE="0.0844896700123817" ESTIMABLE="YES" I2="0.0" ID="CMP-001.79.02" NO="2" P_CHI2="0.7820450277971125" P_Z="0.18396699484535672" STUDIES="8" TAU2="0.0" TOTAL_1="477" TOTAL_2="537" WEIGHT="63.8806322515853" Z="1.3286393148475142">
<NAME>Above lowest quartile</NAME>
<CONT_DATA CI_END="0.5128125613720704" CI_START="-0.24259987277088774" EFFECT_SIZE="0.13510634430059137" ESTIMABLE="YES" MEAN_1="312.0" MEAN_2="308.0" ORDER="17521" SD_1="29.66" SD_2="29.12" SE="0.1927107947139731" STUDY_ID="STD-Bonjour-1995" TOTAL_1="55" TOTAL_2="53" WEIGHT="6.955849078431553"/>
<CONT_DATA CI_END="0.6586912100157563" CI_START="-0.47355455217399833" EFFECT_SIZE="0.09256832892087895" ESTIMABLE="YES" MEAN_1="418.0" MEAN_2="414.0" ORDER="17522" SD_1="43.0" SD_2="42.0" SE="0.28884351220756216" STUDY_ID="STD-Cameron-2004" TOTAL_1="24" TOTAL_2="24" WEIGHT="3.0962569962613915"/>
<CONT_DATA CI_END="0.30378712152378146" CI_START="-0.211071470037911" EFFECT_SIZE="0.046357825742935246" ESTIMABLE="YES" MEAN_1="309.6" MEAN_2="308.2" ORDER="17523" SD_1="28.0" SD_2="32.0" SE="0.13134389091402476" STUDY_ID="STD-Chevalley-2005" TOTAL_1="114" TOTAL_2="118" WEIGHT="14.974160370613857"/>
<CONT_DATA CI_END="0.2574725427227148" CI_START="-0.7158349449146524" EFFECT_SIZE="-0.2291812010959688" ESTIMABLE="YES" MEAN_1="336.18" MEAN_2="351.0" ORDER="17524" SD_1="43.19" SD_2="69.75" SE="0.24829728895905548" STUDY_ID="STD-Courteix-2005" TOTAL_1="22" TOTAL_2="63" WEIGHT="4.190041069753462"/>
<CONT_DATA CI_END="0.4929289406242539" CI_START="-0.3338062753225926" EFFECT_SIZE="0.07956133265083067" ESTIMABLE="YES" MEAN_1="317.09" MEAN_2="311.51" ORDER="17525" SD_1="69.4" SD_2="69.67" SE="0.2109057162447954" STUDY_ID="STD-Johnston-1992" TOTAL_1="45" TOTAL_2="45" WEIGHT="5.807450728357776"/>
<CONT_DATA CI_END="0.5300115286945037" CI_START="-0.06471641800366129" EFFECT_SIZE="0.23264755534542125" ESTIMABLE="YES" MEAN_1="450.0" MEAN_2="438.0" ORDER="17526" SD_1="53.0" SD_2="50.0" SE="0.15171910080728607" STUDY_ID="STD-Matkovic-2004" TOTAL_1="79" TOTAL_2="98" WEIGHT="11.222295885516864"/>
<CONT_DATA CI_END="0.2749570234978052" CI_START="-0.38090719667338463" EFFECT_SIZE="-0.05297508658778973" ESTIMABLE="YES" MEAN_1="479.0" MEAN_2="482.0" ORDER="17527" SD_1="61.0" SD_2="51.0" SE="0.16731537552336753" STUDY_ID="STD-Prentice-2005" TOTAL_1="73" TOTAL_2="70" WEIGHT="9.227637606628175"/>
<CONT_DATA CI_END="0.5639690051480064" CI_START="-0.12316306254107401" EFFECT_SIZE="0.2204029713034662" ESTIMABLE="YES" MEAN_1="427.0" MEAN_2="418.0" ORDER="17528" SD_1="38.0" SD_2="43.0" SE="0.17529201380971549" STUDY_ID="STD-Stear-2003" TOTAL_1="65" TOTAL_2="66" WEIGHT="8.40694051602222"/>
</CONT_SUBGROUP>
</CONT_OUTCOME>
</COMPARISON>
</ANALYSES_AND_DATA>
<FIGURES>
<FIGURE FILENAME="Other figure.jpg" FILE_TYPE="JPG" ID="FIG-01" NO="1" SHORT_VERSION_FIGURE="YES" TYPE="OTHER">
<CAPTION>
<P>Funnel plot of studies with femoral neck BMD outcome at end of supplementation period</P>
</CAPTION>
<FILE>/9j/4AAQSkZJRgABAgAAAQABAAD/2wBDAAgGBgcGBQgHBwcJCQgKDBQNDAsLDBkSEw8UHRofHh0a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=
</FILE>
</FIGURE>
<FIGURE FILENAME="Other figure.jpg" FILE_TYPE="JPG" ID="FIG-02" NO="2" SHORT_VERSION_FIGURE="YES" TYPE="OTHER">
<CAPTION>
<P>Funnel plot of studies with femoral neck BMD outcome at end of longest period of follow-up after supplementation ceased</P>
</CAPTION>
<FILE>/9j/4AAQSkZJRgABAgAAAQABAAD/2wBDAAgGBgcGBQgHBwcJCQgKDBQNDAsLDBkSEw8UHRofHh0a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</FILE>
</FIGURE>
<FIGURE FILENAME="Other figure.jpg" FILE_TYPE="JPG" ID="FIG-03" NO="3" SHORT_VERSION_FIGURE="YES" TYPE="OTHER">
<CAPTION>
<P>Funnel plot of studies with lumbar spine BMD outcome at end of supplementation period</P>
</CAPTION>
<FILE>/9j/4AAQSkZJRgABAgAAAQABAAD/2wBDAAgGBgcGBQgHBwcJCQgKDBQNDAsLDBkSEw8UHRofHh0a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</FILE>
</FIGURE>
<FIGURE FILENAME="Other figure.jpg" FILE_TYPE="JPG" ID="FIG-04" NO="4" SHORT_VERSION_FIGURE="YES" TYPE="OTHER">
<CAPTION>
<P>Funnel plot of studies with lumbar spine BMD outcome at end of longest period of follow-up after supplementation ceased</P>
</CAPTION>
<FILE>/9j/4AAQSkZJRgABAgAAAQABAAD/2wBDAAgGBgcGBQgHBwcJCQgKDBQNDAsLDBkSEw8UHRofHh0a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</FILE>
</FIGURE>
<FIGURE FILENAME="Other figure.jpg" FILE_TYPE="JPG" ID="FIG-05" NO="5" SHORT_VERSION_FIGURE="YES" TYPE="OTHER">
<CAPTION>
<P>Funnel plot of studies with total body BMC outcome at end of supplementation period</P>
</CAPTION>
<FILE>/9j/4AAQSkZJRgABAgAAAQABAAD/2wBDAAgGBgcGBQgHBwcJCQgKDBQNDAsLDBkSEw8UHRofHh0a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</FILE>
</FIGURE>
<FIGURE FILENAME="Other figure.jpg" FILE_TYPE="JPG" ID="FIG-06" NO="6" SHORT_VERSION_FIGURE="YES" TYPE="OTHER">
<CAPTION>
<P>Funnel plot of studies with distal radius BMD outcome at end of supplementation period</P>
</CAPTION>
<FILE>/9j/4AAQSkZJRgABAgAAAQABAAD/2wBDAAgGBgcGBQgHBwcJCQgKDBQNDAsLDBkSEw8UHRofHh0a
HBwgJC4nICIsIxwcKDcpLDAxNDQ0Hyc5PTgyPC4zNDL/2wBDAQkJCQwLDBgNDRgyIRwhMjIyMjIy
MjIyMjIyMjIyMjIyMjIyMjIyMjIyMjIyMjIyMjIyMjIyMjIyMjIyMjIyMjL/wAARCAGQAlgDASIA
AhEBAxEB/8QAHwAAAQUBAQEBAQEAAAAAAAAAAAECAwQFBgcICQoL/8QAtRAAAgEDAwIEAwUFBAQA
AAF9AQIDAAQRBRIhMUEGE1FhByJxFDKBkaEII0KxwRVS0fAkM2JyggkKFhcYGRolJicoKSo0NTY3
ODk6Q0RFRkdISUpTVFVWV1hZWmNkZWZnaGlqc3R1dnd4eXqDhIWGh4iJipKTlJWWl5iZmqKjpKWm
p6ipqrKztLW2t7i5usLDxMXGx8jJytLT1NXW19jZ2uHi4+Tl5ufo6erx8vP09fb3+Pn6/8QAHwEA
AwEBAQEBAQEBAQAAAAAAAAECAwQFBgcICQoL/8QAtREAAgECBAQDBAcFBAQAAQJ3AAECAxEEBSEx
BhJBUQdhcRMiMoEIFEKRobHBCSMzUvAVYnLRChYkNOEl8RcYGRomJygpKjU2Nzg5OkNERUZHSElK
U1RVVldYWVpjZGVmZ2hpanN0dXZ3eHl6goOEhYaHiImKkpOUlZaXmJmaoqOkpaanqKmqsrO0tba3
uLm6wsPExcbHyMnK0tPU1dbX2Nna4uPk5ebn6Onq8vP09fb3+Pn6/9oADAMBAAIRAxEAPwD3+iii
gBKKwtT146bf2tjDpl5fXNxHLKqWxiG1IygYkyOg6yL0z3og8TaXPBavLew2c11K8EVvdSokjTI/
lvGBn5mV/l+UkE4wSCCTldgN6ise61exs7GW8luYXjTzQAJ413vGGLoCzBdw8t85IxtbOADhX1zS
4725tJdUs1ubSIzXELXCB4YwAS7rnKrgg5PHIoswNeiqE19aQfaPOu4o/s8Qmm3yAeVGd2HbPRfl
bk8fKfQ0+3njuIy8MiSoHZNyMGAZWKsOO4III7EEUWYFyiiigAozRWDeeIEtrp7eCwvb3yMfaWtE
VxbAjI3AsGZtvzbEDPjHy/Mu4s3sBu0Vg6h4m0rTV1LfewS3Gm2r3dxaQyo06xqu4nZnI4IxnA5H
PNPute0u2kv4BfWsl3ZQNcT2i3EYlRAoOSGYBRgjliByMkCnZgblFZcuq6dBbtPNf20cO+RPMeZQ
u6MMXGScZUI+R22NnoaZba7pV7qE1ja6pZz3kG7zbaK4R5I9p2tuUHIwSAc9DSswNais2TVLCHU4
9Nkv7VL+VN8Vq0yiV155CZyR8rcgdj6U3+1LLNu/2612XSB4G89cSqWVQV5+YEyIAR3dR3FKz7Aa
lFYreItEFml82s6eLN0Z0uDdJ5bKrBGIbOCAzKpPYsB1NRzeJ9Js5L37beQWUdrdLaPJdSpEjSGJ
JQFJPPyuPfg8YGaLN9AN+isS+8R6JpkoTUNZ060O8pie6SM7gqsRyRzh0OPRge4qzJqthDqcemyX
9ql/Km+K1aZRK688hM5I+VuQOx9KdmBoYoxXL3XjnwzbWRvF1ywuIRPDbs0F3E+xpW2qT82AANzH
/ZRjzip9V8WaJo0GoyXWo2pmsLc3E9qs6ecFwMDYSDliygZxkso7ijlfYWh0dFc+fE+ixWz3dxqd
lb2iyrElxLdxCOQtGsi7W3d1bIBwSBkDaQTa/t3Sf7X/ALJ/tSy/tL/nz+0J533d33M7vu89OnNF
mM1qKxLnX9PtdestEe4Q6jeK8kcAdQwjUElyCQcZGABknkgYVipb+ItGuLM3kWs6fLah2QzpdIyB
lQuw3A4yEBYjsAT0o5WBt0Vl3OpW1nfQW08iRmZSys8qKMh0QLgncSWkUDAIyQCQSoMFj4i0bUI3
ey1nTrlY3RHaG6RwrO21AcHgseAO54FFna4G3RWRFrek3EME0OqWckVxnyXS4QrLh1jO0g8/Oyrx
/EwHUiiDW9KmkuIotUspJLaVYZ1W4QmKRm2KjAH5WLfKAeSeOtFmBr0ViXuvaZps8iXV5awLGjNN
LLcRosJBj+VssCCfOQ9MfMMkbly9Nd0mW1tbtdUsmt7qUQ28y3CFJpCSAiNnDNkEYHPBos7XA2KK
xLrX9PsodPnknQ2t8xEVwrr5QUQvNvLZxs2RtyM9R25qSTXdJhNl5uqWSC/x9jDXCD7TnGPL5+fO
5emeo9aLMDXorHt9d0q91CaxtdUs57yDd5ttFcI8ke07W3KDkYJAOehqXTtW07V7drjTb+1vYVfY
0ltMsihsA4JUkZwRx7iizA0qKxYfEeh3F9HY2+s6fLdyqHjt47pGkdSu8EKDkgr82fTnpUdj4o0a
/ntrWPU7MX1xEsq2X2uJpgGQOPlVjn5TnIJGOQSOaOV9gN+isiDW9JmkuIodUspJLaVYZ1S4QmKR
m2KjAH5WLfKAeSeOtCa5pUl7bWkeqWbXN3EJreFbhC80ZBIdFzllwCcjjg0WYGtRWNb+INPl8OWu
u3FwlnYXEEdwJLp1jCLIAVDEnAPzAdetRReJdIkWE3F5BazT3U1pBFcSojzSRSmJggJ+b5hxjn5h
wCcUWYG9RWTa67pV7fzWNtqlnPeQbvNtorhHkj2na25QcjBIBz0NZmp+ONB0/RH1hdRtruyjd42l
tbmJhvWNpNgy4DOQoAUZOWHGMkJRd7IDqs0Vlxarp09us8N/bSQ7408xJlK7pApQZBxlg6YHfeuO
oqC+1/S9KuJU1C8trJEWNvNubmONSXL4UZbOf3bHkAHnBOGw0mBtUtUPt1p/Zv2/7VF9i8rzvtHm
Dy/Lxu37um3HOemKypPFmjQvbyNqVqbO4glnS9E6fZwsckcbAyZxndKoHuCOvUUX0A6OisF/ElnD
q01hK3ktFHNNJM8kflokSwsxYhsrxOn3gOAT02lltPE+k3k08cd7CvlSpGjNKgWfckLq0Zz8yn7R
Euf7zAdxk5XuBvUlYjeJNFVLxm1jTgtk4S7Y3SYt2LbQJOflJIIwccjFXbG/tdStUu7K5hubeTOy
aCQOjYODhhweQR+FFmBfooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKK
KACiiigDlde8JWPiLV7OTU7O1u7CGzuYHimGWDytDtZOPlIEbjcCCMjHtg3XgW/uFijmFtOr6dFp
s4S8ntIgkbSASeTCFWQMsmTESoXBUMQ24dRql9eJf2mk6aYEvLqKWcT3EZkjjjjKBvkVlLMTIgA3
KMFjn5QrVbnxK2kRtFqNo9xNaQfab+ayC+Vbw7nCysHYNgiN22J5jLtI+b5SzTaSSYOxR1fwdNfj
W44Jk8m7s7gWUMjHy4bqeMpI+0LhRgKQR82ZrgnO+orTwXJHrbtdwQXFj9quboNNe3Egfz/Myn2U
/uUwJmUtltwB+UF8rPL4+sYrmWP+zNTMEH2kz3PlxrHGltII5n+ZwzquVPyBshsDLBlF2HxjZTXD
IbPUUhE9xarObfcsk0Jk3xoqku52xOwIUqcbc7/lp6oRkw+A5xJA9zeNO7TyJetJKWM9rtiVQcr8
zuLS2EgPysHnHdcdnbGYxt5saI4dgAjlgV3HackDkjBI7EkZOMnkrP4jaReqqW1vcz3L3CwLbWzQ
3DFmjkdCWikZAD5LjlhtwC21fmqc+MraOaG3a2u7ieWe6QeTEiELDM6MVRpN0pAjJIiDtgAlF3qp
TT2Y0djRXJ3/AI2srGO6nntL37FD9oVLtVjKTyQK7SRoN+8MBFLyyqp2HDcrm/p+vnUrh7M6Xe2l
1HsaWGcxExxuH2SEo7KVLRsuASwI5UDmlyvcDdrmpbHVrDUr6bSBZSJqMqzTNdu6m3kEaRblVVPm
LtRDsJQ5B+fDDZ0tcdeeINRh1S7kjFr9gstRtdOlgaJjLK03k/vBJuAUL9oX5SjZ2H5hu+UjfUGY
WueAtY1KW6WG4tViZ71lLXMwWT7RDOi/uR+6jKNKoLAM0nzOSrEq2nfeGNWutH1TRUTTGtp/t0tv
dzO7SCS484gbNuI9pmKlwzEqpG0b/l2tA1a+1STV1vrSO1e0vRBHEr7mCGCKQbyON/7w525A6Atj
cY7S91fVLtryyazTTo7qS2a3mR/Ok8uRo5HEgbamGViq7G3BRll3nY+Z7dhWRga34M1vUdPl0y3m
09bQXF/cJI7P5kjXMVyACAuECNcY/i3D5vlI2tqQeFprXWYri3FrHZxasLyOJMrshFh9mCgAYBDd
um3vniqr/EGxuLh7OwXbeJdW8flzmNi0b3MUMjFEcvGwEo+WUI2T907WAur4sSaygu4rK9gtriW3
+zXMsKvHcxyzRxhl2yZTIkUgPtYA5CttZaetg0C90G+m8TrdwxWYtHljlmdpZPn2BcBrcgo8gKKV
mDI64QfMqFX5bV/COuNpOlWUi6fPa6fb2+mRosTzmVftVofOkT5RsKQsWjB+UA/OwOV6m58cabbW
OlX0kN6YtStUuolji3uqPJBGAVUkls3CcLno2MnANjR/FEOtXJtjYX1lKfO8tbnyz5nkyeXLjy3b
G1yo5xnIK5GSEnJWdg0OdbQtch8ZWusJY6fLeSrd3DxSO7QwsUtIFVZ9mVcrGzZ8vkb0xj5xXt/h
9f6a8Dwyrdm3QQRqt/PYl0+zWsRcvECwO61Pycghwc5XFdFd+NLG2uNVjezvjHpkTy3EiLG2NqM+
0pv3pkI+1nVUbAwxDLusal4stdL1ZdMe0vbi7k8oRpbxht7SLOVHJGP+PdwScKMqSQNxVptbBZGV
pPgl9K1C1uIls1WC+ilLRqys0EdgbZU+bceHLEAscKxO4knOfpHgO902WwhuBBPGn2KWaQX9yiRy
QRQphbdcJLzACHYgjcMqQgDbTeO7BTMBZ6g32W3+03bLEu21jV5Y5C7bsEo0LghdxbqgcAkZ7/En
TNMUx6s6xzLcXIfZJGgjhjuZYUfbI4aQkREkRh2yD8o3KCK7DQZc+DdW/sfw3DbvZPc6TYQwOskr
okkkc9pLwwQkKRbOM4zyvHXFTW/AWr6lLdLDcWqxM96ylrmYLJ9ohnRf3I/dRlGlUFgGaT5nJViV
bZl8e2MVxIn9l6mYIPtJnufLjWONLaQRzP8AM4Z1XKn5A2Q2BlgyiO5+JWg2t9fWpeR2tEuCfLki
ZnaBWaRBHv8AMUgRvy6qp28N8y7hXWwaCJoOt2uvT67DFp0tzOzg2j3ToirJDaKx8wREkq9qQBsG
Q4OVI20mm+DLzTdEk0pbmCUC+06eOUgrujtltVbIwcMfs7kDJHK89cTz+Mrn+3dK0xNGvIJ7m6Ed
xFOYS0cLRTMjgpKV5aFz1J2xvwCU3UL34lWu5rbTLGee+S6gjMBkgLGNp0idinmho2+dVCyBGDOu
Vwr7RJvQNDZ8SeHJ9buG2zpDDJpN7p7uQWZWnMO1gvAIAjbPI7fhQfw3qOpeJLLWNTt9OjME8DNa
xytcLthjutjhmjX5/MuFONox5eQxJwLK+NbeJLp5Le6uEtHne8lhiRFtYUnljDuGkyw/cyfc3Mdh
O1dyrVqx8Uw3uorbHT723ilup7SC6l8sxzTRFw6qFcuOIpCCyqML1yQCtUh6FXxV4Xn8Q39g+21e
1iXZPFPkiRftVrKRjBBBSBxg9yB0JIwfEHg7UpLKFQttcD7ZOGjaJp1K3Gp286lk43IsaNvGR0PO
OR2E3iG1t7uWzkSf7THdQ2whCjfL5oBEiLnLRgeYS3byZeuw0zRfEltrtxcRW1rdRrC7IJZAhVip
G4HazGNxuU7JQj8/d4bAm0k+wWRl6b4aux4qTxBqEdkJW+0SGGNjJ5Ejx20S7HZVz8lu+ThSPM24
IyTBY+EbuW2tNO1MxR2+naY+m21xaylpZMmErPhkAhkUwKygF8Mc5+UEyar47ittK1S5tbS6RrZb
yKCe5jAhlubdZSYxhtxBELNuA24BG4PlRYuPHuiWes3Wm3kkkDW6yMzsUJPloXf90GMoG1WIZkCs
ANpO5Nxr0QaFGXwZqM8ulXLy2pu0f7RfuXb55murSdgh25KKtuyJu5CrGvQZEGuaddaXr95qbQpd
JqLzwiA2NxdIsMkNojNIsUbZINuf3ZKhw331wa2NR8Y2ulWBuNW0++sJRMsUcN00CeaWDEYl8zyR
wjnDOCNo4yybqMPxAtLi7nnitpp9MjsYrx54EDeQvmTpMzvu2MqGIYCFmb5igccgV97aCETw5qbe
EvCFsILL7bo/2eaaC8+ZC6WzptBXOGDsMMM7cbgGwFMT+DtWSz1K3iayf+2rWW3vGaV1+yeZNcSk
x/IfOx9pYYPl58sHjdhegg8SW1xqkdoLa6WGWeW2gu2CeVNNHv3xgBt4I8uXllCnYcE5XPQ5obaH
ZHB6l4MvNS0SPS2uIIs32ozySgFtsdyt0q4GBlh9oQkZA4bnpnU8M6LcafcXl3dQJDNcJHHgajcX
rFULkZkmwQMyHChRjk5O7C9RRS5rqwWPPtN8DXen6ZaWkZsk8q20mJxHkKXtblppm+7/ABbiQepY
nOOtLpHg/UdP8LjTpZrZpvtmmz7kZiu23S0Vxyuck27447rnHOPQMUU+YLI8ytvh1cLYW1hcxWs0
Vottbh7i+uLkXEKXEEkn7qT5IQywf6tQwJIG4Bfm1NZ8I6lf6+buCaBbdr+0vGJuZo/lieLdGYUx
G7YjLCV9zfdTACqy9zRRd3uI5CHQdRs/Dfhm3gNtLfaIkRMbyMkUzLbvAw3hSVH7wsDtOdoGBnI5
2P4c38MDW7CyljuI5LaVILu5s4IozcXEgIhiP71dtxjymZQuzAchiR6jRQn2HocXL4Uu5rKztXaz
YRanf3kgnQyxtHOLoKpTjf8A8fCblyAQGGemcrUfBes6ppMsDNZwysZUjEl3LdOqNa3EQBuHQO6+
ZPuCsDty+GIKovpVApKTTA419Klu/F9pNLBJHCYEvL+KMlrc3Ufyw8lQJDhnJONwNvbk7MKGlvNA
vLnxtaa0rQC3h8ncpY7zsjvEOBjHW5j79m9BnraKLsDkT4eu/wDhHp7ASwm6GqPqEWSdjYvTcojH
GVyMKSAcZJAbHJb6HdT+J7LWtQtdMilhiuQUt8uySSCBVbeyje2yJwWwpCsq4IBJ62louwPLNO+H
ur2cdqXuLJpLWOEqod8PJEunkKTt4VmspBuwSA6nBOQNjRPCF3aeK5NavoNMAaW6uEjtlP7qSaO1
XK5Xlv3MwZ+C2/OBuKr3VFPmbWoaHmuneAr2zhsoD5G6x+yxRTyX9zOZY47iCRyI3+SDKwD5FDDJ
UblC/N1un6feWGq6pPtgeK/v1n/1hDRxi2ij6beW3xdMgbTnORtO7RQ23uIWiiikMKKKKACiiigA
ooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigDH1LTo9RMUiXE9pdw7hDd2+3zIw2N
y/MrKVOBlWBGQpxuVSM258IW10rJJf6jieD7NfZkRjexbnbbIWUlRmST/V7MB8DAVQsutGW61vTN
JkmngsLqKd5JIJWheSVPLKRCRSGGVaV8KQx8rrtDg5um6/NZ65caXcTo2lWqXbR3tw5LeXCLbO6Q
nDBGmmRmOT+6G4lgxLV+gF248HadcWs1u010Fmgv7diGXIW8lEkhHy9QR8voOuetU7PwVBKlzFqt
xPcQTXV7N9kEx8kee8o3A4Dq3lSlCobZksQN3zVheFvEniLULUyzXVobnV763jgLQSGK03aely2E
MuWXA24DL8xZ8nO0a9/4j1a2t9SdJNMk/sWxN7dmNHdbrDzqUQ7h5Lf6O2c+ZtZ8c7Ms7NPcNDRt
vCFtBrUWrz6hqF5fRvG5kuJEwxRJ41+VVCqNtw/ChRlQepYsS+ELaRPITUNQit3uJJ5oUkQrKWna
fupKFXdsPGUcfL8xKqRz114v8Q27XN1s0xbO2j1O48rypGkmjs5xHjdvAjZw2M7XAK7ud21b9n4l
1+/1loY7GCCxmurqygnmWPCyQ+YofPnh5ctEcxiNCASd2Eyyae9w0NC/8E2V9HdQT3d79in+0Mlo
rRhIJJ1dZJEOzeWIll4ZmUbzheFxrJpKJrUmqRXE0cskUUMka7SjpH5pUHK5HMxPBH3V7ZB1qKV3
sAtc7ceGra41SS7NzdLDLcRXU9opTyppo9myQkrvBHlxcKwU7BkHLZ6KuA1G4uRqeqagLu7Way1u
xsYEWdxEIZfsu9TEDsYnz5fmZSwyMEbVwLcDqrbTobO51CeJnL304ml3EYDCJI8DjpiNeueSfpVX
+wkTUPtEF9e29q8vnyWMLqsUkmdxY/LvXLYLKrBWOSwO593N+Bby+k/suXU2n+06rpv20EahJcRz
Y8rc7RuoEDZmGEi+TDMD91KLFp7W1XVoby9l1C412e08mW7kkjlh+2vGyrEzFV2RKXBQAgRZJ27g
W07hc0U8CWKTWcn2vUXSzVIrWJpV2QxJNDKkYG3oDAg3HLkEhmOFKzxeELaK0jtDqOoPaW7wG1t2
kQJbrDKkiIAFBYZjRcuWbAOGBZicPSfEuuXOnaQ8LafDazWdqhlmDzqtxLEjBZJPN3o/zghXUh/k
HmhpRtzE8Z63ovgvSbxzDe/ZtHtr69kdRudZAQis8ky7WbYV3r5rM2T5a/KruzfUNDqE8B2CTWch
utQdLNUitYmlXZDEk0MqRgbegMCDccuQSGY4UrqWPhy1sL2K7ilmaSL7XtDEYP2mZZnzx2ZQB7dc
nmuavrm+l8DXJiuLhrl9da3VvtUkLFDqZjCeYuWRdvyZHReg7VXs9S1rTLa8htosXr362MVhLeS6
gySLG0zOskzR7t8WxghkRVVc53kxlWbWrFodLc+FLS9vJ5Ly6vbm3limi+yySDYizDEgDgCQqf7p
cqPlwBsTbl3ngZ5tWs79NX1CW6E6SXFzLMqyARxXCxmNVQICGnGV2hGCncCS2/A1HxzqWreCtWvL
WWysxbaXJJLM0m0yu0k8CNFIjssbBoN6gGTcXVQwxvOmnjK5stJ8UXEptkGlwTz27Su5DS/aryJV
Ys+SCYYwFBHLELgbQHZpBdF0eBIX1G8LXl0tldWaW0ypIN11uluJJxKu3aA5mBym1l+YKUBwbyeE
LaGZ5LXUNRtDM8jXPkyIDOrzSTbCxUsgDTSgGMq2G+8SARHZ63qkviVraf7EthJLJFbFRnzCgbdt
lDkNICpDRMkZHz7WcRMTzPiI60k/jDVbMyMNMcvBK+s3MIgKWkMnFuqmKQBiWw3DEkHihXbtcNDq
7jwdp09rPbtNdBZoL+3YhlyFvJRJIR8vUEfL6DrnrSXXhG2ngvrRtR1FbC8S4BtI5EWONpg3mODt
3MSZHbDsygtkL8q7eD1PXvEEHhzxFYw3t0Jpbi/uLW9A+a2gikud8a8ZIU26JvyCn2qMDG1Q3SWD
T21qurQ3l7Lf3GuzWnky3ckkcsP2142VYmYquyJS4KAECLJO3cCNNLcNDoLzw1bXuu2+rm7uYbqF
4WHlFNpEYnXaQynhhcSA9+mCCM1myeALGRYAup6pH9liWC02yRkW0aSwyxqilCp2tAg3MGZgSGLY
XbB4x8X6j4ckuJbSCGa3sbVbq7DKucMzKilnkjCbjGwBUSsSfuDCh36NrGo6Z4G1nV9RmXUJrG41
GVQqtFuWKaX5MszkDKED+6pUYO3JVna9w0LsngixkW4VLy9iiu/NS9jQx4uo5JZZTGxKEqoM8oBQ
q2G5YkAi7D4dtIDY7ZJz9jvp76PJHMk3nbgePujz3x34Xk855qHxD4qN9a6VcQWVneXF0iLNcQKc
RtDcSf6iO5cjm3wHLgHcwC/ISaeveLtWl8Na95M9lZyadYzCeYs8ZlkMtxbq0TBv3TboN6qd5Yuq
ZUjeSz7hdHcy6PaTa3b6q6ZuYImiXgYOejHjO5QZApzwJZB/Ear2Ohpp1/NeG9vbqRohAgndT5cY
JIXKqGkxnhpC7DLYOWbdB4k1DU7P7LHpgh8xy8ku6H7RIsa43MsIkjZ1G4ZKlmBKgIxbK5n/AAmE
32OeaSTT939rWNjb+XKXSVZktnfY3HmECaQqQBwoJHBppNoegDwLFPY3ltqV5dPFcXF9KsEUoMcR
uGmHmLuXIcRTFdudmSTtLfMbd54K069n/wBInvZLQSzyiy87bCpnSRZugDHd5rtksSp4UqpIPNr8
QdUi8PaZq039jP8A2laxXC7ZHSG3xcW8MokkJPXzyc7R5ZQg+ZjNP1LxXrGn661uVS6vLVJbPbbq
Y4riWSSw8uTymfGVFyRgvzg/Mgbgs7iujqn8MtNGr3GtapNexSiSC8dog8BCsnyoIxFyskgJKEnd
1+VNte48F2t1LLJNqGpu1xarZ3YacEXUO6RmVwVwNxlbldpUYCFBkHnb7xp4otLK5DWWnw3VpaXt
zMbjBOIEgkX93FK4UsJiu0yZxiTOPkNu88VeIVvzotnaw3epQSyiW4gtwUZEjt3yIpJ49v8Ax9KM
+a33M4+b5BJ9GF0dFb+Gra31SO7F1dNDFcS3MFoxTyoZpN++QELvJPmS8MxUbzgDC46GvO7fxNr1
3bT6jG+mQ2yXVnZrb+U07B7iO3IfzllCuqvcZ4X5lTAYbtwyk8Z63ovgrSbxzDe/ZtHtr69kdRud
ZAQis8ky7WbYV3r5rM2T5a/Krrlb6hdHrVJXl1l4g1rT1tVuriK7ubi61CFJCsqrGf7Rgt1JQyEM
qmVmA4IUKgZfmZteLXPEF34iOgxXOmRXNv8AaPPunspHSXYlq67YxMCnF1g5Zs7M8ZwBxGd1RXHP
rM2r6P4YkjDWkevOnneVIfMjja2kmKq4wQSUC7gAcEkbWwRzfifxrqkEOq2yKkVrcwahBZzwkI6S
QQylnV/N3sVaLBHlIFLDDsApcUW9APVqK4q01m7tfC1xdBmmun1iezieYlwm+/eBCRnJVAw+UEZC
4BHUYY8Va1bXGswxXFndXMN9MZJExLFHDBb2wkKrJNEsah5MsDKSjEjD/M6lgPUKWvLNH8Va9eWF
/fQtBNPqN/bixtfKZzCHso7gou6VFfC+rRDId+SwjrX0fxHc6pH4c1VG2/2ndT6fcRLIHiYRLcMJ
UAZlVi0P8LMNrkEvtRgOLQHeUUUUgCiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKK
ACiiigAooooAKKKKACiiigAooooAKKKKACiiigChfWFrqVq9pe20NzbyY3wzoHRsHIyp4PIB/Com
0rT5Le0t30+2aG0dHto2hUrAyDCFBjClR0I6dq1MViTeIdNt9UGny3EgmLrGzCCQxRu2NqPKF2I5
3LhWYE70wPmXImwA+HdDEM9sdH0/ybhI0mj+yptkWMARhhjBCgDaD0xxUkmh6TMbHzdLsnFhj7GW
t0P2bGMeXx8mNq9MdB6VHqPiHTNLuFhu7iRHKCRykEkiwoSQHlZVIiThvmcqPlbn5TjbouwMt9I0
+Xej2FqyOsqMphUhllbdKDx0c8sP4jyc0x9D0qS9ubuTS7Nrm7iMNxM1uheaMgAo7Yyy4AGDxwK1
6zr68h0+1kubqTy4UwCQpYkkgKqqMlmJIAUAkkgAEmi7A0aK5w+K9KWxmu3kuokheNJYpbGdJ8yO
EjxCyCRgzHaCFIJBA6HFiPXrC4t4pk+1xiW4FtElxZzQySSEZwqOgYjGSWAwArEkBWIANus2TSrC
bU49SksLV7+JNkV00KmVF54D4yB8zcA9z61nQ+LdGlcj7XJFFsZ1uLi3lht5FVSxKTOojcbQzZVj
lVLDIBNEfivR5U05lu5N2o3EltaxG3lErvGzLIDGV3qEKnczABe5GRQBoWmk2Fhc3FxZ2NtbTXT7
7iSGFUaZsk5cgZY5J5PqfWo7fQtKsr+a+tdLs4Lyfd5tzFbokkm47m3MBk5IBOepqvZ+JtMvtRa0
gmnMwlkgDPayxxySRlg6JIyhHYFH4Uk4Vj0BIvWN7DqFrHc2snmQvkAlSpBBIZWU4KsCCCpAIIII
BFF2BCmh6XHe213FpdmtzaRCG3mW3QPDGAQERsZVcEjA45NRjw7ofkwW40fTxDbpIkMf2VNsayAi
QKMYAYE7gOuea26KLsCj9itPsnk/ZYPJ83ztnlDb5m/zN+P72/5s9d3PWoLvSrHUBMt7YWtwk6Ik
qzQq4kVGLKGyOQCSQD0JJrVoouwMmbQtJuWTz9LspSnm7d9ujbfNz5uMjjfk7v72TnNE2haTcsnn
6XZSlPN277dG2+bnzcZHG/J3f3snOa1qKLsDNj0qwh1OTUo7C1S/lTZLdLColdeOC+MkfKvBPYel
Vp/DmiXGpjUptG0+W/Dq4untUaUMuNp3kZyMDBzxgVtUtF2BlvpGny70ewtWR1lRlMKkMsrbpQeO
jnlh/EeTmmW2haVZahNfWul2cF5Pu825it0SSTcdzbmAyckAnPU1r0UXYGZc6VZ6j5b31ha3Txo6
I08KuVV12uBkcBhwR3HBp9pY2lkZhaWkNv58rTSmKMJ5kjfedsdWOBknk1oUUXYGRZaHpOmxpFY6
XZWsccpmRYLdECyFdhcADhtpK564OOlOn0LSblk8/S7KUp5u3fbo23zc+bjI435O7+9k5zWrRRd3
AzNR0nTtXt1t9TsLW9hV96x3MKyKGwRkBgRnBPPuaJNKsri8F5c2FrJdBFQTvCrOFVw6jcRnAcBg
OxAPWtOii7A5i38I6VbaVb2FvD5fk/Y91wqoJp/srI0XmMF+b7gH0Jxir66HpUNotpFpdmlssUkK
wpAgQRyEF0C4xtYgEjocc1r0U7sDITQ9JhtFtItLs0tlikhWFIECCOQgugXGNrEAkdDjmlvdD0nU
o3ivtLsrqOSUTOs9ujhpAuwOQRy20Bc9cDHSteild3AoNZWjtLutYD5sqTSZjB3uu3a59WGxMHqN
q+gqn/wjuhmGC3/sfT/Jt0kSGP7Km2NZARIFGMAMCdwHXPNbdFF2Bkromkr9o26ZZAXJl8/ECfvf
Mx5m7j5t21d2eu0ZziltNKsNPEK2Vja26QI6RLDCqCNXYMwXA4BIBIHUgGtWii7AyJtHtLmwhs40
+ypbbTavbgI1syjCmPjAwCRjBUqSpBUkEm0TSbiaeabS7OSW4/1zvboWlwjRjcSOfkZl5/hYjoTW
vRRdgZ7WVq1pNaG1hNtNv82ExjY+8kvuXodxYk565OetVxo2kqIYxpVkIoZUmiUW6YSRFCI6jHDK
qhQRyAABwK2KKLtAYh8O6H5M9sdH08w3CRpNH9lTbIsYAjDDGCFAG0HpjipF0i0S/S7EePJ3tDCA
BHHI5YyShQP9Y24gscnBbGN77teii7AKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAoo
ooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigDhprDWovE9hpY8Xav5FxZXNw7GCz3Bo
3gVQP9HxjErZ47Dp3L3S9Ul1PUbSOwkaG+1iy1Fb3zIxFEkP2bcjgtv3n7M2NqsPnTJHzbdm8/5K
Ho3/AGCr/wD9G2ldBQBwev6bqt++upbaVO66zpY0uN/NiAt2RrhfNly+fLYTqw2B2wGyoOAe8ooo
AKwPEcNxPYRxw2B1CAyg3MCOEmKAEq0LF0CyLJ5bBiwwFJB3Ba36KAPN7/T9bu49KiutH1iextb2
W5iWG/iS9ijEJjSOWQTpklpZTvWRjsjQPuZ2It2Ed4ms3C29rPaX0GjH+zIdWuTMwkeaTzt8iu5k
XKWhbDMUUoBt3YPe0UAecyabql5pGp6Rp+kXthpl9aG0aC9uIpPIaVlj8yAJK4WNI2kYxZVfkjEY
GXNVrTwxr1prDatNYJcTWV7qV5YRLcKMozTeXFz9x5muWZnBICwRBhnp6fRQB5/p1vcWWk+Hk1Kz
utNs/Dyx5nuvKZ7pxA1siRxwySHLGQnGc52KocsSvQ+GrOex0SNLuPyrqeWa7mh3BvKeaV5mj3Dh
thkK7h125wM4rfooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigA
ooooAKKKKACiiigDD8Sz3Fn4X1e6t7qO0ngs5pI7mRSywsqEhyAGJAIzjB6dD0rcrA8Uny/CGuN5
sMWLG4PmXEfmRp+7bl12tuUdxtbI4welb9ABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUU
UAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAc/ef8AJQ9G/wCwVf8A/o20roK5
+8/5KHo3/YKv/wD0baV0FABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQA
UUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQBgeKT5fhDXG82GLFjcHzLiPzI0/dt
y67W3KO42tkcYPSt+sDxSfL8Ia43mwxYsbg+ZcR+ZGn7tuXXa25R3G1sjjB6Vv0AFFFFABRRRQAU
UUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRR
RQBz95/yUPRv+wVf/wDo20roK5+8/wCSh6N/2Cr/AP8ARtpXQUAFFFFABRRRQAUUUUAFFFFABRRR
QAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFA
GB4pPl+ENcbzYYsWNwfMuI/MjT923Lrtbco7ja2Rxg9K36wPFJ8vwhrjebDFixuD5lxH5kafu25d
drblHcbWyOMHpW/QAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFAB
RRRQAUUUUAFFFFABRRRQAUUUUAFFFFAHP3n/ACUPRv8AsFX/AP6NtK6CuCutb1F/HOlSnwrq4ddN
vVERls9zAy2uWH7/ABgYAOSD8wwDzhNQubkanquoreXYnsdcsLCBFuHEQgl+yeYrRA7HJ8+X5mUs
MjBG1cAHfUVymuG9i8T+HHW+kjs5L14XtY12iQ/ZbhyXbqwBRNqjABBJ3Hbt6ugAooooAKKKKACi
iigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKK
KACiiigDA8Uny/CGuN5sMWLG4PmXEfmRp+7bl12tuUdxtbI4welb9YHik+X4Q1xvNhixY3B8y4j8
yNP3bcuu1tyjuNrZHGD0rfoAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKK
ACiiigAooooAKKKKACiiigAooooAKKKKACiiigDn7z/koejf9gq//wDRtpV2TStOn1OLUpdPtJL6
FNkV20KmVF54V8ZA+ZuAe59apXn/ACUPRv8AsFX/AP6NtK6CgCgtjaIYdtrApileePEYGyR925x6
Md75PU7m9TV+iigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACi
iigAooooAKKKKACiiigAooooAKKKKACiiigDA8Uny/CGuN5sMWLG4PmXEfmRp+7bl12tuUdxtbI4
welb9YHik+X4Q1xvNhixY3B8y4j8yNP3bcuu1tyjuNrZHGD0rfoAKKKKACiiigAooooAKKKKACii
igAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigDn7z/koejf
9gq//wDRtpXQVz95/wAlD0b/ALBV/wD+jbSugoAKKKKACiiigAooooAKKKKACiiigAooooAKKKKA
CiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKAMDxSfL8Ia43m
wxYsbg+ZcR+ZGn7tuXXa25R3G1sjjB6Vv1geKT5fhDXG82GLFjcHzLiPzI0/dty67W3KO42tkcYP
St+gBKaTXmPjL4waf4T8TR6N/Z8980e03ro+zyQwBAUEfO205xkDkDOc44f4l6R4u8SeL9N1jRI7
3UNKuYoZtIltAwFvkISW4HlMWw25scY5+UhdaeGlJrnfKmrpsly7H0TRWZpEd9Bo9lHqcyTXyQRr
cypwryhRvYcDgnJ6D6CtMVk9HYoKKKKACiiigBO1J2rmPFvjXSPBempeapJITK+yG3hAaWU8Z2gk
DABySSAOB1IBs+G/EmmeLNGi1TTJhJE/DK3DxOOqOOzDP6gjIIJOSVua2ncV+h0FFFFAwooooAKK
KKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKAOfvP+Sh6N/wBgq/8A/RtpXQVz
95/yUPRv+wVf/wDo20roKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigA
ooooAKKKKACiiigAooooAKKKKAG18/8AxY8SeNtO8fWlrYT3tnZfJ/Zq2mcXTnbu3AZ8xt/y7COm
Pl+bLfQFLTpTUHzNX9RNXM3SJL6fSLKTU4Uhvnt42uYk5VJSo3qOTwDkdT9TWmKKKT1dxhRRRQAU
UUUAYHik+X4Q1xvNhixY3B8y4j8yNP3bcuu1tyjuNrZHGD0rfrA8UkR+ENcbzYYsWNwfMuI/MjT9
23Lrtbco7ja2Rxg9K36AOD8T/C/w34s1eDVtQhnS4TAm+zuEFyoxgScZPAxkENg4zwMaXh3xX4Z1
mefSdA1C1lewQJ5EKlFVFO0bOAGQYAyuQMj1GdbV9Mi1fRr3TZXdYryB4JHQgMFdSpIyCM4PpXlv
w/8Ag9d+F/F51nUdRhmjtN4s1twQZNwZN0gYfL8p+6CeT1wPm1i4zg1OTutkS9HoezUUUVkUFFFF
ABRRRQBw3xB8A2fjzTreGWd7S8tXLW9wF3hQ2N6lMgMCFHcEEDnGQb/g3wfZeDfD6aXZu8xLmWeZ
+DLKQAWx0UYAAA6ADqck9TRQ5zceS/u9hWV7i0UUUDCiiigAooooAKKKKACiiigAooooAKKKKACi
iigAooooAKKKKACiiigAooooA5+8/wCSh6N/2Cr/AP8ARtpVW58STW2qXKrYo+n2t7b2FzObgiUT
TeVs2R7CGT9/Fkl1I+fCnA3ZV14P8Lr410q3Xw5o4hfTrx2jFhFtZlltQpI24JAZgD23H1rVufDc
1zqlyy3yJp91e29/cwG3JlM0PlbNkm8BU/cRZBRifnwwyNoBY1/WL7RYZb5NMSews7drm7me58tg
iglhEgVt7hVJwxQcqAxy23oq5bV9I13Ur22lj1fTkt7Z2kFtNpryI8m/MbtidclF24B43ZfGQmzq
aACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAoooo
AKKKKACiiigApO1Zlpq2n6hcXFvZX9rczWr7LiOGZXaFskYcA5U5B4PofSl1fU49H0e91OVHaKzg
e4kVACxVFLEDJAzgetHK726gaGKz9Wjvp9IvY9MmSG+e3kW2lflUlKnYx4PAOD0P0NeWfD74w3fi
jxedH1HToYY7vebNrckmPaGfbIWPzfKPvADkdMH5fZO1OdOVKVpLXcSaex80+EPD3jfTL/xLfX6S
6dZiwujqUupRmSGdvLk2sQVfzsP8xYBsru5O/DfSxrC8UYj8I643mwR4sbg+ZcR+ZGn7tuWXa25R
3G1sjjB6Vu0VZupK7VvQErIdRRRSGFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUU
AFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFAHP3n/JQ9G/7BV//wCjbSugrn7z/koejf8AYKv/
AP0baV0FABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRR
RQAUUUUAFFFFABRRRQAVl6vZzX+j3tlBcvaTXEDxR3Med0LMpAcYIOQTnqOnWtSihOzuB4R8Mfhh
4n8O+Nv7T1Nls7O1SSP91KHF4GBUAAHIQHD/ADgHIX5c5K+7Y4opaqc5TfNLcSVjmtC8G+HvDuoX
V9pGlQ2lzdf610JPGc7VBJCLn+FcDgccDHSUUVDk27t3YzB8UHy/CGuN5kEWLG4PmXEfmRp+7bll
2tuUdxtbI4welb9YHik+X4Q1xvNhixY3B8y4j8yNP3bcuu1tyjuNrZHGD0rfpgFFFFABRRRQAUUU
UAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQ
Bz95/wAlD0b/ALBV/wD+jbSugrn7z/koejf9gq//APRtpXQUAFFFFABRRRQAUUUUAFFFFABRRRQA
UUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAN7V86+JvEnxBtvi21nZtdLOtxtsNOTP2e4gy21m
XO1gy5LOTlTnldny/RVJVUqqg23FO66iauPoooqRhRRRQAUUUUAFFFFABRRRQAUUUUAYHik+X4Q1
xvNhixY3B8y4j8yNP3bcuu1tyjuNrZHGD0rfrA8Uny/CGuN5sMWLG4PmXEfmRp+7bl12tuUdxtbI
4welb9ABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQ
AUUUUAFFFFABRRRQAUUUUAc/ef8AJQ9G/wCwVf8A/o20roK5+8/5KHo3/YKv/wD0baVLL4h0231Q
afLcSCYusbMIJDFG7Y2o8oXYjncuFZgTvTA+ZcgG3RWJqPiHTNLuFhu7iRHKCRykEkiwoSQHlZVI
iThvmcqPlbn5TjboAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigA
ooooAKKKKACiiigAooooAKKKKACiiigAooooAwPFJ8vwhrjebDFixuD5lxH5kafu25ddrblHcbWy
OMHpW/WB4pPl+ENcbzYYsWNwfMuI/MjT923Lrtbco7ja2Rxg9K36ACiiigAooooAKKKKACiiigAo
oooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooA4K60TUU8
c6VEfFWrl2029YSmKz3KBLa5UfuMYOQTkE/KMEc5kvdL1SXU9RtI7CRob7WLLUVvfMjEUSQ/ZtyO
C2/efszY2qw+dMkfNt2bz/koejf9gq//APRtpXQUAcf4qi1PVtLm0230e6YzpIlvOt1GqRy/Oga4
j3gPAQVbbiTcCQ0YIAPYUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFF
ABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAYHik+X4Q1xvNhixY3B8y4j8yNP3bcuu1
tyjuNrZHGD0rfrA8Uny/CGuN5sMWLG4PmXEfmRp+7bl12tuUdxtbI4welb9ABRRRQAUUUUAFFFFA
BRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAc
/ef8lD0b/sFX/wD6NtK6CufvP+Sh6N/2Cr//ANG2ldBQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQ
AUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAYHik+X
4Q1xvNhixY3B8y4j8yNP3bcuu1tyjuNrZHGD0rfrA8Uny/CGuN5sMWLG4PmXEfmRp+7bl12tuUdx
tbI4welb9ABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABR
RRQAUUUUAFFFFABRRRQAUUUUAc/ef8lD0b/sFX//AKNtK6CufvP+Sh6N/wBgq/8A/RtpXQUAFFFF
ABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUA
FFFFABRRRQAUUUUAFFFFAGB4pPl+ENcbzYYsWNwfMuI/MjT923Lrtbco7ja2Rxg9K36wPFJ8vwhr
jebDFixuD5lxH5kafu25ddrblHcbWyOMHpW/QAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAF
FFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFAHP3n/JQ9G/7BV/8A+jbSugrg
rrW9RfxzpUp8K6uHXTb1REZbPcwMtrlh+/xgYAOSD8wwDzhNQubkanquoreXYnsdcsLCBFuHEQgl
+yeYrRA7HJ8+X5mUsMjBG1cAHfUV59451+902+0+2g/tG3tUuLSWea2spZBPuuo08kOiMANglLL8
rMWiC7gzKfQaACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKK
ACiiigAooooAKKKKACiiigAooooAKKKKAMDxSfL8Ia43mwxYsbg+ZcR+ZGn7tuXXa25R3G1sjjB6
Vv1geKT5fhDXG82GLFjcHzLiPzI0/dty67W3KO42tkcYPSt+gAooooAKKKKACiiigAooooAKKKKA
CiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKAOfvP+Sh6N/2C
r/8A9G2lXZNK06fU4tSl0+0kvoU2RXbQqZUXnhXxkD5m4B7n1qlef8lD0b/sFX//AKNtK6CgCj9i
s/s3k/ZYfJ87z/L8sbfM3+Zvx/e3/Nnru561eoooAKKKKACiiigAooooAKKKKACiiigAooooAKKK
KACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAwPFJ8vwhrjebDFi
xuD5lxH5kafu25ddrblHcbWyOMHpW/WB4pPl+ENcbzYYsWNwfMuI/MjT923Lrtbco7ja2Rxg9K36
ACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooA
KKKKACiiigAooooA5+8/5KHo3/YKv/8A0baV0Fc/ef8AJQ9G/wCwVf8A/o20roKACiiigAooooAK
KKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAoo
ooAKKKKACiiigDA8Uny/CGuN5sMWLG4PmXEfmRp+7bl12tuUdxtbI4welb9YHik+X4Q1xvNhixY3
B8y4j8yNP3bcuu1tyjuNrZHGD0rfoAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooo
oAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigDn7z/koejf8AYKv/AP0baV0Fc/ef8lD0
b/sFX/8A6NtK6CgAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACi
iigAooooAKKKKACiiigAooooAKKKKACiiigAooooAwPFJ8vwhrjebDFixuD5lxH5kafu25ddrblH
cbWyOMHpW/WB4pPl+ENcbzYYsWNwfMuI/MjT923Lrtbco7ja2Rxg9K36ACiiigAooooAKKKKACii
igAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooA5+8/
5KHo3/YKv/8A0baV0FcxrXh/StW1Ow1DW47Oe3tYpbZIL2FHRpJpIQrAtwGym0DGT5mPYzf8IJ4Q
/wChU0P/AMF0P/xNAHQ0Vz3/AAgnhD/oVND/APBdD/8AE0f8IJ4Q/wChU0P/AMF0P/xNAHQ0Vz3/
AAgnhD/oVND/APBdD/8AE0f8IJ4Q/wChU0P/AMF0P/xNAHQ0Vz3/AAgnhD/oVND/APBdD/8AE0f8
IJ4Q/wChU0P/AMF0P/xNAHQ0Vz3/AAgnhD/oVND/APBdD/8AE0f8IJ4Q/wChU0P/AMF0P/xNAHQ0
Vz3/AAgnhD/oVND/APBdD/8AE0f8IJ4Q/wChU0P/AMF0P/xNAHQ0Vz3/AAgnhD/oVND/APBdD/8A
E0f8IJ4Q/wChU0P/AMF0P/xNAHQ0Vz3/AAgnhD/oVND/APBdD/8AE0f8IJ4Q/wChU0P/AMF0P/xN
AHQ0Vz3/AAgnhD/oVND/APBdD/8AE1n6l4c8A6NbrcanonhuzgZwiyXNrbxKWwTgFgBnAJx7GgDa
0HUjrWgabqvk+T9utYrnyt27ZvQNtzgZxnGcCteuEtvBfg3w74bgXV9L0ApZwRRTX93ZwxiRgAu9
mYcFm9SeT1NXLHwt4H1OzS8sPD/h27tZM7JoLKCRGwSDhgMHBBH4UAdfRXPf8IJ4Q/6FTQ//AAXQ
/wDxNH/CCeEP+hU0P/wXQ/8AxNAHQ0Vz3/CCeEP+hU0P/wAF0P8A8TR/wgnhD/oVND/8F0P/AMTQ
B0NFc9/wgnhD/oVND/8ABdD/APE0f8IJ4Q/6FTQ//BdD/wDE0AdDRXPf8IJ4Q/6FTQ//AAXQ/wDx
NH/CCeEP+hU0P/wXQ/8AxNAHQ0Vz3/CCeEP+hU0P/wAF0P8A8TR/wgnhD/oVND/8F0P/AMTQB0NF
c9/wgnhD/oVND/8ABdD/APE0f8IJ4Q/6FTQ//BdD/wDE0AdDRXPf8IJ4Q/6FTQ//AAXQ/wDxNH/C
CeEP+hU0P/wXQ/8AxNAHQ1kyan5XiG00ryc/abWe583d93ynhXbjHOfOznPG3vnip/wgnhD/AKFT
Q/8AwXQ//E1hXHhHwRH4rsIH0/w9FdfZJlXSzaQB7jcyMJAnU7RFIAcH7zcjByAd9RXPf8IJ4Q/6
FTQ//BdD/wDE0f8ACCeEP+hU0P8A8F0P/wATQB0NFc9/wgnhD/oVND/8F0P/AMTR/wAIJ4Q/6FTQ
/wDwXQ//ABNADvFJ8vwhrjebDFixuD5lxH5kafu25ddrblHcbWyOMHpW/XPf8IJ4Q/6FTQ//AAXQ
/wDxNH/CCeEP+hU0P/wXQ/8AxNAHQ0Vz3/CCeEP+hU0P/wAF0P8A8TR/wgnhD/oVND/8F0P/AMTQ
B0NFc9/wgnhD/oVND/8ABdD/APE0f8IJ4Q/6FTQ//BdD/wDE0AdDRXPf8IJ4Q/6FTQ//AAXQ/wDx
NH/CCeEP+hU0P/wXQ/8AxNAHQ0Vz3/CCeEP+hU0P/wAF0P8A8TR/wgnhD/oVND/8F0P/AMTQB0NF
c9/wgnhD/oVND/8ABdD/APE0f8IJ4Q/6FTQ//BdD/wDE0AdDWRoOpHWtA03VfJ8n7daxXPlbt2ze
gbbnAzjOM4FYknhvwDDqcWmzaN4aS/mTfFaPa24ldeeVTGSPlbkDsfSs5PDHgDwtpWm2OuW3hpJ0
t1i+039tbxNcsiqGf5+SScE8n73WgD0Oiue/4QTwh/0Kmh/+C6H/AOJo/wCEE8If9Cpof/guh/8A
iaAOhornv+EE8If9Cpof/guh/wDiaP8AhBPCH/QqaH/4Lof/AImgDoaK57/hBPCH/QqaH/4Lof8A
4mj/AIQTwh/0Kmh/+C6H/wCJoA6Giue/4QTwh/0Kmh/+C6H/AOJo/wCEE8If9Cpof/guh/8AiaAO
hornv+EE8If9Cpof/guh/wDiaP8AhBPCH/QqaH/4Lof/AImgDoaK57/hBPCH/QqaH/4Lof8A4mj/
AIQTwh/0Kmh/+C6H/wCJoA6Giue/4QTwh/0Kmh/+C6H/AOJo/wCEE8If9Cpof/guh/8AiaAOhorn
v+EE8If9Cpof/guh/wDiaP8AhBPCH/QqaH/4Lof/AImgC3JqfleIbTSvJz9ptZ7nzd33fKeFduMc
587Oc8be+eNauVtPC+h6R4otb3S7XTtPn+xXETW9rbJE06s8J3nbgkIVA6H/AFg5HfqqACiiigAo
oooA4vXdP1DVNNsbjU9LgF9a6nZvAlncSXCIn2qAvJyiYYKH52nau75sMwrtKKKACiiigAooooAK
KKKACiiigAooooAKKKKACiiigAri5rnU7PxBpurazpnlwxWl1bEaZ51/hpHt2TIWIOMiKTnbtG0Z
bLAV2lFAHn/2BrfwT4e06+OsWs+mW9m8x062WfY6xFRlSkiyhXXOEVyrCN+AAw6XQJr6fR4X1BZP
PLyBWlj8t5Ig7CJ3XA2u0YRmXC4JI2r90bdFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAV
wOoW1ydT1XTls7sz32uWF/A627mIwRfZPMZpQNiEeRL8rMGOBgHcue+ooAKKKKACiiigAooooAKK
KKACiiigAooooAKKKKACiiigDgdQtrk6nqunLZ3ZnvtcsL+B1t3MRgi+yeYzSgbEI8iX5WYMcDAO
5cniJ7hNWbU9NfWl1JbZreziWwElrPKsjfu3LRloVZwm590auuwhzs3L31FABRRRQAUUUUAFFFFA
BRRRQAUUVyut6lqlvrVvZW09rYW8yqI7u7spLmOWVmK+WSkiCIj5MFz+8MoVeVIIB1VFef3fjLUb
XXbyynsbQ/Z7do0t43YtNeYs9iCUgAI7Xix5KDG3cSASFfo2veI9ftNKW2udLtrqTS4dRvJJbKSR
P9ILeUkaiYHgRybiW7KQOSFAO9ormofEnn+FNK1iO0zc6pFAbaz83kySqCF3YztUEszBSQiM204x
WTB4o1eTUZYZLP8Acpdf2fA8dsjC+njjaWVo2+0YRSIpYwrZ2uV3MSHRQDu6K5S88Z6NY6fLqlxN
JFZxukKSzAQiads/uV8wqd6kYbdhUO4MQUk2QS+PtHXw/wD2xALu8gS3kuZltUEzQIhZSWKkrjej
ICCQ2GYEoruoBZbTBF8QbLUo7aQmTTbuOe4O5gD5lr5aZPCjCuQowM7zjJYnqa5zRtS1J9UuNK1J
bU3cFna3UklqGCbpfMV0AYkkB4WIbjhwCMqS3R0AFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFF
ABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUA
FFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFcxqHhaG+uL3
/iYXsNpqP/H/AGkXleXdfII23FkLrmNVQ7GXgZGGyT09FAHIXfgnTLu/S8knvhfR/bTFdRTbJY3u
QFZwwHLIgCJnO1QowdoIkXwikV9cTWmr6jZ286RxPaWvkpGscaBViRvL8yNMbiAjrtLsV2k5rq6K
AMC+0bzG0VrFIYY9Ku1kS3A2J5flSQlVwPl2rKWAxg7AvAO4V38K2zLEqXd6gjluZhslCkNcS+ZI
wO3KtgyRq64ZUkcAgncOnooA5hvCdnHHHFYPPpqQyie1S0EYS0l2ujNEjKyjejsGUgryWADksVv/
AAlp2oSxyST3yKsUMEqC5ZhcxxMSqTbsmRcPKrBiQwlbdkhSvTUUAYel2E1rLdXl4UfUL11ebyyW
SJVXCRIxGSi8nnGWd2Crv2jcoooAKKKKAP/Z
</FILE>
</FIGURE>
<FIGURE FILENAME="Other figure.jpg" FILE_TYPE="JPG" ID="FIG-07" NO="7" SHORT_VERSION_FIGURE="YES" TYPE="OTHER">
<CAPTION>
<P>Funnel plot of studies with distal radius BMD outcome at end of longest period of follow-up after supplementation ceased</P>
</CAPTION>
<FILE>/9j/4AAQSkZJRgABAgAAAQABAAD/2wBDAAgGBgcGBQgHBwcJCQgKDBQNDAsLDBkSEw8UHRofHh0a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</FILE>
</FIGURE>
<FIGURE FILENAME="Other figure.jpg" FILE_TYPE="JPG" ID="FIG-08" NO="8" SHORT_VERSION_FIGURE="YES" TYPE="OTHER">
<CAPTION>
<P>Funnel plot of studies with upper limb BMD outcome at end of supplementation period</P>
</CAPTION>
<FILE>/9j/4AAQSkZJRgABAgAAAQABAAD/2wBDAAgGBgcGBQgHBwcJCQgKDBQNDAsLDBkSEw8UHRofHh0a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</FILE>
</FIGURE>
<FIGURE FILENAME="Other figure.jpg" FILE_TYPE="JPG" ID="FIG-09" NO="9" SHORT_VERSION_FIGURE="YES" TYPE="OTHER">
<CAPTION>
<P>Funnel plot of studies with upper limb BMD outcome at end of longest period of follow-up after supplementation ceased</P>
</CAPTION>
<FILE>/9j/4AAQSkZJRgABAgAAAQABAAD/2wBDAAgGBgcGBQgHBwcJCQgKDBQNDAsLDBkSEw8UHRofHh0a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==
</FILE>
</FIGURE>
</FIGURES>
<FEEDBACK MODIFIED="2010-02-19 15:28:43 -0500" MODIFIED_BY="[Empty name]">
<FEEDBACK_ITEM ID="FBK-01" MODIFIED="2010-02-19 15:28:43 -0500" MODIFIED_BY="[Empty name]" NO="1">
<TITLE MODIFIED="2010-02-19 15:28:10 -0500" MODIFIED_BY="[Empty name]">Feedback from Tanis Fenton</TITLE>
<DATE_SUBMITTED>
<DATE DAY="5" MONTH="1" YEAR="2010"/>
</DATE_SUBMITTED>
<FEEDBACK_SUMMARY MODIFIED="2010-02-19 15:27:39 -0500" MODIFIED_BY="[Empty name]">
<P>Date of Submission: 05-Jan-2010</P>
<P>Name: Tanis Fenton</P>
<P>Email Address: <A HREF="mailto:tanisfenton@shaw.ca">tanisfenton@shaw.ca</A>
</P>
<P>Personal Description: Occupation Nutrition Researcher</P>
<P> </P>
<P>Feedback: To the Editor:</P>
<P>In the meta-analysis on role of calcium supplementation in children, Winzenberg et al (1) used standardised mean differences (SMD) to summarize their results and to base their conclusions.  Although the use of SMD is recognized as a valid approach in summarizing mean differences across trials in the Cochrane Review methodology (1), its primary purpose is for comparing variables with different units and measurement scales of different length (2). The SMD is calculated by dividing the group differences by the standard deviation.  This converts a variable which has units to a unitless score.  In other words, a variable which once had clinical meaning becomes clinically meaningless.</P>
<P>In Winzenberg et al.?s meta-analysis, all measurements of bone mineral density (BMD) by the included studies were reported as grams per square centimetre (mg/cm2).  Under these circumstances, we believe that the use of SMDs is unnecessary.  An alternate approach is to summarize the treatment effects as absolute differences.  We have re-constructed Table 2 from the meta-analysis by calculating the effect size at the end of supplementation period in terms of g/cm2, the usual units of measurement for BMD (published on-line at: <A HREF="http://www.bmj.com/cgi/eletters/333/7572/775">http://www.bmj.com/cgi/eletters/333/7572/775</A>).  We hope that our re-constructed Table will help clinicians better-appraise the magnitude of effect size for this meta-analysis.</P>
<P>In regards to interpreting the results from the Table, all bone sites show consistent increase in BMD at the end of a median calcium supplementation period of one year.  We disagree with Winzenberg et al.?s claim that the observed relative increase in upper limb body BMD is not clinically important.  Not only is this result statistically significant, but a yearly 0.007 g/cm2 increase (or a 1.8% relative increase) in BMD is a clinically meaningful change.  If this increase continued throughout childhood, it would likely translate to a substantial gain in bone strength.</P>
<P>We are concerned that the results of Winzenberg et al.?s meta-analysis could be construed to imply calcium is not important in childhood, even though the meta-analysis focused on the role of calcium supplementation and did not address calcium requirements. This interpretation of the results was promoted by the accompanying Editorial in the BMJ(3).  It was written by a member of the Physicians Committee for Responsible Medicine, a group that promotes vegan diets devoid of dairy products.  This thinking is at odds with the American Association of Clinical Endocrinologists (4), the National Institutes of Health Consensus Development Panel on Osteoporosis Prevention, Diagnosis and Therapy (5), the Institute of Medicine (6), and the Scientific Advisory Council of Osteoporosis Canada (7).  These groups recommend adequate intakes of calcium and vitamin D, combined with weight bearing physical activity, throughout childhood to promote the attainment of an optimal peak bone mass.  It is likely that calcium intake is a necessary but not sufficient condition for the development of a strong skeleton, as physical activity and calcium both play key roles in the attainment of a high peak bone mass (8).</P>
<P>Until we are absolutely certain about what the minimum and optimum combinations of calcium, vitamin D, foods from plant sources and physical activity are required to achieve a bone mass that will sustain the bones of individuals through their older ages without fragility fractures, it seems prudent to continue to follow the consensus-based recommendations for intakes of calcium and vitamin D.</P>
<P> </P>
<P>Sincerely,</P>
<P> </P>
<P>Tanis R. Fenton, PhD, RD</P>
<P>Department of Community Health Sciences</P>
<P>University of Calgary</P>
<P> </P>
<P>Michael Eliasziw, PhD</P>
<P>Department of Community Health Sciences</P>
<P>University of Calgary</P>
<P>Calgary AB, Canada</P>
<P> </P>
<P>David A. Hanley, MD, FRCPC</P>
<P>Departments of Medicine, Oncology and Community Health Sciences Division of Endocrinology and Metabolism University of Calgary</P>
<P>References</P>
<P>   1.   Winzenberg T, Shaw K, Fryer J, Jones G. Effects of calcium supplementation on bone density in healthy children: meta-analysis of randomised controlled trials. BMJ 2006; 333:775.</P>
<P>   2.   Cohen J. Statistical Power Analysis for the Behavioral Sciences. New York: Academic Press; 1977.</P>
<P>   3.   Lanou AJ. Bone health in children. BMJ 2006; 333:763-4.</P>
<P>   4.   Hodgson SF, Watts NB, Bilezikian JP, Clarke BL, Gray TK, Harris DW et al. American Association of Clinical Endocrinologists medical guidelines for clinical practice for the prevention and treatment of postmenopausal osteoporosis: 2001 edition, with selected updates for 2003. Endocr Pract 2003; 9:544-64.</P>
<P>   5.    Osteoporosis prevention, diagnosis, and therapy. JAMA 2001; 285:785-95.</P>
<P>   6.   Institute of Medicine (IOM). Dietary Reference Intakes for calcium, phosphorus, magnesium, vitamin D and fluoride. The National Academies Press; 1997.</P>
<P>   7.   Brown JP, Josse RG. 2002 clinical practice guidelines for the diagnosis and management of osteoporosis in Canada. CMAJ 2002; 167:S1-34.</P>
<P>   8.   Courteix D, Jaffre C, Lespessailles E, Benhamou L. Cumulative effects of calcium supplementation and physical activity on bone accretion in premenarchal children: a double-blind randomised placebo-controlled trial. Int J Sports Med 2005; 26:332-8.</P>
</FEEDBACK_SUMMARY>
<FEEDBACK_REPLY MODIFIED="2010-02-19 15:28:43 -0500" MODIFIED_BY="[Empty name]">
<P>To the editor</P>
<P>Thank you for the opportunity to respond to the letter from your e-mail of 5<SUP>th</SUP> January 2010.</P>
<P>Addressing the points raised in the letter:</P>
<P>It is valid to use SMDs.  While SMDs require a greater degree of interpretation, because of the recognised variation between methods of measuring bone density we remain of the opinion that this was the most appropriate approach to use in our analysis.</P>
<P>We were surprised at the marked difference in results described by the letter authors in their table compared to our findings.  We therefore repeated our analyses for these three outcomes using the alternative method of weighted mean differences using the inverse variance method and using a fixed effect model as there was no statistical heterogeneity for any result<SUP>1</SUP>.  The results of these analyses are given in detail in figures 1-3 and are entirely consistent with our original analyses using SMDs<SUP>2,3</SUP>.<SUP>  </SUP>Results at the femoral neck and lumbar spine were not statistically significant (p=0.2 and 0.22 respectively) but the distal radius result was significant (p=0.01). This contrasts with the p-values reported in the letter.  Moreover, our re-analysis gives weighted mean differences substantially less for femoral neck and lumbar spine than provided by the letter authors (6.83 and 5.73 g/cm<SUP>2 </SUP>compared to the results given in the letter of 11.7 and 15.2 for femoral neck and lumbar spine respectively) and somewhat less at the upper limb (5.52 g/cm<SUP>2</SUP> vs. 7.0 g/cm<SUP>2</SUP>). </P>
<P>As we do not have details of the letter authors&#8217; analysis approach, we cannot be certain of the reason for the differences between their analyses and ours.  We, however, do stand by our results which are consistent regardless of whether standardised or weighted mean differences are used and which use well established methods as outlined in the Cochrane handbook of Systematic Reviews<SUP>1</SUP>.</P>
<P>The remaining issues raised in the letter relate to interpretation of our original findings.  We argue in our original paper and continue to maintain that:</P>
<UL>
<LI>There are no statistically significant effects of calcium supplementation at the femoral neck or lumbar, two sites of key clinical importance.</LI>
<LI>The small persistent increase seen at the distal radius is not clinically significant in terms of reducing childhood fracture risk.</LI>
<LI>Our subgroup analyses by study duration (&lt;24 months compared to 24 months or more) do not support additive effects on BMD occurring with increased duration of supplementation (as postulated by the letter authors).</LI>
</UL>
<P>We cannot speak for the authors of BMJ editorials accompanying the version of our review published in the BMJ.  However, none of the authors of our review have any conflict of interest with our published work, including membership of the Physicians Committee for Responsible Medicine. </P>
<P>We agree that calcium is important for bone health.  However, our data do not demonstrate improvements in BMD likely to be of clinical or public health significance from calcium supplementation even with dietary calcium intakes as low as 594 mg/day.  Thus, we maintain that potential measures for improving peak bone mass besides calcium supplementation merit urgent exploration.</P>
<P> </P>
<P>Yours sincerely</P>
<P> </P>
<P>Dr Tania Winzenberg</P>
<P>Professor Graeme Jones</P>
<P>Ms Jayne Fryer</P>
<P>Dr Kelly Shaw</P>
<P> </P>
<P>References</P>
<P>1.     Higgins JPT, Green S (editors). <I>Cochrane Handbook for Systematic Reviews of Interventions</I> Version 5.0.2 [updated September 2009]. The Cochrane Collaboration, 2009. Available from <A HREF="http://www.cochrane-handbook.org">www.cochrane-handbook.org</A>. Last Accessed 8<SUP>th</SUP> February 2010.<I> </I>
</P>
<P>2. Winzenberg T, Shaw K, Fryer J, Jones G. Effects of calcium supplementation on bone density in healthy children: meta-analysis of randomised controlled trials. Bmj. 2006 Oct 14;333:775.</P>
<P>3. Winzenberg TM, Shaw K, Fryer J, Jones G. Calcium supplementation for improving bone mineral density in children. The Cochrane Database of Systematic Reviews. 2006;2006:Art. No.: CD005119. DOI: 10.1002/14651858.CD005119.pub2.</P>
</FEEDBACK_REPLY>
<FEEDBACK_CONTRIBUTORS MODIFIED="2010-02-19 14:53:54 -0500" MODIFIED_BY="[Empty name]">
<P>Dr Tania Winzenberg</P>
<P>Professor Graeme Jones</P>
<P>Ms Jayne Fryer</P>
<P>Dr Kelly Shaw</P>
</FEEDBACK_CONTRIBUTORS>
</FEEDBACK_ITEM>
</FEEDBACK>
<APPENDICES/>
<EXTENSIONS/>
</COCHRANE_REVIEW>